0000875320-20-000007.txt : 20200213 0000875320-20-000007.hdr.sgml : 20200213 20200213164857 ACCESSION NUMBER: 0000875320-20-000007 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 149 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200213 DATE AS OF CHANGE: 20200213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 20611531 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 10-K 1 a201910k-main.htm 10-K Document
false--12-31FY20190000875320VERTEX PHARMACEUTICALS INC / MA0.010.01500000000255172000258993000255172000258993000P1MP1M290000000007000000340000071000002700000000.010.011000000000000P5YP7YP3Y33700000P3YP3YP3YP3Y120.01140.01160.01180.0129.07100.0140.0160.0180.01140.00160.00180.00189.3840120.0060801000.33330.33330.33330.0P5YP1YP3YP6MP12M 0000875320 2019-01-01 2019-12-31 0000875320 2020-01-31 0000875320 2019-06-28 0000875320 2017-01-01 2017-12-31 0000875320 2018-01-01 2018-12-31 0000875320 us-gaap:ProductMember 2019-01-01 2019-12-31 0000875320 us-gaap:ProductMember 2018-01-01 2018-12-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2017-01-01 2017-12-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2019-01-01 2019-12-31 0000875320 us-gaap:ProductMember 2017-01-01 2017-12-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2018-01-01 2018-12-31 0000875320 2018-12-31 0000875320 2019-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000875320 us-gaap:CommonStockMember 2016-12-31 0000875320 us-gaap:CommonStockMember 2017-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 0000875320 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-12-31 0000875320 us-gaap:ParentMember 2018-01-01 2018-12-31 0000875320 us-gaap:ParentMember 2019-01-01 2019-12-31 0000875320 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000875320 us-gaap:ParentMember 2017-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000875320 us-gaap:ParentMember 2017-01-01 2017-12-31 0000875320 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000875320 us-gaap:ParentMember 2019-01-01 0000875320 us-gaap:NoncontrollingInterestMember 2017-12-31 0000875320 2016-12-31 0000875320 us-gaap:CommonStockMember 2019-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000875320 us-gaap:RetainedEarningsMember 2018-12-31 0000875320 2017-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000875320 us-gaap:ParentMember 2018-12-31 0000875320 us-gaap:NoncontrollingInterestMember 2018-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000875320 us-gaap:NoncontrollingInterestMember 2016-12-31 0000875320 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000875320 us-gaap:ParentMember 2019-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000875320 us-gaap:RetainedEarningsMember 2019-12-31 0000875320 us-gaap:CommonStockMember 2018-12-31 0000875320 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-12-31 0000875320 us-gaap:RetainedEarningsMember 2016-12-31 0000875320 2018-01-01 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 0000875320 us-gaap:RetainedEarningsMember 2017-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000875320 2017-01-01 0000875320 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000875320 2019-01-01 0000875320 us-gaap:ParentMember 2016-12-31 0000875320 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000875320 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000875320 us-gaap:ParentMember 2018-01-01 0000875320 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000875320 us-gaap:RetainedEarningsMember 2019-01-01 0000875320 us-gaap:NoncontrollingInterestMember 2019-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000875320 us-gaap:RetainedEarningsMember 2017-01-01 0000875320 us-gaap:RetainedEarningsMember 2018-01-01 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000875320 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0000875320 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0000875320 us-gaap:ProductMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0000875320 us-gaap:ProductMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0000875320 srt:RestatementAdjustmentMember us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000875320 srt:ScenarioPreviouslyReportedMember 2018-12-31 0000875320 vrtx:AccountingStandardsUpdate201609ForfeitureRateComponentMember us-gaap:RetainedEarningsMember 2017-01-01 0000875320 vrtx:AccountingStandardsUpdate201609ExcessTaxBenefitMember us-gaap:StateAndLocalJurisdictionMember 2017-01-01 0000875320 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000875320 vrtx:AccountingStandardsUpdate201609ExcessTaxBenefitMember 2017-01-01 0000875320 us-gaap:BuildingMember 2019-01-01 2019-12-31 0000875320 vrtx:ORKAMBIMember 2019-10-01 2019-12-31 0000875320 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-01-01 0000875320 vrtx:ResearchandDevelopmentRestructuringMember 2019-01-01 2019-12-31 0000875320 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0000875320 vrtx:AccountingStandardsUpdate201609ExcessTaxBenefitMember us-gaap:DomesticCountryMember 2017-01-01 0000875320 vrtx:AccountingStandardsUpdate201601FinancialInstrumentsMember us-gaap:RetainedEarningsMember 2018-01-01 0000875320 us-gaap:AccountingStandardsUpdate201601Member us-gaap:RetainedEarningsMember 2018-01-01 0000875320 us-gaap:AccountingStandardsUpdate201616Member 2018-01-01 0000875320 us-gaap:AccountingStandardsUpdate201602Member us-gaap:RetainedEarningsMember 2019-01-01 0000875320 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0000875320 srt:MaximumMember vrtx:ComputersAndSoftwareMember 2019-01-01 2019-12-31 0000875320 srt:MinimumMember vrtx:ComputersAndSoftwareMember 2019-01-01 2019-12-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2017-01-01 2017-12-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2018-01-01 2018-12-31 0000875320 vrtx:ParionSciencesInc.Member 2017-07-01 2017-09-30 0000875320 vrtx:KymeraTherapeuticsMember 2019-05-01 2019-05-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2017-01-01 2017-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-07-01 2019-07-31 0000875320 vrtx:MerckKGaAMember 2017-01-01 2017-01-31 0000875320 us-gaap:OtherIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesInc.Member 2018-12-01 2018-12-31 0000875320 vrtx:BioAxoneBiosciencesInc.Member 2018-01-01 2018-12-31 0000875320 vrtx:ArborBiotechnologiesInc.Member 2018-01-01 2018-12-31 0000875320 vrtx:MolecularTemplatesIncMember 2019-01-01 2019-12-31 0000875320 vrtx:JanssenPharmaceuticalsInc.Member 2017-01-01 2017-12-31 0000875320 vrtx:MerckKGaAMember 2017-01-01 2017-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-07-01 2019-09-30 0000875320 us-gaap:OtherIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2017-07-01 2017-09-30 0000875320 vrtx:CTX001CoCoAgreementMember 2018-01-01 2018-12-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2017-09-30 0000875320 vrtx:CTX001CoCoAgreementMember 2019-01-01 2019-12-31 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedMember 2016-01-01 2016-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-01-01 2019-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-10-01 2019-12-31 0000875320 vrtx:ParionSciencesInc.Member 2017-01-01 2017-12-31 0000875320 vrtx:MerckKGaAMember 2018-12-01 2018-12-31 0000875320 us-gaap:OtherIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2017-09-30 0000875320 vrtx:ExonicsTherapeuticsMember 2019-07-16 2019-07-16 0000875320 vrtx:SemmaTherapeuticsInc.Member 2019-10-10 2019-10-10 0000875320 vrtx:ConcertPharmaceuticalsMember 2017-01-01 2017-12-31 0000875320 vrtx:ExonicsTherapeuticsMember vrtx:CompensatoryMember 2019-07-16 2019-07-16 0000875320 vrtx:NakedIsletsMember vrtx:SemmaTherapeuticsInc.Member 2019-10-10 0000875320 vrtx:PreClinicalTreatmentsForDeviceAssistedCellsMember vrtx:SemmaTherapeuticsInc.Member 2019-10-10 0000875320 vrtx:ExonicsTherapeuticsMember vrtx:NonCompensatoryMember 2019-07-16 2019-07-16 0000875320 vrtx:SemmaTherapeuticsInc.Member 2019-10-10 0000875320 vrtx:SemmaTherapeuticsInc.Member 2019-10-10 0000875320 vrtx:ExonicsTherapeuticsMember 2019-07-16 0000875320 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000875320 vrtx:RestrictedStockandRestrictedStockUnitsMember 2017-01-01 2017-12-31 0000875320 vrtx:RestrictedStockandRestrictedStockUnitsMember 2018-01-01 2018-12-31 0000875320 vrtx:RestrictedStockandRestrictedStockUnitsMember 2019-01-01 2019-12-31 0000875320 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000875320 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0000875320 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0000875320 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0000875320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0000875320 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0000875320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 vrtx:CommercialPaperNotIncludedwithCashandCashEquivalentsDueWithinOneYearMember 2018-12-31 0000875320 us-gaap:CashEquivalentsMember 2018-12-31 0000875320 vrtx:CommercialPaperNotIncludedwithCashandCashEquivalentsDueWithinOneYearMember 2019-12-31 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:CommercialPaperMember 2018-12-31 0000875320 us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 vrtx:U.S.GovernmentSponsoredEnterprisesDebtSecuritiesDueWithinOneYearMember 2019-12-31 0000875320 vrtx:U.S.GovernmentSponsoredEnterprisesDebtSecuritiesDueWithinOneYearMember 2018-12-31 0000875320 us-gaap:AvailableforsaleSecuritiesMember 2018-12-31 0000875320 us-gaap:AvailableforsaleSecuritiesMember 2019-12-31 0000875320 vrtx:USTreasurySecuritiesDueWithinOneYearMember 2018-12-31 0000875320 vrtx:CashAndMoneyMarketFundsMember 2019-12-31 0000875320 us-gaap:EquitySecuritiesMember 2019-01-01 2019-12-31 0000875320 vrtx:CorporateDebtSecuritiesDueWithinOneYearMember 2018-12-31 0000875320 us-gaap:EquitySecuritiesMember 2018-12-31 0000875320 us-gaap:CashEquivalentsMember 2019-12-31 0000875320 vrtx:CashAndMoneyMarketFundsMember 2018-12-31 0000875320 us-gaap:USTreasurySecuritiesMember 2018-12-31 0000875320 vrtx:CorporateDebtSecuritiesDueWithinOneYearMember 2019-12-31 0000875320 us-gaap:EquitySecuritiesMember 2018-01-01 2018-12-31 0000875320 us-gaap:OtherAssetsMember 2019-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2018-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-01-01 2019-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-12-31 0000875320 vrtx:AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember 2019-01-01 2019-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000875320 vrtx:AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember 2019-12-31 0000875320 vrtx:AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember 2017-01-01 2017-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000875320 vrtx:AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember 2016-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-12-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-01-01 2017-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-12-31 0000875320 vrtx:AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember 2018-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000875320 vrtx:AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember 2018-01-01 2018-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000875320 vrtx:AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember 2018-01-01 0000875320 vrtx:AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember 2017-12-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-12-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:RevenueFromContractWithCustomerMember 2017-01-01 2017-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:RevenueFromContractWithCustomerMember 2019-01-01 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:RevenueFromContractWithCustomerMember 2018-01-01 2018-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:NondesignatedMember 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-01-01 2019-12-31 0000875320 srt:MaximumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 srt:MinimumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-12-31 0000875320 us-gaap:LeaseholdImprovementsMember 2018-12-31 0000875320 us-gaap:LeaseholdImprovementsMember 2019-12-31 0000875320 us-gaap:BuildingMember 2018-12-31 0000875320 us-gaap:BuildingMember 2019-12-31 0000875320 us-gaap:FurnitureAndFixturesMember 2019-12-31 0000875320 us-gaap:ComputerEquipmentMember 2019-12-31 0000875320 us-gaap:ComputerEquipmentMember 2018-12-31 0000875320 us-gaap:ComputerSoftwareIntangibleAssetMember 2018-12-31 0000875320 us-gaap:FurnitureAndFixturesMember 2018-12-31 0000875320 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-12-31 0000875320 us-gaap:OtherIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2017-01-01 2017-12-31 0000875320 vrtx:ExonicsTherapeuticsMember 2019-12-31 0000875320 vrtx:SemmaTherapeuticsInc.Member 2019-12-31 0000875320 us-gaap:OtherIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesInc.Member 2018-01-01 2018-12-31 0000875320 us-gaap:OtherIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesInc.Member 2017-01-01 2017-12-31 0000875320 vrtx:FanPierLeasesMember 2018-12-31 0000875320 vrtx:OtherOperatingLeasesMember 2018-12-31 0000875320 srt:MinimumMember 2019-01-01 2019-12-31 0000875320 vrtx:FanPierLeasesMember 2011-01-01 2011-12-31 0000875320 vrtx:SanDiegoLeaseMember 2015-12-31 0000875320 vrtx:FanPierLeasesMember 2011-12-31 0000875320 srt:MaximumMember 2019-01-01 2019-12-31 0000875320 vrtx:SanDiegoLeaseMember 2015-01-01 2015-12-31 0000875320 vrtx:SemmaandExonicsTherapeuticsMember 2019-01-01 2019-12-31 0000875320 vrtx:StockAndOptionPlan2006Member 2019-12-31 0000875320 vrtx:StockandOptionPlan2013Member 2019-12-31 0000875320 vrtx:ShareRepurchaseProgram2018Member 2018-01-01 2018-12-31 0000875320 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0000875320 vrtx:ShareRepurchaseProgram2019Member 2019-01-01 2019-12-31 0000875320 us-gaap:PerformanceSharesMember 2017-01-01 2017-12-31 0000875320 vrtx:ShareRepurchaseProgram2019Member 2019-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0000875320 us-gaap:PerformanceSharesMember 2019-01-01 2019-12-31 0000875320 vrtx:ShareRepurchaseProgram2018Member 2019-01-01 2019-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0000875320 vrtx:StockandOptionPlan2013Member 2018-01-01 2018-12-31 0000875320 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-01 2019-12-31 0000875320 vrtx:StockandOptionPlan2013Member 2019-01-01 2019-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2019-12-31 0000875320 vrtx:ShareRepurchaseProgram2019Member 2019-07-31 0000875320 vrtx:ShareRepurchaseProgram2018Member 2019-06-30 0000875320 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000875320 us-gaap:PerformanceSharesMember 2018-01-01 2018-12-31 0000875320 srt:WeightedAverageMember 2019-12-31 0000875320 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0000875320 vrtx:ShareRepurchaseProgram2018Member 2018-12-31 0000875320 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-01 2019-12-31 0000875320 vrtx:StockandOptionPlan2013Member 2017-01-01 2017-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars160.01toDollars180.00Member 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars140.01toDollars160.0Member 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars29.07toDollars40.00Member 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars120.01toDollars140.0Member 2019-12-31 0000875320 vrtx:ExercisePriceRangefromDollars40.01toDollars60.00Member 2019-12-31 0000875320 vrtx:ExercisePriceRangefromDollars100.01toDollars120.00Member 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars160.01toDollars180.00Member 2019-01-01 2019-12-31 0000875320 vrtx:ExercisePriceRangefromDollars80.01toDollars100.00Member 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars180.01toDollars189.38Member 2019-12-31 0000875320 vrtx:ExercisePriceRangefromDollars40.01toDollars60.00Member 2019-01-01 2019-12-31 0000875320 vrtx:ExercisePriceRangefromDollars60.01toDollars80.00Member 2019-01-01 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars29.07toDollars40.00Member 2019-01-01 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars120.01toDollars140.0Member 2019-01-01 2019-12-31 0000875320 vrtx:ExercisePriceRangefromDollars60.01toDollars80.00Member 2019-12-31 0000875320 vrtx:ExercisePriceRangefromDollars100.01toDollars120.00Member 2019-01-01 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars180.01toDollars189.38Member 2019-01-01 2019-12-31 0000875320 vrtx:ExercisePriceRangefromDollars80.01toDollars100.00Member 2019-01-01 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars140.01toDollars160.0Member 2019-01-01 2019-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0000875320 us-gaap:RestrictedStockMember 2018-12-31 0000875320 us-gaap:RestrictedStockMember 2019-12-31 0000875320 us-gaap:PerformanceSharesMember 2019-12-31 0000875320 us-gaap:PerformanceSharesMember 2018-12-31 0000875320 vrtx:FinancialPerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-01 2019-12-31 0000875320 vrtx:FinancialPerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-01 2019-12-31 0000875320 vrtx:FinancialPerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2019-01-01 2019-12-31 0000875320 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0000875320 us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0000875320 us-gaap:EmployeeStockMember 2017-01-01 2017-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2017-01-01 2017-12-31 0000875320 us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0000875320 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0000875320 us-gaap:CostOfSalesMember 2017-01-01 2017-12-31 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2018-01-01 2018-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2017-01-01 2017-12-31 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2018-01-01 2018-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2017-01-01 2017-12-31 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2019-01-01 2019-12-31 0000875320 us-gaap:StockOptionMember 2019-01-01 2019-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2019-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2019-12-31 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2019-12-31 0000875320 vrtx:NonFinancialPerformanceSharesMember 2019-01-01 2019-12-31 0000875320 vrtx:FinancialPerformanceSharesMember 2019-01-01 2019-12-31 0000875320 us-gaap:ForeignCountryMember 2019-12-31 0000875320 vrtx:DomesticandForeignTaxAuthorityMember 2019-12-31 0000875320 us-gaap:DomesticCountryMember 2019-12-31 0000875320 2018-10-01 2018-12-31 0000875320 vrtx:SemmaTherapeuticsInc.Member 2019-12-31 0000875320 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2019-12-31 0000875320 vrtx:DeferredTaxAssetsMember 2019-12-31 0000875320 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0000875320 srt:MinimumMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember 2019-09-30 0000875320 srt:MinimumMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2019-09-30 0000875320 us-gaap:LineOfCreditMember 2019-09-30 0000875320 srt:MinimumMember us-gaap:LineOfCreditMember 2019-09-01 2019-09-30 0000875320 us-gaap:LetterOfCreditMember 2019-09-30 0000875320 us-gaap:LineOfCreditMember 2019-09-01 2019-09-30 0000875320 srt:MaximumMember us-gaap:LineOfCreditMember 2019-09-01 2019-09-30 0000875320 srt:MaximumMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember 2019-09-30 0000875320 srt:MaximumMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2019-09-30 0000875320 vrtx:WalgreenCo.Member us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0000875320 vrtx:AccredoCurascriptMember us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0000875320 vrtx:McKessonCorporationMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0000875320 vrtx:AccredoCurascriptMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0000875320 vrtx:AccredoCurascriptMember us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2017-01-01 2017-12-31 0000875320 vrtx:McKessonCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0000875320 vrtx:WalgreenCo.Member us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2017-01-01 2017-12-31 0000875320 vrtx:WalgreenCo.Member us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0000875320 vrtx:WalgreenCo.Member us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0000875320 vrtx:AccredoCurascriptMember us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0000875320 vrtx:McKessonCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2017-01-01 2017-12-31 0000875320 vrtx:McKessonCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0000875320 vrtx:McKessonCorporationMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0000875320 vrtx:AccredoCurascriptMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0000875320 vrtx:WalgreenCo.Member us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0000875320 vrtx:OtherCountriesOutsideoftheUnitedStatesandEuropeMember 2018-01-01 2018-12-31 0000875320 vrtx:OutsidetheUnitedStatesMember 2018-01-01 2018-12-31 0000875320 vrtx:OutsidetheUnitedStatesMember 2019-01-01 2019-12-31 0000875320 vrtx:OtherCountriesOutsideoftheUnitedStatesandEuropeMember 2017-01-01 2017-12-31 0000875320 country:US 2018-01-01 2018-12-31 0000875320 country:US 2019-01-01 2019-12-31 0000875320 srt:EuropeMember 2018-01-01 2018-12-31 0000875320 vrtx:OutsidetheUnitedStatesMember 2017-01-01 2017-12-31 0000875320 vrtx:OtherCountriesOutsideoftheUnitedStatesandEuropeMember 2019-01-01 2019-12-31 0000875320 srt:EuropeMember 2017-01-01 2017-12-31 0000875320 country:US 2017-01-01 2017-12-31 0000875320 srt:EuropeMember 2019-01-01 2019-12-31 0000875320 vrtx:OtherCountriesOutsideoftheUnitedStatesandtheUnitedKingdomMember 2018-12-31 0000875320 vrtx:OutsidetheUnitedStatesMember 2018-12-31 0000875320 vrtx:OtherCountriesOutsideoftheUnitedStatesandtheUnitedKingdomMember 2019-12-31 0000875320 country:US 2018-12-31 0000875320 country:GB 2019-12-31 0000875320 vrtx:OutsidetheUnitedStatesMember 2019-12-31 0000875320 country:GB 2018-12-31 0000875320 country:US 2019-12-31 0000875320 vrtx:KalydecoMember 2018-01-01 2018-12-31 0000875320 vrtx:SYMDEKOSYMKEVIMember 2017-01-01 2017-12-31 0000875320 vrtx:SYMDEKOSYMKEVIMember 2019-01-01 2019-12-31 0000875320 vrtx:KalydecoMember 2017-01-01 2017-12-31 0000875320 vrtx:SYMDEKOSYMKEVIMember 2018-01-01 2018-12-31 0000875320 vrtx:KalydecoMember 2019-01-01 2019-12-31 0000875320 vrtx:ORKAMBIMember 2017-01-01 2017-12-31 0000875320 vrtx:ORKAMBIMember 2018-01-01 2018-12-31 0000875320 vrtx:TRIKAFTAMember 2017-01-01 2017-12-31 0000875320 vrtx:ORKAMBIMember 2019-01-01 2019-12-31 0000875320 vrtx:TRIKAFTAMember 2019-01-01 2019-12-31 0000875320 vrtx:TRIKAFTAMember 2018-01-01 2018-12-31 0000875320 vrtx:MerckKGaAandArborBiotechnologiesInc.Member 2018-10-01 2018-12-31 0000875320 2019-01-01 2019-03-31 0000875320 2019-07-01 2019-09-30 0000875320 2019-04-01 2019-06-30 0000875320 2019-10-01 2019-12-31 0000875320 us-gaap:ProductMember 2019-10-01 2019-12-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2019-04-01 2019-06-30 0000875320 vrtx:CollaborativeandRoyaltyMember 2019-07-01 2019-09-30 0000875320 us-gaap:ProductMember 2019-07-01 2019-09-30 0000875320 us-gaap:ProductMember 2019-04-01 2019-06-30 0000875320 us-gaap:ProductMember 2019-01-01 2019-03-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2019-10-01 2019-12-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2019-01-01 2019-03-31 0000875320 2018-04-01 2018-06-30 0000875320 2018-07-01 2018-09-30 0000875320 2018-01-01 2018-03-31 0000875320 us-gaap:ProductMember 2018-04-01 2018-06-30 0000875320 vrtx:CollaborativeandRoyaltyMember 2018-07-01 2018-09-30 0000875320 vrtx:CollaborativeandRoyaltyMember 2018-01-01 2018-03-31 0000875320 us-gaap:ProductMember 2018-01-01 2018-03-31 0000875320 us-gaap:ProductMember 2018-10-01 2018-12-31 0000875320 us-gaap:ProductMember 2018-07-01 2018-09-30 0000875320 vrtx:CollaborativeandRoyaltyMember 2018-04-01 2018-06-30 0000875320 vrtx:CollaborativeandRoyaltyMember 2018-10-01 2018-12-31 xbrli:shares vrtx:pre-clinical_stage_program iso4217:USD xbrli:shares vrtx:segment iso4217:USD vrtx:clinical-stage_program xbrli:pure vrtx:development_program vrtx:position vrtx:target vrtx:vote vrtx:lease utreg:sqft vrtx:term vrtx:period vrtx:building


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549        
FORM 10-K
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Fiscal Year Ended December 31, 2019
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM    TO   
Commission file number 000-19319
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
Massachusetts
(State or other jurisdiction of incorporation or organization)
50 Northern Avenue, Boston, Massachusetts
(Address of principal executive offices)
 
04-3039129
(I.R.S. Employer Identification No.)
02210
(Zip Code)
Registrant’s telephone number, including area code (617) 341-6100
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of Each Class
Trading Symbol
Name of Each Exchange on Which Registered
Common Stock, $0.01 Par Value Per Share
VRTX
The Nasdaq Global Select Market
Securities registered pursuant to Section 12(g) of the Exchange Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.  Yes ☐ No ☒
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):
Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  ☐ No ☒
The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant based on the closing price on June 28, 2019 (the last business day of the registrant’s most recently completed second fiscal quarter of 2019) was $46.7 billion.
As of January 31, 2020, the registrant had 259,268,593 shares of common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the definitive proxy statement for the 2020 Annual Meeting of Shareholders, which we expect to hold on June 3, 2020, are incorporated by reference into Part III of this Annual Report on Form 10-K.



VERTEX PHARMACEUTICALS INCORPORATED
ANNUAL REPORT ON FORM 10-K
TABLE OF CONTENTS
 
 
 
 
 
 
 
 
 
“We,” “us,” “Vertex” and the “Company” as used in this Annual Report on Form 10-K refer to Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries.
“Vertex,” “KALYDECO®,” “ORKAMBI®,” “SYMDEKO®,” “SYMKEVI®” and “TRIKAFTA®” are registered trademarks of Vertex. Other brands, names and trademarks contained in this Annual Report on Form 10-K are the property of their respective owners.
We use the brand name for our products when we refer to the product that has been approved and with respect to the indications on the approved label. Otherwise, including in discussions of our cystic fibrosis development programs, we refer to our compounds by their scientific (or generic) name or VX developmental designation.





PART I
ITEM 1.
BUSINESS
OVERVIEW
We invest in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets.
Cystic Fibrosis
Our goal is to develop treatment regimens that will provide benefits to all patients with cystic fibrosis, or CF, and will enhance the benefits that currently are being provided to patients taking our medicines. Our marketed medicines are TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). We obtained approval from the U.S. Food and Drug Administration, or the FDA, for TRIKAFTA, our triple combination regimen, in October 2019.  This approval increased the number of patients eligible for our medicines in the U.S. by approximately 6,000 and provided an additional treatment option for many patients who are also eligible for one of our previously approved products. We have submitted a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, for this triple combination regimen. The FDA approval and the MAA filing were based on positive data from Phase 3 clinical trials evaluating the triple combination regimen in patients 12 years of age or older (i) who have a copy of the F508del mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene and a second mutation that results in minimal CFTR function, whom we refer to as F508del/Min patients, and (ii) who have two copies of the F508del mutation, whom we refer to as F508del homozygous patients. Our four medicines are collectively approved to treat approximately 60% of the 75,000 CF patients in North America, Europe and Australia. We are focused on obtaining approval for the triple combination in ex-U.S. markets for patients 12 years of age and older and evaluating our triple combination in younger patients, with the goal of having treatments for up to 90% of patients with CF. We are also pursuing other therapeutic approaches to address the remaining 10% of CF patients.
Research and Development
Our goal is to identify and develop new medicines by combining transformative advances in the understanding of human disease and in the science of therapeutics to advance human health.
Small Molecule Programs
Alpha-1 Antitrypsin Deficiency. In 2019, we initiated a Phase 2 clinical trial to evaluate VX-814, our first investigational small molecule corrector for the treatment of alpha-1 antitrypsin, or AAT, deficiency. We expect to obtain data from this clinical trial in 2020. A Phase 1 clinical trial to evaluate VX-864, our second investigational small molecule corrector for the treatment of AAT deficiency, is ongoing in healthy volunteers.
APOL1-Mediated Kidney Diseases. In 2019, we completed a Phase 1 clinical trial evaluating VX-147 as a small molecule inhibitor of APOL1 function, a causal genetic factor in focal segmental glomerulosclerosis, or FSGS, and other proteinuric kidney diseases. In 2020, we expect to initiate a Phase 2 proof of concept clinical trial to evaluate VX-147.
Pain. We believe that NaV1.8 inhibitors have the potential to provide an effective non-opioid treatment for pain. We expect to begin clinical development of a NaV1.8 inhibitor in the first half of 2020.
Cell and Genetic Therapies
Sickle cell disease and beta-thalassemia. We are co-developing CTX001, an investigational gene-editing treatment for beta-thalassemia and sickle cell disease, with CRISPR Therapeutics AG, or CRISPR. Enrollment is ongoing in our two Phase 1/2 clinical trials to evaluate CTX001. In November 2019, we announced positive interim data from the first two patients with these hemoglobinopathies treated with the investigational CRISPR/Cas9 gene-editing therapy CTX001 in our ongoing trials.
Type 1 Diabetes. In 2019, we established a preclinical program to develop cell-based therapies for type 1 diabetes through our acquisition of Semma Therapeutics, Inc., or Semma.


1


Duchenne muscular dystrophy, or DMD, and myotonic dystrophy type 1, or DM1. In 2019, we established preclinical genetic therapy programs for DMD and DM1, through our acquisition of Exonics Therapeutics, Inc., or Exonics, and the expansion of our collaboration with CRISPR.
We plan to continue investing in our research and development programs and fostering scientific innovation, including by continuing to identify additional drug candidates through our internal research efforts and investing in business development transactions to access emerging technologies, drugs and drug candidates.
CYSTIC FIBROSIS
Background
CF is a life-shortening genetic disease affecting approximately 75,000 people in North America, Europe and Australia. CF is caused by a defective or missing CFTR protein resulting from mutations in the CFTR gene. To develop CF, children must inherit two defective CFTR genes, which are referred to as alleles; one allele is inherited from each parent. The vast majority of patients with CF carry at least one of the two of the most prevalent mutations, the F508del mutation or the G551D mutation. The F508del mutation results in a defect in the CFTR protein in which the CFTR protein does not reach the surface of the cells in sufficient quantities. The G551D mutation results in a defect in the CFTR protein in which the defective protein reaches the surface of a cell but does not efficiently transport chloride ions across the cell membrane.
The absence of working CFTR proteins results in poor flow of salt and water into and out of cells in a number of organs, including the lungs. As a result, thick, sticky mucus builds up and blocks the passages in many organs, leading to a variety of symptoms. In particular, mucus builds up and clogs the airways in the lungs, causing chronic lung infections and progressive lung damage. CFTR potentiators such as ivacaftor and VX-561 increase the probability that the CFTR protein channels open on the cell surface, increasing the flow of salt and water into and out of the cell. CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface.
Our Medicines
Our medicines, TRIKAFTA, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO, are collectively approved to treat approximately 60% of the 75,000 CF patients in North America, Europe and Australia. Our approved medicines, including information regarding the indication and age groups for which the medicine is approved, are set forth in the table below.
Product
Scientific Name
Region/Initial Approval
Indication
Eligible Age Group
trikaftarlogoa02.jpg
elexacaftor/tezacaftor/ivacaftor and ivacaftor
U.S. (2019)
CF patients with at least one F508del mutation
12 years of age and older
symdekoa05.jpg
tezacaftor/ivacaftor and ivacaftor
U.S. (2018)
CF patients (i) homozygous for the F508del mutation or (ii) with at least one mutation that is responsive to tezacaftor/ivacaftor

6 years of age and older
symkevikalydecolockup4ca05.jpg
tezacaftor/ivacaftor
European Union (2018)
CF patients (i) homozygous for the F508del mutation or (ii) with one copy of the F508del mutation and one copy of certain mutations that result in residual CFTR activity
12 years of age and older
orkambia15.jpg
lumacaftor/ivacaftor
U.S. (2015)
CF patients homozygous for the F508del mutation
2 years of age and older
lumacaftor/ivacaftor
European Union (2015)
CF patients homozygous for the F508del mutation
2 years of age and older
kalydecoa09.jpg
ivacaftor
U.S. (2012)
CF patients with G551D and other specified mutations
6 months of age and older
ivacaftor
European Union (2012)
CF patients with G551D and other specified mutations
6 months of age and older


2


In addition to the European Union and the United States, we market our products in additional countries, including Australia and Canada. We continuously seek to increase the number of patients eligible to receive our current medicines through label expansions and the approval of new medicines. Activities in support of these efforts include:
TRIKAFTA
•
In October 2019, we received approval from the FDA for TRIKAFTA for the treatment of patients with CF 12 years of age and older who have at least one copy of the F508del mutation.
•
In the fourth quarter of 2019, the MAA we submitted for the triple combination of elexacaftor, tezacaftor, and ivacaftor in patients 12 years of age and older was validated by the EMA.
•
A Phase 3 clinical trial evaluating the triple combination of elexacaftor, tezacaftor and ivacaftor in children six to 11 years of age who are F508del homozygous or who have one copy of the F508del mutation and one minimum function mutation is ongoing.
SYMDEKO/SYMKEVI
•
In June 2019, we obtained approval for SYMDEKO in the United States for children 6 to 11 years of age.
•
In the fourth quarter of 2019, we submitted an application to the EMA to extend the indication of tezacaftor in combination with ivacaftor to patients 6 to 11 years of age.
ORKAMBI
•
In January 2019, we obtained approval for ORKAMBI in the European Union for children 2 to 5 years of age.
KALYDECO
•
In April 2019, we obtained approval for KALYDECO in the United States for infants 6 to <12 months of age.
•
In December 2019, we obtained approval for KALYDECO in the European Union for infants 6 to <12 months of age.
Drug Candidates
•
We are evaluating VX-121, an additional next-generation corrector, and VX-561, a potentiator, in Phase 2 clinical development.
RESEARCH AND DEVELOPMENT PROGRAMS
We invest in research and development in order to discover and develop transformative medicines for people with serious diseases. Our strategy is to combine transformative advances in the understanding of human disease and the science of therapeutics in order to identify and develop new medicines. Our approach to drug discovery historically focused on the research and development of small molecule drugs, which has been validated through our success in moving novel small molecule drug candidates into clinical trials and obtaining marketing approvals for TRIKAFTA, KALYDECO, ORKAMBI and SYMDEKO/SYMKEVI for the treatment of CF and INCIVEK (telaprevir) for the treatment of hepatitis C infection. Over the last several years, we have expanded our research capabilities to include additional innovative therapeutic approaches with a focus on cell and genetic therapies, including:
•
our collaboration with CRISPR in hemoglobinopathies and other diseases;
•
our establishment of preclinical genetic therapy programs for DMD and DM1, through our acquisition of Exonics; and
•
our establishment of a preclinical program to develop cell-based therapies for type 1 diabetes through our acquisition of Semma.
The experience we gained developing medicines for CF and our analysis of research and development programs conducted by other companies in our industry have shaped a disciplined strategy that guides our investments in research and development and external innovation that focuses on:
•
transformative treatments for life-threatening diseases with a high unmet medical need;


3


•
targets validated as playing a causal role in the human biology of a disease;
•
innovative approaches to addressing those targets;
•
biological assays and clinical biomarkers that we believe will be predictive of clinical responses; and
•
efficient clinical and regulatory paths to bring new medicines to patients.
In addition to continuing our research to identify additional drug candidates for the treatment of CF, we are focusing our research and development efforts on developing products for the treatment of serious diseases including AAT deficiency, APOL1-mediated FSGS, pain, sickle cell disease, beta-thalassemia, DMD, DM1 and type 1 diabetes.
To augment our internal programs, we seek to acquire businesses and technologies and to collaborate with biopharmaceutical and technology companies, leading academic research institutions, government laboratories, foundations and other organizations as needed to advance research in our areas of therapeutic interest as well as to access technologies needed to execute on our strategy. We have established such relationships with organizations around the world and intend to extend and leverage that experience to further our research efforts to discover transformational medicines for serious diseases. We will continue to identify and evaluate potential acquisitions and collaborations that may be similar to or different from the transactions that we have engaged in previously.
Small Molecule Programs
Alpha-1 Antitrypsin Deficiency
AAT deficiency is caused by mutations in the SERPINA1 gene that produces AAT protein. To develop AAT deficiency, people must inherit two mutant SERPINA1 alleles (one from each parent). The mutations result in a defect in the AAT protein in which the protein does not fold correctly. This folding defect causes the AAT protein to accumulate in the liver (where it is produced), which can cause liver damage. As a result, the protein fails to reach other organs in adequate quantity and function, particularly in the lungs, where its normal role is to protect them from the digestive effects of certain proteases. The unchecked activity of these proteases can cause auto-digestion of lung tissue and may lead over time to emphysema or chronic pulmonary obstructive disease, and lung infections. Currently, there is no cure or treatment that targets the underlying cause of the disease in both the liver and the lung. Available treatments are aimed at transiently increasing levels of AAT in the blood, but have no effect in the liver. Patients living with AAT deficiency typically experience recurring hospital visits and a shortened life expectancy.
We are seeking to develop medicines to treat AAT deficiency. In the laboratory, we have discovered multiple small molecule correctors that restore normal folding of the mutant AAT protein, with the potential to treat both the liver and lung diseases caused by AAT deficiency. In 2019, we began a Phase 2 clinical trial evaluating VX-814 as a potential treatment for AAT deficiency. In addition, in 2019, we initiated a Phase 1 clinical trial evaluating VX-864, our second investigational small molecule corrector for the treatment of AAT deficiency, in healthy volunteers.
APOL1-Mediated Kidney Diseases
Inherited mutations in the APOL1 gene play a causal role in the biology of FSGS as well as other kidney diseases. FSGS is a rare disease that attacks the kidney’s filtering units, causing leakage of protein into the urine followed later by deterioration in kidney function, scarring, and, ultimately, permanent kidney damage. FSGS is a leading cause of nephrotic syndrome in children and kidney failure in adults. We have discovered multiple novel small molecules that inhibit the function of APOL1 protein with the goal of treating APOL1-mediated FSGS. In 2019, we completed a Phase 1 clinical trial for VX-147, our first investigational oral small molecule medicine for the treatment of FSGS and other serious kidney diseases. We expect to begin a Phase 2 clinical trial to evaluate VX-147 in 2020.
Pain
Pain can develop from a variety of pathophysiological and psychological conditions. Patients with pain can suffer from acute pain (for example, following surgery or an injury), neuropathic pain (when there is damage to a nerve), and musculoskeletal pain. Current treatments may not work well or cause significant side effects. In addition, there is the potential for addiction and the practice of over- and mis-utilization, as well as underutilization of current pain medicines.
Vertex has discovered multiple inhibitors of the sodium channel 1.8, or NaV1.8, as potential treatments for pain. Consistent with our research strategy, the Nav1.8 protein is a validated target for pain based both on inherited mutations that cause pain syndromes as well as through our own clinical trial data. Specifically, we have obtained positive results from three separate Phase 2 clinical trials evaluating VX-150, a NaV1.8 inhibitor, in patients with three different pain conditions: acute,


4


neuropathic and musculoskeletal pain. We continue to focus our research and development efforts on discovering, developing and advancing inhibitors of NaV1.8 as a potential treatment for pain. In the first quarter of 2020, we announced the discontinuation of Phase 1 development of VX-961 and that we expect to begin clinical development of an additional molecule in the first half of 2020.
Out-licenses
Our research team has also discovered several additional first-in-class compounds that were out-licensed to collaborators consistent with our corporate strategy. Several of these compounds are continuing in clinical development. Janssen Pharmaceuticals, Inc., or Janssen, is developing pimodivir, a compound we discovered and licensed to Janssen in 2014, as a potential treatment for the influenza A virus. Janssen is conducting Phase 3 clinical trials of pimodivir in combination with standard of care treatment in patients who are hospitalized or are outpatients at a higher risk of influenza-related complications.
Cell and Genetic Therapies
Sickle Cell Disease and Beta-Thalassemia
Sickle cell disease and beta-thalassemia are hemoglobinopathies, a group of inherited blood disorders that result from gene mutations that alter hemoglobin, a protein in red blood cells that delivers oxygen and removes carbon dioxide throughout the body.
Sickle cell disease is caused by the change of a single amino acid in the hemoglobin gene that causes red cells to change shape in settings of low oxygen. These sickled cells block blood flow and can lead to severe pain, organ damage and shortened life span. Treatment is typically focused on relieving pain and minimizing organ damage, requiring medication and, for some patients, monthly blood transfusions and frequent hospital visits.
Beta-thalassemia is caused by mutations in hemoglobin that lead to severe anemia in patients, which causes fatigue and shortness of breath. In infants, beta-thalassemia causes failure to thrive, jaundice and feeding problems. Complications of beta-thalassemia can lead to an enlarged spleen, liver and/or heart, misshapen bones and delayed puberty. Treatment for beta-thalassemia varies depending on the disease severity for each patient, with severely affected patients requiring regular blood transfusions, as frequently as every two to four weeks. Blood transfusions eventually cause an unhealthy buildup of iron in the patient, leading to organ damage.
We are co-developing CTX001, an investigational gene-editing treatment, for the treatment of hemoglobinopathies, with CRISPR. We are seeking to develop a CRISPR/Cas9-based therapy to treat both beta-thalassemia and sickle cell disease. In November 2019, we announced positive, interim data from the first two patients with severe hemoglobinopathies treated with the investigational CRISPR/Cas9 gene-editing therapy, CTX001, in ongoing Phase 1/2 clinical trials. One patient with severe sickle cell disease received CTX001 in mid-2019 and data for this patient reflect four months of safety and efficacy follow-up. One patient with transfusion-dependent beta-thalassemia received CTX001 in the first quarter of 2019 and data for this patient reflect nine months of safety and efficacy follow-up. These trials are ongoing and additional patients have been enrolled.
Type 1 Diabetes
Type 1 diabetes, or T1D, is a chronic, metabolic disorder caused by an absence of insulin secretion by the beta cells in the pancreas. In patients with T1D the person’s own immune system attacks the insulin-producing islet cells of the pancreas, resulting in a complete lack of insulin. While insulin therapy allows patients to live for decades with the disease, challenges of insulin therapy include inadequate control of blood sugar (both hyper- and hypo-glycemia), burden of care on patients and families, and long-term vascular complications. In 2019, we acquired a preclinical program to develop cell-based therapies for T1D through our acquisition of Semma. We plan to advance this program into clinical development in T1D patients in late 2020 or early 2021.
Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy, or DMD, and myotonic dystrophy type 1, or DM1, are inherited diseases that result in the weakening and breakdown of skeletal muscles over time. In 2019, we acquired preclinical programs to develop genetic therapies for DMD and DM1 through our acquisition of Exonics and the expansion of our collaboration with CRISPR.


5


COMMERCIALIZATION OF OUR MEDICINES
Commercial Organization
Our commercial organization focuses on supporting sales of TRIKAFTA, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO in the markets where these products have been approved. Our sales and marketing organizations are responsible for promoting products to health care providers and obtaining reimbursement for our products from third-party payors, including governmental organizations in the United States and ex-U.S. markets.
Our U.S. field-based CF commercial team is comprised of a small number of individuals to support commercialization of our medicines for CF. We focus our CF marketing efforts in the United States on a relatively small number of physicians and health care professionals who write most of the prescriptions for CF medicines. Many of these physicians and health care professionals are located at a limited number of accredited centers in the United States focused on the treatment of CF. In international markets, we have small sales forces that support KALYDECO, ORKAMBI and SYMDEKO/SYMKEVI in jurisdictions where these products are approved.
We market our products through personal interactions with physicians and allied health care professionals. In addition, our government affairs and public policy group advocates for policies that promote life sciences innovation and increase awareness of the diseases on which we are focusing, with state and federal legislatures, government agencies, public health officials and other policy-makers. We also have established programs in the United States that provide our products to qualified uninsured or underinsured patients at no charge or at a reduced charge, based on specific eligibility criteria.
Reimbursement
Sales of our products depend, to a large degree, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance and managed health care organizations. Increasingly, these third-party payors are becoming stricter in the ways they evaluate medical products and services. Additionally, the containment of health care costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could limit our revenues. Decisions by third-party payors to not cover a product could reduce physician usage of the product.
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, established the Medicare Part D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities, which provide coverage of outpatient prescription drugs. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug plan likely will be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors.
The American Recovery and Reinvestment Act of 2009 provided funding for the federal government to compare the effectiveness of different treatments for the same illness. A plan for the research was to be developed by the Department of Health and Human Services, or HHS, the Agency for Healthcare Research and Quality and the National Institutes of Health, and periodic reports on the status of the research and related expenditures were to be made to the U.S. Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of our products. In the future, it is possible that comparative effectiveness research demonstrating benefits of a competitor’s product could adversely affect the sales of our products. If third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis.


6


The Patient Protection and Affordable Care Act, or ACA, was enacted in March 2010 and was designed to expand coverage for the uninsured while at the same time containing overall health care costs. With regard to pharmaceutical products, among other things, the ACA is designed to expand and increase industry rebates for drugs covered under Medicaid programs, impose an annual fee on branded pharmaceutical manufacturers and make changes to the coverage requirements under the Medicare Part D program.
In Europe and many other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement because patients are unable to access prescription pharmaceutical products that are not reimbursed by their governments. Negotiating reimbursement rates in foreign countries can delay the commercialization of a pharmaceutical product and generally results in a reimbursement rate that is lower than the net price that companies can obtain for the same product in the United States.
In some countries, such as Germany, commercial sales of a new product may begin while the reimbursement rate that a company will receive is under discussion. In other countries, a company must complete the reimbursement discussions prior to the commencement of commercial supply of the pharmaceutical product. The requirements governing drug pricing vary widely from country to country. For example, the member states of the European Union can restrict the range of drugs for which their national health insurance systems provide reimbursement and can control the prices of drugs for human use. In addition, many ex-U.S. government payers require companies to provide health economic assessments of products, which are evaluated by government agencies set up for this purpose. A member state may approve a specific price for the drug or it may instead adopt a system of direct or indirect controls on the total amount of money that a company may receive for supply of a drug. Recently, many countries in the European Union have increased the amount of mandatory discounts imposed on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will reimburse our products. Similarly, it could be the case that such countries may only provide for reimbursement on terms that we do not deem adequate. Additionally, reimbursement discussions in ex-U.S. markets may take a significant period of time.
STRATEGIC TRANSACTIONS, COLLABORATIONS AND STRATEGIC INVESTMENTS
As part of our business strategy, we seek to license or acquire drugs, drug candidates, businesses and other technologies that have the potential to complement our ongoing research and development efforts. In addition, we establish business relationships with collaborators to support our research activities and to lead or support development and/or commercialization of certain drug candidates. We expect to continue to identify and evaluate potential acquisitions, licenses and collaborations that may be similar or different from the transactions that we have engaged in previously.
Strategic Transactions
Acquisitions
In July 2019, we acquired Exonics, a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause DMD and other severe neuromuscular diseases, including DM1. Our acquisition of Exonics enhanced our gene-editing capabilities and supports the potential development of novel therapies for DMD and DM1. In connection with the acquisition, we acquired all of the outstanding equity of Exonics for an upfront payment of approximately $245.0 million plus customary working capital adjustments in cash, and certain potential future payments based primarily upon the successful achievement of specified development and regulatory milestones for the DMD and DM1 programs.
In October 2019, we acquired Semma, a privately-held company focused on the use of stem cell-derived human islets as a potentially curative treatment for T1D. Our acquisition of Semma advanced our cell therapy capabilities and supports the potential development of transformative therapies for T1D. In connection with the acquisition, we acquired all of the outstanding equity of Semma for approximately $950.0 million in cash.
Collaboration and Licensing Arrangements
In-License Agreements
We have entered into various agreements pursuant to which we have obtained access to technologies from third parties and are conducting research and development activities with collaborators. Pursuant to these arrangements, we have obtained development and commercialization rights to resulting drug candidates. Depending on the terms of the arrangements, we may be responsible for the costs of research activities, required to make upfront payments, milestone payments upon the achievement of certain research and development objectives and/or pay royalties on future sales, if any, of commercial


7


products resulting from the collaboration. In our co-development and co-commercialization arrangement with CRISPR, we agreed to split costs and revenues associated with the relevant program. Our current in-license agreements include:
•
Arbor Biotechnologies, Inc. In 2018, we entered into a collaboration with Arbor Biotechnologies, pursuant to which we are focusing on the discovery of novel proteins, including DNA endonucleases, to advance the development of new gene-editing therapies.
•
CRISPR Therapeutics AG. In 2015, we entered into a collaboration with CRISPR for the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We currently are co-developing CTX001 for the treatment of sickle cell disease and beta-thalassemia and, if successful, have agreed to co-commercialize CTX001. In addition, we have exercised options to exclusively license treatments for specific targets, including CF, that were subject to the research program. In 2019, we obtained exclusive worldwide rights to CRISPR’s intellectual property for DMD and DM1 gene-editing products through a new agreement with CRISPR.
•
Kymera Therapeutics, Inc.  In 2019, we entered into a collaboration with Kymera Therapeutics for the research and development of small molecule protein degraders. Under the collaboration, Kymera conducts research activities in multiple targets, and upon designation of a clinical development candidate for a target, we have the option to exclusively license molecules against the target.
•
Moderna Therapeutics, Inc.  In 2016, we entered into a collaboration with Moderna Therapeutics, pursuant to which we are seeking to identify and develop messenger ribonucleic acid, or mRNA, therapeutics for the treatment of CF.
•
Other Arrangements. In 2019, we entered into collaborations with Molecular Templates, Inc. and Ribometrix, Inc. In 2018, we entered into agreements with Genomics plc, Merck KGaA, Darmstadt, Germany, and X-Chem, Inc. in order to support our research and development efforts.
Out-license Agreements
We have entered into various agreements pursuant to which we have out-licensed rights to certain drug candidates to third-party collaborators. Pursuant to these out-license arrangements, our collaborators are responsible for all costs related to the continued development of such drug candidates and obtain development and commercialization rights to these drug candidates. Depending on the terms of the arrangements, our collaborators may be required to make upfront payments, milestone payments upon the achievement of certain research and development objectives and/or pay royalties on future sales, if any, of commercial products licensed under the agreement. Our current out-license agreements include:
•
Janssen Pharmaceuticals, Inc. In 2014, we entered into an agreement with Janssen. Pursuant to this agreement, Janssen Inc. is developing pimodivir for the treatment of influenza. Janssen is evaluating pimodivir in Phase 3 clinical trials in patients with influenza A infection.
•
Merck KGaA, Darmstadt, Germany. In 2017, we entered into a Strategic Collaboration and License Agreement with Merck KGaA, Darmstadt, Germany, pursuant to which we granted an exclusive worldwide license to research, develop and commercialize four oncology research and development programs.
Strategic Investments
In connection with our business development activities, we periodically make equity investments in our collaborators. We hold strategic equity investments in public companies including CRISPR, Moderna Therapeutics and Molecular Templates, as well as certain private companies, including Arbor Biotechnologies, Kymera Therapeutics and Ribometrix. We may make additional strategic equity investments in public or private companies in the future.
Cystic Fibrosis Foundation Therapeutics Incorporated
In 2004, we entered into a collaboration agreement with the Cystic Fibrosis Foundation, or CFF, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc., to support research and development activities. Pursuant to the collaboration agreement, as amended, we have agreed to pay tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor) and royalties ranging from low-single digits to mid-single digits on potential net sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor. For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA (elexacaftor, tezacaftor, and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product.


8


INTELLECTUAL PROPERTY
Patents and other proprietary rights such as trademarks, trade secrets, and copyrights are critical to our business. We actively seek protection for our products and proprietary information by means of U.S. and foreign patents, trademarks and copyrights, as appropriate. In addition, we rely upon trade secret protection and contractual arrangements to protect certain of our proprietary information and products.
Patents provide a period of exclusivity that can make it more difficult for competitors to market and use our technology. We own patents and pending patent applications that relate to compounds, formulations, treatment of diseases, synthetic routes, intermediates and other inventions.
To protect our intellectual property, we typically apply for patents several years before a product receives marketing approval. Under current law, a patent expires 20 years from its first effective filing date. Since the drug development process may last for many years, there may be a period of time in which we have an issued patent but not marketing approval to sell the drug. To compensate for patent term lost while a product is in clinical trials and undergoing review for marketing approval, we may be able to apply for patent term extensions or supplementary protection certificates in some countries. In addition to patent protection, we have market exclusivity from U.S. and European regulatory agencies for the active pharmaceutical agents and, where applicable, their approved orphan indications for a certain time period. Market exclusivity runs concurrently with patent exclusivity.
The table below sets forth the year of projected expiration for the basic product patents or pending patent applications covering each of our approved products. For products that are combinations of two or more active ingredients, the projected expiration of the latest expiring patent or application covering any of the active pharmaceutical ingredients is provided (lumacaftor for ORKAMBI, tezacaftor for SYMDEKO/SYMKEVI and elexacaftor for TRIKAFTA). Patent term extensions, supplementary protection certificates, and pediatric exclusivity periods are not reflected in the expiration dates listed in the table below and may extend protection. In some instances, we also own later-expiring patents relating to solid forms, formulations, methods of manufacture, or the use of these drugs in the treatment of particular diseases or conditions. In some cases, however, such patents may not protect our drug from generic competition after the expiration of the basic patent.
Product/Drug Candidate
Status of United States Patent 
(Projected Expiration)
Status of European Union Patent 
(Projected Expiration)
KALYDECO
Granted (2027)
Granted (2025) 1
ORKAMBI
Granted (2030)
Granted (2026) 2
SYMDEKO/SYMKEVI
Granted (2027)
Granted (2028) 3
TRIKAFTA
Pending (2037)
Pending (2037)
1 Certain European countries have granted supplementary protection certificates for KALYDECO, which expire in 2027.
2 Certain European countries have granted supplementary protection certificates for ORKAMBI, which expire in 2030.
3 Certain European countries have granted supplementary protection certificates for SYMKEVI, which expire in 2033.
In addition to our later-stage programs and marketed products, we actively monitor and file patent applications in the United States and in foreign countries on technology that is in the pre-clinical and early clinical stages. For example, we also own U.S. and foreign patents and patent applications covering the following:
•
CF potentiators and correctors and many other related compounds, and the use of those compounds to treat CF.
•
Other pre-clinical and clinical drug candidates and the use of such drug candidates to treat specified diseases.
•
The manufacture, pharmaceutical compositions, related solid forms, formulations, dosing regimens and methods of use of many of the above compounds.
We own or hold exclusive licenses to several hundred patents in the United States. We own nine issued U.S. patents that cover the active pharmaceutical ingredients in KALYDECO, its marketed formulations, and/or its approved indication. We own 17 issued U.S. patents that cover the active pharmaceutical ingredients in ORKAMBI, its marketed formulations, and/or its approved indication. We own 19 issued U.S. patents that cover the active pharmaceutical ingredients in SYMDEKO, its marketed formulation, and/or its approved indication. We own 18 issued U.S. patents that cover the active pharmaceutical ingredients in TRIKAFTA, its marketed formulation, and/or its approved indication, and the patent application covering elexacaftor is pending in the United States.


9


We cannot be certain, however, that issued patents will be enforceable or provide adequate protection or that pending patent applications will result in issued patents.
From time to time we enter into exclusive and non-exclusive license agreements for proprietary third-party technology used in connection with our research activities. These license agreements typically provide for the payment by us of a license fee, but may also include terms providing for milestone payments or royalties for the development and/or commercialization of our drug products arising from the related research.
MANUFACTURING
As we market and sell our approved products and advance our drug candidates through clinical development toward commercialization, we continue to build and maintain our supply chain and quality assurance resources. We rely on internal capabilities and an international network of third parties to manufacture and distribute our products for commercial sale and post-approval clinical trials and to manufacture and distribute our drug candidates for clinical trials. In addition to establishing supply chains for each new approved product, we need to adapt our supply chain for existing products to include additional formulations that are often required in order to treat younger patients or to increase scale of production for existing products. We currently are focused on ensuring the stability of the supply chains for our current products, including TRIKAFTA.  
We expect that we will continue to rely on third parties to meet our commercial supply needs and a significant portion of our clinical supply needs for the foreseeable future.  We have established our own small-scale manufacturing capabilities in Boston, which we use for clinical trial and commercial supplies. 
Our supply chain for sourcing raw materials and manufacturing drug product ready for distribution is a multi-step international endeavor. In general, these raw materials are available from multiple sources. Third-party contract manufacturers, including some in China, perform different parts of our manufacturing process.  Contract manufacturers may supply us with raw materials, convert these raw materials into drug substance and/or convert the drug substance into final dosage form.  In addition, third parties are used for packaging, warehousing and distribution of products.
Establishing and managing this global supply chain for each of our drugs and drug candidates requires a significant financial commitment and the creation and maintenance of numerous third-party contractual relationships. To ensure the stability of our supply chains, we aim to develop additional sources of manufacture for all steps of our manufacturing processes at the time of, or shortly after, marketing approval. Therefore, at any point in time, we may have a limited number of single source manufacturers for certain steps in our manufacturing processes, particularly for recently launched products.
In order to manufacture our commercial products, we utilize both continuous manufacturing technology as well as batch manufacturing processes.  While continuous process manufacturing has been used in many industries, we believe that we are the first company to obtain FDA approval for a fully-continuous drug product manufacturing process.  
We have developed systems and processes to track, monitor and oversee our third-party manufacturers’ activities, including a quality assurance program intended to ensure that our third-party manufacturers comply with current Good Manufacturing Practices, or GMP.  We regularly evaluate the performance of our third-party manufacturers with the objective of confirming their continuing capabilities to meet our needs efficiently and economically.  Manufacturing facilities, both foreign and domestic, are subject to inspections by or under the authority of the FDA and other U.S. and foreign government authorities.
Compared to the manufacturing processes required for small molecule drugs, the manufacturing processes for genetic and cell-based therapies are typically more complex and challenging, require different systems, equipment and facilities and require different expertise to develop and maintain. In 2019, we gained expertise in these areas through our acquisitions of Exonics and Semma, but in order to successfully develop and commercialize genetic and cell-based therapies, we will need to establish the manufacturing infrastructure, independently or through a third-party network, to manufacture these therapies.
COMPETITION
The pharmaceutical industry is characterized by extensive research efforts, rapid technological progress and intense competition. There are many public and private companies, including pharmaceutical companies and biotechnology companies, engaged in developing products for the indications our drugs are approved to treat and the therapeutic areas we are targeting with our research and development activities. Potential competitors also include academic institutions,


10


government agencies, other public and private research organizations and charitable venture philanthropy organizations that conduct research, seek patent protection and/or establish collaborative arrangements for research, development, manufacturing and commercialization. Mergers and acquisitions in the pharmaceutical, biotechnology and gene therapy industries may result in a larger concentration of resources among a smaller number of our competitors. Some of our competitors may have substantially greater financial, technical, marketing and human resources than we do.
We believe that competition in our industry is based on, among other factors, innovative research, the effective and rapid development of drug candidates, the ability to market and obtain reimbursement for products and the ability to establish effective patent protection. We face competition based on the safety and efficacy of our product and drug candidates, the timing and scope of regulatory approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent protection and other factors. Our competitors may develop or commercialize more effective, safer or more affordable products than we are able to develop or commercialize or obtain more effective patent protection. As a result, our competitors may commercialize products more rapidly or effectively than we do, which would adversely affect our competitive position, the likelihood that our drug candidates, if approved, would achieve and maintain market acceptance and our ability to generate meaningful revenues from our products. Future competitive products may render our products, or future products, obsolete or noncompetitive. Another key element of remaining competitive in our industry is recruiting and retaining leading scientific, technical and management personnel to conduct our research activities and advance our development programs, including with the commercial expertise to effectively market our products.
Cystic Fibrosis
A number of companies are seeking to identify and develop drug candidates for the treatment of CF, including public companies such as AbbVie, Eloxx Pharmaceuticals, Proteostasis Therapeutics, and Translate Bio, and several private companies. Our competitors have research and development programs directed at identifying and developing CFTR potentiators, CFTR correctors and drug candidates with other mechanisms of action or that utilize new therapeutic approaches that seek to address the underlying cause of CF. Our competitors are exploring the development of drug candidates primarily as part of combination regimens of small molecules, and some competitors are exploring development of new therapeutic approaches, including nucleic acid-based therapies, which could provide additional treatment options for patients with CF. Our success in rapidly developing and commercializing our products may increase the resources that our competitors allocate to the development of these potential treatments for CF. If one or more competing therapies are successfully developed as a treatment for patients with CF, our revenues from our current products and/or additional CF products, if then approved, could face significant competitive pressure.
Pipeline
In recent years, we have committed significant research resources to and made significant investments in our pipeline of potential new therapies for alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, pain, beta-thalassemia, sickle cell disease, muscular dystrophy, T1D, and other diseases.  We plan to continue investing in our pipeline, including expanding beyond small molecule therapies and into the discovery and development of gene therapies and cell therapies. Many other pharmaceutical and biotechnology companies are also investing resources for discovery and development of small molecules, gene therapies and cell therapies to treat the same diseases for which we are developing therapies. If any of these competitors develop or successfully commercialize products involving therapies competitive with our pipeline therapies, the potential return on our investment in those pipeline therapies could be impacted.
GOVERNMENT REGULATION
Our operations and activities are subject to extensive regulation by numerous government authorities in the United States, the European Union and other countries. In the United States, the European Union and other countries, drugs are subject to rigorous regulations governing the testing, manufacture, labeling, storage, record keeping, approval, advertising and promotion of our products. As a result of these regulations, product development and product approval processes are very expensive and time consuming. The regulatory requirements applicable to drug development, approval, and marketing are subject to change. In addition, regulations and administrative guidance often are revised or reinterpreted by the agencies in ways that may significantly affect our business and our products. It is impossible to predict whether legislative changes will be enacted, or FDA or comparable ex-U.S. regulations, guidance or interpretations will change.


11


United States Government Regulation
New Drug Application Approval Processes
The process required by the FDA before a drug may be marketed in the United States generally involves the following:
•
completion of preclinical laboratory tests, animal studies and formulation studies conducted according to Good Laboratory Practices, or GLP, and other applicable regulations;
•
submission to the FDA of an IND application, which must become effective before clinical trials in the United States may begin;
•
performance of adequate and well-controlled clinical trials according to Good Clinical Practices, or GCP, to establish the safety and efficacy of the proposed drug for its intended use;
•
submission to the FDA of a New Drug Application, or an NDA;
•
satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product will be produced to assess compliance with GMP; and
•
FDA review and approval of the NDA.
Once a drug candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal pharmacology and toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND, which seeks FDA approval to test the drug candidate in humans. Preclinical or nonclinical testing typically continues even after the IND is submitted.
If the FDA accepts the IND, the drug candidate can then be studied in human clinical trials to determine if the drug candidate is safe and effective. These clinical trials involve three separate phases that often overlap, can take many years and are expensive. These three phases, which are subject to considerable regulation, are as follows:
•
Phase 1. The drug initially is introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and elimination. In the case of some drug candidates for severe or life-threatening diseases, such as cancer, especially when the drug candidate may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.
•
Phase 2. Clinical trials are initiated in a limited patient population intended to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the drug candidate for specific targeted diseases and to determine dosage tolerance and optimal dosage.
•
Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk-benefit ratio of the drug candidate and provide an adequate basis for regulatory approval and product labeling.
Phase 1, Phase 2 and Phase 3 testing may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend a clinical trial at any time for a variety of reasons, including a finding that the healthy volunteers or patients are being exposed to an unacceptable health risk. All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCP. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently in other situations, including the occurrence of serious adverse events. Information about certain clinical trials must be submitted within specific time-frames to the National Institutes of Health for public dissemination on the www.clinicaltrials.gov website.
The results of drug development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug candidate, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the drug candidate. The FDA reviews each NDA submitted to ensure that it is sufficiently complete for substantive review before it accepts it for filing. It may request additional information rather than accept an NDA for filing.


12


Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA reviews an NDA to determine, among other things, whether a drug candidate is safe and effective for its intended use and whether its manufacturing is GMP-compliant to assure and preserve the drug candidate’s identity, strength, quality and purity. The FDA may refer the NDA to an advisory committee for review and recommendation as to whether the NDA should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA, the FDA will inspect the facility or facilities where the drug candidate is manufactured and tested. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.
The FDA may require, as a condition of approval, restricted distribution and use, enhanced labeling, special packaging or labeling, expedited reporting of certain adverse events, pre-approval of promotional materials, restrictions on direct-to-consumer advertising or commitments to conduct additional research post-approval. The FDA will issue a complete response letter if the agency decides not to approve the NDA in its present form.
Biologics License Application Process
Certain of our drug candidates may be regulated by the FDA under the Food, Drug, and Cosmetic Act, or FDCA, and the Public Health Service Act as biologics. Biologics can present special safety, efficacy and manufacturing challenges that may differ from those present in the regulation of small molecule drugs. As such, while similar to the NDA review process described above, in lieu of filing an NDA, biologics require the submission of a Biologics License Application, or BLA, and approval of such BLA by the FDA prior to being marketed in the U.S.
Expedited Review and Approval
The FDA has developed four distinct approaches to make new drugs available as rapidly as possible in cases where there is no available treatment or there are advantages over existing treatments.
The FDA may grant “accelerated approval” to products that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit to patients over existing treatments. For accelerated approval, the product must have an effect on a surrogate endpoint or an intermediate clinical endpoint that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on irreversible morbidity and mortality. When approval is based on surrogate endpoints or clinical endpoints other than survival or morbidity, the sponsor will be required to conduct additional post-approval clinical studies to verify and describe the clinical benefit. These studies are known as “confirmatory trials.” Approval of a drug may be withdrawn or the labeled indication of the drug changed if these trials fail to verify clinical benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with the drug.
The FDA may grant “fast track” status to products that treat serious diseases or conditions and demonstrate the potential to address an unmet medical need. Fast track is a process designed to facilitate the development and expedite the review of such products by providing, among other things, more frequent meetings with the FDA to discuss the product’s development plan and rolling review, which allows submission of individually completed sections of an NDA or BLA for FDA review before the entire submission is completed. Fast track status does not ensure that a product will be developed more quickly or receive FDA approval.
“Breakthrough Therapy” designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint. For drugs and biologics that have been designated as Breakthrough Therapies, robust FDA-sponsor interaction and communication can help to identify the most efficient and expeditious path for clinical development while minimizing the number of patients placed in ineffective control regimens.
The FDA may grant “priority review” status to products that, if approved, would provide significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. Priority review is intended to reduce the time it takes for the FDA to review an NDA or BLA, with the goal to take action on the application within six months from when the application is filed, compared to ten months for a standard review.


13


Manufacturing Quality Control
Among the conditions for NDA or BLA approval is the requirement that the prospective manufacturer’s quality control and manufacturing procedures continually conform with GMP. In complying with GMP, manufacturers must devote substantial time, money and effort in the areas of production, quality control and quality assurance to maintain compliance. Material changes in manufacturing equipment, location or process, may result in additional regulatory review and approval. The FDA, and other regulatory agencies, conduct periodic visits to inspect equipment, facilities, and processes following the initial approval of a product. If a manufacturing facility is not in substantial compliance with the applicable regulations and requirements imposed when the product was approved, regulatory enforcement action may be taken, which may include a warning letter or an injunction against shipment of products from the facility and/or recall of products previously shipped. We rely, and expect to continue to rely, on third parties for the production of our products. Future FDA, state, and foreign inspections may identify compliance issues at the facilities of our contract manufacturers that may disrupt manufacture or distribution of our products, or require substantial resources to correct.
Post-approval Requirements
Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions on the product or complete withdrawal of the product from the market. In addition, under the FDCA the sponsor of an approved drug in the United States may not promote that drug for unapproved, or off-label, uses, although a physician may prescribe a drug for an off-label use in accordance with the practice of medicine. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further FDA review and approval. In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs.
Products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things:
•
record-keeping requirements;
•
reporting of adverse experiences with the product;
•
providing the FDA with updated safety and efficacy information;
•
drug sampling and distribution requirements;
•
notifying the FDA and gaining its approval of specified manufacturing or labeling changes;
•
complying with certain electronic records and signature requirements; and
•
complying with FDA promotion and advertising requirements.
Failure to comply with the applicable U.S. requirements at any time during the drug development process, approval process or after approval, may subject us or our collaborators to administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include:
•
refusal to approve or delay in review of pending applications;
•
withdrawal of an approval or the implementation of limitations on a previously approved indication for use;
•
imposition of a clinical hold, a risk mitigation and evaluation strategy or other safety-related limitations;
•
warning letters or “untitled letters”;
•
product seizures;
•
total or partial suspension of production or distribution; or
•
injunctions, fines, disgorgement, refusals of government contracts, or civil or criminal penalties.


14


Patent Term Restoration and Regulatory Exclusivity
Upon approval, products may be entitled to certain kinds of exclusivity under applicable intellectual property and regulatory regimes. The Drug Price Competition and Patent Term Restoration Act of 1984 (commonly known as the Hatch-Waxman Act) permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. The length of the patent extension is roughly based on 50 percent of the period of time from the filing of an IND for a compound to the submission of the NDA for such compound, plus 100 percent of the time period from NDA submission to regulatory approval. The extension, however, cannot exceed five years and the patent term remaining after regulatory approval cannot exceed 14 years.
If the FDA approves a drug product that contains an active ingredient not previously approved, the product is typically entitled to five years of non-patent regulatory exclusivity. Other products may be entitled to three years of exclusivity if approval was based on the FDA’s reliance on new clinical studies essential to approval submitted by the NDA applicant. If the NDA applicant studies the product for use by children, the FDA may grant pediatric exclusivity, which extends by 180 days each existing exclusivity (patent and regulatory) related to the product.
Biologics are also entitled to exclusivity under the Biologics Price Competition and Innovation Act, which was passed as Title VII to the Patient Protection and Affordable Care Act, or the ACA.  The law provides a pathway for approval of biosimilars following the expiration of 12 years of exclusivity for the innovator biologic and a potential additional 180 day-extension term for conducting pediatric studies. Biologics are also eligible for orphan drug exclusivity, as discussed below. The law also includes an extensive process for the innovator biologic and biosimilar manufacturer to litigate patent infringement, validity, and enforceability prior to the approval of the biosimilar.
Under the Orphan Drug Act, the FDA may grant orphan drug designation to drug candidates intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 people in the United States.
If a drug candidate that has orphan drug designation subsequently receives the first FDA approval for that drug for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years following marketing approval, except in certain very limited circumstances, such as if the later product is shown to be clinically superior to the orphan product. Orphan drug exclusivity, however, also could block the approval of our drug candidates for seven years if a competitor first obtains approval of the same product as defined by the FDA or if our drug candidate is determined to be contained within the competitor’s product for the same indication or disease. KALYDECO, ORKAMBI, SYMDEKO, and TRIKAFTA have been granted orphan drug exclusivity by the FDA.
Foreign Regulation
We conduct clinical trials and market our products in numerous jurisdictions outside the United States. Most of these jurisdictions have clinical trial, product approval and post-approval regulatory processes that are similar in principle to those in the United States. Thus, whether or not we obtain FDA approval for a drug candidate, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the European Union, before we can commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.
Under European Union regulatory systems, a company may submit marketing authorization applications either under a centralized or decentralized procedure. The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat AIDS, cancer, neurodegenerative disorders, or diabetes and optional for those medicines that are highly innovative, provides for the grant of a single marketing authorization that is valid for all European Union member states. In addition to the centralized procedure, Europe also has a nationalized procedure, which requires a separate application to and approval determination by each country; a decentralized procedure, whereby applicants submit identical applications to several countries and receive simultaneous approval; and a mutual recognition procedure, where applicants submit an application to one country for review and other countries may accept or reject the initial decision.
Other Regulations
Pharmaceutical companies are also subject to various laws pertaining to healthcare “fraud and abuse,” including anti-kickback and false claims laws. Anti-kickback laws generally make it illegal to knowingly and willfully solicit, offer, receive


15


or pay any remuneration in return for or to induce the referral of business, including the purchase or prescription of a particular drug that is reimbursed by a state or federal health care program. False claims laws prohibit knowingly and willingly presenting, or causing to be presented for payment to third-party payors (including Medicare and Medicaid), any claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed or claims for medically unnecessary items or services. Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including fines and civil monetary penalties, as well as by the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid). Liability under the false claims laws may also arise when a violation of certain laws or regulations related to the underlying products (e.g., violations regarding improper promotional activity or unlawful payments) contributes to the submission of a false claim. If we were subject to allegations concerning, or convicted of violating, these laws, our business could be harmed.
Laws and regulations have been enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers. The laws and regulations generally limit financial interactions between manufacturers and health care providers or require disclosure to the government and public of such interactions. The laws include U.S. federal and state “sunshine” provisions. The federal sunshine provisions apply to pharmaceutical manufacturers with products reimbursed under certain government programs and require those manufacturers to disclose annually to the federal government (for re-disclosure to the public) certain payments and other transfers of value made to physicians and teaching hospitals and, beginning with disclosures in 2022, to certain non-physician practitioners. State laws may also require disclosure of pharmaceutical pricing information and marketing expenditures. Many of these laws and regulations contain requirements that are subject to interpretation. Outside the United States, other countries have implemented requirements for disclosure of financial interactions with healthcare providers and additional countries may consider or implement such laws.
We are subject to various federal and foreign laws that govern our international business practices with respect to payments to government officials. Those laws include the U.S. Foreign Corrupt Practices Act, or FCPA, which prohibits U.S. companies and their representatives from paying, offering to pay, promising, or authorizing the payment of anything of value to any foreign government official, government staff member, political party, or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA’s definition of a foreign government official. We are also subject to U.K. Bribery Act 2010, or the Bribery Act, which proscribes giving and receiving bribes in the public and private sectors, bribing a foreign public official, and failing to have adequate procedures to prevent employees and other agents from giving bribes. U.S. companies that conduct business in the United Kingdom generally will be subject to the Bribery Act.
Our present and future business has been and will continue to be subject to various other laws and regulations. Various laws, regulations and recommendations relating to data privacy and protection, safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import, export and use and disposal of hazardous or potentially hazardous substances are or may be applicable to our activities. In addition, as we expand our pipeline and contemplate different approaches that may incorporate the use of medical devices, such approaches may necessitate compliance with regulatory laws specifically governing the testing, manufacture, and approval of medical devices. Furthermore, the extent of government regulation, which might result from future legislation or administrative action, cannot accurately be predicted.
EMPLOYEES
As of December 31, 2019, we had approximately 3,000 employees. Of these employees, approximately 2,400 were based in the United States and approximately 600 were based outside the United States. Our employees are not covered by a collective bargaining agreement, except for a small number of employees outside the United States.
A key aspect of remaining competitive in our industry is recruiting and retaining employees, including employees with the scientific and technical expertise to conduct our research activities and advance our development programs and commercial expertise to effectively marketing our products. We consider our relations with our employees to be good and over the last several years have successfully recruited talented and diverse employees to support our expanding business. However, we continue to face intense competition for our personnel from our competitors and other companies throughout our industry and from universities and research institutions.


16


OTHER MATTERS
Financial Information and Significant Customers
The Company operates in one segment, pharmaceuticals. Financial information about our revenue by product and major customers is set forth in Note R, “Segment Information,” to our consolidated financial statements included in this Annual Report on Form 10-K.
Information Available on the Internet
Our internet address is www.vrtx.com. Our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, and all amendments to those reports, are available to you free of charge through the “Investors-SEC Filings” section of our website as soon as reasonably practicable after those materials have been electronically filed with, or furnished to, the Securities and Exchange Commission.
Corporate Information
Vertex was incorporated in Massachusetts in 1989, and our principal executive offices are located at 50 Northern Avenue Boston, Massachusetts 02210.


17


INFORMATION ABOUT OUR EXECUTIVE OFFICERS
The names, ages and positions held by our executive officers are as follows:
Name
 
Age
Position
Jeffrey M. Leiden, M.D., Ph.D.
64
Chairman of the Board, Chief Executive Officer and President
Reshma Kewalramani, M.D.
47
Executive Vice President and Chief Medical Officer
David Altshuler, M.D., Ph.D.
55
Executive Vice President, Global Research and Chief Scientific Officer
Stuart A. Arbuckle
54
Executive Vice President and Chief Commercial Officer
Carmen Bozic, M.D.
57
Executive Vice President, Global Medicines Development and Medical Affairs
Michael Parini, J.D.
45
Executive Vice President and Chief Legal and Administrative Officer
Amit K. Sachdev, J.D.
52
Executive Vice President and Chief Patient Officer
Charles F. Wagner, Jr.
51
Executive Vice President and Chief Financial Officer
Paul M. Silva
53
Senior Vice President and Corporate Controller
Nia Tatsis, Ph.D.
50
Senior Vice President and Chief Regulatory Officer
Dr. Leiden is our Chairman, Chief Executive Officer and President. In July 2019, we announced that Dr. Leiden would be transitioning to the role of Executive Chair in April 2020. He has held the positions of Chief Executive Officer and President since February 2012 after joining us as CEO Designee in December 2011. He has been a member of our Board of Directors since July 2009, the Chairman of our Board of Directors since May 2012, and served as our lead independent director from October 2010 through December 2011. Dr. Leiden was a Managing Director at Clarus Ventures, a life sciences venture capital firm, from 2006 through January 2012. Dr. Leiden was President and Chief Operating Officer of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the Board of Directors of Abbott Laboratories from 2001 to 2006. From 1987 to 2000, Dr. Leiden held several academic appointments, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. He is an elected member of both the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences. Dr. Leiden serves as a director of Massachusetts Mutual Life Insurance Company, an insurance company. Dr. Leiden was a director and the non-executive Vice Chairman of the board of Shire plc, a specialty biopharmaceutical company, from 2006 to January 2012 and a director of Quest Diagnostics, a medical diagnostics company, from December 2014 to May 2019. Dr. Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago.
Dr. Kewalramani is our Executive Vice President and Chief Medical Officer and became a member of our Board of Directors on February 13, 2020. In July 2019, we announced she would be appointed our Chief Executive Officer and President in April 2020. Dr. Kewalramani was our Executive Vice President and Chief Medical Officer since April 2018. She was our Senior Vice President, Late Development from February 2017 until April 2018. From August 2004 to January 2017, she served in roles of increasing responsibility at Amgen Inc., most recently as Vice President, Global Clinical Development, Nephrology & Metabolic Therapeutic Area and as Vice President, U.S. Medical Organization. From 2014 through 2019, Dr. Kewalramani was the industry representative to the FDA’s Endocrine and Metabolic Drug Advisory Committee. She completed her internship and residency in Internal Medicine at the Massachusetts General Hospital and her fellowship in Nephrology at the Massachusetts General Hospital and Brigham and Women’s Hospital combined program. Dr. Kewalramani holds a B.A. from Boston University and an M.D. from Boston University School of Medicine. Dr. Kewalramani also completed the General Management Program at Harvard Business School and is an alumnus of the school.
Dr. Altshuler has been our Executive Vice President, Global Research and Chief Scientific Officer since January 2015 and was a member of our Board of Directors from May 2012 through December 2014. Dr. Altshuler was one of four founding members of the Broad Institute, a research collaboration of Harvard University and the Massachusetts Institute of Technology, The Whitehead Institute and the Harvard Hospitals. He served as the Director of the Institute’s Program in Medical and Population Genetics from 2003 through December 2014 and as the Institute’s Deputy Director and Chief Academic Officer from 2009 through December 2014. Dr. Altshuler joined the faculty at Harvard Medical School and the Massachusetts General Hospital in 2000 and held the academic rank of Professor of Genetics and Medicine from 2008 through December 2014. He served as Adjunct Professor of Biology at MIT from 2012 through December 2014. Dr. Altshuler earned a B.S. from MIT, a Ph.D. from Harvard University and an M.D. from Harvard Medical School. Dr.


18


Altshuler completed his clinical training in Internal Medicine, and in Endocrinology, Diabetes and Metabolism, at the Massachusetts General Hospital.
Mr. Arbuckle is our Executive Vice President and Chief Commercial Officer, a position he has held since September 2012. Prior to joining us, Mr. Arbuckle held multiple commercial leadership roles at Amgen, Inc., a 17,000 person biotechnology company, from July 2004 through August 2012. Mr. Arbuckle has worked in the biopharmaceuticals industry since 1986, including more than 15 years at GlaxoSmithKline plc, where he held sales and marketing roles of increasing responsibility for medicines aimed at treating respiratory, metabolic, musculoskeletal, cardiovascular and other diseases. He served as a member of the Board of Directors of Cerulean Pharma, Inc. from June 2015 through July 2017 and has served as a member of the Board of Directors of ImmunoGen, Inc. since January 2018 and of Rhythm Pharmaceuticals Inc. since July 2019. Mr. Arbuckle holds a BSc in pharmacology and physiology from the University of Leeds.
Dr. Bozic has been our Executive Vice President, Global Medicines Development and Medical Affairs since October 2019. She was our Senior Vice President and Head of Global Clinical Development from May 2019 to October 2019. Prior to joining Vertex, Dr. Bozic spent more than 20 years at Biogen Inc., most recently as Senior Vice President of Global Development and Portfolio Transformation from 2015 to May 2019 and as Senior Vice President of Clinical and Safety Sciences from 2013 to 2015. Dr. Bozic has served as the industry representative to the FDA’s Risk Communication Advisory Committee, and was a member of PhRMA’s Clinical and Preclinical Development Committee and the Board of Managers at BioMotiv. She is a member of the Clinical Advisory Board at Akili Interactive. She received her M.D., C.M., completed her residency, and was Chief Resident in Internal Medicine at McGill University. She completed her fellowship in Pulmonary and Critical Care Medicine at Brigham and Women’s Hospital, and was an Associate Physician at Beth Israel Deaconess Medical Center and Harvard Medical School before joining the biopharmaceutical industry.
Mr. Parini is our Executive Vice President and Chief Legal and Administrative Officer, a position he has held since January 2017. From January 2016 to January 2017, he was our Executive Vice President and Chief Legal Officer. From 2004 until he joined Vertex, Mr. Parini served in various roles of increasing responsibility at Pfizer Inc., a pharmaceutical company, most recently as Senior Vice President and Associate General Counsel. Prior to Pfizer, Mr. Parini was an attorney at Akin, Gump, Strauss, Hauer & Feld, L.L.P. Mr. Parini holds a B.A. from Georgetown University and a J.D. from the Georgetown University Law Center.
Mr. Sachdev is our Executive Vice President and Chief Patient Officer, a role he has held since October 2019. He served as our Executive Vice President and Chief Regulatory Officer from January 2017 until September 2019, and as our Executive Vice President, Policy, Access and Value, from October 2014 through December 2016. In 2010, he established our first international commercial operations in Canada. In 2007, he joined us as a Senior Vice President, and has led our government affairs and public policy activities, as well as our patient advocacy programs. Prior to joining us, Mr. Sachdev served as Executive Vice President, Health of the Biotechnology Industry Organization (BIO) and was the Deputy Commissioner for Policy at the FDA, where he also served in several other senior positions. Prior to the FDA, Mr. Sachdev served as Majority Counsel to the Committee on Energy and Commerce in the United States House of Representatives and practiced law at the Chemical Manufacturers Association, and subsequently at the law firm of Ropes & Gray LLP. He has served as a member of the Board of Directors of Eiger BioPharmaceuticals since May 2019. Mr. Sachdev holds a B.S from Carnegie Mellon University and a J.D. from Emory University School of Law.
Mr. Wagner has been our Executive Vice President and Chief Financial Officer since April 2019. Prior to joining Vertex, Mr. Wagner was Chief Financial Officer and Executive Vice President, Finance, of Ortho Clinical Diagnostics, a Carlyle Group portfolio company, from June 2015 to March 2019. In that role, he led the finance, accounting, tax, treasury, global information systems, lender relations, and acquisitions and divestiture groups, as well as shared leadership over several enterprise-wide projects. From July 2012 to June 2015, Mr. Wagner served as Executive Vice President, Chief Financial Officer of Bruker Corporation, a scientific instruments manufacturer. Prior to that, Mr. Wagner served as Chief Financial Officer for Progress Software Corporation, a provider of enterprise software, and Millipore Corporation, a global provider of products and services in the life science tools market. Mr. Wagner served as a director and chairman of the Audit Committee of Good Start Genetics, Inc. from April 2014 to August 2017 and served as a director and member of the Audit Committee of Bruker Corporation from August 2010 to June 2012.  Mr. Wagner holds a B.S. in accounting from Boston College and a M.B.A from Harvard Business School.
Mr. Silva is our Senior Vice President and Corporate Controller, a position he has held since April 2011. Mr. Silva also served as our interim Chief Financial Officer from January 2019 to April 2019. Mr. Silva joined us in August 2007 as Senior Director, Accounting Operations and was our Vice President and Corporate Controller from September 2008 through April


19


2011. Prior to joining us, he was the Vice President, Internal Reporting at Iron Mountain Incorporated from July 2006 until August 2007 and a consultant to Iron Mountain’s finance department from April 2005 until July 2006. He was the Finance Director of the Bioscience Technologies Division of Thermo Electron Corporation from 2002 to April 2005. Mr. Silva holds a B.S. in accounting from Assumption College.
Dr. Tatsis has been our Senior Vice President, Chief Regulatory Officer since October 2019. She served as our Senior Vice President, Global Regulatory Affairs from September 2017 to October 2019. Prior to joining Vertex, Dr. Tatsis held positions of increasing responsibility at several pharmaceutical companies, including Sanofi, Stemnion, Pfizer, and Wyeth. Most recently, from 2014 to 2017, she was Vice President, Head of Global Regulatory Affairs, at the Sanofi Genzyme Business Unit focused on Inflammation/Immunology, Rare Disease, Multiple Sclerosis, Ophthalmology, Neurology, and Oncology/Immuno-Oncology. Dr. Tatsis also worked as an associate staff scientist and research fellow in Immunology and Vaccine Development at the Wistar Institute and completed a post-doctoral research fellowship in Immunology at Thomas Jefferson University. She received her Ph.D. in Cell and Molecular Biology from the University of Vermont and holds a B.S. in Biology from Temple University.


20


ITEM 1A. RISK FACTORS
RISK FACTORS
Investing in our common stock involves a high degree of risk, and you should carefully consider the risks and uncertainties described below in addition to the other information included or incorporated by reference in this Annual Report on Form 10-K. If any of the following risks or uncertainties actually occurs, our business, financial condition or results of operations would likely suffer, possibly materially. In that case, the trading price of our common stock could decline.
Risks Related to Our Business
All of our product revenues and the vast majority of our total revenues are derived from sales of medicines for the treatment of CF. If we are unable to continue to increase revenues from sales of our CF medicines, our business would be materially harmed and the market price of our common stock would likely decline.
Our net product revenues and the vast majority of our total revenues are derived from the sale of CF medicines. As a result, our future success is dependent upon our ability to increase revenues from sales of our CF medicines. This will require us to gain approval and reimbursement for our triple combination therapy in ex-U.S. markets and successfully develop and commercialize our triple combination therapy for patients with CF less than 12 years of age.
Our concentrated source of revenues presents a number of risks to our business, including:
•
that one or more competing therapies may successfully be developed as a treatment for patients with CF;
•
that reimbursement policies of payors and other third parties may make it difficult to obtain reimbursement or reduce the net price we receive for our products;
•
that we may experience manufacturing or supply disruptions for our CF medicines; and
•
that we may experience adverse developments with respect to development or commercialization of our CF medicines and/or CF drug candidates.
If one or more of the above risks were to materialize, if we are otherwise unable to increase or maintain revenues from sales of our CF medicines, or if we do not meet the expectations of investors or public equity market analysts, our business would be materially harmed and our ability to fund research and development programs for the discovery and development or acquisition of new products would be harmed, which would limit our ability to diversify our revenue base and our stock price would likely be adversely affected.
We are investing significant resources in the research and development of therapies for serious diseases other than CF, and if we are unable to successfully commercialize one or more of these therapies, our business could be materially harmed.
We are investing significant resources in the research and development of medicines for serious diseases including alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, pain, beta-thalassemia, sickle cell disease, type 1 diabetes, DMD and DM1. Some of these programs have progressed into early-stage clinical trials, while others are still in pre-clinical development. Product development is highly uncertain and expensive, and product candidates that may appear promising in the early phases of research and development may fail to reach commercial success for many reasons, including the failure to demonstrate acceptable clinical trial results or obtain marketing approval, the inability to manufacture or commercialize the product candidate on economically feasible terms, or the appearance of safety issues. Even if we gain marketing approval for one or more pipeline products, we cannot be sure that we will obtain market acceptance or adequate reimbursement levels from third-party payors or foreign governments for such products.
Additionally, many of the therapies that we are developing in our pipeline target rare diseases with a limited number of patients.  There can be no guarantee that we will effectively identify patients that are eligible for enrollment in our clinical trials or treatment with our drug candidates. Even if we do successfully identify eligible patients, the number of patients that our drug candidates are able to treat may turn out to be lower than we expect or new patients may become increasingly difficult to identify, each of which may adversely affect our revenues and materially harm our business. For these and other reasons, we may never be successful in expanding our pipeline and future revenue may continue to depend on sales of our CF medicines.


21


We have experienced challenges commercializing products outside of the United States, and our future revenues will be dependent on our ability to obtain adequate reimbursement for our products.
In most ex-U.S. markets, the pricing and reimbursement of therapeutic and other pharmaceutical products is subject to governmental control. Given recent global economic pressures and geopolitical uncertainty, government authorities throughout the world are increasingly attempting to limit or regulate the price of drug products. The reimbursement process in ex-U.S. markets can take a significant period of time and reimbursement decisions are made on a country-by-country basis.
Our medicines treat life-threatening conditions and address relatively small patient populations and our research and development programs are primarily focused on developing medicines to treat similar diseases. Particular attention is being paid by payors, including government and private payors, to these types of medicines given the relative higher cost of these products as compared to other types of pharmaceutical products, and countries are increasingly refusing to reimburse costly medicines. We have experienced challenges in obtaining reimbursement for ORKAMBI in various countries outside the United States, including the United Kingdom and France. For example, we obtained reimbursement for ORKAMBI and SYMKEVI in England in the fourth quarter of 2019, four years after ORKAMBI’s initial approval in 2015. Our future product revenues, including from ORKAMBI, SYMKEVI, and TRIKAFTA, depend on, among other things, our ability to complete reimbursement discussions in ex-U.S. markets for our products. There is no assurance that coverage and reimbursement will be available outside of the United States for our CF or future medicines, and, even if it is available, whether the timing or the level of reimbursement will be sufficient to allow us to market our medicines. Adverse pricing limitations or a delay in obtaining coverage and reimbursement would decrease our future net product revenues and harm our business.
If our competitors bring drugs with superior product profiles to market, our drugs may not be competitive and our revenues could decline.
A number of companies are seeking to identify and develop drug candidates for the treatment of CF and other therapeutic areas we are targeting with our research and development activities. Our success in rapidly developing and commercializing our CF medicines may increase the resources that our competitors allocate to the development of potential competitive treatments. If one or more competing therapies are successfully developed as a treatment for patients with CF or any of the other diseases we are currently targeting in our pipeline, our products and our net product revenues could face competitive pressures. If one or more competing therapies prove to be superior to our then existing products and/or drug candidates, our business could be materially adversely affected.
In addition, our business faces competition from major pharmaceutical companies possessing substantially greater financial resources than we possess. We also face competition from numerous smaller public and private companies, academic institutions, government agencies, public and private research organizations and charitable venture philanthropy organizations that conduct research, seek patent protection and/or establish collaborative arrangements for research, development, manufacturing and commercialization.
Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies also may prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.
Our products and any drugs that we develop in the future may not be able to compete effectively with marketed drugs or new drugs that may be developed by competitors. The risk of competition is particularly important to our company because substantially all of our revenues as well as our most advanced drug candidates are related to the treatment of patients with CF. There are many other companies developing drugs for the same patient populations that we are pursuing. In order to compete successfully in these areas, we must demonstrate improved safety, efficacy and/or tolerability, ease of manufacturing, and gain and maintain market acceptance over competing drugs.
If we discover safety issues with any of our products or if we fail to comply with continuing U.S. and applicable foreign regulations, commercialization efforts for the product could be negatively affected, the approved product could lose its approval or sales could be suspended, and our business could be materially harmed.
Our products are subject to continuing regulatory oversight, including the review of additional safety information. Drugs are more widely used by patients once approval has been obtained and therefore side effects and other problems may be observed after approval that were not seen or anticipated, or were not as prevalent or severe, during pre-approval clinical


22


trials or nonclinical studies. The subsequent discovery of previously unknown or underestimated problems with a product could negatively affect commercial sales of the product, result in restrictions on the product or lead to the withdrawal of the product from the market. Three of our commercial products are combination products, and each of our products shares at least one active pharmaceutical ingredient with another of our products. As a result, if any of our cystic fibrosis products were to experience safety issues, our other cystic fibrosis products may be adversely affected. The reporting of adverse safety events involving our products or public speculation about such events could cause our stock price to decline or experience periods of volatility.
In addition, we and our third-party manufacturers must comply with GMP and other applicable regulations governing the manufacturing and distribution of our products. Regulatory authorities periodically inspect our drug manufacturing facilities, and those of our third-party manufacturers, to evaluate compliance with GMP requirements.
If we or our collaborators, or third-parties acting on our behalf, fail to comply with applicable continuing regulatory requirements, we or our collaborators may be subject to fines, suspension or withdrawal of regulatory approvals for specific products, product recalls and seizures, operating restrictions and/or criminal prosecutions, any of which could have a material adverse effect on our business, reputation, financial condition and results of operations.
If physicians and patients do not accept our drugs, or if patients do not remain on treatment or comply with their prescribed dosing regimen, our product revenues would be materially harmed in future periods.
Our drugs may not gain or maintain market acceptance among physicians and patients. Effectively marketing our drugs and any of our drug candidates, if approved, requires substantial efforts, both prior to launch and after approval. Physicians may elect not to prescribe our drugs, and patients may elect not to take them or may discontinue use of our drugs after initiation of treatment, for a variety of reasons including:
•
prevalence and severity of adverse side effects;
•
lack of reimbursement availability from third-party payors, including governmental entities;
•
lower demonstrated efficacy, safety and/or tolerability compared to alternative treatment methods;
•
lack of cost-effectiveness;
•
a decision to wait for the approval of other therapies in development that have significant perceived advantages over our drug;
•
convenience and ease of administration;
•
other potential advantages of alternative treatment methods; and
•
ineffective sales, marketing and/or distribution support.
If our drugs fail to achieve or maintain market acceptance, we may not be able to generate significant revenues in future periods.
Government and other third-party payors seek to contain costs of health care through legislative and other means. If they fail to provide coverage and adequate reimbursement rates for our products, our revenues will be harmed.
Our sales of products depend in part upon the availability of reimbursement from third-party payors. Third-party payors include government health programs such as Medicare and Medicaid in the United States and the national health care systems in many international markets, managed care providers, private health insurers and other organizations. The trend in the health care industry is cost containment, and efforts of third-party payors to contain or reduce health care costs may adversely affect our ability to establish or maintain appropriate prices for our products or any drugs that we may develop and commercialize. In most ex-U.S. markets, the pricing and reimbursement of therapeutic and other pharmaceutical products is subject to governmental control, and such government authorities are increasingly attempting to limit or regulate the price of drug products. In the United States, there have been, and we expect that there will continue to be, a number of federal and state proposals to implement governmental controls that are similar to those that currently exist in Europe. For example, the ACA required manufacturers of Medicare Part D brand name drugs to provide discounts on those drugs to Medicare Part D beneficiaries during the coverage gap; increased the rebates paid by pharmaceutical companies to state Medicaid programs on drugs covered by Medicaid; and imposed an annual fee, which increases annually, on sales by branded pharmaceutical manufacturers.


23


Third-party payors throughout the world also have been attempting to control drug spending through various other actions. In reimbursement negotiations, many payers are imposing price discounts and caps on total expenditures, and limiting both the types and variety of drugs that they will cover if they are not able to secure them. As part of these negotiations, many ex-U.S. government payers also are requiring companies to establish product cost-effectiveness as a condition of reimbursement and companies’ data-backed explanations are assessed by government agencies set up for this purpose. These cost-effectiveness reviews may not account for many of the benefits provided by innovative medicines, and for the most part, have not taken into account the specific circumstances of products that treat rare diseases. This has led to conclusions that certain medicines, including our products in certain jurisdictions, are not cost effective. As a result, certain countries have declined to reimburse, or delayed their reimbursement of, some of our products. Although not mandated in the United States, various organizations have started advocating for cost-effectiveness analyses in the United States. If U.S. payors were to adopt such assessments and make negative coverage determinations, it could adversely affect our product revenues.
There is also an increase in laws, regulations, and activity related to drug pricing and drug pricing transparency. In the United States, various states, including Nevada, Maryland, Louisiana, New York, California, Washington, Massachusetts, Connecticut, and Oregon, have passed legislation requiring companies to disclose significant amounts of information, including information relating to drug prices, drug price increases, and spending on research, development, and marketing. Although it is not clear what states ultimately will do with the information collected, some laws were designed to obtain additional product discounts, and we likely will continue to see more state action, which could require further disclosures or other actions.
Complying with these laws requires significant personnel and operational resources and deters focus on our business. Additionally, any additional required discounts would adversely affect the pricing of, and revenues from, our products. Finally, while we seek to comply with all statutory and regulatory requirements, we face increased enforcement activity by the U.S. federal government, state governments, and private payors against pharmaceutical and biotechnology companies for pricing and reimbursement-related issues.
In addition, in the United States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals and initiatives to change the health care system in ways that could affect our ability to sell products. For example, in the United States, there have been ongoing federal legislative and administrative efforts as well as legal challenges seeking to repeal, substantially modify or invalidate some or all of the provisions of the ACA. Tax legislation enacted at the end of 2017 eliminated the tax penalty for individuals who do not maintain sufficient health insurance coverage beginning in 2019. The Bipartisan Budget Act of 2018 contained various provisions that affect coverage and reimbursement of drugs, including an increase in the discount that manufacturers of Medicare Part D brand name drugs must provide to Medicare Part D beneficiaries during the coverage gap from 50% to 70%, which started in 2019. There are also a number of bills pending in Congress that would affect drug pricing in the Medicare and Medicaid programs, and HHS recently issued a proposed rule and FDA issued guidance on how pharmaceuticals could be imported into the United States from Canada. As a result, there is uncertainty regarding future changes in the laws and regulations applicable to the health care system and the effect any such changes may have on our business. Some of these proposed and implemented reforms have resulted, or could result, in reduced reimbursement rates and/or more limited access for our current or future products, which would adversely affect our business, operations and financial results.
The increasing availability and use of innovative specialty pharmaceuticals for rare diseases, combined with their relative higher cost as compared to other types of pharmaceutical products, is generating significant third-party payor interest in developing cost-containment strategies targeted to this sector. Government regulations in both U.S. and ex-U.S. markets could further limit the prices that can be charged for our products and may limit our commercial opportunity. The increasing use of cost-effectiveness assessments in markets around the world and the financial challenges faced by many governments may lead to significant adverse effects on our business.
Any legislation or regulatory changes or relaxation of laws that restrict imports of drugs from other countries, revisions to reimbursement or pharmaceuticals under government programs or general budget control actions also could reduce the net price we receive for our products.
We have limited experience developing genetic and cell-based therapies and could experience challenges with these programs, which could result in delays or prevent the development and commercialization of our genetic and cell-based therapies.
We are investing significant financial and other resources in the research and development of genetic and cell-based therapies.  While we have previously successfully developed, manufactured and commercialized several small molecule drugs, we have limited experience with the development, manufacture and commercialization of genetic and cell-based


24


therapies.  Development and commercialization of genetic and cell-based therapies are subject to all of the same risks and uncertainties as development and commercializing small molecules.  In addition:
•
the manufacturing processes for genetic and cell-based therapies are typically more complex and challenging than the manufacturing processes required for small molecule drugs, require different systems, equipment and facilities and require different expertise to develop and maintain;
•
there have been a limited number of FDA approvals for genetic therapies to date, the regulatory requirements governing genetic therapies are continuing to evolve and current and future regulatory positions and interpretations could lead to delays with respect to our genetic therapy programs; and
•
our cell-based therapies include approaches involving devices, which are subject to additional regulatory requirements.
If we are not able to successfully develop or commercialize genetic or cell-based therapies, we will not realize benefits or generate cash flows based on our investments in these programs.
If regulatory authorities interpret any of our conduct, including our marketing practices, as being in violation of applicable health care laws, including fraud and abuse laws, laws prohibiting off-label promotion, disclosure laws or other similar laws, we may be subject to civil or criminal penalties.
We are subject to health care fraud and abuse laws, such as the federal False Claims Act and anti-kickback laws, which prohibit off-label product promotion and other similar laws and regulations both in United States and in non-U.S. markets. While we have a corporate compliance program which, together with our policies and procedures, is designed to actively identify, prevent and mitigate risk through the implementation of compliance policies and systems and the promotion of a culture of compliance, if we are found not to be in full compliance with these laws and regulations, our business could be materially harmed.
The federal anti-kickback law prohibits knowingly and willfully offering, paying, soliciting, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the ordering, furnishing, arranging for or recommending of an item or service that is reimbursable, in whole or in part, by a federal health care program, such as Medicare or Medicaid. The federal statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, patients, purchasers and formulary managers on the other hand, and therefore constrains our marketing practices and our various service arrangements with physicians, including physicians who make clinical decisions to use our products. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly and have been interpreted by courts as such.
Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. Pharmaceutical companies have been prosecuted under these laws for a variety of alleged promotional and marketing activities, such as providing free product to customers with the expectation that the customers would bill federal programs for the product; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in promotion for uses that the FDA has not approved, known as “off-label” uses, that caused claims to be submitted to Medicaid for those off-label uses; submitting inflated “best price” information to the Medicaid Rebate Program; and certain manufacturing-related violations. The scope of this and other laws may expand in ways that make compliance more difficult and expensive.
Although physicians are permitted, based on their medical judgment, to prescribe products for indications other than those approved by the FDA, manufacturers are prohibited from promoting their products for such off-label uses. We market our products to eligible CF patients for whom the applicable product has been approved and provide promotional materials and training programs to physicians regarding the use of each product in these patient populations. These eligible patients do not represent all patients with CF. If the FDA determines that our promotional materials, training or other activities constitute off-label promotion, it could request that we modify our training or promotional materials or other activities, conduct corrective advertising or subject us to regulatory enforcement actions, including the issuance of a warning letter, injunction, seizure, civil fine and criminal penalties. It also is possible that other federal, state or foreign enforcement authorities might take action if they believe that the alleged improper promotion led to the submission and payment of claims for an off-label use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. Even if it is later determined we were not in violation of these laws, we may be faced with negative publicity, incur significant expenses defending our actions and have to divert significant management resources from other matters.


25


In recent years, legislation has been adopted at the federal, state and local level requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports or make periodic public disclosures on sales, marketing, pricing, clinical trials, health care provider payments and other activities. For example, as part of the ACA, the federal government enacted the Physician Payments Sunshine Act (referred to as the Sunshine Act). The Sunshine Act requires pharmaceutical manufacturers to report annually to the Centers for Medicare and Medicaid Services payments or other transfers of value made by that entity to physicians and teaching hospitals (and additional categories of health care practitioners beginning with reports submitted on or after January 1, 2022). We also now have similar reporting obligations throughout the European Union, or the E.U. We expended significant efforts to establish, and are continuing to devote significant resources to maintain and enhance, systems and processes in order to comply with these regulations. Requirements to track and disclose financial interactions with health care providers and organizations increase government and public scrutiny of these financial interactions. Failure to comply with the reporting requirements could result in significant civil monetary penalties.
The sales and marketing practices of our industry have been the subject of increased scrutiny from governmental entities in the United Sates and other countries in which we market our products, and we believe that this trend will continue. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are subject to a variety of interpretations. If our past or present operations are found to be in violation of any such laws or any other governmental regulations that may apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from federal health care programs and/or the curtailment or restructuring of our operations. Any action against us for violation of these laws, even if we successfully defend against them, also could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business.
There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. If we, or our vendors or donation recipients are deemed to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines and penalties.
If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S., we could be subject to additional reimbursement requirements, penalties, sanctions and fines which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
We participate in the Medicaid Drug Rebate Program and a number of other federal and state government pricing programs in the U.S. in order to obtain coverage for our products by certain government health care programs. These programs would generally require us to pay rebates or provide discounts to certain private purchasers or government payers in connection with our products when dispensed to beneficiaries of these programs. In some cases, such as with the Medicaid Drug Rebate Program, the rebates are based on pricing and rebate calculations that we report on a monthly and quarterly basis to the government agencies that administer the programs. The terms, scope and complexity of these government pricing programs change frequently. We may also have reimbursement obligations or be subject to penalties if we fail to provide timely and accurate information to the government, pay the correct rebates or offer the correct discounted pricing. Changes to the price reporting or rebate requirements of these programs would affect our obligations to pay rebates or offer discounts. Responding to current and future changes may increase our costs and the complexity of compliance, will be time-consuming, and could have a material adverse effect on our results of operations.
We are subject to various and evolving laws and regulations governing the privacy and security of personal information, and our failure to comply could adversely affect our business, result in fines and/or criminal penalties, and damage our reputation.
We are subject to data privacy and security laws and regulations in various jurisdictions that apply to the collection, transmission, storage and use of personal information, including health information, and impose significant compliance obligations. In addition, numerous other federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use, disclosure and security of personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. For example, the E.U. General Data Protection Regulation, or GDPR, went into effect in May 2018 and has imposed new obligations on us with respect to our processing of personal data and the cross-border transfer of such data, including higher standards of obtaining consent, more robust transparency requirements, data breach notification requirements, requirements for contractual language with our data processors, and stronger individual data rights. In the United States, California has passed the California Consumer Privacy Act, which went into effect on January 1, 2020, and several states and the federal


26


government are actively considering proposed legislation governing the protection of personal data. Additionally, Brazil has passed the General Data Protection Law (LGPD), which is set to go into effect in August 2020. While we continue to address the implications of the new data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges and our efforts to comply with the evolving data protection rules may be unsuccessful. Each law is also subject to various interpretations by courts and regulatory agencies, creating even more uncertainty.
We must devote significant resources to understanding and complying with this changing landscape. Failure to comply with laws regarding data protection would expose us to risk of enforcement actions taken by data protection authorities, private rights of action in some jurisdictions, and the potential for significant penalties if we are found to be non-compliant. For example, failure to comply with the GDPR and applicable national data protection laws of European Economic Area member states could lead to fines of up to €20,000,000 or up to 4% of the total worldwide annual revenue of the preceding financial year, whichever is higher. Some of these laws and regulations also carry the possibility of criminal sanctions. For example, while we are not directly subject to the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, or HIPAA, we could be subject to penalties, including criminal penalties if we knowingly obtain or disclose individually identifiable health information from a HIPAA-covered health care provider or research institution that has not complied with HIPAA’s requirements for disclosing such information. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business and our reputation.
The EMA has adopted a policy on publication of clinical data whereby it will publish clinical reports submitted as part of MAAs for drugs. The EMA aims to publish reports within 60 days after a decision on the application has been made by the European Commission. The ability of third-parties to review and/or analyze the raw data from our clinical trials may increase the risk of patient confidentiality breaches and could result in enhanced scrutiny of our clinical trials results. Such scrutiny could result in misconceptions being spread about our drugs and drug candidates, even if the underlying analysis of such review turns out to be flawed. These publications could also result in the disclosure of information to our competitors that we might otherwise deem confidential, which could harm our competitive position.
The use of social media platforms presents risks and challenges.
Social media is being used by third parties to communicate about our products and drug candidates and the diseases our therapies are designed to treat. We believe that members of the CF community may be more active on social media as compared to other patient populations due to the demographics of this patient population. Social media practices in the pharmaceutical and biotechnology industries are evolving, which creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media platforms to comment on the effectiveness of, or adverse experiences with, a drug or a drug candidate, which could result in reporting obligations. In addition, our employees may engage on social media in ways that may not comply with our social media policy or with legal or regulatory requirements, which may give rise to liability, lead to the loss of trade secrets and other intellectual property, or result in public disclosure of protected personal information. There is a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. Certain data protection regulations, such as the GDPR in the EU, also apply to personal data contained on social media. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business, including damage to our reputation.
Risks Related to Development, Clinical Testing and Regulation of Our Products and Drug Candidates
Our drug candidates remain subject to clinical testing and regulatory approval. Our future success is dependent on our ability to successfully develop additional drug candidates for both CF and non-CF indications.
Our business depends upon the successful development and commercialization of drug candidates. These drug candidates are in various stages of development and must satisfy rigorous standards of safety and efficacy before they can be approved for sale by the FDA or comparable foreign regulatory authorities. To satisfy these standards, we must allocate resources among our various development programs and must engage in expensive and lengthy testing of our drug candidates. Discovery and development efforts for new pharmaceutical products, including new combination therapies, are resource-intensive and may take 10 to 15 years or longer for each drug candidate. Despite our efforts, our drug candidates may not:
•
offer therapeutic or other improvement over existing competitive therapies;


27


•
show the level of safety and efficacy, including the level of statistical significance, required by the FDA or other regulatory authorities for approval of a drug candidate;
•
meet applicable regulatory standards;
•
be capable of being produced in commercial quantities at acceptable costs; or
•
if approved for commercial sale, be successfully marketed as pharmaceutical products.
We have recently completed and/or have ongoing or planned clinical trials for several of our drug candidates. The strength of our company’s product portfolio and pipeline will depend in large part upon the outcomes of these clinical trials, including clinical trials evaluating our triple combination therapy in younger patients with CF and our earlier-stage clinical trials of potential medicines to treat other diseases. Results of our clinical trials and findings from our nonclinical studies, including toxicology findings in nonclinical studies conducted concurrently with clinical trials, could lead to abrupt changes in our development activities, including the possible cessation of development activities associated with a particular drug candidate or program.
Moreover, clinical data are often susceptible to varying interpretations, and many companies that have believed their drug candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of their drug candidate. Furthermore, results from our clinical trials may not meet the level of statistical significance or otherwise provide the level of evidence or safety and efficacy required by the FDA or other regulatory authorities for approval of a drug candidate.
Many companies in the pharmaceutical and biotechnology industries, including our company, have suffered significant setbacks in later-stage clinical trials even after achieving promising results in earlier-stage clinical trials. For example, the results from completed preclinical studies and clinical trials may not be replicated in later clinical trials, and ongoing clinical trials for our drug candidates may not be predictive of the results we may obtain in later-stage clinical trials or of the likelihood of approval of a drug candidate for commercial sale. In addition, from time to time we report interim data from our clinical trials. Interim data from a clinical trial may not be predictive of final results from the clinical trial.
If we are unable to obtain regulatory approval, we will be unable to commercialize our drug candidates.
The time required to complete clinical trials and to satisfy the FDA and other countries’ regulatory review processes is uncertain and typically takes many years. Our analysis of data obtained from nonclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We also may encounter unanticipated delays or increased costs due to government regulation from future legislation or administrative action or changes in governmental policy during the period of drug development, clinical trials and governmental regulatory review.
We may seek a Fast Track and/or Breakthrough Therapy designation for some of our drug candidates. Drug candidates that receive one or both of these designations may be eligible for, among other things, a priority regulatory review. Each of these designations is within the discretion of the FDA. Accordingly, even if we believe one of our drug candidates meets the criteria for Fast Track and/or Breakthrough Therapy designation, the FDA may disagree and instead determine not to make such designation. The receipt of one or both of these designations for a drug candidate does not guarantee a faster development process, review or approval compared to drugs developed or considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our drugs or drug candidates qualifies for Fast Track and/or Breakthrough Therapy designation, the FDA may later decide to withdraw such designation if it determines that the drug or drug candidate no longer meets the conditions for qualification.
Any failure to obtain regulatory approvals for a drug candidate would prevent us from commercializing that drug candidate. Any delay in obtaining required regulatory approvals could materially adversely affect our ability to successfully commercialize a drug candidate. Furthermore, any regulatory approval to market a drug may be subject to limitations that we do not expect on the indicated uses for which we may market the drug. Any such limitations could reduce the size or demand of the market for the drug.
We also are subject to numerous foreign regulatory requirements governing the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. Non-U.S. jurisdictions have different approval procedures than those required by the FDA, and these jurisdictions may impose additional testing requirements for our drug candidates. The foreign regulatory approval process includes all of the risks associated with the FDA approval process described above, as well as risks attributable to the satisfaction of foreign requirements. Approval by the FDA does not ensure approval by regulatory authorities outside the United States and approval by a foreign regulatory authority does not


28


ensure approval by the FDA. In addition, although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population also must adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt our development of the applicable drug candidate.
If clinical trials are prolonged or delayed, our development timelines for the affected development program could be extended, our costs to develop the drug candidate could increase and the competitive position of the drug candidate could be adversely affected.
We cannot predict whether or not we will encounter problems with any of our completed, ongoing or planned clinical trials that will cause us or regulatory authorities to delay or suspend clinical trials, or delay the analysis of data from our completed or ongoing clinical trials. Among the factors that could delay our development programs are:
•
ongoing discussions with the FDA or comparable foreign authorities regarding the scope or design of our clinical trials and the number of clinical trials we must conduct;
•
delays in enrolling volunteers or patients into clinical trials, including as a result of low numbers of patients that meet the eligibility criteria for the trial;
•
a lower than anticipated retention rate of volunteers or patients in clinical trials;
•
the need to repeat clinical trials as a result of inconclusive results, unforeseen complications in testing or clinical investigator error;
•
inadequate supply or deficient quality of drug candidate materials or other materials necessary for the conduct of our clinical trials;
•
unfavorable FDA or foreign regulatory authority inspection and review of a manufacturing facility that supplied clinical trial materials or its relevant manufacturing records or a clinical trial site or records of any clinical or preclinical investigation;
•
unfavorable scientific results from clinical trials;
•
serious and unexpected drug-related side-effects experienced by participants in our clinical trials or by participants in clinical trials being conducted by our competitors to evaluate drug candidates with similar mechanisms of action or structures to drug candidates that we are developing;
•
favorable results in testing of our competitors’ drug candidates, or FDA or foreign regulatory authority approval of our competitors’ drug candidates; or
•
action by the FDA or a foreign regulatory authority to place a clinical hold or partial clinical hold on a trial or compound or deeming the clinical trial conduct as problematic.
Our ability to enroll patients in our clinical trials in sufficient numbers and on a timely basis is subject to a number of factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites, the availability of effective treatments for the relevant disease, the number of other clinical trials ongoing and competing for patients in the same indication and the eligibility criteria for the clinical trial. In addition, patients may drop out of our clinical trials or may be lost to follow-up medical evaluation after treatment ends, and this could impair the validity or statistical significance of the trials. Delays in patient enrollment or unforeseen drop-out rates may result in increased costs and longer development times.
We, our collaborators, the FDA or other applicable regulatory authorities may suspend clinical trials of a drug candidate at any time if we or they believe the healthy volunteers or patients participating in such clinical trials are being exposed to unacceptable health risks or for other reasons. Any such suspension could materially adversely affect the development of a particular drug candidate and our business.


29


If our processes and systems are not compliant with regulatory requirements, we could be subject to restrictions on marketing our products or could be delayed in submitting regulatory filings seeking approvals for our drug candidates.
We have a number of regulated processes and systems that are required both prior to and following approval of our drugs and drug candidates. These processes and systems are subject to continual review and periodic inspection by the FDA and other regulatory bodies. In addition, the clinical research organizations and other third parties that we work with in our non-clinical studies and clinical trials and our oversight of such parties are subject to similar reviews and periodic inspection by the FDA and other regulatory bodies. If compliance issues are identified at any point in the development and approval process, we may experience delays in filing for regulatory approval for our drug candidates, or delays in obtaining regulatory approval after filing, if at all. Any later discovery of previously unknown problems or safety issues with approved drugs or manufacturing processes, or failure to comply with regulatory requirements, may result in restrictions on such drugs or manufacturing processes, withdrawal of drugs from the market, the imposition of civil or criminal penalties or a refusal by the FDA and/or other regulatory bodies to approve pending applications for marketing approval of new drugs or supplements to approved applications, any of which could have a material adverse effect on our business. In addition, we are party to agreements that transfer responsibility for complying with specified regulatory requirements, such as filing and maintenance of marketing authorizations and safety reporting or compliance with manufacturing requirements, to our collaborators and third-party manufacturers. If our collaborators or third-party manufacturers do not fulfill these regulatory obligations, any drugs for which we or they obtain approval may be subject to later restrictions on manufacturing or sale, which could have a material adverse effect on our business.
Risks Related to Business Development Activities
Our ability to execute on our long-term strategy depends in part on our ability to engage in transactions and collaborations with other entities that add to our pipeline or provide us with new commercial opportunities.
In order to achieve our long-term business objectives, we seek to license or acquire drugs, drug candidates and other technologies that have the potential to complement our ongoing research and development efforts, access emerging technologies and license or acquire pipeline assets with a focus on early-stage assets. We have faced and will continue to face significant competition for the acquisition of rights to these types of drugs, drug candidates and other technologies from a variety of other companies, many of which have significantly more financial resources and experience in business development activities than we have. In addition, non-profit organizations may be willing to provide capital to the companies that control additional drugs, drug candidates or technologies, which may provide incentives for companies to advance these drugs, drug candidates or technologies independently. Also, the cost of acquiring, in-licensing or otherwise obtaining rights to such drugs, drug candidates or other technologies has grown dramatically in recent years and may be at levels that we cannot afford or that we believe are not justified by market potential. As a result, we may not be able to acquire, in-license or otherwise obtain rights to additional drugs, drug candidates or other technologies on acceptable terms or at all.
We may not realize the anticipated benefits of acquisitions of business or technologies, and the integration following any such acquisition may disrupt our business and management.
It is challenging to effectively integrate businesses and technologies that we acquire, including the acquisitions of Semma and Exonics and exclusive licenses that we have acquired from CRISPR, and we may not realize the benefits anticipated from such transactions. Achieving the anticipated benefits of any transaction and successfully integrating acquired businesses or technologies involves a number of risks, including:
•
failure to successfully develop and commercialize the acquired drugs, drug candidates or technologies or to achieve other strategic objectives;
•
delays or inability to progress preclinical programs into clinical development or unfavorable data from clinical trials evaluating the acquired or licensed drug or drug candidates;
•
difficulty in integrating the drugs, drug candidates, technologies, business operations and personnel of an acquired asset or company;
•
disruption of our ongoing business and distraction of our management and employees from daily operations or other opportunities and challenges;
•
the potential loss of key employees of an acquired company;
•
entry into markets in which we have no or limited direct prior experience or where competitors in such markets have stronger market positions;


30


•
potential failure of the due diligence processes to identify significant problems, liabilities or challenges of an acquired company, or acquired or licensed drug, drug candidate or technology, including but not limited to, problems, liabilities or challenges with respect to intellectual property, clinical or non-clinical data, safety, accounting practices, employee, or third party relations and other known and unknown liabilities;
•
liability for activities of the acquired company or licensor before the acquisition or license, including intellectual property infringement claims, violations of laws, commercial disputes, tax liabilities, and other known and unknown liabilities;
•
exposure to litigation or other claims in connection with, or inheritance of claims or litigation risk as a result of an acquisition or license, including but not limited to, claims from terminated employees, customers, former equity holders or other third-parties; and
•
difficulties in the integration of the acquired company’s departments, systems, including accounting, human resource and other administrative systems, technologies, books and records, and procedures, as well as in maintaining uniform standards, controls, including internal control over financial reporting required by the Sarbanes-Oxley Act of 2002 and related procedures and policies.
Acquisitions, licensing arrangements and other strategic transactions are inherently risky, and ultimately, if we do not complete an announced acquisition, collaboration or strategic transaction or integrate an acquired or licensed asset, business or technology successfully and in a timely manner, we may not realize the benefits of the strategic transaction to the extent anticipated. Additionally, we may later incur impairment charges related to assets acquired in any such transaction. For example, we entered into a strategic collaboration and license agreement with Parion Sciences, Inc., or Parion, to develop ENaC inhibitors in 2015 and incurred an impairment charge related to this collaboration in the third quarter of 2017. In addition, even if we achieve the long-term benefits associated with our strategic transactions, our expenses and short-term costs may increase materially and adversely affect our liquidity and short-term net income (loss). Future strategic transactions could result in potentially dilutive issuances of equity securities, the incurrence of debt, the creation of contingent liabilities, impairment expenses related to goodwill, or impairment or amortization expenses related to other intangible assets, all of which could harm our financial condition.
We face risks in connection with existing and future collaborations with respect to the development, manufacture and commercialization of our products and drug candidates.
The risks that we face in connection with our current collaborations, including CRISPR, and any future collaborations, include the following:
•
Our collaborators may change the focus of their development and commercialization efforts or may have insufficient resources to effectively develop our drug candidates. The ability of some of our products and drug candidates to reach their potential could be limited if collaborators decrease or fail to increase development or commercialization efforts related to those products or drug candidates. Our collaboration agreements provide our collaborators with a level of discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations.
•
Collaboration agreements may have the effect of limiting the areas of research and development that we may pursue, either alone or in collaboration with third parties.
•
Collaborators may develop and commercialize, either alone or with others, drugs that are similar to or competitive with the drugs or drug candidates that are the subject of their collaborations with us.
•
Disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of drug candidates, might lead to additional responsibilities for us with respect to drug candidates, or might result in litigation or arbitration. Any such disagreements would divert management attention and resources and be time-consuming and expensive.
•
Collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation.
•
Collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability.


31


•
Investigations and/or compliance or enforcement actions against a collaborator, which may expose us to indirect liability as a result of our partnership with such collaborator.
•
Our collaboration agreements are subject to termination under various circumstances.
Additionally, if a collaborator were to be involved in a business combination with a third party, it might deemphasize or terminate the development or commercialization of any drug candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be harmed.
We may not be able to attract collaborators or external funding for the development and commercialization of certain of our drug candidates.
As part of our ongoing strategy, we may seek additional collaborative arrangements or external funding for certain of our development programs and/or seek to expand existing collaborations to cover additional commercialization and/or development activities. We have a number of research programs and early-stage clinical development programs, some of which are being developed in collaboration with a third party. For example, we have an ongoing collaboration with Janssen, pursuant to which Janssen is developing pimodivir, a drug candidate for the treatment of influenza we discovered. At any time, we may determine that in order to continue development of a drug candidate or program or successfully commercialize a drug we need to identify a collaborator or amend or expand an existing collaboration. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA or other regulatory authorities, the potential market for the subject drug candidate, the costs and complexities of manufacturing and delivering such drug candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of the applicable intellectual property, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. Potentially, and depending on the circumstances, we may desire that a collaborator either agree to fund portions of a drug development program led by us, or agree to provide all of the funding and directly lead the development and commercialization of a program. No assurance can be given that any efforts we make to seek additional collaborative arrangements will be successfully completed on a timely basis or at all. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we are unable to enter into acceptable collaborative relationships, one or more of our development programs could be delayed or terminated and the possibility of our receiving a return on our investment in the program could be impaired.
Risks Related to Third-Party Manufacturing and Reliance on Third Parties
We depend on third-party manufacturers to manufacture our products and the materials we require for our clinical trials. We may not be able to maintain these relationships and could experience supply disruptions outside of our control.
We rely on a worldwide network of third-party manufacturers to manufacture our drugs for commercial use and our drug candidates for clinical trials. As a result of our reliance on these third-party manufacturers and suppliers, we could be subject to significant supply disruptions outside of our control. Our supply chain for sourcing raw materials and manufacturing drug product ready for distribution is a multi-step international endeavor. Third-party contract manufacturers, including some in China, perform different parts of our manufacturing process. Contract manufacturers may supply us with raw materials, convert these raw materials into drug substance and/or convert the drug substance into final dosage form. Third parties are used for packaging, warehousing and distribution of products. Establishing and managing this global supply chain requires a significant financial commitment and the creation and maintenance of numerous third-party contractual relationships. Although we attempt to manage the business relationships with companies in our supply chain, we do not have control over their operations. Supply disruptions may result from a number of factors, including shortages in product raw materials, labor or technical difficulties, regulatory inspections or restrictions, shipping or customs delays or any other performance failure by any third-party manufacturer on which we rely. Any supply disruptions could disrupt sales of our products and/or the timing of our clinical trials.
We require a supply for our medicines for commercial sale and a supply of our drug candidates for use in our clinical trials. While we have developed some internal capabilities, a majority of the manufacturing steps needed to produce our drug candidates and drug products are performed through a third-party manufacturing network. To ensure the stability of our supply chains we aim to develop additional sources of manufacture for all steps of our manufacturing processes at the time of, or shortly after, marketing approval. Therefore, at any point in time, we may have a limited number of single source manufacturers for certain steps in our manufacturing processes, particularly for recently launched products.


32


If we or our third-party manufacturers become unable or unwilling to continue manufacturing product and we are not able to promptly identify another manufacturer, we could experience a disruption in the commercial supply of our then-marketed medicines, which would have a significant effect on patients, our business and our product revenues. Similarly, a disruption in the clinical supply of drug products could delay the completion of clinical trials and affect timelines for regulatory filings. There can be no assurance that we will be able to establish and maintain secondary manufacturers for all of our drug candidates and drug products on a timely basis or at all.
In the course of providing its services, a contract manufacturer may develop process technology related to the manufacture of our products or drug candidates that the manufacturer owns, either independently or jointly with us. This would increase our reliance on that manufacturer or require us to obtain a license from that manufacturer in order to have our products or drug candidates manufactured by other suppliers utilizing the same process.
We rely on third parties to conduct pre-clinical work, clinical trials and other activities, and those third parties may not perform satisfactorily, including failing to meet established deadlines for the completion of such studies and/or trials or failing to satisfy regulatory requirements.
We rely on third parties such as contract research organizations to help manage certain pre-clinical work and our clinical trials and on medical institutions, clinical investigators and clinical research organizations such as the Therapeutic Development Network, which is primarily funded by the CFF, to assist in the design and review of, and to conduct our clinical trials, including enrolling qualified patients. In addition, we engage third party contractors to support numerous other research, commercial and administrative activities. Our reliance on these third parties for clinical development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the clinical trial. Moreover, the FDA requires us to comply with standards, commonly referred to as good laboratory practices and good clinical practices, for conducting, recording and reporting the results of pre-clinical and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected.
If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be required to replace them. Although we believe that there are a number of other third-party contractors we could engage to continue the activities, it may result in a delay of the affected clinical trial, drug development program or applicable activity. If clinical trials are not conducted in accordance with our contractual expectations or regulatory requirements, action by regulatory authorities might significantly and adversely affect the conduct or progress of these clinical trials or in specific circumstances might result in a requirement that a clinical trial be redone. Accordingly, our efforts to obtain regulatory approvals for and commercialize our drug candidates could be delayed. In addition, failure of any third party contractor to conduct activities in accordance with our expectations could adversely affect the relevant research, development, commercial or administrative activity.
Risks Related to Intellectual Property
If our patents do not protect our drugs or our drugs infringe third-party patents, we could be subject to litigation which could result in injunctions preventing us from selling our products or substantial liabilities.
We have numerous issued patents and pending patent applications in the United States, as well as counterparts in other countries. Our success will depend, in significant part, on our ability to obtain and defend U.S. and foreign patents covering our drugs, their uses and our processes, to preserve our trade secrets and to operate without infringing the proprietary rights of third parties. We cannot be certain that any patents will issue from our pending patent applications or, even if patents issue or have issued, that the issued claims will provide us with adequate protection against competitive products or otherwise be commercially valuable.
Due to evolving legal standards relating to the patentability, validity and enforceability of patents covering pharmaceutical inventions and the scope of claims made under these patents, our ability to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions. Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents in the U.S. The Leahy-Smith America Invents Act, or the Leahy-Smith Act, includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The United States Patent Office developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, became effective in March 2013. The first to file provisions limit the rights of an inventor who is the first to invent an invention but is not the first to file an application claiming that invention. U.S. and


33


foreign patent applications typically are maintained in confidence for a period of time after they initially are filed with the applicable patent office. Consequently, we cannot be certain that we were the first to invent, or the first to file patent applications on, our products or drug candidates or their use. If a third party also has filed a U.S. patent application relating to our drugs or drug candidates, their uses, or a similar invention, we may have to participate in legal or administrative proceedings to determine priority of invention. For applications governed by the Lahey-Smith Act, if a third-party has an earlier filed U.S. patent application relating to our drugs or drug candidates, their uses, or a similar invention, we may be unable to obtain an issued patent from our application.
The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Our patents may be challenged by third parties, resulting in the patent being deemed invalid, unenforceable or narrowed in scope, or the third party may circumvent any such issued patents. Also, our pending patent applications may not issue, and we may not receive any additional patents. Our patents might not contain claims that are sufficiently broad to prevent others from utilizing our technologies. For instance, the issued patents relating to our drugs or drug candidates may be limited to a particular molecule or molecules and may not cover similar molecules that have similar clinical properties. Consequently, our competitors may independently develop competing products that do not infringe our patents or other intellectual property. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products.
The laws of many foreign jurisdictions do not protect intellectual property rights to the same extent as in the United States and many companies in our segment of the pharmaceutical industry have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. If we encounter such difficulties in protecting or are otherwise precluded from effectively protecting our intellectual property rights in foreign jurisdictions, our business could be substantially harmed.
Because of the extensive time required for the discovery, development, testing and regulatory review of drug candidates, it is possible that a patent may expire before a drug candidate can be commercialized, or a patent may expire or remain in effect for only a short period following commercialization of such drug candidate. This would result in a minimal or non-existent period of patent exclusivity. If our drug candidates are not commercialized significantly ahead of the expiration date of any applicable patent, or if we have no patent protection on such drug candidates, then, to the extent available we would rely on other forms of exclusivity, such as regulatory exclusivity provided by the FDCA and its counterpart agencies in various jurisdictions, and/or orphan drug exclusivity.
Uncertainty over intellectual property in the pharmaceutical and biotechnology industry has been the source of litigation and other disputes, which is inherently costly and unpredictable.
There is considerable uncertainty within our industry about the validity, scope and enforceability of many issued patents in the United States and elsewhere in the world, and, to date, the law and practice remains in substantial flux both in the agencies that grant patents and in the courts. We cannot currently determine the ultimate scope and validity of patents which may be granted to third parties in the future or which patents might be asserted as being infringed by the manufacture, use and sale of our products.
There has been, and we expect that there may continue to be, significant litigation in the pharmaceutical industry regarding patents and other intellectual property rights. Litigation, arbitrations, administrative proceedings and other legal actions with private parties and governmental authorities concerning patents and other intellectual property rights may be protracted, expensive and distracting to management. Competitors may sue us as a way of delaying the introduction of our drugs or to remove our drugs from the market. Any litigation, including litigation related to Abbreviated New Drug Applications, or ANDA, litigation related to 505(b)(2) applications, interference proceedings to determine priority of inventions, derivations proceedings, inter partes review, oppositions to patents in foreign countries, litigation against our collaborators or similar actions, may be costly and time consuming and could harm our business. We expect that litigation may be necessary in some instances to determine the validity and scope of certain of our proprietary rights. Litigation may be necessary in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products. Ultimately, the outcome of such litigation could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements.
To the extent that valid present or future third-party patents or other intellectual property rights cover our drugs, drug candidates or technologies, we or our strategic collaborators may seek licenses or other agreements from the holders of such rights in order to avoid or settle legal claims. Such licenses may not be available on acceptable terms, which may hinder our


34


ability to, or prevent us from being able to, manufacture and market our drugs. Payments under any licenses that we are able to obtain would reduce our profits derived from the covered products.
We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee’s former employer. Litigation may be necessary to defend against these claims.
In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.
If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.
Risks Related To Our Operations
Risks associated with operating in foreign countries could materially adversely affect our business.
We have expanded our international operations over the past several years in order to market our CF medicines and expand our research and development capabilities. New laws and industry codes in the E.U. and elsewhere have expanded transparency requirements regarding payments and transfers of value as well as patient-level clinical trial data and have expanded protections related to personal data and provided for increased sanctions for violations. Collectively, our expansion and these new requirements are adding to our compliance costs and expose us to potential sanctions for failing to meet the enhanced safeguards and reporting demands in these jurisdictions. In addition, a significant portion of our commercial supply chain, including sourcing of raw materials and manufacturing, is located in China and the E.U. Consequently, we are, and will continue to be, subject to risks related to operating in foreign countries, including risks relating to intellectual property protections and business interruptions. These risks are increased with respect to countries such as China that have substantially different local laws and business practices and weaker protections for intellectual property. Risks associated with operating a global biotechnology company include:
•
differing regulatory requirements for drug approvals and regulation of approved drugs in foreign countries;
•
varying reimbursement regimes and difficulties or the inability to obtain reimbursement for our products in foreign countries in a timely manner;
•
differing patient treatment infrastructures, particularly since our business is focused on the treatment of serious diseases that affect relatively smaller numbers of patients and are typically prescribed by specialist physicians;
•
collectibility of accounts receivable;
•
changes in tariffs, trade barriers and regulatory requirements, the risks of which appear to have increased in the current political environment;
•
economic weakness, including recession and inflation, or political instability in particular foreign economies and markets;
•
differing levels of enforcement and/or recognition of contractual and intellectual property rights;
•
complying with local laws and regulations, which are interpreted and enforced differently across jurisdictions and which can change significantly over time;
•
foreign taxes, including withholding of payroll taxes;


35


•
foreign currency fluctuations, which could result in reduced revenues or increased operating expenses, and other obligations incident to doing business or operating in another country;
•
workforce uncertainty in countries where labor unrest is more common than in the United States;
•
reliance on third-party vendors and suppliers;
•
import and export licensing requirements, tariffs, and other trade and travel restrictions;
•
global or regional public health emergencies that could affect our operations or business;
•
production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
•
business interruptions resulting from geo-political actions, including war and terrorism.
Our revenues are subject to foreign exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge forecasted product revenues denominated in foreign currencies, our efforts to reduce currency exchange losses may not be successful. As a result, currency fluctuations among our reporting currency, the U.S. dollar, and the currencies in which we do business will affect our operating results, often in unpredictable ways.
In addition, our international operations are subject to regulation under U.S. law. For example, the FCPA prohibits U.S. companies and their representatives from offering, promising, authorizing or making payments to foreign officials for the purpose of obtaining or retaining business abroad. In many countries, the health care professionals we regularly interact with may meet the definition of a foreign government official for purposes of the FCPA. We also are subject to import/export control laws. Failure to comply with domestic or foreign laws could result in various adverse consequences, including the possible delay in approval or refusal to approve a product, recalls, seizures, withdrawal of an approved product from the market, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and corresponding bad publicity and negative perception of our company in foreign countries.
If we fail to manage our operations effectively, our business may suffer.
We have expanded and are continuing to expand our global operations and capabilities, which has placed, and will continue to place, significant demands on our management and our operational, research and development and financial infrastructure. To effectively manage our business, we need to:
•
implement and clearly communicate our corporate-wide strategies;
•
enhance our operational and financial infrastructure, including our controls over records and information;
•
enhance our operational, financial and management processes, including our cross-functional decision-making processes and our budget prioritization systems;
•
train and manage our global employee base; and
•
enhance our compliance and legal resources.
Our business faces potential risks relating to the United Kingdom’s withdrawal from the European Union.
Our European headquarters and European research facility are located in the United Kingdom, or the U.K., and a significant portion of our ex-U.S. net product revenues are derived from sales in the U.K. On January 31, 2020, the U.K. formally withdrew from the E.U. (“Brexit”) and began a transition period set to end on December 31, 2020. During the transition period, the U.K. and the E.U. will negotiate their future relationship, including the terms of trade. The effects of Brexit will depend on any agreements the U.K. makes to retain access to E.U. markets, either during the transitional period or more permanently. Brexit could lead to legal uncertainty and potentially divergent national laws and regulations as the U.K. determines which E.U. laws to replace or replicate. Given the lack of comparable precedent, it is unclear what financial, trade, regulatory and legal implications the withdrawal of the U.K. from the E.U. would have and how such withdrawal would affect us. Any of these effects of Brexit, among others, could adversely affect our business, financial condition and operating results.


36


Our business has a substantial risk of product liability claims and other litigation liability. If we do not obtain appropriate levels of insurance, any potential claims could adversely affect our business.
We are or may be involved in various legal proceedings, including securities/shareholder matters and claims related to product liability, intellectual property and breach of contract. Such proceedings may involve claims for, or the possibility of, damages or fines and penalties involving substantial amounts of money or other relief, including but not limited to civil or criminal fines and penalties. If any of these legal proceedings were to result in an adverse outcome, it could have a material adverse effect on our business.
With respect to product liability and clinical trial risks, in the ordinary course of business we are subject to liability claims and lawsuits, including potential class actions, alleging that our products or drug candidates have caused, or could cause, serious adverse events or other injury. We have product liability insurance and clinical trial insurance in amounts that we believe are adequate to cover this risk. However, our insurance may not provide adequate coverage against all potential liabilities. If a claim is brought against us, we might be required to pay legal and other expenses to defend the claim, as well as pay uncovered damage awards resulting from a claim brought successfully against us and these damages could be significant and have a material adverse effect on our financial condition. Furthermore, whether or not we are ultimately successful in defending any such claims, we might be required to direct significant financial and managerial resources to such defense and adverse publicity is likely to result.
A breakdown or breach of our information technology systems could subject us to liability or interrupt the operation of our business.
We maintain and rely extensively on information technology systems and network infrastructures for the effective operation of our business. In the course of our business, we collect, store and transmit confidential information (including personal information and intellectual property), and it is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. The size and complexity of our information technology and information security systems makes such systems potentially vulnerable to service interruptions and to security breaches. A disruption, infiltration or failure of our information technology systems or any of our data centers as a result of software or hardware malfunctions, computer viruses, cyber-attacks, employee theft or misuse, power disruptions, natural disasters, floods or accidents could cause breaches of data security and loss of critical data, which in turn could materially adversely affect our business and subject us to both private and governmental causes of action. While we have implemented security measures in an attempt to minimize these risks to our data and information technology systems and have adopted a business continuity plan to deal with a disruption to our information technology systems, cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. There can be no assurance that our efforts to protect our data and information systems will prevent breakdowns or breaches in our systems that could adversely affect our business. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks or other related liabilities.
If we fail to attract and retain skilled employees or manage our upcoming executive transition, our business could be materially harmed.
Due to the highly technical nature of our drug discovery and development activities, we require the services of highly qualified and trained scientists who have the skills necessary to conduct these activities. In addition, we need to attract and retain employees with experience in marketing and commercialization of medicines. We have entered into employment agreements with some executives and provide stock-related compensation benefits to all of our key employees that vest over time and therefore induce them to remain with us. However, the employment agreements can be terminated by the executive on relatively short notice. The value to employees of stock-related benefits that vest over time — such as restricted stock units and stock options — can be significantly affected by movements in our stock price, and may, at any point in time, be insufficient to counteract more lucrative offers from other companies. We face intense competition for our personnel from our competitors and other companies throughout our industry. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Moreover, the growth of local biotechnology companies and the expansion of major pharmaceutical companies into the Boston area has increased competition for the available pool of skilled employees, especially in technical fields. The high cost of living in Massachusetts can make it difficult to attract employees from other parts of the country to our Massachusetts headquarters. In addition, the available pool of skilled employees would be further reduced if immigration laws change in a manner that increases restrictions on immigration. Our ability to continue to commercialize our products and achieve our research and development objectives depends on our ability to respond effectively to these demands. If we are unable to hire and retain qualified personnel, there could be a material adverse effect on our business.


37


On April 1, 2020, Dr. Jeffrey Leiden will transition to the role of Executive Chairman and Dr. Reshma Kewalramani will become our President and Chief Executive Officer. No assurance can be made about the impact that this transition in management will have on our business.
If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.
Our research and development efforts involve the regulated use of hazardous materials, chemicals and various controlled and radioactive compounds. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed by state, federal and foreign regulations, the risk of loss of, or accidental contamination or injury from, these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We also are subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of biohazardous materials. Although we maintain workers’ compensation insurance to cover us for costs we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We maintain insurance to cover pollution conditions or other extraordinary or unanticipated events relating to our use and disposal of hazardous materials that we believe is appropriate based on the small amount of hazardous materials we generate. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.
If our facilities were to experience a catastrophic loss, our operations would be seriously harmed.
Most of our operations, including our research and development activities, are conducted in a limited number of facilities. If any of our major facilities were to experience a catastrophic loss, due to an earthquake, severe storms, fire or similar event, our operations could be seriously harmed. For example, our corporate headquarters, as well as additional leased space that we use for certain logistical and laboratory operations and manufacturing, are located in a flood zone along the Massachusetts coast. We have adopted a business continuity plan to address most crises. However, if we are unable to fully implement our business continuity plans, we may experience delays in recovery of data and/or an inability to perform vital corporate functions, which could result in a significant disruption in our research, development, manufacturing and/or commercial activities, large expenses to repair or replace the facility and/or the loss of critical data, which could have a material adverse effect on our business.
Risks Related to Holding Our Common Stock
Our stock price may fluctuate.
Market prices for securities of companies such as ours are highly volatile. From January 1, 2019 to December 31, 2019, our common stock traded between $160.95 and $225.66 per share. The market for our stock, like that of other companies in the biotechnology industry, has experienced significant price and volume fluctuations. The future market price of our securities could be significantly and adversely affected by factors such as:
•
the information contained in our quarterly earnings releases, including our net product revenues and operating expenses for completed periods and guidance regarding future periods;
•
announcements of FDA actions with respect to our drugs or our competitors’ drugs, or regulatory filings for our drug candidates or those of our competitors, or announcements of interim or final results of clinical trials or nonclinical studies relating to our drugs, drug candidates or those of our competitors;
•
developments in domestic and international governmental policy or regulation, for example, relating to drug pricing or intellectual property rights;
•
technological innovations or the introduction of new drugs by our competitors;
•
government regulatory action;
•
public concern as to the safety of drugs developed by us or our competitors;
•
developments in patent or other intellectual property rights or announcements relating to these matters;
•
information disclosed by third parties regarding our business or products;


38


•
developments relating specifically to other companies and market conditions for pharmaceutical and biotechnology stocks or stocks in general;
•
business development, capital structuring or financing activities; and
•
general worldwide or national economic, political and capital market conditions.
Following periods of volatility in the market price of a company’s securities, stockholder derivative lawsuits and securities class action litigation are common. Such litigation, if instituted against us or our officers and directors, could result in substantial costs and a diversion of management’s attention and resources.
Our quarterly operating results are subject to significant fluctuation.
Our operating results have fluctuated from quarter to quarter in the past, and we expect that they will continue to do so in the future. Our revenues are primarily dependent on the level of net product revenues from sales of our CF medicines. Our total net product revenues could vary on a quarterly basis based on, among other factors, the timing of orders from our significant customers. Additional factors that have caused quarterly fluctuations to our operating results in recent years include variable amounts of revenues, expenses related to business development activities, changes in the fair value of our strategic investments, impairment charges, charges for excess and obsolete inventories, changes in the fair value of derivative instruments and the consolidation or deconsolidation of variable interest entities. Our revenues also are subject to foreign exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge forecasted product revenues denominated in foreign currencies, our efforts to reduce currency exchange losses may not be successful. As a result, currency fluctuations among our reporting currency, the U.S. dollar, and the currencies in which we do business may affect our operating results, often in unpredictable ways. Our quarterly results also could be materially affected by significant charges, which may or may not be similar to charges we have experienced in the past. Most of our operating expenses relate to our research and development activities, do not vary directly with the amount of revenues and are difficult to adjust in the short term. As a result, if revenues in a particular quarter are below expectations, we are unlikely to reduce operating expenses proportionately for that quarter. These examples are only illustrative and other risks, including those discussed in these “Risk Factors,” could also cause fluctuations in our reported financial results. Our operating results during any one period do not necessarily suggest the results of future periods.
We expect that results from our clinical development activities and the clinical development activities of our competitors will continue to be released periodically, and may result in significant volatility in the price of our common stock.
Any new information regarding our products and drug candidates or competitive products or potentially competitive drug candidates can substantially affect investors’ perceptions regarding our future prospects. We, our collaborators and our competitors periodically provide updates regarding drug development programs, typically through press releases, conference calls and presentations at medical conferences. These periodic updates often include interim or final results from clinical trials conducted by us or our competitors and/or information about our or our competitors’ expectations regarding regulatory filings and submissions as well as future clinical development of our products or drug candidates, competitive products or potentially competitive drug candidates. The timing of the release of information by us regarding our drug development programs is often beyond our control and is influenced by the timing of receipt of data from our clinical trials and by the general preference among pharmaceutical companies to disclose clinical data during medical conferences. In addition, the information disclosed about our clinical trials, or our competitors’ clinical trials, may be based on interim rather than final data that may involve interpretation difficulties and may in any event not accurately predict final results.
Changes in tax laws, regulations and treaties could affect our future taxable income.
We are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate globally.  Our effective tax rate may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of tax authority examinations/audits of our tax filings, adjustments to the value of our uncertain tax positions, changes in accounting for income taxes and changes in tax laws or modifications of treaties in various jurisdictions. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations
We continue to assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations to determine the potential effect on our business and any assumptions we have made about our future taxable income.  We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted.


39


Recommendations from the Organization for Economic Co-operation and Development that are part of the base erosion and profit shifting, or BEPS, framework could result in changes in tax laws in countries where we do business and adversely affect our provision for income taxes and our current rate. If these recommendations (or other changes in law) were adopted by the countries in which we do business, it could adversely affect our provision for income tax and our current rate.
We may need to raise additional capital that may not be available.
We may need to raise additional capital in the future. Any potential public offering, private placement or debt financing may or may not be similar to the transactions that we entered into in the past. Any debt financing may be on terms that, among other things, include conversion features that could result in dilution to our then-existing security holders and restrict our ability to pay interest and dividends—although we do not intend to pay dividends for the foreseeable future. Any equity financings would result in dilution to our then-existing security holders. If adequate funds are not available on acceptable terms, or at all, we may be required to curtail significantly or discontinue one or more of our research, drug discovery or development programs, including clinical trials, incur significant cash exit costs, or attempt to obtain funds through arrangements with collaborators or others that may require us to relinquish rights to certain of our technologies, drugs or drug candidates. Based on many factors, including general economic conditions, additional financing may not be available on acceptable terms, if at all.
Future indebtedness could materially and adversely affect our financial condition, and the terms of our credit agreement impose restrictions on our business, reducing our operational flexibility and creating default risks.
In September 2019, we entered into a credit agreement providing for a $500 million revolving facility. The credit agreement provides that, subject to the satisfaction of certain conditions, we may request that the borrowing capacity under the credit agreement be increased by an additional $500.0 million. All outstanding borrowings under the credit agreement mature on September 17, 2024. If we borrow under our current credit agreements or any future credit agreement, such indebtedness could have important consequences to our business, including increasing our vulnerability to general adverse financial, business, economic and industry conditions, as well as other factors that are beyond our control. The credit agreement requires that we comply with certain financial covenants, including (i) a consolidated leverage ratio covenant and (ii) a consolidated interest coverage ratio covenant, in each case to be measured on a quarterly basis. Further, the credit agreement includes negative covenants, subject to exceptions, restricting or limiting our ability and the ability of our subsidiaries to, among other things, incur additional indebtedness, grant liens, engage in certain investment, acquisition and disposition transactions, pay dividends, repurchase capital stock and enter into transactions with affiliates. As a result, we may be restricted from engaging in business activities that may otherwise improve our business. Failure to comply with the covenants could result in an event of default that could trigger acceleration of our indebtedness, which would require us to repay all amounts owing under the credit agreement and/or our capital leases and could have a material adverse effect on our business. Additionally, our obligations under the credit agreement are unconditionally guaranteed by certain of our domestic subsidiaries.
Issuances of additional shares of our common stock could cause the price of our common stock to decline.
As of December 31, 2019, we had 259.0 million shares of common stock issued and outstanding. As of December 31, 2019, we also had outstanding options to purchase 6.3 million shares of common stock with a weighted-average exercise price of $134.92 per share. Outstanding vested options are likely to be exercised if the market price of our common stock exceeds the applicable exercise price, and, in the future, we expect to issue additional options and restricted stock units to directors and employees. In addition, we may issue additional common stock or restricted securities in the future as part of financing activities or business development activities and any such issuances may have a dilutive effect on our then-existing shareholders. Sales of substantial amounts of our common stock in the open market, or the availability of such shares for sale, could adversely affect the price of our common stock. The issuance of restricted common stock or common stock upon exercise of any outstanding options would be dilutive, and may cause the market price for a share of our common stock to decline.
There can be no assurance that we will repurchase shares of common stock or that we will repurchase shares at favorable prices.
Our Board of Directors has authorized a share repurchase program of up to $500 million to repurchase shares of our common stock. Our stock repurchases will depend upon, among other factors, our cash balances and potential future capital requirements, results of operations, financial condition and other factors that we may deem relevant. We can provide no assurance that we will repurchase stock at favorable prices, if at all.


40


We have adopted anti-takeover provisions and are subject to Massachusetts corporate laws that may frustrate any attempt to remove or replace our current management or effectuate a business combination involving Vertex.
Our corporate charter and by-law provisions and Massachusetts state laws may discourage certain types of transactions involving an actual or potential change of control of Vertex that might be beneficial to us or our security holders. Our by-laws grant the directors a right to adjourn annual meetings of shareholders, and certain provisions of our by-laws may be amended only with an 80% shareholder vote. We may issue shares of any class or series of preferred stock in the future without shareholder approval and upon such terms as our Board of Directors may determine. The rights of the holders of common stock will be subject to, and may be adversely affected by, the rights of the holders of any class or series of preferred stock that may be issued in the future. Massachusetts state law prohibits us from engaging in specified business combinations, unless the combination is approved or consummated in a prescribed manner, and prohibits voting by any shareholder who acquires 20% or more of our voting stock without shareholder approval. As a result, shareholders or other parties may find it more difficult to remove or replace our current management.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K and, in particular, the description of our Business set forth in Item 1, the Risk Factors set forth in this Item 1A and our Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in Item 7 contain or incorporate a number of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding:
•
our expectations regarding the amount of, timing of and trends with respect to our revenues, costs and expenses and other gains and losses, including those related to our net product revenues;
•
our expectations regarding the timing and structure of clinical trials of our drugs and drug candidates, the expected timing of our receipt of data from our ongoing and planned clinical trials and regulatory authority filings and submissions for our drugs or drug candidates;
•
our ability to obtain reimbursement for our medicines in ex-U.S. markets and our ability to otherwise successfully market our medicines or any drug candidates for which we obtain regulatory approval;
•
the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development or support regulatory filings;
•
our beliefs regarding the support provided by clinical trials and preclinical and nonclinical studies of our drug candidates for further investigation, clinical trials or potential use as a treatment;
•
our plan to continue investing in our research and development programs and our strategy to develop our drug candidates, alone or with third party-collaborators;
•
the establishment, development and maintenance of collaborative relationships;
•
potential business development activities;
•
potential fluctuations in foreign currency exchange rates;
•
our ability to use our research programs to identify and develop new drug candidates to address serious diseases and significant unmet medical needs; and
•
our liquidity and our expectations regarding the possibility of raising additional capital.
Any or all of our forward-looking statements in this Annual Report on Form 10-K may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many factors mentioned in this Annual Report on Form 10-K will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially from expected results. We also provide a cautionary discussion of risks and uncertainties under “Risk Factors” above in this Item 1A. These are factors and uncertainties that we think could cause our actual results to differ materially from expected results. Other factors and uncertainties besides those listed there could also adversely affect us.


41


Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “intends,” “expects” and similar expressions are intended to identify forward-looking statements. There are a number of factors and uncertainties that could cause actual events or results to differ materially from those indicated by such forward-looking statements, many of which are beyond our control, including the factors and uncertainties set forth under “Risk Factors” above in this Item 1A. In addition, the forward-looking statements contained herein represent our estimate only as of the date of this filing and should not be relied upon as representing our estimate as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements.
ITEM 1B.
UNRESOLVED STAFF COMMENTS
We did not receive any written comments from the Securities and Exchange Commission prior to the date 180 days before the end of the fiscal year ended December 31, 2019 regarding our filings under the Securities Exchange Act of 1934, as amended, that have not been resolved.
ITEM 2.
PROPERTIES
Corporate Headquarters
We lease approximately 1.1 million square feet of office and laboratory space at our corporate headquarters in Boston, Massachusetts in two buildings pursuant to two leases that we entered into in May 2011. These leases commenced in December 2013 and will extend until December 2028. We have an option to extend the term of the leases for an additional ten years.
Additional United States and Worldwide Locations
In addition to our corporate headquarters, we lease an aggregate of approximately 488,000 square feet of space globally. This space includes logistical, laboratory, commercial and manufacturing operations, as well as laboratory and office space to support our research and development organizations.
ITEM 3.
LEGAL PROCEEDINGS
We are not currently subject to any material legal proceedings.
ITEM 4.
MINE SAFETY DISCLOSURES
Not applicable.


42


PART II
ITEM 5.
MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market Information
Our common stock is traded on The Nasdaq Global Select Market under the symbol “VRTX.”
Shareholders
As of January 31, 2020, there were 1,102 holders of record of our common stock.
Performance Graph
capture2.jpg
We became part of the Standard & Poor’s 500 (“S&P 500®”) Stock Index in 2013.
Dividends
We currently expect that any future earnings will be retained for use in our business. Any future determination to declare cash dividends will be subject to the discretion of our board of directors and applicable law and will depend on various factors, including our results of operations, financial condition, prospects and any other factors deemed relevant by our board of directors. In addition, our credit agreement limits our ability to pay cash dividends on our common stock.


43


Issuer Repurchases of Equity Securities
In January 2018, we announced a share repurchase program (the “2018 Share Repurchase Program”), under which we were authorized to repurchase up to $500.0 million of our common stock by December 31, 2019. As of June 30, 2019, we had repurchased the entire $500.0 million of common stock that was authorized under the 2018 Share Repurchase Program. In July 2019, we approved a new share repurchase program (the “2019 Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $500.0 million of our common stock between August 1, 2019 and December 31, 2020.
The table set forth below shows repurchases of securities by us during the three months ended December 31, 2019, including shares repurchased under our 2019 Share Repurchase Program and a small number of restricted shares repurchased by us from employees pursuant to our equity programs. As of December 31, 2019, we had repurchased $36.0 million of common stock under the share repurchase program and had remaining available $464.0 million to repurchase additional shares pursuant to this program.
Period
 
Total Number
of Shares Purchased (1)
Average Price
Paid per Share
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs (2)
Maximum Number (or approximate dollar value) of
Shares that May Yet be Purchased Under
the Plans or Programs (2)
Oct. 1, 2019 to Oct. 31, 2019
143,306

$
167.47

142,835

$
464,000

Nov. 1, 2019 to Nov. 30, 2019
815

$
0.01

—

$
464,000

Dec. 1, 2019 to Dec. 31, 2019
148

$
0.01

—

$
464,000

Total
144,269

$
166.35

142,835

$
464,000

(1)
Consists of 142,835 shares repurchased pursuant to our 2019 Share Repurchase Program (described in footnote 2 below) at an average price of $168.02 per share and 1,434 restricted shares repurchased for $0.01 per share from our employees pursuant to our equity plans. While we have restricted shares that are continuing to vest under our equity plans that are subject to repurchase rights upon termination of service, we have transitioned our equity program to granting restricted stock units. Unvested restricted stock units are forfeited upon termination of service and do not result in an issuer repurchase that would be reflected in this table.
(2)
Under our 2019 Share Repurchase Program, we are authorized to purchase shares from time to time through open market or privately negotiated transactions. Such purchases may be made pursuant to Rule 10b5-1 plans or other means as determined by our management and in accordance with the requirements of the Securities and Exchange Commission. The approximate dollar value of shares that may yet be repurchased is based solely on shares that may be repurchased under the share repurchase program and excludes any shares that may be repurchased under our employee equity programs.


44


ITEM 6.
SELECTED FINANCIAL DATA
The following unaudited selected consolidated financial data are derived from our audited consolidated financial statements. These data should be read in conjunction with our audited consolidated financial statements and related notes that are included elsewhere in this Annual Report on Form 10-K and with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Item 7.
 
Year Ended December 31,
 
2019
 
2018
 
2017
 
2016
 
2015
Consolidated Statements of Operations Data:
(in thousands, except per share amounts)
Product revenues, net
$
4,160,726

 
$
3,038,325

 
$
2,165,480

 
$
1,683,632

 
$
1,000,324

Collaborative and royalty revenues
2,095

 
9,272

 
323,172

 
18,545

 
32,012

Total revenues
4,162,821

 
3,047,597

 
2,488,652

 
1,702,177

 
1,032,336

Total costs and expenses (1)
2,965,255

 
2,412,447

 
2,365,409

 
1,692,241

 
1,499,215

Provision for (benefit from) income taxes (2)
218,109

 
(1,486,862
)
 
(107,324
)
 
16,665

 
30,381

Net income (loss) attributable to Vertex
$
1,176,810

 
$
2,096,896

 
$
263,484

 
$
(112,052
)
 
$
(556,334
)
Diluted income (loss) from continuing operations per share attributable to Vertex common shareholders
$
4.51

 
$
8.09

 
$
1.04

 
$
(0.46
)
 
$
(2.31
)
Shares used in per diluted share calculations
260,673

 
259,185

 
253,225

 
244,685

 
241,312

 
 
 
 
 
 
 
 
 
 
 
As of December 31,
 
2019
 
2018
 
2017
 
2016
 
2015
Consolidated Balance Sheet Data:
(in thousands)
Cash, cash equivalents and marketable securities
$
3,808,294

 
$
3,168,242

 
$
2,088,666

 
$
1,434,557

 
$
1,042,462

Deferred tax assets (2)
1,190,815

 
1,499,672

 
—

 
—

 
—

Total assets
8,318,465

 
6,245,898

 
3,546,014

 
2,896,787

 
2,498,587

Total current liabilities
1,334,827

 
1,120,290

 
807,260

 
792,537

 
506,167

Long-term debt obligations, excluding current portion
—

 
—

 
—

 
—

 
223,863

Long-term finance leases
538,576

 
581,550

 
583,902

 
521,335

 
515,534

Other long-term liabilities
359,818

 
108,853

 
112,546

 
244,724

 
159,395

Total shareholders’ equity
6,085,244

 
4,435,203

 
2,042,306

 
1,338,191

 
1,093,628

(1)
Total costs and expenses included (i) in 2017, an intangible asset impairment charges of $255.3 million, and (ii) in 2019, 2018 and 2017, collaborative license and asset acquisition expenses of $318.3 million, $111.9 million and $168.7 million, respectively. See Note B, “Collaborative Arrangements.”
(2)
In 2018, we released the valuation allowance on the majority of our net operating losses and other deferred tax assets resulting in a benefit from income taxes of $1.56 billion in the fourth quarter of 2018 and we recorded a $1.50 billion deferred tax asset on our consolidated balance sheet as of December 31, 2018. In 2019, we began recording a provision for income taxes on our pre-tax income approximating statutory rates. See Note P, “Income Taxes.” In 2017, we recorded a benefit from income taxes related to the impairment of intangible assets. See Note K, “Intangible Assets and Goodwill.”


45


ITEM 7.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
OVERVIEW
We invest in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets. We continue to focus on developing and commercializing therapies for the treatment of cystic fibrosis, or CF, and in 2019 we obtained approval in the United States, or U.S., for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor). We are broadening our pipeline through internal research efforts and accessing external innovation through business development transactions.
We have four approved medicines that treat the underlying cause of CF, which is a life-threatening genetic disease. In October 2019, TRIKAFTA , our triple-combination regimen, was approved by the United States Food and Drug Administration, or FDA, for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. This approval increased the number of patients eligible for our medicines in the U.S. by approximately 6,000 and provided an additional treatment option for many patients who are also eligible for one of our previously approved products. We have submitted a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, for this triple combination regimen. Our four medicines are collectively approved to treat approximately 60% of the 75,000 CF patients in North America, Europe and Australia. We are focused on obtaining approval for the triple combination in ex-U.S. markets for patients 12 years of age and older and evaluating our triple combination in younger patients, with the goal of having treatments for up to 90% of patients with CF. We are also pursuing other therapeutic approaches to address the remaining 10% of CF patients.
Our small molecule programs include programs focused on developing treatments for alpha-1 antitrypsin, or AAT, deficiency, APOL1-mediated kidney diseases and pain. We are evaluating CTX001, a genetic therapy as a potential treatment for sickle cell disease and beta-thalassemia, in a Phase 1/2 clinical trial in collaboration with CRISPR Therapeutics AG, or CRISPR. In 2019, through a series of strategic transactions, we established preclinical genetic therapy programs for Duchenne muscular dystrophy, or DMD, and myotonic dystrophy type 1, or DM1, and a preclinical program to develop cell-based therapies for type 1 diabetes, or T1D.
Financial Highlights
Over the last three years, our product revenues have increased significantly and we have limited the growth of our expenses, which has allowed us to create significant operating margins and reinvest in our business.
Revenues
Over the last three years, our net product revenues have increased as we obtained approvals for TRIKAFTA and SYMDEKO/SYMKEVI and expanded access to our medicines.

chart-642b38eab6d652b2af8a01.jpg
 
Expenses
Our combined R&D and SG&A expenses increased from $1.97 billion in 2018 to $2.41 billion in 2019 primarily due to research expenses associated with our business development activities. In 2019, cost of sales was approximately 13.2% of our net product revenues.
Balance Sheetchart-4a9cf4c4b68f5058a30.jpg


46



Business Highlights
Cystic Fibrosis
•
Obtained approval in October 2019 from the FDA for TRIKAFTA for treatment of patients with CF 12 years of age and older who have at least one F508del mutation.
•
TRIKAFTA was approved approximately three months after we submitted the NDA for the triple combination regimen and within four years of discovery of the final component of the triple combination regimen.
•
Submitted a MAA to the European Medicines Agency, or EMA, for the triple combination of elexacaftor, tezacaftor and ivacaftor in patients 12 years of age and older.
 
•
Conducting a Phase 3 clinical trial evaluating elexacaftor/tezacaftor/ivacaftor and ivacaftor in children 6 to 11 years of age who have two F508del mutations or one F508del mutation and one minimal function mutation.
•
Obtained a positive opinion from the EMA’s Committee for Medicinal Products for Human Use for KALYDECO for infants as young as six months old.
•
Obtained reimbursement of ORKAMBI and/or SYMDEKO/SYMKEVI for eligible patients in several important ex-U.S. markets, including England, France, Australia, Scotland and Spain.

Pipeline
•
AAT Deficiency: We initiated a Phase 2 proof-of-concept clinical trial for VX-814, our first investigational oral small molecule corrector for the treatment of alpha-1 antitrypsin, or AAT, deficiency, in order to evaluate VX-814 in patients with AAT deficiency who have two copies of the Z mutation. A Phase 1 clinical trial of VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, is ongoing in healthy volunteers.
•
APOL1-mediated Kidney Disease: In the fourth quarter of 2019, we completed a Phase 1 clinical trial evaluating VX-147, our first investigational oral small molecule for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases, in healthy volunteers. We plan to initiate a Phase 2 proof-of-concept clinical trial in 2020 to evaluate the reduction in protein levels with VX-147 in FSGS patients.
•
Sickle Cell Disease and Beta-Thalassemia: Enrollment is ongoing in Phase 1/2 clinical trials evaluating CTX001 for the treatment of severe
 
sickle cell disease and beta-thalassemia. Along with our collaborator, CRISPR, we announced positive, interim data from the first two patients with these hemoglobinopathies treated with the investigational CRISPR/Cas9 gene-editing therapy CTX001 in the ongoing Phase 1/2 trials. We expect to provide additional data for this program in 2020.
•
Pain: We plan to initiate clinical development of a novel NaV1.8 inhibitor for the treatment of pain in the first half of 2020.
•
Type 1 diabetes: Acquired cell-based therapy programs that we are advancing as potential treatments for T1D by acquiring Semma Therapeutics. We plan to advance this program into clinical development in T1D patients in late 2020 or early 2021.
•
DMD and DM1: Acquired Exonics and expanded our collaboration with CRISPR in July 2019, in order to support a pre-clinical program to develop treatments for DMD and DM1.


Research
We are continuing to invest in our research programs and fostering scientific innovation in order to identify and develop transformative medicines. Our strategy is to combine transformative advances in the understanding of human disease and the science of therapeutics in order to identify and develop new medicines. We believe that pursuing research in diverse areas allows us to balance the risks inherent in drug development and may provide drug candidates that will form our pipeline in future years. To supplement our internal research programs, we acquire technologies and programs and collaborate with biopharmaceutical and technology companies, leading academic research institutions, government laboratories, foundations


47


and other organizations as needed to advance research in our areas of therapeutic interest and to access technologies needed to execute on our strategy.
Drug Discovery and Development
Discovery and development of a new pharmaceutical product is a difficult and lengthy process that requires significant financial resources along with extensive technical and regulatory expertise. Potential drug candidates are subjected to rigorous evaluations, driven in part by stringent regulatory considerations, designed to generate information concerning efficacy, side-effects, proper dosage levels and a variety of other physical and chemical characteristics that are important in determining whether a drug candidate should be approved for marketing as a pharmaceutical product. Most chemical compounds that are investigated as potential drug candidates never progress into development, and most drug candidates that do advance into development never receive marketing approval. Because our investments in drug candidates are subject to considerable risks, we closely monitor the results of our discovery, research, clinical trials and nonclinical studies and frequently evaluate our drug development programs in light of new data and scientific, business and commercial insights, with the objective of balancing risk and potential. This process can result in abrupt changes in focus and priorities as new information becomes available and as we gain additional understanding of our ongoing programs and potential new programs, as well as those of our competitors.
If we believe that data from a completed registration program support approval of a drug candidate, we submit an NDA to the FDA requesting approval to market the drug candidate in the United States and seek analogous approvals from comparable regulatory authorities in jurisdictions outside the United States. To obtain approval, we must, among other things, demonstrate with evidence gathered in nonclinical studies and well-controlled clinical trials that the drug candidate is safe and effective for the disease it is intended to treat and that the manufacturing facilities, processes and controls for the manufacture of the drug candidate are adequate. The FDA and ex-U.S. regulatory authorities have substantial discretion in deciding whether or not a drug candidate should be granted approval based on the benefits and risks of the drug candidate in the treatment of a particular disease, and could delay, limit or deny regulatory approval. If regulatory delays are significant or regulatory approval is limited or denied altogether, our financial results and the commercial prospects for the drug candidate involved will be harmed.
Regulatory Compliance
Our marketing of pharmaceutical products is subject to extensive and complex laws and regulations. We have a corporate compliance program designed to actively identify, prevent and mitigate risk through the implementation of compliance policies and systems and through the promotion of a culture of compliance. Among other laws, regulations and standards, we are subject to various U.S. federal and state laws, and comparable laws in other jurisdictions, pertaining to health care fraud and abuse, including anti-kickback and false claims laws, and laws prohibiting the promotion of drugs for unapproved or off-label uses. Anti-kickback laws generally make it illegal for a prescription drug manufacturer to knowingly and willfully solicit, offer, receive or pay any remuneration in return for or to induce the referral of business, including the purchase or prescription of a particular drug that is reimbursed by a state or federal health care program. False claims laws prohibit anyone from knowingly or willfully presenting for payment to third-party payors, including Medicare and Medicaid, claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. We are subject to laws and regulations that regulate the sales and marketing practices of pharmaceutical manufacturers, as well as laws such as the U.S. Foreign Corrupt Practices Act, which govern our international business practices with respect to payments to government officials. In addition, we are subject to various data protection and privacy laws and regulations in the U.S., E.U., Canada, Australia and other jurisdictions. We expect to continue to devote substantial resources to maintain, administer and expand these compliance programs globally.
Reimbursement
Sales of our products depend, to a large degree, on the extent to which our products are reimbursed by third-party payors, such as government health programs, commercial insurance and managed health care organizations. We dedicate substantial management and other resources in order to obtain and maintain appropriate levels of reimbursement for our products from third-party payors, including governmental organizations in the United States and ex-U.S. markets.
In the United States, we have worked successfully with third party-payors in order to promptly obtain appropriate levels of reimbursement for our first three CF medicines and have begun working with these stakeholders to obtain reimbursement for TRIKAFTA. We plan to continue to engage in discussions with numerous commercial insurers and managed health care organizations, along with government health programs that are typically managed by authorities in the individual states, to ensure that payors recognize the significant benefits that our medicines provide by treating the underlying cause of cystic fibrosis and continue to provide access to our medicines.


48


In Europe and other ex-U.S. markets, we seek government reimbursement for our medicines on a country-by-country basis. This is necessary for each new medicine, as well as, in most countries, label expansions for our current medicines. We successfully obtained reimbursement for KALYDECO in each significant ex-U.S. market within two years of approval. We experienced significant challenges in obtaining reimbursement for ORKAMBI in certain ex-U.S. markets. In the fourth quarter of 2019, we obtained reimbursement for ORKAMBI and SYMKEVI in the United Kingdom and ORKAMBI in France, four years after ORKAMBI’s initial approval in 2015. With this approval, we now have obtained reimbursement for ORKAMBI or SYMKEVI in most of our significant ex-U.S. markets. In some ex-U.S. markets, including Ireland, Denmark and Australia, our reimbursement agreements include innovative arrangements that provide a pathway to access and rapid reimbursement for certain future CF medicines. We recently filed a MAA with the EMA for the triple combination regimen of elexacaftor, tezacaftor and ivacaftor and, if approved, we would need to seek government reimbursement on a country-by-country basis, in most European markets. In December 2019, we reached an agreement with the government in Ireland to expand the existing reimbursement agreement to include the triple combination regimen pending approval by the EMA.
Strategic Transactions
Acquisitions
As part of our business strategy, we seek to acquire drugs, drug candidates and other technologies and businesses that have the potential to complement our ongoing research and development efforts. In 2019, we invested significantly in business development transactions designed to augment our pipeline. We expect to continue to identify and evaluate potential acquisitions that may be similar to or different from the transactions that we have engaged in previously.
In July 2019, we acquired Exonics, a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause DMD and other severe neuromuscular diseases, including DM1. Our acquisition of Exonics enhanced our gene-editing capabilities and supports the potential development of novel therapies for DMD and DM1. In connection with the acquisition, we acquired all of the outstanding equity of Exonics for an upfront payment of approximately $245.0 million plus customary working capital adjustments in cash, and certain potential future payments based primarily upon the successful achievement of specified development and regulatory milestones for the DMD and DM1 programs.
In October 2019, we acquired Semma, a privately-held company focused on the use of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes. Our acquisition of Semma advanced our cell therapy capabilities and supports the potential development of transformative therapies for T1D. In connection with the acquisition, we acquired all of the outstanding equity of Semma for approximately $950.0 million in cash.
Both of these acquisitions were accounted for as business combinations. As of the acquisition date for each transaction, the cash payments, as well as the fair value of contingent consideration for Exonics, were allocated primarily to goodwill and the fair value of several in-process research and development assets that we acquired.  The fair value of contingent consideration related to Exonics was recorded as a liability and will be adjusted on a quarterly basis in the future. As a result, these acquisitions are primarily reflected in additional assets and liabilities on our consolidated balance sheet.  Operating expenses incurred by Exonics and Semma after the acquisition dates and specific expenses associated with the acquisitions are reflected in our consolidated statement of operations for 2019.
Please refer to Note C, “Acquisitions,” and our critical accounting policies, “Acquisitions,” for further information regarding the significant judgments and estimates related to our acquisitions.
Collaboration and Licensing Arrangements
We enter into arrangements with third parties, including collaboration and licensing arrangements, for the development, manufacture and commercialization of drugs, drug candidates and other technologies that have the potential to complement our ongoing research and development efforts. We expect to continue to identify and evaluate collaboration and licensing opportunities that may be similar to or different from the collaborations and licenses that we have engaged in previously.
In-License Agreements
We have entered into collaborations with biotechnology and pharmaceutical companies in order to acquire rights or to license drug candidates or technologies that enhance our pipeline and/or our research capabilities. Over the last several years, we entered into collaboration agreements with:
•
Arbor Biotechnologies, Inc., or Arbor, pursuant to which we are collaborating on the discovery of novel proteins, including DNA endonucleases, to advance the development of new gene-editing therapies.


49


•
CRISPR, pursuant to which we have been collaborating since 2015 on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. In 2019, we obtained the exclusive worldwide rights to CRISPR’s intellectual property for DMD and DM1 gene-editing products through a new agreement with CRISPR.
•
Kymera Therapeutics, or Kymera, pursuant to which we are looking to advance small molecule protein degraders against multiple targets.
•
Molecular Templates, Inc., pursuant to which we are collaborating on the discovery and development of novel targeted conditioning regimens to enhance the hematopoietic stem cell transplant process.
Generally, when we in-license a technology or drug candidate, we make upfront payments to the collaborator, assume the costs of the program and/or agree to make contingent payments, which could consist of milestone, royalty and option payments. Most of these collaboration payments are expensed as research and development expenses; however, depending on many factors, including the structure of the collaboration, the significance of the drug candidate that we license to the collaborator’s operations and the other activities in which our collaborators are engaged, the accounting for these transactions can vary significantly. Our research and development expenses included $318.3 million in 2019, $111.9 million in 2018 and $168.7 million in 2017 related to upfront and milestone payments pursuant to our collaboration agreements.
Upfront payments and expenses incurred in connection with the collaborations listed above are being expensed as research or development expenses because the collaboration represents a small portion of each of these collaborator’s overall business. In contrast, Parion Sciences, Inc., or Parion, and BioAxone Biosciences, Inc., or BioAxone, with whom we previously collaborated, were historically accounted for as variable interest entities, or VIEs, and included in our consolidated financial statements. In 2017 and 2018, we determined that the requirements for consolidation were no longer met with respect to Parion and BioAxone, respectively. As a result, we deconsolidated Parion and BioAxone from our consolidated financial statements as of September 30, 2017 and December 31, 2018, respectively, and did not consolidate any VIEs in 2019.
A collaborator that we account for as a VIE may engage in activities unrelated to our collaboration. The revenues and expenses unrelated to the programs we in-license from our VIEs have historically been immaterial to our consolidated financial statements. With respect to each of Parion and BioAxone, the activities unrelated to our collaborations with these entities represented approximately 2% or less of our total revenues and total expenses on an annual basis during the periods that we consolidated these collaborators.
Out-License Agreements
We also have out-licensed internally-developed programs to collaborators who are leading the development of these programs. These out-license arrangements include our agreements with:
•
Janssen Pharmaceuticals, Inc., or Janssen, which is evaluating pimodivir in Phase 3 clinical trials for the treatment of influenza; and
•
Merck KGaA, Darmstadt, Germany, which licensed oncology research and development programs from us in early 2017.
Pursuant to these out-licensing arrangements, our collaborators are responsible for the research, development and commercialization costs associated with these programs, and we are entitled to receive contingent milestone and/or royalty payments. As a result, we do not expect to incur significant expenses in connection with these programs and have the potential for future collaborative and royalty revenues resulting from these programs.
Please refer to Note B, “Collaborative Arrangements,” for further information regarding our VIEs, in-license agreements and out-license agreements.
Strategic Investments
In connection with our business development activities, we have periodically made equity investments in our collaborators. As of December 31, 2019, we held strategic equity investments in several public companies, including CRISPR, and certain private companies, and we plan to make additional strategic equity investments in the future. While we invest the majority of our cash, cash equivalents and marketable securities in instruments that meet specific credit quality standards and limit our exposure to any one issue or type of instrument, our strategic investments are maintained and managed separately from our other cash, cash equivalents and marketable securities.


50


Until December 31, 2017, changes in the fair value of these strategic investments were reflected on our consolidated balance sheet, but did not affect our net income until the related gains or losses were realized. As a result of accounting guidance, effective January 1, 2018, changes in the fair value of equity investments with readily determinable fair values (including publicly traded securities such as CRISPR) were recorded to other income (expense), net in our consolidated statement of operations in 2019 and 2018. For equity investments without readily determinable fair values including equity investments in private companies, each reporting period we are required to re-evaluate the carrying value of the investment, which may result in other income (expense).
In 2019 and 2018, we recorded within other income (expense), net gains of $197.6 million and $2.6 million related to changes in the fair value of our strategic investments and from sales of certain investments. To the extent that we continue to hold strategic investments, particularly strategic investments in publicly traded companies, we will record other income (expense) related to these strategic investments on a quarterly basis. Due to the high volatility of stocks in the biotechnology industry, we expect the value of these strategic investments to fluctuate and that the increases or decreases in the fair value of these strategic investments will continue to have material impacts on our net income (expense) and our profitability on a quarterly and/or annual basis.


51


RESULTS OF OPERATIONS
 
 
 
 
 
 
 
2019/2018
Comparison
 
2018/2017
Comparison
 
 
 
 
 
 
 
Increase/(Decrease)
 
Increase/(Decrease)
 
2019
 
2018
 
2017
 
$
 
%
 
$
 
%
 
(in thousands)
 
(in thousands, except percentages)
Revenues
$
4,162,821

 
$
3,047,597

 
$
2,488,652

 
$
1,115,224

 
37
%
 
$
558,945

 
22
%
Operating costs and expenses
2,965,255

 
2,412,447

 
2,365,409

 
552,808

 
23
%
 
47,038

 
2
%
Income from operations
1,197,566

 
635,150

 
123,243

 
562,416

 
89
%
 
511,907

 
415
%
Other non-operating income (expense), net
197,353

 
(25,116
)
 
32,917

 
**

 
**

 
**

 
**

Provision for income taxes
218,109

 
(1,486,862
)
 
(107,324
)
 
**

 
**

 
**

 
**

Net income attributable to Vertex
$
1,176,810

 
$
2,096,896

 
$
263,484

 
$
(920,086
)
 
**

 
$
1,833,412

 
**

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income per diluted share attributable to Vertex common shareholders
$
4.51

 
$
8.09

 
$
1.04

 
 
 
 
Diluted shares used in per share calculations
260,673

 
259,185

 
253,225

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
** Not meaningful
Net Income and Income from Operations
Our income from operations increased to $1.20 billion in 2019 compared to $635.2 million in 2018 and $123.2 million in 2017, primarily as a result of the approval of SYMDEKO/SYMKEVI in 2018 and TRIKAFTA in 2019, and continued strong net product revenues from KALYDECO and ORKAMBI. The increased net product revenues were partially offset by increased operating costs and expenses primarily attributable to increased cost of sales due to increased net product revenues and increased research expenses associated with our business development activities.
Net income attributable to Vertex in 2018 included a one-time non-cash benefit from income taxes of $1.56 billion resulting from our release of our valuation allowance. As a result of this one-time cash benefit in 2018, net income attributable to Vertex was higher in 2018 than 2019 and 2017.
Earnings Per Share
In 2019, 2018 and 2017, net income attributable to Vertex was $4.51, $8.09, $1.04, respectively, per diluted share. The higher diluted earnings per share in 2018 as compared to 2019 and 2017 was due primarily to the benefit from income taxes as a result of the release of our valuation allowance, which increased net income attributable to Vertex by $6.03 per diluted share in 2018.
Revenues
 
 
 
 
 
 
 
2019/2018
Comparison
 
2018/2017
Comparison
 
 
 
 
 
 
 
Increase/(Decrease)
 
Increase/(Decrease)
 
2019
 
2018
 
2017
 
$
 
%
 
$
 
%
 
(in thousands)
 
(in thousands, except percentages)
Product revenues, net
$
4,160,726

 
$
3,038,325

 
$
2,165,480

 
$
1,122,401

 
37
 %
 
$
872,845

 
40
 %
Collaborative and royalty revenues
2,095

 
9,272

 
323,172

 
(7,177
)
 
(77
)%
 
(313,900
)
 
(97
)%
Total revenues
$
4,162,821

 
$
3,047,597

 
$
2,488,652

 
$
1,115,224

 
37
 %
 
$
558,945

 
22
 %


52


Product Revenues, Net
 
2019
 
2018
 
2017
 
(in thousands)
TRIKAFTA
$
420,105

 
$
—

 
$
—

SYMDEKO/SYMKEVI
1,417,668

 
768,657

 
—

ORKAMBI
1,331,891

 
1,262,166

 
1,320,850

KALYDECO
991,062

 
1,007,502

 
844,630

Product revenues, net
$
4,160,726

 
$
3,038,325

 
$
2,165,480

In 2019, our net product revenues increased by $1.12 billion as compared to 2018. In 2018, our net product revenues increased by $872.8 million as compared to 2017. The increase in total net product revenues in 2019 was primarily due to the increasing number of patients being treated with SYMDEKO/SYMKEVI, the October 2019 approval of TRIKAFTA in the United States, label expansions for KALYDECO and ORKAMBI and expanded access to our medicines in ex-U.S. markets. In 2019, 2018 and 2017, our net product revenues included product revenues of $1.1 billion, $682.4 million, and 501.8 million, respectively, from ex-U.S. markets.
We expect that our net product revenues will increase in 2020 due to increasing numbers of patients being treated with our medicines as a result of the approval of TRIKAFTA, label expansions for our previously approved products and expanded access to our medicines. TRIKAFTA increases the number of patients eligible for our medicines by providing the first treatment option for a significant number of patients with CF, and provides a new treatment option for many patients who are eligible for one of our previously approved medicines. As a result, the approval of TRIKAFTA in the United States is resulting in increased net product revenues as well as a shift of net product revenues from our previously approved products to TRIKAFTA.
TRIKAFTA
TRIKAFTA was approved by the FDA in October 2019. TRIKAFTA net product revenues were $420.1 million in 2019, all of which were recognized in the fourth quarter of 2019. We recently submitted a MAA to the EMA for the triple combination regimen of elexacaftor, tezacaftor and ivacaftor. We expect TRIKAFTA net product revenues will increase significantly in 2020 as compared to 2019.
SYMDEKO/SYMKEVI
SYMDEKO/SYMKEVI net product revenues were $1.42 billion in 2019 as compared to $768.7 million in 2018. SYMDEKO was approved by the FDA in February 2018 and SYMKEVI was approved in the European Union in November 2018. In the fourth quarter of 2019, some patients in the United States began switching from SYMDEKO to TRIKAFTA.
ORKAMBI
ORKAMBI net product revenues were $1.33 billion in 2019, $1.26 billion in 2018 and $1.32 billion in 2017. We have continued to increase the number of patients eligible for ORKAMBI through label expansions and additional ex-U.S. reimbursement arrangements. These increases in eligible patients have been offset by a portion of the patients who were being treated with ORKAMBI switching to SYMDEKO/SYMKEVI or TRIKAFTA.
From 2015 into the fourth quarter of 2019, we distributed ORKAMBI through early access programs in France. Upon adopting ASC 606, Revenue from Contracts with Customers, in the first quarter of 2018, we began recognizing a portion of the amounts collected related to shipments of ORKAMBI through early access programs as net product revenues, based on an estimated transaction price that reflected the consideration we expected to retain that would not be subject to a significant reversal in amounts recognized. Prior to adopting ASC 606, we had not recognized any net product revenues from sales of ORKAMBI in France because the price was not fixed or determinable at the time of delivery. Upon reaching an agreement with the French government for ORKAMBI in the fourth quarter of 2019, including the final amount for ORKAMBI distributed through early access programs, we recognized an adjustment to increase net product revenues related to prior period shipments of ORKAMBI distributed through early access programs of $155.8 million. Please refer to “Critical Accounting Policies - Revenue Recognition” below for a discussion of our accounting treatment for our early access program for ORKAMBI in France.


53


KALYDECO
KALYDECO net product revenues were $991.1 million in 2019, $1.01 billion in 2018 and $844.6 million in 2017. KALYDECO net product revenues in 2019 were similar to KALYDECO net product revenues in 2018. The increases in 2018 as compared to 2017 were primarily due to additional patients being treated with KALYDECO as we completed reimbursement discussions in various ex-U.S. jurisdictions and as we increased the number of patients eligible to receive KALYDECO through label expansions.
Collaborative and Royalty Revenues
Our collaborative and royalty revenues were $2.1 million, $9.3 million and $323.2 million in 2019, 2018 and 2017, respectively. In 2017, our collaborative and royalty revenues included (i) $230.0 million in revenues related to a one-time upfront payment earned in 2017 from Merck KGaA, Darmstadt, Germany, (ii) a $25.0 million milestone related to our license agreement with Janssen for the treatment of influenza and (iii) $40.0 million in revenues related to upfront and milestone payments earned by one of our VIEs pursuant to a license agreement entered into with a third party. We were not a party to the license agreement between the VIE and the third party, and we had no economic interest in either the license or these milestone payments. In 2017 through 2019, our collaborative and royalty revenues also include a small amount of revenues related to a cash payment we received in 2008 when we sold our rights to certain HIV royalties and reimbursements for research and development activities related to our collaborative arrangements.
Our collaborative revenues have historically fluctuated significantly from one period to another and may continue to fluctuate in the future. Our future royalty revenues will be dependent on if, and when, our collaborators, including Janssen and Merck KGaA, Darmstadt, Germany are able to successfully develop drug candidates that we have out-licensed to them.
Operating Costs and Expenses
 
 
 
 
 
 
 
2019/2018
Comparison
 
2018/2017
Comparison
 
 
 
 
 
 
 
Increase/(Decrease)
 
Increase/(Decrease)
 
2019
 
2018
 
2017
 
$
 
%
 
$
 
%
 
(in thousands)
 
(in thousands, except percentages)
Cost of sales
$
547,758

 
$
409,539

 
$
275,119

 
$
138,219

 
34
%
 
$
134,420

 
49
%
Research and development expenses
1,754,540

 
1,416,476

 
1,324,625

 
338,064

 
24
%
 
91,851

 
7
%
Sales, general and administrative expenses
658,498

 
557,616

 
496,079

 
100,882

 
18
%
 
61,537

 
12
%
Change in fair value of contingent consideration
4,459

 
—

 
—

 
4,459

 
**

 
—

 
**

Restructuring (income) expenses
—

 
(184
)
 
14,246

 
184

 
**

 
(14,430
)
 
**

Intangible asset impairment charges
—

 
29,000

 
255,340

 
(29,000
)
 
**

 
(226,340
)
 
**

Total costs and expenses
$
2,965,255

 
$
2,412,447

 
$
2,365,409

 
$
552,808

 
23
%
 
$
47,038

 
2
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
** Not meaningful
Cost of Sales
Our cost of sales primarily consists of the cost of producing inventories that corresponded to product revenues for the reporting period, plus the third-party royalties payable on our net sales of our products. Pursuant to our agreement with the CFF, our tiered third-party royalties on sales of TRIKAFTA, SYMDEKO/SYMKEVI, KALYDECO and ORKAMBI, calculated as a percentage of net sales, range from the single digits to the sub-teens. As a result of the tiered royalty rate, which resets annually, our cost of sales as a percentage of net product revenues are lower at the beginning of each calendar year.
Over the last several years, our cost of sales has been increasing primarily due to increased net product revenues. Our costs of sales as a percentage of net product revenues has been approximately 13% for each of 2019, 2018 and 2017. In 2020, we expect our total cost of sales will increase due to expected increases in our net product revenues and our cost of sales as a percentage of total net product revenues will be similar to our cost of sales as a percentage of total net product revenues in 2019.


54


Research and Development Expenses
 
 
 
 
 
 
 
2019/2018
Comparison
 
2018/2017
Comparison
 
 
 
 
 
 
 
Increase/(Decrease)
 
Increase/(Decrease)
 
2019
 
2018
 
2017
 
$
 
%
 
$
 
%
 
(in thousands)
 
(in thousands, except percentages)
Research expenses
$
732,772

 
$
438,360

 
$
311,206

 
$
294,412

 
67
%
 
$
127,154

 
41
 %
Development expenses
1,021,768

 
978,116

 
1,013,419

 
43,652

 
4
%
 
(35,303
)
 
(3
)%
Total research and development expenses
$
1,754,540

 
$
1,416,476

 
$
1,324,625

 
$
338,064

 
24
%
 
$
91,851

 
7
 %
Our research and development expenses include internal and external costs incurred for research and development of our drugs and drug candidates and expenses related to certain technology that we acquire or license through business development transactions. We do not assign our internal costs, such as salary and benefits, stock-based compensation expense, laboratory supplies and other direct expenses and infrastructure costs, to individual drugs or drug candidates, because the employees within our research and development groups typically are deployed across multiple research and development programs. These internal costs are significantly greater than our external costs, such as the costs of services provided to us by clinical research organizations and other outsourced research, which we allocate by individual program. All research and development costs for our drugs and drug candidates are expensed as incurred.
Over the past three years, we have incurred $4.5 billion in research and development expenses associated with drug discovery and development. The successful development of our drug candidates is highly uncertain and subject to a number of risks. In addition, the duration of clinical trials may vary substantially according to the type, complexity and novelty of the drug candidate and the disease indication being targeted. The FDA and comparable agencies in foreign countries impose substantial requirements on the introduction of therapeutic pharmaceutical products, typically requiring lengthy and detailed laboratory and clinical testing procedures, sampling activities and other costly and time-consuming procedures. Data obtained from nonclinical and clinical activities at any step in the testing process may be adverse and lead to discontinuation or redirection of development activities. Data obtained from these activities also are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The duration and cost of discovery, nonclinical studies and clinical trials may vary significantly over the life of a project and are difficult to predict. Therefore, accurate and meaningful estimates of the ultimate costs to bring our drug candidates to market are not available.
In 2017, 2018 and 2019, costs related to our CF programs represented the largest portion of our development costs. Any estimates regarding development and regulatory timelines for our drug candidates are highly subjective and subject to change. Until we have data from Phase 3 clinical trials, we cannot make a meaningful estimate regarding when, or if, a clinical development program will generate revenue and cash flow.
Research Expenses
 
 
 
 
 
 
 
2019/2018
Comparison
 
2018/2017
Comparison
 
 
 
 
 
 
 
Increase/(Decrease)
 
Increase/(Decrease)
 
2019
 
2018
 
2017
 
$
 
%
 
$
 
%
 
(in thousands)
 
(in thousands, except percentages)
Research Expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
Salary and benefits
$
134,642

 
$
87,773

 
$
81,229

 
$
46,869

 
53
%
 
$
6,544

 
8
%
Stock-based compensation expense
69,417

 
62,925

 
60,122

 
6,492

 
10
%
 
2,803

 
5
%
Outsourced services and other direct expenses
116,575

 
89,355

 
85,319

 
27,220

 
30
%
 
4,036

 
5
%
Collaboration and asset acquisition expenses
307,828

 
111,600

 
8,425

 
196,228

 
**

 
103,175

 
**

Infrastructure costs
104,310

 
86,707

 
76,111

 
17,603

 
20
%
 
10,596

 
14
%
Total research expenses
$
732,772

 
$
438,360

 
$
311,206

 
$
294,412

 
67
%
 
$
127,154

 
41
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
** Not meaningful


55


We expect to continue to invest in our research programs with a focus on identifying drug candidates with the goal of creating transformative medicines for serious diseases. Our research expenses increased by 67% in 2019 as compared to 2018 primarily as a result of a $196.2 million increase associated with our business development activities, as well as increased expenses related to additional headcount and increased infrastructure costs. In 2019, our business development activities included collaborative upfront and option payments to CRISPR, Kymera and Molecular Templates, which are reflected in “Collaboration and asset acquisition expenses” in the table above. The increase in salary and benefits in 2019 was primarily related to costs associated with our acquisitions of Exonics and Semma. In 2018, our research expenses increased as compared to 2017 primarily due to $111.6 million in expenses associated with our business development activities, including collaborative upfront payments of $65.0 million to Merck KGaA, Darmstadt, Germany and $30.0 million to Arbor.
Development Expenses
 
 
 
 
 
 
 
2019/2018
Comparison
 
2018/2017
Comparison
 
 
 
 
 
 
 
Increase/(Decrease)
 
Increase/(Decrease)
 
2019
 
2018
 
2017
 
$
 
%
 
$
 
%
 
(in thousands)
 
(in thousands, except percentages)
Development Expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
Salary and benefits
$
249,860

 
$
220,128

 
$
208,769

 
$
29,732

 
14
 %
 
$
11,359

 
5
 %
Stock-based compensation expense
155,141

 
140,187

 
121,778

 
14,954

 
11
 %
 
18,409

 
15
 %
Outsourced services and other direct expenses
425,149

 
471,338

 
397,155

 
(46,189
)
 
(10
)%
 
74,183

 
19
 %
Collaboration and asset acquisition expenses
10,440

 
250

 
160,250

 
10,190

 
**

 
(160,000
)
 
**

Infrastructure costs
181,178

 
146,213

 
125,467

 
34,965

 
24
 %
 
20,746

 
17
 %
Total development expenses
$
1,021,768

 
$
978,116

 
$
1,013,419

 
$
43,652

 
4
 %
 
$
(35,303
)
 
(3
)%
 
 
 
 
 
 
 
 
 
** Not meaningful
Our development expenses increased by $43.7 million, or 4%, in 2019 as compared to 2018 and decreased by $35.3 million, or 3%, in 2018 as compared to 2017. The increase in 2019 as compared to 2018 was primarily due to increased headcount and infrastructure costs to support our advancing pipeline and increased milestones related to our collaborative agreements, partially offset by decreased expenses related to our CF programs. The decrease in 2018 as compared to 2017 was primarily due to increased costs associated with clinical trial expenses, including Phase 3 clinical trials evaluating elexacaftor as part of our triple combination regimen, which were more than offset by a $160.0 million payment to Concert Pharmaceuticals Inc. in connection with the acquisition of VX-561 in 2017 for which there were no comparable expenses in 2018.
Sales, General and Administrative Expenses
 
 
 
 
 
 
 
2019/2018
Comparison
 
2018/2017
Comparison
 
 
 
 
 
 
 
Increase/(Decrease)
 
Increase/(Decrease)
 
2019
 
2018
 
2017
 
$
 
%
 
$
 
%
 
(in thousands)
 
(in thousands, except percentages)
Sales, general and administrative expenses
$
658,498

 
$
557,616

 
$
496,079

 
$
100,882

 
18
%
 
$
61,537

 
12
%
Sales, general and administrative expenses increased by 18% in 2019 as compared to 2018, and by 12% in 2018 as compared to 2017. These increases were primarily due to increased global support for our medicines and incremental investment to support the launch of our triple combination regimen. We expect our sales, general and administrative expenses to continue to increase in 2020.
Contingent Consideration
In 2019, the increase in the fair value of contingent consideration of $4.5 million was due to changes in market interest rates and the time value of money related to the contingent development and regulatory milestone payments resulting from our acquisition of Exonics. There were no similar amounts in 2018 or 2017. In future periods, we expect the fair value of


56


contingent consideration to increase or decrease based on, among other things, our estimates of the probability of achieving and the timing of these contingent development and regulatory milestone payments, as well as the time value of money changes in market interest rates.
Restructuring Expenses
We did not record any restructuring expenses in 2019. Restructuring income was insignificant in 2018. In 2017, we recorded restructuring expenses of $14.2 million, primarily related to our decision to consolidate our research activities into our Boston, Milton Park and San Diego locations and to close our research site in Canada.
Intangible Asset Impairment Charge
In 2018, we recorded a $29.0 million impairment charge related to VX-210 that was licensed from BioAxone in 2014. In 2017, we recorded a $255.3 million impairment charge related to Parion’s pulmonary ENaC platform that we licensed from Parion in 2015 and a benefit from income taxes of $97.7 million related to this impairment charge. Both of these impairment charges, and the related benefits from income taxes, were attributable to non-controlling interest because we consolidated these entities as VIEs. There were no corresponding intangible asset impairment charges in 2019.
Other Non-Operating Income (Expense), Net
Interest Income
Interest income increased from $11.7 million in 2017 to $38.4 million in 2018 and $63.7 million in 2019, primarily due to an increase in our cash equivalents and marketable securities and prevailing market interest rates. Our future interest income will be dependent on the amount of, and prevailing market interest rates on, our outstanding cash equivalents and marketable securities.
Interest Expense
Interest expense was $58.5 million in 2019, $72.5 million in 2018 and $69.3 million in 2017. The majority of our interest expense in these periods was related to imputed interest expense associated with our leased corporate headquarters in Boston and our research site in San Diego. On January 1, 2019, we adopted ASC 842, Leases, which resulted in a reduction in our imputed interest expense associated with these leases beginning in 2019. Our future interest expense will be dependent on whether, and to what extent, we borrow amounts under our credit facility.
Other Income (Expense), Net
In 2019, we recorded net other income of $192.2 million primarily related to changes in the fair value of our strategic investments. In 2018, we recorded net other expense of $0.8 million. In 2017, we recorded net other expense of $81.4 million primarily related to the deconsolidation of Parion.
In 2019 and 2018, our other income (expense), net included realized and unrealized gains totaling $197.6 million and $2.6 million, respectively, related to our strategic investments. We expect that, due to the volatility of the stock price of biotechnology companies, our other income (expense), net will fluctuate in future periods based on increases or decreases in the fair value of our strategic investments.


57


Noncontrolling Interest (VIEs)
In 2019, we had no noncontrolling interest because we did not consolidate any VIEs into our consolidated statement of operations. In 2018 and 2017, the net loss attributable to noncontrolling interest recorded on our consolidated statements of operations reflects Parion (through September 30, 2017) and BioAxone’s (through December 31, 2018) net loss for the reporting period, adjusted for any changes in the noncontrolling interest holders’ claim to net assets, including contingent milestone, royalty and option payments. A summary of net loss attributable to noncontrolling interest related to our VIEs for 2018 and 2017 is as follows:
 
2018
 
2017
 
(in thousands)
Loss attributable to noncontrolling interest before benefit from income taxes and changes in fair value of contingent payments
$
31,191

 
$
223,379

Benefit from income taxes
(3,668
)
 
(114,090
)
(Increase) decrease in fair value of contingent payments
(17,730
)
 
62,560

Net loss attributable to noncontrolling interest
$
9,793

 
$
171,849

In 2018, the net loss attributable to noncontrolling interest was primarily related to the $29.0 million impairment charge related to VX-210 offset by an increase in the fair value of the contingent payments payable by us to BioAxone of $17.7 million. In 2017, the net loss attributable to noncontrolling interest was primarily related to the $255.3 million impairment charge related to Parion’s pulmonary ENaC platform, a decrease in fair value of the contingent payments payable by us to Parion of $69.6 million upon deconsolidation and a benefit from income taxes of $126.2 million related to these charges.
Income Taxes
In 2017 and 2018, we were profitable from a U.S. federal income tax perspective and used a portion of our net operating losses to offset this income since becoming profitable. Until the fourth quarter of 2018, we maintained a valuation allowance on the majority of our net operating losses and other deferred tax assets. Due to this valuation allowance, we did not record a significant provision for income taxes in 2017 and the nine months ended September 30, 2018. In the fourth quarter of 2018, we released the valuation allowance, resulting in a non-cash credit to net income of $1.56 billion. Further information on the release of the valuation allowance and significant judgments related to its release can be found below in “Critical Accounting Policies - Income Taxes.”
In 2019, we recorded a provision for income taxes of $218.1 million. Starting in 2019, we began recording a provision for income taxes approximating statutory rates on our pre-tax income and continued to utilize our net operating losses to offset income. Our effective tax rate for 2019 is lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation and research and development tax credits partially offset by a change in our valuation allowance as well as the tax impact of our officers’ compensation. Due to our ability to offset our pre-tax income against previously benefited net operating losses, we expect the majority of our tax provision to represent a non-cash expense until our net operating losses have been fully utilized.
In 2017, we recorded a benefit from income taxes of $107.3 million, primarily due to a total benefit from income taxes of $114.1 million attributable to noncontrolling interest related to the impairment of Parion’s pulmonary ENaC platform and decrease in the fair value of the contingent payments payable by us to Parion.
LIQUIDITY AND CAPITAL RESOURCES
The following table summarizes the components of our financial condition as of December 31, 2019 and 2018:
 
 
 
 
 
Increase/(Decrease)
 
2019
 
2018
 
$
 
%
 
(in thousands, except percentages)
Cash, cash equivalents and marketable securities
$
3,808,294

 
$
3,168,242

 
$
640,052

 
20
 %
Working Capital:
 
 
 
 
 
 
 
Total current assets
$
4,822,829

 
$
3,843,109

 
$
979,720

 
25
 %
Total current liabilities
(1,334,827
)
 
(1,120,292
)
 
(214,535
)
 
(19
)%
Total working capital
$
3,488,002

 
$
2,722,817

 
$
765,185

 
28
 %


58


As of December 31, 2019, total working capital was $3.5 billion, which represented an increase of $765.2 million from $2.7 billion as of December 31, 2018. The most significant items that increased total working capital in 2019 were $1.6 billion of cash provided by operations and $343.2 million of cash received from issuances of common stock under our employee benefit plans and partially offset by $1.2 billion of cash used to acquire Exonics and Semma and $192.0 million of cash used to repurchase shares of our common stock.
Sources of Liquidity
As of December 31, 2019, we had cash, cash equivalents and marketable securities of $3.8 billion, which represented an increase of $640.1 million from $3.2 billion as of December 31, 2018. We intend to rely on our existing cash, cash equivalents and marketable securities together with cash flows from product sales as our primary source of liquidity.
We may borrow up to $500.0 million pursuant to a revolving credit facility that we entered into in 2019. We may repay and reborrow amounts under the revolving credit agreement without penalty. Subject to certain conditions, we may request that the borrowing capacity under this credit agreement be increased by an additional $500.0 million, up to a total of $1.0 billion. Other possible sources of future liquidity include commercial debt, public and private offerings of our equity and debt securities, strategic sales of assets or businesses and financial transactions. Negative covenants in our credit agreement may prohibit or limit our ability to access these sources of liquidity.
Future Capital Requirements
We have significant future capital requirements including:
•
significant expected operating expenses to conduct research and development activities and to operate our organization; and
•
substantial facility and capital lease obligations, including leases for two buildings in Boston, Massachusetts that continue through 2028.
In addition:
•
We have entered into certain collaboration agreements with third parties that include the funding of certain research, development and commercialization efforts with the potential for future milestone and royalty payments by us upon the achievement of pre-established developmental and regulatory targets and/or commercial targets, and we may enter into additional business development transactions, including acquisitions, collaborations and equity investments, that require additional capital.
•
We have reached an agreement with the French government and will repay a portion of the amounts we have collected under the ORKAMBI early access programs in France to the French government in 2020 based on the difference between the invoiced amount and the final amount for ORKAMBI distributed through these programs as reflected in the structure of the agreement with the French government.
•
To the extent we borrow amounts under the credit agreement we entered into in 2019, we would be required to repay any outstanding principal amounts in 2024.
As of December 31, 2019, $464.0 million remained available to fund repurchases under the 2019 Share Repurchase Program that we announced in July 2019.
We expect that cash flows from our products together with our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. The adequacy of our available funds to meet our future operating and capital requirements will depend on many factors, including the amounts of future revenues generated by our products, and the potential introduction of one or more of our other drug candidates to the market, the level of our business development activities and the number, breadth, cost and prospects of our research and development programs.
Financing Strategy
We may raise additional capital by borrowing under credit agreements, through public offerings or private placements of our securities or securing new collaborative agreements or other methods of financing. We will continue to manage our capital structure and will consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.


59


CONTRACTUAL COMMITMENTS AND OBLIGATIONS
The following table sets forth our commitments and obligations as of December 31, 2019:
 
Payments Due by Period
 
2020
 
2021-2022
 
2023-2024
 
2025 and later
 
Total
 
(in thousands)
Fan Pier Leases
$
66,540

 
$
145,177

 
$
150,560

 
$
311,884

 
$
674,161

Finance leases, excluding Fan Pier Leases
17,724

 
31,355

 
25,499

 
113,367

 
187,945

Operating leases
14,598

 
49,778

 
67,451

 
368,597

 
500,424

Research and development costs
51,934

 
565

 
18

 
—

 
52,517

Total contractual commitments and obligations
$
150,796

 
$
226,875

 
$
243,528

 
$
793,848

 
$
1,415,047

Leases
We lease two buildings that are located at Fan Pier in Boston, Massachusetts. We commenced lease payments on these two buildings in December 2013 and the initial lease periods end in December 2028. We also lease office and laboratory space in San Diego, California. We commenced lease payments for this building in the second quarter of 2019 pursuant to a 16 year lease. The future minimum rental payments that we are obligated to pay related to the San Diego building are included in “Finance leases, excluding Fan Pier Leases,” which also reflects leases of equipment that are accounted for as finance leases. The remainder of our real estate leases are reflected in “Operating leases” in the table above.
Research and Development Costs
The amounts reflected in “Research and development costs” do not include certain payments we anticipate making to clinical research organizations, or CROs, because these contracts are cancelable, at our option, with notice. However, we historically have not cancelled such contracts. As of December 31, 2019, we had accrued $40.2 million related to these contracts for costs incurred for services provided through December 31, 2019, and we have approximately $200.6 million in cancelable future commitments based on existing contracts as of December 31, 2019. These amounts reflect planned expenditures based on existing contracts and do not reflect any future modifications to, or terminations of, existing contracts or anticipated or potential new contracts.
Collaborative Arrangements and Asset Acquisitions
We have entered into certain research and development collaboration agreements with third parties and acquired certain assets that include the funding of certain development, manufacturing and commercialization efforts with the potential for future milestone and royalty payments by us upon the achievement of pre-established developmental, regulatory and/or commercial targets. Our obligation to fund these efforts is contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause the discontinuance of the programs. These payments include:
•
CFF: We pay royalties, which are included in cost of sales, to CFF on sales of our CF products.
•
Research and Development Milestones: The majority of our in-license agreements and our acquisitions have milestone and royalty payments payable by us upon the successful achievement of pre-established developmental, regulatory and/or commercial targets or net sales. Contingent payments under these agreements become due and payable only upon achievement of certain milestones and are not included in the contractual obligations table above.
Tax-related Obligations
We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of December 31, 2019, our liabilities associated with uncertain tax positions were $33.9 million.


60


Other Funding Commitments
Our table detailing contractual commitments and obligations does not include severance payment obligations to certain of our executive officers in the event of a not-for-cause employment termination under existing employment contracts. We will provide information regarding these obligations annually in our proxy statement for our annual meeting of shareholders.
In addition, we began distributing ORKAMBI through early access programs in France in 2015. We received payment from the French government based on the invoiced amount and remained in reimbursement discussions for ORKAMBI in France until November 2019, when we reached an agreement for historical and future shipments of ORKAMBI with the French government. Based on the structure of the agreement with the French government, we will pay the difference between the amounts collected based on the invoiced amount and the final amount for ORKAMBI distributed through early access programs to the French government in 2020.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These items are monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are reflected in reported results for the period in which the change occurs. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate.
We believe that our application of the following accounting policies, each of which requires significant judgments and estimates on the part of management, are the most critical to aid in fully understanding and evaluating our reported financial results:
•
revenue recognition;
•
acquisitions, including intangible assets, goodwill and contingent consideration; and
•
income taxes.
Our accounting policies, including the ones discussed below, are more fully described in the Notes to our consolidated financial statements, including Note A, “Nature of Business and Accounting Policies,” included in this Annual Report on Form 10-K.


61


Revenue Recognition
Product Revenues, Net
We generate product revenues from sales in the United States and in international markets. We sell our products principally to a limited number of specialty pharmacy and specialty distributors in the United States, which account for the largest portion of our total revenues, and make international sales primarily to specialty distributors and retail chains, as well as hospitals and clinics, many of which are government-owned or supported customers, collectively, our customers. Our customers in the United States subsequently resell our products to patients and health care providers. We contract with government agencies so that our products will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. We recognize net product revenues from sales of our products when our customers obtain control of our products, which typically occurs upon delivery to our customers. Revenues from our product sales are recorded at the net sales price, or “transaction price,” which requires us to make several significant estimates regarding the net sales price.
The most significant estimate we are required to make is related to government and private payor rebates, chargebacks, discounts and fees, collectively rebates. The value of the rebates provided to third-party payors per course of treatment vary significantly and are based on government-mandated discounts and our arrangements with other third-party payors. In order to estimate our total rebates, we estimate the percentage of prescriptions that will be covered by each third-party payor, which is referred to as the payor mix. We track available information regarding changes, if any, to the payor mix for our products, to our contractual terms with third-party payors and to applicable governmental programs and regulations and levels of our products in the distribution channel. We adjust our estimated rebates based on new information, including information regarding actual rebates for our products, as it becomes available. Claims by third-party payors for rebates are submitted to us significantly after the related sales, potentially resulting in adjustments in the period in which the new information becomes known. Our credits to revenue related to prior period sales, excluding the adjustment to the transaction price for ORKAMBI distributed through early access programs in France, have not been significant (typically less than 1% of gross product revenues) and primarily related to U.S. rebates.
The following table summarizes activity related to our accruals for rebates (including our refund liability to the French government related to ORKAMBI distributed through early access programs in France as described below) for the three years ended December 31, 2019:
 
(in thousands)
Balance as of December 31, 2016
$
81,927

Provision related to current year sales
176,996

Adjustments related to prior year(s) sales
(8,943
)
Credits/payments made
(137,765
)
Balance as of December 31, 2017
$
112,215

Provision related to current year sales and the adoption of ASC 606
684,299

Adjustments related to prior year(s) sales
(22,099
)
Credits/payments made
(229,361
)
Balance as of December 31, 2018
$
545,054

Provision related to current year sales
655,980

Adjustments related to prior year(s) sales
(95,480
)
Credits/payments made
(469,832
)
Balance as of December 31, 2019
$
635,722

We have also entered into annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. We defer a portion of the consideration received, which includes upfront payments and fees, for shipments made up to the annual reimbursement limit as “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. In order to estimate the portion of the consideration received to recognize as revenue and the portion of the amount to defer, we rely on our forecast of the number of units we will distribute during the applicable annual period in each international market in which our contracts with government-owned and supported customers limit the amount of annual reimbursement we can receive. Our forecasts are based on, among other things, our historical experience.


62


The preceding estimates and judgments materially affect our recognition of net product revenues. Changes in our estimates of net product revenues could have a material effect on net product revenues recorded in the period in which we determine that change occurs.
French Early Access Programs
In 2015, we began distributing ORKAMBI through early access programs in France and remained engaged in reimbursement discussions with the French government for ORKAMBI, including ORKAMBI distributed through early access programs, until November 2019, when we reached an agreement with the French government. From the time we began distributing ORKAMBI through early access programs in France, we have expected that the difference between the amounts collected based on the invoiced amount and the final amount for ORKAMBI distributed through these programs would be returned to the French government. Our refund liability related to the early access programs in France is classified in “Accrued expenses” on our consolidated balance sheets.
Pursuant to the revenue recognition accounting guidance that was applicable until December 31, 2017, our ORKAMBI net product revenues for 2015, 2016 and 2017 did not include any net product revenues from sales of ORKAMBI in France. Upon adopting ASC 606, in the first quarter of 2018, we began recognizing ORKAMBI net product revenues in France based on a transaction price that reflected our estimate of consideration we expected to retain that would not be subject to a significant reversal in amounts recognized, which resulted in revenue representing a portion of the invoiced amount. We recognized ORKAMBI net product revenues from shipments of ORKAMBI in France based on this estimate from the first quarter of 2018 through the third quarter of 2019.
Upon reaching an agreement with the French government for ORKAMBI, including the final amount for ORKAMBI distributed through early access programs in France in the fourth quarter of 2019, we updated the transaction price related to ORKAMBI distributed through early access programs and recognized net product revenues of $155.8 million related to these shipments, which occurred from 2015 through the date of our agreement with the French government, because the final amount for these shipments exceeded our previous estimate.
Acquisitions
We are required to make several significant judgments and estimates in order to calculate the purchase price for our business combinations and then allocate it to the assets that we have acquired and the liabilities that we have assumed on our consolidated balance sheet. The most significant judgments and estimates relate to the fair value of the in-process research and development assets and contingent consideration liabilities related to these business combinations. Based on these judgments and estimates, the fair value of the goodwill that we record as a result of these business combinations may be material. Once recorded, these assets are subject to quarterly impairment analysis and our contingent consideration liability is adjusted quarterly, which requires similar judgments and estimates.
Intangible Assets
In 2019, we recorded in-process research and development assets related to our acquisitions of Exonics and Semma totaling $400.0 million on our consolidated balance sheet. Each of these assets is accounted for as an indefinite-lived intangible asset and is maintained on our consolidated balance sheet until either the project underlying it is completed or the asset becomes impaired. When we determine that an asset has become impaired or we abandon a project, we write down the carrying value of the related intangible asset to its fair value and record an impairment charge in the period in which the impairment occurs. In 2018 and 2017, we recorded full impairment charges of $29.0 million and $255.3 million for the in-process research and development assets that had previously been recorded on our consolidated balance sheets related to our collaborations with BioAxone and Parion, respectively.
To determine the fair value of our in-process research and development assets, we utilize the multi-period excess earnings method of the income approach, which requires us to make estimates of the probability of technical and regulatory success, development cost assumptions, revenue projections and growth rates, commercial cost estimates and appropriate discount rates. These assumptions require significant management judgment and reasonable changes in the assumptions can cause material changes to the fair value of the intangible assets. Due to the pre-clinical nature of Exonics and Semma’s programs, these significant assumptions could be affected by future economic and market conditions.
Contingent Consideration
As of December 31, 2019, we recorded $176.5 million of liabilities on our consolidated balance sheet attributable to the fair value of the contingent development and regulatory payments that we may owe to Exonics’ former equity holders upon


63


the achievement of certain events. Our acquisition of Semma did not include similar contingent payments; therefore, we are not required to record contingent consideration liabilities related to our acquisition of Semma.
We record an increase or a decrease in the fair value of the contingent consideration liability on our consolidated balance sheet and in our consolidated statement of operations on a quarterly basis. We determine the fair value of our contingent consideration liability using a probability weighted discounted cash flow method of the income approach, which requires us to make estimates of the timing of regulatory and commercial milestone achievement and the corresponding estimated probability of technical and regulatory success rates. Significant judgment is used in determining the appropriateness of these assumptions during each reporting period. Reasonable changes in these assumptions can cause material changes to the fair value of our contingent consideration liability. Due to the pre-clinical nature of Exonics’ DMD and DM1 programs, these significant assumptions could be affected by future economic and market conditions.
Goodwill
In 2019, we recorded goodwill of $554.6 million and $397.1 million related to our acquisitions of Semma and Exonics, respectively. Goodwill reflects the difference between the fair value of the consideration transferred and the fair value of the net assets acquired. Thus, the goodwill that we record is dependent on the significant judgments and estimates inherent in the fair value of our in-process research and development assets and contingent consideration liabilities.
Income Taxes
We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities using enacted tax rates in effect for years in which the temporary differences are expected to reverse. If our estimate of the tax effect of reversing temporary differences is (i) not reflective of actual outcomes, (ii) modified to reflect new developments or interpretations of the tax law, or (iii) revised to incorporate new accounting principles, or changes in the expected timing or manner of the reversal, our results of operations could be materially impacted.
We are engaged in research and development activities and incurred significant net operating losses for a number of years before recently becoming profitable. Since we started generating profits, we have used a portion of our net operating losses and maintained a valuation allowance on the majority of our net operating losses and other deferred tax assets until December 31, 2018. Accordingly, we did not report any tax benefits relating to our net operating loss carryforwards and income tax credit carryforwards that are available for utilization in future periods. As of December 31, 2018, we released the valuation allowance on the majority of our net operating losses and other deferred tax assets resulting in a non-cash benefit from income taxes of $1.56 billion in the fourth quarter of 2018.
We provide a valuation allowance when it is more likely than not that deferred tax assets will not be realized. On a periodic basis, we reassess our valuation allowances on our deferred tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In the fourth quarter of 2018, we reassessed our valuation allowances and considered positive evidence including significant cumulative consolidated and U.S. income over the three years ended December 31, 2018, revenue growth, clinical program progression, including the advancement and clinical trial data from our triple combination regimens, and expectations regarding future profitability, and negative evidence, including potential impact of competition on our projections and cumulative losses in the jurisdictions. After assessing both the positive evidence and the negative evidence, we released the valuation allowance on the majority of our net operating losses and other deferred tax assets as of December 31, 2018.
Significant judgment is required in making these assessments to maintain or reverse our valuation allowances and, to the extent our future expectations change we would have to assess the recoverability of these deferred tax assets at that time. The determination to release the majority of our valuation allowances increased our net income by $1.56 billion, or $6.03 per share in 2018. In 2019, we recorded a significant provision for income tax, which was the result of utilizing previously benefitted deferred tax assets.
RECENT ACCOUNTING PRONOUNCEMENTS
Refer to Note A, “Nature of Business and Accounting Policies,” in the accompanying notes to the consolidated financial statements for a discussion of recent accounting pronouncements and new accounting pronouncements adopted during 2019.
ITEM 7A.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As part of our investment portfolio, we own financial instruments that are sensitive to market risks. The investment portfolio is used to preserve our capital until it is required to fund operations, including our research and development


64


activities. None of these market risk-sensitive instruments are held for trading purposes. We do not have derivative financial instruments in our investment portfolio.
Interest Rate Risk
We invest our cash in a variety of financial instruments, principally securities issued by the U.S. government and its agencies, investment-grade corporate bonds and commercial paper, and money market funds. These investments are denominated in U.S. Dollars. All of our interest-bearing securities are subject to interest rate risk and could decline in value if interest rates fluctuate. Substantially all of our investment portfolio consists of marketable securities with active secondary or resale markets to help ensure portfolio liquidity, and we have implemented guidelines limiting the term-to-maturity of our investment instruments. Due to the conservative nature of these instruments, we do not believe that we have a material exposure to interest rate risk. If interest rates were to increase or decrease by 1%, the fair value of our investment portfolio would increase or decrease by an immaterial amount.
In 2019, we entered into a credit agreement. Loans under the credit agreement bear interest, at our option, at either a base rate or a Eurocurrency rate, in each case plus an applicable margin. The applicable margin on base rate loans ranges from 0.125% to 0.50% and the applicable margin on Eurocurrency loans ranges from 1.125% to 1.50%, in each case, based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period). We do not believe that changes in interest rates related to the credit agreement would have a material effect on our financial statements. As of December 31, 2019, we had no principal or interest outstanding. A portion of our “Interest expense” in 2020 will be dependent on whether, and to what extent, we borrow amounts under the existing facility.
Foreign Exchange Market Risk
As a result of our foreign operations, we face exposure to movements in foreign currency exchange rates, primarily the Euro and British Pound against the U.S. Dollar. The current exposures arise primarily from cash, accounts receivable, intercompany receivables and payables, payables and accruals and inventories. Both positive and negative effects to our net revenues from international product sales from movements in exchange rates are partially mitigated by the natural, opposite effect that exchange rates have on our international operating costs and expenses.
We have a foreign currency management program with the objective of reducing the effect of exchange rate fluctuations on our operating results and forecasted revenues and expenses denominated in foreign currencies. We currently have cash flow hedges for the Euro, British Pound, Canadian Dollar and Australian Dollar related to a portion of our forecasted product revenues that qualify for hedge accounting treatment under U.S. GAAP. We do not seek hedge accounting treatment for our foreign currency forward contracts related to monetary assets and liabilities that impact our operating results. As of December 31, 2019, we held foreign exchange forward contracts that were designated as cash flow hedges with notional amounts totaling $728.4 million and had a net fair value of $2.4 million recorded on our consolidated balance sheet.
Although not predictive in nature, we believe a hypothetical 10% threshold reflects a reasonably possible near-term change in exchange rates. Assuming that the December 31, 2019 exchange rates were to change by a hypothetical 10%, the fair value recorded on our consolidated balance sheet related to our foreign exchange forward contracts that were designated as cash flow hedges as of December 31, 2019 would change by approximately $72.8 million. However, since these contracts hedge a specific portion of our forecasted product revenues denominated in certain foreign currencies, any change in the fair value of these contracts is recorded in “Accumulated other comprehensive (loss) income” on our consolidated balance sheet and is reclassified to earnings in the same periods during which the underlying product revenues affect earnings. Therefore, any change in the fair value of these contracts that would result from a hypothetical 10% change in exchange rates would be entirely offset by the change in value associated with the underlying hedged product revenues resulting in no impact on our future anticipated earnings and cash flows with respect to the hedged portion of our forecasted product revenues.
ITEM 8.
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The information required by this Item 8 is contained on pages F-1 through F-59 of this Annual Report on Form 10-K.
ITEM 9.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
Not applicable.


65


ITEM 9A.
CONTROLS AND PROCEDURES
(1) Evaluation of Disclosure Controls and Procedures. The Company’s chief executive officer and chief financial officer, after evaluating the effectiveness of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Annual Report on Form 10-K, have concluded that, based on such evaluation, the Company’s disclosure controls and procedures were effective. In designing and evaluating the disclosure controls and procedures, the Company’s management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and the Company’s management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
(2) Management’s Annual Report on Internal Control Over Financial Reporting. The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) and Rule 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, the Company’s principal executive and principal financial officers and effected by the Company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The Company’s internal control over financial reporting includes those policies and procedures that:
•
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
•
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
•
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
The Company’s management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2019. In making this assessment, it used the criteria set forth in the Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on its assessment, the Company’s management has concluded that, as of December 31, 2019, the Company’s internal control over financial reporting is effective based on those criteria.
On July 16, 2019 and October 10, 2019, the Company completed its acquisition of Exonics Therapeutics, Inc. (“Exonics”) and Semma Therapeutics, Inc. (“Semma”), respectively.  As a result, management has excluded the operations of Exonics and Semma from its assessment of internal control over financial reporting.  The total and net assets of Exonics and Semma excluded from management’s assessment represent less than 1% of the Company’s related consolidated financial statement amounts, as of and for the year ended December 31, 2019. The total costs and expenses of each of Exonics and Semma excluded from management’s assessment represent 1.4%, of the Company’s related consolidated financial statement amounts, as of and for the year ended December 31, 2019.
The Company’s independent registered public accounting firm, Ernst & Young LLP, issued an attestation report on the Company’s internal control over financial reporting. See Section 4 below.
(3) Changes in Internal Controls. The Company’s management has extended its oversight and monitoring processes that support internal control over financial reporting to include operations of Exonics and Semma. The Company’s management is continuing to integrate the acquired operations of Exonics and Semma into the Company’s overall internal control over financial reporting process. However, management has excluded Exonics and Semma from its assessment of internal controls over financial reporting set forth above.
During the quarter ended December 31, 2019, there were no other changes in the Company’s internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.


66


(4) Report of Independent Registered Public Accounting Firm
To the Shareholders and the Board of Directors of
Vertex Pharmaceuticals Incorporated

Opinion on Internal Control over Financial Reporting
We have audited Vertex Pharmaceuticals Incorporated’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Vertex Pharmaceuticals Incorporated (the “Company”) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on the COSO criteria.
As indicated in the accompanying Management’s Annual Report on Internal Control Over Financial Reporting, management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of Semma Therapeutics, Inc. and Exonics Therapeutics, Inc., which are included in the 2019 consolidated financial statements of the Company and constituted less than 1% of the Company’s total and net assets, respectively, as of December 31, 2019 and 1.4% of the Company’s total costs and expenses for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of Semma Therapeutics, Inc. and Exonics Therapeutics, Inc.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of Vertex Pharmaceuticals Incorporated as of December 31, 2019 and 2018, the related consolidated statements of operations, comprehensive income (loss), shareholders’ equity and noncontrolling interest, and cash flows for each of the three years in the period ended December 31, 2019, and the related notes and our report dated February 13, 2020 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission of the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.


67


/s/ Ernst & Young LLP
 
Boston, Massachusetts
February 13, 2020


68


ITEM 9B.
OTHER INFORMATION
On February 13, 2020, Dr. Kewalramani was elected to our Board of Directors. Under her employment agreement, Dr. Kewalramani had been scheduled to join our Board of Directors on April 1, 2020. In addition, there are no transactions involving the Company and Dr. Kewalramani that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.


69


PART III
Portions of our definitive Proxy Statement for the 2020 Annual Meeting of Shareholders, or 2020 Proxy Statement, are incorporated by reference into this Part III of our Annual Report on Form 10-K.
ITEM 10.
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The information regarding directors required by this Item 10 will be included in our 2020 Proxy Statement and is incorporated herein by reference. We expect this information to be provided under “Election of Directors,” “Corporate Governance and Risk Management,” “Shareholder Proposals for the 2020 Annual Meeting and Nominations for Director,” “Delinquent Section 16(a) Reports” and “Code of Conduct.” The information regarding executive officers required by this Item 10 is included in Part I of this Annual Report on Form 10-K.
ITEM 11.
EXECUTIVE COMPENSATION
The information required by this Item 11 will be included in the 2020 Proxy Statement and is incorporated herein by reference. We expect this information to be provided under “Compensation Committee Interlocks and Insider Participation,” “Compensation Discussion and Analysis,” “Compensation and Equity Tables,” “Director Compensation,” “Management Development and Compensation Committee Report” and/or “Corporate Governance and Risk Management.”
ITEM 12.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The information required by this Item 12 will be included in the 2020 Proxy Statement and is incorporated herein by reference. We expect this information to be provided under “Security Ownership of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information.”
ITEM 13.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
The information required by this Item 13 will be included in the 2020 Proxy Statement and is incorporated herein by reference. We expect this information to be provided under “Election of Directors,” “Corporate Governance and Risk Management,” and “Audit and Finance Committee.”
ITEM 14.
PRINCIPAL ACCOUNTANT FEES AND SERVICES
The information required by this Item 14 will be included in the 2020 Proxy Statement and is incorporated herein by reference. We expect this information to be provided under “Ratification of the Appointment of Independent Registered Public Accounting Firm.”


70


PART IV
ITEM 15.
EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a)(1) The Financial Statements required to be filed by Items 8 and 15(c) of Form 10-K, and filed herewith, are as follows:
 
Page Number in
this Form 10-K
Report of Independent Registered Public Accounting Firm
Consolidated Statements of Operations for the years ended December 31, 2019, 2018 and 2017
Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2019, 2018 and 2017
Consolidated Balance Sheets as of December 31, 2019 and 2018
Consolidated Statements of Shareholders’ Equity and Noncontrolling Interest for the years ended December 31, 2019, 2018 and 2017
Consolidated Statements of Cash Flows for the years ended December 31, 2019, 2018 and 2017
Notes to Consolidated Financial Statements
(a)(2) Financial Statement Schedules have been omitted because they are either not applicable or the required information is included in the consolidated financial statements or notes thereto listed in (a)(1) above.
(a)(3) Exhibits.
The following is a list of exhibits filed as part of this Annual Report on Form 10-K.
Exhibit Number
Exhibit Description
Filed with
this report
Incorporated by
Reference herein
from—Form
or Schedule
Filing Date/
Period Covered
SEC File/
Reg.  Number
Plan of Acquisition
 
 
 
2.1
 
10-Q
 (Exhibit 2.1)
October 31, 2019
000-19319
2.2
 
10-Q
 (Exhibit 10.1)
August 1, 2019
000-19319
Governance Documents
 
 
 
3.1
 
10-Q
(Exhibit 3.1)
July 26, 2018
000-19319
3.2
 
10-Q
(Exhibit 3.2)
July 26, 2018
000-19319
Stock Certificate
 
 
 
4.1
 
10-K (Exhibit 4.1)
February 15, 2018
000-19319
4.2
X
 
 
 
Collaboration Agreement
 
 
 
10.1
 
10-Q/A
(Exhibit 10.2)
August 19, 2011
000-19319
10.2
 
10-K
(Exhibit 10.9)
March 16, 2006
000-19319
10.3
 
10-Q/A
(Exhibit 10.6)
August 19, 2011
000-19319


71


Exhibit Number
Exhibit Description
Filed with
this report
Incorporated by
Reference herein
from—Form
or Schedule
Filing Date/
Period Covered
SEC File/
Reg.  Number
10.4
 
10-Q
(Exhibit 10.3)
August 9, 2011
000-19319
10.5
 
10-K
(Exhibit 10.05)
February 23, 2017
000-19319
Leases
 
 
 
10.6
 
10-Q
(Exhibit 10.4)
August 9, 2011
000-19319
10.7
 
10-Q
(Exhibit 10.5)
August 9, 2011
000-19319
Financing Agreements
10.8

 
10-Q
(Exhibit 10.1)
October 31, 2019
000-19319
Equity Plans
 
 
 
10.9
 
10-Q
(Exhibit 10.1)
October 25, 2018
000-19319
10.10
 
8-K
(Exhibit 10.2)
May 15, 2006
000-19319
10.11
 
10-K
(Exhibit 10.20)
February 13, 2015
000-19319
10.12
 
DEF 14A
(Appendix A)
April 26, 2019
000-19319
10.13
 
10-K
(Exhibit 10.17)
February 13, 2015
000-19319
10.14
 
10-K
(Exhibit 10.18)
February 13, 2015
000-19319
10.15
 
10-K
(Exhibit 10.25)
February 16, 2016
000-19319
10.16
 
10-K
(Exhibit 10.19)
February 13, 2015
000-19319
10.17
X
 
 
 
10.18
 
10-K
(Exhibit 10.27)
February 16, 2016
000-19319
10.19
 
DEF 14A
(Appendix B)
April 26, 2019
000-19319
Agreements with Executive Officers and Directors
 
 
 
10.20
 
8-K
(Exhibit 10.1)
December 2, 2016
000-19319
10.21
 
10-K
(Exhibit 10.35)
February 22, 2012
000-19319
10.22
 
8-K
(Exhibit 10.3)
July 25, 2019
000-19319
10.23
 
8-K
(Exhibit 10.1)
July 25, 2019
000-19319
10.24
 
8-K
(Exhibit 10.2)
July 25, 2019
000-19319
10.25
 
10-Q
(Exhibit 10.1)
November 6, 2012
000-19319
10.26
 
10-Q
(Exhibit 10.2)
November 6, 2012
000-19319
10.27
 
10-K
(Exhibit 10.34)
February 16, 2016
000-19319
10.28
 
10-K
(Exhibit 10.35)
February 16, 2016
000-19319


72


Exhibit Number
Exhibit Description
Filed with
this report
Incorporated by
Reference herein
from—Form
or Schedule
Filing Date/
Period Covered
SEC File/
Reg.  Number
10.29
 
10-K
 (Exhibit 10.40)
February 23, 2017
000-19319
10.30
 
10-K
 (Exhibit 10.41)
February 23, 2017
000-19319
10.31
 
10-K
 (Exhibit 10.42)
February 23, 2017
000-19319
10.32
 
10-K
 (Exhibit 10.43)
February 23, 2017
000-19319
10.33
 
10-Q
(Exhibit 10.1)
May 1, 2019
000-19319
10.34
 
10-Q
(Exhibit 10.2)
May 1, 2019
000-19319
10.35
X
 
 
 
10.36
 
10-Q
(Exhibit 10.13)
November 9, 2004
000-19319
10.37
 
10-K
(Exhibit 10.66)
February 17, 2009
000-19319
10.38
 
10-K (Exhibit 10.46)
February 15, 2018
000-19319
10.39
 
10-K (Exhibit 10.39)
February 13, 2019
000-19319
Subsidiaries
 
 
 
 
21.1
X
 
 
 
Consent
 
 
 
 
23.1
X
 
 
 
Certifications
 
 
 
 
31.1
X
 
 
 
31.2
X
 
 
 
32.1
X
 
 
 
101.INS
XBRL Instance
X
 
 
 
101.SCH
XBRL Taxonomy Extension Schema
X
 
 
 
101.CAL
XBRL Taxonomy Extension Calculation
X
 
 
 
101.LAB
XBRL Taxonomy Extension Labels
X
 
 
 
101.PRE
XBRL Taxonomy Extension Presentation
X
 
 
 
101.DEF
XBRL Taxonomy Extension Definition
X
 
 
 
*    Management contract, compensatory plan or agreement.
†
Confidential portions of this document have been redacted according to the applicable rules.


73


Item 16. FORM 10-K SUMMARY
Not applicable.



74

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Vertex Pharmaceuticals Incorporated
 
 
 
February 13, 2020
By:
/s/ Jeffrey M. Leiden
 
 
Jeffrey M. Leiden
Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
 
Name
 
 
 
Title
 
 
 
 
Date
 
 
 
 
 
/s/ Jeffrey M. Leiden
 
 
Jeffrey M. Leiden
Chair of the Board, President and Chief Executive Officer (Principal Executive Officer)
February 13, 2020
 
 
 
/s/ Charles F. Wagner, Jr.
 
 
Charles F. Wagner, Jr.
Executive Vice President and Chief Financial Officer (Principal Financial Officer)
February 13, 2020
 
 
 
/s/ Paul M. Silva
 
 
Paul M. Silva
Senior Vice President and Corporate Controller (Principal Accounting Officer)
February 13, 2020
 
 
 
/s/ Reshma Kewalramani
 
 
Reshma Kewalramani
Executive Vice President, Chief Medical Officer and Director
February 13, 2020
 
 
 
/s/ Sangeeta N. Bhatia
 
 
Sangeeta N. Bhatia
Director
February 13, 2020
 
 
 
/s/ Lloyd Carney
 
 
Lloyd Carney
Director
February 13, 2020
 
 
 
/s/ Alan Garber
 
 
Alan Garber
Director
February 13, 2020
 
 
 
/s/ Terrence C. Kearney
 
 
Terrence C. Kearney
Director
February 13, 2020
 
 
 
/s/ Yuchun Lee
 
 
Yuchun Lee
Director
February 13, 2020
 
 
 
/s/ Margaret G. McGlynn
 
 
Margaret G. McGlynn
Director
February 13, 2020
 
 
 
/s/ Bruce I. Sachs
 
 
Bruce I. Sachs
Director
February 13, 2020
 
 
 
/s/ William D. Young
 
 
William D. Young
Director
February 13, 2020



75


Report of Independent Registered Public Accounting Firm
To the Shareholders and the Board of Directors of
Vertex Pharmaceuticals Incorporated

Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Vertex Pharmaceuticals Incorporated (the “Company”) as of December 31, 2019 and 2018, the related consolidated statements of operations, comprehensive income (loss), shareholders’ equity and noncontrolling interest, and cash flows for each of the three years in the period ended December 31, 2019, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 13, 2020 expressed an unqualified opinion thereon.
Adoption of New Accounting Standards
ASU No. 2014-09
As discussed in Note A to the consolidated financial statements, the Company changed its method for recognizing revenue as a result of the adoption of Accounting Standard Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), and the amendments in ASUs 2015-14, 2016-08, 2016-10 and 2016-12 effective January 1, 2018.
ASU No. 2016-01
As discussed in Note A to the consolidated financial statements, on January 1, 2018, the Company changed its method of presenting changes in the fair value of its investments in corporate equity securities as a result of the adoption of ASU No. 2016-01, Financial Instruments (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.
ASU No. 2016-02
As discussed in Note A to the consolidated financial statements, the Company changed its method for lease accounting as a result of the adoption of ASU No. 2016-02, Leases (Topic 842), and the related amendments effective January 1, 2019.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.


F-1


Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) related to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
 
 
Revenue Recognition - Payor Mix Impact on Measuring Variable Consideration
Description of the Matter
 
As discussed in Note A to the Company’s consolidated financial statements, the Company records product sales at the net sales price, or “transaction price,” which requires the Company to make several significant estimates regarding the net sales price. The most significant estimates relate to government rebates, chargebacks, discounts and fees, collectively rebates. Due to the delay in receipt of claims by third-party payors, the Company estimates the percentage of prescriptions that will be covered by each third-party payor, which is referred to as the payor mix. Rebate accruals inclusive of estimated amounts due for claims not yet received or processed are recorded within accrued expenses on the Company’s consolidated balance sheet.
Auditing the measurement of the Company’s net product revenues was especially complex and judgmental due to the significant estimation required in determining the amount of consideration that will be collected net of estimates for payor rebates. In particular, the net sales price is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with ultimate collection from third-party payors.
How We Addressed the Matter in Our Audit
 
We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company’s revenue recognition process, including controls over the underlying assumptions and inputs used by management to estimate amounts due to third-party payors and the completeness and accuracy of the data used in the estimates. We also tested the Company’s controls to assess the completeness and accuracy of the current and historical data that supports the estimate.
Our audit procedures to test the Company’s recognition of net product revenues included, among others, assessing the methodology used to determine the estimate and testing the significant assumptions and the underlying data used by the Company in its analysis, which included historical claims data. To assess the payor mix assumptions we tested contracted rates, historical claims and payment data and related trends, and other relevant factors. We also assessed the historical accuracy of the Company’s estimates of third-party payor rebates.



F-2


 
 
Accounting for the Impacts of Business Combinations
Description of the Matter
 
As described in Note C and Note E to the Company’s consolidated financial statements, the Company closed two business combinations during 2019; the acquisition of all outstanding shares of Exonics Therapeutics, Inc. (“Exonics”) for upfront consideration of $266.3 million and contingent milestones of up to $728.0 million and the acquisition of all outstanding shares of Semma Therapeutics, Inc. (“Semma”) for total upfront consideration of $936.8 million. Assets and liabilities recognized as part of the business combinations are recorded at fair value with $13.0 million and $387.0 million of in-process-research development intangible assets recognized for Exonics at July 16, 2019 and Semma at October 10, 2019, respectively, and $172.0 million recognized at July 16, 2019 for the contingent consideration liability for Exonics. The contingent liability for Exonics is remeasured to fair value at each reporting period and the amount recorded at December 31, 2019 was $176.5 million.
Auditing the Company's accounting for its acquisitions of Exonics and Semma was especially complex due to the significant estimation and judgment required by management in determining the fair value of in-process-research and development intangible assets acquired for Exonics and Semma and the contingent consideration liability for Exonics. The significant estimation was primarily due to the judgmental nature of the inputs to the valuation models used to measure the fair value of the in-process research and development intangible assets and contingent consideration, as well as the sensitivity of the respective fair values to the underlying significant assumptions. The Company used the multi-period excess earnings method of the income approach to measure the fair value of the in-process-research and development intangible assets acquired and a probability weighted discounted cash flow method of the income approach to measure the fair value of contingent consideration. The significant assumptions used to estimate the fair value of the in-process-research and development intangible assets acquired included the estimated probability of technical and regulatory success rates, development cost assumptions, revenue projections and growth rates, commercial cost estimates and discount rates. The significant assumptions used to estimate the fair value of contingent consideration included the estimated timing of regulatory and commercial milestone achievement and the corresponding estimated probability of technical and regulatory success rates applied by management. Given the pre-clinical nature of the assets acquired, these significant assumptions are forward-looking and could be affected by future economic and market conditions.
How We Addressed the Matter in Our Audit
 
We obtained an understanding, evaluated the design and tested the operating effectiveness of the controls over the Company’s accounting for acquisitions. Our testing of controls included controls over the valuation of the intangible assets acquired and contingent consideration, including the valuation models used and the underlying assumptions used to develop such estimates, and controls over the completeness and accuracy of the data used to develop the estimates.
To test the estimated fair value of the intangible assets and contingent consideration, we performed audit procedures that included, among others, evaluating the Company's use of the income approach (the multi-period excess earnings method and probability weighted discounted cash flow method), testing the significant assumptions used in the model, as described above, and assessing the completeness and accuracy of the underlying data. We compared the significant assumptions to current industry, and market data, to the assumptions used to value similar assets in other acquisitions and to other guideline companies within the same industry. We involved our valuation professionals to assist with our evaluation of the methodology used by the Company and significant assumptions included in the fair value estimates.
/s/ Ernst & Young LLP
 
We have served as the Company’s auditor since 2005.
Boston, Massachusetts
February 13, 2020



F-3


VERTEX PHARMACEUTICALS INCORPORATED
Consolidated Statements of Operations
(in thousands, except per share amounts)
 
Year Ended December 31,
 
2019
 
2018
 
2017
Revenues:
 
 
 
 
 
Product revenues, net
$
4,160,726

 
$
3,038,325

 
$
2,165,480

Collaborative and royalty revenues
2,095

 
9,272

 
323,172

Total revenues
4,162,821

 
3,047,597

 
2,488,652

Costs and expenses:
 
 
 
 
 
Cost of sales
547,758

 
409,539

 
275,119

Research and development expenses
1,754,540

 
1,416,476

 
1,324,625

Sales, general and administrative expenses
658,498

 
557,616

 
496,079

Change in fair value of contingent consideration
4,459

 
—

 
—

Restructuring (income) expenses
—

 
(184
)
 
14,246

Intangible asset impairment charges
—

 
29,000

 
255,340

Total costs and expenses
2,965,255

 
2,412,447

 
2,365,409

Income from operations
1,197,566

 
635,150

 
123,243

Interest income
63,678

 
38,352

 
11,748

Interest expense
(58,502
)
 
(72,471
)
 
(69,298
)
Other income (expense), net
192,177

 
(790
)
 
(81,382
)
Income (loss) before provision for (benefit from) income taxes
1,394,919

 
600,241

 
(15,689
)
Provision for (benefit from) income taxes
218,109

 
(1,486,862
)
 
(107,324
)
Net income
1,176,810

 
2,087,103

 
91,635

Loss attributable to noncontrolling interest
—

 
9,793

 
171,849

Net income attributable to Vertex
$
1,176,810

 
$
2,096,896

 
$
263,484

 
 
 
 
 
 
Amounts per share attributable to Vertex common shareholders:
 
 
 
 
 
Net income:
 
 
 
 
 
Basic
$
4.58

 
$
8.24

 
$
1.06

Diluted
$
4.51

 
$
8.09

 
$
1.04

Shares used in per share calculations:
 
 
 
 
 
Basic
256,728

 
254,292

 
248,858

Diluted
260,673

 
259,185

 
253,225

The accompanying notes are an integral part of the consolidated financial statements.


F-4


VERTEX PHARMACEUTICALS INCORPORATED
Consolidated Statements of Comprehensive Income (Loss)
(in thousands)
 
Year ended December 31,
 
2019
 
2018
 
2017
Net income
$
1,176,810

 
$
2,087,103

 
$
91,635

Changes in other comprehensive (loss) income:
 
 
 
 
 
Unrealized holding gains on marketable securities, net of tax of zero, zero and $(2.7) million, respectively
1,039

 
58

 
6,954

Unrealized (losses) gains on foreign currency forward contracts, net of tax of $7.0 million, $(7.1) million and $3.4 million, respectively
(14,003
)
 
27,438

 
(26,530
)
Foreign currency translation adjustment
10,332

 
8,855

 
(13,169
)
Total changes in other comprehensive (loss) income
(2,632
)
 
36,351

 
(32,745
)
Comprehensive income
1,174,178

 
2,123,454

 
58,890

Comprehensive loss attributable to noncontrolling interest
—

 
9,793

 
171,849

Comprehensive income attributable to Vertex
$
1,174,178

 
$
2,133,247

 
$
230,739

The accompanying notes are an integral part of the consolidated financial statements.


F-5


VERTEX PHARMACEUTICALS INCORPORATED
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
 
December 31,
 
2019
 
2018
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
3,109,322

 
$
2,650,134

Marketable securities
698,972

 
518,108

Accounts receivable, net
633,518

 
409,688

Inventories
167,502

 
124,360

Prepaid expenses and other current assets
213,515

 
140,819

Total current assets
4,822,829

 
3,843,109

Property and equipment, net
745,080

 
812,005

Goodwill
1,002,158

 
50,384

Intangible assets
400,000

 
—

Deferred tax assets
1,190,815

 
1,499,672

Other assets
157,583

 
40,728

Total assets
$
8,318,465

 
$
6,245,898

Liabilities and Shareholders’ Equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
87,610

 
$
110,987

Accrued expenses
1,116,912

 
958,899

Other current liabilities
130,305

 
50,406

Total current liabilities
1,334,827

 
1,120,292

Long-term finance lease liabilities
538,576

 
581,550

Long-term contingent consideration
176,500

 
—

Other long-term liabilities
183,318

 
108,853

Total liabilities
2,233,221

 
1,810,695

Commitments and contingencies
—

 
—

Shareholders’ equity:
 
 
 
Preferred stock, $0.01 par value; 1,000 shares authorized; none issued and outstanding
—

 
—

Common stock, $0.01 par value; 500,000 shares authorized, 258,993 and 255,172 shares issued and outstanding, respectively
2,589

 
2,546

Additional paid-in capital
7,937,606

 
7,421,476

Accumulated other comprehensive (loss) income
(1,973
)
 
659

Accumulated deficit
(1,852,978
)
 
(2,989,478
)
Total shareholders’ equity
6,085,244

 
4,435,203

Total liabilities and shareholders’ equity
$
8,318,465

 
$
6,245,898


The accompanying notes are an integral part of the consolidated financial statements.


F-6


VERTEX PHARMACEUTICALS INCORPORATED
Consolidated Statements of Shareholders’ Equity and Noncontrolling Interest
(in thousands)
 
Common Stock
 
Additional
Paid-in Capital
 
Accumulated
Other
Comprehensive Income (Loss)
 
Accumulated Deficit
 
Total Vertex
Shareholders’ Equity
 
Noncontrolling
Interest
 
Total
Shareholders’ Equity
 
Shares
 
Amount
 
 
 
 
 
 
Balance, December 31, 2016
248,301

 
$
2,450

 
$
6,506,795

 
$
21,173

 
$
(5,373,836
)
 
$
1,156,582

 
$
181,609

 
$
1,338,191

Cumulative effect adjustment for adoption of new accounting guidance
—

 
—

 
9,371

 
—

 
(9,371
)
 
—

 
—

 
—

Other comprehensive loss, net of tax
—

 
—

 
—

 
(32,745
)
 
—

 
(32,745
)
 
—

 
(32,745
)
Net income (loss)
—

 
—

 
—

 
—

 
263,484

 
263,484

 
(171,849
)
 
91,635

Issuance of common stock under benefit plans
4,952

 
62

 
345,554

 
—

 
—

 
345,616

 
57

 
345,673

Stock-based compensation expense
—

 
—

 
295,642

 
—

 
—

 
295,642

 
—

 
295,642

VIE noncontrolling interest upon deconsolidation
—

 
—

 
—

 
—

 
—

 
—

 
3,910

 
3,910

Balance, December 31, 2017
253,253

 
$
2,512

 
$
7,157,362

 
$
(11,572
)
 
$
(5,119,723
)
 
$
2,028,579

 
$
13,727

 
$
2,042,306

Cumulative effect adjustment for adoption of new accounting guidance
—

 
—

 
—

 
(24,120
)
 
33,349

 
9,229

 
—

 
9,229

Other comprehensive income, net of tax
—

 
—

 
—

 
36,351

 
—

 
36,351

 
—

 
36,351

Net income (loss)
—

 
—

 
—

 
—

 
2,096,896

 
2,096,896

 
(9,793
)
 
2,087,103

Repurchases of common stock
(2,094
)
 
(21
)
 
(350,022
)
 
—

 
—

 
(350,043
)
 
—

 
(350,043
)
Issuance of common stock under benefit plans
4,013

 
55

 
288,480

 
—

 
—

 
288,535

 
—

 
288,535

Stock-based compensation expense
—

 
—

 
325,656

 
—

 
—

 
325,656

 
—

 
325,656

VIE noncontrolling interest upon deconsolidation
—

 
—

 
—

 
—

 
—

 
—

 
(3,540
)
 
(3,540
)
Other VIE activity
—

 
—

 
—

 
—

 
—

 
—

 
(394
)
 
(394
)
Balance, December 31, 2018
255,172

 
$
2,546

 
$
7,421,476

 
$
659

 
$
(2,989,478
)
 
$
4,435,203

 
$
—

 
$
4,435,203

Cumulative effect adjustment for adoption of new accounting guidance
—

 
—

 
—

 
—

 
(40,310
)
 
(40,310
)
 
—

 
(40,310
)
Other comprehensive loss, net of tax
—

 
—

 
—

 
(2,632
)
 
—

 
(2,632
)
 
—

 
(2,632
)
Net income
—

 
—

 
—

 
—

 
1,176,810

 
1,176,810

 
—

 
1,176,810

Repurchases of common stock
(1,074
)
 
(10
)
 
(192,005
)
 
—

 
—

 
(192,015
)
 
—

 
(192,015
)
Issuance of common stock under benefit plans
4,895

 
53

 
345,926

 
—

 
—

 
345,979

 
—

 
345,979

Stock-based compensation expense
—

 
—

 
362,209

 
—

 
—

 
362,209

 
—

 
362,209

Balance, December 31, 2019
258,993

 
$
2,589

 
$
7,937,606

 
$
(1,973
)
 
$
(1,852,978
)
 
$
6,085,244

 
$
—

 
$
6,085,244

The accompanying notes are an integral part of the consolidated financial statements.


F-7


VERTEX PHARMACEUTICALS INCORPORATED
Consolidated Statements of Cash Flows
(in thousands)
 
Year Ended December 31,
 
2019
 
2018
 
2017
Cash flows from operating activities:
 
 
 
 
 
Net income
$
1,176,810

 
$
2,087,103

 
$
91,635

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
 
 
Stock-based compensation expense
360,489

 
325,047

 
293,236

Depreciation expense
106,941

 
72,420

 
61,397

Deferred income taxes (including benefit from valuation allowance release in 2018)
167,387

 
(1,512,325
)
 
(120,513
)
Gains on equity securities
(197,597
)
 
(2,558
)
 
—

Increase in fair value of contingent consideration
4,459

 
—

 
—

Intangible asset impairment charges
—

 
29,000

 
255,340

Acquired in-process research and development
—

 
—

 
160,000

Deconsolidation of VIE
—

 
1,077

 
76,644

Other non-cash items, net
16,942

 
32,502

 
14,439

Changes in operating assets and liabilities:
 
 
 
 
 
Accounts receivable, net
(225,587
)
 
(108,152
)
 
(71,759
)
Inventories
(64,047
)
 
(31,965
)
 
(47,484
)
Prepaid expenses and other assets
35,440

 
16,684

 
(111,063
)
Accounts payable
(22,785
)
 
36,554

 
8,753

Accrued expenses
172,881

 
302,755

 
255,178

Other liabilities
37,997

 
22,144

 
(20,861
)
Net cash provided by operating activities
1,569,330

 
1,270,286

 
844,942

Cash flows from investing activities:
 
 
 
 
 
Payments to acquire businesses, net of cash acquired
(1,154,212
)
 
—

 
—

Purchases of available-for-sale debt securities
(537,196
)
 
(431,918
)
 
(532,581
)
Maturities of available-for-sale debt securities
475,924

 
431,576

 
369,214

Sale of equity securities
94,936

 
—

 
—

Expenditures for property and equipment
(75,451
)
 
(95,524
)
 
(99,421
)
Investment in equity securities
(39,319
)
 
(83,471
)
 
—

Investment in note receivable
—

 
(15,000
)
 
—

Decrease in restricted cash due to deconsolidation of VIE
—

 
(7,896
)
 
(61,602
)
Purchase of in-process research and development
—

 
—

 
(160,000
)
Other investing activities
—

 
75

 
1,061

Net cash used in investing activities
(1,235,318
)
 
(202,158
)
 
(483,329
)
Cash flows from financing activities:
 
 
 
 
 
Issuances of common stock under benefit plans
343,244

 
289,293

 
344,840

Repurchases of common stock
(192,015
)
 
(350,043
)
 
—

Payments on finance leases
(39,185
)
 
—

 
—

Advance from collaborator
12,500

 
7,500

 
12,500

Proceeds related to capital lease and construction financing lease obligations
10,046

 
20,840

 
34,666

Repayments of advanced funding
(5,866
)
 
(5,027
)
 
(4,266
)
Payments on capital lease and construction financing lease obligations
—

 
(33,388
)
 
(19,336
)
Payments on revolving credit facility
—

 
—

 
(300,000
)
Other financing activities
(1,951
)
 
(394
)
 
—

Net cash provided by (used in) financing activities
126,773

 
(71,219
)
 
68,404

Effect of changes in exchange rates on cash
1,643

 
(6,182
)
 
5,802

Net increase in cash, cash equivalents and restricted cash
462,428

 
990,727

 
435,819

Cash, cash equivalents and restricted cash—beginning of period
2,658,253

 
1,667,526

 
1,231,707

Cash, cash equivalents and restricted cash—end of period
$
3,120,681

 
$
2,658,253

 
$
1,667,526

 
 
 
 
 
 
Supplemental disclosure of cash flow information:
 
 
 
 
 
Cash paid for interest
$
55,554

 
$
66,458

 
$
68,696

Cash paid for income taxes
$
24,730

 
$
12,402

 
$
6,414

Capitalization of costs related to construction financing lease obligation
$
—

 
$
3,389

 
$
40,855

Issuances of common stock from employee benefit plans receivable
$
2,820

 
$
86

 
$
844

The accompanying notes are an integral part of the consolidated financial statements.


F-8


VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements
A.
Nature of Business and Accounting Policies
Business
Vertex Pharmaceuticals Incorporated (“Vertex” or the “Company”) invests in scientific innovation to create transformative medicines for serious diseases. The Company’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (“CF”) and advancing research and development programs in other indications. The Company’s marketed products are TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor), which are approved to treat patients with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (“CFTR”) gene.
As of December 31, 2019, the Company had cash, cash equivalents and marketable securities of $3.8 billion. The Company expects that cash flows from the sales of its products, together with the Company’s cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months.
The Company is subject to risks common to companies in its industry including, but not limited to, the dependence on revenues from its CF products, competition, uncertainty about clinical trial outcomes and regulatory approvals, uncertainties relating to pharmaceutical pricing and reimbursement, uncertainty related to international expansion, uncertain protection of proprietary technology, the need to comply with government regulations, share price volatility, dependence on collaborative relationships and potential product liability.
Basis of Presentation
The accompanying consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (“VIEs”). In 2017, the Company deconsolidated Parion Sciences, Inc. (“Parion”), a VIE the Company had consolidated since 2015. In 2018, the Company deconsolidated BioAxone Biosciences, Inc. (“BioAxone”), a VIE the Company had consolidated since 2014. As of December 31, 2019 and 2018, the Company did not have any consolidated VIEs. All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals. Please refer to Note R, “Segment Information,” for enterprise-wide disclosures regarding the Company’s revenues, major customers and long-lived assets by geographic area. The Company has reclassified certain items from the prior year’s consolidated financial statements to conform to the current year’s presentation.
Use of Estimates
The preparation of consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these consolidated financial statements have been made in connection with (i) determining the transaction price of revenues, (ii) accounting for acquisitions, including intangible assets, goodwill and contingent consideration and (iii) evaluating deferred tax asset valuation allowances and the provision for income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.


F-9

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


Revenue Recognition
Pursuant to Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. 
The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon delivery.
Product Revenues, Net
The Company sells its products principally to a limited number of specialty pharmacy and specialty distributors in the United States, which account for the largest portion of its total revenues, and makes international sales primarily to specialty distributors and retail chains, as well as hospitals and clinics, many of which are government-owned or supported (collectively, its “Customers”). The Company’s Customers in the United States subsequently resell the products to patients and health care providers. In accordance with ASC 606, the Company recognizes net product revenues from sales when the Customers obtain control of the Company’s products, which typically occurs upon delivery to the Customer. The Company’s payment terms are approximately 30 days in the United States and consistent with prevailing practice in international markets.
Revenues from product sales are recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from (a) invoice discounts for prompt payment and distribution fees, (b) government and private payor rebates, chargebacks, discounts and fees and (c) costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves are classified as reductions to “Accounts receivable, net” if payable to a Customer or “Accrued expenses” if payable to a third-party.  Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns.  The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.  Actual amounts of consideration ultimately received may differ from the Company’s estimates.  If actual results vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.
Invoice Discounts and Distribution Fees: The Company generally provides invoice discounts on product sales to its Customers for prompt payment and pays fees for distribution services, such as fees for certain data that Customers provide to the Company. The Company estimates that, based on its experience, its Customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.
Rebates, Chargebacks, Discounts and Fees: The Company contracts with government agencies (its “Third-party Payors”) so that products will be eligible for purchase by, or partial or full reimbursement from, such Third-party Payors. The Company estimates the rebates, chargebacks, discounts and fees it will provide to Third-party Payors and deducts


F-10

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


these estimated amounts from its gross product revenues at the time the revenues are recognized. For each product, the Company estimates the aggregate rebates, chargebacks and discounts that it will provide to Third-party Payors based upon (i) the Company’s contracts with these Third-party Payors, (ii) the government-mandated discounts and fees applicable to government-funded programs, (iii) information obtained from the Company’s Customers and other third-party data regarding the payor mix for such product and (iv) historical experience.
Other Incentives: Other incentives that the Company offers include co-pay mitigation rebates provided by the Company to commercially insured patients who have coverage and who reside in states that permit co-pay mitigation programs. Based upon the terms of the Company’s co-pay mitigation programs, the Company estimates average co-pay mitigation amounts for each of its products in order to establish appropriate accruals.
The Company makes significant estimates and judgments that materially affect its recognition of net product revenues. The Company adjusts its estimated rebates, chargebacks and discounts based on new information, including information regarding actual rebates, chargebacks and discounts for its products, as it becomes available. Claims by third-party payors for rebates, chargebacks and discounts frequently are submitted to the Company significantly after the related sales, potentially resulting in adjustments in the period in which the new information becomes known. The Company’s credits to product revenue related to prior period sales have not been significant and primarily related to rebates and discounts.
The Company excludes taxes collected from Customers relating to product sales and remitted to governmental authorities from revenues.
Contract Liabilities
The Company recorded contract liabilities of $62.3 million and $24.9 million as of December 31, 2019 and 2018, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement the Company can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees.  The Company defers a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. The Company’s product revenue contracts include performance obligations that are one year or less.
The Company’s contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as the Company’s fiscal year. In these markets the Company recognizes revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year. During the year ended December 31, 2019, the Company recorded $24.9 million of revenues that were recorded as contract liabilities at the beginning of the year.
French Early Access Programs
Pursuant to ASC 605, Revenue Recognition (“ASC 605”), which was applicable until December 31, 2017, the Company only recognized revenues from product sales if it determined that the price was fixed or determinable at the time of delivery. If the Company determined that the price was not fixed or determinable, it deferred the recognition of revenues. If the Company was able to determine that the price was fixed or determinable, it recognized the net product revenues associated with the units.
In 2015, the Company began distributing ORKAMBI through early access programs in France and remained engaged in reimbursement discussions with the French government until November 2019, when the Company reached an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs. From the time the Company began distributing ORKAMBI through early access programs in France, it expected the difference between the amounts collected based on the invoiced amount and the final amount for ORKAMBI distributed through early access programs would be returned to the French government. As a result, the Company has classified a refund liability related to the early access programs in France within “Accrued expenses” on its consolidated balance sheets.


F-11

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


Pursuant to the revenue recognition accounting guidance that was applicable until December 31, 2017, the Company’s ORKAMBI net product revenues for 2015, 2016 and 2017 did not include any net product revenues from sales of ORKAMBI in France because the price was not fixed or determinable at the time of delivery. Upon adopting ASC 606 in 2018, the Company recorded an $8.3 million cumulative effect adjustment to “Accumulated deficit” primarily related to shipments of ORKAMBI under the early access programs in France. The Company determined the amount of the adjustment based upon (i) the status of reimbursement discussions in France upon adoption, (ii) its estimate of the amount of consideration it expected to retain related to ORKAMBI sales in France that occurred on or prior to December 31, 2017 that would not be subject to a significant reversal in amounts recognized and (iii) recognition of costs previously deferred related to the ORKAMBI sales in France. Please refer to Recent Accounting Pronouncements included in this Note A, “Nature of Business and Accounting Policies,” below for more information regarding the revenue recognition guidance adopted as of January 1, 2018.
For ORKAMBI sales in France that occurred after December 31, 2017 under the early access programs, the Company recognized net product revenues based on a transaction price that reflected the Company’s estimate of consideration it expected to retain that would not be subject to a significant reversal in amounts recognized. When determining if variable consideration should be constrained, the Company considers whether there are factors outside its control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. The Company recognized ORKAMBI net product revenues from sales in France based on this estimate from the first quarter of 2018 through the third quarter of 2019. Upon reaching an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs in November 2019, the Company updated the transaction price to reflect the final amount for ORKAMBI distributed through early access programs. As a result, the Company recognized net product revenues of $155.8 million related to prior period ORKAMBI early access program sales in the fourth quarter of 2019 because the updated transaction price for ORKAMBI distributed through these programs exceeded the Company’s previous estimate of the consideration it expected to retain that would not be subject to a significant reversal in amounts recognized. Additionally, the Company’s refund liability no longer requires estimation as of December 31, 2019 and will be paid to the French government in 2020.
Collaborative and Royalty Revenues
The Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms of these agreements typically include payment to the Company related to one or more of the following: nonrefundable, upfront license fees; development and commercial milestones; funding of research and/or development activities; and royalties on net sales of licensed products. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaborator.
For each collaborative research, development and/or commercialization agreement that results in revenue, the Company identifies all material performance obligations, which may include a license to intellectual property and know-how, research and development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimate of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.
Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. In order to account for these agreements, the Company must develop assumptions that require judgment to determine the standalone selling price, which may include (i) the probability of obtaining marketing approval for the drug candidate, (ii) estimates regarding the timing of and the expected costs to develop and commercialize the drug candidate, (iii) estimates of future cash flows from potential product sales with respect to the drug candidate and (iv) appropriate discount and tax rates. Standalone selling prices used to perform the initial allocation are not updated after contract


F-12

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.
Upfront License Fees: If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related nonrefundable, upfront license fees based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license.  For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.  The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Development and Regulatory Milestone Payments: Depending on facts and circumstances, the Company may conclude that it is appropriate to include certain milestones in the estimated transaction price or that it is appropriate to fully constrain the milestones. A milestone payment is included in the transaction price in the reporting period that the Company concludes that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods. This may result in revenues from certain milestones and a corresponding contract asset being recorded in a reporting period before the milestone is achieved. Milestone payments that have not been included in the transaction price to date are fully constrained until the Company concludes that their achievement is probable and that recognition of the related revenue will not result in a significant reversal in amounts recognized in future periods. The Company re-evaluates the probability of achievement of such development milestones and any related constraint each reporting period and adjusts its estimate of the overall transaction price, including the amount of collaborative revenue that it has recorded, if necessary. The Company has not recorded any significant development or regulatory milestone revenues the three years ended December 31, 2019.
Research and Development Activities/Transition Services: If the Company is entitled to reimbursement from its collaborators for specified research and development expenses, it accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as collaborative revenues or an offset to research and development expenses in accordance with the provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations.
Sales-based Milestone and Royalty Payments: The Company’s collaborators may be required to pay the Company sales-based milestones or royalties on future sales of commercial products.  The Company recognizes revenues related to sales-based milestone and royalties upon the later to occur of (i) achievement of the collaborator’s underlying sales or (ii) satisfaction of any performance obligation(s) related to these sales, in each case assuming the license to the Company’s intellectual property is deemed to be the predominant item to which the sales-based milestones and/or royalties relate. The Company has not recorded any sales-based milestones or royalties revenues during the three years ended December 31, 2019.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentration of credit risk consist principally of money market funds and marketable securities. The Company places these investments with highly rated financial institutions, and, by policy, limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company also maintains a foreign currency hedging program that includes foreign currency forward contracts with several counterparties. The Company has not experienced any credit losses related to these financial instruments and does not believe it is exposed to any significant credit risk related to these instruments.
The Company also is subject to credit risk from its accounts receivable related to its product sales and collaborators. The Company evaluates the creditworthiness of each of its customers and has determined that all of its material customers are


F-13

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


creditworthy. To date, the Company has not experienced significant losses with respect to the collection of its accounts receivable. The Company believes that its allowance for doubtful accounts was adequate at December 31, 2019. Please refer to Note R, “Segment Information,” for further information.
Cash and Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.
Marketable Securities
As of December 31, 2019, the Company’s marketable securities consisted of investments in available-for-sale debt securities, including government-sponsored enterprise securities, corporate debt securities and commercial paper, and corporate equity securities with readily determinable fair values. The Company classifies marketable securities available to fund current operations as current assets on its consolidated balance sheets. Marketable securities are classified as long-term assets on the consolidated balance sheets if (i) they have been in an unrealized loss position for longer than one year and (ii) the Company has the ability and intent to hold them (a) until the carrying value is recovered and (b) such holding period may be longer than one year. The Company’s marketable securities are stated at fair value. The fair value of these securities is based on quoted prices for identical or similar assets.
The Company records unrealized gains (losses) on available-for-sale debt securities as a component of “Accumulated other comprehensive (loss) income,” which is a separate component of shareholders’ equity on its consolidated balance sheet, until such gains and losses are realized.
Pursuant to the adoption of Accounting Standards Update (“ASU”) 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”) on January 1, 2018, the Company began recording changes in the fair value of its investments in corporate equity securities to “Other income (expense), net” in the Company’s consolidated statements of operations. Prior to its adoption of ASU 2016-01 in 2018, the Company recorded changes in the fair value of its investments in corporate equity securities to “Accumulated other comprehensive (loss) income.”
The Company reviews investments in marketable debt securities for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers whether it has an intent to sell, or whether it is more likely than not that the Company will be required to sell, the investment before recovery of the investment’s amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company’s investment policy, the severity and the duration of the impairment and changes in value subsequent to year-end. If a decline in the fair value is considered other-than-temporary, based on available evidence, the unrealized loss is transferred from other comprehensive income (loss) to the consolidated statements of operations.
Realized gains and losses are determined using the specific identification method and are included in “Other income (expense), net” in the consolidated statements of operations.
Accounts Receivable
The Company deducts invoice discounts for prompt payment and fees for distribution services from its accounts receivable based on its experience that the Company’s Customers will earn these discounts and fees. The Company’s estimates for its allowance for doubtful accounts, which have not been significant to date, are determined based on existing contractual payment terms and historical payment patterns.
Stock-based Compensation Expense
The Company expenses the fair value of employee stock options and other forms of stock-based employee compensation over the associated employee service period on a straight-line basis. Stock-based compensation expense is determined based on the fair value of the award at the grant date and is adjusted each period to reflect actual forfeitures and the outcomes of certain performance conditions.


F-14

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


For awards with performance conditions in which the award does not vest unless the performance condition is met, the Company recognizes expense if, and to the extent that, the Company estimates that achievement of the performance condition is probable. If the Company concludes that vesting is probable, it recognizes expense from the date it reaches this conclusion through the estimated vesting date.
The Company provides to employees who have rendered a certain number of years’ to the Company and meet certain age requirements, partial or full acceleration of vesting of these equity awards, subject to certain conditions including a notification period, upon a termination of employment other than for cause. Approximately 5% of the Company’s employees were eligible for partial or full acceleration of any of their equity awards as of December 31, 2019. The Company recognizes stock-based compensation expense related to these awards over a service period reflecting qualified employees’ eligibility for partial or full acceleration of vesting.
Research and Development Expenses
The Company expenses as incurred all research and development expenses, including amounts funded by research and development collaborations. The Company capitalizes nonrefundable advance payments made by the Company for research and development activities and expenses the payments as the related goods are delivered or the related services are performed.
Research and development expenses are comprised of costs incurred by the Company in performing research and development activities, including salary and benefits; stock-based compensation expense; outsourced services and other direct expenses, including clinical trial and pharmaceutical development costs; collaboration and asset acquisition payments; expenses associated with drug supplies that are not being capitalized; and infrastructure costs, including facilities costs and depreciation expense.
Inventories
The Company values its inventories at the lower-of-cost or net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and writes down any excess and obsolete inventories to their net realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases are capitalized and recorded upon sale in “Cost of sales” in the consolidated statements of operations. Shipping and handling costs incurred for product shipments are recorded as incurred in “Cost of sales” in the consolidated statements of operations.
The Company capitalizes inventories produced in preparation for initiating sales of a drug candidate when the related drug candidate is considered to have a high likelihood of regulatory approval and the related costs are expected to be recoverable through sales of the inventories. In determining whether or not to capitalize such inventories, the Company evaluates, among other factors, information regarding the drug candidate’s safety and efficacy, the status of regulatory submissions and communications with regulatory authorities and the outlook for commercial sales, including the existence of current or anticipated competitive drugs and the availability of reimbursement. In addition, the Company evaluates risks associated with manufacturing the drug candidate and the remaining shelf-life of the inventories.
Property and Equipment
Property and equipment are recorded at cost. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset, generally seven to ten years for furniture and equipment, three to five years for computers and software and for leasehold improvements, the shorter of the useful life of the improvements or the estimated remaining life of the associated lease. Maintenance and repairs to an asset that do not improve or extend its life are charged to operations. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the Company’s consolidated statements of operations. The Company performs an assessment of the fair value of the assets if indicators of impairment are identified during a reporting period and records the assets at the lower of the net book value or the fair value of the assets.


F-15

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


The Company capitalizes internal costs incurred to develop software for internal use during the application development stage. Amortization of capitalized internally developed software costs is recorded in depreciation expense over the useful life of the related asset.
Leases
The Company adopted ASU 2016-02, Leases (Topic 842) (“ASC 842”) as of January 1, 2019. Under ASC 842, the Company determines whether the arrangement contains a lease at the inception of an arrangement. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its consolidated balance sheet and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12 months.
A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.
Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease.
The Company does not separate lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.
Finance leases are recorded in “Property and equipment, net,” “Other current liabilities” and “Long-term finance lease liabilities” and operating leases are recorded in “Other assets,” “Other current liabilities” and “Other long-term liabilities” on the Company’s consolidated balance sheet.
Prior to the adoption of ASC 842 on January 1, 2019, the Company applied build-to-suit accounting and was the deemed owner of its leased corporate headquarters in Boston and research site in San Diego, for which it was recognizing depreciation expense over the buildings’ useful lives and imputed interest on the corresponding construction financing lease obligations. The Company also recorded leases for equipment as capital leases pursuant to the accounting guidance that was effective until December 31, 2018.
The assets and liabilities associated with the Company’s capital lease agreements were recorded at the present value of the minimum lease payments at the inception of the lease agreement. The assets were depreciated using the straight-line method over the shorter of the useful life of the related asset or the remaining life of the associated lease. Amortization of capital lease assets was included in depreciation expense.


F-16

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


Income Taxes
Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax bases of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. On a periodic basis, the Company reassesses the valuation allowance on its deferred income tax assets weighing positive and negative evidence to assess the recoverability of its deferred tax assets. The Company includes, among other things, its recent financial performance and its future projections in this periodic assessment.
The Company records liabilities related to uncertain tax positions by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company does not believe any such uncertain tax positions currently pending will have a material adverse effect on its consolidated financial statements.
Variable Interest Entities
The Company reviews each collaboration agreement pursuant to which it licenses assets owned by a collaborator in order to determine whether or not it has a variable interest via the license agreement with the collaborator and if the variable interest is a variable interest in the collaborator as a whole. In assessing whether the Company has a variable interest in the collaborator as a whole, the Company considers and makes judgments regarding the purpose and design of the entity, the value of the licensed assets to the collaborator, the value of the collaborator’s total assets and the significant activities of the collaborator. If the Company has a variable interest in the collaborator as a whole, the Company assesses whether or not the Company is the primary beneficiary of that VIE based on a number of factors, including (i) which party has the power to direct the activities that most significantly affect the VIE’s economic performance, (ii) the parties’ contractual rights and responsibilities pursuant to the collaboration agreement and (iii) which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE. If the Company determines it is the primary beneficiary of a VIE at the onset of the collaboration agreement, the collaboration is treated as a business combination and the Company consolidates the financial statements of the VIE into the Company’s consolidated financial statements. On a quarterly basis, the Company evaluates whether it continues to be the primary beneficiary of any consolidated VIEs. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, it deconsolidates the VIE in the period that the determination is made.
Fair Value of In-process Research and Development Assets and Contingent Payments
The present-value models the Company uses to estimate the fair values of in-process research and development assets and contingent payments pursuant to collaborations and acquisitions incorporate significant assumptions.
The Company’s discounted cash flow models pertaining to in-process research and development assets include: (i) assumptions regarding the probability of obtaining marketing approval for a drug candidate; (ii) the timing of and the expected costs to develop and commercialize a drug candidate; (iii) estimates of future cash flows from potential product sales with respect to a drug candidate; and (iv) appropriate discount and tax rates.
The Company bases its estimates of the probability of achieving the milestones relevant to the fair value of contingent payments, which could include milestone, royalty and option payments, on industry data. Estimates included in the discounted cash flow models pertaining to contingent payments also include: (i) estimate regarding the timing of the relevant development and commercial milestones and royalties, (ii) and appropriate discount rates. Please refer to Note E, “Fair Value Measurements,” for further information.
In-process Research and Development Assets
The Company records the fair value of in-process research and development assets as of the transaction date of a business combination. Each of these assets is accounted for as an indefinite-lived intangible asset and is maintained on the Company’s consolidated balance sheet until either the project underlying it is completed or the asset becomes impaired. If the asset becomes impaired or is abandoned, the carrying value of the related intangible asset is written down to its fair value, and an impairment charge is recorded in the period in which the impairment occurs. If a project is completed, the carrying


F-17

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


value of the related intangible asset is amortized as a part of “Cost of sales” over the remaining estimated life of the asset beginning in the period in which the project is completed. In-process research and development assets are tested for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist.
In-process research and development that is acquired in a transaction that does not qualify as a business combination under GAAP and that does not have an alternative future use is expensed in the period in which it is acquired.
Goodwill
The difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is allocated to goodwill. Goodwill is evaluated for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist.
Deconsolidation
Upon the occurrence of certain events and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its subsidiaries, including consolidated VIEs. If the Company determines it no longer has a controlling interest, the subsidiary is deconsolidated. The Company records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i) the aggregate of (a) the fair value of any consideration received, (b) the fair value of any retained noncontrolling investment in the former subsidiary and (c) the carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii) the carrying amount of the former subsidiary’s assets and liabilities.
Discontinued Operations
The Company assesses whether a deconsolidation is required to be presented as discontinued operations in its consolidated financial statements on the deconsolidation date. This assessment is based on whether or not the deconsolidation represents a strategic shift that has or will have a major effect on the Company’s operations or financial results. If the Company determines that a deconsolidation requires presentation as a discontinued operation on the deconsolidation date, or at any point during the one year period following such date, it will present the former subsidiary as a discontinued operation in current and comparative period financial statements.
Embedded Derivatives
Embedded derivatives are required to be bifurcated from the host instruments and recorded at fair value if the derivatives are not clearly and closely related to the host instruments on the date of issuance. The Company did not have any material embedded derivatives that required bifurcation recorded on its consolidated balance sheets as of December 31, 2019 and 2018, respectively.
Hedging Activities
The Company recognizes the fair value of hedging instruments that are designated and qualify as hedging instruments pursuant to GAAP, foreign currency forward contracts, as either assets or liabilities on the consolidated balance sheets. Changes in the fair value of these instruments are recorded each period in “Accumulated other comprehensive (loss) income” as unrealized gains and losses until the forecasted underlying transaction occurs. Unrealized gains and losses on these foreign currency forward contracts are included in “Prepaid expenses and other current assets” or “Other assets,” and “Other current liabilities” or “Other long-term liabilities,” respectively, on the Company’s consolidated balance sheets depending on the remaining period until their contractual maturity. Realized gains and losses for the effective portion of such contracts are recognized in “Product revenues, net” in the consolidated statement of operations in the same period that it recognizes the product revenues that were impacted by the hedged foreign exchange rate changes. The Company classifies the cash flows from hedging instruments in the same category as the cash flows from the hedged items.
Certain of the Company’s hedging instruments are subject to master netting arrangements to reduce the risk arising from such transactions with its counterparties. The Company presents unrealized gains and losses on its foreign currency forward contracts on a gross basis within its consolidated balance sheets.


F-18

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


The Company also enters into foreign currency forward contracts with contractual maturities of less than one month designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities including intercompany balances. These contracts are not designated as hedging instruments pursuant to GAAP. Realized gains and losses for such contracts are recognized in “Other income (expense), net” in the consolidated statement of operations each period.
Restructuring Expenses
The Company records costs and liabilities associated with exit and disposal activities based on estimates of fair value in the period the liabilities are incurred. The Company’s exit and disposal activities have primarily been associated with the Company’s facilities, but also have included the termination of employees in some cases. The Company’s initial estimate of its liabilities for net ongoing costs associated with its facility obligations are recorded at fair value on the cease use date. On a quarterly basis, the Company evaluates and adjusts these liabilities as appropriate for changes in circumstances. Changes to the Company’s estimate of these liabilities are recorded as additional restructuring expenses (credits). These costs are included in “Restructuring (income) expenses” on the Company’s consolidated statements of operations.
The Company has adopted several plans to restructure its facilities and operations for which it has incurred restructuring expenses. The only significant restructuring event during the three years ended December 31, 2019 commenced in February 2017 upon the Company’s decision to consolidate its research activities into its Boston, Milton Park and San Diego locations. The Company closed its research site in Canada as a result of this decision affecting approximately 70 positions. The Company’s lease for its research site in Canada expired in October 2018. As of December 31, 2019 and 2018, the Company has no restructuring liabilities recorded on its consolidated balance sheet and does not anticipate any additional charges related to this restructuring event in the future.
Comprehensive Income (Loss)
Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss), which includes foreign currency translation adjustments and unrealized gains and losses on foreign currency forward contracts and certain marketable securities. For purposes of comprehensive income (loss) disclosures, the Company records provisions for or benefits from income taxes related to the unrealized gains and losses on foreign currency forward contracts and certain marketable securities. The Company does not record provisions for or benefits from income taxes related to the cumulative translation adjustment, as the Company intends to permanently reinvest undistributed earnings in its foreign subsidiaries.
Foreign Currency Translation and Transactions
The majority of the Company’s operations occur in entities that have the U.S. dollar denominated as their functional currency. The assets and liabilities of the Company’s entities with functional currencies other than the U.S. dollar are translated into U.S. dollars at rates of exchange in effect at the end of the year. Revenue and expense amounts for these entities are translated using the average exchange rates for the period. Net unrealized gains and losses resulting from foreign currency translation are included in “Accumulated other comprehensive (loss) income.” Net foreign currency exchange transaction losses, which are included in “Other income (expense), net” on the Company’s consolidated statement of operations, were $5.2 million, $1.1 million and $5.5 million for 2019, 2018 and 2017, respectively. These net foreign currency exchange losses are presented net of the impact of the foreign currency forward contracts designed to mitigate their effect on the Company’s consolidated statement of operations.
Net Loss Per Share Attributable to Vertex Common Shareholders
Basic and diluted net loss per share attributable to Vertex common shareholders are presented in conformity with the two-class method required for participating securities. Under the two-class method, earnings are allocated to (i) Vertex common shares, excluding unvested restricted stock, and (ii) participating securities, based on their respective weighted-average shares outstanding for the period. Shares of unvested restricted stock granted under the Company’s Amended and Restated 2006 Stock and Option Plan have the non-forfeitable right to receive dividends on an equal basis with other outstanding common stock. As a result, these unvested shares of restricted stock are considered participating securities under the two-class method. Potentially dilutive shares result from the assumed exercise of outstanding stock options (the proceeds of which are then assumed to have been used to repurchase outstanding stock using the treasury stock method).


F-19

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


Basic net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.
Recently Adopted Accounting Standards
Leases
In 2016, the Financial Accounting Standards Board (“FASB”) issued ASC 842, which amends a number of aspects of lease accounting and requires entities to recognize right-of-use assets and liabilities on the balance sheet. ASC 842 became effective on January 1, 2019.
Until December 31, 2018, the Company applied build-to-suit accounting and was the deemed owner of its leased corporate headquarters in Boston and research site in San Diego, for which it was recognizing depreciation expense over the buildings’ useful lives and imputed interest on the corresponding construction financing lease obligations. Under the amended guidance that became effective January 1, 2019, the Company accounts for these buildings as finance leases, resulting in increased depreciation expense over the respective lease terms of approximately 15 years, which are significantly shorter than the buildings’ useful lives of 40 years. The amended guidance also results in a reduction in imputed interest expense in the initial years of each finance lease term.
In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”), which offered a transition option to entities adopting ASC 842. Under ASU 2018-11, entities could elect to apply ASC 842 using a modified-retrospective adoption approach resulting in a cumulative effect adjustment to accumulated deficit at the beginning of the year in which the new lease standard is adopted, rather than adjustments to the earliest comparative period presented in their financial statements. The Company adopted ASC 842 using the modified-retrospective method. As of January 1, 2019, the Company recorded a cumulative effect adjustment to increase its “Accumulated deficit” by $40.3 million related to the adjustments to its build-to-suit leases described in the previous paragraph.
The Company elected the package of transition practical expedients for leases that commenced prior to January 1, 2019, allowing it not to reassess (i) whether any expired or existing contracts contain leases, (ii) the lease classification for any expired or existing leases and (iii) the initial indirect costs for any existing leases.
Additionally, the Company recorded, upon adoption of ASC 842 on January 1, 2019, operating lease assets of $61.7 million and corresponding liabilities of $71.9 million related to its real estate leases that are not treated as finance leases under ASC 842. The difference between these assets and liabilities was primarily attributable to prepaid or accrued lease payments. The Company also reclassified amounts that were recorded as “Capital lease obligations, current portion” and “Capital lease obligations, excluding current portion” as of December 31, 2018 to “Other current liabilities” and “Long-term finance lease liabilities,” respectively, on January 1, 2019. These adjustments had no impact on the Company’s consolidated statement of operations and had no impact on the Company’s accumulated deficit.


F-20

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


The cumulative effect of applying ASC 842 on the Company’s consolidated balance sheet as of January 1, 2019 was as follows:
 
Balance as of
 
 
 
Balance as of
 
December 31, 2018 ^
 
Adjustments
 
January 1, 2019
Assets
(in thousands)
Prepaid expenses and other current assets
$
140,819

 
$
(2,930
)
 
$
137,889

Property and equipment, net
812,005

 
(53,920
)
 
758,085

Deferred tax assets
1,499,672

 
11,236

 
1,510,908

Other assets
—

 
61,674

 
61,674

Total assets
$
6,245,898

 
$
16,060

 
$
6,261,958

Liabilities and Shareholders’ Equity
 
 
 
 
 
Capital lease obligations, current portion
$
9,817

 
$
(9,817
)
 
$
—

Other current liabilities
40,589

 
34,304

 
74,893

Capital lease obligations, excluding current portion
19,658

 
(19,658
)
 
—

Construction financing lease obligation, excluding current portion
561,892

 
(561,892
)
 
—

Long-term finance lease liabilities
—

 
569,487

 
569,487

Other long-term liabilities
26,280

 
43,946

 
70,226

Accumulated deficit
(2,989,478
)
 
(40,310
)
 
(3,029,788
)
Total liabilities and shareholders’ equity
$
6,245,898

 
$
16,060

 
$
6,261,958

^ As reported in the Company’s 2018 Annual Report on Form 10-K.

“Other assets” and “Other long-term liabilities” in the table above relate primarily to the Company’s operating leases. Please refer to Note M, “Leases,” for further information regarding the Company’s leases as well as certain disclosures required by ASC 842.
Derivatives and Hedging
In 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815) (“ASU 2017-12”), which helps simplify certain aspects of hedge accounting and enables entities to more accurately present their risk management activities in their financial statements. ASU 2017-12 became effective January 1, 2019. The adoption of ASU 2017-12 did not have a significant effect on the Company’s consolidated financial statements.
Revenue Recognition
In 2014, the FASB issued ASC 606. The new guidance became effective January 1, 2018. ASC 606 applies a more principles-based approach to recognizing revenue. Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted ASC 606 on January 1, 2018 using the modified-retrospective adoption method for all contracts that were not completed as of the date of adoption. Under the modified-retrospective method, the Company recognized the cumulative effect of applying the standard within “Accumulated deficit” on its consolidated balance sheet as of January 1, 2018.
For all reporting periods, the Company has not disclosed the value of unsatisfied performance obligations for all product revenue contracts with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. 
Based on the Company’s review of existing customer contracts as of January 1, 2018, it concluded that the only significant impact that the adoption of ASC 606 had on its financial statements related to shipments of ORKAMBI under early access programs in France. Prior to the adoption of ASC 606, the Company did not recognize revenue on the proceeds received from sales of ORKAMBI under early access programs in France because the price was not fixed or determinable based on the status of ongoing pricing discussions. As of January 1, 2018, the Company recorded a cumulative effect


F-21

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


adjustment to its accumulated deficit of $8.3 million related to the adoption of ASC 606, which primarily represented the Company’s estimated amount of consideration it expected to retain related to these shipments that would not be subject to a significant reversal in amounts recognized, net of costs previously deferred related to these shipments. Please refer to “Product Revenues, Net” above for further information related to the impact of the new revenue recognition on these sales.
The impact of adoption on the Company’s consolidated statement of operations for the year ended December 31, 2018 was as follows:
 
Year Ended December 31, 2018
 
As Reported
under ASC 606
 
Balances
without Adoption of ASC 606
 
Effect of Change
Higher/(Lower)
 
(in thousands)
Product revenues, net
$
3,038,325

 
$
3,019,484

 
$
18,841

Cost of sales
409,539

 
402,925

 
6,614

Income from operations
635,150

 
622,923

 
12,227

Net income attributable to Vertex
$
2,096,896

 
$
2,084,669

 
$
12,227

 
 
 
 
 
 
Amounts per share attributable to Vertex common shareholders:
 
 
 
 
 
Net income:
 
 
 
 
 
Basic
$
8.24

 
$
8.20

 
$
0.04

Diluted
$
8.09

 
$
8.04

 
$
0.05


ASC 606 did not have an aggregate impact on the Company’s net cash provided by operating activities, but resulted in offsetting changes in certain assets and liabilities presented within net cash provided by operating activities in the Company’s consolidated statement of cash flows.
Equity Investments
In 2016, the FASB issued ASU 2016-01, which amended guidance related to the recording of financial assets and financial liabilities. Under ASU 2016-01, equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of an investee) are measured at fair value with changes in fair value recognized in net income (loss). However, an entity has the option to measure equity investments without readily determinable fair values at (i) fair value or (ii) cost adjusted for changes in observable prices minus impairment. Changes in measurement under either alternative are recognized in net income (loss). ASU 2016-01 became effective January 1, 2018 and required the modified-retrospective adoption method. As of January 1, 2018, the Company held publicly traded equity investments and equity investments accounted for under the cost method. As a result, in 2018, the Company recorded a $25.1 million cumulative effect adjustment to “Accumulated deficit” related to its publicly traded equity investments equal to the unrealized gain, net of tax, that was recorded in “Accumulated other comprehensive (loss) income” as of December 31, 2017. The adoption of ASU 2016-01 had no effect on the Company’s equity investments accounted for under the cost method because the original cost basis of these investments was recorded on the Company’s consolidated balance sheet as of December 31, 2017. In 2019 and 2018, the Company recorded net unrealized gains of $132.5 million and $2.6 million, respectively, to “Other income (expense), net” in its consolidated statement of operations related to the change in fair value of its equity investments.
Intra-Entity Transfers
In 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”), which removes the previous exception in GAAP prohibiting an entity from recognizing current and deferred income tax expenses or benefits related to the transfer of assets, other than inventory, within the consolidated entity. The exception to defer the recognition of any tax impact on the transfer of inventory within the consolidated entity until it is sold to a third party remains unaffected. ASU 2016-16 became effective January 1, 2018. In 2018, upon adoption of ASU 2016-16, the Company recorded a deferred tax asset and corresponding full valuation allowance of $204.7 million equal to the unamortized cost of


F-22

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


intellectual property rights transferred to the United Kingdom in 2014 multiplied by an appropriate statutory rate. There was no cumulative effect adjustment to “Accumulated deficit” using the modified-retrospective adoption method.
Goodwill
In 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) (“ASU 2017-04”) related to measurements of goodwill. ASU 2017-04 modifies the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value, which eliminates Step 2 from the goodwill impairment test. An entity would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to the related reporting unit. The Company early adopted ASU 2017-04 and utilized this approach for annual and interim goodwill impairment tests conducted after January 1, 2018. The adoption of ASU 2017-04 did not have a significant effect on the Company’s consolidated financial statements.
Cash Flows - Restricted Cash
In 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) Restricted Cash (“ASU 2016-18”), which requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and restricted cash. Therefore, amounts described as restricted cash should be included with cash and cash equivalents when reconciling the beginning of period and end of period amounts shown on the statement of cash flows.  ASU 2016-18 became effective January 1, 2018 and was effective on a retrospective basis. The cash, cash equivalents and restricted cash balances for the years ended December 31, 2019 through 2016, which are presented in the Company’s consolidated statements of cash flows subsequent to the adoption of ASU 2016-18, consisted of the following:
 
As of December 31,
 
2019
 
2018
 
2017
 
2016
 
(in thousands)
Cash and cash equivalents
$
3,109,322

 
$
2,650,134

 
$
1,665,412

 
$
1,183,945

Prepaid expenses and other current assets
8,004

 
4,910

 
2,114

 
47,762

Other assets
3,355

 
3,209

 
—

 
—

Cash, cash equivalents and restricted cash per statement of cash flows
$
3,120,681

 
$
2,658,253

 
$
1,667,526

 
$
1,231,707


The Company’s restricted cash, if any, is included in “Prepaid expenses and other current assets” and “Other assets” in its consolidated balance sheets. As of December 31, 2017 and 2016, the Company recorded BioAxone’s cash and cash equivalents as “Prepaid expenses and other current assets” because the Company did not have any interest in or control over BioAxone’s cash and cash equivalents.
Stock-Based Compensation - Improvements
In 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”), which simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 became effective January 1, 2017. ASU 2016-09 eliminated the requirement that excess tax benefits were realized as a reduction in current taxes payable before the associated tax benefit could be recognized as an increase in additional paid-in capital. This created a deferred tax asset of $410.8 million relating to federal and state net operating losses (“NOLs”) that were fully reserved by an equal increase in the Company’s valuation allowance as of January 1, 2017. The Company recorded deferred tax assets of $404.7 million relating to federal NOLs and $6.1 million relating to state NOLs, both of which were offset by a full valuation allowance. Upon adoption, the Company also elected to change its accounting policy to account for forfeitures of options and awards as they occur. The change was applied on a modified-retrospective basis with a cumulative effect adjustment to increase “Accumulated deficit” by $9.4 million as of January 1, 2017. This change also resulted in an increase to the deferred tax asset of $3.4 million, which was offset by a full valuation allowance. As a result, there was no cumulative effect adjustment to accumulated deficit related to income taxes. The provisions related to the recognition of excess tax benefits in the Company’s consolidated statement of


F-23

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


operations and classification in the consolidated statement of cash flows were adopted prospectively, and as such, the prior periods were not retrospectively adjusted.
Recently Issued Accounting Standards
Internal-Use Software
In 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”), which clarifies the accounting for implementation costs in cloud computing arrangements.  ASU 2018-15 was effective on January 1, 2020. The Company expects the adoption of ASU 2018-15 will result in an insignificant amount of additional assets recorded on its consolidated balance sheet.
Fair Value Measurement
In 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which modifies the disclosure requirements for fair value measurements. ASU 2018-13 was effective on January 1, 2020. The Company expects the adoption of ASU 2018-13 will result in additional disclosures related to its assets and liabilities that are valued based on Level 3 inputs.
Credit Losses
In 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 was effective on January 1, 2020. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on its consolidated financial statements.
B.
Collaborative Arrangements
The Company has entered into numerous agreements pursuant to which it collaborates with third parties on research, development and commercialization programs, including in-license and out-license agreements.
In-license Agreements
The Company has entered into a number of license agreements in order to advance and obtain access to technologies and services related to its research and early-development activities. The Company is generally required to make an upfront payment upon execution of the license agreement; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from the collaboration.
Pursuant to the terms of its in-license agreements, the Company’s collaborators typically lead the discovery efforts and the Company leads all preclinical, development and commercialization activities associated with the advancement of any drug candidates and funds all expenses.
The Company typically can terminate its in-license agreements by providing advance notice to its collaborators; the required length of notice is dependent on whether any product developed under the license agreement has received marketing approval. The Company’s license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.
CRISPR Therapeutics AG
In 2015, the Company entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. The Company had the exclusive right to license certain CRISPR Cas9-based targets. In the fourth quarter of 2019, the Company paid an aggregate of $30.0 million to exclusively license three CRISPR-Cas9-based targets, including CF, pursuant to the CRISPR Agreement. The Company recorded the $30.0 million total option payment to “Research and development expenses” in the fourth quarter of 2019. For each of the three targets that the Company elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on net product sales.
In 2017, the Company entered into a co-development and co-commercialization agreement with CRISPR pursuant to the terms of the CRISPR Agreement, under which the Company and CRISPR are co-developing and will co-commercialize CTX001 (the “CTX001 Co-Co Agreement”) for the treatment of hemoglobinopathy, including treatments for sickle cell disease and beta-thalassemia. As part of the collaboration, the Company and CRISPR share equally all development costs and potential worldwide revenues related to potential hemoglobinopathy treatments, including treatments for beta-thalassemia and sickle cell disease. The Company concluded that the CTX001 Co-Co Agreement is a cost-sharing arrangement, which results in the net impact of the arrangement being recorded in “Research and development expenses” in its consolidated statements of operations. During the years ended December 31, 2019 and 2018, the net expense related to the CTX001 Co-Co Agreement was $30.1 million and $19.7 million, respectively. Net expense related to the CTX001 Co-Co Agreement during the year ended December 31, 2017 was not significant.
In July 2019, the Company entered into a separate strategic collaboration and license agreement (the “CRISPR DMD/DM1 Agreement”) with CRISPR. Pursuant to this agreement, the Company received an exclusive worldwide license to CRISPR’s existing and future intellectual property for duchenne muscular dystrophy (“DMD”) and myotonic dystrophy type 1 (“DM1”) and the Company made an upfront payment of $175.0 million to CRISPR. The Company concluded that it did not have any alternative future use for the acquired in-process research and development and recorded the upfront payment to “Research and development expenses” in the third quarter of 2019. CRISPR has the potential to receive up to $825.0 million in research, development, regulatory and commercial milestones for the DMD and DM1 programs as well as royalties on net product sales. CRISPR has the option to co-develop and co-commercialize all DM1 products globally and forego the milestones and royalties associated with the DM1 program. The Company will fund all expenses associated with the


F-24

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


collaboration except for research costs for specified guide RNA research conducted by CRISPR, which the Company and CRISPR will share equally.
Please refer to Note F, “Marketable Securities and Equity Investments,” for information regarding the Company’s investment in CRISPR’s common stock.
Kymera Therapeutics Inc.
In May 2019, the Company entered into a strategic research and development collaboration agreement with Kymera Therapeutics Inc. (“Kymera”) to advance small molecule protein degraders against multiple targets. Kymera’s proprietary platform technology is being applied in the collaboration activities in exchange for an upfront payment of $50.0 million. The Company has the exclusive right to license up to six protein targets, for each of which Kymera may receive up to $170.0 million in payments, including development, regulatory and commercial milestones as well as royalties on net product sales. In addition to the upfront payment, the Company purchased $20.0 million of Kymera’s preferred stock. The Company determined that the fair value of its investment in Kymera’s preferred stock, which does not have a readily determinable fair value, approximated $20.0 million and classified the investment in “Other assets.”
The Company determined that substantially all of the fair value of the Kymera collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development and recorded the $50.0 million upfront payment to “Research and development expenses.”
Other In-License Agreements
In addition to the collaborative arrangements described above, the Company has entered into additional in-license agreements that it does not consider to be individually significant to its financial statements. In addition to the payments described above, the Company recorded upfront, option and milestone payments totaling $63.3 million in 2019, $46.9 million in 2018 and $8.7 million in 2017 to “Research and development expenses,” which included a $25.9 million upfront payment to Molecular Templates, Inc. (“Molecular”) in 2019 and a $30.0 million upfront payment to Arbor Biotechnologies, Inc. (“Arbor”) in 2018.
For Molecular and Arbor and several other in-license agreements that are not individually significant to the Company’s financial statements. The Company determined that substantially all of the fair value of each individual agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development associated with the agreements and recorded the related portion of the upfront payments to “Research and development expenses.” Please refer to Note E, “Fair Value Measurements,” and Note F, “Marketable Securities and Equity Investments,” for further information regarding the Company’s investments in its collaborators.
Variable Interest Entities (VIEs)
The Company licensed rights to certain drug candidates from these third-party collaborators, which has resulted in the consolidation of the third-parties’ financial statements into the Company’s consolidated financial statements as VIEs for certain periods of time. The Company deconsolidated the financial statements of Parion as of September 30, 2017 and BioAxone as of December 31, 2018 from its consolidated financial statements. As of December 31, 2018, and continuing through 2019, the Company had no consolidated VIEs reflected in its financial statements. Please refer to Note K, “Intangible Assets and Goodwill,” for further information regarding the impairment of Parion’s pulmonary ENaC platform and BioAxone’s VX-210 program that were related to these collaborations.
Parion Sciences, Inc.
In 2015, the Company entered into a strategic collaboration and license agreement (the “Parion Agreement”) with Parion to develop investigational epithelial sodium channel (“ENaC”) inhibitors for the potential treatment of CF and all other pulmonary diseases. The Parion Agreement was terminated in January 2020.  Following execution of the Parion Agreement, the Company determined that it had a variable interest in Parion via the Parion Agreement, and that the variable interest


F-25

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


represented a variable interest in Parion as a whole because the fair value of the ENaC inhibitors represented more than half of the total fair value of Parion’s assets. The Company also concluded that it was the primary beneficiary as it had the power to direct the activities that most significantly affect the economic performance of Parion and that it had the obligation to absorb losses and right to receive benefits that potentially could be significant to Parion.  Accordingly, the Company consolidated Parion’s financial statements beginning in June 2015.
In the second quarter of 2017, Parion signed a license agreement with an affiliate of Shire plc related to the development of a drug candidate for the potential treatment of dry eye disease; however, the Company continued to consolidate Parion as a VIE because it determined that there was no substantive change in the design of Parion subsequent to Parion’s agreement with Shire. Based on the consolidation of Parion’s financial statements, during the year ended December 31, 2017, the Company recognized $40.0 million of collaborative revenues and (ii) a tax provision of $14.8 million, both of which were attributable to noncontrolling interest related to payments that Parion received from Shire in the year ended December 31, 2017.
As of September 30, 2017, the Company determined that the $255.3 million fair value of Parion’s pulmonary ENaC platform had declined significantly based on data received in September 2017 from a Phase 2 clinical trial of VX-371 that did not meet its primary efficacy endpoint. Based on this data, the Company evaluated the fair value of Parion’s pulmonary ENaC platform using the discounted cash flow approach from the perspective of a market participant and determined that the fair value of the intangible asset was zero as of September 30, 2017. The Company recorded a $255.3 million impairment charge in the third quarter of 2017. After evaluating the results of the clinical trial and based on the decrease in the fair value of Parion’s pulmonary ENaC platform relative to Parion’s other activities, the Company determined that it was no longer the primary beneficiary of Parion as it no longer had the power to direct the significant activities of Parion. Accordingly, the Company deconsolidated Parion as of September 30, 2017. The impairment charge, the decrease in the fair value of the contingent payments payable by the Company to Parion of $69.6 million and the benefit from income taxes of $126.2 million resulting from these charges that were recorded in the third quarter of 2017 were attributable to noncontrolling interest. The benefit from income taxes consisted of benefits of $97.7 million attributable to the impairment charge and $28.5 million attributable to the decrease in the fair value of contingent payments. The net effect of these charges and impact of the deconsolidation was a loss of $7.1 million recorded in “Other income (expense), net” attributable to Vertex in the consolidated statement of operations for the year ended December 31, 2017.
BioAxone Biosciences, Inc.
In 2014, the Company entered into a license and collaboration agreement (the “BioAxone Agreement”) with BioAxone, which resulted in the consolidation of BioAxone as a VIE beginning in October 2014.
In October 2018, the Company announced it would stop clinical development of VX-210 and terminate the Phase 2b clinical trial of VX-210 based on the recommendation of the clinical trial’s Data Safety Monitoring Board and the Company’s review of interim data. In December 2018, the Company notified BioAxone of its intent to terminate the BioAxone Agreement and executed a release that immediately allowed BioAxone to control development of its neurological programs other than VX-210 without the Company’s consent. As a result of this decision, the Company recorded a $29.0 million impairment charge related to VX-210 that was attributable to noncontrolling interest.
As a result, the Company deconsolidated BioAxone as of December 31, 2018 because it determined that it no longer was the primary beneficiary of BioAxone as it no longer had the power to direct the significant activities of BioAxone. The net impact of the deconsolidation was not material to the Company’s consolidated statement of operations.
The Company concluded that the deconsolidations of Parion and BioAxone, based on clinical data that did not meet expectations, were not developments that represented a significant strategic shift or had a material impact on the Company’s overall operations and financial results or its plans to focus on developing and commercializing therapies for the treatment of CF and advancing its research and development programs in additional diseases. Therefore, the Company did not present the results related to Parion and BioAxone as discontinued operations in its consolidated statements of operations for the three years ended December 31, 2019.


F-26

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


Aggregate VIE Financial Information
An aggregate summary of net loss attributable to noncontrolling interest related to the Company’s VIEs for the years ended December 31, 2018 and 2017 was as follows:
 
2018
 
2017
 
(in thousands)
Loss attributable to noncontrolling interest before benefit from income taxes and changes in fair value of contingent payments
$
31,191

 
$
223,379

Benefit from income taxes
(3,668
)
 
(114,090
)
(Increase) decrease in fair value of contingent payments
(17,730
)
 
62,560

Net loss attributable to noncontrolling interest
$
9,793

 
$
171,849


The increase in the noncontrolling interest holders’ claim to net assets with respect to the fair value of the contingent payments for the year ended December 31, 2018 was primarily due to the expiration of the Company’s option to purchase BioAxone that increased the probability that a $10.0 million license continuation fee for VX-210 would be paid. The decrease in the noncontrolling interest holders’ claim to net assets with respect to the fair value of the contingent payments for the year ended December 31, 2017 was primarily due to the decrease in the fair value of Parion’s pulmonary ENaC platform described above.
Out-license Agreements
The Company has entered into licensing agreements pursuant to which it has out-licensed rights to certain drug candidates to third-party collaborators. Pursuant to these out-license agreements, the Company’s collaborators become responsible for all costs related to the continued development of such drug candidates and obtain development and commercialization rights to these drug candidates. Depending on the terms of the agreements, the Company’s collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and may also be required to pay royalties on future sales, if any, of commercial products resulting from the collaboration. The termination provisions associated with these collaborations are generally the same as those described above related to the Company’s in-license agreements.
Merck KGaA, Darmstadt, Germany
In January 2017, the Company entered into a strategic collaboration and license agreement (the “Oncology Agreement”) with Merck KGaA, Darmstadt, Germany (the “Licensee”). Pursuant to the Oncology Agreement, the Company granted the Licensee an exclusive worldwide license to research, develop and commercialize four oncology research and development programs including two clinical-stage programs targeting DNA damage repair: its ataxia telangiectasia and Rad3-related protein kinase inhibitor program, or ATR program, including VX-970 and VX-803, and its DNA-dependent protein kinase inhibitor program, or DNA-PK program, including VX-984. In addition, the Company granted the Licensee exclusive, worldwide rights to two pre-clinical programs.
The Oncology Agreement provided for an upfront payment from the Licensee to the Company of $230.0 million. The Company evaluated the deliverables, primarily consisting of a license to the four programs and the obligation to complete certain fully-reimbursable research and development and transition activities as directed by the Licensee, pursuant to the Oncology Agreement, under the multiple element arrangement accounting guidance that was applicable in 2017. The Company concluded that the license had stand-alone value from the research and development and transition activities based on the resources and know-how possessed by the Licensee, and thus concluded that there are two units of accounting in the arrangement. The Company determined the relative selling price of the units of accounting based on the Company’s best estimate of selling price. The Company utilized key assumptions to determine the best estimate of selling price for the license, which included future potential net sales of licensed products, development timelines, reimbursement rates for personnel costs, discount rates, and estimated third-party development costs. The Company utilized a discounted cash flow model to determine its best estimate of selling price for the license and determined the best estimate of selling price for the research and development and transition activities based on what it would sell the services for separately. Given the significance of the best estimate of selling price for the license as compared to the best estimate of selling price for the


F-27

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


research and development and transition services, reasonable changes in the assumptions used in the discounted cash flow model would not have a significant impact on the relative selling price allocation. Based on this analysis, the Company recognized the $230.0 million upfront payment upon delivery of the license as well as research and development and transition activities during the year ended December 31, 2017. The Company records the reimbursement for the research and development and transition activities in its consolidated statements of operations as collaborative revenue primarily due to the fact that it is the primary obligor in the arrangement. The Company’s activities related to the research and development and transition activities under the Oncology Agreement were substantially complete as of December 31, 2017.
In December 2018, the Company entered into an agreement with Merck KGaA, Darmstadt, Germany (the “DNA-PK Agreement”) whereby the Company licensed the two lead Vertex DNA-PK compounds from its DNA-PK program for use in the field of gene integration for six specific indications. In exchange for this exclusive worldwide license to research, develop and commercialize the DNA-PK program for the specified indications within the field of gene integration, the Company made an upfront payment of $65.0 million. Merck KGaA, Darmstadt, Germany has the potential to receive additional milestones, primarily related to approval and reimbursement in various markets, as well as royalties on net product sales.
The Company evaluated the DNA-PK Agreement and concluded it represents a modification of the Oncology Agreement pursuant to ASC 606. As of December 2018, when the Company entered into the DNA-PK Agreement, the Company had completed its obligations under the Oncology Agreement, but the Oncology Agreement was an open contract pursuant to ASC 606 since the Company could receive future royalty payments from the commercialization of the licensed programs under the Oncology Agreement.
In applying ASC 606, the Company determined that the license granted under the DNA-PK Agreement is distinct from the license granted by the Company under the Oncology Agreement since the license to the two lead Vertex DNA-PK compounds is capable of being distinct as the Company is able to benefit from the license via its ability to internally develop and commercialize the two lead Vertex DNA-PK compounds in the six named indications in the field of gene-editing, and the license is not dependent on Merck KGaA, Darmstadt, Germany providing any specialized services to the Company. In addition, the license to the two lead Vertex DNA-PK compounds granted to the Company under the DNA-PK Agreement is distinct from the license granted by the Company under the Oncology Agreement as the rights conveyed in the licenses differ and both parties have the ability to commercially benefit from the licenses on their own. Furthermore, the consideration attributable to the license of the two lead Vertex DNA-PK compounds represents fair value. Therefore, the Company determined it should account for the DNA-PK Agreement as a separate agreement.
The Company determined that substantially all of the fair value of the DNA-PK Agreement was attributable to a single in-process research and development asset that did not constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development and recorded the $65.0 million payment to “Research and development expenses” accordingly.
Janssen Pharmaceuticals, Inc.
In 2014, the Company entered into an agreement with Janssen Pharmaceuticals, Inc. (“Janssen”). Pursuant to the agreement, Janssen has an exclusive worldwide license to develop and commercialize certain drug candidates for the treatment of influenza, including pimodivir. The Company recognized a $25.0 million milestone in 2017, based on a Phase 3 clinical trial that Janssen initiated.
Cystic Fibrosis Foundation
The Company has a research, development and commercialization agreement that was originally entered into in 2004 with Cystic Fibrosis Foundation (“CFF”), as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc. This agreement was most recently amended in 2016 (the “2016 Amendment”). Pursuant to the agreement, as amended, the Company agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor, and tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor). For combination products, such as ORKAMBI,


F-28

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


SYMDEKO/SYMKEVI and TRIKAFTA (elexacaftor, tezacaftor, and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product.
Pursuant to the 2016 Amendment, the Company received an upfront payment of $75.0 million and is receiving development funding from CFF of up to $6.0 million annually. The Company concluded that the upfront payment plus any future development funding represent a form of financing pursuant to ASC 730 and thus records the amounts as a liability on the consolidated balance sheet, primarily reflected in “Other long-term liabilities.” The Company reduces this liability over the estimated royalty term of the agreement and reflects the reductions as an offset to “Cost of sales” and as “Interest expense.”
C.
Acquisitions
Business Acquisitions
Exonics Therapeutics, Inc.
On July 16, 2019, the Company completed its acquisition of Exonics Therapeutics, Inc. (“Exonics”), a privately held biotechnology company focused on creating transformative gene-editing therapies to repair mutations that cause DMD and other severe neuromuscular diseases, including DM1. The Company acquired Exonics for an upfront payment of approximately $245.0 million, customary working capital adjustments and approximately $70.0 million in deferred payments. Exonics’ equity holders may receive an additional $728.0 million upon the successful achievement of specified development and regulatory milestones for the DMD and DM1 programs.
The Company concluded that Exonics’ intellectual property, assembled workforce and scientific expertise, has the potential to produce therapies for patients with DMD and DM1; therefore, it accounted for the acquisition as a business combination. The Company determined that the purchase price related to the Exonics business combination was $438.4 million, which consisted of (i) the upfront payment as adjusted for customary working capital adjustments, and (ii) the estimated fair value related to $678.3 million of contingent development and regulatory milestones attributable to the purchase of Exonics’ outstanding shares on July 16, 2019. The remaining portion, or $49.7 million, of the development and regulatory milestones and the $70.0 million in deferred payments were determined to be compensatory, as they relate to post-acquisition services, and will be expensed to “Research and development expenses” as incurred.
The purchase price consisted of the following:
 
(in thousands)
Upfront payment (adjusted for customary working capital adjustments)
$
266,315

Fair value of contingent development and regulatory payments
172,041

Total purchase price
$
438,356


The Company’s methodology for determining the fair value of the contingent development and regulatory payments is described in Note E, “Fair Value Measurements.”
The Company allocated the purchase price to the following assets acquired and liabilities assumed:
 
July 16, 2019
 
(in thousands)
Cash and cash equivalents
$
19,535

Goodwill
397,141

Intangible asset
13,000

Net other assets
8,680

Total purchase price
$
438,356


The “Goodwill” represents the difference between the fair value of the consideration transferred and the fair value of the assets and liabilities acquired. The goodwill was attributable to Exonics’ technological expertise, assembled workforce, the potential additional therapeutic programs that may be discovered utilizing Exonics’ DMD and DM1 programs and synergies


F-29

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


from combining these programs with the Company’s current gene-editing capabilities through its collaboration with CRISPR. None of the goodwill is expected to be deductible for income tax purposes. The “Intangible asset” is a single in-process research and development asset related to Exonics’ DMD and DM1 programs. The Company concluded that the intangible asset was a single asset based on similarities between the DMD and DM1 programs including (i) their pre-clinical stage of development, (ii) the development activities and technologies necessary to further develop them, which will be managed on a combined basis, (iii) anticipated pricing and (iv) patient populations. The fair value of the intangible asset was determined through a discounted cash flow analysis utilizing Level 3 fair value inputs related to the development and commercialization of therapies for DMD and DM1. As of December 31, 2019, the Company’s accounting for the Exonics business combination is complete.
Semma Therapeutics, Inc.
On October 10, 2019, the Company completed its acquisition of Semma Therapeutics, Inc. (“Semma”), a privately held biotechnology company primarily focused on the use of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes. The Company acquired Semma in exchange for a purchase price of $936.8 million.
The Company allocated the purchase price to the following assets acquired and liabilities assumed:
 
October 10, 2019
 
(in thousands)
Cash and cash equivalents
$
29,331

Property and equipment, net
17,111

Goodwill
554,633

Intangible assets
387,000

Deferred tax liability
(54,160
)
Net other assets
2,849

Total purchase price
$
936,764


The “Goodwill” represents the difference between the fair value of the consideration transferred and the fair value of the assets and liabilities acquired. The goodwill was attributable to the technological expertise in cell therapy of Semma’s assembled workforce, the potential synergies from combining Semma’s proprietary platform with the Company’s clinical development capabilities and the potential additional therapeutic programs that may be discovered utilizing Semma’s proprietary platform. None of the goodwill is expected to be deductible for income tax purposes.
The “Intangible assets” are in-process research and development assets of $379.0 million and $8.0 million related to Semma’s pre-clinical treatments for device-assisted cells and naked islets, respectively. Semma produces human pancreatic beta cells, or islets, that could potentially help type 1 diabetes patients produce appropriate levels of insulin and safely control hypoglycemia. The “naked islets treatment” is intended for a small portion of the type 1 diabetes patient population who are already receiving immunosuppression therapy and can receive the islets without their immune system destroying them. For the majority of type 1 diabetes patients, who are not receiving immunosuppression therapy, Semma is seeking to develop a “device-assisted cells treatment” alternative, which includes a novel device that is designed to encapsulate and protect the islets from the immune system. The device could potentially enable durable implantation without the need for ongoing immunosuppressive therapy.
The Company determined that device-assisted cells and the naked islets were two separate assets based on, among other things, (i) the separate type 1 diabetes patient populations expected to receive the treatments and (ii) the clinical and regulatory risks and costs associated with developing the islets versus developing and manufacturing the device.
The fair values of the intangible assets were determined through a discounted cash flow analysis utilizing Level 3 fair value inputs including (i) assumptions regarding the probability of obtaining marketing approval for the treatments;(ii) estimates regarding the timing of and the expected costs to develop and commercialize the treatments; (iii) estimates of future cash flows from potential product sales with respect to treatments; and (iv) appropriate discount and tax rates.
The Company’s “Deferred tax liability” in the table above is recorded as a reduction to “Deferred tax assets” on the Company’s consolidated balance sheet.


F-30

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


As of December 31, 2019, the Company’s accounting for the Exonics and Semma business combinations is complete. The Company has not provided pro forma information because the operations of Exonics and Semma did not have a material effect on its consolidated financial statements. The Company’s consolidated financial statements reflect the operations of Exonics and Semma as of December 31, 2019 and for the periods from July 16, 2019 and October 10, 2019 to December 31, 2019, respectively.
Asset Acquisition
Concert Pharmaceuticals
In 2017, the Company acquired certain CF assets including VX-561 (the “Concert Assets”) from Concert Pharmaceuticals Inc. (“Concert”) pursuant to an asset purchase agreement (the “Concert Agreement”). VX-561 is an investigational CFTR potentiator that has the potential to be used as part of combination regimens of CFTR modulators to treat CF. Pursuant to the Concert Agreement, the Company paid Concert $160.0 million in cash for the Concert Assets. If VX-561 is approved as part of a combination regimen to treat CF, Concert could receive up to an additional $90.0 million in milestones based on regulatory approval in the United States and reimbursement in the United Kingdom, Germany or France. The Company determined that substantially all of the fair value of the Concert Agreement was attributable to a single in-process research and development asset, VX-561, which did not constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development asset. Thus, the Company recorded the $160.0 million upfront payment to “Research and development expenses” in 2017. The total cost of the transaction was $165.1 million including $5.1 million of transaction costs that were recorded to “Sales, general and administrative expenses.”
D.
Earnings Per Share
Basic net income per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock, restricted stock units and performance-based restricted stock units, or “PSUs,” that have been issued but are not yet vested. Diluted net income per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.


F-31

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


The following table sets forth the computation of basic and diluted net income per share for the periods ended:
 
2019
 
2018
 
2017
 
(in thousands, except per share amounts)
Basic net income attributable to Vertex per common share calculation:
 
 
 
 
 
Net income attributable to Vertex common shareholders
$
1,176,810

 
$
2,096,896

 
$
263,484

Less: Undistributed earnings allocated to participating securities
—

 
(501
)
 
(293
)
Net income attributable to Vertex common shareholders—basic
$
1,176,810

 
$
2,096,395

 
$
263,191

 
 
 
 
 
 
Basic weighted-average common shares outstanding
256,728

 
254,292

 
248,858

Basic net income attributable to Vertex per common share
$
4.58

 
$
8.24

 
$
1.06

 
 
 
 
 
 
Diluted net income attributable to Vertex per common share calculation:
 
 
 
 
 
Net income attributable to Vertex common shareholders
$
1,176,810

 
$
2,096,896

 
$
263,484

Less: Undistributed earnings allocated to participating securities
—

 
(492
)
 
(288
)
Net income attributable to Vertex common shareholders—diluted
$
1,176,810

 
$
2,096,404

 
$
263,196

 
 
 
 
 
 
Weighted-average shares used to compute basic net income per common share
256,728

 
254,292

 
248,858

Effect of potentially dilutive securities:
 
 
 
 
 
Stock options
2,231

 
2,913

 
2,797

Restricted stock and restricted stock units (including PSUs)
1,700

 
1,963

 
1,542

Employee stock purchase program
14

 
17

 
28

Weighted-average shares used to compute diluted net income per common share
260,673

 
259,185

 
253,225

Diluted net income attributable to Vertex per common share
$
4.51

 
$
8.09

 
$
1.04


The Company did not include the securities in the following table in the computation of the net income per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period.
 
2019
 
2018
 
2017
 
(in thousands)
Stock options
2,833

 
2,217

 
3,554

Unvested restricted stock and restricted stock units (including PSUs)
6

 
5

 
411


E.
Fair Value Measurements
The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability.


F-32

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. The Company maintains strategic investments separately from the investment policy that governs its other cash, cash equivalents and marketable securities as described in Note F, “Marketable Securities and Equity Investments.” As of December 31, 2019, the Company’s investments were in money market funds, government-sponsored enterprise securities, corporate debt securities, commercial paper and corporate equity securities. Additionally, the Company utilizes foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on its consolidated statement of operations.
As of December 31, 2019, the Company’s financial assets and liabilities that were subject to fair value measurements were valued using both observable and unobservable inputs. The Company’s financial assets valued based on Level 1 inputs consisted of money market funds, government-sponsored enterprise securities and corporate equity securities. The Company’s financial assets and liabilities valued based on Level 2 inputs consisted of certain corporate equity securities as described below, corporate debt securities, commercial paper, which consisted of investments in highly-rated investment-grade corporations and foreign currency forward contracts with reputable and creditworthy counterparties. As discussed further below, the Company’s financial liabilities valued based on Level 3 inputs consisted of acquisition related contingent milestones. During 2019, 2018 and 2017, the Company did not record any other-than-temporary impairment charges related to its financial assets.
The following tables set forth the Company’s financial assets and liabilities subject to fair value measurements (and does not include $2.3 billion and $1.4 billion of cash as of December 31, 2019 and 2018, respectively):
 
Fair Value Measurements as of December 31, 2019
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
791,039

 
$
791,039

 
$
—

 
$
—

Corporate debt securities
6,070

 
—

 
6,070

 
—

Commercial paper
29,472

 
—

 
29,472

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
282,084

 
261,797

 
20,287

 
—

Government-sponsored enterprise securities
12,733

 
12,733

 
—

 
—

Corporate debt securities
301,799

 
—

 
301,799

 
—

Commercial paper
102,356

 
—

 
102,356

 
—

Prepaid expenses and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
9,725

 
—

 
9,725

 
—

Total financial assets
$
1,535,278

 
$
1,065,569

 
$
469,709

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other current liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(5,533
)
 
$
—

 
$
(5,533
)
 
$
—

Long-term contingent consideration
(176,500
)
 
—

 
—

 
(176,500
)
Other long-term liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
(1,821
)
 
—

 
(1,821
)
 
—

Total financial liabilities
$
(183,854
)
 
$
—

 
$
(7,354
)
 
$
(176,500
)



F-33

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


 
Fair Value Measurements as of December 31, 2018
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
1,226,603

 
$
1,226,603

 
$
—

 
$
—

U.S. Treasury securities
5,966

 
5,966

 
—

 
—

Government-sponsored enterprise securities
7,123

 
7,123

 
—

 
—

Commercial paper
58,268

 
—

 
58,268

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
167,323

 
153,733

 
13,590

 
—

U.S. Treasury securities
6,026

 
6,026

 
—

 
—

Government-sponsored enterprise securities
10,704

 
10,704

 
—

 
—

Corporate debt securities
233,665

 
—

 
233,665

 
—

Commercial paper
100,390

 
—

 
100,390

 
—

Prepaid expenses and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
19,023

 
—

 
19,023

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
1,514

 
—

 
1,514

 
—

Total financial assets
$
1,836,605

 
$
1,410,155

 
$
426,450

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other current liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(340
)
 
$
—

 
$
(340
)
 
$
—

Other long-term liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
(108
)
 
—

 
(108
)
 
—

Total financial liabilities
$
(448
)
 
$
—

 
$
(448
)
 
$
—


Please refer to Note F, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
Fair Value of Corporate Equity Securities
The Company maintains strategic investments in corporate equity securities separately from the investment policy that governs its other cash, cash equivalents and marketable securities. The Company classifies its investments in publicly traded companies as “Marketable securities” on its consolidated balance sheets. Generally, the Company’s investments in the common stock of these publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of the Company’s investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments. During the year ended December 31, 2019, the Company transferred the fair value of one of its strategic investments in a publicly traded company from Level 2 to Level 1 upon the expiration of transfer restrictions associated with this investment. Please refer to Note F, “Marketable Securities and Equity Investments,” for further information on these investments.
Fair Value of Contingent Consideration
The Company’s contingent consideration liabilities, which are related to development and regulatory milestones potentially payable to Exonics’ former equity holders, are classified as Level 3 within the valuation hierarchy. The Company bases its estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to rare diseases. The discount rates used in the valuation model for contingent payments represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and


F-34

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


commercialization of a drug candidate in the pharmaceutical industry, the Company's estimates regarding the fair value of contingent consideration will change in the future, resulting in adjustments to the fair value of the Company’s contingent consideration liabilities, and the effect of any such adjustments could be material.
The following table represents a rollforward of the fair value of the Company’s contingent consideration liabilities:
 
Year Ended December 31, 2019
 
(in thousands)
Balance at December 31, 2018
$
—

Contingent consideration related to acquisition of Exonics
172,041

Increase in fair value of contingent payments
4,459

Balance at December 31, 2019
$
176,500


The “Increase in fair value of contingent payments” in the table above was due to changes in market interest rates and the time value of money.
Fair Value of Intangible Asset    
The fair value of the Company’s in-process research and development intangible assets, which totaled $400.0 million as of December 31, 2019, was determined through discounted cash flow models utilizing Level 3 fair value inputs. Please refer to Note C, “Acquisitions,” for further information on the key assumptions utilized to determine the fair value of the in-process research and development assets that the Company acquired as a result of its acquisitions of Semma and Exonics in 2019.


F-35

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


F.
Marketable Securities and Equity Investments
A summary of the Company’s cash equivalents and marketable securities, which are recorded at fair value (and do not include $2.3 billion and $1.4 billion of cash as of December 31, 2019 and 2018, respectively), is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of December 31, 2019
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
791,039

 
$
—

 
$
—

 
$
791,039

Corporate debt securities
6,070

 
—

 
—

 
6,070

Commercial paper
29,470

 
3

 
(1
)
 
29,472

Total cash equivalents
826,579

 
3

 
(1
)
 
826,581

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
12,689

 
44

 
—

 
12,733

Corporate debt securities
301,458

 
391

 
(50
)
 
301,799

Commercial paper
102,240

 
121

 
(5
)
 
102,356

Total marketable debt securities
416,387

 
556

 
(55
)
 
416,888

Corporate equity securities
113,829

 
168,255

 
—

 
282,084

Total marketable securities
$
530,216

 
$
168,811

 
$
(55
)
 
$
698,972

 
 
 
 
 
 
 
 
As of December 31, 2018
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
1,226,603

 
$
—

 
$
—

 
$
1,226,603

U.S. Treasury securities
5,967

 
—

 
(1
)
 
5,966

Government-sponsored enterprise securities
7,124

 
—

 
(1
)
 
7,123

Commercial paper
58,271

 
—

 
(3
)
 
58,268

Total cash equivalents
1,297,965

 
—

 
(5
)
 
1,297,960

Marketable securities:
 
 
 
 
 
 
 
U.S Treasury securities
6,026

 
—

 
—

 
6,026

Government-sponsored enterprise securities
10,704

 
—

 
—

 
10,704

Corporate debt securities
234,088

 
27

 
(450
)
 
233,665

Commercial paper
100,498

 
—

 
(108
)
 
100,390

Total marketable debt securities
351,316

 
27

 
(558
)
 
350,785

Corporate equity securities
133,157

 
40,619

 
(6,453
)
 
167,323

Total marketable securities
$
484,473

 
$
40,646

 
$
(7,011
)
 
$
518,108

Available-for-sale debt securities were classified on the Company’s consolidated balance sheets as follows:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Cash and cash equivalents
$
826,581

 
$
1,297,960

Marketable securities
416,888

 
350,785

Total
$
1,243,469

 
$
1,648,745




F-36

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


Available-for-sale debt securities by contractual maturity were as follows:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Matures within one year
$
1,137,942

 
$
1,647,500

Matures after one year through five years
105,527

 
1,245

Total
$
1,243,469

 
$
1,648,745


The Company has a limited number of available-for-sale debt securities in insignificant loss positions as of December 31, 2019, which it does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investments at maturity. The Company did not record any charges for other-than-temporary declines in the fair value of available-for-sale debt securities or gross realized gains or losses in 2019, 2018 or 2017.
As of December 31, 2019 and 2018, the total fair value of the Company’s strategic investments in the common stock of publicly traded companies, which was primarily related to its investment in CRISPR, was $282.1 million and $167.3 million, respectively, and was classified as “Marketable securities” on its consolidated balance sheets.
Pursuant to the adoption of ASU 2016-01 on January 1, 2018, the Company began recording changes in the fair value of its investments in strategic corporate equity securities, which are primarily attributable to its investment in CRISPR, to “Other income (expense), net” in the Company’s consolidated statements of operations. Prior to its adoption of ASU 2016-01, the Company recorded changes in the fair value of its investments in corporate equity securities to “Accumulated other comprehensive (loss) income” on its consolidated balance sheet until the related gains or losses were realized. The Company continues to record unrealized gains (losses) on available-for-sale debt securities as a component of “Accumulated other comprehensive (loss) income” until such gains and losses are realized.
During the year ended December 31, 2019 and 2018, the Company recorded unrealized gains of $132.5 million and $2.6 million, respectively, which were primarily related to the Company’s strategic investment in CRISPR. As noted above, unrealized gains or losses were recorded to “Accumulated other comprehensive (loss) income” during the year ended December 31, 2017.
During the year ended December 31, 2019, the Company recorded realized gains of $65.1 million related to sales of CRISPR’s common stock. The Company utilized a weighted-average cost basis to calculate the realized gain. There were no sales of CRISPR’s common stock in the years ended December 31, 2018 or 2017.
As of December 31, 2019, the carrying value of the Company’s equity investments without readily determinable fair values, which are recorded in “Other assets” on its consolidated balance sheets, was $40.8 million.


F-37

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


G.
Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
 
 
 
Unrealized Holding Gains (Losses), Net of Tax
 
 
 
Foreign Currency Translation Adjustment
 
On Available-For-Sale Debt Securities
 
On Equity Securities
 
On Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2016
$
(7,862
)
 
$
(10
)
 
$
17,531

 
$
11,514

 
$
21,173

Other comprehensive (loss) income before reclassifications
(13,169
)
 
(584
)
 
7,538

 
(29,175
)
 
(35,390
)
Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
—

 
2,645

 
2,645

Net current period other comprehensive (loss) income
(13,169
)
 
(584
)
 
7,538

 
(26,530
)
 
(32,745
)
Balance at December 31, 2017
$
(21,031
)
 
$
(594
)
 
$
25,069

 
$
(15,016
)
 
$
(11,572
)
Other comprehensive income before reclassifications
8,855

 
58

 
—

 
25,664

 
34,577

Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
—

 
1,774

 
1,774

Net current period other comprehensive income
8,855

 
58

 
—

 
27,438

 
36,351

Amounts reclassified to accumulated deficit pursuant to adoption of new accounting standard
949

 
—

 
(25,069
)
 
—

 
(24,120
)
Balance as of December 31, 2018
$
(11,227
)
 
$
(536
)
 
$
—

 
$
12,422

 
$
659

Other comprehensive income before reclassifications
10,332

 
1,039

 
—

 
11,513

 
22,884

Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
—

 
(25,516
)
 
(25,516
)
Net current period other comprehensive income (loss)
10,332

 
1,039

 
—

 
(14,003
)
 
(2,632
)
Balance as of December 31, 2019
$
(895
)
 
$
503

 
$
—

 
$
(1,581
)
 
$
(1,973
)

H.
    Hedging
Foreign currency forward contracts - Designated as hedging instruments
The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company’s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from one to eighteen months. The Company recognizes realized gains and losses for the effective portion of such contracts in “Product revenues, net” in its consolidated statements of operations in the same period that it recognizes the product revenues that were impacted by the hedged foreign exchange rate changes.
The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company’s risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of December 31, 2019, all hedges were determined to be highly effective.


F-38

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


Prior to the adoption of ASU 2017-12 on January 1, 2019, the Company did not record any ineffectiveness related to its foreign currency forward contracts that were designated as hedging instruments in the years ended December 31, 2018 and 2017. ASU 2017-12 eliminated the requirement to separately measure and report hedge ineffectiveness.
The Company considers the impact of its counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of December 31, 2019 and December 31, 2018, credit risk did not change the fair value of the Company’s foreign currency forward contracts.
The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP:
 
As of December 31,
 
2019
 
2018
Foreign Currency
(in thousands)
Euro
$
501,197

 
$
335,179

Australian dollar
89,705

 
52,820

British pound sterling
87,032

 
73,460

Canadian dollar
50,452

 
43,759

Total foreign currency forward contracts
$
728,386

 
$
505,218


Foreign currency forward contracts - Not designated as hedging instruments
The Company also enters into foreign currency forward contracts with contractual maturities of less than one month that are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under GAAP. The Company recognizes realized gains and losses for such contracts in “Other income (expense), net” in its consolidated statements of operations each period. As of December 31, 2019, the notional amount of the Company’s outstanding foreign currency forward contracts where hedge accounting under GAAP is not applied was $412.1 million.
During the three years ended December 31, 2019, the Company recognized the following related to foreign currency forward contacts in its consolidated statements of operations:
 
December 31,
 
2019
 
2018
 
2017
 
(in thousands)
Designated as hedging instruments - Reclassified from AOCI
 
 
 
 
 
Product revenues, net
$
32,546

 
$
(1,252
)
 
$
768

Not designated as hedging instruments
 
 
 
 
 
Other income (expense), net
$
4,838

 
$
623

 
$
14,129

 
 
 
 
 
 
Total reported in the Consolidated Statement of Operations
 
 
 
 
 
Product revenues, net
$
4,160,726

 
$
3,038,325

 
$
2,165,480

Other income (expense), net
$
192,177

 
$
(790
)
 
$
(81,382
)



F-39

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


The following table summarizes the fair value of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on its consolidated balance sheets:
As of December 31, 2019
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid expenses and other current assets
 
$
9,725

 
Other current liabilities
 
$
(5,533
)
Other assets
 
—

 
Other long-term liabilities
 
(1,821
)
Total assets
 
$
9,725

 
Total liabilities
 
$
(7,354
)
As of December 31, 2018
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid expenses and other current assets
 
$
19,023

 
Other current liabilities
 
$
(340
)
Other assets
 
1,514

 
Other long-term liabilities
 
(108
)
Total assets
 
$
20,537

 
Total liabilities
 
$
(448
)

As of December 31, 2019, the Company expects amounts that are related to foreign exchange forward contracts designated as cash flow hedges under GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company’s consolidated balance sheets:
 
As of December 31, 2019
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
9,725

 
$
—

 
$
9,725

 
$
(7,354
)
 
$
2,371

Total liabilities
(7,354
)
 
—

 
(7,354
)
 
7,354

 
—

 
As of December 31, 2018
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
20,537

 
$
—

 
$
20,537

 
$
(448
)
 
$
20,089

Total liabilities
(448
)
 
—

 
(448
)
 
448

 
—


I.
Inventories
Inventories consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Raw materials
$
26,247

 
$
9,677

Work-in-process
107,021

 
87,944

Finished goods
34,234

 
26,739

Total
$
167,502

 
$
124,360




F-40

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


J.
Property and Equipment
Property and equipment, net consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Buildings
$
648,003

 
$
657,438

Furniture and equipment
317,567

 
280,908

Software
167,547

 
162,601

Leasehold improvements
241,178

 
103,428

Computers
63,325

 
59,073

Total property and equipment, gross
1,437,620

 
1,263,448

Less: accumulated depreciation
(692,540
)
 
(451,443
)
Total property and equipment, net
$
745,080

 
$
812,005


The Company recorded depreciation expense of $106.9 million, $72.4 million and $61.4 million in 2019, 2018 and 2017, respectively. The Company’s capital lease amortization is included in depreciation expense.
K.
Intangible Assets and Goodwill
Intangible Assets
As of December 31, 2019, the Company had $400.0 million of in-process research and development intangible assets classified as “Other assets” on its consolidated balance sheet. As of December 31, 2018, the Company had no in-process research and development intangible assets recorded on its consolidated balance sheet. In 2019, the Company recorded $387.0 million and $13.0 million of in-process research and development intangible assets related to its acquisitions of Semma and Exonics, respectively. In 2018 and 2017, the Company recorded intangible asset impairment charges of $29.0 million related to VX-210 that was licensed from BioAxone in 2014 and $255.3 million related to Parion’s pulmonary ENaC platform, respectively. Please refer to Note B, “Collaborative Arrangements,” for further information regarding the events and circumstances associated with these impairment charges.
Goodwill
As of December 31, 2019 and December 31, 2018, goodwill of $1.00 billion and $50.4 million was recorded on the Company’s consolidated balance sheet. During 2019, the Company recorded goodwill of $554.6 million and $397.1 million related to its acquisitions of Semma and Exonics, respectively.
Please refer to “Note C, “Acquisitions,” for further information on the in-process research and development intangible assets and goodwill that the Company acquired in 2019.


F-41

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


L.
Additional Balance Sheet Detail
Accrued expenses consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Payroll and benefits
$
159,464

 
$
124,753

Research, development and commercial contract costs
105,663

 
115,300

Product revenue allowances
641,368

 
550,002

Royalty payable
98,578

 
101,108

Tax related accruals
72,293

 
43,281

Other
39,546

 
24,455

Total
$
1,116,912

 
$
958,899


Other current liabilities consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Contract liabilities
$
62,332

 
$
24,870

Finance lease liabilities
30,293

 
5,271

Other
37,680

 
20,265

Total
$
130,305

 
$
50,406


Other long-term liabilities consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Advance from collaborator
$
88,762

 
$
82,573

Operating lease liabilities
84,292

 
—

Other
10,264

 
26,280

Total
$
183,318

 
$
108,853


M.
Leases
Finance Leases
The Company’s finance lease assets and liabilities primarily relate to its corporate headquarters in Boston and research site in San Diego (the “Buildings”). These Buildings are classified as finance leases because the present value of the sum of the lease payments associated with the Buildings exceeds substantially all of the fair value of the Buildings. The Company also has outstanding finance leases for equipment.
Prior to the adoption of ASC 842 on January 1, 2019, the Company was deemed for accounting purposes to be the owner of the Buildings during their construction periods and recorded project construction costs incurred by its landlords. Upon completion of the Buildings, the Company determined that the underlying leases did not meet the criteria for “sale-leaseback” treatment. Accordingly, the Company depreciated the Buildings over 40 years and recorded interest expense associated with the financing obligations for the Buildings. The Company bifurcated the lease payments pursuant to the Buildings into (i) a portion that was allocated to the Buildings and (ii) a portion that is allocated to the land on which the Buildings were constructed. The portion of the lease obligations allocated to the land was treated as an operating lease.


F-42

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


Pursuant to ASC 842, the Company adjusted the amounts recorded on its consolidated balance sheet as of January 1, 2019 for the Buildings to reflect the present value of the lease payments over the remaining lease term related to the Buildings. The finance lease assets associated with the Buildings are amortized to depreciation expense using the straight-line method over the remaining lease term, which is significantly shorter than the Buildings’ useful lives. The Company continues to record interest expense associated with the finance lease liabilities for the Buildings.
Corporate Headquarters
In 2011, the Company entered into two lease agreements, pursuant to which the Company leases approximately 1.1 million square feet of office and laboratory space in two buildings in Boston, Massachusetts for a term of 15 years. Base rent payments commenced in December 2013, and will continue through December 2028. The Company utilizes this initial period as its lease term. The Company has an option to extend the lease term for an additional ten years.
San Diego Lease
In 2015, the Company entered into a lease agreement pursuant to which the Company leases approximately 170,000 square feet of office and laboratory space in San Diego, California for a term of 16 years. Base rent payments commenced in the second quarter of 2019, and will continue through May 2034. The Company utilizes this initial period as its lease term. The Company has an option to extend the lease term for up to two additional five-year terms. The Company placed this building into service in the second quarter of 2018.
Operating Leases
The Company’s operating leases relate to its real estate leases that are not classified as finance leases.
Aggregate Lease Information Related to the Application of ASC 842
The following information is disclosed in accordance with ASC 842, which became effective January 1, 2019. The components of lease cost recorded in the Company’s consolidated statement of operations were as follows:
 
2019
 
 
Operating lease cost
$
11,972

Finance lease cost
 
Amortization of leased assets
49,778

Interest on lease liabilities
52,839

Variable lease cost
27,997

Sublease income
(6,391
)
Net lease cost
$
136,195


The Company’s variable lease cost during 2019 primarily related to operating expenses, taxes and insurance associated with its finance leases. The Company’s sublease income during 2019 primarily related to subleases for an insignificant portion of the Company’s corporate headquarters.


F-43

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


The Company’s leases are included on its consolidated balance sheets as follows:
 
As of December 31, 2019
 
As of December 31, 2018 ^
 
(in thousands)
Finance leases
 
 
 
Property and equipment, net
$
445,336

 
$
640,952

Total finance lease assets
$
445,336

 
$
640,952

 
 
 
 
Capital lease obligations, current portion
$
—

 
$
9,817

Other current liabilities
38,795

 
5,271

Capital lease obligations, excluding current portion
—

 
19,658

Construction financing lease obligation, excluding current portion
—

 
561,892

Long-term finance lease liabilities
538,576

 
—

Total finance lease liabilities
$
577,371

 
$
596,638

 
 
 
 
Operating leases
 
 
 
Other assets
$
88,202

 
$
—

Total operating lease assets
$
88,202

 
$
—

 
 
 
 
Other current liabilities
$
11,504

 
$
—

Other long-term liabilities
84,292

 
—

Total operating lease liabilities
$
95,796

 
$
—

^ As reported in the Company’s 2018 Annual Report on Form 10-K.

Maturities of the Company’s finance and operating lease liabilities in accordance with ASC 842 as of December 31, 2019 were as follows:
Year
 
Finance Leases
 
Operating Leases
 
Total
 
 
(in thousands)
2020
 
$
84,264

 
$
14,598

 
$
98,862

2021
 
89,440

 
12,907

 
102,347

2022
 
87,092

 
12,610

 
99,702

2023
 
85,257

 
12,451

 
97,708

2024
 
90,802

 
11,488

 
102,290

Thereafter
 
425,251

 
51,251

 
476,502

Total lease payments
 
862,106

 
115,305

 
977,411

Less: amount representing interest
 
(284,735
)
 
(19,509
)
 
(304,244
)
Present value of lease liabilities
 
$
577,371

 
$
95,796

 
$
673,167


The weighted-average remaining lease terms and discount rates related to the Company’s leases were as follows:
 
As of December 31, 2019
Weighted-average remaining lease term (in years)
 
Finance leases
9.74

Operating leases
9.70

 
 
Weighted-average discount rate
 
Finance leases
9.04
%
Operating leases
3.75
%



F-44

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


Supplemental cash flow information related to the Company’s leases was as follows:
 
December 31, 2019
 
(in thousands)
Cash paid for amounts included in the measurement of lease liabilities:
 
Operating cash flows from operating leases
$
10,650

Operating cash flows from finance leases
$
50,527

Financing cash flows from finance leases
$
39,185

 
 
Right-of-use assets obtained in exchange for lease obligations
 
Operating leases *
$
34,605

Finance leases
$
—

* Includes $33.7 million acquired in 2019 pursuant to the Company’s acquisitions of Semma and Exonics.

Additional Lease Information Related to the Application of ASC 840
The following information is disclosed in accordance with ASC 840, Leases (Topic 840) (“ASC 840”), which was applicable until December 31, 2018. As of December 31, 2018, future minimum commitments under the Company’s real estate leases with initial terms of more than one year were as follows:
Year
 
Fan Pier
Leases
 
Other
Leases
 
Total Lease
Commitments
 
 
(in thousands)
2019
 
$
66,540

 
$
18,531

 
$
85,071

2020
 
72,589

 
23,397

 
95,986

2021
 
72,589

 
21,656

 
94,245

2022
 
72,589

 
21,172

 
93,761

2023
 
72,589

 
21,482

 
94,071

Thereafter
 
389,855

 
185,336

 
575,191

Total minimum lease payments
 
$
746,751

 
$
291,574

 
$
1,038,325


As of December 31, 2018, the Company’s total sublease income to be received related to its facility leases was $6.2 million. During 2018 and 2017, rental expenses were $17.3 million and $19.2 million, respectively.
The capital leases, which were related to equipment and leasehold improvements, bore interest at rates ranging from less than 1% to 6% per year. The Company’s capital lease amortization was included in depreciation expense during 2018 and 2017. The following table set forth the Company’s future minimum payments due under capital leases as of December 31, 2018:
Year
 
(in thousands)
2019
 
$
10,770

2020
 
7,282

2021
 
5,649

2022
 
3,300

2023
 
1,974

Thereafter
 
3,085

Total payments
 
32,060

Less: amount representing interest
 
(2,585
)
Present value of payments
 
$
29,475




F-45

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


N.
Common Stock, Preferred Stock and Equity Plans
Common Stock and Preferred Stock
The Company is authorized to issue 500,000,000 shares of common stock. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by the Company’s Board of Directors, and to share ratably in the Company’s assets legally available for distribution to the Company’s shareholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption or conversion rights. The holders of common stock do not have cumulative voting rights.
The Company is authorized to issue 1,000,000 shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by the Company’s shareholders. As of December 31, 2019 and 2018, the Company had no shares of preferred stock issued or outstanding.
Share Repurchase Program
During 2018, the Company’s Board of Directors approved a share repurchase program (the “2018 Share Repurchase Program”), pursuant to which the Company was authorized to repurchase up to $500.0 million of its common stock between February 1, 2018 and December 31, 2019.
During the years ended December 31, 2019 and 2018, the Company repurchased 832,186 and 2,093,891 shares, respectively, of its common stock under the 2018 Share Repurchase Program for an aggregate of $150.0 million and $350.0 million, respectively, including commissions and fees. As of June 30, 2019, the Company had repurchased the entire $500.0 million it was authorized to repurchase of its common stock under the 2018 Share Repurchase Program.
In July 2019, the Company’s Board of Directors approved a new share repurchase program (the “2019 Share Repurchase Program”), pursuant to which the Company is authorized to repurchase up to $500.0 million of its common stock between August 1, 2019 and December 31, 2020. The Company expects to fund further repurchases of its common stock through a combination of cash on hand and cash generated by operations. During the year ended December 31, 2019, the Company repurchased 213,548 shares of its common stock under the 2019 Share Repurchase Program for an aggregate of $36.0 million including commissions and fees. As of December 31, 2019, there is a total of $464.0 million remaining for repurchases under the 2019 Share Repurchase Program.
Under the 2018 and 2019 Share Repurchase Programs, the Company is authorized to purchase shares from time to time through open market or privately negotiated transactions. Such purchases are made pursuant to Rule 10b5-1 plans or other means as determined by the Company’s management and in accordance with the requirements of the SEC.
Stock and Option Plans
The purpose of each of the Company’s stock and option plans is to attract, retain and motivate its employees, consultants and directors. Awards granted under these plans can be nonstatutory stock options (“NSOs”), incentive stock options (“ISOs”), restricted stock units (“RSUs”) including performance-based RSUs (“PSUs”), restricted stock (“RSs”), or other equity-based awards, as specified in the individual plans.


F-46

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


Shares issued under all of the Company’s plans are funded through the issuance of new shares. The following table contains information about the Company’s equity plans:
 
 
 
 
 
 
As of December 31, 2019
Title of Plan
 
Group Eligible
 
Type of Award
Granted
 
Awards
Outstanding
 
Additional Awards
Authorized for
Grant
2013 Stock and Option Plan
 
Employees, Non-employee Directors and Consultants
 
NSO,
RS, RSU and PSU
 
9,577,268

 
15,778,703

2006 Stock and Option Plan
 
Employees, Non-employee Directors and Consultants
 
NSO,
RS and RSU
 
651,842

 
—

 
 
 
 
Total
 
10,229,110

 
15,778,703


All options granted under the Company’s 2013 Stock and Option Plan (“2013 Plan”) and 2006 Stock and Option Plan (“2006 Plan”) were granted with an exercise price equal to the fair value of the underlying common stock on the date of grant. As of December 31, 2019, the stock and option plan under which the Company is authorized to make new equity awards is the Company’s 2013 Plan. Under the 2013 Plan, no stock options can be awarded with an exercise price less than the fair market value on the date of grant. In the three years ended December 31, 2019, the Company’s shareholders approved increases in the number of shares authorized for issuance pursuant to the 2013 Stock and Option Plan of (i) 5,000,000 shares in 2019, (ii) 8,000,000 shares in 2018 and (iii) 6,750,000 shares in 2017.
During the three years ended December 31, 2019, grants to current employees and directors primarily had a grant date that was the same as the date the award was approved by the Company’s Board of Directors. During the three years ended December 31, 2019, for grants to new employees and directors, the date of grant for awards was the employee’s first day of employment or the date the director was elected to the Company’s Board of Directors. All options awarded under the Company’s stock and option plans expire not more than 10 years from the grant date.
Stock Options
The following table summarizes information related to the outstanding and exercisable options during the year ended December 31, 2019:
 
Stock Options
 
Weighted-average
Exercise Price
 
Weighted-average
Remaining
Contractual Life
 
Aggregate Intrinsic
Value
 
(in thousands)
 
(per share)
 
(in years)
 
(in thousands)
Outstanding at December 31, 2018
8,551

 
$
111.46

 
 
 
 
Granted
1,521

 
$
184.50

 
 
 
 
Exercised
(3,327
)
 
$
95.57

 
 
 
 
Forfeited
(467
)
 
$
146.59

 
 
 
 
Expired
(6
)
 
$
182.96

 
 
 
 
Outstanding at December 31, 2019
6,272

 
$
134.92

 
7.12
 
$
522,740

Exercisable at December 31, 2019
3,333

 
$
114.15

 
6.06
 
$
346,943


The aggregate intrinsic value in the table above represents the total pre-tax amount, net of exercise price, that would have been received by option holders if all option holders had exercised all options with an exercise price lower than the market price on the last business day of 2019, which was $218.26 based on the average of the high and low price of the Company’s common stock on that date.
The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during 2019, 2018 and 2017 was $325.9 million, $258.2 million and $302.8 million, respectively. The total cash received by the Company as a result of employee stock option exercises during 2019, 2018 and 2017 was $317.8 million, $263.4 million and $323.3 million, respectively.


F-47

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


The following table summarizes information about stock options outstanding and exercisable at December 31, 2019:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
 
Weighted-average
Remaining
Contractual Life
 
Weighted-average
Exercise Price
 
Number
Exercisable
 
Weighted-average
Exercise Price
 
 
(in thousands)
 
(in years)
 
(per share)
 
(in thousands)
 
(per share)
$29.07–$40.00
 
108

 
1.58
 
$
37.62

 
108

 
$
37.62

$40.01–$60.00
 
277

 
2.55
 
$
49.69

 
277

 
$
49.69

$60.01–$80.00
 
140

 
4.31
 
$
74.55

 
136

 
$
74.53

$80.01–$100.00
 
1,670

 
6.25
 
$
89.42

 
1144

 
$
90.10

$100.01–$120.00
 
243

 
5.11
 
$
109.23

 
241

 
$
109.17

$120.01–$140.00
 
454

 
5.67
 
$
129.77

 
447

 
$
129.85

$140.01–$160.00
 
1,036

 
8.10
 
$
155.50

 
383

 
$
155.39

$160.01–$180.00
 
720

 
8.46
 
$
168.04

 
233

 
$
164.48

$180.01–$189.38
 
1,624

 
8.90
 
$
185.41

 
364

 
$
184.85

Total
 
6,272

 
7.12
 
$
134.92

 
3,333

 
$
114.15


Restricted Stock and Restricted Stock Units (excluding PSUs)
The following table summarizes the restricted stock unit and restricted stock activity of the Company during the year ended December 31, 2019:
 
Restricted Stock Units (excluding PSUs)
 
Restricted Stock
 
Number of Shares
 
Weighted-average
Grant-date
Fair Value
 
Number of Units
 
Weighted-average
Grant-date
Fair Value
 
(in thousands)
 
(per share)
 
(in thousands)
 
(per share)
Unvested at December 31, 2018
2,717

 
$
140.10

 
480

 
$
104.91

Granted
1,717

 
$
181.87

 
—

 
$
—

Vested
(974
)
 
$
133.15

 
(375
)
 
$
108.23

Cancelled
(329
)
 
$
149.83

 
(13
)
 
$
100.79

Unvested at December 31, 2019
3,131

 
$
163.61

 
92

 
$
91.97


The total fair value of restricted stock units that vested during 2019, 2018 and 2017 (measured on the date of vesting) was $178.2 million, $104.8 million and $33.2 million, respectively. The total fair value of restricted stock that vested during 2019, 2018 and 2017 (measured on the date of vesting) was $70.7 million, $114.5 million and $157.0 million, respectively.
Performance-based RSUs (PSUs)
The potential range of shares issuable pursuant to the Company’s PSU awards range from 0% to 200% of the target shares based on financial and non-financial measures. Fifty percent of PSUs that could be earned have a one-year performance period with the amount actually earned dependent upon the Company’s financial performance and with vesting of the earned shares in three equal installments over a three-year period. The remaining 50% of PSUs that could be earned have a three-year performance period with the amount actually earned dependent upon the achievement of multiple clinical development milestones and with the earned shares cliff vesting at the end of the three-year performance period.


F-48

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


The following table summarizes the PSU activity of the Company during the year ended December 31, 2019:
 
Performance-Based RSU
 
Number of Units
 
Weighted-average
Grant-date
Fair Value
 
(in thousands)
 
(per share)
Unvested at December 31, 2018 (1)
759

 
$
110.50

Granted (2)
449

 
$
183.48

Vested
(403
)
 
$
109.23

Cancelled
(71
)
 
$
104.61

Unvested at December 31, 2019
734

 
$
143.21

 
 
 
 
(1) “Unvested” represents the Company’s PSUs at target to the extent performance has not been certified plus the actual number of shares that continue to be subject to service conditions for which the performance has been achieved and certified.
(2) “Granted” represents (i) the target number of shares issuable for grants during 2019 and (ii) any change in the number of shares issuable pursuant to outstanding PSUs based on performance certification during 2019.

The total fair value of PSUs that vested during 2019, 2018 and 2017 (measured on the date of vesting) was $73.3 million $23.2 million and $1.3 million, respectively.
Employee Stock Purchase Plan
The Company has an employee stock purchase plan (the “ESPP”). The ESPP permits eligible employees to enroll in a twelve-month offering period comprising two six-month purchase periods. Participants may purchase shares of the Company’s common stock, through payroll deductions, at a price equal to 85% of the fair market value of the common stock on the first day of the applicable twelve-month offering period, or the last day of the applicable six-month purchase period, whichever is lower. Purchase dates under the ESPP occur on or about May 14 and November 14 of each year. During 2019, the Company’s shareholders approved an increase in the number of shares authorized for issuance pursuant to the ESPP of 2,000,000 shares. As of December 31, 2019, there were 2,199,376 shares of common stock authorized for issuance pursuant to the ESPP.
In 2019, the following shares were issued to employees under the ESPP:
 
Year Ended December 31, 2019
 
(in thousands,
except per share amount)
Number of shares
202,693

Average price paid per share
$
138.18


Employee Benefits
The Company has a 401(k) retirement plan (the “Vertex 401(k) Plan”) in which substantially all of its permanent U.S. employees are eligible to participate. Participants may contribute up to 60% of their annual compensation to the Vertex 401(k) Plan, subject to statutory limitations. The Company may declare discretionary matching contributions to the Vertex 401(k) Plan. The Company pays matching contributions in the form of cash. For the years ended December 31, 2019, 2018 and 2017, the Company contributed approximately $15.8 million, $13.9 million and $12.3 million to the plan, respectively.
O.
Stock-based Compensation Expense
The Company recognizes share-based payments to employees as compensation expense using the fair value method. The fair value of stock options and shares purchased pursuant to the ESPP is calculated using the Black-Scholes option pricing model. The fair value of restricted stock and restricted stock units, including PSUs, is based on the intrinsic value on the date of grant. Stock-based compensation, measured at the grant date based on the fair value of the award, is typically recognized as expense ratably over the requisite service period.


F-49

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


The effect of stock-based compensation expense during the three years ended December 31, 2019 was as follows:
 
2019
 
2018
 
2017
 
(in thousands)
Stock-based compensation expense by line item:
 
 
 
 
 
Cost of sales
$
5,575

 
$
4,543

 
$
2,500

Research and development expenses
224,558

 
203,112

 
181,900

Sales, general and administrative expenses
130,356

 
117,392

 
108,836

Total stock-based compensation expense included in costs and expenses
360,489

 
325,047

 
293,236

Income tax effect
(124,225
)
 
—

 
—

Total stock-based compensation included in costs and expenses, net of tax
$
236,264

 
$
325,047

 
$
293,236


The Company maintained a valuation allowance on the majority of its NOLs and other deferred tax assets until December 31, 2018. Therefore, there was no “Income tax effect” of stock-based compensation expense for the years ended December 31, 2018 and 2017.
The stock-based compensation expense by type of award during the three years ended December 31, 2019 was as follows:
 
2019
 
2018
 
2017
 
(in thousands)
Stock-based compensation expense by type of award:
 
 
 
 
 
Restricted stock and restricted stock units (including PSUs)
$
254,276

 
$
207,845

 
$
181,258

Stock options
96,737

 
107,854

 
105,367

ESPP share issuances
11,196

 
9,933

 
9,017

Stock-based compensation expense related to inventories
(1,720
)
 
(585
)
 
(2,406
)
Total stock-based compensation expense included in costs and expenses
$
360,489

 
$
325,047

 
$
293,236


The Company capitalizes stock-based compensation expense to inventories, all of which is attributable to employees who support the Company’s manufacturing operations for the Company’s products.
The following table sets forth the Company’s unrecognized stock-based compensation expense as of December 31, 2019, by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of December 31, 2019
 
Unrecognized Expense
 
Weighted-average Recognition Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Restricted stock and restricted stock units (including PSUs)
$
374,185

 
2.05
Stock options
$
130,153

 
2.50
ESPP share issuances
$
4,724

 
0.55

Stock Options
The Company issues stock options with service conditions, which are generally the vesting periods of the awards. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. The Black-Scholes option pricing model uses the option exercise price as well as estimates and assumptions related to the expected price volatility of the Company’s stock, the rate of return on risk-free investments, the expected period during which the options will be outstanding, and the expected dividend yield for the Company’s stock to estimate the fair value of a stock option on the grant date. The options granted during 2019, 2018 and 2017 had a weighted-average grant-date fair value per share of $61.32, $60.83 and $43.27, respectively.


F-50

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


The fair value of each option granted during 2019, 2018 and 2017 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:
 
2019
 
2018
 
2017
Expected stock price volatility
36.99
%
 
40.50
%
 
45.31
%
Risk-free interest rate
2.32
%
 
2.61
%
 
1.94
%
Expected term of options (in years)
4.27

 
4.55

 
4.68

Expected annual dividends
—

 
—

 
—


The weighted-average valuation assumptions were determined as follows:
•
Expected stock price volatility: Expected stock price volatility is calculated using the trailing one month average of daily implied volatilities prior to the grant date. Implied volatility is based on options to purchase the Company’s stock with remaining terms of greater than one year that are regularly traded in the market.
•
Risk-free interest rate: The Company bases the risk-free interest rate on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected option term.
•
Expected term of options: The expected term of options represents the period of time options are expected to be outstanding. The Company uses historical data to estimate employee exercise and post-vest termination behavior. The Company believes that all groups of employees exhibit similar exercise and post-vest termination behavior and therefore does not stratify employees into multiple groups in determining the expected term of options.
•
Expected annual dividends: The estimate for annual dividends is $0.00 because the Company has not historically paid, and does not intend for the foreseeable future to pay, a dividend.
Restricted Stock, Restricted Stock Units and Performance-based Restricted Stock Units
The Company awards restricted stock and restricted stock units with service conditions, which are generally the vesting periods of the awards.
The Company grants PSUs to certain members of senior management. Half of the PSUs contain financial goals as the performance metric and the other half contain non-financial goals. A target number of shares is established for each award, however the actual number of shares that are issued when an award vests may range from zero to 200% of the target amount depending upon the level of achievement of the applicable performance metric. The financial-based PSUs vest in three equal installments over a three-year period and are expensed ratably over that same period based upon an assessment of the likely level of achievement. The non-financial based PSUs cliff vest at the end of the three-year performance period and are expensed on a straight-line basis over that same period based upon an assessment of the likely level of achievement.
Prior to 2017, the Company also awarded, to certain members of senior management, on an annual basis, restricted stock and restricted stock units that vested upon the earlier of the satisfaction of (i) a performance condition or (ii) a service condition.
Employee Stock Purchase Plan
The weighted-average fair value of each purchase right granted during 2019, 2018 and 2017 was $47.79, $44.04 and $35.90, respectively. The following table reflects the weighted-average assumptions used in the Black-Scholes option pricing model for 2019, 2018 and 2017:
 
2019
 
2018
 
2017
Expected stock price volatility
33.43
%
 
36.51
%
 
39.09
%
Risk-free interest rate
2.08
%
 
2.36
%
 
1.24
%
Expected term (in years)
0.74

 
0.75

 
0.75

Expected annual dividends
—

 
—

 
—




F-51

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


The expected stock price volatility for ESPP offerings is based on implied volatility. The Company bases the risk-free interest rate on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term. The expected term represents purchases and purchase periods that take place within the offering period. The expected annual dividends estimate is $0.00 because the Company has not historically paid, and does not for the foreseeable future intend to pay, a dividend.
P.
Income Taxes
The components of income (loss) before provision for (benefit from) income taxes during the three years ended December 31, 2019 consisted of the following:
 
2019
 
2018
 
2017
 
(in thousands)
United States
$
1,263,379

 
$
812,086

 
$
330,340

Foreign
131,540

 
(211,845
)
 
(346,029
)
Income (loss) before provision for (benefit from) income taxes
$
1,394,919

 
$
600,241

 
$
(15,689
)

The components of the provision for (benefit from) income taxes during the three years ended December 31, 2019 consisted of the following:
 
2019
 
2018
 
2017
 
(in thousands)
Current taxes:
 
 
 
 
 
Federal
$
—

 
$
772

 
$
11,559

Foreign
37,194

 
15,600

 
3,576

State
13,528

 
9,018

 
5,025

Total current taxes
50,722

 
25,390

 
20,160

Deferred taxes:
 
 
 
 
 
Federal
184,312

 
(1,105,053
)
 
(113,805
)
Foreign
(24,797
)
 
(364,919
)
 
(3,222
)
State
7,872

 
(42,280
)
 
(10,457
)
Total deferred taxes
167,387

 
(1,512,252
)
 
(127,484
)
Provision for (benefit from) income taxes
$
218,109

 
$
(1,486,862
)
 
$
(107,324
)



F-52

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


A reconciliation of the provision for (benefit from) income taxes as computed by applying the U.S. federal statutory rate of 21% for the years ended December 31, 2019 and 2018 and 35% for the year ended December 31, 2017 to the provision for (benefit from) income taxes is as follows:
 
2019
 
2018
 
2017
 
(in thousands)
Income (loss) before provision for (benefit from) income taxes
$
1,394,919

 
$
600,241

 
$
(15,689
)
 
 
 
 
 
 
Expected provision for (benefit from) income taxes
292,933

 
126,051

 
(5,491
)
State taxes, net of federal benefit
8,478

 
8,680

 
4,742

Foreign income tax rate differential
6,178

 
23,427

 
77,801

Tax credits
(59,459
)
 
(52,629
)
 
(58,204
)
Benefit from income taxes attributable to valuation allowances
(2,672
)
 
(1,563,169
)
 
(575,801
)
Permanent items
4,822

 
1,421

 
15,324

Tax rate change
—

 
—

 
575,192

Stock compensation (benefit) shortfalls and cancellations
(56,324
)
 
(49,044
)
 
(21,453
)
Officer’s compensation
10,666

 
8,310

 
6,501

Deconsolidation of VIE
—

 
(9,390
)
 
(126,183
)
Uncertain tax positions
14,070

 
15,431

 
—

Other
(583
)
 
4,050

 
248

Provision for (benefit from) income taxes
$
218,109

 
$
(1,486,862
)
 
$
(107,324
)

The Company is subject to U.S. federal, state, and foreign income taxes. The Company’s provision for income taxes in 2019 has increased compared to historical amounts due to the release of the Company’s valuation allowance on the majority of its NOLs and other deferred tax assets as of December 31, 2018. Starting in 2019, the Company began recording a provision for income taxes approximating statutory rates on its pre-tax income. The Company’s effective tax rate for 2019 is lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation and research and development tax credits partially offset by a change in the Company’s valuation allowance as well as the tax impact of officer compensation. Due to the Company's ability to offset its pre-tax income against previously benefited NOLs, the majority of its tax provision represents a non-cash expense until its NOLs have been fully utilized.
In 2019, the “Benefit from income taxes attributable to valuation allowances” in the tax rate reconciliation table above related to a release of a valuation allowance in the United Kingdom of $30.5 million related to the execution of a reimbursement agreement in France in November 2019, partially offset by an increase in the valuation allowance in the United States on state credits and NOLs. In 2018, the change in the “Benefit from income taxes attributable to valuation allowances” was primarily related to the release of the Company’s valuation allowances on the majority of its NOLs and other deferred tax assets related to the United States and the United Kingdom. In 2017, the “Benefit from income taxes attributable to valuation allowances” was primarily due to the utilization of NOLs in the United States and a decrease in the U.S. federal corporate tax rate from 35% to 21% partially offset by the adoption of ASU 2016-09.
In 2018 and 2017, “Deconsolidation of VIE” in the Company’s tax rate reconciliation above related to the impairments of VX-210 and Parion’s pulmonary ENaC platform, respectively, and the decreases in the Company’s fair value of the contingent payments to BioAxone and Parion associated with these deconsolidations, respectively. Please refer to Note K, “Intangible Assets and Goodwill,” for further information regarding these impairments.
The Company operates in foreign tax jurisdictions, which impose income taxes at different rates than the United States. The impact of these rate differences, which are primarily related to the Company’s operations in the United Kingdom, is included in the “Foreign income tax rate differential” in the Company’s tax rate reconciliation above. Other items that affected the Company’s tax rate reconciliation table were related to equity and executive compensation, research and development credits and Orphan Drug Credits during the three years ended December 31, 2019.


F-53

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred taxes were as follows:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Deferred tax assets:
 
 
 
Net operating loss
$
512,256

 
$
882,014

Tax credit carryforwards
549,543

 
487,635

Intangible assets
275,290

 
241,775

Deferred revenues
18,833

 
19,311

Stock-based compensation
85,199

 
93,915

Accrued expenses
44,367

 
17,795

Finance lease liabilities
119,160

 
130,849

Operating lease assets
13,114

 
—

  Other
8,596

 
6,831

Gross deferred tax assets
1,626,358

 
1,880,125

Valuation allowance
(205,192
)
 
(168,491
)
Total deferred tax assets
1,421,166

 
1,711,634

Deferred tax liabilities:
 
 
 
Property and equipment
(101,235
)
 
(128,407
)
Acquired intangibles
(87,160
)
 
—

Deferred revenue
—

 
(73,357
)
Unrealized gain
(28,838
)
 
(10,198
)
Operating lease liabilities
(13,118
)
 
—

Net deferred tax assets
$
1,190,815

 
$
1,499,672


In 2019, the Company completed acquisitions of Semma and Exonics, resulting in the inclusion of these entities deferred tax bases into the Company’s consolidated deferred tax assets and deferred tax liabilities. As of the acquisition date, Semma’s deferred tax liabilities were $54.2 million. Exonics’ deferred tax assets were not material to the Company’s financial statements.
On a periodic basis, the Company reassesses the valuation allowance on its deferred income tax assets weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In the fourth quarter of 2018, the Company assessed the valuation allowance and considered positive evidence, including significant cumulative consolidated and U.S. income over the three years ended December 31, 2018, revenue growth, clinical trial data from the Company’s triple combination regimens, competitor clinical progress and expectations regarding future profitability, and negative evidence, including the potential impact of competition on the Company’s projections and cumulative losses in one of the jurisdictions. After assessing both the positive evidence and the negative evidence, the Company determined it was more likely than not that its deferred tax assets would be realized in the future and released the valuation allowance on the majority of its NOLs and other deferred tax assets as of December 31, 2018, resulting in a benefit from income taxes of $1.56 billion.  As of December 31, 2019, the Company maintained a valuation allowance of $205.2 million related primarily to U.S. state and foreign tax attributes.
As of December 31, 2019, the Company had NOL carryforwards of $1.5 billion, of which $1.3 billion were subject to expiration and $181.1 million had an indefinite carryforward period, and tax credits of $399.0 million for U.S. federal income tax purposes. As of December 31, 2019, the Company had NOL carryforwards of $903.7 million and tax credits of $161.7 million for U.S. state income tax purposes. These U.S. federal and state NOL carryforwards and tax credits expire at various dates through 2039 and may be used to offset future federal and state income tax liabilities, respectively. As of December 31, 2019, the Company had foreign net operating loss carryforwards of $896.9 million, including $16.0 million that were subject to expiration at various dates through 2039 and $880.9 million that had an indefinite carryforward period.


F-54

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


Unrecognized tax benefits during the three years ended December 31, 2019 were as follows:
 
2019
 
2018
 
2017
 
(in thousands)
Balance at beginning of the period
$
19,549

 
$
3,814

 
$
—

Increases related to current period tax positions
14,407

 
9,704

 
3,814

Increases related to prior period tax positions
598

 
6,031

 
—

Decreases related to prior period tax positions
(156
)
 
—

 
—

Settlement with Tax Authorities
(478
)
 
—

 
—

Balance at end of period
$
33,920

 
$
19,549

 
$
3,814


As of December 31, 2019, the Company has classified $13.4 million and $20.5 million of its unrecognized tax benefits as credits to “Deferred tax assets” and “Accrued expenses,” respectively, on its consolidated balance sheet.
The Company has reviewed the tax positions taken, or to be taken, in its tax returns for all tax years currently open to examination by a taxing authority. Unrecognized tax benefits represent the aggregate tax effect of differences between tax return positions and the benefits recognized in the financial statements. As of December 31, 2019 and 2018, the Company had $33.9 million and $19.5 million, respectively, of gross unrecognized tax benefits, which would affect the Company’s tax rate if recognized. As of December 31, 2017, the Company had $3.8 million of gross unrecognized tax benefits, which would not affect the Company’s tax rate if recognized. The Company does not expect that its unrecognized tax benefits will materially change within the next twelve months. The Company accrues interest and penalties related to unrecognized tax benefits as a component of its “Provision for (benefit from) income taxes.” As of December 31, 2019, no significant interest or penalties were accrued. The Company did not recognize any material interest or penalties related to uncertain tax positions during the three years ended December 31, 2019.
As of December 31, 2019, foreign earnings, which were not significant, have been retained indefinitely by the Company’s foreign subsidiaries for indefinite reinvestment. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company could be subject to withholding taxes payable to the various foreign countries.
The Company files U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States or any other major taxing jurisdiction for years before 2011, except where the Company has NOLs or tax credit carryforwards that originate before 2011. The Company has various income tax examinations ongoing at any time throughout the world. During the year ended December 31, 2019, the Company concluded tax examinations with Austria, Canada, Germany and Italy, with no material adjustments.
Q.
Commitments and Contingencies
Revolving Credit Facility
In September 2019, the Company and certain of its subsidiaries entered into a Credit Agreement (the “2019 Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein. The 2019 Credit Agreement provides for a $500.0 million unsecured revolving facility, which was not drawn upon at closing. Amounts drawn pursuant to the 2019 Credit Agreement, if any, may be used to finance the Company’s working capital needs, and for general corporate or other lawful purposes. The Company had no borrowings outstanding under the 2019 Credit Agreement as of December 31, 2019. The 2019 Credit Agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the borrowing capacity under the 2019 Credit Agreement be increased by an additional $500.0 million. The 2019 Credit Agreement, which matures on September 17, 2024, supersedes the Company’s credit agreement entered into in 2016 with Bank of America, N.A serving in the same capacity. Additionally, the 2019 Credit Agreement provides a sublimit of $50.0 million for letters of credit.
Direct costs related to the 2019 Credit Agreement, which were not material to the Company’s financial statements, were deferred and will be recorded over the term of the 2019 Credit Agreement.


F-55

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


Any amounts borrowed under the 2019 Credit Agreement will bear interest, at the Company's option, at either a base rate or a Eurocurrency rate, in each case plus an applicable margin. Under the 2019 Credit Agreement, the applicable margins on base rate loans range from 0.125% to 0.50% and the applicable margins on Eurocurrency loans range from 1.125% to 1.50%, in each case based on the Company's consolidated leverage ratio (the ratio of the Company's total consolidated funded indebtedness to the Company's consolidated EBITDA for the most recently completed four fiscal quarter period).
Any amounts borrowed pursuant to the 2019 Credit Agreement are guaranteed by certain of the Company’s existing and future domestic subsidiaries, subject to certain exceptions.
The 2019 Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including financial covenants to maintain (i) subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition and (ii) a consolidated interest coverage ratio (the ratio of the Company’s consolidated EBITDA to its consolidated interest expenses for the most recently completed four fiscal quarter period) of 2.50 to 1.00, in each case measured on a quarterly basis. The 2019 Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.
Guaranties and Indemnifications
As permitted under Massachusetts law, the Company’s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors’ and officers’ liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.
The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company, and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company’s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of the Company’s contractual obligations arising out of the research or clinical testing of the Company’s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company’s contractual obligations. The indemnification provisions appearing in the Company’s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no material contingent liabilities accrued as of December 31, 2019 or 2018.


F-56

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


R.
Segment Information
Segment reporting is prepared on the same basis that the Company’s chief executive officer, who is the Company’s chief operating decision maker, manages the business, makes operating decisions and assesses performance. The Company operates in one segment, pharmaceuticals. Enterprise-wide disclosures about revenues, significant customers, and property and equipment, net by location are presented below.
Revenues by Product
Product revenues, net consisted of the following:
 
2019
(as reported under ASC 606)
 
2018
(as reported under ASC 606)
 
2017
(as reported under ASC 605)
 
(in thousands)
TRIKAFTA
$
420,105

 
$
—

 
$
—

SYMDEKO/SYMKEVI
1,417,668

 
768,657

 
—

ORKAMBI
1,331,891

 
1,262,166

 
1,320,850

KALYDECO
991,062

 
1,007,502

 
844,630

Total product revenues, net
$
4,160,726

 
$
3,038,325

 
$
2,165,480


Revenues by Geographic Location
Net product revenues are attributed to countries based on the location of the customer. Collaborative and royalty revenues are attributed to countries based on the location of the Company’s subsidiary associated with the collaborative arrangement related to such revenues. Total revenues from external customers and collaborators by geographic region consisted of the following:
 
2019
(as reported under ASC 606)
 
2018
(as reported under ASC 606)
 
2017
(as reported under ASC 605)
 
(in thousands)
United States
$
3,062,555

 
$
2,365,079

 
$
1,986,786

Outside of the United States
 
 
 
 
 
Europe
885,762

 
543,179

 
420,317

Other
214,504

 
139,339

 
81,549

Total revenues outside of the United States
1,100,266

 
682,518

 
501,866

Total revenues
$
4,162,821

 
$
3,047,597

 
$
2,488,652


Significant Customers
Gross revenues and accounts receivable from each of the Company’s customers who individually accounted for 10% or more of total gross revenues and/or 10% or more of total gross accounts receivable consisted of the following:
 
Percent of Total Gross
Revenues
 
Percent of Gross Accounts Receivable
 
Year Ended December 31,
 
As of December 31,
 
2019
(as reported under ASC 606)
 
2018
(as reported under ASC 606)
 
2017
(as reported under ASC 605)
 
2019
 
2018
McKesson Corporation
17
%
 
14
%
 
<10
%
 
22
%
 
16
%
Walgreen Co.
15
%
 
20
%
 
17
%
 
14
%
 
16
%
Accredo/Curascript
14
%
 
14
%
 
14
%
 
15
%
 
10
%



F-57

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


Long-lived Assets by Location
Long-lived assets by location consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
United States
$
768,572

 
$
778,157

Outside of the United States
 
 
 
United Kingdom
57,383

 
30,496

Other
7,327

 
3,352

Total long-lived assets outside of the United States
64,710

 
33,848

      Total long-lived assets
$
833,282

 
$
812,005


S.
Quarterly Financial Data (unaudited)
The following tables set forth the Company’s quarterly financial data for the two years ended December 31, 2019:
 
Three Months Ended
 
March 31,
2019
 
June 30,
2019
 
September 30,
2019
 
December 31,
2019
 
(in thousands, except per share amounts)
Revenues:
 
 
 
 
 
 
 
Product revenues, net (1)
$
857,253

 
$
940,380

 
$
949,828

 
$
1,413,265

Collaborative and royalty revenues
1,182

 
913

 
—

 
—

Total revenues
858,435

 
941,293

 
949,828

 
1,413,265

Costs and expenses:
 
 
 
 
 
 
 
Cost of sales
95,092

 
135,740

 
131,914

 
185,012

Research and development expenses (2)
339,490

 
379,091

 
555,948

 
480,011

Sales, general and administrative expenses
147,045

 
156,502

 
159,674

 
195,277

Change in fair value of contingent consideration
—

 
—

 
2,959

 
1,500

Total costs and expenses
581,627

 
671,333

 
850,495

 
861,800

Income from operations
276,808

 
269,960

 
99,333

 
551,465

Interest income
15,615

 
18,076

 
17,628

 
12,359

Interest expense
(14,868
)
 
(14,837
)
 
(14,548
)
 
(14,249
)
Other income (expense), net (3)
42,610

 
53,939

 
(31,747
)
 
127,375

Income before provision for income taxes
320,165

 
327,138

 
70,666

 
676,950

Provision for income taxes (4)
51,534

 
59,711

 
13,148

 
93,716

Net income attributable to Vertex
$
268,631

 
$
267,427

 
$
57,518

 
$
583,234

 
 
 
 
 
 
 
 
Amounts per share attributable to Vertex common shareholders:
 
 
 
 
 
 
 
Net income:
 
 
 
 
 
 
 
    Basic
$
1.05

 
$
1.04

 
$
0.22

 
$
2.26

    Diluted
$
1.03

 
$
1.03

 
$
0.22

 
$
2.23

Shares used in per share calculations:
 
 
 
 
 
 
 
    Basic
255,695

 
256,154

 
256,946

 
258,003

    Diluted
260,175

 
259,822

 
260,473

 
262,108



F-58

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


 
Three Months Ended
 
March 31,
2018
 
June 30,
2018
 
September 30,
2018
 
December 31,
2018
 
(in thousands, except per share amounts)
Revenues:
 
 
 
 
 
 
 
Product revenues, net
$
637,729

 
$
749,912

 
$
782,511

 
$
868,173

Collaborative and royalty revenues
3,070

 
2,245

 
2,024

 
1,933

Total revenues
640,799

 
752,157

 
784,535

 
870,106

Costs and expenses:
 
 
 
 
 
 
 
Cost of sales
71,613

 
104,382

 
111,255

 
122,289

Research and development expenses (2)
310,553

 
337,532

 
330,510

 
437,881

Sales, general and administrative expenses
129,808

 
137,303

 
137,295

 
153,210

Restructuring (income) expenses
(76
)
 
62

 
(174
)
 
4

Intangible asset impairment charge
—

 
—

 
—

 
29,000

Total costs and expenses
511,898

 
579,279

 
578,886

 
742,384

Income from operations
128,901

 
172,878

 
205,649

 
127,722

Interest income
5,789

 
8,049

 
10,543

 
13,971

Interest expense
(16,886
)
 
(18,155
)
 
(18,686
)
 
(18,744
)
Other income (expense), net (3)
96,838

 
53,819

 
(60,995
)
 
(90,452
)
Income before (benefit from) provision for income taxes
214,642

 
216,591

 
136,511

 
32,497

(Benefit from) provision for income taxes (4)
(12,659
)
 
10,341

 
8,055

 
(1,492,599
)
Net income
227,301

 
206,250

 
128,456

 
1,525,096

(Income) loss attributable to noncontrolling interest (5)
(17,038
)
 
1,110

 
290

 
25,431

Net income attributable to Vertex
$
210,263

 
$
207,360

 
$
128,746

 
$
1,550,527

 
 
 
 
 
 
 
 
Amounts per share attributable to Vertex common shareholders:
 
 
 
 
 
 
 
Net income:
 
 
 
 
 
 
 
    Basic
$
0.83

 
$
0.82

 
$
0.51

 
$
6.08

    Diluted
$
0.81

 
$
0.80

 
$
0.50

 
$
5.97

Shares used in per share calculations:
 
 
 
 
 
 
 
    Basic
253,231

 
254,135

 
254,905

 
254,868

    Diluted
258,526

 
258,584

 
259,788

 
259,812


1.
In the fourth quarter of 2019, the Company updated its transaction price and recognized net product revenues of $155.8 million related to prior period ORKAMBI sales upon reaching a reimbursement agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs. See Note A, “Nature of Business and Accounting Policies.”
2.
In the third quarter of 2019, the Company incurred research and development expenses of $175.0 million related to its CRISPR DMD/DM1 Agreement. In the fourth quarter of 2018, the Company incurred research and development expenses of $95.0 million to related license agreements with Merck KGaA, Darmstadt, Germany, and Arbor. See Note B, “Collaborative Arrangements.”
3.
In 2019 and 2018, “Other income (expense), net” was primarily related to changes in the fair value of the Company’s equity investment in CRISPR. See Note F, “Marketable Securities and Equity Investments.”
4.
In the fourth quarter of 2018, the Company released the valuation allowance on the majority of its NOLs and other deferred tax assets as of December 31, 2018 resulting in a benefit from income taxes of $1.56 billion. Starting in 2019, the Company began recording a provision for income taxes approximating statutory rates on its pre-tax income. See Note P, “Income Taxes.”
5.
In 2018, the Company had a noncontrolling interest in BioAxone, which it consolidated as a VIE until December 31, 2018. Following the deconsolidation of BioAxone as of December 31, 2018, the Company did not have a noncontrolling interest in any entities in 2019. See Note B, “Collaborative Arrangements.”


F-59
 EX-4.2 2 a10k2019-exhibit42.htm EXHIBIT 4.2 Exhibit
Exhibit 4.2


DESCRIPTION OF SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF
THE SECURITIES EXCHANGE ACT OF 1934

Vertex Pharmaceuticals Incorporated (the “Company” or “Vertex”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.01 per share (“Common Stock”).

DESCRIPTION OF CAPITAL STOCK

The following summary of our capital stock is based on the provisions of the Massachusetts Business Corporation Act (the “MBCA”), our Restated Articles of Organization, as amended, (the “Articles”) and our Amended and Restated By-laws, as amended (the “By-laws”). This description does not purport to be complete and is subject to, and qualified in its entirety by reference to the full text of our Articles and our By-laws, each of which is filed and incorporated by reference as an exhibit to our Annual Report on Form 10-K, of which this Exhibit is a part, and the MBCA. You should read our Articles and Bylaws and the applicable provisions of the MBCA for a complete statement of provisions described under this caption “Description of Capital Stock” and for other provisions that may be important to you.

Authorized Capital Shares

Our authorized capital stock consists of 500,000,000 shares of Common Stock and 1,000,000 shares of preferred stock, par value $0.01 per share (“Preferred Stock”). The number of authorized shares of any class may be increased or decreased by an amendment to our Articles proposed by our board of directors and approved by a majority of voting shares voted on the issue at a meeting at which a quorum exists.

Description of Common Stock

Dividend Rights

After satisfaction of any dividend rights of holders of Preferred Stock, holders of Common Stock are entitled ratably to any dividend declared by our board of directors out of funds legally available for this purpose.

Voting Rights

Each stockholder of record of our Common Stock is entitled to one vote for each share held on every matter properly submitted to the stockholders for their vote. Generally, a matter submitted for stockholder action shall be approved with a majority of the votes properly cast, except when a larger vote is required by law, our Articles or our By-laws. Other than in a contested election where directors are elected by a plurality vote, a director nominee shall be elected to the board of directors if the votes properly cast in favor of election of a director exceed the votes properly withheld in such election.

Holders of our Common Stock do not have cumulative voting rights.

Liquidation Rights

Upon our liquidation, dissolution or winding up, the holders of our Common Stock are entitled to receive ratably our net assets available, if any, after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock.



Exhibit 4.2

Other Rights and Preferences

Holders of our Common Stock have no preemptive, subscription, redemption, conversion or exchange rights and no sinking fund provisions. There are no restrictions on alienability of our Common Stock or liabilities to further calls or assessments by the Company.

The rights, preferences and privileges of holders of Common Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.

Anti-Takeover Effects of Provisions of Massachusetts Law

We are subject to Chapter 110F of the Massachusetts General Laws, an anti-takeover law. In general, this statute prohibits a publicly-held Massachusetts corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person becomes an interested stockholder, unless (i) prior to the date such stockholder became an interested stockholder, the board of directors approved the business combination or transaction which resulted in the stockholder becoming interested, (ii) the interested stockholder acquires 90% of the outstanding voting stock of the corporation (excluding shares held by certain affiliates of the corporation) at the time it becomes an interested stockholder, or (iii) the business combination is approved by both the board of directors and at least two-thirds of the outstanding voting stock of the corporation (excluding shares held by the interested stockholder). Generally, an “interested stockholder” is a person who, together with affiliates and associates, owns (or at any time within the prior three years did own) 5% or more of the outstanding voting stock of the corporation. A “business combination” includes a merger, a stock or asset sale, and certain other transactions resulting in a financial benefit to the interested stockholders.

We are subject to Chapter 110D of the Massachusetts General Laws, entitled “Regulation of Control Share Acquisitions.” In general, this statute provides that any stockholder of a corporation subject to this statute who acquires 20% or more of the outstanding voting stock of a corporation may not vote such stock unless the stockholders of the corporation so authorize. The board of directors may amend our by-laws to exclude us from this statute prospectively.

NASDAQ Listing

Our Common Stock is listed on the NASDAQ Global Select Market under the symbol “VRTX.”





EX-10.17 3 a10k2019-exhibit1017.htm EXHIBIT 10.17 Exhibit

Exhibit 10.17


VERTEX PHARMACEUTICALS INCORPORATED
2013 STOCK AND OPTION PLAN

Form of Restricted Stock Unit Award

This Agreement sets forth the terms and conditions of a Restricted Stock Unit Award granted pursuant to the provisions of the 2013 Stock and Option Plan (as it may be amended or restated, the “Plan”) of Vertex Pharmaceuticals Incorporated (the “Company”) to the Participant whose name appears below, of a contingent entitlement of the Participant to receive the number of Shares of Common Stock of the Company set forth below, pursuant to the provisions of the Plan and on the following express terms and conditions. Capitalized terms not otherwise defined herein shall have the same meanings as set forth in the Plan, and any Restricted Stock Units evidenced hereby are granted subject to the terms of the Plan.

1.    Name of Participant to whom the Restricted Stock Unit Award is granted:

Participant Name: #ParticipantName#
Employee ID: #EmployeeID#

2.    Number of Shares of Common Stock in the Restricted Stock Unit Award (the “Shares”):

#QuantityGranted# Shares

3.    Date of grant of the Restricted Stock Unit Award:

#GrantDate# (“MM/DD/YYYY”)

4.    Vesting.

4.1    Vesting Schedule. Except as otherwise provided in this Section 4, the Restricted Stock Unit Award shall vest according to the Appendix: Vesting Schedule.

On each vesting date, the Participant shall be entitled to receive the applicable number of shares of Common Stock that shall thereafter be delivered by the Company to the Participant in accordance with this Agreement and the Plan within two business days of the applicable vesting date. Except as provided in Section 4.2 or 4.3 of this Agreement, upon any Termination of Service of the Participant for any reason, vesting of the Shares shall immediately cease, and the unvested portion of the Restricted Stock Unit Award shall immediately be forfeited.

4.2     Termination for Cause.

(a)    If the Participant’s employment with the Company is terminated due to Cause, any portion of the Restricted Stock Unit Award that has not vested prior to the date written notice of such termination is provided to the Participant shall be immediately forfeited. If the Participant is notified that the Company is investigating or evaluating whether the Company will terminate Participant’s employment or other service to the Company for Cause, the Company may, at its election, suspend the vesting of this Restricted Stock Unit Award by written notice to the Participant. If after such notification it is determined or otherwise agreed that Participant’s service to the Company will not be terminated for Cause, vesting of the Shares shall resume pursuant to the original schedule and any Shares that would have vested during such suspension immediately shall vest.

Revision Date: January 2020        Page 1



Exhibit 10.17


(b)    “Cause” shall mean (i) the Participant’s dishonesty or fraud, or (ii) the willful misconduct by the Participant or willful failure by the Participant to perform his or her responsibilities to the Company (including, without limitation, any material breach by the Participant of any provision of any Company policy or any employment, consulting, advisory, nondisclosure, non-competition or other similar agreement between the Participant and the Company), in each case as determined in good faith by the Company, which determination shall be conclusive.

4.3    Career Employment Provision. If a Participant experiences a Termination of Service other than for Cause, and the Participant is a Qualified Participant (as defined below), then (a) an additional number of Shares equal to (i) the sum of 50% plus 10% for each full year of service as an Employee and/or a Non-Employee Director to the Company or an Affiliate in excess of five (5) full years of service multiplied by (ii) the number of unvested Shares subject to this Restricted Stock Unit Award immediately prior to the Participant’s Termination of Service, shall vest on the date of the Termination of Service and (b) any remaining unvested Shares shall be forfeited. A “Qualified Participant” shall mean a Participant (i) who is at least fifty-five (55) years old, (ii) who has completed at least five (5) full years of service as an Employee and/or a Non-Employee Director to the Company or an Affiliate, (iii) whose age plus full years of service as an Employee and/or a Non-Employee Director to the Company or an Affiliate is 65 or greater and (iv) who has completed a mandatory transitional period of employment with the Company following notice of the Termination of Service, the duration of which will be no fewer than twelve (12) months, except as may be determined by the Company in its sole discretion or as may be required by applicable law.

5.    Agreement with respect to Tax Payments, Withholding and Sale of a Portion of Shares. The Participant acknowledges and agrees that any income or other taxes, fees or social security or comparable contributions due from the Participant with respect to the vesting of the Restricted Stock Unit Award or the issuance of Shares pursuant to this Agreement shall be the Participant’s responsibility. In connection with the foregoing, the Participant agrees that the Company shall be entitled to hold back Shares based on the Fair Market Value of the Shares on the Vesting Date in satisfaction of tax withholding requirements. The Participant agrees to pay to the Company as soon as practicable, including through payroll, the amount of any tax withholding, that is for whatever reason, not satisfied through such hold back. The Participant further acknowledges that the Restricted Stock Unit Award made hereunder is subject to Participant’s acceptance of the terms of this Section 5, and other terms and provisions of this Agreement.

6.    Restrictions on Transfer. Except as provided in Section 10 of the Plan, this Restricted Stock Unit Award may not be sold, transferred, assigned, hypothecated, pledged, encumbered or otherwise disposed of, whether voluntarily or by operation of law, at any time before the Participant receives Shares. Any such purported transfer shall be null and void, and shall not be recognized by the Company or recorded on its books.

7.    No Rights as a Shareholder. The Participant shall have no rights as a shareholder, including voting and dividend rights, with respect to the Restricted Stock Unit Award subject to this Agreement.

8.    No Obligation to Maintain Relationship. The Participant acknowledges that: (i) the Company is not obligated by the Plan or this Restricted Stock Unit Award to continue the Participant as an Employee, Non-Employee Director, consultant or advisor of the Company or an Affiliate; (ii) the Plan is discretionary in nature and may be modified, suspended or terminated by the Company at any time; (iii) the grant of this Restricted Stock Unit Award is a one-time benefit that does not create any contractual or other right to receive future grants of equity, or benefits in lieu thereof; (iv) all determinations with respect to any such future grants, including, but not limited to, the times when restricted stock unit awards shall be granted, the number of shares subject to each restricted stock unit award, and the time or times

Revision Date: January 2020        Page 2



Exhibit 10.17

when each restricted stock unit award shall vest, will be at the sole discretion of the Company; (v) the Participant’s participation in the Plan is voluntary; (vi) the value of this Restricted Stock Unit Award is an extraordinary item of compensation which is outside the scope of the Participant’s employment or consulting contract, if any; and (vii) this Restricted Stock Unit Award is not part of normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments.

9.    Code Section 409A. Pursuant to Section 25 of the Plan, if and to the extent (i) any portion of any payment, compensation or other benefit provided to a Participant pursuant to this Restricted Stock Unit Award in connection with his or her employment termination constitutes “nonqualified deferred compensation” within the meaning of Section 409A of the Code and (ii) the Participant is a specified employee as defined in Section 409A(a)(2)(B)(i) of the Code, in each case as determined by the Company in accordance with its procedures, by which determinations the Participant (through accepting this Restricted Stock Unit Award) agrees that he or she is bound, such portion of the payment, compensation or other benefit shall not be paid before the day that is six months plus one day after the date of “separation from service” (as determined under Section 409A of the Code), except as Section 409A of the Code may then permit.

10.    Plan. The Participant hereby acknowledges receipt of a copy of the Plan as presently in effect and the Prospectus with respect thereto. All of the terms and provisions of the Plan, and any additional terms and conditions provided to Participants located outside of the United States, are incorporated herein by reference, and this Restricted Stock Unit Award is subject to those terms and provisions in all respects.



VERTEX PHARMACEUTICALS INCORPORATED

By: ________________________________________


Revision Date: January 2020        Page 3


 EX-10.35 4 a10k2019-exhibit1035.htm EXHIBIT 10.35 Exhibit


Exhibit 10.35


May 18, 2012


Paul M. Silva
23 Tammer Lane
Hopkinton, MA 01748


RE:    Amended and Restated Change of Control Agreement

Dear Paul:

You are a key member of the senior management team of Vertex Pharmaceuticals Incorporated (the “Company”). As a result, the Company would like to provide you with the following “change of control” benefits to help ensure that if the Company becomes involved in a “change of control” transaction, there will be no distraction from your attention to the needs of the Company.

I.
Definitions. For the purposes of this Amended and Restated Change of Control Agreement (this “Agreement”), capitalized terms shall have the following meanings:

1.
“Cause” shall mean:

(a)
your conviction of a crime involving moral turpitude;

(b)
your willful refusal or failure to follow a lawful directive or instruction of the Company’s Board of Directors or the individual(s) to whom you report, provided that you receive prior written notice of the directive(s) or instruction(s) that you failed to follow, and provided further that the Company, in good faith, gives you 30 days to correct such failure and further provided that if you correct the failure(s), any termination of your employment on account of such failure shall not be treated for purposes of this Agreement as a termination of employment for “Cause”;

(c)
in carrying out your duties you commit (i) willful gross negligence, or (ii) willful gross misconduct, resulting in either case in material harm to the Company, unless such act, or failure to act, was believed by you, in good faith, to be in the best interests of the Company; or

(d)
your violation of the Company’s policies made known to you regarding confidentiality, securities trading or inside information.

2.
“Change of Control” shall mean that:

(a)
any “person” or “group” as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934 (the “Act”), becomes a beneficial owner, as such term is used in Rule 13d-3 promulgated under the Act, of securities of the Company representing more than 50% of the combined voting power of the outstanding securities of the Company having the right to vote in the election of directors; or

(b)
all or substantially all the business or assets of the Company are sold or disposed of, or the Company or a subsidiary of the Company combines with another company pursuant to a merger, consolidation, or other similar transaction, other than (i) a transaction solely for the purpose of reincorporating the Company or one of its subsidiaries in a different jurisdiction or recapitalizing or reclassifying the Company’s stock; or (ii) a merger or consolidation in which the shareholders of the Company immediately prior to such merger or consolidation continue to own at least a




majority of the outstanding voting securities of the Company or the surviving entity immediately after the merger or consolidation.

3.
“Code” shall mean the Internal Revenue Code of 1986, as amended.

4.
“Disability” shall mean a disability as determined under the Company's long-term disability plan or program in effect at the time the disability first occurs, or if no such plan or program exists at the time of disability, then a “disability” as defined Section 22(e)(3) of the Code.

5.
“Good Reason” shall mean one of the following events has occurred without your consent:

(a)
your annual base salary is decreased;

(b)
the office to which you are assigned is relocated to a place 35 or more miles away; or

(c)
following a Change of Control, the Company’s successor fails to assume the Company’s rights and obligations under this Agreement;

provided that Good Reason shall not exist unless and until within 30 days after the event giving rise to Good Reason under (a), (b) or (c) above has occurred, you deliver a written termination notice to the Company stating that an event giving rise to Good Reason has occurred and identifying with reasonable detail the event that you assert constitutes Good Reason under (a), (b) or (c) above and the Company fails or refuses to cure or eliminate the event giving rise to Good Reason on or within 30 days after receiving your notice. To avoid doubt, the termination of your employment would become effective at the close of business on the thirtieth day after the Company receives your termination notice, unless the Company cures or eliminates the event giving rise to Good Reason prior to such time.

6.
“Termination Date” shall mean the last day of your employment with the Company.

II.
Severance Benefits upon Change of Control. If:

(A)
your employment is terminated by the Company (except for termination for Cause or due to a Disability) and the Termination Date is within 90 days prior to a Change of Control or within 12 months after a Change of Control; or

(B)
you, of your own initiative, (i) terminate your employment for Good Reason (in accordance with the notice and cure provisions set forth in Section I.5 above) and (ii) the event giving rise to Good Reason occurs within 90 days prior to a Change of Control or within 12 months after a Change of Control;
then, you shall receive the following benefits:
1.
Severance Payment. In exchange for your execution within 60 days of the Termination Date of a general release, in a form satisfactory to the Company, of all claims against the Company, its subsidiaries, and its and their officers, directors and representatives, that becomes enforceable and irrevocable within such 60-day period, the Company shall make a cash payment (the “Severance Payment”) to you in an amount equal to:

(a)
(i) your annual base salary (provided, however, that if you terminate your employment for Good Reason based on a reduction in your annual base salary, then the annual base salary to be used in calculating the Severance Payment shall be your annual base salary in effect immediately prior to such reduction in annual base salary) plus your target bonus under any bonus program applicable to you for the year in which the Termination Date occurs, multiplied




by (ii) 50% plus 3.846% for each year of continuous service with the Company (up to a maximum of 100%); plus

(b)
all cash incentive compensation awards earned by you but not paid prior to the Termination Date; provided that, if a fiscal year has been completed and the incentive award for such fiscal year has not been determined, the incentive compensation for such completed fiscal year shall equal the target bonus for such fiscal year.

Except with respect to any portion of the Severance Payment that is delayed as set forth in this paragraph, the Severance Payment shall be made in cash within ten days after the execution by you of the general release referred to above and expiration without revocation of any applicable revocation periods under such general release (or, if the Change of Control resulting in your becoming entitled to such benefits occurs after such execution and expiration, within ten days after the Change of Control), provided that, if the 60-day period during which the general release is required to become effective and irrevocable begins in one calendar year and ends in another calendar year, the Severance Payment shall not be made before the first day of the second calendar year. The Severance Payment shall be divided into two portions, consisting of a portion that does not constitute “nonqualified deferred compensation” within the meaning of Section 409A of the Code and a portion, if any, that does constitute nonqualified deferred compensation. If you are a “specified employee” as defined in Section 409A(a)(2)(B)(i) of the Code, the commencement of the delivery of any such payments that constitute nonqualified deferred compensation payable upon a “separation from service” under Section 409A(a)(2)(A)(i) of the Code will be delayed until the first business day that is more than six months after your Termination Date. The determination of whether, and the extent to which, any of the payments to be made to you hereunder are nonqualified deferred compensation shall be made after the application of all applicable exclusions, including those set forth under Treasury Reg. § 1.409A-1(b)(9). Any payments that are intended to qualify for the exclusion for separation pay due to involuntary separation from service set forth in Reg. §1.409A-1(b)(9)(iii) must be paid no later than the last day of the second taxable year following the taxable year in which the Termination Date occurs. To the extent that the termination of your employment does not constitute a separation of service under Section 409A(a)(2)(A)(i) of the Code (as the result of further services that are reasonably anticipated to be provided by you to the Company at the time your employment is terminated), the payment of any non-qualified deferred compensation will be further delayed until the first business day that is more than six months after the date of a subsequent event constituting a separation of service under Section 409A(a)(2)(A)(i) of the Code.

2.    Accelerated Vesting.

(a)
On the Termination Date, stock options for the purchase of the Company’s securities held by you as of the Termination Date and not then exercisable shall immediately become exercisable in full. The options to which this accelerated vesting applies shall remain exercisable until the earlier of (a) the end of the 90-day period immediately following the later of (i) the Termination Date or (ii) the date of the Change of Control and (b) the date the stock option(s) would otherwise expire; and

(b)
On the Termination Date, the Company’s lapsing repurchase right with respect to shares of restricted stock held by you shall lapse in full (subject to your making satisfactory arrangements with the Company providing for the payment to the Company of all required withholding taxes).

Notwithstanding anything to the contrary in this Agreement, the terms of any option agreement or restricted stock agreement shall govern the acceleration, if any, of vesting or lapsing of the Company’s repurchase rights and period of exercisability of such awards, as applicable, except to the extent that the terms of this Agreement are more favorable to you.

3.
Continued Insurance Coverage. If COBRA coverage is elected by you, the Company shall pay the cost of insurance continuation premiums on your behalf (whether or not covered by COBRA) to continue




standard medical, dental and life insurance coverage for you (or the cash equivalent of same if you are ineligible for continued coverage) until the earlier of (i) the date 12 months after the Termination Date or (ii) the date you begin receiving substantially equivalent coverage and benefits through a subsequent employer.

4.
No Mitigation. You shall not be required to mitigate the amount of the Severance Payment or any other benefit provided under this Agreement by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for in this Agreement be reduced (except as provided in Article II Section 3(ii)) by any compensation earned by you as the result of other employment, by retirement benefits, or be offset against any amount claimed to be owed by you to the Company or otherwise (except for any required withholding taxes); provided, that if the Company makes any other severance payments to you under any other program or agreement, such amounts shall be offset against the payments the Company is obligated to make pursuant to this Agreement.

III.
Miscellaneous.

1.
Employee’s Obligations. Upon the termination of employment, you shall promptly deliver to the Company all property of the Company and all material documents, statistics, account records, programs and other similar tangible items which may by in your possession or under your control and which relate in a material way to the business or affairs of the Company or its subsidiaries, and no copies of any such documents or any part thereof shall be retained by you.

2.
Entire Agreement. This Agreement and the “Employee Non-Disclosure, Non-Competition & Inventions Agreement” previously executed by you covers the entire understanding of the parties as to the subject matter hereof, superseding all prior understandings and agreements related hereto, including the previous Change of Control Agreement between you and the Company. No modification or amendment of the terms and conditions of this Agreement shall be effective unless in writing and signed by the parties or their respective duly authorized agents, provided, however, that the Company may, without your consent, unilaterally adopt amendments that may be required so that this Agreement continues to comply with applicable law or regulation, including without limitation Section 409A of the Code, provided such amendments do not adversely affect the benefits to be provided to you under Section II of this Agreement.

3.
Governing Law. This Agreement shall be governed by the laws of The Commonwealth of Massachusetts, as applied to contracts entered into and performed entirely in Massachusetts by Massachusetts residents.

4.
Successors and Assigns. This Agreement may be assigned by the Company upon a sale, transfer or reorganization of the Company. Upon a Change of Control, the Company shall require the successor to assume the Company’s rights and obligations under this Agreement. The Company’s failure to do so shall constitute a material breach of this Agreement. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their successors, permitted assigns, legal representatives and heirs.

Kindly indicate your acceptance of the foregoing by signing and dating this Agreement as noted below, and returning one fully executed original to my attention.

Very truly yours,

Vertex Pharmaceuticals Incorporated


By: /s/ Jeffrey M. Leiden, M.D., Ph.D.                
Jeffrey M. Leiden, M.D., Ph.D.




President, Chairman and
Chief Executive Officer



ACCEPTED AND AGREED:

/s/ Paul M. Silva    
Paul M. Silva
Sr. Vice President

    
Date: May 18, 2012



 EX-21.1 5 a10k2019-exhibit211.htm EXHIBIT 21.1 Exhibit


Exhibit 21.1

Subsidiaries of Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (San Diego) LLC, a Delaware limited liability company
 
Vertex Securities Corporation, a Massachusetts corporation

Vertex Pharmaceuticals (Distribution) Incorporated, a Delaware corporation
 
Vertex Pharmaceuticals (Cayman) Limited, a Cayman Islands company (3)

Vertex Pharmaceuticals (Cayman II) Limited, a Cayman Islands company

Vertex Pharmaceuticals (Cayman III) Limited, a Cayman Islands company (5)

Vertex Pharmaceuticals (Cayman 509) Limited, a Cayman Islands company

Vertex Pharmaceuticals (Cayman 765) Limited, a Cayman Islands company

Vertex Pharmaceuticals (Cayman 787) Limited, a Cayman Islands company
 
Vertex Pharmaceuticals (Delaware) LLC, a Delaware limited liability company

Vertex Pharmaceuticals (Puerto Rico) LLC, a Delaware limited liability company
Vertex Pharmaceuticals (Canada) Incorporated, a Canadian company (1)

Vertex Pharmaceuticals (Singapore) Pte. Ltd., a Singapore company

Vertex Holdings, Inc., a Delaware corporation
 
Vertex Pharmaceuticals (Europe) Limited, a United Kingdom company (5)

Vertex Pharmaceuticals (Switzerland) Sàrl, a Swiss company
 
Vertex Pharmaceuticals (Ireland) Limited, an Irish company (6)
 
Vertex Pharmaceuticals (U.K.) Limited, a United Kingdom company (6)
 
Vertex Pharmaceuticals (France) SAS, a French company
 
Vertex Pharmaceuticals (Germany) GmbH, a German company

Vertex Pharmaceuticals (Australia) Pty. Ltd., an Australian company

Vertex Pharmaceuticals (Spain), S.L., a Spanish company
 
Vertex Pharmaceuticals (Netherlands) B.V., a Dutch company

Vertex Pharmaceuticals (Italy) S.r.L., an Italian company

Vertex Farmaceutica do Brasil LTDA, a Brazilian company (4)
Vertex Pharmaceuticals GmbH, an Austrian company (6)
Vertex Pharmaceuticals (Portugal), Unipessoal Lda., a Portuguese company (6)
Vertex Pharmaceuticals (CH) GmbH, a Swiss company (6)




Vertex Pharmaceuticals (Sweden) AB, a Sweden company (6)
Vertex Pharmaceuticals Single Member Societe Anonyme, a Greek company (6)
Vertex Pharmaceuticals (Poland) sp. z.o.o (5) (6)
The Vertex Foundation, Inc., a Delaware corporation
Torreyana Insurance Company, Inc., a Vermont corporation
Vertex Pharmaceuticals (Czech Republic) s.r.o (6)
Exonics Therapeutics, Inc., a Delaware corporation

Semma Therapeutics, Inc., a Delaware corporation

CytoSolv, Inc., a Rhode Island corporation (7)

------------------------------
(1) a subsidiary of Vertex Pharmaceuticals (Delaware) LLC
(2) a subsidiary of Vertex Pharmaceuticals (Singapore) Pte. Ltd.
(3) a subsidiary of Vertex Holdings, Inc.
(4) a subsidiary of Vertex Pharmaceuticals (UK) Limited
(5) a subsidiary of Vertex Pharmaceuticals (Cayman) Limited
(6) a subsidiary of Vertex Pharmaceuticals (Europe) Limited
(7) a subsidiary of Semma Therapeutics, Inc.




 EX-23.1 6 a10k2019-exhibit231.htm EXHIBIT 23.1 Exhibit
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1)
Registration Statement (Form S-3 No. 333-229656) of Vertex Pharmaceuticals Incorporated,
(2)
Registration Statements (Form S-8 Nos. 333-134482, 333-150946, 333-160442, 333-166803 and 333-184787) pertaining to the Vertex Pharmaceuticals Incorporated Amended and Restated 2006 Stock and Option Plan (formerly known as the Vertex Pharmaceuticals Incorporated 2006 Stock and Option Plan),
(3)
Registration Statement (Form S-8 Nos. 333-184784 and 333-232945) pertaining to the Vertex Pharmaceuticals Incorporated Employee Stock Purchase Plan, and
(4)
Registration Statements (Form S-8 Nos. 333-226363, 333-219559, 333-188737, 333-197466, 333-206075 and 333-232948) pertaining to the Amended and Restated Vertex Pharmaceuticals Incorporated 2013 Stock and Option Plan (formerly known as the Vertex Pharmaceuticals Incorporated 2013 Stock and Option Plan);
of our reports dated February 13, 2020, with respect to the consolidated financial statements of Vertex Pharmaceuticals Incorporated and the effectiveness of internal control over financial reporting of Vertex Pharmaceuticals Incorporated, included in this Annual Report (Form 10-K) of Vertex Pharmaceuticals Incorporated for the year ended December 31, 2019.
/s/ Ernst & Young LLP
Boston, Massachusetts
February 13, 2020

EX-31.1 7 a10k2019-exhibit311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION
I, Jeffrey M. Leiden, certify that:
1.
I have reviewed this Annual Report on Form 10-K of Vertex Pharmaceuticals Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 


Date:
February 13, 2020
/s/ Jeffrey M. Leiden
 
 
 
 
 
Jeffrey M. Leiden
 
 
Chief Executive Officer and President



 EX-31.2 8 a10k2019-exhibit312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATION
I, Charles F. Wagner, Jr., certify that:
1.
I have reviewed this Annual Report on Form 10-K of Vertex Pharmaceuticals Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
February 13, 2020
/s/ Charles F. Wagner, Jr.
 
 
 
 
 
Charles F. Wagner, Jr.
 
 
Executive Vice President and Chief Financial Officer



 EX-32.1 9 a10k2019-exhibit321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
SECTION 906 CEO/CFO CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) each of the undersigned officers of Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Annual Report on Form 10-K for the year ended December 31, 2019 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date:
February 13, 2020
 
 
 
/s/ Jeffrey M. Leiden
 
 
 
 
 
Jeffrey M. Leiden
 
 
Chief Executive Officer and President
 
 
 
Date:
February 13, 2020
 
 
 
/s/ Charles F. Wagner, Jr.
 
 
 
 
 
Charles F. Wagner, Jr.

 
 
Executive Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
 





 EX-101.SCH 10 vrtx-20191231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2107100 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - Acquisitions - Concert Pharmaceuticals (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Acquisitions - Exonics Therapeutics - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Acquisitions - Exonics Therapeutics (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Acquisitions - Semma Therapeutics - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - Acquisitions - Semma Therapeutics (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Additional Balance Sheet Detail link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Additional Balance Sheet Detail (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Additional Balance Sheet Detail (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Additional Balance Sheet Detail (Tables) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - - Cash Flow Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Collaborative Arrangements - Aggregate VIE Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Collaborative Arrangements - BioAxone Biosciences, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Collaborative Arrangements - CRISPR Therapeutics AG (Details) link:presentationLink link:calculationLink link:definitionLink 2402409 - Disclosure - Collaborative Arrangements - Cystic Fibrosis Foundation Therapeutics Incorporated (Details) link:presentationLink link:calculationLink link:definitionLink 2402408 - Disclosure - Collaborative Arrangements - Janssen Pharmaceuticals, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Collaborative Arrangements - Kymera and Other In-License Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 2402407 - Disclosure - Collaborative Arrangements - Merck KGaA (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Collaborative Arrangements - Parion Sciences, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Collaborative Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2422402 - Disclosure - Commitments and Contingencies - Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2422401 - Disclosure - Commitments and Contingencies - Revolving Credit Facility (Details) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Common Stock, Preferred Stock and Equity Plans link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Common Stock and Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2418410 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Employee Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2418409 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2418405 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Outstanding and Vested Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 2418408 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Performance-based RSUs (PSUs) (Details) link:presentationLink link:calculationLink link:definitionLink 2418407 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Restricted Stock and Restricted Stock Units and PSUs (Details) link:presentationLink link:calculationLink link:definitionLink 2418403 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Share Repurchase Program (Details) link:presentationLink link:calculationLink link:definitionLink 2418404 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Stock and Option Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2418406 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Stock Options Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - Common Stock, Preferred Stock and Equity Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 1002001 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Shareholders' Equity and Noncontrolling Interest link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Hedging link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - Hedging - Derivative Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Hedging - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408406 - Disclosure - Hedging - Offsetting Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Hedging (Tables) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2421402 - Disclosure - Income Taxes - Components of Income and Provision for (Benefit from) Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2421405 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2421403 - Disclosure - Income Taxes - Effective Income Tax Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2421404 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2321301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2421406 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2416409 - Disclosure - Leases - Capital Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Leases - Components of Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2416408 - Disclosure - Leases - Future Minimum Commitments Under Real Estate Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2416405 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2416405 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2416405 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2416407 - Disclosure - Leases - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - Leases - Weighted-Average Remaining Lease Terms and Discount Rates (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Marketable Securities and Equity Investments link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Marketable Securities and Equity Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Nature of Business and Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Nature of Business and Accounting Policies - Business Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2401411 - Disclosure - Nature of Business and Accounting Policies - Equity Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2401408 - Disclosure - Nature of Business and Accounting Policies - Foreign Currency Gain (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2401410 - Disclosure - Nature of Business and Accounting Policies - Impact of Adopted to the Condensed Consolidated Statement of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 2401412 - Disclosure - Nature of Business and Accounting Policies - Intra-Equity Transfers (Details) link:presentationLink link:calculationLink link:definitionLink 2401409 - Disclosure - Nature of Business and Accounting Policies - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Nature of Business and Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2401406 - Disclosure - Nature of Business and Accounting Policies - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2401407 - Disclosure - Nature of Business and Accounting Policies - Restructuring Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - Nature of Business and Accounting Policies - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2401413 - Disclosure - Nature of Business and Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - Nature of Business and Accounting Policies - Share-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2401414 - Disclosure - Nature of Business and Accounting Policies - Stock-Based Compensation - Improvement (Details) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Nature of Business and Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - - Notional Amount (Details) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Property and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Property and Equipment - Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2124100 - Disclosure - Quarterly Financial Data (unaudited) link:presentationLink link:calculationLink link:definitionLink 2424403 - Disclosure - Quarterly Financial Data (unaudited) - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2424402 - Disclosure - Quarterly Financial Data (unaudited) - Quarterly Financial Data (Details) link:presentationLink link:calculationLink link:definitionLink 2324301 - Disclosure - Quarterly Financial Data (unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2423405 - Disclosure - Segment Information - Property and Equipment, Net by Location (Details) link:presentationLink link:calculationLink link:definitionLink 2423403 - Disclosure - Segment Information - Revenue by Geographic Location (Details) link:presentationLink link:calculationLink link:definitionLink 2423402 - Disclosure - Segment Information - Revenues by Product (Details) link:presentationLink link:calculationLink link:definitionLink 2423404 - Disclosure - Segment Information - Significant Customers (Details) link:presentationLink link:calculationLink link:definitionLink 2323301 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Stock-based Compensation Expense link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Stock-based Compensation Expense - (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Stock-based Compensation Expense (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 vrtx-20191231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 vrtx-20191231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 vrtx-20191231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Equity [Abstract] Class of Treasury Stock [Table] Class of Treasury Stock [Table] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Share Repurchase Program 2018 Share Repurchase Program 2018 [Member] Share Repurchase Program 2018 [Member] Share Repurchase Program 2019 Share Repurchase Program 2019 [Member] Share Repurchase Program [Member] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Number of shares authorized to be repurchased Stock Repurchase Program, Authorized Amount Repurchases of common stock (shares) Stock Repurchased During Period, Shares Repurchases of common stock Stock Repurchased During Period, Value Number of shares remaining for repurchases Stock Repurchase Program, Remaining Authorized Repurchase Amount Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative [Table] Derivative [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Other current liabilities Other Current Liabilities [Member] Other assets Other Assets [Member] Other long-term liabilities Other Noncurrent Liabilities [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as hedging instruments Designated as Hedging Instrument [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Foreign currency forward contracts Foreign Exchange Forward [Member] Derivative [Line Items] Derivative [Line Items] Fair value - assets Foreign Currency Cash Flow Hedge Asset at Fair Value Total assets Derivative Asset, Fair Value, Gross Asset Fair value - liabilities Foreign Currency Cash Flow Hedge Liability at Fair Value Total liabilities Derivative Liability, Fair Value, Gross Liability Segment Reporting [Abstract] Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Credit Concentration Risk Credit Concentration Risk [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Revenues, Gross Revenue Benchmark [Member] Accounts Receivable Accounts Receivable [Member] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] McKesson Corporation McKesson Corporation [Member] McKesson Corporation [Member] Walgreen Co. Walgreen Co. [Member] Walgreen Co. [Member] Accredo/Curascript Accredo/Curascript [Member] Accredo/Curascript [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration risk percentage (less than for CVS/Caremark 2017 revenue) Concentration Risk, Percentage Accounting Policies [Abstract] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Accumulated Deficit Retained Earnings [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-16 Accounting Standards Update 2016-16 [Member] Accounting standards update 2016-01 Accounting Standards Update 2016-01 [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Deferred tax assets Deferred Tax Assets, Gross Cumulative effect adjustment for adoption of new accounting guidance Cumulative Effect of New Accounting Principle in Period of Adoption Income Tax Disclosure [Abstract] Schedule of components of income (loss) before provision for (benefit from) income taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of components of provision for (benefit from) income taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Reconciliation of the provision for (benefit from) income taxes Income Tax Expense (Benefit) Continuing Operations, Income Tax Reconciliation [Table Text Block] This block of text may be used to disclose all or parts of the required information for reconciliation of income tax provisions. Schedule of deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Summary of income tax contingencies Summary of Income Tax Contingencies [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of collaborative arrangement summary of items related to variable interest entities Schedule Of Collaborative Arrangement Summary Of Items Related To Variable Interest Entities [Table Text Block] Represents details pertaining to Variable Interest Entities assets and liabilities included in the company's condensed consolidated balance sheets. Collaborative Arrangements by Agreement [Axis] Collaborative Arrangements by Agreement [Axis] Significant terms of collaboration arrangements, by individual agreement. Collaborative Arrangement Agreement [Domain] Collaborative Arrangement Agreement [Domain] Listing of significant collaboration agreements. ORKAMBI ORKAMBI [Member] ORKAMBI [Member] Accounting Standards Update 2014-09 Accounting Standards Update 2014-09 [Member] Contract liabilities Contract with Customer, Liability Revenues related to performance obligations Contract with Customer, Liability, Revenue Recognized Cumulative effect adjustment to accumulated deficit Revenues Revenue from Contract with Customer, Excluding Assessed Tax Percentage of employees eligible for acceleration of equity awards (less than) (percent) Percentage of employees eligible for acceleration of equity awards Percentage of employees eligible for acceleration of equity awards Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Cystic Fibrosis Foundation Therapeutics Incorporated Cystic Fibrosis Foundation Therapeutics Incorporated [Member] Collaboration agreement entered into with Cystic Fibrosis Foundation Therapeutics Inc., for the development, manufacture and commercialization of a product of the entity. Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative funding Collaborative Arrangement Research Development Funding This element represents the funding under collaborative agreement 2016 amendment for research and development. Additional collaborative funding Additional Collaborative Funding This element represents the additional annual funding under collaborative agreement 2016 amendment for research and development. Share-based Payment Arrangement [Abstract] Stock-based compensation expense by line item Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Stock-based compensation expense by type of award Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Unrecognized stock-based compensation expense, net of estimated forfeitures Schedule of Unrecognized Share-based Compensation Expense [Table Text Block] Disclosure as of the latest balance-sheet date presented of the total compensation cost related to outstanding, nonvested share-based compensation awards not yet recognized, net of estimated forfeitures, and the weighted average period over which those unrecognized costs are expected to be reported. Schedule of assumptions used to estimate the grant date fair value of options Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of assumptions used to estimate the grant date fair value employee stock purchase plan Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States UNITED STATES United Kingdom UNITED KINGDOM Other Other Countries Outside of the United States and the United Kingdom [Member] Other Countries Outside of the United States and the United Kingdom [Member] Total revenues outside of the United States Outside the United States [Member] Outside the United States [Member] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Total long-lived assets Long-Lived Assets Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Deferred tax assets: Components of Deferred Tax Assets [Abstract] Net operating loss Deferred Tax Assets, Operating Loss Carryforwards Tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Intangible assets Deferred Tax Assets Intangibles The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets related to intangible assets. Deferred revenues Deferred Tax Assets, Deferred Income Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Accrued expenses Deferred Tax Assets, Accrued Expenses and Other The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from currently nondeductible expenses in accrued and other expenses, which can only be deducted for tax purposes when such items are actually incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. Finance lease liabilities Deferred Tax Assets, Lease Obligation Deferred Tax Assets, Lease Obligation Operating lease assets Deferred Tax Assets, Operating Lease Assets Deferred Tax Assets, Operating Lease Assets Other Deferred Tax Assets, Other Gross deferred tax assets Valuation allowance Deferred Tax Assets, Valuation Allowance Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Acquired intangibles Deferred Tax Liabilities, Intangible Assets Deferred revenue Deferred Tax Liabilities, Tax Deferred Income Unrealized gain Deferred Tax Liabilities, Investments Operating lease liabilities Deferred Tax Liabilities, Leasing Arrangements Unrealized gain Deferred Tax Assets, Net Inventory Disclosure [Abstract] Schedule of Inventories by Type Schedule of Inventory, Current [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] Tranche one Share-based Payment Arrangement, Tranche One [Member] Tranche two Share-based Payment Arrangement, Tranche Two [Member] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Performance-based RSUs Performance Shares [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Potential awards, percent of target shares, minimum Share-Based Compensation By Share-Based Payment Award, Award Percentage Of Target, Minimum Share-Based Compensation By Share-Based Payment Award, Award Percentage Of Target, Minimum Potential awards, percent of target shares, maximum Share-Based Compensation By Share-Based Payment Award, Award Percentage Of Target, Maximum Share-Based Compensation By Share-Based Payment Award, Award Percentage Of Target, Maximum Percent of awards in tranche Share-Based Compensation By Share-Based Payment Award, Percent of Awards in Tranche Share-Based Compensation By Share-Based Payment Award, Percent of Awards in Tranche Performance period Share-Based Compensation by Share-Based Payment Award, Performance Period Share-Based Compensation by Share-Based Payment Award, Performance Period Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Restricted stock vested in period, total fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Restricted stock and Restricted Stock Units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Beginning of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period End of the period (in shares) Restricted stock and Restricted Stock Units, weighted-average grant-date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Weighted-average grant-date fair value, as of the beginning of the period (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted average fair value (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant-date fair value, vested (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted-average grant-date fair value, cancelled (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted-average grant-date fair value, as of the end of the period (usd per share) Investments, Debt and Equity Securities [Abstract] Marketable Securities and Equity Investments Cash, Cash Equivalents, and Marketable Securities [Text Block] Janssen Janssen Pharmaceuticals, Inc. [Member] Collaboration agreement entered into with Janssen Pharmaceutical, N.V. for the development, manufacture and commercialization of a product of the entity. Collaborative and royalty revenues Collaborative Revenues The aggregate revenue from collaborative revenues. It includes the revenues earned by the entity from nonrefundable, up-front license fees; net reimbursements of research and/or development efforts, including manufacturing services; and milestone payments. Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of the cash and cash equivalents and available-for-sale investments held by the entity. Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Money market funds Cash and Money Market Funds [Member] Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time. Corporate debt securities Corporate Debt Securities, Due Within One Year [Member] Corporate Debt Securities, Due Within One Year [Member] U.S. Treasury securities US Treasury Securities [Member] Government-sponsored enterprise securities US Government-sponsored Enterprises Debt Securities [Member] Commercial paper Commercial Paper [Member] Cash Equivalents Cash Equivalents [Member] Total marketable debt securities Available-for-sale Securities [Member] U.S Treasury securities US Treasury Securities, Due Within One Year [Member] US Treasury Securities, Due Within One Year [Member] Government-sponsored enterprise securities U.S. Government Sponsored Enterprises Debt Securities, Due Within One Year [Member] U.S. Government Sponsored Enterprises Debt Securities, Due Within One Year [Member] Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents, Due Within One Year [Member] Commercial Paper, Not Included with Cash and Cash Equivalents, Due Within One Year Corporate equity securities Equity Securities [Member] Summary of cash, cash equivalents and marketable securities Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items] -- None. No documentation exists for this element. -- Amortized Cost Cash, Cash Equivalents, Available-for-sale Securities, Amortized Cost This item represents the cost of cash and cash equivalents and debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any. Gross Unrealized Gains Cash, Cash Equivalents, Available-for-sale Securities, Gross Unrealized Gain This item represents the gross unrealized gains for cash, cash equivalents and securities which are categorized neither as held-to-maturity nor trading securities. Such gross unrealized gains are the excess of the fair value over the carrying value as of the reporting date. Gross Unrealized Losses Cash, Cash Equivalents, Available-for-sale Securities, Unrealized Loss, Gross This item represents the gross unrealized losses for cash, cash equivalents and securities which are categorized neither as held-to-maturity nor trading securities. Such gross unrealized losses are the excess of the carrying value over the fair value as of the reporting date. Fair Value Cash and Cash Equivalents, Fair Value Disclosure Available-for-sale Debt Securities Debt Securities, Available-for-sale [Abstract] Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Fair Value Debt Securities, Available-for-sale Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract] Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract] Amortized Cost Equity Securities, FV-NI, Cost Gross Unrealized Gains Equity Securities, FV-NI, Unrealized Gain Gross Unrealized Losses Equity Securities, FV-NI, Unrealized Loss Fair Value Equity Securities, FV-NI Amortized Cost Debt and Equity Securities, Cost Debt and Equity Securities, Cost Gross Unrealized Gains Debt and Equity Securities, Unrealized Gain Debt and Equity Securities, Unrealized Gain Gross Unrealized Losses Debt and Equity Securities, Unrealized Loss Debt and Equity Securities, Unrealized Loss Fair Value Debt and Equity Securities, Fair Value Debt and Equity Securities, Fair Value Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Semma Therapeutics, Inc. Semma Therapeutics, Inc. [Member] Semma Therapeutics, Inc. [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Property and equipment, net Property, Plant and Equipment, Net Goodwill Goodwill Intangible asset Other Indefinite-lived Intangible Assets Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Net other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Total purchase price Business Combination, Consideration Transferred Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Marketable Securities Marketable Securities, Policy [Policy Text Block] Accounts Receivable Accounts Receivable [Policy Text Block] Stock-based Compensation Expense Compensation Related Costs, Policy [Policy Text Block] Research and Development Expenses Research, Development, and Computer Software, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Variable Interest Entities Consolidation, Variable Interest Entity, Policy [Policy Text Block] Fair Value of In-process Research and Development Assets and Contingent Payments In-process Research and Development Assets and Contingent Payments [Policy Text Block] Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets and contingent payments of an acquired entity to be used in the research and development activities of the combined enterprise. In-process Research and Development Assets Goodwill and Intangible Assets Indefinite-Lived Assets [Policy Text Block] Describes an entity's accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets. Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Deconsolidation and Discounted Operations Deconsolidation and Discounted Operations [Policy Text Block] Deconsolidation and Discounted Operations [Policy Text Block] Embedded Derivatives and Hedging Activities Derivatives, Policy [Policy Text Block] Restructuring Expenses Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block] Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Foreign Currency Translation and Transactions Foreign Currency Transactions and Translations Policy [Policy Text Block] Net Loss Per Share Attributable to Vertex Common Stockholders Earnings Per Share, Policy [Policy Text Block] Recently Adopted/Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Leases [Abstract] Weighted-average remaining lease term (in years) Weighted-Average Remaining Lease [Abstract] Weighted-Average Remaining Lease [Abstract] Finance leases Finance Lease, Weighted Average Remaining Lease Term Operating leases Operating Lease, Weighted Average Remaining Lease Term Weighted-average discount rate (in percent) Weighted Average Discount Rate [Abstract] Weighted Average Discount Rate [Abstract] Finance leases Finance Lease, Weighted Average Discount Rate, Percent Operating leases Operating Lease, Weighted Average Discount Rate, Percent Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Maximum Maximum [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2013 Stock and Option Plan Stock and Option Plan 2013 [Member] Stock and Option Plan 2013 [Member] 2006 Stock and Option Plan Stock and Option Plan 2006 [Member] The element describes the details pertaining to the 2006 Stock and Option Plan. Awards outstanding (shares) Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Outstanding, Number Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Outstanding, Number Additional awards authorized for grant (shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Additional shares authorized (shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Pre-Clinical Treatments For Device-Assisted Cells Pre-Clinical Treatments For Device-Assisted Cells [Member] Pre-Clinical Treatments For Device-Assisted Cells [Member] Naked Islets Naked Islets [Member] Naked Islets [Member] Property Subject to or Available for Operating Lease, by Major Property Class [Table] Property Subject to or Available for Operating Lease, by Major Property Class [Table] Name of Property [Axis] Name of Property [Axis] Name of Property [Domain] Name of Property [Domain] Fan Pier Leases Fan Pier Leases [Member] Represents the fan pier leases. Other Leases Other Operating Leases [Member] Represents the other operating leases. Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] 2019 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2020 Operating Leases, Future Minimum Payments, Due in Two Years 2021 Operating Leases, Future Minimum Payments, Due in Three Years 2022 Operating Leases, Future Minimum Payments, Due in Four Years 2023 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total minimum lease payments Operating Leases, Future Minimum Payments Due Accounting standards update 2016-01, financial instruments Accounting Standards Update 2016-01, Financial Instruments [Member] Accounting Standards Update 2016-01, Financial Instruments [Member] Cumulative effect adjustment for adoption of new accounting guidance Unrealized gains to other (expense) income, net Unrealized Gain (Loss) on Investments ESPP share issuances Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Offering period (in months) Share-based Compensation Arrangement by Share-based Payment Award, Offering Period Share-based Compensation Arrangement by Share-based Payment Award, Offering Period Number of purchase periods Share-based Compensation Arrangement by Share-based Payment Award, Number of Purchase Periods Share-based Compensation Arrangement by Share-based Payment Award, Number of Purchase Periods Duration of purchase period Share-based Compensation Arrangement by Share-based Payment Award, Duration of Purchase Period Share-based Compensation Arrangement by Share-based Payment Award, Duration of Purchase Period Eligible employee purchase price percentage of fair value Share-based Compensation Arrangement by Share-based Payment Award, Eligible Employee Purchase Price Percentage of Fair Value This element represents the percentage of the fair market value of the entity's common stock on the first day of the applicable offering period or last day of the applicable purchase period that eligible employees may purchase shares of the entity's common stock under the employee stock purchase plan. Increase in the number of shares authorized for issuance (shares) Stock Repurchase Program, Number of Shares Authorized to be Repurchased Number of shares authorized (shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of shares (shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Average price paid per share (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased Statement of Comprehensive Income [Abstract] Unrealized holding gains (losses) on marketable securities, tax Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax Unrealized (losses) gains on foreign currency forward contracts, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Unrealized (losses) gains on foreign currency forward contracts, tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax Raw materials Inventory, Raw Materials, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total Inventory, Net Fair Value Disclosures [Abstract] Financial assets and liabilities subject to fair value measurements (excluding restricted cash and cash equivalents (VIE)) Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of fair value of our contingent consideration liabilities Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Statement of Financial Position [Abstract] Preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (shares) Preferred Stock, Shares Outstanding Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (shares) Common Stock, Shares Authorized Common stock, shares issued (shares) Common Stock, Shares, Issued Common stock, shares outstanding (shares) Common Stock, Shares, Outstanding Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Cash Flow Hedging Cash Flow Hedging [Member] Currency [Axis] Currency [Axis] All Currencies [Domain] All Currencies [Domain] Euro Euro Member Countries, Euro Australian dollar Australia, Dollars British pound sterling United Kingdom, Pounds Canadian dollar Canada, Dollars Derivative term Derivative, Term of Contract Notional amount of foreign currency forward contract Derivative, Notional Amount Europe Europe [Member] Other Other Countries Outside of the United States and Europe [Member] Other Countries Outside of the United States and Europe [Member] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Adjustments to reconcile net income to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Depreciation expense Depreciation, Depletion and Amortization Deferred income taxes (including benefit from valuation allowance release in 2018) Increase (Decrease) in Other Deferred Liability Gains on equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Increase in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Intangible asset impairment charges Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Acquired in-process research and development Research and Development in Process Deconsolidation of VIE Gain (Loss) on Sale of Investments Other non-cash items, net Other Noncash Income (Expense) Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses Increase (Decrease) in Accrued Liabilities Other liabilities Increase (Decrease) in Other Operating Liabilities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Payments to acquire businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Purchases of available-for-sale debt securities Payments to Acquire Debt Securities, Available-for-sale Purchases of available-for-sale debt securities Payments to Acquire Available-for-sale Securities Maturities of available-for-sale debt securities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale Sale of equity securities Proceeds from Sale of Debt and Equity Securities, FV-NI, Held-for-investment Expenditures for property and equipment Payments to Acquire Property, Plant, and Equipment Investment in equity securities Payment to Acquire Preferred Stock Payment to Acquire Preferred Stock Investment in note receivable Payments to Acquire Notes Receivable Decrease in restricted cash due to deconsolidation of VIE Increase (Decrease) in Restricted Cash and Investments Purchase of in-process research and development Payments to Acquire in Process Research and Development Other investing activities Payments for (Proceeds from) Other Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Issuances of common stock under benefit plans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised Repurchases of common stock Payments for Repurchase of Common Stock Payments on finance leases Finance Lease, Principal Payments Advance from collaborator Proceeds From Collaborative Funding Proceeds From Collaborative Funding Proceeds related to capital lease and construction financing lease obligations Proceeds On Construction Capital Lease Obligations Proceeds On Construction Capital Lease Obligations Repayments of advanced funding Repayments of Collaborative Funding Repayments of Collaborative Funding Payments on capital lease and construction financing lease obligations Payments on Construction Financing Lease Obligations Payments on Construction Financing Lease Obligations Payments on revolving credit facility Repayments of Lines of Credit Other financing activities Proceeds from (Payments for) Other Financing Activities Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Effect of changes in exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents and restricted cash—beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash—end of period Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for income taxes Income Taxes Paid, Net Capitalization of costs related to construction financing lease obligation Noncash or Part Noncash Acquisition, Fixed Assets Acquired Issuances of common stock from employee benefit plans receivable Conversion of Stock, Amount Issued Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Balance at beginning of the period Unrecognized Tax Benefits Increases related to current period tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Increases related to prior period tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Decreases related to prior period tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Settlement with Tax Authorities Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Balance at end of period Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Product Product [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Product revenues, net Revenue from Contract with Customer Benchmark [Member] Other (expense) income, net Other Nonoperating Income (Expense) [Member] Not designated as hedging instrument Not Designated as Hedging Instrument [Member] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Gain (loss) on derivatives designated as hedging instruments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Gain (loss) on derivatives not designated as hedging instruments Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Gain (loss) on cash flow hedging instruments Unrealized Gain (Loss) on Cash Flow Hedging Instruments Product revenues, net Other income (expense), net Other Nonoperating Income (Expense) Kymera Therapeutics Kymera Therapeutics [Member] Kymera Therapeutics [Member] Molecular Templates, Inc Molecular Templates, Inc [Member] Molecular Templates, Inc [Member] Arbor Arbor Biotechnologies, Inc. [Member] Arbor Biotechnologies, Inc. [Member] Up-front payment Collaborative Arrangement Up-front License Fee The amount of the up-front license fee paid by the entity pursuant to a collaborative arrangement. Right to license, number of targets (up to) Collaborative Arrangement, Right To License, Number Of Targets Collaborative Arrangement, Right To License, Number Of Targets Collaborative arrangement development and regulatory potential milestone payments maximum Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized. Investment in collaborative partner, pursuant to convertible loan agreement Collaborative Arrangement, Investment in Collaborative Partner, Amount Collaborative Arrangement, Investment in Collaborative Partner, Amount Schedule of stock and stock equity plans Schedule of Stock and Stock Option, Equity Plans [Table Text Block] This schedule discloses the information pertaining to stock and stock option plans relating to the entity's equity. Outstanding and vested options Share-based Payment Arrangement, Option, Activity [Table Text Block] Stock options outstanding and exercisable Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Restricted stock and restricted stock units activity Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] PSU activity Share-based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block] Shares issued under Employee Stock Purchase Plan Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Property, Plant and Equipment [Abstract] Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments Disclosure [Text Block] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Non Compensatory Non Compensatory [Member] Non Compensatory [Member] Compensatory Compensatory [Member] Compensatory [Member] Exonics Therapeutics Exonics Therapeutics [Member] Exonics Therapeutics [Member] Payments to acquire businesses Payments to Acquire Businesses, Gross Future payments to acquire businesses Future Payments To Acquire Businesses Payments made in future to acquire businesses. Acquisition related development and regulatory potential milestone payments maximum Acquisition Related Development And Regulatory Potential Milestone Payments Maximum Acquisition Related Development And Regulatory Potential Milestone Payments Maximum Income Statement [Abstract] Statement [Table] Statement [Table] Product revenues, net Collaborative and royalty revenues Collaborative and Royalty [Member] Collaborative and Royalty [Member] Statement [Line Items] Statement [Line Items] Revenues: Revenue from Contract with Customer [Abstract] Costs and expenses: Costs and Expenses [Abstract] Cost of sales Cost of Goods and Services Sold Research and development expenses Research and Development Expense Sales, general and administrative expenses Selling, General and Administrative Expense Change in fair value of contingent consideration Restructuring (income) expenses Restructuring Charges Total costs and expenses Costs and Expenses Income from operations Operating Income (Loss) Interest income Investment Income, Interest and Dividend Interest expense Interest Expense Income (loss) before provision for (benefit from) income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Provision for (benefit from) income taxes Income Tax Expense (Benefit) Net income Loss attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Net income attributable to Vertex Net Income (Loss) Attributable to Parent Net income: Earnings Per Share [Abstract] Basic (usd per share) Earnings Per Share, Basic Diluted (usd per share) Earnings Per Share, Diluted Shares used in per share calculations: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Schedule of Reclassifications out of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Payables and Accruals [Abstract] Accrued expenses Accrued Liabilities, Current [Abstract] Payroll and benefits Employee-related Liabilities, Current Research, development and commercial contract costs Accrued Research Development and Commercial Contract Costs This element represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for R&D and commercial of the entity. It is used to reflect the current portion of liabilities (due within one year or within the normal operating cycle, if longer). Product revenue allowances Product Sales Accrued Liabilities Total of product sales allowances and reserves that reflect a liability established to represent expected future costs. Royalty payable Accrued Royalties, Current Tax related accruals Taxes Payable, Current Other Other Accrued Liabilities, Current Total Accrued Liabilities, Current Other current liabilities Other Liabilities, Current [Abstract] Contract liabilities Other Contract Liabilities Current Other Contract liabilities, Current Finance lease liabilities Finance Lease, Liability, Current Capital lease obligations Capital Lease Obligations, Other Liabilities, Current Capital Lease Obligations, Other Liabilities, Current Other Other Sundry Liabilities, Current Total Other Liabilities, Current Other long-term liabilities Other Liabilities, Noncurrent [Abstract] Advance from collaborator Advance From Collaborator, Noncurrent Advance From Collaborator Operating lease liabilities Operating Lease, Liability, Noncurrent Other Other Sundry Liabilities, Noncurrent Total Other Liabilities, Noncurrent Statement of Stockholders' Equity [Abstract] Total Vertex Shareholders' Equity Parent [Member] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Noncontrolling Interest Noncontrolling Interest [Member] Statement [Line Items] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance (shares) Shares, Outstanding Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Other comprehensive (loss) income, net of tax Other Comprehensive Income (Loss), Net of Tax Net income (loss) Repurchases of common stock (shares) Repurchases of common stock Issuance of common stock under benefit plans (shares) Stock Issued During Period, Shares, Employee Benefit Plan Issuance of common stock under benefit plans Stock Issued During Period, Value, Employee Benefit Plan Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition VIE noncontrolling interest upon deconsolidation Noncontrolling Interest, Increase (Decrease) From Deconsolidation, Variable Interest Entity Noncontrolling Interest, Increase (Decrease) From Deconsolidation, Variable Interest Entity Other VIE activity Stockholders' Equity, Other Balance (shares) Balance Accumulated Other Comprehensive Income (Loss) Stockholders' Equity Note Disclosure [Text Block] Schedule of business price consideration Schedule of Business Acquisitions, by Acquisition [Table Text Block] Schedule of purchase price assumed assets and liabilities Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Earnings Per Share Earnings Per Share [Text Block] Finance Leases Finance Lease, Liability, Payment, Due [Abstract] 2020 Finance Lease, Liability, Payments, Due Next Twelve Months 2021 Finance Lease, Liability, Payments, Due Year Two 2022 Finance Lease, Liability, Payments, Due Year Three 2023 Finance Lease, Liability, Payments, Due Year Four 2024 Finance Lease, Liability, Payments, Due Year Five Thereafter Finance Lease, Liability, Payments, Due after Year Five Total lease payments Finance Lease, Liability, Payment, Due Less: amount representing interest Finance Lease, Liability, Undiscounted Excess Amount Present value of lease liabilities Finance Lease, Liability Operating Leases Lessee, Operating Lease, Liability, Payment, Due [Abstract] 2020 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less: amount representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Present value of lease liabilities Operating Lease, Liability Total Finance Leas and Operating Lease, Liabilities, Payments, Due [Abstract] Finance Leas and Operating Lease, Liabilities, Payments, Due [Abstract] 2020 Finance Lease And Operating Lease, Liability, Payment, Due Next Twelve Months Finance Lease And Operating Lease, Liability, Payment, Due Next Twelve Months 2021 Finance Lease And Operating Lease, Liability, Payment, Due Year Two Finance Lease And Operating Lease, Liability, Payment, Due Year Two 2022 Finance Lease And Operating Lease, Liability, Payment, Due Year Three Finance Lease And Operating Lease, Liability, Payment, Due Year Three 2023 Finance Lease And Operating Lease, Liability, Payments, Due Year Four Finance Lease And Operating Lease, Liability, Payments, Due Year Four 2024 Finance Lease And Operating Lease, Liability, Payments, Due Year Five Finance Lease And Operating Lease, Liability, Payments, Due Year Five Thereafter Finance Lease And Operating Lease, Liability, Payments, Due After Year Five Finance Lease And Operating Lease, Liability, Payments, Due After Year Five Total lease payments Finance Lease And Operating Lease, Liability, Payments, Due Finance Lease And Operating Lease, Liability, Payments, Due Less: amount representing interest Finance Lease And Operating Lease, Liability, Undiscounted Excess Amount Finance Lease And Operating Lease, Liability, Undiscounted Excess Amount Present value of lease liabilities Finance Lease And Operating Lease, Liability Finance Lease And Operating Lease, Liability Quarterly Financial Information Disclosure [Abstract] Quarterly Financial Data (unaudited) Quarterly Financial Information [Text Block] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Buildings Building [Member] Restatement [Axis] Restatement [Axis] Restatement [Domain] Restatement [Domain] Previously Reported Previously Reported [Member] Adjustments Restatement Adjustment [Member] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Length of lease Lessee, Finance Lease, Term of Contract Property and equipment useful life Property, Plant and Equipment, Useful Life Operating lease assets Operating Lease, Right-of-Use Asset Present value of lease liabilities Assets Assets [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Property and equipment, net Deferred tax assets Deferred Income Tax Assets, Net Other assets Other Assets Total assets Assets Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Capital lease obligations, current portion Capital Lease Obligations, Current Other current liabilities Other Liabilities, Excluding Capital Lease Obligations, Current Other Liabilities, Excluding Capital Lease Obligations, Current Capital lease obligations, excluding current portion Capital Lease Obligations, Noncurrent Construction financing lease obligation, excluding current portion Construction Financing Obligation, Noncurrent Represents the noncurrent portion of a lease liability recorded as a result of capitalizing the landlord's costs of constructing facilities associated with building leases. Long-term finance lease liabilities Finance Lease, Liability, Noncurrent Other long-term liabilities Accumulated deficit Retained Earnings (Accumulated Deficit) Total liabilities and shareholders’ equity Liabilities and Equity Summary of Accrued expenses and other current liabilities Schedule of Accrued Liabilities [Table Text Block] Summary Other Current Liabilities Other Current Liabilities [Table Text Block] Summary of Other Long Term Liabilities Other Noncurrent Liabilities [Table Text Block] Schedule of quarterly financial data Quarterly Financial Information [Table Text Block] Income (loss) before provision for (benefit from) income taxes Expected provision for (benefit from) income taxes Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount State taxes, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Foreign income tax rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Amount Benefit from income taxes attributable to valuation allowances Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Permanent items Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount Tax rate change Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Stock compensation (benefit) shortfalls and cancellations Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount Officer’s compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount Deconsolidation of VIE Effective Income Tax Rate Reconciliation, Deconsolidation Of Variable Interest Entity, Amount Effective Income Tax Rate Reconciliation, Deconsolidation Of Variable Interest Entity, Amount Uncertain tax positions Effective Income Tax Rate Reconciliation, Uncertian Tax Positions, Amount Effective Income Tax Rate Reconciliation, Uncertian Tax Positions, Amount Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Provision for (benefit from) income taxes Schedule of earning per share, basic and diluted, by common shares Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of antidilutive securities excluded from computation of earnings per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Revenues by Product Revenue from External Customers by Products and Services [Table Text Block] Revenues and Property and Equipment by Location Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Significant Customers Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Fair Value Measurements Fair Value Disclosures [Text Block] Hedging Derivative Instruments and Hedging Activities Disclosure [Text Block] Depreciation expense Depreciation Schedule of Indefinite-Lived Intangible Assets by Major Class [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Other Intangible Assets Other Intangible Assets [Member] Variable Interest Entities [Axis] Variable Interest Entities [Axis] Variable Interest Entity, Classification [Domain] Variable Interest Entity, Classification [Domain] Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] BioAxone Biosciences, Inc BioAxone Biosciences Inc. [Member] BioAxone Biosciences Inc. Parion Sciences, Inc Parion Sciences, Inc. [Member] Parion Sciences, Inc. Indefinite-Lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Goodwill Income Taxes Income Tax Disclosure [Text Block] Matures within one year Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value Matures after one year through five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value Total Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Prepaid expenses and other current assets Restricted Cash and Cash Equivalents, Current Other assets Restricted Cash and Cash Equivalents, Noncurrent Cash, cash equivalents and restricted cash per statement of cash flows Cover page. Document Type Document Annual Report Document Annual Report Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Public Float Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Cash Cash Leases Lessee, Finance Leases [Text Block] Leases Lessee, Operating Leases [Text Block] Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis] Exercise Price Range [Axis] Exercise Price Range [Domain] Exercise Price Range [Domain] $29.07–$40.00 Exercise Price Range From Dollars 29.07 to Dollars 40.00 [Member] Exercise Price Range From Dollars 29.07 to Dollars 40.00 [Member] $40.01–$60.00 Exercise Price Range from Dollars 40.01 to Dollars 60.00 [Member] Represents the range of exercise prices from $40.01 to $60.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $60.01–$80.00 Exercise Price Range from Dollars 60.01 to Dollars 80.00 [Member] Represents the range of exercise prices from $60.01 to $80.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $80.01–$100.00 Exercise Price Range from Dollars 80.01 to Dollars 100.00 [Member] Represents the range of exercise prices from $80.01 to $100.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $100.01–$120.00 Exercise Price Range from Dollars 100.01 to Dollars 120.00 [Member] Represents the range of exercise prices from $100.01 to $120.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $120.01–$140.00 Exercise Price Range From Dollars 120.01 to Dollars 140.0 [Member] Exercise Price Range From Dollars 120.01 to Dollars 140.0 $140.01–$160.00 Exercise Price Range From Dollars 140.01 to Dollars 160.0 [Member] Exercise Price Range From Dollars 140.01 to Dollars 160.0 $160.01–$180.00 Exercise Price Range From Dollars 160.01 to Dollars 180.00 [Member] Exercise Price Range From Dollars 160.01 to Dollars 180.00 [Member] $180.01–$189.38 Exercise Price Range From Dollars 180.01 to Dollars 189.38 [Member] Exercise Price Range From Dollars 180.01 to Dollars 189.38 [Member] Stock options outstanding and exercisable Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Exercise price, low end of range (usd per share) Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Exercise price, high end of range (usd per share) Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Options outstanding (in shares) Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Options outstanding, weighted-average remaining contractual life Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term Options outstanding, weighted-average exercise price (usd per share) Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price Options exercisable (in shares) Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Options exercisable, weighted-average exercise price (usd per share) Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price Fair value of intangible asset Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure (Increase) decrease in fair value of contingent payments Income tax expense (benefit), attributable to intangible asset impairment Income Tax Expense (Benefit), Attributable To Intangible Asset Impairment Income Tax Expense (Benefit), Attributable To Intangible Asset Impairment Income tax expense (benefit), attributable to decrease in the fair value of contingent consideration liability Income Tax Expense (Benefit), Attributable To Decrease In The Fair Value Of Contingent Consideration Liability Income Tax Expense (Benefit), Attributable To Decrease In The Fair Value Of Contingent Consideration Liability Deconsolidation,loss, amount Deconsolidation, Gain (Loss), Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Furniture and equipment Furniture and Fixtures [Member] Computers and software Computers and Software [Member] Represents the computer and software used in business. Minimum Minimum [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Domestic Tax Authority Domestic Tax Authority [Member] State and Local Jurisdiction State and Local Jurisdiction [Member] Accounting standards update 2016-09, excess tax benefit Accounting Standards Update 2016-09, Excess Tax Benefit [Member] Accounting Standards Update 2016-09, Excess Tax Benefit Accounting standards update 2016-09, forfeiture rate component Accounting Standards Update 2016-09, Forfeiture Rate Component [Member] Accounting Standards Update 2016-09, Forfeiture Rate Component Operating loss carryforwards Operating Loss Carryforwards Cumulative effect adjustment for adoption of new accounting guidance Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Other nonoperating income (expense) Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Notional amount of foreign currency forward contract Derivative term (less than) Foreign Currency Translation Foreign Currency Translation [Abstract] Net foreign currency transaction loss Foreign Currency Transaction Gain (Loss), before Tax Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Corporate Headquarters San Diego Lease San Diego Lease [Member] San Diego Lease [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Number of leases Lease Agreement, Number of Leases Represents the number of leases entered by the reporting entity. Area of real estate property (in square feet) Area of Real Estate Property Lease agreements number of buildings Lease Agreements Number of Buildings Represents number of buildings under lease agreements. Option to extend lease term Optional term of lease agreement (in years) Lessee, Operating Lease, Renewal Term Length of lease Lessee Leasing Arrangements, Capital Leases, Term of Contract Lessee Leasing Arrangements, Capital Leases, Term of Contract Amount of optional renewal terms Amount of Optional Renewal Terms Amount of Optional Renewal Terms Optional renewal term length Lessee Leasing Arrangements, Capital Leases, Renewal Term Lessee Leasing Arrangements, Capital Leases, Renewal Term Sublease income 2018 Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals Rental expense Operating Leases, Rent Expense Capital leases, imputed interest rate Capital leases, Imputed Interest Rate Capital leases, Imputed Interest Rate Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Software Computer Software, Intangible Asset [Member] Leasehold improvements Leasehold Improvements [Member] Computers Computer Equipment [Member] Total property and equipment, gross Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, Before Accumulated Depreciation And Amortization Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, Before Accumulated Depreciation And Amortization Total property and equipment, gross Property, Plant and Equipment, Gross Less: accumulated depreciation Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, Accumulated Depreciation And Amortization Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, Accumulated Depreciation And Amortization Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Total property and equipment, net Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, After Accumulated Depreciation And Amortization Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, After Accumulated Depreciation And Amortization Total property and equipment, net Indemnification claims Indemnification Claims Amount of indemnification claims currently outstanding Contingent liabilities Contingent Liabilities Amount of material contingent liabilities outstanding Common Stock, Preferred Stock and Equity Plans Common Stock, Preferred Stock and Equity Plans Disclosure [Text Block] Disclosures related to shares available for future issuance, descriptions of the stock and option plans, and the rights associated with each share. Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] CRISPR Therapeutics CRISPR Therapeutics AG [Member] CRISPR Therapeutics AG Marketable securities, fair value, investment in common stock Investments, Fair Value Disclosure Other-than-temporary declines in fair value of available-for-sale debt securities Other than Temporary Impairment Losses, Investments Gross realized gains or losses Proceeds from Sale of Debt Securities, Available-for-sale Realized investment gains (losses) Realized Investment Gains (Losses) Equity securities without readily determinable fair value, amount Equity Securities without Readily Determinable Fair Value, Amount Upfront payment (adjusted for customary working capital adjustments) Payments To Acquire Businesses, Adjusted For Working Capital Payments To Acquire Businesses, Adjusted For Working Capital Fair value of contingent development and regulatory payments Business Combination, Contingent Consideration, Liability, Increase From Acquisitions Business Combination, Contingent Consideration, Liability, Increase From Acquisitions Total purchase price Cash and cash equivalents Net other assets Cost of sales Cost of Sales [Member] Research and development expenses Research and Development Expense [Member] Sales, general and administrative expenses Selling General and Administrative Expense [Member] The allocation (or location) of expense to (in) selling, general and administrative expense. Restricted stock and restricted stock units (including PSUs) Employee Restricted Stock Option [Member] An arrangement whereby certain members of senior management are entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Stock options Share-based Payment Arrangement, Option [Member] Financial performance shares Financial Performance Shares [Member] Financial Performance Shares Non-financial performance shares Non-Financial Performance Shares [Member] Non-Financial Performance Shares Tranche three Share-based Payment Arrangement, Tranche Three [Member] Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type [Axis] Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type [Axis] This element represents the grouping of share-based compensation award types. Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type [Domain] Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type [Domain] This element represents an individual share-based compensation award type. Stock Options Equity Option [Member] Employee stock purchase plan Employee Stock [Member] Stock-based compensation expense: Share-based Compensation Allocation [Abstract] -- None. No documentation exists for this element. -- Stock-based compensation expense Share-based Payment Arrangement, Expensed and Capitalized, Amount Income tax effect Share-based Payment Arrangement, Expense, Tax Benefit Total stock-based compensation included in costs and expenses, net of tax Share-based Payment Arrangement, Expense, after Tax Stock-based compensation expense related to inventories Share-based Payment Arrangement, Amount Capitalized Allocated stock-based compensation expense Share-based Payment Arrangement, Expense Type of award: Share-based Payment Arrangement, Additional Disclosure [Abstract] Unrecognized Expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Weighted-average Recognition Period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted-average grant-date fair value, granted (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average assumptions for options and ESPP subscriptions granted Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Expected stock price volatility (percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk-free interest rate (percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected term of options (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected annual dividends Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments Vesting rights percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Additional Balance Sheet Detail Additional Financial Information Disclosure [Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Balance at December 31, 2018 Business Combination, Contingent Consideration, Liability Contingent consideration related to acquisition of Exonics Balance at December 31, 2019 Operating Loss and Tax Credit, Carryforwards [Table] Operating Loss and Tax Credit, Carryforwards [Table] Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization and tax credit carryforwards. Deferred Tax Assets Deferred Tax Assets [Member] Deferred Tax Assets [Member] Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities [Member] Domestic and Foreign Tax Authority Domestic and Foreign Tax Authority [Member] Domestic and Foreign Tax Authority [Member] Foreign Tax Authority Foreign Tax Authority [Member] Tax Carryforwards [Line Items] Tax Carryforwards [Line Items] -- None. No documentation exists for this element. -- Decrease in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Business combination, recognized identifiable assets acquired and liabilities assumed, deferred tax liabilities, current Income tax (benefit) resulting in the release of valuation allowance Income Tax (Benefit) Resulting in the Release of Valuation Allowance Income Tax (Benefit) Resulting in the Release of Valuation Allowance Valuation allowance Operating loss carryforwards, subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Operating loss carryforwards, not subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Tax credit carryforwards Tax Credit Carryforward, Amount Unrecognized tax benefits Income tax penalties and interest accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Line of Credit Facility [Table] Line of Credit Facility [Table] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Base Rate Base Rate [Member] Eurodollar Eurodollar [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Line of Credit Line of Credit [Member] Letter of Credit Letter of Credit [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Line of credit facility, current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Line of credit facility, additional borrowing capacity Line Of Credit Facility Additional Borrowing Capacity Amount of increased borrowing capacity available in the future. Interest rate (percent) Debt Instrument, Interest Rate, Stated Percentage Debt covenant, consolidated leverage ratio Debt Covenant, Consolidated Leverage Ratio Consolidated leverage ratio that must be maintained in order to be in compliance with debt covenants. Debt covenant, minimum consolidated EBITDA Debt Covenant, Minimum Consolidated EBITDA Minimum consolidated EBITDA that must be maintained in order to be in compliance with debt covenants. Components of income (loss) before provision for (benefit from) income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] United States Income (Loss) from Continuing Operations before Income Taxes, Domestic Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Current taxes: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Current Federal Tax Expense (Benefit) Foreign Current Foreign Tax Expense (Benefit) State Current State and Local Tax Expense (Benefit) Total current taxes Current Income Tax Expense (Benefit) Deferred taxes: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) Foreign Deferred Foreign Income Tax Expense (Benefit) State Deferred State and Local Income Tax Expense (Benefit) Total deferred taxes Deferred Income Tax Expense (Benefit) Restricted Stock Units (excluding PSUs) Restricted Stock Units (RSUs) [Member] Restricted Stock Restricted Stock [Member] Weighted-average grant-date fair value, granted (usd per share) Nature of Business and Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Changes in other comprehensive (loss) income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Unrealized holding gains on marketable securities, net of tax of zero, zero and $(2.7) million, respectively Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Unrealized (losses) gains on foreign currency forward contracts, net of tax of $7.0 million, $(7.1) million and $3.4 million, respectively Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Unrealized (losses) gains on foreign currency forward contracts, net of tax of $7.0 million, $(7.1) million and $3.4 million, respectively Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Total changes in other comprehensive (loss) income Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss attributable to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive income attributable to Vertex Comprehensive Income (Loss), Net of Tax, Attributable to Parent Interim Reporting [Table] Interim Reporting [Table] Interim Reporting [Table] Interim Reporting [Line Items] Interim Reporting [Line Items] [Line Items] for Interim Reporting [Table] Revenues: Revenues [Abstract] Research and development expenses Sales, general and administrative expenses Restructuring (income) expenses Interest income (Benefit from) provision for income taxes Net income: Shares used in per share calculations: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Balances without Adoption of ASC 606 Calculated under Revenue Guidance in Effect before Topic 606 [Member] Effect of Change Higher/(Lower) Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Income from operations Net income attributable to Vertex common shareholders Amounts per share attributable to Vertex common shareholders: Earnings Per Share, Basic and Diluted [Abstract] Net income: Net Income (Loss) Attributable to Parent [Abstract] Segment Information Segment Reporting Disclosure [Text Block] Stock Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Stock options outstanding at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Stock options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Stock options exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Stock options forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Stock options expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Stock options outstanding at end of period (in shares) Stock options exercisable at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted-average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted-average exercise price outstanding at beginning of period (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted average exercise price, granted (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average exercise price, exercised (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted average exercise price, forfeited (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted average exercise price, expired (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Weighted-average exercise price outstanding at end of period (usd per share) Weighted average exercise price exercisable at the end of the period (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted-average Remaining Contractual Life Weighted Average, Remaining Contractual Life [Abstract] -- None. No documentation exists for this element. -- Weighted-average Remaining Contractual Life, outstanding (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted-average Remaining Contractual Life, exercisable (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Aggregate intrinsic value [Abstract] -- None. No documentation exists for this element. -- Aggregate intrinsic value, outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate intrinsic value, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Weighted Average Weighted Average [Member] Market share price (usd per share) Share Price Total intrinsic value of stock options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Total cash received from employees as a result of employee stock option exercises Proceeds from Stock Options Exercised Collaborative Arrangements Collaborative Arrangement Disclosure [Text Block] Schedule of Collaborative Arrangement Agreements [Table] Schedule of Collaborative Arrangement Agreements [Table] A schedule reflecting significant collaboration agreements in which the entity is a participant. Merck KGaA and Arbor Merck KGaA and Arbor Biotechnologies, Inc. [Member] Merck KGaA and Arbor Biotechnologies, Inc. [Member] Schedule of Collaborative Arrangement Agreements [Line Items] Schedule of Collaborative Arrangement Agreements [Line Items] -- None. No documentation exists for this element. -- Collaborative arrangement, development and commercialization rights potential maximum milestone payments Collaborative Arrangement, Development and Commercialization Rights Potential Maximum Milestone Payments Collaborative Arrangement, Development and Commercialization Rights Potential Maximum Milestone Payments Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Money market funds Money Market Funds [Member] Corporate debt securities Corporate Debt Securities [Member] U.S. Treasury securities Government-sponsored enterprise securities Commercial paper Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Recurring basis Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Fair value of financial assets and liabilities Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Financial instruments carried at fair value (asset position): Assets, Fair Value Disclosure [Abstract] Cash equivalents Marketable securities Foreign currency forward contracts Derivative Asset Total financial assets Assets, Fair Value Disclosure Financial instruments carried at fair value (liability position): Financial Liabilities Fair Value Disclosure [Abstract] Foreign currency forward contracts Derivative Liability Long-term contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Total financial liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Merck KGaA Merck KGaA [Member] Merck KGaA Right to license, number of development programs Collaborative Arrangement, Right To License, Number Of Development Programs Collaborative Arrangement, Right To License, Number Of Development Programs Right to license, number of clinical stage programs Collaborative Arrangement, Right to License, Number Of Clinical Stage Programs Collaborative Arrangement, Right To License, Number Of Clinical Stage Programs Number of pre-clinical stage programs Collaborative Arrangement, Right to License, Number Of Pre-Clinical Stage Programs Collaborative Arrangement, Right to License, Number Of Pre-Clinical Stage Programs Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] Research and development restructuring Research and Development Restructuring [Member] Research and Development Restructuring Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Number of positions eliminated Restructuring and Related Cost, Number of Positions Eliminated Concert Pharmaceuticals Concert Pharmaceuticals [Member] Concert Pharmaceuticals Collaborative arrangement, additional maximum milestone payments based on regulatory approval Collaborative Arrangement, Additional Maximum Milestone Payments Based on Regulatory Approval Collaborative Arrangement, Additional Maximum Milestone Payments Based on Regulatory Approval Collaborative arrangement, purchase price Business Combination, Consideration VIE The fair value of the consideration from the Company to VIE that does not constitute consideration transferred pursuant to ASC 805, Business Combinations. Collaborative arrangement, transaction costs Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed Maximum percentage of annual compensation contributed by the participant (percent) Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Defined contribution plan, cost Defined Contribution Plan, Cost Operating lease cost Operating Lease, Cost Finance lease cost Lease, Cost [Abstract] Amortization of leased assets Finance Lease, Right-of-Use Asset, Amortization Interest on lease liabilities Finance Lease, Interest Expense Variable lease cost Variable Lease, Cost Sublease income Sublease Income Net lease cost Lease, Cost Lessor, Lease, Description [Table] Lessor, Lease, Description [Table] Semma and Exonics Therapeutics Semma and Exonics Therapeutics [Member] Semma and Exonics Therapeutics [Member] Lessor, Lease, Description [Line Items] Lessor, Lease, Description [Line Items] Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Lessee [Abstract] Cash Flow, Lessee [Abstract] Operating cash flows from operating leases Operating Lease, Payments Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Financing cash flows from finance leases Right-of-use assets obtained in exchange for lease obligations Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract] Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract] Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Finance leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Number of operating segments Number of Operating Segments Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] TRIKAFTA TRIKAFTA [Member] TRIKAFTA [Member] SYMDEKO/SYMKEVI SYMDEKO/SYMKEVI [Member] SYMDEKO/SYMKEVI [Member] KALYDECO KALYDECO [Member] KALYDECO inventories, net Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Cash, cash equivalents and marketable securities Cash, Cash Equivalents and Marketable Securities This element represents the carrying value as of the balance sheet date of cash, cash equivalents and marketable securities. Summary of cash, cash equivalents and marketable securities Cash, Cash Equivalents and Investments [Table Text Block] Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract] Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract] Loss attributable to noncontrolling interest before benefit from income taxes and changes in fair value of contingent payments Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest Net loss attributable to noncontrolling interest Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock options Unvested restricted stock and restricted stock units (including PSUs) Restricted stock and restricted stock units (including PSUs) Restricted Stock and Restricted Stock Units [Member] Restricted Stock and Restricted Stock Units Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Basic net income attributable to Vertex per common share calculation: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Less: Undistributed earnings allocated to participating securities Undistributed Earnings (Loss) Allocated to Participating Securities, Basic Net income attributable to Vertex common shareholders—basic Net Income (Loss) Available to Common Stockholders, Basic Basic weighted-average common shares outstanding Basic net income (loss) attributable to Vertex per common share (usd per share) Diluted net income attributable to Vertex per common share calculation: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Less: Undistributed earnings allocated to participating securities Undistributed Earnings, Diluted Net income attributable to Vertex common shareholders—diluted Net Income (Loss) Available to Common Stockholders, Diluted Share-based payment arrangements (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Employee stock purchase plan (in shares) Incremental Common Shares Attributable to Dilutive Effect, Other Incremental Common Shares Attributable to Dilutive Effect, Other Weighted-average shares used to compute diluted net income per common share (in shares) Diluted net income (loss) attributable to Vertex per common share (usd per share) Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Stock-based Compensation Expense Share-based Payment Arrangement [Text Block] Inventories Inventory Disclosure [Text Block] Schedule of New Accounting Pronouncements and Changes in Accounting Principles Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Schedule of Cash and Cash Equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Offsetting Derivative Assets [Abstract] Offsetting Derivative Assets [Abstract] Gross Amounts Recognized Gross Amounts Offset Derivative Asset, Fair Value, Gross Liability Gross Amounts Presented Gross Amounts Not Offset Derivative Asset, Not Offset, Policy Election Deduction Legal Offset Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Offsetting Derivative Liabilities [Abstract] Offsetting Derivative Liabilities [Abstract] Gross Amounts Recognized Gross Amounts Offset Derivative Liability, Fair Value, Gross Asset Gross Amounts Presented Gross Amounts Not Offset Derivative Liability, Not Offset, Policy Election Deduction Legal Offset Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election 2019 Capital Leases, Future Minimum Payments, Remainder of Fiscal Year 2020 Capital Leases, Future Minimum Payments Due in Two Years 2021 Capital Leases, Future Minimum Payments Due in Three Years 2022 Capital Leases, Future Minimum Payments Due in Four Years 2023 Capital Leases, Future Minimum Payments Due in Five Years Thereafter Capital Leases, Future Minimum Payments Due Thereafter Total payments Capital Leases, Future Minimum Payments Due Less: amount representing interest Capital Leases, Future Minimum Payments, Interest Included in Payments Present value of payments Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments Property and equipment, net Finance Lease, Right-Of-Use Asset, Gross Finance Lease, Right-Of-Use Asset, Gross Property and equipment, net Capital Leased Assets, Gross Total finance lease assets Finance Lease, Right-of-Use Asset Total finance lease assets Capital Leased Assets Capital Leased Assets Capital lease obligations, current portion Other current liabilities Finance Leases, Other Current Liabilities Finance Leases, Other Current Liabilities Other current liabilities Capital lease obligations, excluding current portion Construction financing lease obligation, excluding current portion Total finance lease liabilities Capital Lease Obligations Total operating lease assets Other current liabilities Operating Lease, Liability, Current Long-term operating lease liabilities CTX001 Co-Co Agreement CTX001 Co-Co Agreement [Member] CTX001 Co-Co Agreement [Member] Collaborative arrangement research and development expenses Collaborative Arrangement Research and Development Expenses Collaborative Arrangement Research and Development Expenses Lease cost Lease, Cost [Table Text Block] Components of lease in balance sheets Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Finance lease, liability, maturity Finance Lease, Liability, Maturity [Table Text Block] Weighted-average remaining lease terms and discount rates Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related to Leases [Table Text Block] Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related to Leases [Table Text Block] Supplemental cash flow information Lease, Supplemental Cash Flow Information [Table Text Block] Lease, Supplemental Cash Flow Information [Table Text Block] Lessee, operating lease, liability, maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of future minimum rental payments for operating leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of future minimum lease payments for capital leases Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] Schedule of Cash Flow Hedging Instruments Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Derivative Instruments, Gain (Loss) Derivative Instruments, Gain (Loss) [Table Text Block] Schedule of Foreign Exchange Contracts Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Derivatives Offsetting Offsetting Liabilities [Table Text Block] Derivatives Offsetting Offsetting Assets [Table Text Block] Assets Current assets: Assets, Current [Abstract] Marketable securities Marketable Securities, Current Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Inventories Prepaid expenses and other current assets Total current assets Assets, Current Property and equipment, net Intangible assets Intangible Assets, Net (Excluding Goodwill) Deferred tax assets Other assets Other Assets, Noncurrent Liabilities and Shareholders’ Equity Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Other current liabilities Total current liabilities Liabilities, Current Capital lease obligations, excluding current portion Capital Lease Obligation and Construction Financing Obligation, Noncurrent Capital Lease Obligation and Construction Financing Obligation, Noncurrent Long-term contingent consideration Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Shareholders’ equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, $0.01 par value; 1,000 shares authorized; none issued and outstanding Preferred Stock, Value, Issued Common stock, $0.01 par value; 500,000 shares authorized, 258,993 and 255,172 shares issued and outstanding, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Total shareholders’ equity Acquisitions Business Combination Disclosure [Text Block] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] On Available-For-Sale Debt Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] On Equity Securities Accumulated Net Equity Investment Gain (Loss) Attributable to Parent [Member] Accumulated Net Equity Investment Gain (Loss) Attributable to Parent [Member] On Foreign Currency Forward Contracts Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] On Foreign Currency Forward Contracts Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] AOCI Attributable to Parent Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Other comprehensive (loss) income before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Amounts reclassified from accumulated other comprehensive income (loss) Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Common stock, number of votes per share Common Stock, Votes Per Each Share Common Stock, Votes Per Each Share EX-101.PRE 14 vrtx-20191231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 capture2.jpg begin 644 capture2.jpg M_]C_X 02D9)1@ ! 0$ D "0 #_X1#T17AI9@ 34T *@ @ ! $[ ( M . (2H=I 0 ! (6)R= $ < 0T.H< < @, /@ M FMC.60G/SX-"CQX.GAM M<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&('AM;&YS M.G)D9CTB:'1T<#HO+W=W=RYW,RYO&UL;G,Z M#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K M970@96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5 M&AD8%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @* M"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ*BHJ_\ $0@"#0*V P$B (1 0,1 ?_$ !\ $% 0$! M 0$! ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" M P $$042(3%!!A-180'EZ@X2% MAH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ M ! @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,082 M05$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3 ME)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+C MY.7FY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:*** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,#<&P,@8!I:* "BBB@ M HHHH **9--%;6\D]Q(D4,2EY))&"JB@9))/0 =ZXW2/C#X"UW7ET;2_$EO- M?.YCC1HY(UD;.,*[*%8D],$Y[9H [6D "C"@ 9SQ69IGB32M9U34].TVZ\ZZ MTJ58;R/RW7RG89 R0 >!VS6+=_%+P=8^'9-=NM8\O38[YM/>?[+,<3J"2FT) MNZ \XQ[T ==17,ZW\1?"OASP[8:[K&K+!INH[?LLZPR2>;N7>,*JDCY>>15W M3?%NB:OK4FDZ?>^=?16L=X\7E.N(9 "C9( YR.,Y]10!LT5S-Y\1/"UA8ZW> M7>J>7!H,R0:B_P!GE/D.[!5& N6R2.5R*Z2.198DDC.4=0RG'4&@!U%<[/X] M\,VWC:'PC/JB)KDZ[H[3RGY&TL,OMV@X!."<]/45G^)OBSX)\':R=*\1ZU]C MO519#%]DFD^5NARB$?K0!V) 888 C.>:6N)TGXQ>!=_>@#:HK@K_XV_#[2X;*6_UYH4O[875L6L;C]Y$79 V!'Q\R-UQTST(-;GA+ MQWX<\$_B'X5\<&=?"^L0WSV_,D6QXY%''S;' 8KR!D#&>*Y^ M?X^?#6VN)()_$FV6)RCK]@N3@@X(XCH ]$P-Q; R1@FEKD9/BGX,AN=%MY=; M1)==1)-/4P2_OE=MJD_+\@)X^;%;6I^)-*T;5-,T[4KKR;K596ALX_+=O-=1 MDC(! X/?% &I117%>(OC!X&\)ZY-H^OZY]DOX IDA^R3OMW*&'*H0>"#UH [ M6BN27XI>#)/!K^*H]A?&;P%XEU MRVTC1->^TWUTQ6&+['.FX@$GED ' /4T =S17GM]\=OAQIVH7%C>>(_+N+:5 MH94^PW!VNIP1D1X/([5O>&/B!X9\9W$\'AO4_MLEO$DTB_9Y8]J/]T_.HSG% M '1@!5"J !@ =J6N6O/B5X2L--U6_N]6\NUT>\^PWTGV:4^3-G&S 7+<]UR M/>J.@_&3P#XFUF'2M%\0QS7LY(BBDMYHMY] 70#/MG)H [>BL72/&&A:]K6I MZ1I6H+/?Z3)Y=Y!Y;HT39(_B ##(/*Y'YBJ=M\1O"=WIEO?PZU"8+JX:UMPR M.DDTJL%94C(#M@L,D @#D\6VH6<5W87$5U;3*'BFA<.CJ>A##@ MCZ5-0 4A )!(!(.1[4M% !1110 4444 %%%% !2 $D DY/O2T4 %%%% !1 M110 4444 (0&4JP!!&"#WI:** "BBB@ HHHH **** $P-P; R!@&EHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH \X^/S7B_!+7?L U:>JGX>G0 M?#+:N-+&F>?#_8HDQY8?;\FS'&,>OR],]J[&:&*YMY(+B-)895*21R*&5U(P M00>H([5QND?![P%H6O+K.E^&[>&^1S)&[222+&V6?FQZQYKWCQ3\+/!?C34DU#Q)H<=W=JFSSEFDB9AV#&-EW8[9SBKT_@3PS<:#IN MB/I,2:;IO27.L^#IO#%\LC?\(# M8W:S2-D*\QNUAC&/:/D=J]=^'LJ0_&VZBE=4DN/"M@T2L<%P%0''KBO0+CX< M>%+LZZ9])5CX@*'4R)Y!Y^PY7HWR\\_+C/?-1^(OACX.\5VUC!K^B1W:V$0A MMF\V2-T0# 7>K!B/8D^M 'B'BJ1)_ 'QHN(&62%M25@J);JS,>@ 7DUB#X<^$U\$R^$H]&BCT.8JTMK'(Z>8P96#,X;>3E5Y M)SP!TK#L_@3\.;"X\^S\/-%+L=-ZW]SD!E*M_P M.X8B@#PC4/$4^K6&L^-[ M;PWXAFU-_$":M8:K'8,;-;6W^18WFSP NX' QE0/6O8/CCJ=OK7[.E[JEDVZ MWO8[.XB/JKRQL/T->BV?AO2;#PNOAVTLU325MVMA;;F(\M@05R3DY!/.<\U1 MF\ ^&[GP0GA"?3FDT) JK:M=:U>WGA6/QK\+-.++=:YK$']DK@X\F[(,@'^RJJ%/NQKZ&O\ PQI&IZSI M.JWUIYM[HYD-C+YKCR=ZA6X!PV0H^\#5:^\$^'M2\7V7BB^TU9=9L8_+M[HR M.-B_-_"#M/WVY()Y]A0!Y-K6EZ]HGQ]T72_AXNDI<67A".!!JWF>5Y*SN/\ MEGSNX7]:]:\)_P#"6_V?-_PG/]B_;/-_<_V/YOE^7@?>\SG=G/3C&*S_ !7\ M+?!WC?58]2\3Z/\ ;KN*$0))]JFCP@9F PC@=6;G&>:M>$? 'AGP(EVOA73? ML"WA0SCSY)=^W.W[['&-QZ>M '*?M$?\D.UK_?M__1Z5G>,C:+\=OAZ?$!4: M<+68V9N,>4+O V]>-^=F/?;CG%>F>(O#FE>+-#GT?7[7[783E3)#YC)NVL&' M*D$<@'K4?B#PKH?BO1O[*\0Z;#?V>05CE!RA P&5A\RG&1D$'!/K0!Y]XQ-M M_P -%>!1HVS^UO)N_P"TO*'S?9?+^3S<=L[]N>_X5/XS_P"3BOAO_P!<=2_] M)S76>$_AYX5\#F=O"^C0V+W'$DN]Y)&''R[W)8+P#@'&>:T+_P ,Z1J?B#3M M;O;4R:CIBRI:3B5U,0D7:_ (!R#CD'';% 'S9XSU3_A,M?\ 'U_%X>\1:DZF M+3]&U#3-/,L-H;9][[I 1M#. >,D!L^E=SJGB5/&&J?!S7DQNO;J9I0.BRB, M+(!]'##\*]:\.>&M)\):,FE>'[3[)9([.(_,>0[F.22S$D\^IKG+KX-^ [S0 M[71[G0M^GVDTD\$'VR<"-Y,;R"'S@X''0=AS0!W%>"ZE=^-;#XZ>/;OP#::5 M>3P6-F]Q;Z@)2\JB$$+$$(RW7@D=J]0\)_#3PEX&O)[KPMI/V&:XC$&])L?$FH:]:VOEZGJ21QW4_F.?,5!A1M)VC ] * /F_45 M@U#]G77_ !/#?Q7.HZ]KL5S?01P^5'9S^8N8MN2>-V=Q.2&!]S[?X=_X6C_; MD/\ PEG_ B']E8;SO[,^U>?G:=NW?\ +][&<]LU/=_"OP;>V^K07&C?N-8G M6XOHDN9D2613D-M5P%.2<[<9[YJEHOP5\ >'M:MM6T?0/L][:OOAE^V7#[6Z M9PSD'KW% &5\2?\ DKWPP_Z_+S_T4E,\+R)#^TKXXAE=4EGT^RDB0GEU6-0Q M [@$@?C7?ZEX;TG5]8TO5-1M?.O-)=Y+*7S'7RF< ,< @-D =0:R_%GPV\(^ M.;FWN/%&C1WL]NACCF$LD3A!^(Y!,_W<@.58B1>XZCD5U%_<^*O$/QB\->%_B@^D:6MC<+JVFW&DV\A2_FCP1$ M))&RO?(P#\H'=37JS_#KPH_@]/"W]C1)HR.L@M8Y'3+*00Q96#,<@9)))[YJ M[XB\(Z'XK6R_MZQ^TM87 N;6197B>&0=&5T(8=N,XR >PH ^?8DO_#/Q"\8_ M$32/-E&C>()+;5+5#_KK*0C>0/56"M^&3]VNU^"N@:/XK^$D2ZQ;?;K5=3NY M$A>1Q&^6."R @-C.1N!VG!&",UZ=8^$]$TUM7-I8*O\ ;4K3:@&=G$[,,,2& M) !!Q@8%.\->%]'\'Z*ND^';/['9([.L7FO)AFY)RY)_6@#1M;=+.TBMHFD9 M(D"*996E<@#'+L2S'W))-2T44 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %1SSQ6MO)/<.(XHD+N[=%4#))_ M"I*CN;:"\M9;6\ACGMYD,""#@@T >/:!KNI:?JGWUO%;WMC;7$,+!XXYH5=48# ( M!& 0":B;0='>%H7TJQ:)K86;(;9"I@'2(C'W!D_+TYZ4 <-<>*-93Q+-=#4_ M+@A\1PZ*-',4>UXG19O^6E18M6 MU#X91C$>H:N+Q8\_=TV7,\W!_A,BRQ=_]8*[GPCX'TOP:EW_ &:6DENRGF2- M#!#A4SM0)#'&@ +.?NY)4OF^5NW;-^,[< M\XSC/- 'E*;B*T>^U"R\B=K)+>)8%E"&+Y_M#S PJS*RE2'<@ M!0IK..J:YIMQI7BVXU>ZU6_'@B]U/[/-# L1?_1G\O"1JVS

]^">LW=W=B[FN=&NYG=4V!"T3GRP, M@)G9\PW?+\W.:T+>#P-X?U6VT:TB\/:9J#2_:+:QB6"&4R%2GF)&,'<5W+N MSC(JU9:GX6U2:\T;3KW1[R259)+NQ@EBD9U8X=GC!.02V"2.<\]: /+=;\(3 MV7P[U75H]!T'P]##XEFSDAL[8W&^Y:56AB#;(QQ%\K2;MN3G=@5V%EXC\-^)+ZY\/6$EG MJMNMGNG$+1S6Q0L4,38)&>.5(Q@BL"[\:?#W4;RXL-3@TV6&:[;3KN:Z2W: M&W0RKYI+?E0)9Q.+)&@M4/V>.9AOXXQ'QN;'89P<4 <3J_CW6FCL]0T^^ MOE\M=+%S#!;V@LXWN&C9TE,K>>[,C\>4 %RO7YC6E<>+=8M-!UKQ0=8B$EM) MJ4%MH,\4?ER&V\P+L( E+XB\QOF(VEL*, CI#:>$;GQ3-82Z#IS7EGID,_VJ M2SB*+;,TBH@?K@>4QQT QCVI:=XC\)SZ+=>/;?1Q;W3XMYI6LD2^E8LB1Q$C MDE\Q;06Z,F<=@#FK?Q5XKL;B"UN[RZ:*34-+ FU!K W#)/*8Y%V6S,HC8*"C M$!LE@"<9JMJ^I7^K^)+>YDU21EL-4U>VBB2*%H]D=L?D8%#GNIR?7OS6^=8\ M):-X?U?3;CP.=,6/R)+G0S8V@-TLTBQ1R (YA<;QCELC;SCC.II"^';^[30+ MOP='H\]J@O;>QO;.V*[?]7YL9B9T!'"GD, 5XP1D Q?#FM:EJ$,+RZ]#HEKI M5GIG[DV\*P7)FC1F#Y4%=Q/EH(RH#=F^[7)>)?%VK:CH>L0-?W]WIFJ^']5N M(S=P6D4+K&%$;VZQ,9E7!8?OB2&F:%+N[LXU M-O$B[A)"W)$17E2,=#P*K:;)X4FU"*UN_!"Z.-:\PV\U[IUNBWY9"74A&9E9 MDR2LH5B-PQD$ BL=9U>+QK;17VI7 TZZO6M+9(8[:6S?;;L_E$@B>.<&-F) M;*?*1CYAC-\>:KJ&B^*=>O\ 1[A;:]CT&P$4K1B0*6O9%.5/!X)_^M71ZG=Z M1HWC=/[.\'2:EKUS9F>2[L(+5)1"I6/#2RR(3_", G@#TJK_ ,)OX*U.]CCU MJ*TLY+RU&^35EAC!,<[I]G9F8[G66.0[1D9!()ZT 9;:[K]MKD_AA];N)=^N MQ6*:L\$ N(8FLOM)&!&(BQ92H)3HW0D U5USQ5K5I!JIM/%43)X=T4Z@MQ%# M 4U:42RJ4DR" !Y C81%#OD/3Y5'<:G)X/FU&70M8?0WO=4*/+I]T83)=D8V M%HVY?&P8)!^[QTJC<7OPZD6U6[N?"[+HK;+82R6Y%@P&<)G_ %9'EYXQ]SVH M Y&_\3^)"NL7L>O2V*1>)K31XH&MH#';Q2?9R[$LFXL/-85O!E8$A/NPMP#DCHK^T\%^+;6:Q MBU#3)DCN;?5[R.SFA;S=NQT>8JXP<8J2)O &I^$)(H#X;N_#EBV9 M$0V\EG;M][D#Y%/S9[=?>@#B]'\VU/1M2U36(/[/U+0IHVO([#[0K371!!\A M6CVC:CJ"-V1SE3@^IS:CX.@M8+N>\T..#5(5M(9GEA"WD0SMB5B<.HW'"C(^ M8\NG>'XK;?%97%L((%3I?(&30!QVG>,? M%-QXE^U>3HZU_:<^H^%I+QD\N-!;EYH"438!\@.0-VYOE.6/;>\,Z_X-\0ZU_;&@6. MGM?W)NK>34(Q;"9A;LB$%E;>RE3&RD9&W83MRH*NGPZFT&_U.UNO#EK87;M! M=:G:R6Z*SN59E:4<;B0IY.V"Z\F5B5"&_<3'G< MI[ CC'#'O@C@?#OB+7/"'@?3;RUO6U"";1-4O(]/E@01PR6[J4*E0'((8[@S M'/.-O 'JC:GH/B/5(M)>"WU1/LL>J03,DI^)'AL=3MO[90?V MQ!*;;5["47 B,"AXV#HORJ%W(&0D!6W MW/]J>"O _AT7FGG1M,L;N-KFWCL M?)A%\0F?W0! D8C&,=A]* . DU:/3_BLGB?4$7^S+[59-,L9H@K7372JMJ;:4D@1P%DDE5.?F7<2 MI(4R:=X/GU^^UZ2TT#08YCX@N"NO22D7UOMF!W1J(>HQ\O[T>_H?0AI7@_4[ M[[@#D/'_AY_$U_H5FMQH>RWFFNVM=8@-RDY6(H"(-R[POFDDEO MERIP:X&_NK+7] N[^\T^UL8K#P:+W2(8 !':7 DF!EM^!@@QP;6 !P5_O<^R M:KHNE:]:K:ZYIEGJ5NCB18KRW69%8 @, P(S@D9]S1>:'I.HM:-J&EV5TUBX M>U,]NCFW88P4R/E/ Y&.@H \L8/+K,^L7D8'B2'Q3I]E'*R@31VSQ0;XE[B, MI).Q X)+'J.-CXCZA=:1XD.I:?+Y-W9^$M9G@DVAMCI]G93@@@X('!&*[Q]& MTN36(]7DTVT;4HX_*2]:!3,B<_*'QN Y/&>YI]WI>GW[%KZQMKDM"]N3-"KY MB?&^/D?=; R.AP,T >8W'B?Q)I&P6Y+51L]5UG2]4OM'TN]U"^EOO$EU'->6*68NI/*LX6VKYVV$-P2WR] M$;"CJ/69=&TN=)UGTVTE6Y@6WG#P*1+$N<1MD .*NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110!Y;XD\/^*M1\7RO;V$XL$UO3[Y?LQLT M@N(8F@+M(6'GM,-K8&578@ )("LRQ\!ZS_86C61MELIXUUB.>=70F'[2S^6W M!YSE#QGH,XQ7JM% '!>#-)U:'Q-%>ZCX?_L>&WT*WTW)GB?S)(V).WRV/[L M_*2%/7*KQ5*U\+ZP/B';7<^EM]BMM=N[_P"U-+$5,GS60*;IW<*YG5P(F5E!,>6&P?*>, M=[XAT"[O-!T"PMX?M7V+4+-[@22AOW<9&]B6QNX]LGT[5U5% 'D=QX'\46]_ MKVEV,1?2KVQM-(LKU;A \-F9YFE!!.WA' MBC3M6MH9KB/55MU#RQ,$>+;&L:Y>$*$8J0&B&XX(QZ+10!Y1=>&O$$FAZK#I M6DZO;Z=_H)M=)U+5$N9VDBN5DD=':9U1?+4 *9 "5Z#J=76;;Q1K-_<:[I>B M7&F7EII,]A807=Q!YKS3R1YE/ER,@2,1J?O;B=PQP-WH5% 'EU[\,]2M89=' MTS4[R^T[4M$;2Y9KL0(+(PC-LVV-$+)\TBGAFY7G J_>R>+=?\0:#'J/A:2Q MT^QO8KFYN%NH)#Y@CD4[ ),M%N93O(5\$?N^I7T*B@#D-9\)MK?Q"MK^[%[' M81:6\/G6>HRVK>:958*3$ZL1M!/.1^-8VN^!)1>:O%HFE1FS?PE-I=IF126F M9W;82YW$L2I+-U/).:](HH \DU/PUXNN]:A4:?.MK#JNF7A%NUDD$\4)@WM( MQ'GM,I5^ZKL0 $X"M?T/P=JUI_PA_P!KT]5_L[6]3O+S,D9\M)?M7E/P>2?, MCZ9(R,XP<>F44 >.VO@;Q'IWAG3(;+1;1KFV\/:G:26\QA>-II9XI$1E)*MN M"N>QPW\UF+FY2$2JR$0[8@RDJZY."- MOS;LA?6J* /)O$/A77=4OI=0M]#O+&WU'3[BSETW3KBQW O,SDSF9&51(&RY MB+D,/X^M/G\)^(+/4[BQM=)FN[6ZUS2=1^WF[B*I%;BW64-N*NS@PL>$P0>N M?EKU:B@#QR[\!^)=0M;FP2Q^S?NM?A6XEGC\N3[7<1RP_=8MM90P.5R,'(Z9 MWM9B\1:A)9W^F^$KG23'>#S7MGT^34=@MW4.GFEH5&6"9WERI(P!7HM% 'G/ MPY\+:YH5_;2:U:>5Y6EO;.XFC<-)]LFDXVXR"C*V=J]>@.0$A\)ZM_PFMA?3 M6(-I#XDO+]W,B';"]D8XWQG/^LP,=1UP!S7H]% 'CZ^#O$.G:*\2Z!_:+7FB MWFE?9EN(5%JSW$CHS;F \ME=<[26&Q1M/:1O VOC7&CFBU*6TO)].NLVUQ9Q MP0-;QQ*1(SQM,&5HBR^5E3N RN6:O7** ..\+:-J&G>(;O5+S3A FKAI/(61 M2=.(=FV'#%3YA?>VS/[S=DL"I'8T44 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 45P?Q"^(MSX.UC1-+T[2X;V[U1V*?:;I;='"LBF-&/!D)<8!P!W-6M9\=W M?A_Q#96VKZ(+;3+VX-O#=&]5IW80-*SB!0?D&TJ3OSG'RX() .RHKS6W^+CR M6<7VC0EAO;^"QN=+MQ>;EN([R4QQ>8_E_NB",L,-@="W2NP\*^(?^$ETB2Y> MV^R7-M=SV=U )/,6.6*0HP5\#XM%F5@>DJ'A MED49QSMYZ<9JI#\,KM/&TFMW6MP7]M]D6PMK:[L7>2SM]FQQ%()@JN_5G*$] M0, D'T*B@#S6W^$Z?!8VVEW LMJV\=G(9(A(F\^:23\Q!7(Z! M:[#PKX>_X1K2)+9[G[774XC\M9)99"[%4R=JY; &3P.IZUM44 95C; M06GB._2UACA1K:!V6- H+%YLDX[\#GVK5K.@_P"1FO?^O.W_ /0YJT: "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH Y'QE\0K/P?J&G6#:;?:I>WV76 MWL8PSK$I 9@"1N.6 "C)-66\?Z"/&:^%XYY)=1%F]Y,$CRMNBA3A^X?^+?@K6?&=II\&C6VF2-"Y*75P[PW-C(2-LT4JY^48!9, DJO/&*TK MGP7>R>+])U6"\A1;72[FTN;C!6:6:01 2X P3^[Y).>G6@"K8_%[0[ZQDG%A MJ<,ACM9;6VDCB\R\6YV0C+,,8']?M?$>E?;;..:'9-);S0 M3@"2"6-RCHP!(R&!Z$CN"17F.G_"GQ';6J,USID$]F;">."&>1HM1NK>8R/< MSL4!22484D!SZDX KT#P7H%SX?T6YCU%X6O+Z_N;^=8&+1QO-*S[%) ) ! R M0,XS@=* -"#_ )&:]_Z\[?\ ]#FK1K)L;9+;Q)J"QM*P:UMV/F2M(<[YNA8G M ]AQ6M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114-W=VUA:275]<16 MUO$NZ2:9PB(/4D\ 4 35PGQ>UC1-,\$*GB&:V^SRZC8L]M/M;SXDO(7D&P_> M&Q6R.F.M:/\ ;.L^)OE\,0G3M//75[V$[I!_TPA."V>SOA>X#BM/1O#.GZ)- M)&=,\,Z;J+: MO-MATN:UDN3;?8+GF40_=^;&5!8#"\Y.![#6-HOBK3-?U/5+'3W=IM,F\J7< M _)7PS_ #Z"KCWMK%>Q M6I W#)'3(]: )Z*RH_%'A^6&^EBUS37CTXXO76[ MC(M3DC$AS\G(/7'0U>L[VUU&SBN]/N8;JVF7='-!('1QZAAP10!5@_Y&:]_Z M\[?_ -#FK1K.@_Y&:]_Z\[?_ -#FK1H **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BL[6=>T[0;9)=2N-C2MLAA12\L[_W(T&6=O8 UB_8]>\59.J-+H.D-TLX) M,7=PO_321?\ 5#_9C);_ &QR* +6I>*U6]ETOP[:G6=5C^62*-]L-L?^F\N" M$_W0"Y[*:9:^%&N[R+4?%ET-6O(SNA@";+2U/^Q%D[F']]\MZ;>E;>G:;9:1 M8QV>F6L5K;1C"Q1*% ]_K[]ZHWNM2?:+BPT6V^V:C%$DFR7?% Q &9=I&<9 M.T9.!TH U7D2-=TCJ@R!ECCD\ 5RFOZ]KM[X.3GGBM M:@#S/2+#5])O?#":7X6UR(:>OV&\NKZ>QQ-:ORS/YH7-KI M,>CO?>?I(BGC:"Y)EMHMJ*US$BC&;1MW;TEFY"_P"ZH9O]F@#H)IH[>%YIY$BBC4L[NP"J M!U))Z"N8/B/4?$7[OP9;I]D;AM9O$/D8]84X:8^_RI_M'I3X?",[M M=5D1@\=C&A2SA(.0?+))D8?WG)]0%KHYYX;6VDGN)$AAA0O)([!510,DD]@! M0!DZ-X8L])N7OI9)=0U288FU"[(:5A_=7M&O^R@ ]L\UH7VIVFG&W%Y+L:YF M6"%%4LTCGL 3ZDGH "3@ FLPZC?:["1H!^R6DT"2PZM(BR+)DCA(]P.=N?F M; !QPPK0L-)M--FNIK9&\^\D\VXE>1G:1L8[DX [*, =@* *$=IJ.N6Z-K2- MIULZ2Q3:;'(LAF1LJN^0#*G'.$/7^(]*UK2TM["SBM;*".WMX5"1Q1*%5%'0 M #H*FHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@".6>*#9Y\J1[W")O8#(;G4M$GUUKAH3## 9/WD1V M2-^Y"' Z_(AWD9P?7OA7_P BC<^1C^SO[5O?[,V_<^R?:'\K9_L8^[VQC'&* M .C@_P"1FO?^O.W_ /0YJT:R;%KAO$FH?:HHHV^RVX41R%P5WS8)RHP?;GZU MK4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 445'/?>-/'QBFBTGP;?076K+._V@1(9Q%Y7)A?8K;2[[8R3C:"[<%:WM,\< M:;J^B0ZI8VNJR0RNL>W^S)PP8CG@IR 006&0",9H Z.BLB3Q):Q&3S+35 ([ M@6Y*Z;.^YCGYAM0DIQ]_[HXYI9/%&CP-(+J[-J([G[*S7,+Q*9#G !8 $''! M&0>,'D4 :U%5K;4K&]:5;.\M[AH93#*(I58QR#.4.#PPP<@\\59H **** "B MBB@ HHHH **Q]3\7>'](G^SZAJ]K'<]K59-\S?2-/[=3NO@S_;.G6O MB9;V/0/MMI&#;68]O*4Y<>TC/7 M0P6]KIUFL-K##:VT*X6.-0B(OL!P!0!SA\-ZMKWS>+M3Q;'_ )A6F,T<)]I) M>))?_'%(."IKH[2SMM/M([6PMXK:WB7;'#"@1$'H . *S)/$*7+-#H4#:E.U MOY\,JAEM7&0 //VE<]3A=QPIXI)-"EU7SO\ A(;DW-M,(B-/C^6&)E )^8 / M)EL_>PI&!M]0!_\ PD$5U=-;Z+"=3>&[%M=O%(JI:GJVXD\D=-JY.< XHL]$ MD:2WN]>:UZ* "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".6"*?9Y\2 M2;'#IO4':PZ$9Z$>M2444 %%%% &=!_R,U[_ ->=O_Z'-6C6=!_R,U[_ ->= MO_Z'-6C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !115&]UK3K"\AL[JZC6[N%=X;4'=+*%4LVU!R M> >@]J +U!.!DUCK?:OJ*(;&P2PAFMV(GOB3+#)DA08%^\. 3EU.".^:3_A' M(;O)UNYFU3S+86\T$YQ;2<@EO)'RY) Y.2!P.IR /NO$VFP27,%O(U_>6R+) M):62^=* V-ORCIG<#SC@YZ_:DU#5]0E@GD5XXH) M?LWD 9^57B"O@YYRQZ#&.T=)+B0:7:%[F83S,T*L9)!G#$GJ1DX],UH MT4 #II?$=[K-CXFU?3I[U(HY([=+1T58P0JKYL#L!EF;&>K-5[PUX=3P MU87%K'J%Y?\ VBZDNFDNQ$"KR'+ "-$4 MENG5FKA[N[TRZ\:>)[2^G\0ZCJ M<.H1):Z9I.JW4)2$V=NP)6.5(XU+M)\[E023R35KP39^*=7\-LEQK4FEV<6H M7T**K&[O=J7E.M_ GA^.=;B]L?[5NE.12VBE#WS3D1G_ )9+Y=M%@#L3N/J35AI?B0FS-KX9?=-M8QRS MG9'_ 'L$#)'/&?\ ZW8T4 <+'JGCIC"MXEEIS37)MUW:/+= =,2$Q7)"H<]6 M(Q@YQ38=4U2[, G\:V5HUQ.UM$AT-[5I)!C*J)I"2>1]:[RB@#C+6T.J)&P^ M(]W=1R.8T6R:S17<8)4$1%LC(X#=ZG'A#PW/Y9U&^N]4,K;4%[JLLJ.?01[] MF?HM=(^GV878 M\'-XLM[O3/!NAW'A>&X&GWA1E3,^,RE_+PJ1DPKDD!O,D/.RO9H+.VM8Q M';6T,**=P6.,* ?7 KCX_ALT>@SZ,/%^NG3[D2B:!X;%O,\TL9-Q-MDEBS$G M.>: -VUNM>OTMI'TZ'2XW+_:([F82S(/X-H3*9)Y/S''OGA;?PZC"&36;NXU M6ZCCDB9YFV1.KYR#"N(SP=N2I..I-:-A:_8=.MK0SS7)@B6+SYR#))M &YB M 6.,G '/:IZ &QQI#$L<*+'&@VJBC 4>@%.HHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q_XYW% M[:3:/>0ZM,EA9A[B\T^QOQ;7@4,I^TQCH^P!AAOER5ZYK5CU'7)?C%HIGUES MHNH:/<36MFB>7M"B$^9+V:0EV[84 8'+9[C6?#>B^(OLW]NZ7:ZA]ED\V#[1 M$'\MO49^@R.AQS5J?3;&ZNEN;FRMYITC>)99(E9E1L;E!(S@X&1T.!0!XA!K M&HSPW5SX?U?6Y?"EWJ>FZ4-3OKZ1I;MS<[;F>%R08D(8)E-JY!V@$<>E?#>] MNKOP[?1W=Q-=)9ZO?6=M//(9'DACG=4RY)+D 8W'DXYYK3M?!7A6QAN(;+PS MH]O%=1^5<)%81(LR9SM8!?F&>QK4L[*UTZSBM-/MH;6VA7;'#!&$1!Z!1P!0 M!0L9GF\2:@9+>6W*VMNH$A4EAOFY&TGCZ\^U:U9T'_(S7O\ UYV__H"1T,"Z?%Y4D2C[RM(Q;=G/4!>G&* +U_J M5CI<"S:G>6]G$[K&LEQ*L:EVX"@D]3Z5136YKR0+I6FW$RI=?9YY+E&ME11G M^.:LVVBZ=9W5Q@KF?.UGQA_QY/<:'H38(N@-E MY>+_ + (_;'$DO?'* MIVR?FKJJ .:7X<>"@H\SPGHT[?Q2W%C'-(Y]6=P68^Y)-;FGZ;8Z181V6E6= MO8VD6?+M[:)8XTR23A5 R23]35FB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BB@D*I+' '))[4 %%4--UW2-9:4:/J MME?F$XE%K<)+Y9]#M)Q^-7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BO-_BMXWUWPA>:+'I(L[.RNY")]2OX9'MT<,H6*1D_U0;<3 MO/93@<&K=UX_U&W^(D>BR:0(M*&F7%X;QGW&Z>-8V/DX(^0!\;F'S'.,;>0# MO:*\CM_BGKXM;*"[M]--_K-KIEWI[Q0R"*W6]F,864%\N4QG*E=W3"]:Z6W\ M::@_PQ\1ZW+#;'5-"&H0N%1A!++:EP&"[MP5M@.-V1DC/>@#IH/^1FO?^O.W M_P#0YJT:^)6)*F209(Y,9 MXZ;O3G^-7@]H!+8RZA?AHFG06^GR@O&N=S*'5=P&#DC(&#Z&@#OZ*\QT[XU6 MNNWD%MH>@WJM<0O/#)JLB6D,'(X- 'K5%>7WVIZE=6MC);>,X[V2\@>X^SQ M7UM81A$!W$.(I7(7:X)5L#::-,L?#^H6G63 XVW%TD9SZ8)JA_PG_AY_^/.> M[O\ T^P:=<7(/XQH17/>'FM-,NK-K37/!%G;2Q-<"#3-,$330KG>ROY^ !M; MG:0-I]*U+[58=0ODDT_Q];V=M=0M/;PV\=O(6C0'>RLP;2)KA;VV,'FW$:;MQQY93 P+;S51=6[31+= M-&RE$)W.NR->FTB@"?\ M_Q$.O@VZ/\ NW]O_5Q1_P )3J[H] MI*/R6G-);O;>+_$4HEB:XB"?O Z)G/\ RR/]TC!Y/;M5S4KR'5[F MVGL=<\2:<);=I(TLM,8H0A;);S+=P'X("M@GC .1D R_$WQ(%A_9<%HTFB27 M=X8I[K7-'N/)AC$$LF00T:L=T:CA^ Q.,"K/AOQ7>:EXLM=/_P"$B\/Z_97- MA%(S&T:H7WR+A2F3VYQ7)> _#.L7GQ-$_BBVU.^:XTF>:.2ZM!I=SYN] M&?:RNLGRN0H89"JZ@;1T /I.BO+EO_BEX>E)MO#B:YINTE8+C5(VNHO3]YM0 M-QS@AV[;CUK3M/B!]HN8+34M5TCP]J#6S>=8:G%(LR3'=M*[F0.GW3P3NPV& M'6@#OJ*QX[+6)XXFGUV, VS([65FJ!I#G$J[VDQ@$84Y&1SD'%*N@%MAO-7U M2Y*VS6[YN/)\P'.7/E!,/SPRXQ@$8(S0!KDX&35*[UG3+'>+W4+6 I"9V$DR MJ1&!DO@G[HQUJLOA?1\J9K3[45MC:YO)7N"T1SE6\PG=G)R3DFKEII>GV"QB MQL;:V$2>7&(8538G7:,#@<]* *0\3:?+_P >8NKS=:FZ1K:TD=)$]%<+L+'L MN<^U U;4YR?LF@W #6WG1R74\<2F0](F +.I]3M('O6O10!D$>(K@,-VFV(> MV&" ]P8Y^,_W R#GT)]NE(=$NKB-EU'6[Z426RPR1VY6W4.,$R(4'F*QQTWD M $UL44 9!+>26Y)F>2-<;0S.26Y4')ZGD\\U6U_PL-P_$X )K-TC1;JZU!==\2JC:B 1:VBMNCT]#U53_%(1]Y_P !A>JZ-H]W M<:@->\1JO]HE2MM:JVZ/3XSU53T:0_Q/WZ#Y1ST% !1110 45@:EXLBLM4ET M^RTO4M7N;=%DN5L(T(MPW*[B[J"Q SM7+8P<IVFLZ7!J&G2^;;7"[D M8J5/H00>00<@@\@@@T 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHJO>W]GIUNUQJ%U!:0KUDGD"*/Q/% %BBLJ_U^"TL[:YM+:[U5;M=UO_ M &=#YPD4@$'?D(H((P68 T65[J^H6%T[Z7_9,^TBU%Y(DQ+8."ZQM@#.. V3 MZB@#5J&[O;6PMVN+ZYAMH5&6DFD"*/J3Q618:/K2WT=WJWB26XV'/V6TM(X( M&XQR&#N>O]^I7\):!+JKZE<:/:7%\[;C<7$0E=?]TMG:/88% #[_ ,0V=E9V MUS%%=ZA'=C= =.M7N XP"#N0%5!!X+$ ]JPO$IUGQ-X%U6WM] N;68^68[2\ MFB!O8U=6DB.QV"AT5DY(^]SBNQ50JA5 P !TI: /.]"-_K7B31+LZ0UE+I MWG?:KD:;+9(L#1E5M0)#ND^6.A(SZ)110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110!RGC?P'!XWA@AN=6U&QA4-'/#;2#R[B) MOO*R," V,@.!N&35Z;P?ISJ))'EN V^5@-H)W.3@;1V&!7344 >%6_P $_$XO MK'33\1G>#1#:WEJC:0NT.LDI3($H+8(8Y).=QKW6LZ#_ )&:]_Z\[?\ ]#FK M1H **** "BBB@ HHHH **** "BBB@#,USP_I_B.UAM]56X9()UN(C;W,X[]A5*R\$:-8ZO:ZG&VIS7=IO\AKO6+NY5-R[6^625EY!]/3 MT%=!10 5E:_X9TKQ-9K;ZO:K+Y9+0RJ=LD+8QN1AR#^AZ'(XK5HH \^CMIO MVDSZ7>E;'1I&WKKVE6\4+V[G&6GB"%%)P,R!2AYW*O4]-HT6O0W"_;M3L=6T MZ2/='<) 89N<%<[24<$9Y 3MP:VR P((R#P0>]%7U+6Y/$;?[!PC?[)R2 7%\:Z1%?&SU8SZ/<>88T&I1&%)3G V2G]V^?16 M)]N:Z"LW3-4TWQ)I9EMBLT1)CF@FCP\3CJDB-RK#T(J'5M DU"\6]L=9U'2[ MM$V!K>4/$P&2 T,@9#U.2 &Q_%P, &Q160]QJVDZ&DEW =AH U:** M* "BBB@ HHHH **** "BBL+Q)XST/PI&IUF[:.1UW)##"\LC#.!\J D9) R< M#/% %_6=9LM TJ74-3E\N"+ X4LSL3A451RS$D *.23BL?0]*OM2U%/$7B:+ MRKO:18Z>2&73XSUSC@RL/O-V^Z.,ELO3[37/$CGQ)J&FBSO('(TC3-3.U+53 MP9Y FXF5E)XXVCY1C)8]%I>FZS#>?:M9UTW9*E?LEO:I#;J2>HSND)'3[^/: M@"YJ6L:;H\*RZMJ%K8QNP56N9EC#$\ #)Y-5=5UN?3[E;:RT34=3F9-W^C*B MQJ,DYIFE:9K%M=^?JWB![]2A7[/':1PQ \? M-W?CG^+'-;%% 'G6I?#[58?$%]J&C7\]W#J+++-#=:W=V9BE"A=X,'WUVJHV MD#&W[V#@;MCX%L4T2TL]4N;RYGA,LDLUO>3VRR22R-)(VV-QQO9L9R0.,UU% M% &5:^&].L]*N-.MOMB6]P27/V^O0?=(J"P\)V>FWT=S;7VL,8 M\XCN-6N)T/&.5D=LUN44 85[X?U&XOI;FR\5ZM8B0Y%ND=M)$OMAX2V/HPJQ M?6NN_P!GVT>DZK9QW,8Q--?6+3";C^ZDD>TD\YY'M6K10!E::VOI!<_VQ'IT MLBJ#;_8V=!(<'(8,#MYQR">I].:MKKFM-=Q07_A2\A61PK7$%W;RQQY_B;+J M^/HI/M6_10!B:EXLT[2+]K6_AU)"H!$T>F7$L)R/^>B(5S[$BIY/$NBP:/%J MMYJ=M9V$S;$GO)! I;)&WY\8/!XZ\5J4$!@01D'@@]Z *ECJ^FZGG^S=0M;O M R?L\RR8'KP:M!@PRI!'J#5:WTRPL[AI[2QMH)G&UI(H55F'H2!FLAO '@]I MS/\ \(MHZS%MQE2QC5R?7ZMDD(7.<98'C))_&N8@^ M&*6VCR>'+;4+>'PO+.99-/CT]%F=2VXQF8-@KP!G9OVC&[/- '5VWB/1+S4! M86FL:?/>$$BWBND:0@=3M!S5&Y\:Z1!=S6L0U"\N(7,;I9Z=/-M8'!&Y4*\? M6MBUL+.R4+9VD%NHZ"*,*!^56* ,K4M3U"WAMVTK1)]0:==QS-' L/3 ?<=V M3GLIZ'..,EFVO76G7/\ :$5CIMTP(MS!*UTJ<<%LJF>>P_.M6B@##T_0M2AO MH[O4_$E_?-&21;K'%# <@CE57<>O=C4Y\+Z$VK/JDFD64M^YW&ZE@5Y ?9B" M1T'2M6B@ P,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ KSVU^)EU>_%+4_"]KHHEMM,1O/9;E1=9"!_,6% ML;HR651@DY(/3IZ%7G>M?#"Z\0_$./7-7UI9;"W1OLT:6RQW,(:-D,0E'!C^ M=FY!;) ).,T 5=*^+\^I:;)*WAY$NGGM+6VCCOB\1GN&V^1+)Y0\J2/JZ;6* MY'4D"NT\*>(1XFT/[:;?[+/'<36MQ!OWB.6*1HW ; W#*Y!P,@C@'BN+M/A! M/!!"\WB!'OK&*PAT^6.P\N.-;1RT9DC\P^8QW$,0R<'@"NT\*>'AX9T/[$;C M[5/)<375Q/LV"2661I'(7)VC+8 R< #DGF@"S!_R,U[_ ->=O_Z'-6C638VM MO:>)-06U@B@5[6W=A&@4,Q>;).._O6M0 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% &!K'AHSZC_;.AW T_6D0*9<$Q72CI',@^\OHWWE['J#)H M?B,:E,^GZE:MIFL0+NELI6#;ESCS(FZ21G^\.G1@IXK;K,UOP_8Z_;Q)>JZ3 M0/YEM=0-LFMW_O(PZ'U'0C@@CB@#3I&574JZAE88((R"*Y:W\0WOA^X2Q\:& M-8G<1VNL1KMAG)X"RC_EC(>G/R,>A!.T=50!SUMX*TS3;J*;0Y;S2$CD#FVL MK@K;N ?N^2V8U!'!VJIQW&!B?4QXHBOC+HQTFZM2!BUNQ+ X/?\ ?+O&#_US MX]ZVJ* ,N;4]0L]'ANKG19[BZ9L2VNGS)+Y?7Y@TACW#@=!GGIUKG;SQ/?ZU MKNG:#I:7^@2722S375Y9 .$CV_)%NRC.2X.?F 56XY!';50U?0].UZU2#5+? MS5BD$D3J[1R1. 1N1U(93@D9!!P2.] ''>'/'H36-1T;4WUG4OLIB:&\/A^Z MCD*R;ODE180 05SN"JK*PQR#74ZMKTFF7:6\&B:IJ4CIO!LXDV#DC!=W50>. MA/<58TC0].T&U>#2[?REED,DKL[222N0!N=V)9C@ 9))P .U7Z ,I+[5[K0W MN+?2%M+\G"6FH7*J,9'+/%Y@'&3@9Y&..M1Z7#XD-X)M;O--$&TC[+9V[Y!] M3*S\_P#? K9K/UG6[+0K,7%_(V781PPQKOEG<]$1!RS'T'U. ": ,+6_#GAN MSM;G5?%4]U?6ZL79+Z[EEAR3PBP ["22 %"DG@GY4 =+17,0_$;PM<6EU"&ZMY(+F))H9%*O'(H97!Z@@\$5R_]E:OX M3&_PYOU325R6TB>3]["/^G>1CT_Z9N<>C*.*ZRB@#,T;Q%INNI(+"<^?"=L] MK,ACF@;T>-L,OY8/8FM.LG6?#6FZY)%/=1O%>0#$%[;2&*>'V61><'NIRI[@ MUG!?%NB?*AM_$MH.AD9;6[4>^!Y4A_[]T =/17-#QUIL'RZO9ZKI,@^\MYI\ MFQ?^VJ!HS^#FL#6_B;I\FOZ?I_AWQ7X>MH9K:XFN;F[C-R$='A5(PJ31[2PD M<\D_B45YUHGQ U.?7M1TUH&\1^5:V\]O+I.E26:DR-,K!FGE*[?W:D. M& .6'.TUNG3?$NOC&M7L>BV3?>L]+D9IW'HUP0-ON$4'T>@"QJWBE8+YM(T& MW_M76=N3;H^V.W'9IY,$1CVY8]E-.T?PU]FU ZSK4XU'6G0IY^W;';H>L<*$ MG8O3)R6;')/ &EI>DV&B6*V>DVD5I;J2VR)<98]6/3WJY0 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 5X[JGA#Q)C?#_1KW1?#4JZI%]GNKS4+J^:WW*QA$TSNJ%E)!(4C. M"1G.">IZ>B@#)L;9+;Q)J"QM*P:UMV/F2M(<[YNA8G ]AQ6M6=!_R,U[_P!> M=O\ ^AS5HT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 5B:WX;;5]5LM2MM9U#2;NSAF@62R6!MZ2M&S!A+&XZPI@@ ]?6 MMNB@#$T3PVVD:K>ZEE;=%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 5F#Q'HQ\1G0!J=J=66+SC9>:/,">NWZ MKJ7PIH\LT]R7FN(M9LP;:.0PD+=0W"@E%)5$(R6^: M0;1Q@ ]AGUW2+47QN=5LH1I^TWADN$7[-N&5\S)^3(((SC(-6;2\MM0LXKNP MN(KJVF4/%-"X='4]"&'!'TKP+3?"7BO1M4UI]5TJ:ZCCUK2=1OKF"26Y:\*$ M-,\:^4OF#)+%5'RD!0#C->K?#6QN[+PG*;V"6V%SJ5[=003(4>.&2X=T!0\H M2&SMZC/.#D4 ;D'_ ",U[_UYV_\ Z'-6C638K<+XDU#[5+%(WV6W*F.,H N^ M; .6.3[\?2M:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBH_/B^ MT?9_-3SMF_R]PW;@"2BBB@#.@_Y&:]_Z\[?_ -#FK1K.@_Y&:]_Z M\[?_ -#FK1H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP::73=)_ M:0N+AYEU0W+O]H+&:WN]*_<XTI+A7D:SBG(DNKM=Q* MARP!+\E5^8D)-0^U111M]EMPHCD+@KOFP3E1@^W/UK6K.@_Y&:]_Z\[?_P!#FK1H M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ*Y,XM)C:!#<;&\H29 MVEL<9QVS0!+17@WAKQSXJ2RN='UO6[N'Q#/K-G93P7-G%OLA+*5DE@<9CD0X M95!!VE<\@@5ZE\/]9O=:\-2MJDOVBZL]0NK%KC:JF80S.BN54 E0,X &\:.2"*)=LD.,_F.04>#&S<=O_+3K MMQGWS0!K45G?VG=_] 2__P"^X/\ X[1_:=W_ - 2_P#^^X/_ ([0!HT5G?VG M=_\ 0$O_ /ON#_X[1_:=W_T!+_\ [[@_^.T :-%9W]IW?_0$O_\ ON#_ ..T M?VG=_P#0$O\ _ON#_P".T :-%9W]IW?_ $!+_P#[[@_^.T?VG=_] 2__ .^X M/_CM &C16=_:=W_T!+__ +[@_P#CM']IW?\ T!+_ /[[@_\ CM &C16=_:=W M_P! 2_\ ^^X/_CM']IW?_0$O_P#ON#_X[0!HT5DVNHZDMG"+S1KQK@1J)2CP M;2^.\MVMU,O[F-RI8)M7KM)' MWMW?IBK= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3) M8HYX7AGC62*12KHZY5@>""#U%/HH X_3?A7X2TK3KJRM]/D:*Y:,EI+J1I(A M&VZ-8Y-VZ,(>5VD$'O3M)\3^#=$\+M_8MZ&TRROCIX%M'+<.]RS;F170:'XN\'^"_$UEX+T* M-+V_UZ9M/6)X MM:.J 3*C.JDJ$(5"1SMR,9H [^T\5Z)?6=E=6U^C07T4DT M+LK*"D?^L+9 V;>AW8P>#S4!\;^'!X-?Q8=4C&AHK,;PHVT@/LX&-Q^88&!S MQC.17+^%/ D/V.WT_6='NAI=II@MDBU26*26>66X::X:01NZX9HX6QD@[B#T M(KEM0^%OB?4O@O8:+N@@NM/AOF_L>6)9%N)I)',3>8)51656^4G< 6R1D# ! M[9#,EQ!'-"VZ.10ZG&,@C(I]4=$@NK70;&WU%HWNHK=$E,2;%W!0#@;FQ^9J M]0 4444 %%%% !1110 56U#4+32=.GO]2N([6TMT,DLTK85%'*7&WS@A"'GC()XSP#@]J *MY\0_"]A::?=76I,L&HV@ MO8)$MI7 MSMQ+)M4^4GSK\S[1S['%O6?&&@^'[._NM9U*.TAT[9]I=U;Y"XR MJC ^9B/X5R?:O.=;T#Q?=>!O"/@[^Q+UM&CTNVCUY["XMA.[1HH^S*9)D !* MG)/AWXCW:-'/KU[=336,,DB9B&4BC(8ML4F&)#UXW$= MS0!W=UXJTJS\11Z%(]U)J$D<690@D,8EV^67"$,4#;@.U8GQ%\(-XA.BWV MGZ='=:E8ZI:2>XM1%-<&)E\Z8M,&R<[57;P&R<[>0,<*-A^8X!XP3D933?&&AZOK4NE:?>F:[C5WQY,BI($?8YCD*A)-K':=I M.#P:Y2;X>#3_ !/X%O=*T^.5])S#?WNY=_E+:O&F2QR06;H,\L2?6JWP[\*> M)?#.N06MS]MCTZW@NDNY+B^$T%X[3[H'@BWDQ80MN^5.3_$?FH ]/HHHH ** M** "BBB@ HHHH *RY?$NC0^(3H&] M5TZZOK*_D,%I%'/*9;6:)O+D_P!6ZHZ!G5L?*R@@]LU9?Q?HBWVIV45U)=7> MDK&U[;V=M+<21>82%&V-6)/!X&2!R0!7GWAOPYXIU*\FU#Q=I%Y!JNJZE:RW M\CS6YMK:UMV:6*&()*S%=ZJ#D MYG((W&MS1_"=WX9\:>+]1T+28H;6\T^W- MD$= +BX7SF?(SG)9UR6QG/6@#J/#_BC2O%$-W)HLTT@L[@VUP)K26!HY0 2A M615.0",\<9K7KG_ NB2^'O ^EZ?>#_35@$EZQ()>X?YY6)'4EV;FN@H **** M "BBB@ HHHH ***;)&LL3QR#*.I5AZ@T 8+>._#:V>H72ZHDL.FW:V5R88WD M(G;:!$H4$NV6 PN>>.H-6+'Q7HNHVME<6E[OCOI)(H=T3H=\88R*RL 4*[&S MN P1CJ0*X2T\/^)O!&A>,$\#^'H3<7>I(=)@66)8UB\F-#)AG ^4JWRD@DX[ M&K/A+P,1:VMAKFF7QL8;"X2Y_M22%I+VYN90TSL(I' X3CGI)CDYH Z-OB+X M6&BVVJQ:H;BSN[B2VMWM;:6=IGCW;]B(I9@ C''5AD$?A7D2>!-=M/"&DV+:+)+!::OJ$\]C87,4%P(93+Y+12 M[UV#YEW!74E20V@0R2S2L%5% R22> *Y MZY^(WA:TTFPU.;4G-IJ%NUU;O':32$PKC=*RJA9$&X99@ ,\UJZ_HUGKVB3V M&HVD=Y"X#B&495G4[ER.APP!YXKRV]\/>-4^%_A7P9;Z-=K9/9B#Q!+97%L; MA(P,&"/S)54E^06R0 >_2@#TO5/%V@Z-:WUSJ>I16\&GV\=S<2L"56.0L$P0 M,,6*, JY;IQ\PS%=^-_#UEJ=OI]SJ&RXN%B9<02,B"4XC\QPNV/>00H9N09*F(X8L V #0!ZS1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %4M5UK2M"M5NMQJ M[10!S?\ PL;P1_T.7A__ ,&D'_Q5<_J7Q(UM MD9G:13&FV*0,5$8)Y&-Z\P\0:II-Q-:Q6LJV:6S)(L; M2,A(EA<@@S/T([>E &3H'Q6\+:GI"W&J^(?#^FW8FFADMQK$4BCRY7C#JS;" MRL%#@[1D,*TO^%C>"/\ H>YV M>9(\LKRN3L55^\[< 8K2H Y?7?$M[HGCSP[ILL4!TG6?.MVF*MYD5RJ[T&< MXVL PQC.1UKGM&^*SW.FB\NM+GOVU&[O6TFUTN)?,>QMS@SN9) O)]",[E"@ M\FNB^('@P>.?"XTR._;3;N&YBNK2^6+S&MY4;[P7(R=I9>H^]^%86L?"*PO= M-\.P6$E@DF@V;V48U'3%O8)49 "QB9EPX90P;=U+9!S0!/J?Q9TRW81Z)I>H M:W+)H@UR-K;RHX_LQ+#*OI\-8(]4FN4U#;!+X;&@F&.T2/ W MLQE&S"#[_P!P( /TK!/P5\Q-,:XU+2KF>TTN'2I9;K0H[@-%"?W%]"T&2P@;6Y+E)+B]MGG$8BA\P859$ZX(Z]ZIZG\.+F_ M\;6_BB#Q!):WMC)"EA&EO^YAME!$L#(' ;S-V2W!&U<#CG4\4^!K'Q;X@T"_ MU46]Q::1).\EC9HZ:3//+IGF/L69I/[O!Q=N?AT;A/&H.J[ M3XJM8K^?/WL?+Z>]4-5^$W]IV.L6W]M>5_:>BVNE;OLF?+ M\@D^9C?SG/W>,>IH UT^).D'QQ#X6GMKRVN[EI5MY9Q$J3>6I9F";_,"':VU MV0*VWY2>,MT_XEZ5?Z;<:J^GZK::/%;37<6J3VH^SW$,1(9E*,S+G&55U5F' M0&L72_A%+IOB:QU ZY#+9V>I7FH"V_L_;+.URA5A)+YAW$ @ [1QP<\8NZ?\ M-;NW\+3>%+_Q$UQX=^Q3V4%K%9)',$W=M;16ES'$' N$=XI3MD(V'RW!P2P(P5%5=;^*GV?2K6[T'1; MN^,OB)="D60QH0XE".5!<9+ $)D@9P6P!@TK;X.M:V-J8-1TFUU&RO;6[MI[ M+0(K>+= &'[U%??(7WMD^8 .-H'.;:_"RX3PRE@NO(U]%XB_M^.Z>QRGF^9Y MFQHQ("5SD<,/PH GM?B?;M=W5B+*^U741JUW9065C:)')LMU5G8EYBK!=RC= MN4L6 "59\2?%+2/"NGVE]JNG:K':W,*3-+) L'D[C@(5E=&:3AB8T#, ,D8( MSG6_PMO--UJ36](U^FU.]O5DFT\R0^7=*H:(H) 25:-6#!AW!4YJOXI^$ M=]XE>ZDD\4C[3?:3%IEW=7.FI+*P20R%HRKHL89C\RA2"!V/- %BW^*T%AH^ MLZAXCCCV6OB6;1+)+0JAFQ@H6:60(#C<2Q95P/SZ'4_%,T?PSU/Q/96%Q:7% MKIUQ=1VFIV[1NCQHQ"R)G.,KV.".0<$&L1?AC)'H&J:X-[2OA['I/PGN_!,.HNR7-I![Q%*'YI-Y7+8. 2 M/0]:W;#QU9ZGKDUC9:7JDMK#=R63:HENK6OG1C+J2&WJ 2P 0-T&[CD J_P#"V]#%DU])9:G%8R6MU=V-T\*! M-02W5FD\H;]P.U2RB0)N R.*>GQ/MI/[#6+PYKCSZ^DLNG0!;<--'&B.9"3- MA 5D&-Q!^4Y XSD-\'GGT6'1KO7_ #=/TZRO;324%D%DMQ<1M'NE;?B4HCD# M CSU.3S4^L^#-?3Q+X!;P_<1+'H%E=6T]]/"'C4M%$B[HO,5F#;&^ZW'&3Z@ M%Y/BSHESI]M=Z78:IJ/F6#:C<0VT">990JY1C*&=?F#JZ[$+,2C8! S5FY^) M.F1Z[;:7IVG:GJSW&EIJZRV$*.@M&8KYF"X9CP#M52QW#:&.0,.R^$,VC6$< M6@^(?LUQ/IN& (.W-7;OX46DSW,=IJ4 MMK9R^%U\.1Q"/+QHK,1(7R-W#8*X&>>>: ,_6/C1:Q>#O$NHZ+I-Q)J6@K&) M[2YE@(B,A*JSF*5AA6!#(#O!&"!G(WI/B7ID&L?8+K3M2@$4]O:WETZ1&&RN M)P#'#(RR$EN5!9 R L,L.<<]_P *;FN-%\1V%]K\!_MO3[2Q3[)IOD1VJV^0 MA5/,;(/&1DG3/:S:__8]S?7,0\ERJ,9!$0^[>#X6SQZU:S0:ZJ:7::\VN0V1LLR"1PV^,R[QE=S,1\N1G!W<$>AT M%%%% !67=>)]!L;BZ@OM;TZVFLHUENHYKN-&@1B &<$Y4$LN">N1ZUJ44 9$ MGBWPY%YWF^(-+3[/"EQ-NO8QY<3XVNW/"G#N'K6!!\5_#,OB^_T674K* M""TMUF%_)>((G/READ\ 21X;.&.\#[AKMJXJQ^&R6+:: -Z3Q;X>9@^T?O&5?+*9Y'-:OBCX=W'BS6[ M:;5=7MY=.M;N*[MX9--4W-L5*EDBN%8;4.O3'-Z_\"O[9 MWN!%=6DC270DB,C+Y@E4(<@@?(>HK:\:>-KO0_"NB7^F0!+O6;RVMTCEM);H MQ+("[GRHB'6\']A:NFF7$4H=FEM!<1S+@@HZY5LF6(T M?6UM]5@BO([B]GL_-2<71W2D1"1=A#8*_,< 8.[.:+3X/V>G7=O;:?J1CT*. MYM+R6QD@WRR36T82,B;< JG9&S#822IP0#P >CT444 %%%% &3JWBOP]H-PE MOKFO:9ILTB;TCO+R.%F7.,@,02,@\^U+%XH\/SZ++J\&N:;)ID+;9;U+N,PH M>!@N#M!Y'4]Q6K10!Y_-\8M ?5KJTT8IK,5DN^XELKR!V*A=S-%'OWRA5Y8J M,<$#)!%;\OQ!\&V\K17'BW0X94.&CEU&%64^A!;(/L:JZEX'-[T43+FX4 ,2@S\P (.1G@YKR_7/C!>Z)XY\9^'[FTM532]-:YTB MX9'VRSI:"=HI?FYSDD8V\(1R>:]:KSCQ3\'[/Q5_PE9O-2,G65IK:2-'JVI6\DMJK!5,2,49= M@AM67PUU'0- M8L+[POK]O;?8]"BT7;?Z?XA27_A7PK>>'8K=[_Q0Z16 MWV@DQ6Y\LO*S@$%MFUAM!&3@9'6M'0_$.J+XRO?"WB(6DUY%9QW]M>64311S M0LQ1@T;.Y1EX))4G=U!&:D\(>!=9T'QMJ&NZ]KR:Z]W:"VAD,+0M:()6D\I0676KS3+*\@C7[/(822%.9"^_:I).T+GH>HK4\,_ M#?1O#^J:EJEQ:6-_J=YJMQJ,5\]BBS6XE;/EASEOER1D$9R>!5&Q^&'V.]L+ MC^U]_P!CU^ZUK;]FQO\ .##ROO\ &-WWN^.@H -5^,&A:)JUWI^I6.I0S6]O M<7"ADB#3+""6VQF3S%R 2I=55@"02,5)1G?YJJ/,SNXQM^[WSU% ":-\3M M*UJ25(--U:)AI:ZM;J]LKM=VQ8J&B2-F8G(QM(!Y'&#FJ=G\8=#OVFMK6PU" M74X[V.Q738FMY99)'0N,.DIB "J^27&W80<' -*;X.K/I@LWUUU \*KX=WI; M;3E7#";[_3(P4[C/S5%:_"&]MM7-M-=MIPM52XMX8N)'=9'48!( VEMV M1MW#FDO/BAH%K#J$T:W5U!8Z1'K!F@C4K+!(3MV98'=\O0@?6LW7_A=<>(6T M^^U'6+&_UBUMYK:2XU/18KF!UD.X%8-RA60@;22W&0V[)--\1?"=]46YBTC6 MX]-@O-%CT>X1M/1\QQDE60(T:H?F(("XQP O! !5O/BS6+[ZY5BZ\@@,RA25(!/&>>U/X33:A+K:QZ['#;:P;"25&L2SQR6GEA2&\P M#:RQD$$9!;.>,'4TGP)J&CM<6%IXC:+0)I[F<645FJSYGR2IG+'Y59F9=J*W M0%B!R 9UY\7+.72_$D>EV5Q;:QHVDR:DEOJ"QX95!QO2.0NASMRC[' 8<"NY MT6]DU'0=/OIPJRW-M',X084%E!.,]N:\UTSX+W-GIUS:7'B*WD23PY)H$(M] M+\D1HS;O-8>:=S[BY;IN+=N<^F:58_V9H]E8>9YOV6W2'?MQNVJ!G';.* += M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 97B6QU'4O#]S9Z+?&PO)@$2X!QY8) M 8]"?NY.!M)Z!DSN'GL\VJZ7\0M-N-;UJZO8&>*U==.U/BVG/V:/RYK?:L;J M6F+%PH?$P(10@(]$\1:[#X;T*;5+FWGN4B>.,0VP7S':218U W,J_><=2*P1 M-HDOB.UUO7_"HT?5(HI5BO\ 4GLA(D2IN=MR3,< 9&1DJ"W0$D@'.ZQJ&MV4 MGBZWN-9N9O\ 3M+@\V-O)%I#/*B2^7@Y3".?FR6!^;/'&9=ZE=N]QIAW&M^"I=(FU&[U/07T[5 M&^S2W4MQ"8;L@$>6SD[7.,C:<\9JMJDW@2UMSH=Y#H4SZ3&UW%HP6!I(=B%] MR0'[IVDD$ <'KS0!E^)O%.HZ5H7A?4!&C75S!/-*)&D1=Z:?--RBLH8;D'# M@=1A@"*=O\0M;T^=I/$?]EFPM?L4][<6T$D?DPW4@#C8?B'XL?5;>&71[1(H5LC?AC'$$- MR00!))<*5*A@H CDWNA VYXS-0\<^+=1TQK::XL=*NVOM.DA\BW=M\$EVB92 M5)F2:-MR L&1B ZF-=P8>@3ZGX$O]4?4[F]\.W-_I!$;W M7.,9')QUIMU9^ M.T2>_O;;PY:Z7J[1RSW,L<"07K9+QLS'Y9#DE@3GU% '& M2_%3Q'%:WVH/I-I'8O\ :H[)IY(H]CQ3"(,V+AI)%!.7Q%'L]3UKI/"FI:K% MJ/C5M:NUU"73[V/8ML&6, 6<+%8T9F*9.25R?F)ZYK39O ]KK\L3GP_#J^KI MY'M2FT7PY!IR.L;S7":6UM%'&T%]7U/Q'X0FGFDMK;4DN;JS,T4),6^&9XA((RV<'9G:6/7J: M982^ H9[VWTM_#DA[UHZ9JN@/I%S=>'KF MPN;.$O-+_9TD;KN;,C'Y#C] '#Z8S:A\.;!]8U77KZ]^UWT,$%C? M-!<7THN)53+QE2-H'JL:@Y884;;,-MJ>H%].U?7I9+G3[6UT]A#J#V2ZA?\ ME&:1?,0;UR#$^$_%8T6UUGP,MM;ZA')<:0=4L;26*7>OFN$ MV/)L9E^L3^%?!ER-9N@J:LFGWB=6N7262-MTN29$S'P>"XPSN7?PQ36+.VL9-9:Y-H(BP2 M)W6Z,!*J\BY) )5#(,DA=W>N1?XAZ^EX-:>YM)(K71+UI;$VTUN@G2ZCCW2J M[9C90.RJ MV2Q;:NYF^8A3S3(9_!Z>++3PM9Z1:&\M[&=HUBL4$5I$?+WQ;L *6$R,4'8@ ML &7< 8DGC+Q.==N/#45SH2:E;2RE]2FMI1;,B6\;N1\RC)WL J,V#G M 3P?XKU'4/'VLZ7)<0FT>^:>*9Y6N$E06EL3#;MD !6D$A)&"'X4Y8KV+^$/ M#4NCQZ3)X>TI]-BD\V.S:RC,*/S\P3;M!Y/.,\FK@T?3!,)AIUH)5G^TAQ N MX2[/+\S./O;/EW=<<=* ./OO&FK0>+KB"%;!=,L]6M-*EMI(W^TS-.BMYJ/N MVJJF1?E*'(1_F':O#XHUF]^"6.0R] M0,'!)[>31=*EUF+5Y=,LWU.%/+CO6MU,R+S\H?&X#YCQGN?6G#2M.&EIIHL+ M46"*J+:B%?*51T 3& !@8&.U 'F%Y\3O$6FVMQ?W,.E36LC:I#;1+%)&T+VL M_EH\CEV#(1DL JXQD'M39/%WBO2/$VJZ5$T.K:E=:K%;1-#$##$JV2RD)#)< M(%)P3M\T?Q-ST/IPT32@H4:99X!E('V=>/-.9>W\9.6_O=\U47P=X972Y--7 MPYI(L)'#O:BQB\IV'1BFW!(]<4 *1E%L@!:( 1L>.J!5"GMM&,8I;;1+"VTFTTTV M\<]O:>68EFC5MK(05?&,!@P!! &#TQ0!YK:_$KQ*NFP7%[%I+MJ-@MQ:>5!( MBVSF[BMLRYD.]!YP:@D1 M8QESYY'%>C'0-'-OY!TFQ,/D-;>6;9-ODL>M 'GNM>/=>U"'7M.TR;3; M$V5OJLC7,@<,T=LXC"HP<;'&XDOR%('RU7T[QMXD&ZRTN2Q67_2I'GOUGN=P M@M;608'FC&XRL#@@#KC.=WI$GA'PW-8P64OA[2GM;9]\$#6492)L8W*NW . M!D>E68]!TB)R\6E62,0X++;H#AE56[=U1 ?4*H["@#@;+XB:WJ5Q;W<*:9;6 M+:C8:>]I,CFX8W$,4S2*^\# $I"KM.=I;/&VKWC'QMK/A_7-5CL8K.2RTS2( M+UDDB8RRR32S1 ;_ #%554HK$D= PR,[ET[CX=:/=>++/79F?=8F/[-:QVUM M''$(UPBAUB$I4'Y@ID*YQQ@ 5T)298ANPC$CE?F M;@\?,?4T >4ZK\0_$NF6D\VI6%K%J.FQ7[A3*%#F.U65/,@AN9 IRV-KNQ(P MPV[N-67X@ZQH-U?-XE73Y;'3KA4NKBT@>+:DEKYT?#.W.\&,GG<73 7G/:1> M%?#T%@MC#H.F1VBB15MTLXQ&!(,. N,?,.#Z]ZM2Z1ILZSK-I]K(+AD:8/ I M\TIC86XY*[1C/3 QTH \[MO'_BP>(TL[W2K%+>TGM;/46+1P*)IHDY]:KQ>$_#M MO;S00:!I<4,\JSRQI91A9)%.5=@!@L#R">10!YO&1S$093T,9&*\K)Y<3!@$($9^8A_F=1CUZV;0=(N&S<:592G=&^7MT; MYH_]6>1U7)VGMVIU[HNE:E>6EWJ.F6=WW5W@;(.48C*G('(]!0!P M.E:UJN@^$O&_B+4+O^T[JUU"Z6%'>588UB)51M:1@B#.3M X'.2,UE2:_P"* M[7QM=Z>MY9:AJ37WE6X1ITME;^RY9E'DB7@%E7*L6'.X8.TCUF.PM(H9HHK6 M%([AF>9%C 61F^\6'&- TKRO[+T/3;+R7,D7V:TCC\MRI4L-H&# MM9AD=F([T >;:M\4[P[=&)7(SNKU$: M%I B,8TJR$;1Q1E!;I@I$'VN[JZ;0M--Q>(Z7,QLX M]\ZN,,'.,L"."#UH H^!]?O/$&B3RZJ(EO;6Z>VG1+9[-V;:P##.U MW4\$,0<#HZHV&AZ3I44$6EZ7964=N'$*6]ND8B#D%MH4#&2 3CKBKU !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110!@^-?#\GBCPG/I$0@;SIK=G6 MY_U;(DZ.RD8.*-/Q?*NCZA=>9>*+'4;IY(Q%/'"H\RX$ >=E, M&73<40MO)=B MIQN &#ZE10!PGBO0[U? NBZ=8B5M9MC#;6T]M$SK$S1F&60L!A4$;R-EL#(4 M1M\,_%5]=&?5[VPGE:."&1VNY76017L$^5C\L)$ICC9?+08!526;<67K MO''A:^U^ZTB]TQ@\NG22EK=M2N+$2+(FW(F@!=2"!Q@@@L..M==10!YG!\,K MZUL7MX&TZ,;]&*"-I=J+9RAW4;]S8QD)EFZ\D5GI\+_$/V>TLG;2%AT[36TZ M"Y6:0RW2_;+>99)%\O"DK"V0"WS-U(/'KE% 'DFN_#?4%\,Q"2:UW68U65_* MAEG,IN+M9XEV(A9P0@5P 3CH&K>\%0:IJMKXMO\ 4--&F-K%WFWC9)4# 6T< M9;$D:28W*>612<9QC!/>T4 >:#P%X@UOPSI&@>(6T[3K;2=.DMHKBPNI+B26 M5K5K828:.,( LCMC+9.WD8YATSX>Z]I\MKJBV^F_VE97%O(EM+K%[=1W*QPS M1'?-,K%,>>615C.TKR6W?+ZC10!Y>?AKJC:W%=2PZ68)_L4D\-O?7=M!:/ P M)6.VC(24952I :]2HH \IN/A?K6HPW>EW5QIUI87%_=7POK5G:Y5I;5K<)L*@,JK9*Y)Q\AS@AQ4G_".WB>+M M%U3[2EQ%IVE7%E*TK'S99': ANA'_+)LG/4CK7244 1V[3-;1-=1I'.4!D2- MRZJV.0&(!(SWP,^@J2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$! end GRAPHIC 16 chart-4a9cf4c4b68f5058a30.jpg begin 644 chart-4a9cf4c4b68f5058a30.jpg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end GRAPHIC 17 chart-642b38eab6d652b2af8a01.jpg begin 644 chart-642b38eab6d652b2af8a01.jpg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kalydecoa09.jpg KALYDECO begin 644 kalydecoa09.jpg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end GRAPHIC 19 orkambia15.jpg ORKAMBI begin 644 orkambia15.jpg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end GRAPHIC 20 symdekoa05.jpg SYMDEKO begin 644 symdekoa05.jpg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end GRAPHIC 21 symkevikalydecolockup4ca05.jpg SYMKEVI begin 644 symkevikalydecolockup4ca05.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0 Z17AI9@ 34T *@ @ U$0 $ M ! 0 %$1 0 ! 7$5$2 0 ! 7$0 #_VP!# (! 0(! M 0(" @(" @(" P4# P,# P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L, M# P,!PD.#PT,#@L,# S_VP!# 0(" @,# P8# P8," <(# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P 1" "K M 8P# 2( A$! Q$!_\0 'P 04! 0$! 0$ $" P0%!@<("0H+ M_\0 M1 @$# P($ P4%! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$( M(T*QP152T? D,V)R@@D*%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W M^/GZ_\0 'P$ P$! 0$! 0$! 0 $" P0%!@<("0H+_\0 M1$ @$" M! 0#! <%! 0 0)W $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 5 M8G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F M9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! M (1 Q$ /P#]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHK)\9>+=.\!>$M4US5[R.PTK1K26_O; MF3.RV@B0O)(V.<*JDG'I1JW9 :I'S4;<&OSB^!?_ 61PD9GA4YA1F(&X,^W<,@#)'WQ\3/B1IOPE\!:AXB MU9Y%L--C#N(QEY"2%5%!P-S,0!D@<]A7;BLMQ.&G&%>#BY;>9M4P]2FTIJUS MI%/-5-5UVQT1%-]>6MF)#M0SRK&&/H,D9KPWX ?M[Z)\\2?\+[DO+Z&\FT2XMX8M)D" MEH5 10\8QP&\W>2.I# ],5>'RZE?%\5<M>]D_$& S*FJ^7UHS7D]5ZK=/R9RU\-6H3Y:L7%GY" M_L]_\&R6K?#7]I[1=?\ $7Q$TG5O!/AW5(=2AAM+*2'4-2$+B1(I%;,<(9E M8J[G;G&"05_5#XT?"JS^-7PRU/PS>R201:@BA)T78FI6\4:K,B[FMT:15>0#U523GMU[5\H?L+?&SQI MJO[0>FZ5/K6KZSINJ+-]MAN[F2X5%6-G$H+$[2&"\C&;V/7/V:OV ;CX-?%"W\2:QK=KJ#:;O^Q06T3*&9E*;W M+=,!C\HSS@YXP?IL_LLMQ9P0S:3-!;RW(E5XHU)1O*,91LJ"ZE=N,,4\KQN/PT\Q;7+#Y.R5W9% M1PM2K3=;2R_0R?VE_P#@Y*^*W@S]JG7K'P=H7A./P/X:U:?3HK'4+622YU2* M&5HVEEE$@,;/M)4( $R 0^#G]C?@9\4[7XZ?!;PAXVL;>:SL_%VBV>M6\,IS M)#'_V@[[XB:I;^*K"ZUB].H:GI.G:BD. MFZC.S%I'=3$TJ^8Q+-Y4J#))&,FOM#P_H%GX5T*STW3K:&ST_3H$M;:WB4+' M#$BA410.BJH [ 5.<8K+:M*E'!0<9)>]^'WOS#%5*$H15*-GU+QY]Z,Y%4= M7UVST*U\VZN8K>/U<]?IZ_05P?B;X^1Q[H]+@:0]/-E&U?P7J?QQ]*_-^(., MLHR:/-CJR4ND5K)^B6OWV083+L1B7:C%OSZ?>>E9S0>37FOP>\>7_B+Q->0W MUPTWF1"1 D'@^W>NCA?B3#9Y@5C\*FHMM6=KJSMK9O?6>ZDU:QC9]W-Q&HY&/X M@/Y_GZX_$?&OA7$9GE]/&86+E*BW=+?E=KM+K:R^3/J.%\PA0K2I5'92M9^: M_P [GFF=U;7ASQYJGA5E%K=/Y0_Y92?-&?P[?A@UC'-(%8=Z_E# YCB\#6]M MA:DJK0+;^<#&S,-T+@\$-GH M#TYR/4UT'@[X8^&O ,MQ/H>@Z/I,EWS*]G:)"T@ZX)4#Y?;H*\&[>]>K_ OQ M?)J-E)IEPVZ2U7=$2>2G0C\#C\"!VK^E_"[Q6QF88I91FTE*4E[LEHVTKVDE M9.ZV:2U/AL^R"%"G]8P^RW7ZHL?'^Y\ ZA\/+[0?B-)H4OAWQ!$UI<66J%6C MO$.,@(>3@X.1RIP<@@&O.OV._P#@GE\"/V4M2NO%/PG\):7I]UKT'E'58]0G MU)WMRV[RXI)I)-D9(&0A&[8N[)48\S_X*(_ [QCXQ^)^GZWI.E:IKVF-8):J MEE UP]JZNY8%$!(!W [L8)R.PKU_]@WX:Z_\*?@6UKXBAFL[B\OY;R&VE;]Y M:Q,D:A6'\)+*S;>V[G!R*_IJ=Z."YH57:6\4]'ZKR\SY?54[*6_0]=\1>*+/ MPM8&XO)5BCZ*/XF/H!W->:>)?CU>WP:/3(5LUZ>9( TA^@^Z/UKG?B%XMD\7 M^))IMQ^SQDI O8(._P!3U_\ U5A#@U_&?'?B]F.*Q53"95/V=&+:4E\4K=;[ MI/I8^[RGANC"FJF(7-)ZV>R\K=?.Y8OM2N=5G::ZFEFD;J78L:K;O:EQGO5G M2='NM=O4MK.%II9/X5'3W)[#W-?B\8XG&U^57G4D_-MM_>W<^G]RE"[LDODD M=I^S_IS7'B&ZNMO[N"#9GW9@1^BFO7@,"L+P%X.C\%^'X[<-OF8[Y7_O,?3V M'05OB%!R****^Z M/+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH *"-PHHHWW Y7Q1\*M)\3.TC1?9[ MAN?-A^4D^XZ'\L^]>0?%OP_#\(!:RZA>0_9;V4Q12!2#N S\PYP/?./I7T03 MZ5XY^UWH \2Z/I,!56VRR/S]%']:_%?%3@S)7E-;-'24*L+/FCI=MI:I:/?L M?39!F6)^LPP_->+OH]=DWIV.#M;J.\@66&2.:-QE71@RL/8BNH^$=^UCX]LO M[LNZ-AZ@J/[CQ%\0M-L;ZU M6WO%F#H\>?+E //!Y!QSU.>:_FOAFC.AG&%KT7>U2#\]T?<9@U+"U(RZQ?Y' MU=]ZL7X@Z@VG>#=1E5MK+"RJ?0G@?SK:/"US'Q>F6T^'&J32-MCCC#,Q[ ," M37]P<2UIT\HQ-2G\2IS:]>5V/RK!14L1",MFU^:/#*S/$7B_3?"L.Z^NHX6( MRL?WI'^BCD_7I7 :U\3=:\43-#ID?]G6I) DQNF<>N>B_AR/6H]!^&$M]<&: MX\R:60Y:21BS,?4D\U_ ]/ KFYJ\K:[+<_7W4=O=/ISPA\"_MEO#=:E<_)(@ M98H>N#R,L?Y ?C7HFA^&['PW;^396\<"XYVCEOJ>I_&F^$7W>%M-]K:/G_@( MK1[U_4$CLJ*S#N%+ X[XQ5TJ88ZG@\+4Q=;X81 MF [LG-.5@1Q7Y5_L0?\%$?BAJO[4/AW2_$OB2Z\1:/XFO5L;JVN M(XP(VER$DC*J-A5R#A?E*Y&.A'ZICYQFN_,\LJX*HJ=5IW5]#Y?@GCC \3X2 M>+P2E%1ERM25G>R=]&]&F/HHHKS3[0:%Q7FO[1%HS6FFW/\ !&[Q_BP!'_H) MKTSI6+XS\-Q^+_#]Q9-\K.,QL1]QAT/^>QKY'CG)9YMD>(P-+XI1NO-Q::7S M:L>AE>*6'Q4*LMD]?1Z/\SYXE@CNUVNNZM'X2^$[=?BKI-Q&OS1RNV /^F;5 M'JVESZ)?26US&T,T1PP/\QZ@^M;_ ,&XMWQ!L3_<#M]?D8?UK^+^$\/6I<08 M7#54XOVL$T]&O>5TTS]-S"I&6"G4C_*[?<>Z'C\JYKXNV']J?#;6K? _?6CK MS]*Z5AFLCQY%YW@W5%"[MUK)@>^TXK^YN(*?/EF(@NL)+\&?E6%E:M!^:_,^ M8])\(6NF+]U6:M:.,*N%7\ *=T%==\)/ DGB/68[R:,BQM7W$D<2..0!_,_E MWK^"\BR?%9OF4,%ATY.3MY)=6_)(_6L9BJ>&H.K/9?CY?,]>\/VK6&AVD+<- M'"BGV( %7@<-00%%*1CFO]!,-15&E&DMHI)?)6/Q^4N:3EW%HHHKH)"@T44 M1YR:,+JS;4I+4I#:VBOL^T32,%12V#M49))P3A M3@$X!^,_V??^"S7B;Q9\8=)TGQAX?T&/1=:O8[-9M-$T:?;;A1110 4444 %%%(SA!R0/K0 H&*;]T8JG>:]8Z<5^T7E MK#N.!OE5=WTR:EM]0@NHU:.:-U89!5@0?I3Y);V,?K%)OE4E?U+-% ;(I&=4 M&6(4>YI&U^HM%-219!\K*WT-.H!.^J"BBB@ HHS36F16P64'T)H$Y);CJ*:T MBH,LRK]30DBR#Y65OH: YE>P8VT;C2%E09.%^IK&UKX@Z#XM227J[&T7Q3@.0,K#V(XJVO I--;FD*D9J\7<***AN+V.TC9I)(XU4$DLV .I-+<)225V2 M _[-.KG[;XG>';J_-K#KNCR70)4PK>1F3(ZC;G/%;L:\$_X*;'_C!OQY_P!> MT/\ Z415U9;_ +U3_P 2_-'@<9?\B'&_]>JG_I+/RN_8J_Y.U^'?_8>M/_1@ MK]RE_P!4OT_I7X:_L5?\G:_#O_L/6G_HP5^Y2_ZI?I7TG&7^\4_\)^+_ $H- N97L8_BCP3I_BZ M#;>6X9U'R2J=KK]#_0\5B^$?A#%X0\1+>PWDDB*C)Y;H,\_[0/\ 2NPSBFLZ MQ_Q*/QQFOG<5PGE.*QL,PJT8NK%IJ2NG=;7M:_S.N.85Z=)TE-\KTMT_$D89 MJMJM@NHZ=/;YQYR-'GTR"*S-6^)'A_0;KR;[6])LYO[DUVD;?D2#6I::G;7\ M2O!<0S(W(9'!!KZ"MA_:4W"HM)*WJF>=3QE)SM":NNS5SB=$^ FFZ?(LEY<3 M7I7^#'EH?J!D_K7;V5C#I]NL,$:11H,*J+M4#V%3J<"C<,5X>2\,Y9E,7'+Z M,87W:W?JWJ_O/1Q..KXAWK2;_+[AU%-29'.%96^AIV:]XY%)/5!1110,**,T MUY5C^\RK]30)M+5GE'[9/[.*_M4_ ;5O"<=ZNFWD[)<6=PZEHXYHV#+O Y*G ME3CD;LX)&*^)_P!G;_@CEXXT7XR:1J7B[4- M=#T6]BNY/L<\D\M[Y;!PB@H MH56(P68@@9PIK]+L\Y'-,699&P&4D=@:]/!YQB<+1E0HO1^6WH?"<0^'>29S MF-+-,=!NI3LE:5DTG=)KK9OI;S)(UV1JO]T8IU'04WS5SC8?=Z+0=1 M11F@84444 *O$5U]CTO2HM\C ;FD8G"HB_Q.S$*!ZGL, MFORA_:<_X*>_$;X_:O=6^FZI=>#_ UN(@L=,E,4[IGCS9UP[,1U"E4[;3U/ MO7_!<_XCW48\"^$XG9+.0SZI-O$'BKQ)8VNJP>%_)BL;*X4/#Y\FYC*Z'AMBJ H.1ER<94&OMLGP>'PN!>8 MXB/,^B[:V7S;/YA\1.(LXS[B>/!^45'2@K*XA M66*0>C*P((^HH7&#;M*BN7M_2-I?1WY*:GA\PFJJUO;2_P FFOO9^4/P'_X* M[?%#X5W5O;^(+BW\;:1'@-%>@0W2K_LSH,_C(K_X>R?\%+/VIM3^+W[(WP_\ M4^";[4]-\+^*KV:+4E1S#,)8U(6WD*]MR3$C.&V*>1@CU#XX?\$=?AO\3M8_ MM#P_/?>"[B1LSP6($MI+SR1$WW#V^0A1_=KT+QO^PWXFZ;]G+FO)R3323TDDTFFGWT/C?_@D%^U=J7ACXT2> ].X9X_.TW M7?#M\)%##]Y:W,,F>1ZJZ]/:OW+_ &<_C%9_'WX*>'?%MBR>3K-HLLB [O(E M'RR1D^J2!U^JU'%F7JG4CB::TEH_7_@HV\ >+*F*P=7(\9)NI1=U??E;LUKK MH_S.YHHHKY _HHS_ !)KUIX7\/WFI7TT=K9Z? ]Q/*YPL:(I8L?8 $_A7XA? M&_\ :L\7_&+XU:EXP.NZU8S27;2Z7J?C>?[ H5\.+9?FN&'J"NV,CTFKX!_8!^ W_# M1'[4/AW1KB'SM)T^3^U-3#+N4P0D'8WL[F-/^!U]SPWA:='"U,=66FMO1;_> M]#^6O&K/,7F.>X3AG+9/FO%RLVO>DU:]NRU^9]*?\%0?CAXZTC]FGX-:;>:E M>:;>^+-+:\U\0$P23W$4-J2C;<87?,Y*=,A>.!5/_@DO^U7<> /#7Q C\9>( M9V\)^'K&'4HWO9FE^Q,79&2/))_>$J @ZMC RQSK?\%X5\N;X5J.BQZJ/_2. MOA/P+H.M>/-?M/"^BBXN+OQ#=PV\=K&^U;B4L5CW=L N3D\ $GBO1R[ T<5E M-II14FVWVLW^FA\EQAQ-F.1\>RG0E*I*G&$(QN]7*DDDUU3D[M=3W[]K/_@I MUX\_:&\075GX?OM0\)>%=Y2WL[*4Q7=TO0&:5#NR?[BD(,X^;&X^&W7P<\:- MIS:I<>%?%!M),R-=OID_EMURQ=X>34>6:^]/IKU3/A*\N(/#/-Z<9U75PT];:\LDG MJK-NTEO>_P!Z/U:_;]_X*2Z?^RR6\->&X;?6?&TT0D9),FVTM&Y5I<$%F8H77V,.VI>(-4(W2D.WW5)X\R1L@9X #'!"X/ZY_" M#X#^$?@1X8CTCPKH5AI-FJ@,(H\R3$?Q.YRTC>[$FN"IB,'DL52C#GJVNWV^ M>MO)(^KPN6<1>)%2>.K5WA\$FU"*O[UO)-)M=6W:^B/PU\4_##Q-X'B6;6O# MNNZ/&W"O>V$MNI_%U%=G\"/VR?B)^SGJ=O+X=\1WRV$!&=,NY#<6,B]U,;'" MYZ;DVMZ$5^W]_I=MJ%K)!<6\,\,RE'CD0%74\$$'C!]#7YO_ /!4_P#X)\Z3 M\,= D^(_@>QBTW2TF2/6=-A&V"WWL%2>)>BJ6*JR#@;E( &ZNC <18?&S6&Q M--+FT75-]M5IY'C\4^#^;<,X=YQDN+E/V:O*UXR26[5FTTMVNQ]??L5?MFZ+ M^V+\.Y-0M8?[-U[2V6+5--:3>UNQ'RNAX+1O@X) Y5AVR:/_ 4WY_8>\>?] M>T.1_P!O$5?F9_P3V^-\_P "OVK?"]]YS1Z;K%RNDZ@N<*\,[! 6]DDV/_P# M\*_3/_@ID=W[#7CQAT:U@(_\"(J\3'96L%F=.,/ADTUY:JZ^1^E\+\<5.)." M<;5Q5O;4Z=2,[:7]QM2MTNM_-,_*_P#8J_Y.U^'?_8>M/_1@K]RE_P!6OTK\ M-?V*O^3M?AW_ -AZT_\ 1@K]RD_U:_2M^,_]XAZ?J>5]'#_D48G_ *^?^VH; MU_STJEXB\06/A/1;O4M2NH+*QLHFFGGG<1QPHHRS,QX &XG<1QPHHRS,QX &+E.55<;5Y8:16[[?\$_3^/N/L%PQ@O;5 MO>JROR0OJWW?9+J_DAG[?_\ P42UC]H[Q?/HOA;4+[2_ NG2%81"[0R:LP_Y M:R8P=F?N1GM@D;N%^L?^"-&L>+M:_9WU23Q%-J5UHZZB4T66\-^(*SA3Y9-1=TG&V] MND4MEU:OZ\5^VC^WGX9_8^T&.&=5UCQ3?1E[+289=K;>0)96Y\N/(QG!9CD* M#AB/S"^.G[=?Q0_:'U.1M6\27UII\Q*IIFF.UK:A3T4JIS)]9"Q]ZXOQ=XL\ M3?M)?%N;4+Y[C6O$WB>]6..->6DDD8+'%&,_*HRJJO0 5^JW[$?_!.;PM^S M'X;LM2U:TM-<\<2J);C4)$\R.R;'^KMPP^55Y&_ =LG) PJ]GL<%DU",JT>> MJ_ZT[)=SY[^T^(_$?,ZF'R^JZ&"IO5JZ5NE[-.4GVO9'Y?:)^RA\3O$FFK=6 M/P_\7S6[#%_C5X4GT7Q3HMCK&GS CRYH_FC)&-R, M,,C>C*01ZUR4^+^:7+6I)Q\O^#N?08KZ/*HTO:9=CI1K1U3:LK^J=UZZV/A' M]B__ (+ WC:I:>'?BNT4D-PRPP^((D$?DL< ?:44!=OK(H&.ZD98?6'[=_C7 M7O"W['7C+7/!UTT>J0V*2P75N=S10&1/.D1AT*PF1@PZ8!SQFOS!_;P_8VO? MV/OBK'8QSS7WAK6%>XTB[D7YRJD;XI".#)'N7)& P96P,D#ZQ_X)'_M++\8O MAQK'PD\5-_:#Z79NVG^>Q;[18-^[D@8DY/EEP!_L.!P%J\RRW#*,,SPBO!-- MKHU?\.S1R\$\:9Q]8Q'!7$$W&NXRC3FWJFT[)OK=:Q>Y\B?L1E).63.\'KE<9P2#^UD$RSPI(K*RL,@@] MO:OPG_:9^"=U^SQ\=/$7@^[60II=TWV61^L]N_SPOZ9,;+G'0Y':OU*_X)<_ M'O\ X7A^RKI,-U/YFL>%6_L>\R4Y[G,10$GJRO1Q3@X5*,,;1V>CMV M>J?Z!X$\18G"X_%<,YC)\\6Y13>S3M)*_?1V\F?2E%&:*^'/ZB(V?9EJ_'O_ M (*0_M7:I\:/VEM9M-,UJ^B\-^&9CIUC#!.RQ-)'Q+-A3AF:3< W=%3G%?I) M^W7\?E_9R_9I\0Z_',L.K30_8=+&?F:ZE!5"/79S(1Z1FOQS^"GPLU#XZ?%S M0?"NG[C>:]>I 7 W&)"'Q%#9S06.H MS$M=>2;KR$D+'DN%)VN>2 C9)YKY!_8#^.OBKPM^USX1\O6]4GAU[4TLM0AG MNGDCNTE^5BX)^9@6W GD, :_0O\ ;[\'V/P__P""=GBK0],A%OI^DZ7:6=M$ M/X(XY854?D!]:_,7]BHY_:T^'?\ V'[3_P!&+7;E/LJV#Q-515I.73I:Z1\U MQ]/'Y9Q%DV!=:3=.%)/5ZOGLW\[6=^A^O'[6OQ7U;X4?"(SZ!Y"^(=;U"ST7 M2Y+A=T-O/=3I"LCCN$#%L="5 /!-?*FC7^I:I^T+-X'TKQ-XN7Q5#>W-NNNM MXFO)KJ)H(1+]JFLY%%B]L7*1F%1NPW&<9'V;\;?A%8_'/X8ZAX;U":XM8[T( M\5U;MMFLYHW62*:,]F2158>N,=":^>[W]DCXHZO+;V,E_P"![&ZM]5DU8>+[ M0W@U(7#P^0\ZV?$2.\7#)YQBR<[.!CYK+ZU"%-J5KZ[_ "L_-+70_;>+\MS/ M$8N%2@I2@N6R5NC?,MURR::M+RM='MO[*7Q@NOCU\ /#OBF^@CMM0OX9(KN. M('RUGAE>&79GG:9(V(&3P1R>M>CK\IKF/A#\+].^#'PVT?PMHZ2+INBVZV\) M=MTCXY9W/&69B6) &2QX%=.!CK7CUY0=23A\-W;TZ'Z!E=.O3P=*&)=ZBBE) M]VEJ_O'4445F=Q\ ?\%P?@YJ&K>'/"7CBS@DFL]':73M1906\E92K1.?1=RL MI)_B=!W%?*G[#G[:NJ?L:_$"ZNX[3^UO#^LJD>IV(;RW;83LEC;H)%W-P>&# M$''#+^RWBOPKIWCCP]>:3JUG;ZAINH1-#<6TR!XYD88*L#7Y[_M,?\$6;Z/4 MKG5?AAJ=O+:R,7&BZE(5>'_9BFYW#L!)@@#EV-?:9+F^%GA/J&,T71O9J]]> MS71G\T>)7A_GE#//]:N&[RJ:.45;F32M=)[IK1K5^1]8? G]OWX6_'VWA32/ M$UE9:E, #IVI,+6[#'^$*YQ(1ZQEA[U[0DBRUM80 +*> M7[5:;1V$,FY%STRH!]QQ6F(X3IU%SX.JFO/5?>O\CEROQ^Q>#FL-Q'@I1DMW M&Z?SC*WY_(_7#".+6+5F^P.QX M E5B6A[#=N9.R^OA)\E:-NW9^C/WSAGB M[*\_P_UG+*BDNJVDGV:>J]=GT/RI_P""P?[-[?"SX\1>,=/M_+T?QH#))L7" MPWJ "0'T\Q=KY/5O,]*]$_X(E_M#_9;_ %[X:ZA/\LX.KZ2&;HPPL\8^OR. M/^FAKZU_;G_9WC_::_9TUWP_'#')J\,?V[278XV748)3![;@6C)[+(:_'7X, M?$[4O@%\9-#\46<H>'+Y97A;*,Z@[98F[C>A=#W 8U]IETEF65RPTOCCH MOEL_T/YJXPP\^"^.J.=4%:A7=Y6VUTFO7[2^1^]87)I7; ]AUK'\$>+K'X@^ M#]+US39EN-/U:UBO+:4?\M(Y%#J?Q!'%U?!TZ,IU522]YNUO/8_JK%9E0H8*6.E)V9)F[D*NYS[*:_=?P'X.L?A_X,TG0M-A\C3](M M(K2WC'\$<:!5'Y 5]QQ%6CA,'3P%/JE?T7^;U/YC\' M6WR!\DTS+&&_[]F4?B*]+_X+QG;>_"WV35?YV=<[_P $,_\ DKGC;_L%0?\ MHTUI1DX\/7CV?XR:.+-,/3K>+JA45US0?S5)-?17Y^?UR,D7*M MZ$5^(G[>G@^W\"_MB?$'3[;"PC56N0 .%,ZK.0!V ,A&*_;LC/?M7XM_\%+1 M_P 9Q?$#_KZ@_P#26&OL.#9/ZU)?W?U1_._TCJ<7D="HUJJJ2?DXRO\ ?9'W M#_P18^'\7AS]F"^USRL7/B+5IG:0KAFCA B5<]P&60_5S7V)C/Y5\S_\$BO^ M3'O#?_7U??\ I5+7TP#\O%>#G,G+'5&_YF?J7AQAX4>&,#"FK+V<7\VKO[VV M'WOPK@_VFO"=OXX_9[\:Z51[BN\;@?C7+_&0?\ M%I?$W_8+N?\ T4U<>'DU4BUW1]-FU.,\%5A-73C)->33/P2LKV33KN&XA;RY MH'$D;8^ZP.0?SK]F/^"E?_)B7CC_ *]+?_T?%7XQ5^SW_!2P_P#&"/C?_KSM M_P#T?%7Z!Q%_O>%]?UB?R+X._P#(BSY?].__ &VH?EC^Q3S^UK\._P#L/VG_ M *,6OV\U?5[7P]HUQ?7UQ#:V=G"TTT\SB..)%&69B> H ))/ %?AW^R%JMOH M7[3_ (#OKV>&UM;/6;>:::5@B1(K@LS,> H ))/ KVS_ (*)?\%%;O\ :-U* M;PCX3N)[/P+9R8ED!*2:VZGAF'40@C*H>2<,W.U5,^RJKC<;3A#2*CJ^VOY] MD5X6<>8'ACAK%5\1[U24[0@GK)\J^Y+J_P!2/_@H]_P4,N/VF=OOVB-5M?%OB^VGL? MN MXDAB;,?$T?G1-] MV1&+9(I8D C6_MUPBSQJ, M 8X5U PI((P& &V;1GE^ 4,"M.KZKS]7WZ'F\ U,+Q9Q;+$\43O.UX0:M%M: MJ.NR2U2Z]7W^G]%T>U\/:3:V-C;PV=G9Q+##!"@CCB11A551P% X KX(_ MX+F?%"2VTCP3X-AD(CNI9M6O%!Q_JP(X?J,R2G'J@K] ]V"O\O6ORL_X+;7$ MK_M4:)&Q;R5\-PM&,<;C)X.UGQ#I4=TRM=9#6QF*=55$E9))WT_K4_&_#?Q6R[AW)88%X2I. M=VY2BE:3;TZ]%9?(_;?SE'\2T>9N^J@]1577?VB/C)XHT2[TW4O$WCB^L+Z%[>X@FEF>.:-U*LK \% M2"01Z&H/V8O@IXM^(7QW\*V>D:'JDDT>JVT\DWV=TCM(TE5FE=\85552%^ M'4_[RA@>XP:\[(:L<;@*F!GNEIZ=/N9]CXJX&KPSQ5A>*<(O=J-.27\RTDO+ MFC][N?OP!N7^5)7!_LS_ !GM?V@/@3X9\66VQ?[8LU>9%/$,ZY25/^ R*Z_A MFMGXK?$:P^$?PXUSQ-J;;;'1+.6[EP?F8(I.T?[1(P!W)%?"RHSC4]DU[U[6 M\]C^I*.9X>I@ECU)>S<5._2UKW^X_./_ (+3?'X^,/B]I/@&SFS9^%HA=WR@ M\-=RJ"H/^Y"01_UV85T__!$O]GK[7JVO?$K4(?DM@=)THL.KG#3R#Z#8@/O( M.U?$NNZOK?Q]^+MQ>/&UYX@\7:H6$:_\M)YY?E1?0;F"@=ABOVZ_9R^#MG\ MO@GX<\)6.UH]'LUCDD48\^8_-+)C_;D9F_&ON M\.<+4XLXSQ'$F(7[JB_=3[[07R2OIUL?]>\/_I1%7Y6?L4_\ MG:_#O_L/VG_HQ:_5/_@IQ_R8[X\_Z]X?_2B*ORL_8I_Y.U^'?_8?M/\ T8M' M#?\ R*ZWJ_R0O&;_ )+?+?2G_P"G&?N7'_JU^E.IL?\ JU^E.KX$_K".R"BB MB@H**** (VX_I2KQ7P]\8?\ @LQIGPO^.NK>&(/!MSJ>BZ'?/I]Y?"^\NX:2 M-BDICB*%2%96 !<;L9RN:^F?@)^U3X'_ &DM%6\\*Z]:7TBH&GLG;R[NU]I( MF^88/&[E3C@D.LCS+%U,#A,1%U8-IQV;:T M=KVO;NKGHLUO'#_ !Y_X)O_ K^/%K/)=>';?0]6ER1J.DJ M+6;=K J0RY."."003^BG_!';XU:A\3OV:)M'U21[B?P?>G3[>5R68VQ17B4 MD_W,L@]%117R9_P5X^.NB_&#]HJTT_0[B&^M?"=D;*XN8VW*]RSEI$4]&" ( M"1_%N':OI7_@B+X)O-$_9[\0:U<(T=OKFL,+4$<2)$BH7'L7W+]4-?=YU4E6 MR>%7$+W]'\_^"M3^6?#C#4LO\1*^!R>3EATIIV=U9).U^J4K),^U'C#>_K7Y M$?\ !5[]G+_A2'[2=QK&GVQAT/QJKZC 0,*ER#BX0?\ BLGI^]P.E?KSC-> M!?\ !1W]G'_AH_\ 9IU:TM+=IM>T,?VKI2H,M)+$IS$/7S$+J!_>93VKY?A_ M,/JN+BY?#+1_/K\F?MWBUPDL]R"K3IJ]6G[\.[:6J^:NK=['D7_!%[]HG_A- MOA#J/@+4+@-J'A.7SK(,WS26Y;F^;_JY_.>*\3)U^!(9'?_ &CF5)]^16:?Y1\]3ZO_ M .")?P _MSQCKWQ&OHAY6CK_ &5INY>#-( TS@^JQE%^DK5^E)&VO,_V1/@5 M#^SI^SUX;\*JJ_:K&V$EZXY\VYD/F2G/<;V('^R .U>F[>*^'SK'?6L7*HMM MEZ+_ #W/Z@\..&5D604,$U:=N:7^*6K^[;Y'YW?\%Y>;OX6_[FJ_SLZYW_@A ME_R5WQK_ -@J#_T::Z+_ (+R_P#'Y\+O]S5?YV=<[_P0S_Y*[XU_[!4'_HTU M]72_Y)WY/_TH_!<9_P G@7K'_P!,H_32BBBO@#^M!K'Y?PK\6?\ @I\-?]?5]_Z52U]-'I7S+_P2+_Y,=\-? M]?5]_P"E4M?31Z5X.;?[[5_Q/\S]5\/_ /DF\#_UZA_Z2AO<_A7,_&7_ ))) MXE_[!=S_ .BFKINY_"N9^,O_ "2/Q+_V"[G_ -%-7'0_B+U1])F/^ZU/\+_( M_ OM7[/?\%+/^3$?&W_7G;_^CXJ_&'M7[/?\%+/^3$?&W_7G;_\ H^*OT'B+ M_>L+Z_K$_D'P?_Y$>??]>_\ VVH?C%GBOM'_ ()M?\$V)?C-^;OV4O"]AXS_ &E/ NDZI:QWVG7^M6T5 MQ;R#,*H M4=');]EY>?F<_@=X>X3.:LLUQ_O0I224.CE:]WW2[=7N?.O_ 4&_88L/VHO MA6LFBVMK9^+O#L6[2I541K-&.3:N>FQL 6!_*'P)XY\2?L]_%.VU;3 M9+K1?$?AV[(*2H5:-U)5XI$.,@_,K*>H)%?O@O7ZU\$_\%9_V$E\3Z==?%+P MG9?\3.S3=KUI$G_'W"H_X^5 _C0 ;O5!NX*G=X_#><*/^QXG6$MK]&^C\F?I M/C)X=3K17$>2KEKTK.2CHVEM)6^U'\5Z'U%^R3^U%HO[5_PDL_$6ELMM>)B# M4K%FW26-P -R'U4]5;^)2.AR!\=_\%S_ (<20:OX&\61QNT,T=QI5P_\*,") M(A]6!F_[XKY7_8Y_:NU?]DKXN6^O6+37&DW>V#5]/!^6]M\]AT\Q,ED;L<@_ M*S _JA^T%\.?#_[?/[)=S#H=]:WD.M6RZAHM]SMBN$Y0GC*\[D<$;E#.,9&* MJI@_[)S&%9?PV]^U]&GZ?BC+ \1+C_@[$99*RQE.*;CMS.+337^*UGV;]#XS M_P"")7Q6M?#WQ?\ $WA&\>-6\364=S:!S]Z6W+[D7_:*2,WTB/I7Z<>1%G_5 MI_WR*_!'0M:\1_L]_%B&\A6?1O$WA6_R4D7YH)HVPR,.XX*D=""1T-?K_P#L M;_MR>%OVM/"$#6UQ;Z=XHMHLZAHTLG[Z$CAG3/,D9/1ATR <'BCBK+Y^U^N4 MM8R2O;HUU]&C/P*XPPOU)\.XYJ%:E)\J>ETW=I7ZIWTWL_4]Q^R0_P#/./\ M[Y%'V2+_ )YQ_P#?(J0,&Z4UI%0?,P7ZFOC[L_H[V<+7LB/[+&!_JX_^^10L M*QL-JJOT%?-G[9O_ 4K\(_LP65QI>FR6WB;QE]Q=-@F_=V9S@M<.N=F,YV? M?/' !W#C_P#@F[_P4.\3_M9>/]<\/>*-'TV":RLSJ-O=Z;%)'#&GF*ABD#N_ MS?."I!&0K9&1FO0CE.+>'>*<;07?_(^,EQYD4]? MIQ7EW[8?P&A_:/\ V>_$?A=HXS>W5N9K"1\#R;J/YXCGL"PP3_=9AWJ\EQWU M3%QJ=-GZ/^KF'B5PO'/LAK8-*]1+FA_BCJE\U=?,^/\ _@B-\??(F\2?#B^F M)W8UC2PQ_P!V.=0?^_3!1ZR'UKI_^"V'Q^'A[X] \3+%/'<>'M0'VN IMD:/F.>(@] M&,;.O/0GVK7_ &Q_CS-^TM^T7X@\31L\EC/-]ETQ,$;;6/Y(_E/(+8+D'HTA MK[B62IYHL7;W+)B_P S^E_"WA99%P_1P\U:I/WY]^9]'Z*R^1X/_P %./\ DQWQY_U[P_\ MI1%7Y6?L4_\ )VOP[_[#]I_Z,6OU3_X*Z M;=D_9+R4X+.C@$QNQR2"&5B<_)R3\ _$?X$_$3]FCQ&DFO:%KOANZM9?W-^B MLL8?L8[B,E"?]ULU^[A5?QJ&XT^&]@:.:&.6.12K!UW!@>H(/6OI,OXFQ%"" MI5%SQ7?>WK_FC\4XN\$_#WPA<7#G+.=(@W/]3M MY_&K'A7]DWX9^"K];O2O /A.QNHSE9XM+@$B?1MN1^!KTO\ 6++T^=8=RVM>;T]+V_$_*C]D;_@GEXX_:CUVUN'L;KP_P"$=P>? M5[N$H)8^X@5L&1CS@CY!W(X!_7OX9?#S2?A-X%TOPWH=HMEI6D0+;V\0[ =R M>[,222>36Y'&L/"JJ_04_.%^E>!FN<5L=)<^D5LE_6K/U7@'PXR[A>C) MT&YU9Z2FU9M=DNBOK:[\VQ3R*1EWH5V\,,4H97QCFL_Q'XALO">BW>HZE=6] MG96<33S3SR"..%%&69F/ SDUY,4V[(_0:E2$8.HA85P_P"W1^TPW[5/[0.I>((-RZ+:J+#2 M8V4JWV9"2'(/1G9F\>UJV!C? M"T9NIY.ST2\G+5+L?3*#:H^E*3BBBOS4_M4_/?\ X+M^'KZ\TOX;ZI%:S2:= M9/J%M<7"KF.&27[,8U8]BPBDQ_NFL+_@AAX8OI/&GCK6!;R?V:EI;6?GD81I M2[/L![D+R<=,KGJ*_177O#MAXKTB:PU.RM;^SN!ME@N(EDCD'7#*P(/XBH_# M'A33/!FEI9:3I]EIEC'DK;VL"PQJ3R<*H &?I7O1SRV6_4%'YWZ7OL?D];PR M]IQDN*76TT?);6ZAR;WVMKL:E%%%>"?K W.ZOQI_X*D>&K[P]^V[XRDN[>2* M/4FMKNUD93MN(C;Q+N4]P&5E/NI':OV5(K$\6_#?0?'KVYUS1-+UC[*2T/VR MT2?R2<9*[@<9P.GI7K9+FGU&NZKCS)JWY,_/?$G@7_6G+8X&-7V;C)23M=.R M:::NNC/#/^"5'A^^\._L1^$X[ZUFLY+J2ZN8TE7:SQ27$CH^.N&4A@>X(/0@ MU]'#I38H%@4*JA548 XIZ_2N'%8AUZTJS5N9M_>?69#E:RW+J& 4N94HQC? M:]DE<&&2*POB/HTWB'X?:Y86^W[1>6$\,>[H69& S^)%;_:FE7M/(;=Q@]Z_9 M?_@H9X=OO$_[$WCBST^VFN[K^STE$4:[G*QR1N^!WPJL?PKU./X9^'HO%)UU M="TE=:((-\+2,7)!&/\ 6;=W3CKTK=V;UVLN5/4&OH,RSYXJI1J*%O9N^^[N MG^A^0\%^%"R/ X_!SK\_UI9^(W[!'AB^\6?M@> +?3X7N) M+?5HKN7:/]7%%^\D<^@"J?T'>OVX1=@'KCDUA^&/AEX?\&ZC=7NDZ#I&EWE\ M&O +X5P-3"RJ^TE M.7,VE9)622M=]M1_6FR1+-&5895A@BG#I17CGZ0TFK,_)S_@I]^PBW[/?C.3 MQEX8L0/!>N3YFAA7":/<-R8\#[L3G)3LIRG'R9]*_P""'/CSQ)-JWC#PZWG7 M'A6WACO0S@E;2Z9MNU3T'F*&)'_3,'C)S^A>K:):Z_ILUG?6L-Y:7"E)89XQ M)'(IZAE.01[&JOA7P5I/@;3/L6BZ7I^DV98N8;.W6"/<>IVJ ,GUKZ*IQ!*K M@7A*T>9Z6EZ?J?C>!\(Z. XI6?Y?6]G3U;II=6G=)WMRMN]K:'S?^WQ_P3?T MO]JJ!O$&@R6NB^-[>+9Y[KBWU-0,*D^T$A@.%D ) X(8!=OYB_$WX,>//V9O M&,<.O:/K'AG4+67-M>+N2-V'1H9T^5OJC<>U?O!M]N:HZUX=L?$FFRV>H6=K M?6MPNV6&>)9$D'H0P(/XT97Q)7PL/95%S0[/=>C[>1/''@WEV>8AX_"3="ON MY)73?=JZU\TUYW/QI\&?\%*_C9X&L8[6U\=7UU;Q#A+^VANV;C',DB-(?7[U M9/Q _;X^,7Q1T[['K'C[6FM6&UDL_*L XZ$,8$3<#Z'(-?JYJW[ _P '=:N? M.F^'?AE7/7R+)(%/X)@?I5SPI^Q9\*?!%Y'<:;\/_"\%Q&^^.5M.CEDC/JK, M"5_ BO6_UARU/GCA_>]%^9\-_P 0?XRJ1^KU]5H;*,9Y(UN>2VOORK6U^]V_,> M*"-PQ117A'ZH?D7_ ,%9?V(+&S:'0?&N;Z.15_=I=_\MTS_>9L M2_\ ;1L=#C#_ ."8O[.$OQ__ &F=-N+JU>;P_P"$V75+]BO[MG4_N(CV^>0 ME3U2-Z_73QM\/=$^).AMI?B#1]-UO3Y&#M;WUJEQ$6'0[7!&1V/:H?A]\+_# MWPIT4Z;X;T/2]#L=Q]K-Z[;:>9T*+L4+Z#%+117R1^_;:'A_\ MP46\.WOBG]C#QY9Z?;37ET;%9A%&NYV6.5'8@=\*K'\*_+']@CPQ?>+/VP? M-OI]O)<26^JQ7OV[*;ATSQ6%X8^&7A[P;J-Q>Z3H M.D:9>7AS/-:V<<,DW.?F95!;GGGO7O99G7U3"U,/RWYKV=]KJQ^3\9>&:SW/ M,)G'MN14>5.-KW49+Q%EM3,X@ MSDIJ(CU D>FZ978#Z$5D?&S]M#XF?M#:;]A\5>*KR^TW<&^Q0QQVMNQ!!&]( MU4/@@$%]Q%?K!XX_8E^$OCN[:;4O 'AMII#N>6WM1:R.?5FBVDGZU'\/?V(? MA+X"U>.ZTWP#X>2XB8/'+<0?:GB8="IE+%2,<$8Q7VT<]P$5[54/?]%^9_-- M;PIXJJ?[#4S1NB]&G*>W^';Y7/A/_@FU_P $[M2^-?BW3_&GC#3Y+/P7ILJW M%M;W,95M;D'*@*?^6 ."S'A\;1G+%?U6C011A0/E48QZ40P+ -J*%7T%.9<- M7R>9YI5QU7VD]%T78_>N!>!\%PQ@/JF%]Z4G>:?;!11 M10 444V+[OXF@!U%!&:* "BBB@ HHHH **** "B@\BB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BH0Y^V.O\(12![DG_"IJ "BBB@ HHHH &**** /_9 end GRAPHIC 22 trikaftarlogoa02.jpg begin 644 trikaftarlogoa02.jpg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end XML 23 R87.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets and Goodwill (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2018
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2017
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Oct. 10, 2019
Indefinite-Lived Intangible Assets [Line Items]                    
Intangible asset $ 0 $ 0         $ 400,000,000.0 $ 0    
Intangible asset impairment charges   29,000,000 $ 0 $ 0 $ 0   0 29,000,000 $ 255,340,000  
Goodwill 50,384,000 $ 50,384,000         1,002,158,000 50,384,000    
Semma Therapeutics, Inc.                    
Indefinite-Lived Intangible Assets [Line Items]                    
Intangible asset             387,000,000.0     $ 387,000,000
Goodwill             554,600,000     $ 554,633,000
Exonics Therapeutics                    
Indefinite-Lived Intangible Assets [Line Items]                    
Intangible asset             13,000,000.0      
Goodwill             $ 397,100,000      
Other Intangible Assets | Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences, Inc                    
Indefinite-Lived Intangible Assets [Line Items]                    
Intangible asset impairment charges $ 29,000,000.0             $ 29,000,000.0 29,000,000  
Other Intangible Assets | Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc                    
Indefinite-Lived Intangible Assets [Line Items]                    
Intangible asset impairment charges           $ 255,300,000     $ 255,300,000  
XML 24 R77.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]    
Matures within one year $ 1,137,942 $ 1,647,500
Matures after one year through five years 105,527 1,245
Total $ 1,243,469 $ 1,648,745
XML 25 R73.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Financial instruments carried at fair value (asset position):    
Marketable securities $ 1,243,469 $ 1,648,745
Financial instruments carried at fair value (liability position):    
Long-term contingent consideration (176,500) 0
Recurring basis    
Financial instruments carried at fair value (asset position):    
Total financial assets 1,535,278 1,836,605
Financial instruments carried at fair value (liability position):    
Total financial liabilities (183,854) (448)
Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Total financial assets 1,065,569 1,410,155
Financial instruments carried at fair value (liability position):    
Total financial liabilities 0 0
Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Total financial assets 469,709 426,450
Financial instruments carried at fair value (liability position):    
Total financial liabilities (7,354) (448)
Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Total financial assets 0 0
Financial instruments carried at fair value (liability position):    
Total financial liabilities (176,500) 0
Corporate equity securities | Recurring basis    
Financial instruments carried at fair value (asset position):    
Marketable securities 282,084 167,323
Corporate equity securities | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Marketable securities 261,797 153,733
Corporate equity securities | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Marketable securities 20,287 13,590
Corporate equity securities | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Marketable securities 0 0
U.S. Treasury securities    
Financial instruments carried at fair value (asset position):    
Cash equivalents   5,966
U.S. Treasury securities | Recurring basis    
Financial instruments carried at fair value (asset position):    
Marketable securities 12,733 6,026
U.S. Treasury securities | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Marketable securities 12,733 6,026
U.S. Treasury securities | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Marketable securities 0 0
U.S. Treasury securities | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Marketable securities 0 0
Government-sponsored enterprise securities    
Financial instruments carried at fair value (asset position):    
Cash equivalents   7,123
Government-sponsored enterprise securities | Recurring basis    
Financial instruments carried at fair value (asset position):    
Marketable securities   10,704
Government-sponsored enterprise securities | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Marketable securities   10,704
Government-sponsored enterprise securities | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Marketable securities   0
Government-sponsored enterprise securities | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Marketable securities   0
Corporate debt securities | Recurring basis    
Financial instruments carried at fair value (asset position):    
Marketable securities 301,799 233,665
Corporate debt securities | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Marketable securities 0 0
Corporate debt securities | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Marketable securities 301,799 233,665
Corporate debt securities | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Marketable securities 0 0
Commercial paper    
Financial instruments carried at fair value (asset position):    
Cash equivalents 29,472 58,268
Commercial paper | Recurring basis    
Financial instruments carried at fair value (asset position):    
Marketable securities 102,356 100,390
Commercial paper | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Marketable securities 0 0
Commercial paper | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Marketable securities 102,356 100,390
Commercial paper | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Marketable securities 0 0
Money market funds | Recurring basis    
Financial instruments carried at fair value (asset position):    
Cash equivalents 791,039 1,226,603
Money market funds | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Cash equivalents 791,039 1,226,603
Money market funds | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Cash equivalents 0 0
Money market funds | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Cash equivalents 0 0
Corporate debt securities | Recurring basis    
Financial instruments carried at fair value (asset position):    
Cash equivalents 6,070  
Corporate debt securities | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Cash equivalents 0  
Corporate debt securities | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Cash equivalents 6,070  
Corporate debt securities | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Cash equivalents 0  
U.S. Treasury securities | Recurring basis    
Financial instruments carried at fair value (asset position):    
Cash equivalents   5,966
U.S. Treasury securities | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Cash equivalents   5,966
U.S. Treasury securities | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Cash equivalents   0
U.S. Treasury securities | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Cash equivalents   0
Government-sponsored enterprise securities | Recurring basis    
Financial instruments carried at fair value (asset position):    
Cash equivalents   7,123
Government-sponsored enterprise securities | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Cash equivalents   7,123
Government-sponsored enterprise securities | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Cash equivalents   0
Government-sponsored enterprise securities | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Cash equivalents   0
Commercial paper | Recurring basis    
Financial instruments carried at fair value (asset position):    
Cash equivalents 29,472 58,268
Commercial paper | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Cash equivalents 0 0
Commercial paper | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Cash equivalents 29,472 58,268
Commercial paper | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Cash equivalents 0 0
Other assets | Foreign currency forward contracts | Recurring basis    
Financial instruments carried at fair value (asset position):    
Foreign currency forward contracts   1,514
Other assets | Foreign currency forward contracts | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Foreign currency forward contracts   0
Other assets | Foreign currency forward contracts | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Foreign currency forward contracts   1,514
Other assets | Foreign currency forward contracts | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Foreign currency forward contracts   0
Prepaid expenses and other current assets | Foreign currency forward contracts | Recurring basis    
Financial instruments carried at fair value (asset position):    
Foreign currency forward contracts 9,725 19,023
Prepaid expenses and other current assets | Foreign currency forward contracts | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Foreign currency forward contracts 0 0
Prepaid expenses and other current assets | Foreign currency forward contracts | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Foreign currency forward contracts 9,725 19,023
Prepaid expenses and other current assets | Foreign currency forward contracts | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Foreign currency forward contracts 0 0
Other current liabilities | Recurring basis    
Financial instruments carried at fair value (liability position):    
Long-term contingent consideration (176,500)  
Other current liabilities | Recurring basis | Level 1    
Financial instruments carried at fair value (liability position):    
Long-term contingent consideration 0  
Other current liabilities | Recurring basis | Level 2    
Financial instruments carried at fair value (liability position):    
Long-term contingent consideration 0  
Other current liabilities | Recurring basis | Level 3    
Financial instruments carried at fair value (liability position):    
Long-term contingent consideration (176,500)  
Other current liabilities | Foreign currency forward contracts | Recurring basis    
Financial instruments carried at fair value (liability position):    
Foreign currency forward contracts (5,533) (340)
Other current liabilities | Foreign currency forward contracts | Recurring basis | Level 1    
Financial instruments carried at fair value (liability position):    
Foreign currency forward contracts 0 0
Other current liabilities | Foreign currency forward contracts | Recurring basis | Level 2    
Financial instruments carried at fair value (liability position):    
Foreign currency forward contracts (5,533) (340)
Other current liabilities | Foreign currency forward contracts | Recurring basis | Level 3    
Financial instruments carried at fair value (liability position):    
Foreign currency forward contracts 0 0
Other long-term liabilities | Foreign currency forward contracts | Recurring basis    
Financial instruments carried at fair value (liability position):    
Foreign currency forward contracts (1,821) (108)
Other long-term liabilities | Foreign currency forward contracts | Recurring basis | Level 1    
Financial instruments carried at fair value (liability position):    
Foreign currency forward contracts 0 0
Other long-term liabilities | Foreign currency forward contracts | Recurring basis | Level 2    
Financial instruments carried at fair value (liability position):    
Foreign currency forward contracts (1,821) (108)
Other long-term liabilities | Foreign currency forward contracts | Recurring basis | Level 3    
Financial instruments carried at fair value (liability position):    
Foreign currency forward contracts $ 0 $ 0
XML 26 R83.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Hedging - Offsetting Derivatives (Details) - Foreign currency forward contracts - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Offsetting Derivative Assets [Abstract]    
Gross Amounts Recognized $ 9,725 $ 20,537
Gross Amounts Offset 0 0
Gross Amounts Presented 9,725 20,537
Gross Amounts Not Offset (7,354) (448)
Legal Offset 2,371 20,089
Offsetting Derivative Liabilities [Abstract]    
Gross Amounts Recognized (7,354) (448)
Gross Amounts Offset 0 0
Gross Amounts Presented (7,354) (448)
Gross Amounts Not Offset 7,354 448
Legal Offset $ 0 $ 0
XML 27 R112.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and Contingencies - Revolving Credit Facility (Details)
 1 Months Ended
Sep. 30, 2019
USD ($)
Line of Credit  
Line of Credit Facility [Line Items]  
Line of credit facility, current borrowing capacity $ 500,000,000.0
Line of credit facility, additional borrowing capacity 500,000,000.0
Debt covenant, minimum consolidated EBITDA 2.50
Letter of Credit  
Line of Credit Facility [Line Items]  
Line of credit facility, additional borrowing capacity $ 50,000,000.0
Minimum | Line of Credit  
Line of Credit Facility [Line Items]  
Debt covenant, consolidated leverage ratio 3.50
Minimum | Base Rate | Line of Credit  
Line of Credit Facility [Line Items]  
Interest rate (percent) 0.125%
Minimum | Eurodollar | Line of Credit  
Line of Credit Facility [Line Items]  
Interest rate (percent) 1.125%
Maximum | Line of Credit  
Line of Credit Facility [Line Items]  
Debt covenant, consolidated leverage ratio 4.00
Maximum | Base Rate | Line of Credit  
Line of Credit Facility [Line Items]  
Interest rate (percent) 0.50%
Maximum | Eurodollar | Line of Credit  
Line of Credit Facility [Line Items]  
Interest rate (percent) 1.50%
XML 28 R116.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Information - Significant Customers (Details) - Credit Concentration Risk
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenues, Gross | McKesson Corporation      
Concentration Risk [Line Items]      
Concentration risk percentage (less than for CVS/Caremark 2017 revenue) 17.00% 14.00% 10.00%
Revenues, Gross | Walgreen Co.      
Concentration Risk [Line Items]      
Concentration risk percentage (less than for CVS/Caremark 2017 revenue) 15.00% 20.00% 17.00%
Revenues, Gross | Accredo/Curascript      
Concentration Risk [Line Items]      
Concentration risk percentage (less than for CVS/Caremark 2017 revenue) 14.00% 14.00% 14.00%
Accounts Receivable | McKesson Corporation      
Concentration Risk [Line Items]      
Concentration risk percentage (less than for CVS/Caremark 2017 revenue) 22.00% 16.00%  
Accounts Receivable | Walgreen Co.      
Concentration Risk [Line Items]      
Concentration risk percentage (less than for CVS/Caremark 2017 revenue) 14.00% 16.00%  
Accounts Receivable | Accredo/Curascript      
Concentration Risk [Line Items]      
Concentration risk percentage (less than for CVS/Caremark 2017 revenue) 15.00% 10.00%  
XML 29 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Nature of Business and Accounting Policies - Restructuring Expenses (Details)
 12 Months Ended
Dec. 31, 2019
position
Research and development restructuring  
Restructuring Cost and Reserve [Line Items]  
Number of positions eliminated 70
XML 30 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Cash flows from operating activities:      
Net income $ 1,176,810 $ 2,087,103 $ 91,635
Adjustments to reconcile net income to net cash provided by operating activities:      
Stock-based compensation expense 360,489 325,047 293,236
Depreciation expense 106,941 72,420 61,397
Deferred income taxes (including benefit from valuation allowance release in 2018) 167,387 (1,512,325) (120,513)
Gains on equity securities (197,597) (2,558) 0
Increase in fair value of contingent consideration 4,459 0 0
Intangible asset impairment charges 0 29,000 255,340
Acquired in-process research and development 0 0 160,000
Deconsolidation of VIE 0 1,077 76,644
Other non-cash items, net 16,942 32,502 14,439
Changes in operating assets and liabilities:      
Accounts receivable, net (225,587) (108,152) (71,759)
Inventories (64,047) (31,965) (47,484)
Prepaid expenses and other assets 35,440 16,684 (111,063)
Accounts payable (22,785) 36,554 8,753
Accrued expenses 172,881 302,755 255,178
Other liabilities 37,997 22,144 (20,861)
Net cash provided by operating activities 1,569,330 1,270,286 844,942
Cash flows from investing activities:      
Payments to acquire businesses, net of cash acquired (1,154,212) 0 0
Purchases of available-for-sale debt securities (537,196) (431,918)  
Purchases of available-for-sale debt securities     (532,581)
Maturities of available-for-sale debt securities 475,924 431,576 369,214
Sale of equity securities 94,936 0 0
Expenditures for property and equipment (75,451) (95,524) (99,421)
Investment in equity securities (39,319) (83,471) 0
Investment in note receivable 0 (15,000) 0
Decrease in restricted cash due to deconsolidation of VIE   (7,896) (61,602)
Purchase of in-process research and development 0 0 (160,000)
Other investing activities 0 75 1,061
Net cash used in investing activities (1,235,318) (202,158) (483,329)
Cash flows from financing activities:      
Issuances of common stock under benefit plans 343,244 289,293 344,840
Repurchases of common stock (192,015) (350,043) 0
Payments on finance leases (39,185)    
Advance from collaborator 12,500 7,500 12,500
Proceeds related to capital lease and construction financing lease obligations 10,046 20,840 34,666
Repayments of advanced funding (5,866) (5,027) (4,266)
Payments on capital lease and construction financing lease obligations 0 (33,388) (19,336)
Payments on revolving credit facility 0 0 (300,000)
Other financing activities (1,951) (394) 0
Net cash provided by (used in) financing activities 126,773 (71,219) 68,404
Effect of changes in exchange rates on cash 1,643 (6,182) 5,802
Net increase in cash, cash equivalents and restricted cash 462,428 990,727 435,819
Cash, cash equivalents and restricted cash—beginning of period 2,658,253 1,667,526 1,231,707
Cash, cash equivalents and restricted cash—end of period 3,120,681 2,658,253 1,667,526
Supplemental disclosure of cash flow information:      
Cash paid for interest 55,554 66,458 68,696
Cash paid for income taxes 24,730 12,402 6,414
Capitalization of costs related to construction financing lease obligation 0 3,389 40,855
Issuances of common stock from employee benefit plans receivable $ 2,820 $ 86 $ 844
XML 31 R54.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Nature of Business and Accounting Policies - Equity Investments (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Jan. 01, 2019
Jan. 01, 2018
Jan. 01, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative effect adjustment for adoption of new accounting guidance     $ 40,310 $ (9,229) $ 0
Unrealized gains to other (expense) income, net $ 132,500 $ 2,600      
Accumulated Deficit          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative effect adjustment for adoption of new accounting guidance     $ 40,310 (33,349) $ 9,371
Accounting standards update 2016-01, financial instruments | Accumulated Deficit          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative effect adjustment for adoption of new accounting guidance       $ 25,100  
XML 32 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Statement of Comprehensive Income [Abstract]      
Unrealized holding gains (losses) on marketable securities, tax $ 0.0 $ 0.0 $ (2.7)
Unrealized (losses) gains on foreign currency forward contracts, tax $ 7.0    
Unrealized (losses) gains on foreign currency forward contracts, tax   $ (7.1) $ 3.4
XML 33 R58.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborative Arrangements - CRISPR Therapeutics AG (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jul. 31, 2019
Dec. 31, 2019
Sep. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Investment in collaborative partner, pursuant to convertible loan agreement       $ 63,300,000 $ 46,900,000 $ 8,700,000
CRISPR Therapeutics            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaborative funding   $ 30,000,000.0        
Collaborative arrangement development and regulatory potential milestone payments maximum $ 825,000,000.0     410,000,000.0    
Collaborative arrangement, development and commercialization rights potential maximum milestone payments     $ 175,000,000.0      
CTX001 Co-Co Agreement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaborative arrangement research and development expenses       $ 30,100,000 $ 19,700,000  
XML 34 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Additional Balance Sheet Detail (Tables)
 12 Months Ended
Dec. 31, 2019
Payables and Accruals [Abstract]  
Summary of Accrued expenses and other current liabilities
Accrued expenses consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Payroll and benefits
$
159,464

 
$
124,753

Research, development and commercial contract costs
105,663

 
115,300

Product revenue allowances
641,368

 
550,002

Royalty payable
98,578

 
101,108

Tax related accruals
72,293

 
43,281

Other
39,546

 
24,455

Total
$
1,116,912

 
$
958,899
Summary Other Current Liabilities
Other current liabilities consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Contract liabilities
$
62,332

 
$
24,870

Finance lease liabilities
30,293

 
5,271

Other
37,680

 
20,265

Total
$
130,305

 
$
50,406
Summary of Other Long Term Liabilities
Other long-term liabilities consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Advance from collaborator
$
88,762

 
$
82,573

Operating lease liabilities
84,292

 
—

Other
10,264

 
26,280

Total
$
183,318

 
$
108,853
XML 35 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accumulated Other Comprehensive Income (Loss) (Tables)
 12 Months Ended
Dec. 31, 2019
Equity [Abstract]  
Schedule of Reclassifications out of Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
 
 
 
Unrealized Holding Gains (Losses), Net of Tax
 
 
 
Foreign Currency Translation Adjustment
 
On Available-For-Sale Debt Securities
 
On Equity Securities
 
On Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2016
$
(7,862
)
 
$
(10
)
 
$
17,531

 
$
11,514

 
$
21,173

Other comprehensive (loss) income before reclassifications
(13,169
)
 
(584
)
 
7,538

 
(29,175
)
 
(35,390
)
Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
—

 
2,645

 
2,645

Net current period other comprehensive (loss) income
(13,169
)
 
(584
)
 
7,538

 
(26,530
)
 
(32,745
)
Balance at December 31, 2017
$
(21,031
)
 
$
(594
)
 
$
25,069

 
$
(15,016
)
 
$
(11,572
)
Other comprehensive income before reclassifications
8,855

 
58

 
—

 
25,664

 
34,577

Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
—

 
1,774

 
1,774

Net current period other comprehensive income
8,855

 
58

 
—

 
27,438

 
36,351

Amounts reclassified to accumulated deficit pursuant to adoption of new accounting standard
949

 
—

 
(25,069
)
 
—

 
(24,120
)
Balance as of December 31, 2018
$
(11,227
)
 
$
(536
)
 
$
—

 
$
12,422

 
$
659

Other comprehensive income before reclassifications
10,332

 
1,039

 
—

 
11,513

 
22,884

Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
—

 
(25,516
)
 
(25,516
)
Net current period other comprehensive income (loss)
10,332

 
1,039

 
—

 
(14,003
)
 
(2,632
)
Balance as of December 31, 2019
$
(895
)
 
$
503

 
$
—

 
$
(1,581
)
 
$
(1,973
)
XML 36 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions (Tables)
 12 Months Ended
Dec. 31, 2019
Business Combinations [Abstract]  
Schedule of business price consideration
The purchase price consisted of the following:
 
(in thousands)
Upfront payment (adjusted for customary working capital adjustments)
$
266,315

Fair value of contingent development and regulatory payments
172,041

Total purchase price
$
438,356
Schedule of purchase price assumed assets and liabilities
The Company allocated the purchase price to the following assets acquired and liabilities assumed:
 
October 10, 2019
 
(in thousands)
Cash and cash equivalents
$
29,331

Property and equipment, net
17,111

Goodwill
554,633

Intangible assets
387,000

Deferred tax liability
(54,160
)
Net other assets
2,849

Total purchase price
$
936,764


The Company allocated the purchase price to the following assets acquired and liabilities assumed:
 
July 16, 2019
 
(in thousands)
Cash and cash equivalents
$
19,535

Goodwill
397,141

Intangible asset
13,000

Net other assets
8,680

Total purchase price
$
438,356
XML 37 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings Per Share
 12 Months Ended
Dec. 31, 2019
Earnings Per Share [Abstract]  
Earnings Per Share
Earnings Per Share
Basic net income per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock, restricted stock units and performance-based restricted stock units, or “PSUs,” that have been issued but are not yet vested. Diluted net income per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.
The following table sets forth the computation of basic and diluted net income per share for the periods ended:
 
2019
 
2018
 
2017
 
(in thousands, except per share amounts)
Basic net income attributable to Vertex per common share calculation:
 
 
 
 
 
Net income attributable to Vertex common shareholders
$
1,176,810

 
$
2,096,896

 
$
263,484

Less: Undistributed earnings allocated to participating securities
—

 
(501
)
 
(293
)
Net income attributable to Vertex common shareholders—basic
$
1,176,810

 
$
2,096,395

 
$
263,191

 
 
 
 
 
 
Basic weighted-average common shares outstanding
256,728

 
254,292

 
248,858

Basic net income attributable to Vertex per common share
$
4.58

 
$
8.24

 
$
1.06

 
 
 
 
 
 
Diluted net income attributable to Vertex per common share calculation:
 
 
 
 
 
Net income attributable to Vertex common shareholders
$
1,176,810

 
$
2,096,896

 
$
263,484

Less: Undistributed earnings allocated to participating securities
—

 
(492
)
 
(288
)
Net income attributable to Vertex common shareholders—diluted
$
1,176,810

 
$
2,096,404

 
$
263,196

 
 
 
 
 
 
Weighted-average shares used to compute basic net income per common share
256,728

 
254,292

 
248,858

Effect of potentially dilutive securities:
 
 
 
 
 
Stock options
2,231

 
2,913

 
2,797

Restricted stock and restricted stock units (including PSUs)
1,700

 
1,963

 
1,542

Employee stock purchase program
14

 
17

 
28

Weighted-average shares used to compute diluted net income per common share
260,673

 
259,185

 
253,225

Diluted net income attributable to Vertex per common share
$
4.51

 
$
8.09

 
$
1.04


The Company did not include the securities in the following table in the computation of the net income per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period.
 
2019
 
2018
 
2017
 
(in thousands)
Stock options
2,833

 
2,217

 
3,554

Unvested restricted stock and restricted stock units (including PSUs)
6

 
5

 
411
XML 38 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Hedging
 12 Months Ended
Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Hedging Hedging
Foreign currency forward contracts - Designated as hedging instruments
The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company’s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from one to eighteen months. The Company recognizes realized gains and losses for the effective portion of such contracts in “Product revenues, net” in its consolidated statements of operations in the same period that it recognizes the product revenues that were impacted by the hedged foreign exchange rate changes.
The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company’s risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of December 31, 2019, all hedges were determined to be highly effective.
Prior to the adoption of ASU 2017-12 on January 1, 2019, the Company did not record any ineffectiveness related to its foreign currency forward contracts that were designated as hedging instruments in the years ended December 31, 2018 and 2017. ASU 2017-12 eliminated the requirement to separately measure and report hedge ineffectiveness.
The Company considers the impact of its counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of December 31, 2019 and December 31, 2018, credit risk did not change the fair value of the Company’s foreign currency forward contracts.
The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP:
 
As of December 31,
 
2019
 
2018
Foreign Currency
(in thousands)
Euro
$
501,197

 
$
335,179

Australian dollar
89,705

 
52,820

British pound sterling
87,032

 
73,460

Canadian dollar
50,452

 
43,759

Total foreign currency forward contracts
$
728,386

 
$
505,218


Foreign currency forward contracts - Not designated as hedging instruments
The Company also enters into foreign currency forward contracts with contractual maturities of less than one month that are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under GAAP. The Company recognizes realized gains and losses for such contracts in “Other income (expense), net” in its consolidated statements of operations each period. As of December 31, 2019, the notional amount of the Company’s outstanding foreign currency forward contracts where hedge accounting under GAAP is not applied was $412.1 million.
During the three years ended December 31, 2019, the Company recognized the following related to foreign currency forward contacts in its consolidated statements of operations:
 
December 31,
 
2019
 
2018
 
2017
 
(in thousands)
Designated as hedging instruments - Reclassified from AOCI
 
 
 
 
 
Product revenues, net
$
32,546

 
$
(1,252
)
 
$
768

Not designated as hedging instruments
 
 
 
 
 
Other income (expense), net
$
4,838

 
$
623

 
$
14,129

 
 
 
 
 
 
Total reported in the Consolidated Statement of Operations
 
 
 
 
 
Product revenues, net
$
4,160,726

 
$
3,038,325

 
$
2,165,480

Other income (expense), net
$
192,177

 
$
(790
)
 
$
(81,382
)

The following table summarizes the fair value of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on its consolidated balance sheets:
As of December 31, 2019
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid expenses and other current assets
 
$
9,725

 
Other current liabilities
 
$
(5,533
)
Other assets
 
—

 
Other long-term liabilities
 
(1,821
)
Total assets
 
$
9,725

 
Total liabilities
 
$
(7,354
)
As of December 31, 2018
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid expenses and other current assets
 
$
19,023

 
Other current liabilities
 
$
(340
)
Other assets
 
1,514

 
Other long-term liabilities
 
(108
)
Total assets
 
$
20,537

 
Total liabilities
 
$
(448
)

As of December 31, 2019, the Company expects amounts that are related to foreign exchange forward contracts designated as cash flow hedges under GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company’s consolidated balance sheets:
 
As of December 31, 2019
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
9,725

 
$
—

 
$
9,725

 
$
(7,354
)
 
$
2,371

Total liabilities
(7,354
)
 
—

 
(7,354
)
 
7,354

 
—

 
As of December 31, 2018
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
20,537

 
$
—

 
$
20,537

 
$
(448
)
 
$
20,089

Total liabilities
(448
)
 
—

 
(448
)
 
448

 
—
XML 39 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Additional Balance Sheet Detail
 12 Months Ended
Dec. 31, 2019
Payables and Accruals [Abstract]  
Additional Balance Sheet Detail
Additional Balance Sheet Detail
Accrued expenses consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Payroll and benefits
$
159,464

 
$
124,753

Research, development and commercial contract costs
105,663

 
115,300

Product revenue allowances
641,368

 
550,002

Royalty payable
98,578

 
101,108

Tax related accruals
72,293

 
43,281

Other
39,546

 
24,455

Total
$
1,116,912

 
$
958,899


Other current liabilities consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Contract liabilities
$
62,332

 
$
24,870

Finance lease liabilities
30,293

 
5,271

Other
37,680

 
20,265

Total
$
130,305

 
$
50,406


Other long-term liabilities consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Advance from collaborator
$
88,762

 
$
82,573

Operating lease liabilities
84,292

 
—

Other
10,264

 
26,280

Total
$
183,318

 
$
108,853
XML 40 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
The components of income (loss) before provision for (benefit from) income taxes during the three years ended December 31, 2019 consisted of the following:
 
2019
 
2018
 
2017
 
(in thousands)
United States
$
1,263,379

 
$
812,086

 
$
330,340

Foreign
131,540

 
(211,845
)
 
(346,029
)
Income (loss) before provision for (benefit from) income taxes
$
1,394,919

 
$
600,241

 
$
(15,689
)

The components of the provision for (benefit from) income taxes during the three years ended December 31, 2019 consisted of the following:
 
2019
 
2018
 
2017
 
(in thousands)
Current taxes:
 
 
 
 
 
Federal
$
—

 
$
772

 
$
11,559

Foreign
37,194

 
15,600

 
3,576

State
13,528

 
9,018

 
5,025

Total current taxes
50,722

 
25,390

 
20,160

Deferred taxes:
 
 
 
 
 
Federal
184,312

 
(1,105,053
)
 
(113,805
)
Foreign
(24,797
)
 
(364,919
)
 
(3,222
)
State
7,872

 
(42,280
)
 
(10,457
)
Total deferred taxes
167,387

 
(1,512,252
)
 
(127,484
)
Provision for (benefit from) income taxes
$
218,109

 
$
(1,486,862
)
 
$
(107,324
)

A reconciliation of the provision for (benefit from) income taxes as computed by applying the U.S. federal statutory rate of 21% for the years ended December 31, 2019 and 2018 and 35% for the year ended December 31, 2017 to the provision for (benefit from) income taxes is as follows:
 
2019
 
2018
 
2017
 
(in thousands)
Income (loss) before provision for (benefit from) income taxes
$
1,394,919

 
$
600,241

 
$
(15,689
)
 
 
 
 
 
 
Expected provision for (benefit from) income taxes
292,933

 
126,051

 
(5,491
)
State taxes, net of federal benefit
8,478

 
8,680

 
4,742

Foreign income tax rate differential
6,178

 
23,427

 
77,801

Tax credits
(59,459
)
 
(52,629
)
 
(58,204
)
Benefit from income taxes attributable to valuation allowances
(2,672
)
 
(1,563,169
)
 
(575,801
)
Permanent items
4,822

 
1,421

 
15,324

Tax rate change
—

 
—

 
575,192

Stock compensation (benefit) shortfalls and cancellations
(56,324
)
 
(49,044
)
 
(21,453
)
Officer’s compensation
10,666

 
8,310

 
6,501

Deconsolidation of VIE
—

 
(9,390
)
 
(126,183
)
Uncertain tax positions
14,070

 
15,431

 
—

Other
(583
)
 
4,050

 
248

Provision for (benefit from) income taxes
$
218,109

 
$
(1,486,862
)
 
$
(107,324
)

The Company is subject to U.S. federal, state, and foreign income taxes. The Company’s provision for income taxes in 2019 has increased compared to historical amounts due to the release of the Company’s valuation allowance on the majority of its NOLs and other deferred tax assets as of December 31, 2018. Starting in 2019, the Company began recording a provision for income taxes approximating statutory rates on its pre-tax income. The Company’s effective tax rate for 2019 is lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation and research and development tax credits partially offset by a change in the Company’s valuation allowance as well as the tax impact of officer compensation. Due to the Company's ability to offset its pre-tax income against previously benefited NOLs, the majority of its tax provision represents a non-cash expense until its NOLs have been fully utilized.
In 2019, the “Benefit from income taxes attributable to valuation allowances” in the tax rate reconciliation table above related to a release of a valuation allowance in the United Kingdom of $30.5 million related to the execution of a reimbursement agreement in France in November 2019, partially offset by an increase in the valuation allowance in the United States on state credits and NOLs. In 2018, the change in the “Benefit from income taxes attributable to valuation allowances” was primarily related to the release of the Company’s valuation allowances on the majority of its NOLs and other deferred tax assets related to the United States and the United Kingdom. In 2017, the “Benefit from income taxes attributable to valuation allowances” was primarily due to the utilization of NOLs in the United States and a decrease in the U.S. federal corporate tax rate from 35% to 21% partially offset by the adoption of ASU 2016-09.
In 2018 and 2017, “Deconsolidation of VIE” in the Company’s tax rate reconciliation above related to the impairments of VX-210 and Parion’s pulmonary ENaC platform, respectively, and the decreases in the Company’s fair value of the contingent payments to BioAxone and Parion associated with these deconsolidations, respectively. Please refer to Note K, “Intangible Assets and Goodwill,” for further information regarding these impairments.
The Company operates in foreign tax jurisdictions, which impose income taxes at different rates than the United States. The impact of these rate differences, which are primarily related to the Company’s operations in the United Kingdom, is included in the “Foreign income tax rate differential” in the Company’s tax rate reconciliation above. Other items that affected the Company’s tax rate reconciliation table were related to equity and executive compensation, research and development credits and Orphan Drug Credits during the three years ended December 31, 2019.
Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred taxes were as follows:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Deferred tax assets:
 
 
 
Net operating loss
$
512,256

 
$
882,014

Tax credit carryforwards
549,543

 
487,635

Intangible assets
275,290

 
241,775

Deferred revenues
18,833

 
19,311

Stock-based compensation
85,199

 
93,915

Accrued expenses
44,367

 
17,795

Finance lease liabilities
119,160

 
130,849

Operating lease assets
13,114

 
—

  Other
8,596

 
6,831

Gross deferred tax assets
1,626,358

 
1,880,125

Valuation allowance
(205,192
)
 
(168,491
)
Total deferred tax assets
1,421,166

 
1,711,634

Deferred tax liabilities:
 
 
 
Property and equipment
(101,235
)
 
(128,407
)
Acquired intangibles
(87,160
)
 
—

Deferred revenue
—

 
(73,357
)
Unrealized gain
(28,838
)
 
(10,198
)
Operating lease liabilities
(13,118
)
 
—

Net deferred tax assets
$
1,190,815

 
$
1,499,672


In 2019, the Company completed acquisitions of Semma and Exonics, resulting in the inclusion of these entities deferred tax bases into the Company’s consolidated deferred tax assets and deferred tax liabilities. As of the acquisition date, Semma’s deferred tax liabilities were $54.2 million. Exonics’ deferred tax assets were not material to the Company’s financial statements.
On a periodic basis, the Company reassesses the valuation allowance on its deferred income tax assets weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In the fourth quarter of 2018, the Company assessed the valuation allowance and considered positive evidence, including significant cumulative consolidated and U.S. income over the three years ended December 31, 2018, revenue growth, clinical trial data from the Company’s triple combination regimens, competitor clinical progress and expectations regarding future profitability, and negative evidence, including the potential impact of competition on the Company’s projections and cumulative losses in one of the jurisdictions. After assessing both the positive evidence and the negative evidence, the Company determined it was more likely than not that its deferred tax assets would be realized in the future and released the valuation allowance on the majority of its NOLs and other deferred tax assets as of December 31, 2018, resulting in a benefit from income taxes of $1.56 billion.  As of December 31, 2019, the Company maintained a valuation allowance of $205.2 million related primarily to U.S. state and foreign tax attributes.
As of December 31, 2019, the Company had NOL carryforwards of $1.5 billion, of which $1.3 billion were subject to expiration and $181.1 million had an indefinite carryforward period, and tax credits of $399.0 million for U.S. federal income tax purposes. As of December 31, 2019, the Company had NOL carryforwards of $903.7 million and tax credits of $161.7 million for U.S. state income tax purposes. These U.S. federal and state NOL carryforwards and tax credits expire at various dates through 2039 and may be used to offset future federal and state income tax liabilities, respectively. As of December 31, 2019, the Company had foreign net operating loss carryforwards of $896.9 million, including $16.0 million that were subject to expiration at various dates through 2039 and $880.9 million that had an indefinite carryforward period.
Unrecognized tax benefits during the three years ended December 31, 2019 were as follows:
 
2019
 
2018
 
2017
 
(in thousands)
Balance at beginning of the period
$
19,549

 
$
3,814

 
$
—

Increases related to current period tax positions
14,407

 
9,704

 
3,814

Increases related to prior period tax positions
598

 
6,031

 
—

Decreases related to prior period tax positions
(156
)
 
—

 
—

Settlement with Tax Authorities
(478
)
 
—

 
—

Balance at end of period
$
33,920

 
$
19,549

 
$
3,814


As of December 31, 2019, the Company has classified $13.4 million and $20.5 million of its unrecognized tax benefits as credits to “Deferred tax assets” and “Accrued expenses,” respectively, on its consolidated balance sheet.
The Company has reviewed the tax positions taken, or to be taken, in its tax returns for all tax years currently open to examination by a taxing authority. Unrecognized tax benefits represent the aggregate tax effect of differences between tax return positions and the benefits recognized in the financial statements. As of December 31, 2019 and 2018, the Company had $33.9 million and $19.5 million, respectively, of gross unrecognized tax benefits, which would affect the Company’s tax rate if recognized. As of December 31, 2017, the Company had $3.8 million of gross unrecognized tax benefits, which would not affect the Company’s tax rate if recognized. The Company does not expect that its unrecognized tax benefits will materially change within the next twelve months. The Company accrues interest and penalties related to unrecognized tax benefits as a component of its “Provision for (benefit from) income taxes.” As of December 31, 2019, no significant interest or penalties were accrued. The Company did not recognize any material interest or penalties related to uncertain tax positions during the three years ended December 31, 2019.
As of December 31, 2019, foreign earnings, which were not significant, have been retained indefinitely by the Company’s foreign subsidiaries for indefinite reinvestment. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company could be subject to withholding taxes payable to the various foreign countries.
The Company files U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States or any other major taxing jurisdiction for years before 2011, except where the Company has NOLs or tax credit carryforwards that originate before 2011. The Company has various income tax examinations ongoing at any time throughout the world. During the year ended December 31, 2019, the Company concluded tax examinations with Austria, Canada, Germany and Italy, with no material adjustments.
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Nature of Business and Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (“VIEs”). In 2017, the Company deconsolidated Parion Sciences, Inc. (“Parion”), a VIE the Company had consolidated since 2015. In 2018, the Company deconsolidated BioAxone Biosciences, Inc. (“BioAxone”), a VIE the Company had consolidated since 2014. As of December 31, 2019 and 2018, the Company did not have any consolidated VIEs. All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals. Please refer to Note R, “Segment Information,” for enterprise-wide disclosures regarding the Company’s revenues, major customers and long-lived assets by geographic area.
Use of Estimates
Use of Estimates
The preparation of consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these consolidated financial statements have been made in connection with (i) determining the transaction price of revenues, (ii) accounting for acquisitions, including intangible assets, goodwill and contingent consideration and (iii) evaluating deferred tax asset valuation allowances and the provision for income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Revenue Recognition
The Company makes significant estimates and judgments that materially affect its recognition of net product revenues. The Company adjusts its estimated rebates, chargebacks and discounts based on new information, including information regarding actual rebates, chargebacks and discounts for its products, as it becomes available. Claims by third-party payors for rebates, chargebacks and discounts frequently are submitted to the Company significantly after the related sales, potentially resulting in adjustments in the period in which the new information becomes known. The Company’s credits to product revenue related to prior period sales have not been significant and primarily related to rebates and discounts.
The Company excludes taxes collected from Customers relating to product sales and remitted to governmental authorities from revenues.
Contract Liabilities
The Company recorded contract liabilities of $62.3 million and $24.9 million as of December 31, 2019 and 2018, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement the Company can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees.  The Company defers a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. The Company’s product revenue contracts include performance obligations that are one year or less.
The Company’s contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as the Company’s fiscal year. In these markets the Company recognizes revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year. During the year ended December 31, 2019, the Company recorded $24.9 million of revenues that were recorded as contract liabilities at the beginning of the year.
French Early Access Programs
Pursuant to ASC 605, Revenue Recognition (“ASC 605”), which was applicable until December 31, 2017, the Company only recognized revenues from product sales if it determined that the price was fixed or determinable at the time of delivery. If the Company determined that the price was not fixed or determinable, it deferred the recognition of revenues. If the Company was able to determine that the price was fixed or determinable, it recognized the net product revenues associated with the units.
In 2015, the Company began distributing ORKAMBI through early access programs in France and remained engaged in reimbursement discussions with the French government until November 2019, when the Company reached an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs. From the time the Company began distributing ORKAMBI through early access programs in France, it expected the difference between the amounts collected based on the invoiced amount and the final amount for ORKAMBI distributed through early access programs would be returned to the French government. As a result, the Company has classified a refund liability related to the early access programs in France within “Accrued expenses” on its consolidated balance sheets.
Pursuant to the revenue recognition accounting guidance that was applicable until December 31, 2017, the Company’s ORKAMBI net product revenues for 2015, 2016 and 2017 did not include any net product revenues from sales of ORKAMBI in France because the price was not fixed or determinable at the time of delivery. Upon adopting ASC 606 in 2018, the Company recorded an $8.3 million cumulative effect adjustment to “Accumulated deficit” primarily related to shipments of ORKAMBI under the early access programs in France. The Company determined the amount of the adjustment based upon (i) the status of reimbursement discussions in France upon adoption, (ii) its estimate of the amount of consideration it expected to retain related to ORKAMBI sales in France that occurred on or prior to December 31, 2017 that would not be subject to a significant reversal in amounts recognized and (iii) recognition of costs previously deferred related to the ORKAMBI sales in France. Please refer to Recent Accounting Pronouncements included in this Note A, “Nature of Business and Accounting Policies,” below for more information regarding the revenue recognition guidance adopted as of January 1, 2018.
For ORKAMBI sales in France that occurred after December 31, 2017 under the early access programs, the Company recognized net product revenues based on a transaction price that reflected the Company’s estimate of consideration it expected to retain that would not be subject to a significant reversal in amounts recognized. When determining if variable consideration should be constrained, the Company considers whether there are factors outside its control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. The Company recognized ORKAMBI net product revenues from sales in France based on this estimate from the first quarter of 2018 through the third quarter of 2019. Upon reaching an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs in November 2019, the Company updated the transaction price to reflect the final amount for ORKAMBI distributed through early access programs. As a result, the Company recognized net product revenues of $155.8 million related to prior period ORKAMBI early access program sales in the fourth quarter of 2019 because the updated transaction price for ORKAMBI distributed through these programs exceeded the Company’s previous estimate of the consideration it expected to retain that would not be subject to a significant reversal in amounts recognized. Additionally, the Company’s refund liability no longer requires estimation as of December 31, 2019 and will be paid to the French government in 2020.
Collaborative and Royalty Revenues
The Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms of these agreements typically include payment to the Company related to one or more of the following: nonrefundable, upfront license fees; development and commercial milestones; funding of research and/or development activities; and royalties on net sales of licensed products. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaborator.
For each collaborative research, development and/or commercialization agreement that results in revenue, the Company identifies all material performance obligations, which may include a license to intellectual property and know-how, research and development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimate of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.
Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. In order to account for these agreements, the Company must develop assumptions that require judgment to determine the standalone selling price, which may include (i) the probability of obtaining marketing approval for the drug candidate, (ii) estimates regarding the timing of and the expected costs to develop and commercialize the drug candidate, (iii) estimates of future cash flows from potential product sales with respect to the drug candidate and (iv) appropriate discount and tax rates. Standalone selling prices used to perform the initial allocation are not updated after contract
inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.
Upfront License Fees: If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related nonrefundable, upfront license fees based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license.  For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.  The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Development and Regulatory Milestone Payments: Depending on facts and circumstances, the Company may conclude that it is appropriate to include certain milestones in the estimated transaction price or that it is appropriate to fully constrain the milestones. A milestone payment is included in the transaction price in the reporting period that the Company concludes that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods. This may result in revenues from certain milestones and a corresponding contract asset being recorded in a reporting period before the milestone is achieved. Milestone payments that have not been included in the transaction price to date are fully constrained until the Company concludes that their achievement is probable and that recognition of the related revenue will not result in a significant reversal in amounts recognized in future periods. The Company re-evaluates the probability of achievement of such development milestones and any related constraint each reporting period and adjusts its estimate of the overall transaction price, including the amount of collaborative revenue that it has recorded, if necessary. The Company has not recorded any significant development or regulatory milestone revenues the three years ended December 31, 2019.
Research and Development Activities/Transition Services: If the Company is entitled to reimbursement from its collaborators for specified research and development expenses, it accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as collaborative revenues or an offset to research and development expenses in accordance with the provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations.
Sales-based Milestone and Royalty Payments: The Company’s collaborators may be required to pay the Company sales-based milestones or royalties on future sales of commercial products.  The Company recognizes revenues related to sales-based milestone and royalties upon the later to occur of (i) achievement of the collaborator’s underlying sales or (ii) satisfaction of any performance obligation(s) related to these sales, in each case assuming the license to the Company’s intellectual property is deemed to be the predominant item to which the sales-based milestones and/or royalties relate. The Company has not recorded any sales-based milestones or royalties revenues during the three years ended December 31, 2019.
Revenue Recognition
Pursuant to Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. 
The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon delivery.
Product Revenues, Net
The Company sells its products principally to a limited number of specialty pharmacy and specialty distributors in the United States, which account for the largest portion of its total revenues, and makes international sales primarily to specialty distributors and retail chains, as well as hospitals and clinics, many of which are government-owned or supported (collectively, its “Customers”). The Company’s Customers in the United States subsequently resell the products to patients and health care providers. In accordance with ASC 606, the Company recognizes net product revenues from sales when the Customers obtain control of the Company’s products, which typically occurs upon delivery to the Customer. The Company’s payment terms are approximately 30 days in the United States and consistent with prevailing practice in international markets.
Revenues from product sales are recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from (a) invoice discounts for prompt payment and distribution fees, (b) government and private payor rebates, chargebacks, discounts and fees and (c) costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves are classified as reductions to “Accounts receivable, net” if payable to a Customer or “Accrued expenses” if payable to a third-party.  Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns.  The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.  Actual amounts of consideration ultimately received may differ from the Company’s estimates.  If actual results vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.
Invoice Discounts and Distribution Fees: The Company generally provides invoice discounts on product sales to its Customers for prompt payment and pays fees for distribution services, such as fees for certain data that Customers provide to the Company. The Company estimates that, based on its experience, its Customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.
Rebates, Chargebacks, Discounts and Fees: The Company contracts with government agencies (its “Third-party Payors”) so that products will be eligible for purchase by, or partial or full reimbursement from, such Third-party Payors. The Company estimates the rebates, chargebacks, discounts and fees it will provide to Third-party Payors and deducts
these estimated amounts from its gross product revenues at the time the revenues are recognized. For each product, the Company estimates the aggregate rebates, chargebacks and discounts that it will provide to Third-party Payors based upon (i) the Company’s contracts with these Third-party Payors, (ii) the government-mandated discounts and fees applicable to government-funded programs, (iii) information obtained from the Company’s Customers and other third-party data regarding the payor mix for such product and (iv) historical experience.
Other Incentives: Other incentives that the Company offers include co-pay mitigation rebates provided by the Company to commercially insured patients who have coverage and who reside in states that permit co-pay mitigation programs. Based upon the terms of the Company’s co-pay mitigation programs, the Company estimates average co-pay mitigation amounts for each of its products in order to establish appropriate accruals.
Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentration of credit risk consist principally of money market funds and marketable securities. The Company places these investments with highly rated financial institutions, and, by policy, limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company also maintains a foreign currency hedging program that includes foreign currency forward contracts with several counterparties. The Company has not experienced any credit losses related to these financial instruments and does not believe it is exposed to any significant credit risk related to these instruments.
The Company also is subject to credit risk from its accounts receivable related to its product sales and collaborators. The Company evaluates the creditworthiness of each of its customers and has determined that all of its material customers are
creditworthy. To date, the Company has not experienced significant losses with respect to the collection of its accounts receivable. The Company believes that its allowance for doubtful accounts was adequate at December 31, 2019.
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.
Marketable Securities
Marketable Securities
As of December 31, 2019, the Company’s marketable securities consisted of investments in available-for-sale debt securities, including government-sponsored enterprise securities, corporate debt securities and commercial paper, and corporate equity securities with readily determinable fair values. The Company classifies marketable securities available to fund current operations as current assets on its consolidated balance sheets. Marketable securities are classified as long-term assets on the consolidated balance sheets if (i) they have been in an unrealized loss position for longer than one year and (ii) the Company has the ability and intent to hold them (a) until the carrying value is recovered and (b) such holding period may be longer than one year. The Company’s marketable securities are stated at fair value. The fair value of these securities is based on quoted prices for identical or similar assets.
The Company records unrealized gains (losses) on available-for-sale debt securities as a component of “Accumulated other comprehensive (loss) income,” which is a separate component of shareholders’ equity on its consolidated balance sheet, until such gains and losses are realized.
Pursuant to the adoption of Accounting Standards Update (“ASU”) 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”) on January 1, 2018, the Company began recording changes in the fair value of its investments in corporate equity securities to “Other income (expense), net” in the Company’s consolidated statements of operations. Prior to its adoption of ASU 2016-01 in 2018, the Company recorded changes in the fair value of its investments in corporate equity securities to “Accumulated other comprehensive (loss) income.”
The Company reviews investments in marketable debt securities for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers whether it has an intent to sell, or whether it is more likely than not that the Company will be required to sell, the investment before recovery of the investment’s amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company’s investment policy, the severity and the duration of the impairment and changes in value subsequent to year-end. If a decline in the fair value is considered other-than-temporary, based on available evidence, the unrealized loss is transferred from other comprehensive income (loss) to the consolidated statements of operations.
Realized gains and losses are determined using the specific identification method and are included in “Other income (expense), net” in the consolidated statements of operations.
Accounts Receivable
Accounts Receivable
The Company deducts invoice discounts for prompt payment and fees for distribution services from its accounts receivable based on its experience that the Company’s Customers will earn these discounts and fees. The Company’s estimates for its allowance for doubtful accounts, which have not been significant to date, are determined based on existing contractual payment terms and historical payment patterns.
Stock-based Compensation Expense
Stock-based Compensation Expense
The Company expenses the fair value of employee stock options and other forms of stock-based employee compensation over the associated employee service period on a straight-line basis. Stock-based compensation expense is determined based on the fair value of the award at the grant date and is adjusted each period to reflect actual forfeitures and the outcomes of certain performance conditions.
For awards with performance conditions in which the award does not vest unless the performance condition is met, the Company recognizes expense if, and to the extent that, the Company estimates that achievement of the performance condition is probable. If the Company concludes that vesting is probable, it recognizes expense from the date it reaches this conclusion through the estimated vesting date.
The Company provides to employees who have rendered a certain number of years’ to the Company and meet certain age requirements, partial or full acceleration of vesting of these equity awards, subject to certain conditions including a notification period, upon a termination of employment other than for cause. Approximately 5% of the Company’s employees were eligible for partial or full acceleration of any of their equity awards as of December 31, 2019. The Company recognizes stock-based compensation expense related to these awards over a service period reflecting qualified employees’ eligibility for partial or full acceleration of vesting.
Research and Development Expenses
Research and Development Expenses
The Company expenses as incurred all research and development expenses, including amounts funded by research and development collaborations. The Company capitalizes nonrefundable advance payments made by the Company for research and development activities and expenses the payments as the related goods are delivered or the related services are performed.
Research and development expenses are comprised of costs incurred by the Company in performing research and development activities, including salary and benefits; stock-based compensation expense; outsourced services and other direct expenses, including clinical trial and pharmaceutical development costs; collaboration and asset acquisition payments; expenses associated with drug supplies that are not being capitalized; and infrastructure costs, including facilities costs and depreciation expense.
Inventories
Inventories
The Company values its inventories at the lower-of-cost or net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and writes down any excess and obsolete inventories to their net realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases are capitalized and recorded upon sale in “Cost of sales” in the consolidated statements of operations. Shipping and handling costs incurred for product shipments are recorded as incurred in “Cost of sales” in the consolidated statements of operations.
The Company capitalizes inventories produced in preparation for initiating sales of a drug candidate when the related drug candidate is considered to have a high likelihood of regulatory approval and the related costs are expected to be recoverable through sales of the inventories. In determining whether or not to capitalize such inventories, the Company evaluates, among other factors, information regarding the drug candidate’s safety and efficacy, the status of regulatory submissions and communications with regulatory authorities and the outlook for commercial sales, including the existence of current or anticipated competitive drugs and the availability of reimbursement. In addition, the Company evaluates risks associated with manufacturing the drug candidate and the remaining shelf-life of the inventories.
Property and Equipment
Property and Equipment
Property and equipment are recorded at cost. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset, generally seven to ten years for furniture and equipment, three to five years for computers and software and for leasehold improvements, the shorter of the useful life of the improvements or the estimated remaining life of the associated lease. Maintenance and repairs to an asset that do not improve or extend its life are charged to operations. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the Company’s consolidated statements of operations. The Company performs an assessment of the fair value of the assets if indicators of impairment are identified during a reporting period and records the assets at the lower of the net book value or the fair value of the assets.
The Company capitalizes internal costs incurred to develop software for internal use during the application development stage. Amortization of capitalized internally developed software costs is recorded in depreciation expense over the useful life of the related asset.
Leases
Leases
The Company adopted ASU 2016-02, Leases (Topic 842) (“ASC 842”) as of January 1, 2019. Under ASC 842, the Company determines whether the arrangement contains a lease at the inception of an arrangement. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its consolidated balance sheet and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12 months.
A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.
Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease.
The Company does not separate lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.
Finance leases are recorded in “Property and equipment, net,” “Other current liabilities” and “Long-term finance lease liabilities” and operating leases are recorded in “Other assets,” “Other current liabilities” and “Other long-term liabilities” on the Company’s consolidated balance sheet.
Prior to the adoption of ASC 842 on January 1, 2019, the Company applied build-to-suit accounting and was the deemed owner of its leased corporate headquarters in Boston and research site in San Diego, for which it was recognizing depreciation expense over the buildings’ useful lives and imputed interest on the corresponding construction financing lease obligations. The Company also recorded leases for equipment as capital leases pursuant to the accounting guidance that was effective until December 31, 2018.
The assets and liabilities associated with the Company’s capital lease agreements were recorded at the present value of the minimum lease payments at the inception of the lease agreement. The assets were depreciated using the straight-line method over the shorter of the useful life of the related asset or the remaining life of the associated lease. Amortization of capital lease assets was included in depreciation expense.
Income Taxes
Income Taxes
Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax bases of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. On a periodic basis, the Company reassesses the valuation allowance on its deferred income tax assets weighing positive and negative evidence to assess the recoverability of its deferred tax assets. The Company includes, among other things, its recent financial performance and its future projections in this periodic assessment.
The Company records liabilities related to uncertain tax positions by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company does not believe any such uncertain tax positions currently pending will have a material adverse effect on its consolidated financial statements.
Variable Interest Entities
Variable Interest Entities
The Company reviews each collaboration agreement pursuant to which it licenses assets owned by a collaborator in order to determine whether or not it has a variable interest via the license agreement with the collaborator and if the variable interest is a variable interest in the collaborator as a whole. In assessing whether the Company has a variable interest in the collaborator as a whole, the Company considers and makes judgments regarding the purpose and design of the entity, the value of the licensed assets to the collaborator, the value of the collaborator’s total assets and the significant activities of the collaborator. If the Company has a variable interest in the collaborator as a whole, the Company assesses whether or not the Company is the primary beneficiary of that VIE based on a number of factors, including (i) which party has the power to direct the activities that most significantly affect the VIE’s economic performance, (ii) the parties’ contractual rights and responsibilities pursuant to the collaboration agreement and (iii) which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE. If the Company determines it is the primary beneficiary of a VIE at the onset of the collaboration agreement, the collaboration is treated as a business combination and the Company consolidates the financial statements of the VIE into the Company’s consolidated financial statements. On a quarterly basis, the Company evaluates whether it continues to be the primary beneficiary of any consolidated VIEs. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, it deconsolidates the VIE in the period that the determination is made.
Fair Value of In-process Research and Development Assets and Contingent Payments
Fair Value of In-process Research and Development Assets and Contingent Payments
The present-value models the Company uses to estimate the fair values of in-process research and development assets and contingent payments pursuant to collaborations and acquisitions incorporate significant assumptions.
The Company’s discounted cash flow models pertaining to in-process research and development assets include: (i) assumptions regarding the probability of obtaining marketing approval for a drug candidate; (ii) the timing of and the expected costs to develop and commercialize a drug candidate; (iii) estimates of future cash flows from potential product sales with respect to a drug candidate; and (iv) appropriate discount and tax rates.
The Company bases its estimates of the probability of achieving the milestones relevant to the fair value of contingent payments, which could include milestone, royalty and option payments, on industry data. Estimates included in the discounted cash flow models pertaining to contingent payments also include: (i) estimate regarding the timing of the relevant development and commercial milestones and royalties, (ii) and appropriate discount rates.
In-process Research and Development Assets
In-process Research and Development Assets
The Company records the fair value of in-process research and development assets as of the transaction date of a business combination. Each of these assets is accounted for as an indefinite-lived intangible asset and is maintained on the Company’s consolidated balance sheet until either the project underlying it is completed or the asset becomes impaired. If the asset becomes impaired or is abandoned, the carrying value of the related intangible asset is written down to its fair value, and an impairment charge is recorded in the period in which the impairment occurs. If a project is completed, the carrying
value of the related intangible asset is amortized as a part of “Cost of sales” over the remaining estimated life of the asset beginning in the period in which the project is completed. In-process research and development assets are tested for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist.
In-process research and development that is acquired in a transaction that does not qualify as a business combination under GAAP and that does not have an alternative future use is expensed in the period in which it is acquired.
Goodwill
Goodwill
The difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is allocated to goodwill. Goodwill is evaluated for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist.
Deconsolidation and Discounted Operations
Deconsolidation
Upon the occurrence of certain events and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its subsidiaries, including consolidated VIEs. If the Company determines it no longer has a controlling interest, the subsidiary is deconsolidated. The Company records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i) the aggregate of (a) the fair value of any consideration received, (b) the fair value of any retained noncontrolling investment in the former subsidiary and (c) the carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii) the carrying amount of the former subsidiary’s assets and liabilities.
Discontinued Operations
The Company assesses whether a deconsolidation is required to be presented as discontinued operations in its consolidated financial statements on the deconsolidation date. This assessment is based on whether or not the deconsolidation represents a strategic shift that has or will have a major effect on the Company’s operations or financial results. If the Company determines that a deconsolidation requires presentation as a discontinued operation on the deconsolidation date, or at any point during the one year period following such date, it will present the former subsidiary as a discontinued operation in current and comparative period financial statements.
Embedded Derivatives and Hedging Activities
Embedded Derivatives
Embedded derivatives are required to be bifurcated from the host instruments and recorded at fair value if the derivatives are not clearly and closely related to the host instruments on the date of issuance. The Company did not have any material embedded derivatives that required bifurcation recorded on its consolidated balance sheets as of December 31, 2019 and 2018, respectively.
Hedging Activities
The Company recognizes the fair value of hedging instruments that are designated and qualify as hedging instruments pursuant to GAAP, foreign currency forward contracts, as either assets or liabilities on the consolidated balance sheets. Changes in the fair value of these instruments are recorded each period in “Accumulated other comprehensive (loss) income” as unrealized gains and losses until the forecasted underlying transaction occurs. Unrealized gains and losses on these foreign currency forward contracts are included in “Prepaid expenses and other current assets” or “Other assets,” and “Other current liabilities” or “Other long-term liabilities,” respectively, on the Company’s consolidated balance sheets depending on the remaining period until their contractual maturity. Realized gains and losses for the effective portion of such contracts are recognized in “Product revenues, net” in the consolidated statement of operations in the same period that it recognizes the product revenues that were impacted by the hedged foreign exchange rate changes. The Company classifies the cash flows from hedging instruments in the same category as the cash flows from the hedged items.
Certain of the Company’s hedging instruments are subject to master netting arrangements to reduce the risk arising from such transactions with its counterparties. The Company presents unrealized gains and losses on its foreign currency forward contracts on a gross basis within its consolidated balance sheets.
The Company also enters into foreign currency forward contracts with contractual maturities of less than one month designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities including intercompany balances. These contracts are not designated as hedging instruments pursuant to GAAP. Realized gains and losses for such contracts are recognized in “Other income (expense), net” in the consolidated statement of operations each period.
Restructuring Expenses
Restructuring Expenses
The Company records costs and liabilities associated with exit and disposal activities based on estimates of fair value in the period the liabilities are incurred. The Company’s exit and disposal activities have primarily been associated with the Company’s facilities, but also have included the termination of employees in some cases. The Company’s initial estimate of its liabilities for net ongoing costs associated with its facility obligations are recorded at fair value on the cease use date. On a quarterly basis, the Company evaluates and adjusts these liabilities as appropriate for changes in circumstances. Changes to the Company’s estimate of these liabilities are recorded as additional restructuring expenses (credits). These costs are included in “Restructuring (income) expenses” on the Company’s consolidated statements of operations.
Comprehensive Income (Loss)
Comprehensive Income (Loss)
Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss), which includes foreign currency translation adjustments and unrealized gains and losses on foreign currency forward contracts and certain marketable securities. For purposes of comprehensive income (loss) disclosures, the Company records provisions for or benefits from income taxes related to the unrealized gains and losses on foreign currency forward contracts and certain marketable securities. The Company does not record provisions for or benefits from income taxes related to the cumulative translation adjustment, as the Company intends to permanently reinvest undistributed earnings in its foreign subsidiaries.
Foreign Currency Translation and Transactions
Foreign Currency Translation and Transactions
The majority of the Company’s operations occur in entities that have the U.S. dollar denominated as their functional currency. The assets and liabilities of the Company’s entities with functional currencies other than the U.S. dollar are translated into U.S. dollars at rates of exchange in effect at the end of the year. Revenue and expense amounts for these entities are translated using the average exchange rates for the period. Net unrealized gains and losses resulting from foreign currency translation are included in “Accumulated other comprehensive (loss) income.” Net foreign currency exchange transaction losses, which are included in “Other income (expense), net” on the Company’s consolidated statement of operations
Net Loss Per Share Attributable to Vertex Common Stockholders
Net Loss Per Share Attributable to Vertex Common Shareholders
Basic and diluted net loss per share attributable to Vertex common shareholders are presented in conformity with the two-class method required for participating securities. Under the two-class method, earnings are allocated to (i) Vertex common shares, excluding unvested restricted stock, and (ii) participating securities, based on their respective weighted-average shares outstanding for the period. Shares of unvested restricted stock granted under the Company’s Amended and Restated 2006 Stock and Option Plan have the non-forfeitable right to receive dividends on an equal basis with other outstanding common stock. As a result, these unvested shares of restricted stock are considered participating securities under the two-class method. Potentially dilutive shares result from the assumed exercise of outstanding stock options (the proceeds of which are then assumed to have been used to repurchase outstanding stock using the treasury stock method).
Basic net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.
Recently Adopted/Issued Accounting Standards
Recently Adopted Accounting Standards
Leases
In 2016, the Financial Accounting Standards Board (“FASB”) issued ASC 842, which amends a number of aspects of lease accounting and requires entities to recognize right-of-use assets and liabilities on the balance sheet. ASC 842 became effective on January 1, 2019.
Until December 31, 2018, the Company applied build-to-suit accounting and was the deemed owner of its leased corporate headquarters in Boston and research site in San Diego, for which it was recognizing depreciation expense over the buildings’ useful lives and imputed interest on the corresponding construction financing lease obligations. Under the amended guidance that became effective January 1, 2019, the Company accounts for these buildings as finance leases, resulting in increased depreciation expense over the respective lease terms of approximately 15 years, which are significantly shorter than the buildings’ useful lives of 40 years. The amended guidance also results in a reduction in imputed interest expense in the initial years of each finance lease term.
In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”), which offered a transition option to entities adopting ASC 842. Under ASU 2018-11, entities could elect to apply ASC 842 using a modified-retrospective adoption approach resulting in a cumulative effect adjustment to accumulated deficit at the beginning of the year in which the new lease standard is adopted, rather than adjustments to the earliest comparative period presented in their financial statements. The Company adopted ASC 842 using the modified-retrospective method. As of January 1, 2019, the Company recorded a cumulative effect adjustment to increase its “Accumulated deficit” by $40.3 million related to the adjustments to its build-to-suit leases described in the previous paragraph.
The Company elected the package of transition practical expedients for leases that commenced prior to January 1, 2019, allowing it not to reassess (i) whether any expired or existing contracts contain leases, (ii) the lease classification for any expired or existing leases and (iii) the initial indirect costs for any existing leases.
Additionally, the Company recorded, upon adoption of ASC 842 on January 1, 2019, operating lease assets of $61.7 million and corresponding liabilities of $71.9 million related to its real estate leases that are not treated as finance leases under ASC 842. The difference between these assets and liabilities was primarily attributable to prepaid or accrued lease payments. The Company also reclassified amounts that were recorded as “Capital lease obligations, current portion” and “Capital lease obligations, excluding current portion” as of December 31, 2018 to “Other current liabilities” and “Long-term finance lease liabilities,” respectively, on January 1, 2019. These adjustments had no impact on the Company’s consolidated statement of operations and had no impact on the Company’s accumulated deficit.
The cumulative effect of applying ASC 842 on the Company’s consolidated balance sheet as of January 1, 2019 was as follows:
 
Balance as of
 
 
 
Balance as of
 
December 31, 2018 ^
 
Adjustments
 
January 1, 2019
Assets
(in thousands)
Prepaid expenses and other current assets
$
140,819

 
$
(2,930
)
 
$
137,889

Property and equipment, net
812,005

 
(53,920
)
 
758,085

Deferred tax assets
1,499,672

 
11,236

 
1,510,908

Other assets
—

 
61,674

 
61,674

Total assets
$
6,245,898

 
$
16,060

 
$
6,261,958

Liabilities and Shareholders’ Equity
 
 
 
 
 
Capital lease obligations, current portion
$
9,817

 
$
(9,817
)
 
$
—

Other current liabilities
40,589

 
34,304

 
74,893

Capital lease obligations, excluding current portion
19,658

 
(19,658
)
 
—

Construction financing lease obligation, excluding current portion
561,892

 
(561,892
)
 
—

Long-term finance lease liabilities
—

 
569,487

 
569,487

Other long-term liabilities
26,280

 
43,946

 
70,226

Accumulated deficit
(2,989,478
)
 
(40,310
)
 
(3,029,788
)
Total liabilities and shareholders’ equity
$
6,245,898

 
$
16,060

 
$
6,261,958

^ As reported in the Company’s 2018 Annual Report on Form 10-K.

“Other assets” and “Other long-term liabilities” in the table above relate primarily to the Company’s operating leases. Please refer to Note M, “Leases,” for further information regarding the Company’s leases as well as certain disclosures required by ASC 842.
Derivatives and Hedging
In 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815) (“ASU 2017-12”), which helps simplify certain aspects of hedge accounting and enables entities to more accurately present their risk management activities in their financial statements. ASU 2017-12 became effective January 1, 2019. The adoption of ASU 2017-12 did not have a significant effect on the Company’s consolidated financial statements.
Revenue Recognition
In 2014, the FASB issued ASC 606. The new guidance became effective January 1, 2018. ASC 606 applies a more principles-based approach to recognizing revenue. Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted ASC 606 on January 1, 2018 using the modified-retrospective adoption method for all contracts that were not completed as of the date of adoption. Under the modified-retrospective method, the Company recognized the cumulative effect of applying the standard within “Accumulated deficit” on its consolidated balance sheet as of January 1, 2018.
For all reporting periods, the Company has not disclosed the value of unsatisfied performance obligations for all product revenue contracts with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. 
Based on the Company’s review of existing customer contracts as of January 1, 2018, it concluded that the only significant impact that the adoption of ASC 606 had on its financial statements related to shipments of ORKAMBI under early access programs in France. Prior to the adoption of ASC 606, the Company did not recognize revenue on the proceeds received from sales of ORKAMBI under early access programs in France because the price was not fixed or determinable based on the status of ongoing pricing discussions. As of January 1, 2018, the Company recorded a cumulative effect
adjustment to its accumulated deficit of $8.3 million related to the adoption of ASC 606, which primarily represented the Company’s estimated amount of consideration it expected to retain related to these shipments that would not be subject to a significant reversal in amounts recognized, net of costs previously deferred related to these shipments. Please refer to “Product Revenues, Net” above for further information related to the impact of the new revenue recognition on these sales.
The impact of adoption on the Company’s consolidated statement of operations for the year ended December 31, 2018 was as follows:
 
Year Ended December 31, 2018
 
As Reported
under ASC 606
 
Balances
without Adoption of ASC 606
 
Effect of Change
Higher/(Lower)
 
(in thousands)
Product revenues, net
$
3,038,325

 
$
3,019,484

 
$
18,841

Cost of sales
409,539

 
402,925

 
6,614

Income from operations
635,150

 
622,923

 
12,227

Net income attributable to Vertex
$
2,096,896

 
$
2,084,669

 
$
12,227

 
 
 
 
 
 
Amounts per share attributable to Vertex common shareholders:
 
 
 
 
 
Net income:
 
 
 
 
 
Basic
$
8.24

 
$
8.20

 
$
0.04

Diluted
$
8.09

 
$
8.04

 
$
0.05


ASC 606 did not have an aggregate impact on the Company’s net cash provided by operating activities, but resulted in offsetting changes in certain assets and liabilities presented within net cash provided by operating activities in the Company’s consolidated statement of cash flows.
Equity Investments
In 2016, the FASB issued ASU 2016-01, which amended guidance related to the recording of financial assets and financial liabilities. Under ASU 2016-01, equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of an investee) are measured at fair value with changes in fair value recognized in net income (loss). However, an entity has the option to measure equity investments without readily determinable fair values at (i) fair value or (ii) cost adjusted for changes in observable prices minus impairment. Changes in measurement under either alternative are recognized in net income (loss). ASU 2016-01 became effective January 1, 2018 and required the modified-retrospective adoption method. As of January 1, 2018, the Company held publicly traded equity investments and equity investments accounted for under the cost method. As a result, in 2018, the Company recorded a $25.1 million cumulative effect adjustment to “Accumulated deficit” related to its publicly traded equity investments equal to the unrealized gain, net of tax, that was recorded in “Accumulated other comprehensive (loss) income” as of December 31, 2017. The adoption of ASU 2016-01 had no effect on the Company’s equity investments accounted for under the cost method because the original cost basis of these investments was recorded on the Company’s consolidated balance sheet as of December 31, 2017. In 2019 and 2018, the Company recorded net unrealized gains of $132.5 million and $2.6 million, respectively, to “Other income (expense), net” in its consolidated statement of operations related to the change in fair value of its equity investments.
Intra-Entity Transfers
In 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”), which removes the previous exception in GAAP prohibiting an entity from recognizing current and deferred income tax expenses or benefits related to the transfer of assets, other than inventory, within the consolidated entity. The exception to defer the recognition of any tax impact on the transfer of inventory within the consolidated entity until it is sold to a third party remains unaffected. ASU 2016-16 became effective January 1, 2018. In 2018, upon adoption of ASU 2016-16, the Company recorded a deferred tax asset and corresponding full valuation allowance of $204.7 million equal to the unamortized cost of
intellectual property rights transferred to the United Kingdom in 2014 multiplied by an appropriate statutory rate. There was no cumulative effect adjustment to “Accumulated deficit” using the modified-retrospective adoption method.
Goodwill
In 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) (“ASU 2017-04”) related to measurements of goodwill. ASU 2017-04 modifies the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value, which eliminates Step 2 from the goodwill impairment test. An entity would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to the related reporting unit. The Company early adopted ASU 2017-04 and utilized this approach for annual and interim goodwill impairment tests conducted after January 1, 2018. The adoption of ASU 2017-04 did not have a significant effect on the Company’s consolidated financial statements.
Cash Flows - Restricted Cash
In 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) Restricted Cash (“ASU 2016-18”), which requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and restricted cash. Therefore, amounts described as restricted cash should be included with cash and cash equivalents when reconciling the beginning of period and end of period amounts shown on the statement of cash flows.  ASU 2016-18 became effective January 1, 2018 and was effective on a retrospective basis. The cash, cash equivalents and restricted cash balances for the years ended December 31, 2019 through 2016, which are presented in the Company’s consolidated statements of cash flows subsequent to the adoption of ASU 2016-18, consisted of the following:
 
As of December 31,
 
2019
 
2018
 
2017
 
2016
 
(in thousands)
Cash and cash equivalents
$
3,109,322

 
$
2,650,134

 
$
1,665,412

 
$
1,183,945

Prepaid expenses and other current assets
8,004

 
4,910

 
2,114

 
47,762

Other assets
3,355

 
3,209

 
—

 
—

Cash, cash equivalents and restricted cash per statement of cash flows
$
3,120,681

 
$
2,658,253

 
$
1,667,526

 
$
1,231,707


The Company’s restricted cash, if any, is included in “Prepaid expenses and other current assets” and “Other assets” in its consolidated balance sheets. As of December 31, 2017 and 2016, the Company recorded BioAxone’s cash and cash equivalents as “Prepaid expenses and other current assets” because the Company did not have any interest in or control over BioAxone’s cash and cash equivalents.
Stock-Based Compensation - Improvements
In 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”), which simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 became effective January 1, 2017. ASU 2016-09 eliminated the requirement that excess tax benefits were realized as a reduction in current taxes payable before the associated tax benefit could be recognized as an increase in additional paid-in capital. This created a deferred tax asset of $410.8 million relating to federal and state net operating losses (“NOLs”) that were fully reserved by an equal increase in the Company’s valuation allowance as of January 1, 2017. The Company recorded deferred tax assets of $404.7 million relating to federal NOLs and $6.1 million relating to state NOLs, both of which were offset by a full valuation allowance. Upon adoption, the Company also elected to change its accounting policy to account for forfeitures of options and awards as they occur. The change was applied on a modified-retrospective basis with a cumulative effect adjustment to increase “Accumulated deficit” by $9.4 million as of January 1, 2017. This change also resulted in an increase to the deferred tax asset of $3.4 million, which was offset by a full valuation allowance. As a result, there was no cumulative effect adjustment to accumulated deficit related to income taxes. The provisions related to the recognition of excess tax benefits in the Company’s consolidated statement of
operations and classification in the consolidated statement of cash flows were adopted prospectively, and as such, the prior periods were not retrospectively adjusted.
Recently Issued Accounting Standards
Internal-Use Software
In 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”), which clarifies the accounting for implementation costs in cloud computing arrangements.  ASU 2018-15 was effective on January 1, 2020. The Company expects the adoption of ASU 2018-15 will result in an insignificant amount of additional assets recorded on its consolidated balance sheet.
Fair Value Measurement
In 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which modifies the disclosure requirements for fair value measurements. ASU 2018-13 was effective on January 1, 2020. The Company expects the adoption of ASU 2018-13 will result in additional disclosures related to its assets and liabilities that are valued based on Level 3 inputs.
Credit Losses
In 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 was effective on January 1, 2020. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on its consolidated financial statements.
XML 42 R107.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Components of Income and Provision for (Benefit from) Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Components of income (loss) before provision for (benefit from) income taxes                      
United States                 $ 1,263,379 $ 812,086 $ 330,340
Foreign                 131,540 (211,845) (346,029)
Income (loss) before provision for (benefit from) income taxes $ 676,950 $ 70,666 $ 327,138 $ 320,165 $ 32,497 $ 136,511 $ 216,591 $ 214,642 1,394,919 600,241 (15,689)
Current taxes:                      
Federal                 0 772 11,559
Foreign                 37,194 15,600 3,576
State                 13,528 9,018 5,025
Total current taxes                 50,722 25,390 20,160
Deferred taxes:                      
Federal                 184,312 (1,105,053) (113,805)
Foreign                 (24,797) (364,919) (3,222)
State                 7,872 (42,280) (10,457)
Total deferred taxes                 167,387 (1,512,252) (127,484)
Provision for (benefit from) income taxes $ 93,716 $ 13,148 $ 59,711 $ 51,534 $ (1,492,599) $ 8,055 $ 10,341 $ (12,659) $ 218,109 $ (1,486,862) $ (107,324)
XML 43 R103.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Common Stock, Preferred Stock and Equity Plans - Performance-based RSUs (PSUs) (Details) - Performance-based RSUs - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Potential awards, percent of target shares, minimum 0.00%    
Potential awards, percent of target shares, maximum 200.00%    
Restricted stock vested in period, total fair value $ 73.3 $ 23.2 $ 1.3
Restricted stock and Restricted Stock Units      
Beginning of the period (in shares) 759    
Granted (in shares) 449    
Vested (in shares) (403)    
Cancelled (in shares) (71)    
End of the period (in shares) 734 759  
Restricted stock and Restricted Stock Units, weighted-average grant-date fair value      
Weighted-average grant-date fair value, as of the beginning of the period (usd per share) $ 110.50    
Weighted average fair value (usd per share) 183.48    
Weighted-average grant-date fair value, vested (usd per share) 109.23    
Weighted-average grant-date fair value, cancelled (usd per share) 104.61    
Weighted-average grant-date fair value, as of the end of the period (usd per share) $ 143.21 $ 110.50  
Tranche one      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Percent of awards in tranche 50.00%    
Performance period 1 year    
Vesting period 3 years    
Tranche two      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Percent of awards in tranche 50.00%    
Performance period 3 years    
Vesting period 3 years    
XML 44 R92.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Maturities of Operating and Financing Lease Liabilities (Details)
$ in Thousands
Dec. 31, 2019
USD ($)
Finance Leases  
2020 $ 84,264
2021 89,440
2022 87,092
2023 85,257
2024 90,802
Thereafter 425,251
Total lease payments 862,106
Less: amount representing interest (284,735)
Present value of lease liabilities 577,371
Operating Leases  
2020 14,598
2021 12,907
2022 12,610
2023 12,451
2024 11,488
Thereafter 51,251
Total lease payments 115,305
Less: amount representing interest (19,509)
Present value of lease liabilities 95,796
Total  
2020 98,862
2021 102,347
2022 99,702
2023 97,708
2024 102,290
Thereafter 476,502
Total lease payments 977,411
Less: amount representing interest 304,244
Present value of lease liabilities $ 673,167
XML 45 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborative Arrangements - Aggregate VIE Financial Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2017
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]                        
Provision for (benefit from) income taxes $ 93,716 $ 13,148 $ 59,711 $ 51,534 $ (1,492,599) $ 8,055 $ 10,341 $ (12,659)   $ 218,109 $ (1,486,862) $ (107,324)
(Increase) decrease in fair value of contingent payments $ (1,500) $ (2,959) $ 0 $ 0           (4,459) 0 0
Net loss attributable to noncontrolling interest         $ 25,431 $ 290 $ 1,110 $ (17,038)   $ 0 9,793 171,849
Parion Sciences, Inc                        
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]                        
Provision for (benefit from) income taxes                 $ (126,200)      
(Increase) decrease in fair value of contingent payments                 $ 69,600      
BioAxone Biosciences, Inc                        
Schedule of Collaborative Arrangement Agreements [Line Items]                        
Up-front payment                     10,000  
Variable Interest Entity, Primary Beneficiary                        
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]                        
Loss attributable to noncontrolling interest before benefit from income taxes and changes in fair value of contingent payments                     31,191 223,379
Provision for (benefit from) income taxes                     (3,668) (114,090)
(Increase) decrease in fair value of contingent payments                     (17,730) 62,560
Net loss attributable to noncontrolling interest                     $ 9,793 171,849
Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc                        
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]                        
Provision for (benefit from) income taxes                       $ 14,800
XML 46 R66.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions - Exonics Therapeutics - Additional Information (Details) - Exonics Therapeutics
$ in Thousands
Jul. 16, 2019
USD ($)
Business Acquisition [Line Items]  
Payments to acquire businesses $ 245,000
Future payments to acquire businesses 70,000
Acquisition related development and regulatory potential milestone payments maximum 728,000
Total purchase price 438,356
Non Compensatory  
Business Acquisition [Line Items]  
Acquisition related development and regulatory potential milestone payments maximum 678,300
Compensatory  
Business Acquisition [Line Items]  
Acquisition related development and regulatory potential milestone payments maximum $ 49,700
XML 47 R96.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Capital Leases (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
Leases [Abstract]  
2019 $ 10,770
2020 7,282
2021 5,649
2022 3,300
2023 1,974
Thereafter 3,085
Total payments 32,060
Less: amount representing interest (2,585)
Present value of payments $ 29,475
XML 48 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Nature of Business and Accounting Policies - Property and Equipment (Details)
 12 Months Ended
Dec. 31, 2019
Furniture and equipment | Minimum  
Property, Plant and Equipment [Line Items]  
Property and equipment useful life 7 years
Furniture and equipment | Maximum  
Property, Plant and Equipment [Line Items]  
Property and equipment useful life 10 years
Computers and software | Minimum  
Property, Plant and Equipment [Line Items]  
Property and equipment useful life 3 years
Computers and software | Maximum  
Property, Plant and Equipment [Line Items]  
Property and equipment useful life 5 years
XML 49 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Quarterly Financial Data (unaudited) (Tables)
 12 Months Ended
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]  
Schedule of quarterly financial data
The following tables set forth the Company’s quarterly financial data for the two years ended December 31, 2019:
 
Three Months Ended
 
March 31,
2019
 
June 30,
2019
 
September 30,
2019
 
December 31,
2019
 
(in thousands, except per share amounts)
Revenues:
 
 
 
 
 
 
 
Product revenues, net (1)
$
857,253

 
$
940,380

 
$
949,828

 
$
1,413,265

Collaborative and royalty revenues
1,182

 
913

 
—

 
—

Total revenues
858,435

 
941,293

 
949,828

 
1,413,265

Costs and expenses:
 
 
 
 
 
 
 
Cost of sales
95,092

 
135,740

 
131,914

 
185,012

Research and development expenses (2)
339,490

 
379,091

 
555,948

 
480,011

Sales, general and administrative expenses
147,045

 
156,502

 
159,674

 
195,277

Change in fair value of contingent consideration
—

 
—

 
2,959

 
1,500

Total costs and expenses
581,627

 
671,333

 
850,495

 
861,800

Income from operations
276,808

 
269,960

 
99,333

 
551,465

Interest income
15,615

 
18,076

 
17,628

 
12,359

Interest expense
(14,868
)
 
(14,837
)
 
(14,548
)
 
(14,249
)
Other income (expense), net (3)
42,610

 
53,939

 
(31,747
)
 
127,375

Income before provision for income taxes
320,165

 
327,138

 
70,666

 
676,950

Provision for income taxes (4)
51,534

 
59,711

 
13,148

 
93,716

Net income attributable to Vertex
$
268,631

 
$
267,427

 
$
57,518

 
$
583,234

 
 
 
 
 
 
 
 
Amounts per share attributable to Vertex common shareholders:
 
 
 
 
 
 
 
Net income:
 
 
 
 
 
 
 
    Basic
$
1.05

 
$
1.04

 
$
0.22

 
$
2.26

    Diluted
$
1.03

 
$
1.03

 
$
0.22

 
$
2.23

Shares used in per share calculations:
 
 
 
 
 
 
 
    Basic
255,695

 
256,154

 
256,946

 
258,003

    Diluted
260,175

 
259,822

 
260,473

 
262,108

 
Three Months Ended
 
March 31,
2018
 
June 30,
2018
 
September 30,
2018
 
December 31,
2018
 
(in thousands, except per share amounts)
Revenues:
 
 
 
 
 
 
 
Product revenues, net
$
637,729

 
$
749,912

 
$
782,511

 
$
868,173

Collaborative and royalty revenues
3,070

 
2,245

 
2,024

 
1,933

Total revenues
640,799

 
752,157

 
784,535

 
870,106

Costs and expenses:
 
 
 
 
 
 
 
Cost of sales
71,613

 
104,382

 
111,255

 
122,289

Research and development expenses (2)
310,553

 
337,532

 
330,510

 
437,881

Sales, general and administrative expenses
129,808

 
137,303

 
137,295

 
153,210

Restructuring (income) expenses
(76
)
 
62

 
(174
)
 
4

Intangible asset impairment charge
—

 
—

 
—

 
29,000

Total costs and expenses
511,898

 
579,279

 
578,886

 
742,384

Income from operations
128,901

 
172,878

 
205,649

 
127,722

Interest income
5,789

 
8,049

 
10,543

 
13,971

Interest expense
(16,886
)
 
(18,155
)
 
(18,686
)
 
(18,744
)
Other income (expense), net (3)
96,838

 
53,819

 
(60,995
)
 
(90,452
)
Income before (benefit from) provision for income taxes
214,642

 
216,591

 
136,511

 
32,497

(Benefit from) provision for income taxes (4)
(12,659
)
 
10,341

 
8,055

 
(1,492,599
)
Net income
227,301

 
206,250

 
128,456

 
1,525,096

(Income) loss attributable to noncontrolling interest (5)
(17,038
)
 
1,110

 
290

 
25,431

Net income attributable to Vertex
$
210,263

 
$
207,360

 
$
128,746

 
$
1,550,527

 
 
 
 
 
 
 
 
Amounts per share attributable to Vertex common shareholders:
 
 
 
 
 
 
 
Net income:
 
 
 
 
 
 
 
    Basic
$
0.83

 
$
0.82

 
$
0.51

 
$
6.08

    Diluted
$
0.81

 
$
0.80

 
$
0.50

 
$
5.97

Shares used in per share calculations:
 
 
 
 
 
 
 
    Basic
253,231

 
254,135

 
254,905

 
254,868

    Diluted
258,526

 
258,584

 
259,788

 
259,812


1.
In the fourth quarter of 2019, the Company updated its transaction price and recognized net product revenues of $155.8 million related to prior period ORKAMBI sales upon reaching a reimbursement agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs. See Note A, “Nature of Business and Accounting Policies.”
2.
In the third quarter of 2019, the Company incurred research and development expenses of $175.0 million related to its CRISPR DMD/DM1 Agreement. In the fourth quarter of 2018, the Company incurred research and development expenses of $95.0 million to related license agreements with Merck KGaA, Darmstadt, Germany, and Arbor. See Note B, “Collaborative Arrangements.”
3.
In 2019 and 2018, “Other income (expense), net” was primarily related to changes in the fair value of the Company’s equity investment in CRISPR. See Note F, “Marketable Securities and Equity Investments.”
4.
In the fourth quarter of 2018, the Company released the valuation allowance on the majority of its NOLs and other deferred tax assets as of December 31, 2018 resulting in a benefit from income taxes of $1.56 billion. Starting in 2019, the Company began recording a provision for income taxes approximating statutory rates on its pre-tax income. See Note P, “Income Taxes.”
5.
In 2018, the Company had a noncontrolling interest in BioAxone, which it consolidated as a VIE until December 31, 2018. Following the deconsolidation of BioAxone as of December 31, 2018, the Company did not have a noncontrolling interest in any entities in 2019. See Note B, “Collaborative Arrangements.”
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Common Stock, Preferred Stock and Equity Plans (Tables)
 12 Months Ended
Dec. 31, 2019
Equity [Abstract]  
Schedule of stock and stock equity plans The following table contains information about the Company’s equity plans:
 
 
 
 
 
 
As of December 31, 2019
Title of Plan
 
Group Eligible
 
Type of Award
Granted
 
Awards
Outstanding
 
Additional Awards
Authorized for
Grant
2013 Stock and Option Plan
 
Employees, Non-employee Directors and Consultants
 
NSO,
RS, RSU and PSU
 
9,577,268

 
15,778,703

2006 Stock and Option Plan
 
Employees, Non-employee Directors and Consultants
 
NSO,
RS and RSU
 
651,842

 
—

 
 
 
 
Total
 
10,229,110

 
15,778,703
Outstanding and vested options
The following table summarizes information related to the outstanding and exercisable options during the year ended December 31, 2019:
 
Stock Options
 
Weighted-average
Exercise Price
 
Weighted-average
Remaining
Contractual Life
 
Aggregate Intrinsic
Value
 
(in thousands)
 
(per share)
 
(in years)
 
(in thousands)
Outstanding at December 31, 2018
8,551

 
$
111.46

 
 
 
 
Granted
1,521

 
$
184.50

 
 
 
 
Exercised
(3,327
)
 
$
95.57

 
 
 
 
Forfeited
(467
)
 
$
146.59

 
 
 
 
Expired
(6
)
 
$
182.96

 
 
 
 
Outstanding at December 31, 2019
6,272

 
$
134.92

 
7.12
 
$
522,740

Exercisable at December 31, 2019
3,333

 
$
114.15

 
6.06
 
$
346,943
Stock options outstanding and exercisable
The following table summarizes information about stock options outstanding and exercisable at December 31, 2019:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
 
Weighted-average
Remaining
Contractual Life
 
Weighted-average
Exercise Price
 
Number
Exercisable
 
Weighted-average
Exercise Price
 
 
(in thousands)
 
(in years)
 
(per share)
 
(in thousands)
 
(per share)
$29.07–$40.00
 
108

 
1.58
 
$
37.62

 
108

 
$
37.62

$40.01–$60.00
 
277

 
2.55
 
$
49.69

 
277

 
$
49.69

$60.01–$80.00
 
140

 
4.31
 
$
74.55

 
136

 
$
74.53

$80.01–$100.00
 
1,670

 
6.25
 
$
89.42

 
1144

 
$
90.10

$100.01–$120.00
 
243

 
5.11
 
$
109.23

 
241

 
$
109.17

$120.01–$140.00
 
454

 
5.67
 
$
129.77

 
447

 
$
129.85

$140.01–$160.00
 
1,036

 
8.10
 
$
155.50

 
383

 
$
155.39

$160.01–$180.00
 
720

 
8.46
 
$
168.04

 
233

 
$
164.48

$180.01–$189.38
 
1,624

 
8.90
 
$
185.41

 
364

 
$
184.85

Total
 
6,272

 
7.12
 
$
134.92

 
3,333

 
$
114.15
Restricted stock and restricted stock units activity
The following table summarizes the restricted stock unit and restricted stock activity of the Company during the year ended December 31, 2019:
 
Restricted Stock Units (excluding PSUs)
 
Restricted Stock
 
Number of Shares
 
Weighted-average
Grant-date
Fair Value
 
Number of Units
 
Weighted-average
Grant-date
Fair Value
 
(in thousands)
 
(per share)
 
(in thousands)
 
(per share)
Unvested at December 31, 2018
2,717

 
$
140.10

 
480

 
$
104.91

Granted
1,717

 
$
181.87

 
—

 
$
—

Vested
(974
)
 
$
133.15

 
(375
)
 
$
108.23

Cancelled
(329
)
 
$
149.83

 
(13
)
 
$
100.79

Unvested at December 31, 2019
3,131

 
$
163.61

 
92

 
$
91.97
PSU activity
The following table summarizes the PSU activity of the Company during the year ended December 31, 2019:
 
Performance-Based RSU
 
Number of Units
 
Weighted-average
Grant-date
Fair Value
 
(in thousands)
 
(per share)
Unvested at December 31, 2018 (1)
759

 
$
110.50

Granted (2)
449

 
$
183.48

Vested
(403
)
 
$
109.23

Cancelled
(71
)
 
$
104.61

Unvested at December 31, 2019
734

 
$
143.21

 
 
 
 
(1) “Unvested” represents the Company’s PSUs at target to the extent performance has not been certified plus the actual number of shares that continue to be subject to service conditions for which the performance has been achieved and certified.
(2) “Granted” represents (i) the target number of shares issuable for grants during 2019 and (ii) any change in the number of shares issuable pursuant to outstanding PSUs based on performance certification during 2019.
Shares issued under Employee Stock Purchase Plan
In 2019, the following shares were issued to employees under the ESPP:
 
Year Ended December 31, 2019
 
(in thousands,
except per share amount)
Number of shares
202,693

Average price paid per share
$
138.18
XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Nature of Business and Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Schedule of New Accounting Pronouncements and Changes in Accounting Principles
The cumulative effect of applying ASC 842 on the Company’s consolidated balance sheet as of January 1, 2019 was as follows:
 
Balance as of
 
 
 
Balance as of
 
December 31, 2018 ^
 
Adjustments
 
January 1, 2019
Assets
(in thousands)
Prepaid expenses and other current assets
$
140,819

 
$
(2,930
)
 
$
137,889

Property and equipment, net
812,005

 
(53,920
)
 
758,085

Deferred tax assets
1,499,672

 
11,236

 
1,510,908

Other assets
—

 
61,674

 
61,674

Total assets
$
6,245,898

 
$
16,060

 
$
6,261,958

Liabilities and Shareholders’ Equity
 
 
 
 
 
Capital lease obligations, current portion
$
9,817

 
$
(9,817
)
 
$
—

Other current liabilities
40,589

 
34,304

 
74,893

Capital lease obligations, excluding current portion
19,658

 
(19,658
)
 
—

Construction financing lease obligation, excluding current portion
561,892

 
(561,892
)
 
—

Long-term finance lease liabilities
—

 
569,487

 
569,487

Other long-term liabilities
26,280

 
43,946

 
70,226

Accumulated deficit
(2,989,478
)
 
(40,310
)
 
(3,029,788
)
Total liabilities and shareholders’ equity
$
6,245,898

 
$
16,060

 
$
6,261,958

^ As reported in the Company’s 2018 Annual Report on Form 10-K.

The impact of adoption on the Company’s consolidated statement of operations for the year ended December 31, 2018 was as follows:
 
Year Ended December 31, 2018
 
As Reported
under ASC 606
 
Balances
without Adoption of ASC 606
 
Effect of Change
Higher/(Lower)
 
(in thousands)
Product revenues, net
$
3,038,325

 
$
3,019,484

 
$
18,841

Cost of sales
409,539

 
402,925

 
6,614

Income from operations
635,150

 
622,923

 
12,227

Net income attributable to Vertex
$
2,096,896

 
$
2,084,669

 
$
12,227

 
 
 
 
 
 
Amounts per share attributable to Vertex common shareholders:
 
 
 
 
 
Net income:
 
 
 
 
 
Basic
$
8.24

 
$
8.20

 
$
0.04

Diluted
$
8.09

 
$
8.04

 
$
0.05
Schedule of Cash and Cash Equivalents The cash, cash equivalents and restricted cash balances for the years ended December 31, 2019 through 2016, which are presented in the Company’s consolidated statements of cash flows subsequent to the adoption of ASU 2016-18, consisted of the following:
 
As of December 31,
 
2019
 
2018
 
2017
 
2016
 
(in thousands)
Cash and cash equivalents
$
3,109,322

 
$
2,650,134

 
$
1,665,412

 
$
1,183,945

Prepaid expenses and other current assets
8,004

 
4,910

 
2,114

 
47,762

Other assets
3,355

 
3,209

 
—

 
—

Cash, cash equivalents and restricted cash per statement of cash flows
$
3,120,681

 
$
2,658,253

 
$
1,667,526

 
$
1,231,707
XML 54 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases
 12 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Leases
Leases
Finance Leases
The Company’s finance lease assets and liabilities primarily relate to its corporate headquarters in Boston and research site in San Diego (the “Buildings”). These Buildings are classified as finance leases because the present value of the sum of the lease payments associated with the Buildings exceeds substantially all of the fair value of the Buildings. The Company also has outstanding finance leases for equipment.
Prior to the adoption of ASC 842 on January 1, 2019, the Company was deemed for accounting purposes to be the owner of the Buildings during their construction periods and recorded project construction costs incurred by its landlords. Upon completion of the Buildings, the Company determined that the underlying leases did not meet the criteria for “sale-leaseback” treatment. Accordingly, the Company depreciated the Buildings over 40 years and recorded interest expense associated with the financing obligations for the Buildings. The Company bifurcated the lease payments pursuant to the Buildings into (i) a portion that was allocated to the Buildings and (ii) a portion that is allocated to the land on which the Buildings were constructed. The portion of the lease obligations allocated to the land was treated as an operating lease.
Pursuant to ASC 842, the Company adjusted the amounts recorded on its consolidated balance sheet as of January 1, 2019 for the Buildings to reflect the present value of the lease payments over the remaining lease term related to the Buildings. The finance lease assets associated with the Buildings are amortized to depreciation expense using the straight-line method over the remaining lease term, which is significantly shorter than the Buildings’ useful lives. The Company continues to record interest expense associated with the finance lease liabilities for the Buildings.
Corporate Headquarters
In 2011, the Company entered into two lease agreements, pursuant to which the Company leases approximately 1.1 million square feet of office and laboratory space in two buildings in Boston, Massachusetts for a term of 15 years. Base rent payments commenced in December 2013, and will continue through December 2028. The Company utilizes this initial period as its lease term. The Company has an option to extend the lease term for an additional ten years.
San Diego Lease
In 2015, the Company entered into a lease agreement pursuant to which the Company leases approximately 170,000 square feet of office and laboratory space in San Diego, California for a term of 16 years. Base rent payments commenced in the second quarter of 2019, and will continue through May 2034. The Company utilizes this initial period as its lease term. The Company has an option to extend the lease term for up to two additional five-year terms. The Company placed this building into service in the second quarter of 2018.
Operating Leases
The Company’s operating leases relate to its real estate leases that are not classified as finance leases.
Aggregate Lease Information Related to the Application of ASC 842
The following information is disclosed in accordance with ASC 842, which became effective January 1, 2019. The components of lease cost recorded in the Company’s consolidated statement of operations were as follows:
 
2019
 
 
Operating lease cost
$
11,972

Finance lease cost
 
Amortization of leased assets
49,778

Interest on lease liabilities
52,839

Variable lease cost
27,997

Sublease income
(6,391
)
Net lease cost
$
136,195


The Company’s variable lease cost during 2019 primarily related to operating expenses, taxes and insurance associated with its finance leases. The Company’s sublease income during 2019 primarily related to subleases for an insignificant portion of the Company’s corporate headquarters.
The Company’s leases are included on its consolidated balance sheets as follows:
 
As of December 31, 2019
 
As of December 31, 2018 ^
 
(in thousands)
Finance leases
 
 
 
Property and equipment, net
$
445,336

 
$
640,952

Total finance lease assets
$
445,336

 
$
640,952

 
 
 
 
Capital lease obligations, current portion
$
—

 
$
9,817

Other current liabilities
38,795

 
5,271

Capital lease obligations, excluding current portion
—

 
19,658

Construction financing lease obligation, excluding current portion
—

 
561,892

Long-term finance lease liabilities
538,576

 
—

Total finance lease liabilities
$
577,371

 
$
596,638

 
 
 
 
Operating leases
 
 
 
Other assets
$
88,202

 
$
—

Total operating lease assets
$
88,202

 
$
—

 
 
 
 
Other current liabilities
$
11,504

 
$
—

Other long-term liabilities
84,292

 
—

Total operating lease liabilities
$
95,796

 
$
—

^ As reported in the Company’s 2018 Annual Report on Form 10-K.

Maturities of the Company’s finance and operating lease liabilities in accordance with ASC 842 as of December 31, 2019 were as follows:
Year
 
Finance Leases
 
Operating Leases
 
Total
 
 
(in thousands)
2020
 
$
84,264

 
$
14,598

 
$
98,862

2021
 
89,440

 
12,907

 
102,347

2022
 
87,092

 
12,610

 
99,702

2023
 
85,257

 
12,451

 
97,708

2024
 
90,802

 
11,488

 
102,290

Thereafter
 
425,251

 
51,251

 
476,502

Total lease payments
 
862,106

 
115,305

 
977,411

Less: amount representing interest
 
(284,735
)
 
(19,509
)
 
(304,244
)
Present value of lease liabilities
 
$
577,371

 
$
95,796

 
$
673,167


The weighted-average remaining lease terms and discount rates related to the Company’s leases were as follows:
 
As of December 31, 2019
Weighted-average remaining lease term (in years)
 
Finance leases
9.74

Operating leases
9.70

 
 
Weighted-average discount rate
 
Finance leases
9.04
%
Operating leases
3.75
%

Supplemental cash flow information related to the Company’s leases was as follows:
 
December 31, 2019
 
(in thousands)
Cash paid for amounts included in the measurement of lease liabilities:
 
Operating cash flows from operating leases
$
10,650

Operating cash flows from finance leases
$
50,527

Financing cash flows from finance leases
$
39,185

 
 
Right-of-use assets obtained in exchange for lease obligations
 
Operating leases *
$
34,605

Finance leases
$
—

* Includes $33.7 million acquired in 2019 pursuant to the Company’s acquisitions of Semma and Exonics.

Additional Lease Information Related to the Application of ASC 840
The following information is disclosed in accordance with ASC 840, Leases (Topic 840) (“ASC 840”), which was applicable until December 31, 2018. As of December 31, 2018, future minimum commitments under the Company’s real estate leases with initial terms of more than one year were as follows:
Year
 
Fan Pier
Leases
 
Other
Leases
 
Total Lease
Commitments
 
 
(in thousands)
2019
 
$
66,540

 
$
18,531

 
$
85,071

2020
 
72,589

 
23,397

 
95,986

2021
 
72,589

 
21,656

 
94,245

2022
 
72,589

 
21,172

 
93,761

2023
 
72,589

 
21,482

 
94,071

Thereafter
 
389,855

 
185,336

 
575,191

Total minimum lease payments
 
$
746,751

 
$
291,574

 
$
1,038,325


As of December 31, 2018, the Company’s total sublease income to be received related to its facility leases was $6.2 million. During 2018 and 2017, rental expenses were $17.3 million and $19.2 million, respectively.
The capital leases, which were related to equipment and leasehold improvements, bore interest at rates ranging from less than 1% to 6% per year. The Company’s capital lease amortization was included in depreciation expense during 2018 and 2017. The following table set forth the Company’s future minimum payments due under capital leases as of December 31, 2018:
Year
 
(in thousands)
2019
 
$
10,770

2020
 
7,282

2021
 
5,649

2022
 
3,300

2023
 
1,974

Thereafter
 
3,085

Total payments
 
32,060

Less: amount representing interest
 
(2,585
)
Present value of payments
 
$
29,475
Leases
Leases
Finance Leases
The Company’s finance lease assets and liabilities primarily relate to its corporate headquarters in Boston and research site in San Diego (the “Buildings”). These Buildings are classified as finance leases because the present value of the sum of the lease payments associated with the Buildings exceeds substantially all of the fair value of the Buildings. The Company also has outstanding finance leases for equipment.
Prior to the adoption of ASC 842 on January 1, 2019, the Company was deemed for accounting purposes to be the owner of the Buildings during their construction periods and recorded project construction costs incurred by its landlords. Upon completion of the Buildings, the Company determined that the underlying leases did not meet the criteria for “sale-leaseback” treatment. Accordingly, the Company depreciated the Buildings over 40 years and recorded interest expense associated with the financing obligations for the Buildings. The Company bifurcated the lease payments pursuant to the Buildings into (i) a portion that was allocated to the Buildings and (ii) a portion that is allocated to the land on which the Buildings were constructed. The portion of the lease obligations allocated to the land was treated as an operating lease.
Pursuant to ASC 842, the Company adjusted the amounts recorded on its consolidated balance sheet as of January 1, 2019 for the Buildings to reflect the present value of the lease payments over the remaining lease term related to the Buildings. The finance lease assets associated with the Buildings are amortized to depreciation expense using the straight-line method over the remaining lease term, which is significantly shorter than the Buildings’ useful lives. The Company continues to record interest expense associated with the finance lease liabilities for the Buildings.
Corporate Headquarters
In 2011, the Company entered into two lease agreements, pursuant to which the Company leases approximately 1.1 million square feet of office and laboratory space in two buildings in Boston, Massachusetts for a term of 15 years. Base rent payments commenced in December 2013, and will continue through December 2028. The Company utilizes this initial period as its lease term. The Company has an option to extend the lease term for an additional ten years.
San Diego Lease
In 2015, the Company entered into a lease agreement pursuant to which the Company leases approximately 170,000 square feet of office and laboratory space in San Diego, California for a term of 16 years. Base rent payments commenced in the second quarter of 2019, and will continue through May 2034. The Company utilizes this initial period as its lease term. The Company has an option to extend the lease term for up to two additional five-year terms. The Company placed this building into service in the second quarter of 2018.
Operating Leases
The Company’s operating leases relate to its real estate leases that are not classified as finance leases.
Aggregate Lease Information Related to the Application of ASC 842
The following information is disclosed in accordance with ASC 842, which became effective January 1, 2019. The components of lease cost recorded in the Company’s consolidated statement of operations were as follows:
 
2019
 
 
Operating lease cost
$
11,972

Finance lease cost
 
Amortization of leased assets
49,778

Interest on lease liabilities
52,839

Variable lease cost
27,997

Sublease income
(6,391
)
Net lease cost
$
136,195


The Company’s variable lease cost during 2019 primarily related to operating expenses, taxes and insurance associated with its finance leases. The Company’s sublease income during 2019 primarily related to subleases for an insignificant portion of the Company’s corporate headquarters.
The Company’s leases are included on its consolidated balance sheets as follows:
 
As of December 31, 2019
 
As of December 31, 2018 ^
 
(in thousands)
Finance leases
 
 
 
Property and equipment, net
$
445,336

 
$
640,952

Total finance lease assets
$
445,336

 
$
640,952

 
 
 
 
Capital lease obligations, current portion
$
—

 
$
9,817

Other current liabilities
38,795

 
5,271

Capital lease obligations, excluding current portion
—

 
19,658

Construction financing lease obligation, excluding current portion
—

 
561,892

Long-term finance lease liabilities
538,576

 
—

Total finance lease liabilities
$
577,371

 
$
596,638

 
 
 
 
Operating leases
 
 
 
Other assets
$
88,202

 
$
—

Total operating lease assets
$
88,202

 
$
—

 
 
 
 
Other current liabilities
$
11,504

 
$
—

Other long-term liabilities
84,292

 
—

Total operating lease liabilities
$
95,796

 
$
—

^ As reported in the Company’s 2018 Annual Report on Form 10-K.

Maturities of the Company’s finance and operating lease liabilities in accordance with ASC 842 as of December 31, 2019 were as follows:
Year
 
Finance Leases
 
Operating Leases
 
Total
 
 
(in thousands)
2020
 
$
84,264

 
$
14,598

 
$
98,862

2021
 
89,440

 
12,907

 
102,347

2022
 
87,092

 
12,610

 
99,702

2023
 
85,257

 
12,451

 
97,708

2024
 
90,802

 
11,488

 
102,290

Thereafter
 
425,251

 
51,251

 
476,502

Total lease payments
 
862,106

 
115,305

 
977,411

Less: amount representing interest
 
(284,735
)
 
(19,509
)
 
(304,244
)
Present value of lease liabilities
 
$
577,371

 
$
95,796

 
$
673,167


The weighted-average remaining lease terms and discount rates related to the Company’s leases were as follows:
 
As of December 31, 2019
Weighted-average remaining lease term (in years)
 
Finance leases
9.74

Operating leases
9.70

 
 
Weighted-average discount rate
 
Finance leases
9.04
%
Operating leases
3.75
%

Supplemental cash flow information related to the Company’s leases was as follows:
 
December 31, 2019
 
(in thousands)
Cash paid for amounts included in the measurement of lease liabilities:
 
Operating cash flows from operating leases
$
10,650

Operating cash flows from finance leases
$
50,527

Financing cash flows from finance leases
$
39,185

 
 
Right-of-use assets obtained in exchange for lease obligations
 
Operating leases *
$
34,605

Finance leases
$
—

* Includes $33.7 million acquired in 2019 pursuant to the Company’s acquisitions of Semma and Exonics.

Additional Lease Information Related to the Application of ASC 840
The following information is disclosed in accordance with ASC 840, Leases (Topic 840) (“ASC 840”), which was applicable until December 31, 2018. As of December 31, 2018, future minimum commitments under the Company’s real estate leases with initial terms of more than one year were as follows:
Year
 
Fan Pier
Leases
 
Other
Leases
 
Total Lease
Commitments
 
 
(in thousands)
2019
 
$
66,540

 
$
18,531

 
$
85,071

2020
 
72,589

 
23,397

 
95,986

2021
 
72,589

 
21,656

 
94,245

2022
 
72,589

 
21,172

 
93,761

2023
 
72,589

 
21,482

 
94,071

Thereafter
 
389,855

 
185,336

 
575,191

Total minimum lease payments
 
$
746,751

 
$
291,574

 
$
1,038,325


As of December 31, 2018, the Company’s total sublease income to be received related to its facility leases was $6.2 million. During 2018 and 2017, rental expenses were $17.3 million and $19.2 million, respectively.
The capital leases, which were related to equipment and leasehold improvements, bore interest at rates ranging from less than 1% to 6% per year. The Company’s capital lease amortization was included in depreciation expense during 2018 and 2017. The following table set forth the Company’s future minimum payments due under capital leases as of December 31, 2018:
Year
 
(in thousands)
2019
 
$
10,770

2020
 
7,282

2021
 
5,649

2022
 
3,300

2023
 
1,974

Thereafter
 
3,085

Total payments
 
32,060

Less: amount representing interest
 
(2,585
)
Present value of payments
 
$
29,475
XML 55 R9999.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Label Element Value
Additional Paid-in Capital [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 9,371,000
Parent [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption (40,310,000)
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 9,229,000
XML 56 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies
Revolving Credit Facility
In September 2019, the Company and certain of its subsidiaries entered into a Credit Agreement (the “2019 Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein. The 2019 Credit Agreement provides for a $500.0 million unsecured revolving facility, which was not drawn upon at closing. Amounts drawn pursuant to the 2019 Credit Agreement, if any, may be used to finance the Company’s working capital needs, and for general corporate or other lawful purposes. The Company had no borrowings outstanding under the 2019 Credit Agreement as of December 31, 2019. The 2019 Credit Agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the borrowing capacity under the 2019 Credit Agreement be increased by an additional $500.0 million. The 2019 Credit Agreement, which matures on September 17, 2024, supersedes the Company’s credit agreement entered into in 2016 with Bank of America, N.A serving in the same capacity. Additionally, the 2019 Credit Agreement provides a sublimit of $50.0 million for letters of credit.
Direct costs related to the 2019 Credit Agreement, which were not material to the Company’s financial statements, were deferred and will be recorded over the term of the 2019 Credit Agreement.
Any amounts borrowed under the 2019 Credit Agreement will bear interest, at the Company's option, at either a base rate or a Eurocurrency rate, in each case plus an applicable margin. Under the 2019 Credit Agreement, the applicable margins on base rate loans range from 0.125% to 0.50% and the applicable margins on Eurocurrency loans range from 1.125% to 1.50%, in each case based on the Company's consolidated leverage ratio (the ratio of the Company's total consolidated funded indebtedness to the Company's consolidated EBITDA for the most recently completed four fiscal quarter period).
Any amounts borrowed pursuant to the 2019 Credit Agreement are guaranteed by certain of the Company’s existing and future domestic subsidiaries, subject to certain exceptions.
The 2019 Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including financial covenants to maintain (i) subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition and (ii) a consolidated interest coverage ratio (the ratio of the Company’s consolidated EBITDA to its consolidated interest expenses for the most recently completed four fiscal quarter period) of 2.50 to 1.00, in each case measured on a quarterly basis. The 2019 Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.
Guaranties and Indemnifications
As permitted under Massachusetts law, the Company’s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors’ and officers’ liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.
The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company, and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company’s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of the Company’s contractual obligations arising out of the research or clinical testing of the Company’s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company’s contractual obligations. The indemnification provisions appearing in the Company’s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no material contingent liabilities accrued as of December 31, 2019 or 2018.
XML 57 R93.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Weighted-Average Remaining Lease Terms and Discount Rates (Details)
Dec. 31, 2019
Weighted-average remaining lease term (in years)  
Finance leases 9 years 8 months 26 days
Operating leases 9 years 8 months 12 days
Weighted-average discount rate (in percent)  
Finance leases 9.04%
Operating leases 3.75%
XML 58 R63.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborative Arrangements - Merck KGaA (Details) - Merck KGaA
$ in Millions
 1 Months Ended 12 Months Ended
Dec. 31, 2018
USD ($)
Jan. 31, 2017
pre-clinical_stage_program
clinical-stage_program
development_program
Dec. 31, 2017
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Right to license, number of development programs | development_program   4  
Right to license, number of clinical stage programs | clinical-stage_program   2  
Number of pre-clinical stage programs | pre-clinical_stage_program   2  
Collaborative arrangement development and regulatory potential milestone payments maximum     $ 230.0
Up-front payment $ 65.0    
XML 59 R67.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions - Exonics Therapeutics (Details) - USD ($)
 12 Months Ended
Jul. 16, 2019
Dec. 31, 2019
Dec. 31, 2018
Business Acquisition [Line Items]      
Fair value of contingent development and regulatory payments   $ 172,041,000  
Goodwill   1,002,158,000 $ 50,384,000
Intangible asset   $ 400,000,000.0 $ 0
Exonics Therapeutics      
Business Acquisition [Line Items]      
Upfront payment (adjusted for customary working capital adjustments) $ 266,315,000    
Fair value of contingent development and regulatory payments 172,041,000    
Total purchase price 438,356,000    
Cash and cash equivalents 19,535,000    
Goodwill 397,141,000    
Intangible asset 13,000,000    
Net other assets $ 8,680,000    
XML 60 R97.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Common Stock, Preferred Stock and Equity Plans - Common Stock and Preferred Stock (Details)
 12 Months Ended
Dec. 31, 2019
vote
shares
Dec. 31, 2018
shares
Equity [Abstract]    
Common stock, shares authorized (shares) 500,000,000 500,000,000
Common stock, number of votes per share | vote 1  
Preferred stock, shares authorized (shares) 1,000,000 1,000,000
Preferred stock, shares issued (shares) 0 0
Preferred stock, shares outstanding (shares) 0 0
XML 61 R106.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-based Compensation Expense - (Details) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Stock-based compensation expense:      
Stock-based compensation expense $ 360,489,000 $ 325,047,000 $ 293,236,000
Income tax effect (124,225,000) 0 0
Total stock-based compensation included in costs and expenses, net of tax 236,264,000 325,047,000 293,236,000
Stock-based compensation expense related to inventories (1,720,000) (585,000) (2,406,000)
Allocated stock-based compensation expense 360,489,000 $ 325,047,000 $ 293,236,000
Stock Options      
Weighted-average assumptions for options and ESPP subscriptions granted      
Expected annual dividends $ 0.00    
Employee stock purchase plan      
Weighted-average assumptions for options and ESPP subscriptions granted      
Expected stock price volatility (percent) 33.43% 36.51% 39.09%
Risk-free interest rate (percent) 2.08% 2.36% 1.24%
Expected term of options (in years) 22 days 22 days 22 days
Expected annual dividends $ 0 $ 0 $ 0
Weighted average fair value (usd per share) $ 47.79 $ 44.04 $ 35.90
Restricted stock and restricted stock units (including PSUs)      
Stock-based compensation expense:      
Stock-based compensation expense $ 254,276,000 $ 207,845,000 $ 181,258,000
Type of award:      
Unrecognized Expense $ 374,185,000    
Weighted-average Recognition Period 2 years 18 days    
Stock options      
Stock-based compensation expense:      
Stock-based compensation expense $ 96,737,000 $ 107,854,000 $ 105,367,000
Type of award:      
Unrecognized Expense $ 130,153,000    
Weighted-average Recognition Period 2 years 6 months    
Weighted-average grant-date fair value, granted (usd per share) $ 61.32 $ 60.83 $ 43.27
Weighted-average assumptions for options and ESPP subscriptions granted      
Expected stock price volatility (percent) 36.99% 40.50% 45.31%
Risk-free interest rate (percent) 2.32% 2.61% 1.94%
Expected term of options (in years) 4 years 3 months 7 days 4 years 6 months 18 days 4 years 8 months 4 days
Expected annual dividends $ 0 $ 0 $ 0
ESPP share issuances      
Stock-based compensation expense:      
Stock-based compensation expense 11,196,000 9,933,000 9,017,000
Type of award:      
Unrecognized Expense $ 4,724,000    
Weighted-average Recognition Period 16 days    
Performance-based RSUs      
Weighted-average assumptions for options and ESPP subscriptions granted      
Potential awards, percent of target shares, minimum 0.00%    
Potential awards, percent of target shares, maximum 200.00%    
Weighted average fair value (usd per share) $ 183.48    
Performance-based RSUs | Tranche one      
Weighted-average assumptions for options and ESPP subscriptions granted      
Vesting period 3 years    
Performance-based RSUs | Tranche two      
Weighted-average assumptions for options and ESPP subscriptions granted      
Vesting period 3 years    
Financial performance shares      
Weighted-average assumptions for options and ESPP subscriptions granted      
Vesting period 3 years    
Financial performance shares | Tranche one      
Weighted-average assumptions for options and ESPP subscriptions granted      
Vesting rights percentage 33.33%    
Financial performance shares | Tranche two      
Weighted-average assumptions for options and ESPP subscriptions granted      
Vesting rights percentage 33.33%    
Financial performance shares | Tranche three      
Weighted-average assumptions for options and ESPP subscriptions granted      
Vesting rights percentage 33.33%    
Non-financial performance shares      
Weighted-average assumptions for options and ESPP subscriptions granted      
Vesting period 3 years    
Cost of sales      
Stock-based compensation expense:      
Stock-based compensation expense $ 5,575,000 4,543,000 2,500,000
Research and development expenses      
Stock-based compensation expense:      
Stock-based compensation expense 224,558,000 203,112,000 181,900,000
Sales, general and administrative expenses      
Stock-based compensation expense:      
Stock-based compensation expense $ 130,356,000 $ 117,392,000 $ 108,836,000
XML 62 R102.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Common Stock, Preferred Stock and Equity Plans - Restricted Stock and Restricted Stock Units and PSUs (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Restricted Stock Units (excluding PSUs)      
Restricted stock and Restricted Stock Units      
Beginning of the period (in shares) 2,717    
Granted (in shares) 1,717    
Vested (in shares) (974)    
Cancelled (in shares) (329)    
End of the period (in shares) 3,131 2,717  
Restricted stock and Restricted Stock Units, weighted-average grant-date fair value      
Weighted-average grant-date fair value, as of the beginning of the period (usd per share) $ 140.10    
Weighted-average grant-date fair value, granted (usd per share) 181.87    
Weighted-average grant-date fair value, vested (usd per share) 133.15    
Weighted-average grant-date fair value, cancelled (usd per share) 149.83    
Weighted-average grant-date fair value, as of the end of the period (usd per share) $ 163.61 $ 140.10  
Restricted stock vested in period, total fair value $ 178.2 $ 104.8 $ 33.2
Restricted Stock      
Restricted stock and Restricted Stock Units      
Beginning of the period (in shares) 480    
Granted (in shares) 0    
Vested (in shares) (375)    
Cancelled (in shares) (13)    
End of the period (in shares) 92 480  
Restricted stock and Restricted Stock Units, weighted-average grant-date fair value      
Weighted-average grant-date fair value, as of the beginning of the period (usd per share) $ 104.91    
Weighted-average grant-date fair value, granted (usd per share) 0    
Weighted-average grant-date fair value, vested (usd per share) 108.23    
Weighted-average grant-date fair value, cancelled (usd per share) 100.79    
Weighted-average grant-date fair value, as of the end of the period (usd per share) $ 91.97 $ 104.91  
Restricted stock vested in period, total fair value $ 70.7 $ 114.5 157.0
Performance-based RSUs      
Restricted stock and Restricted Stock Units      
Beginning of the period (in shares) 759    
Granted (in shares) 449    
Vested (in shares) (403)    
Cancelled (in shares) (71)    
End of the period (in shares) 734 759  
Restricted stock and Restricted Stock Units, weighted-average grant-date fair value      
Weighted-average grant-date fair value, as of the beginning of the period (usd per share) $ 110.50    
Weighted-average grant-date fair value, granted (usd per share) 183.48    
Weighted-average grant-date fair value, vested (usd per share) 109.23    
Weighted-average grant-date fair value, cancelled (usd per share) 104.61    
Weighted-average grant-date fair value, as of the end of the period (usd per share) $ 143.21 $ 110.50  
Restricted stock vested in period, total fair value $ 73.3 $ 23.2 $ 1.3
Potential awards, percent of target shares, minimum 0.00%    
Potential awards, percent of target shares, maximum 200.00%    
Performance-based RSUs | Tranche one      
Restricted stock and Restricted Stock Units, weighted-average grant-date fair value      
Percent of awards in tranche 50.00%    
Performance period 1 year    
Vesting period 3 years    
Performance-based RSUs | Tranche two      
Restricted stock and Restricted Stock Units, weighted-average grant-date fair value      
Percent of awards in tranche 50.00%    
Performance period 3 years    
Vesting period 3 years    
XML 63 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Revenues by Product
Product revenues, net consisted of the following:
 
2019
(as reported under ASC 606)
 
2018
(as reported under ASC 606)
 
2017
(as reported under ASC 605)
 
(in thousands)
TRIKAFTA
$
420,105

 
$
—

 
$
—

SYMDEKO/SYMKEVI
1,417,668

 
768,657

 
—

ORKAMBI
1,331,891

 
1,262,166

 
1,320,850

KALYDECO
991,062

 
1,007,502

 
844,630

Total product revenues, net
$
4,160,726

 
$
3,038,325

 
$
2,165,480
Revenues and Property and Equipment by Location
Long-lived assets by location consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
United States
$
768,572

 
$
778,157

Outside of the United States
 
 
 
United Kingdom
57,383

 
30,496

Other
7,327

 
3,352

Total long-lived assets outside of the United States
64,710

 
33,848

      Total long-lived assets
$
833,282

 
$
812,005


Total revenues from external customers and collaborators by geographic region consisted of the following:
 
2019
(as reported under ASC 606)
 
2018
(as reported under ASC 606)
 
2017
(as reported under ASC 605)
 
(in thousands)
United States
$
3,062,555

 
$
2,365,079

 
$
1,986,786

Outside of the United States
 
 
 
 
 
Europe
885,762

 
543,179

 
420,317

Other
214,504

 
139,339

 
81,549

Total revenues outside of the United States
1,100,266

 
682,518

 
501,866

Total revenues
$
4,162,821

 
$
3,047,597

 
$
2,488,652
Significant Customers
Gross revenues and accounts receivable from each of the Company’s customers who individually accounted for 10% or more of total gross revenues and/or 10% or more of total gross accounts receivable consisted of the following:
 
Percent of Total Gross
Revenues
 
Percent of Gross Accounts Receivable
 
Year Ended December 31,
 
As of December 31,
 
2019
(as reported under ASC 606)
 
2018
(as reported under ASC 606)
 
2017
(as reported under ASC 605)
 
2019
 
2018
McKesson Corporation
17
%
 
14
%
 
<10
%
 
22
%
 
16
%
Walgreen Co.
15
%
 
20
%
 
17
%
 
14
%
 
16
%
Accredo/Curascript
14
%
 
14
%
 
14
%
 
15
%
 
10
%
XML 64 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases (Tables)
 12 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Lease cost The components of lease cost recorded in the Company’s consolidated statement of operations were as follows:
 
2019
 
 
Operating lease cost
$
11,972

Finance lease cost
 
Amortization of leased assets
49,778

Interest on lease liabilities
52,839

Variable lease cost
27,997

Sublease income
(6,391
)
Net lease cost
$
136,195
Components of lease in balance sheets
The Company’s leases are included on its consolidated balance sheets as follows:
 
As of December 31, 2019
 
As of December 31, 2018 ^
 
(in thousands)
Finance leases
 
 
 
Property and equipment, net
$
445,336

 
$
640,952

Total finance lease assets
$
445,336

 
$
640,952

 
 
 
 
Capital lease obligations, current portion
$
—

 
$
9,817

Other current liabilities
38,795

 
5,271

Capital lease obligations, excluding current portion
—

 
19,658

Construction financing lease obligation, excluding current portion
—

 
561,892

Long-term finance lease liabilities
538,576

 
—

Total finance lease liabilities
$
577,371

 
$
596,638

 
 
 
 
Operating leases
 
 
 
Other assets
$
88,202

 
$
—

Total operating lease assets
$
88,202

 
$
—

 
 
 
 
Other current liabilities
$
11,504

 
$
—

Other long-term liabilities
84,292

 
—

Total operating lease liabilities
$
95,796

 
$
—

^ As reported in the Company’s 2018 Annual Report on Form 10-K.
Finance lease, liability, maturity
Maturities of the Company’s finance and operating lease liabilities in accordance with ASC 842 as of December 31, 2019 were as follows:
Year
 
Finance Leases
 
Operating Leases
 
Total
 
 
(in thousands)
2020
 
$
84,264

 
$
14,598

 
$
98,862

2021
 
89,440

 
12,907

 
102,347

2022
 
87,092

 
12,610

 
99,702

2023
 
85,257

 
12,451

 
97,708

2024
 
90,802

 
11,488

 
102,290

Thereafter
 
425,251

 
51,251

 
476,502

Total lease payments
 
862,106

 
115,305

 
977,411

Less: amount representing interest
 
(284,735
)
 
(19,509
)
 
(304,244
)
Present value of lease liabilities
 
$
577,371

 
$
95,796

 
$
673,167
Weighted-average remaining lease terms and discount rates
The weighted-average remaining lease terms and discount rates related to the Company’s leases were as follows:
 
As of December 31, 2019
Weighted-average remaining lease term (in years)
 
Finance leases
9.74

Operating leases
9.70

 
 
Weighted-average discount rate
 
Finance leases
9.04
%
Operating leases
3.75
%
Supplemental cash flow information
Supplemental cash flow information related to the Company’s leases was as follows:
 
December 31, 2019
 
(in thousands)
Cash paid for amounts included in the measurement of lease liabilities:
 
Operating cash flows from operating leases
$
10,650

Operating cash flows from finance leases
$
50,527

Financing cash flows from finance leases
$
39,185

 
 
Right-of-use assets obtained in exchange for lease obligations
 
Operating leases *
$
34,605

Finance leases
$
—

* Includes $33.7 million acquired in 2019 pursuant to the Company’s acquisitions of Semma and Exonics.
Lessee, operating lease, liability, maturity
Maturities of the Company’s finance and operating lease liabilities in accordance with ASC 842 as of December 31, 2019 were as follows:
Year
 
Finance Leases
 
Operating Leases
 
Total
 
 
(in thousands)
2020
 
$
84,264

 
$
14,598

 
$
98,862

2021
 
89,440

 
12,907

 
102,347

2022
 
87,092

 
12,610

 
99,702

2023
 
85,257

 
12,451

 
97,708

2024
 
90,802

 
11,488

 
102,290

Thereafter
 
425,251

 
51,251

 
476,502

Total lease payments
 
862,106

 
115,305

 
977,411

Less: amount representing interest
 
(284,735
)
 
(19,509
)
 
(304,244
)
Present value of lease liabilities
 
$
577,371

 
$
95,796

 
$
673,167
Schedule of future minimum rental payments for operating leases
The following information is disclosed in accordance with ASC 840, Leases (Topic 840) (“ASC 840”), which was applicable until December 31, 2018. As of December 31, 2018, future minimum commitments under the Company’s real estate leases with initial terms of more than one year were as follows:
Year
 
Fan Pier
Leases
 
Other
Leases
 
Total Lease
Commitments
 
 
(in thousands)
2019
 
$
66,540

 
$
18,531

 
$
85,071

2020
 
72,589

 
23,397

 
95,986

2021
 
72,589

 
21,656

 
94,245

2022
 
72,589

 
21,172

 
93,761

2023
 
72,589

 
21,482

 
94,071

Thereafter
 
389,855

 
185,336

 
575,191

Total minimum lease payments
 
$
746,751

 
$
291,574

 
$
1,038,325
Schedule of future minimum lease payments for capital leases The following table set forth the Company’s future minimum payments due under capital leases as of December 31, 2018:
Year
 
(in thousands)
2019
 
$
10,770

2020
 
7,282

2021
 
5,649

2022
 
3,300

2023
 
1,974

Thereafter
 
3,085

Total payments
 
32,060

Less: amount representing interest
 
(2,585
)
Present value of payments
 
$
29,475
XML 65 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Nature of Business and Accounting Policies - Share-Based Compensation (Details)
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Percentage of employees eligible for acceleration of equity awards (less than) (percent) 5.00%
XML 66 R113.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and Contingencies - Contingencies (Details) - USD ($)
Dec. 31, 2019
Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]    
Indemnification claims $ 0  
Contingent liabilities $ 0 $ 0.0
XML 67 R117.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Information - Property and Equipment, Net by Location (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total long-lived assets $ 833,282 $ 812,005
United States    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total long-lived assets 768,572 778,157
United Kingdom    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total long-lived assets 57,383 30,496
Other    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total long-lived assets 7,327 3,352
Total revenues outside of the United States    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total long-lived assets $ 64,710 $ 33,848
XML 68 R86.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Property, Plant and Equipment [Abstract]      
Depreciation expense $ 106.9 $ 72.4 $ 61.4
XML 69 R76.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Available-for-sale Debt Securities    
Fair Value $ 1,243,469 $ 1,648,745
Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract]    
Amortized Cost 530,216 484,473
Gross Unrealized Gains 168,811 40,646
Gross Unrealized Losses (55) (7,011)
Fair Value 698,972 518,108
Money market funds    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 791,039 1,226,603
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Fair Value 791,039 1,226,603
Corporate debt securities    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 6,070  
Gross Unrealized Gains 0  
Gross Unrealized Losses 0  
Fair Value 6,070  
Available-for-sale Debt Securities    
Amortized Cost 301,458 234,088
Gross Unrealized Gains 391 27
Gross Unrealized Losses (50) (450)
Fair Value 301,799 233,665
U.S. Treasury securities    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost   5,967
Gross Unrealized Gains   0
Gross Unrealized Losses   (1)
Fair Value   5,966
Government-sponsored enterprise securities    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost   7,124
Gross Unrealized Gains   0
Gross Unrealized Losses   (1)
Fair Value   7,123
Commercial paper    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 29,470 58,271
Gross Unrealized Gains 3 0
Gross Unrealized Losses (1) (3)
Fair Value 29,472 58,268
Cash Equivalents    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 826,579 1,297,965
Gross Unrealized Gains 3 0
Gross Unrealized Losses (1) (5)
Fair Value 826,581 1,297,960
Total marketable debt securities    
Available-for-sale Debt Securities    
Amortized Cost 416,387 351,316
Gross Unrealized Gains 556 27
Gross Unrealized Losses (55) (558)
Fair Value 416,888 350,785
U.S Treasury securities    
Available-for-sale Debt Securities    
Amortized Cost   6,026
Gross Unrealized Gains   0
Gross Unrealized Losses   0
Fair Value   6,026
Government-sponsored enterprise securities    
Available-for-sale Debt Securities    
Amortized Cost 12,689 10,704
Gross Unrealized Gains 44 0
Gross Unrealized Losses 0 0
Fair Value 12,733 10,704
Commercial paper    
Available-for-sale Debt Securities    
Amortized Cost 102,240 100,498
Gross Unrealized Gains 121 0
Gross Unrealized Losses (5) (108)
Fair Value 102,356 100,390
Corporate equity securities    
Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract]    
Amortized Cost 113,829 133,157
Gross Unrealized Gains 168,255 40,619
Gross Unrealized Losses 0 (6,453)
Fair Value $ 282,084 $ 167,323
XML 70 R72.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements - Additional Information (Details) - USD ($)
$ in Billions
Dec. 31, 2019
Dec. 31, 2018
Fair Value Disclosures [Abstract]    
Cash $ 2.3 $ 1.4
XML 71 R82.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Hedging - Derivative Fair Value (Details) - Foreign currency forward contracts - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Derivative [Line Items]    
Total assets $ 9,725 $ 20,537
Total liabilities (7,354) (448)
Designated as hedging instruments    
Derivative [Line Items]    
Total assets 9,725 20,537
Total liabilities (7,354) (448)
Prepaid expenses and other current assets | Designated as hedging instruments    
Derivative [Line Items]    
Fair value - assets 9,725 19,023
Other current liabilities | Designated as hedging instruments    
Derivative [Line Items]    
Fair value - liabilities (5,533) (340)
Other assets | Designated as hedging instruments    
Derivative [Line Items]    
Fair value - assets 0 1,514
Other long-term liabilities | Designated as hedging instruments    
Derivative [Line Items]    
Fair value - liabilities $ (1,821) $ (108)
XML 72 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 3,109,322 $ 2,650,134
Marketable securities 698,972 518,108
Accounts receivable, net 633,518 409,688
Inventories 167,502 124,360
Prepaid expenses and other current assets 213,515 140,819
Total current assets 4,822,829 3,843,109
Property and equipment, net 745,080  
Property and equipment, net   812,005
Goodwill 1,002,158 50,384
Intangible assets 400,000 0
Deferred tax assets 1,190,815 1,499,672
Other assets 157,583 40,728
Total assets 8,318,465 6,245,898
Current liabilities:    
Accounts payable 87,610 110,987
Accrued expenses 1,116,912 958,899
Other current liabilities 130,305 50,406
Total current liabilities 1,334,827 1,120,292
Long-term finance lease liabilities 538,576  
Capital lease obligations, excluding current portion   581,550
Long-term contingent consideration 176,500 0
Other long-term liabilities 183,318 108,853
Total liabilities 2,233,221 1,810,695
Commitments and contingencies 0 0
Shareholders’ equity:    
Preferred stock, $0.01 par value; 1,000 shares authorized; none issued and outstanding 0 0
Common stock, $0.01 par value; 500,000 shares authorized, 258,993 and 255,172 shares issued and outstanding, respectively 2,589 2,546
Additional paid-in capital 7,937,606 7,421,476
Accumulated other comprehensive (loss) income (1,973) 659
Accumulated deficit (1,852,978) (2,989,478)
Total shareholders’ equity 6,085,244 4,435,203
Total liabilities and shareholders’ equity $ 8,318,465 $ 6,245,898
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborative Arrangements - Kymera and Other In-License Agreements (Details)
$ in Millions
 1 Months Ended 12 Months Ended
May 31, 2019
USD ($)
target
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Investment in collaborative partner, pursuant to convertible loan agreement   $ 63.3 $ 46.9 $ 8.7
Kymera Therapeutics        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Up-front payment $ 50.0      
Right to license, number of targets (up to) | target 6      
Collaborative arrangement development and regulatory potential milestone payments maximum $ 170.0      
Investment in collaborative partner, pursuant to convertible loan agreement $ 20.0      
Molecular Templates, Inc        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Up-front payment   $ 25.9    
Arbor        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Up-front payment     $ 30.0  
XML 74 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover Page - USD ($)
$ in Billions
 12 Months Ended
Dec. 31, 2019
Jan. 31, 2020
Jun. 28, 2019
Cover page.      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2019    
Document Transition Report false    
Entity File Number 000-19319    
Entity Registrant Name VERTEX PHARMACEUTICALS INC / MA    
Entity Incorporation, State or Country Code MA    
Entity Tax Identification Number 04-3039129    
Entity Address, Address Line One 50 Northern Avenue    
Entity Address, City or Town Boston    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02210    
City Area Code 617    
Local Phone Number 341-6100    
Title of 12(b) Security Common Stock, $0.01 Par Value Per Share    
Trading Symbol VRTX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 46.7
Entity Common Stock, Shares Outstanding   259,268,593  
Entity Central Index Key 0000875320    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2019    
Document Fiscal Period Focus FY    
Amendment Flag false    
Documents Incorporated by Reference
Portions of the definitive proxy statement for the 2020 Annual Meeting of Shareholders, which we expect to hold on June 3, 2020, are incorporated by reference into Part III of this Annual Report on Form 10-K.
    
XML 75 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Nature of Business and Accounting Policies
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Nature of Business and Accounting Policies
Nature of Business and Accounting Policies
Business
Vertex Pharmaceuticals Incorporated (“Vertex” or the “Company”) invests in scientific innovation to create transformative medicines for serious diseases. The Company’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (“CF”) and advancing research and development programs in other indications. The Company’s marketed products are TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor), which are approved to treat patients with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (“CFTR”) gene.
As of December 31, 2019, the Company had cash, cash equivalents and marketable securities of $3.8 billion. The Company expects that cash flows from the sales of its products, together with the Company’s cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months.
The Company is subject to risks common to companies in its industry including, but not limited to, the dependence on revenues from its CF products, competition, uncertainty about clinical trial outcomes and regulatory approvals, uncertainties relating to pharmaceutical pricing and reimbursement, uncertainty related to international expansion, uncertain protection of proprietary technology, the need to comply with government regulations, share price volatility, dependence on collaborative relationships and potential product liability.
Basis of Presentation
The accompanying consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (“VIEs”). In 2017, the Company deconsolidated Parion Sciences, Inc. (“Parion”), a VIE the Company had consolidated since 2015. In 2018, the Company deconsolidated BioAxone Biosciences, Inc. (“BioAxone”), a VIE the Company had consolidated since 2014. As of December 31, 2019 and 2018, the Company did not have any consolidated VIEs. All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals. Please refer to Note R, “Segment Information,” for enterprise-wide disclosures regarding the Company’s revenues, major customers and long-lived assets by geographic area. The Company has reclassified certain items from the prior year’s consolidated financial statements to conform to the current year’s presentation.
Use of Estimates
The preparation of consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these consolidated financial statements have been made in connection with (i) determining the transaction price of revenues, (ii) accounting for acquisitions, including intangible assets, goodwill and contingent consideration and (iii) evaluating deferred tax asset valuation allowances and the provision for income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Revenue Recognition
Pursuant to Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. 
The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon delivery.
Product Revenues, Net
The Company sells its products principally to a limited number of specialty pharmacy and specialty distributors in the United States, which account for the largest portion of its total revenues, and makes international sales primarily to specialty distributors and retail chains, as well as hospitals and clinics, many of which are government-owned or supported (collectively, its “Customers”). The Company’s Customers in the United States subsequently resell the products to patients and health care providers. In accordance with ASC 606, the Company recognizes net product revenues from sales when the Customers obtain control of the Company’s products, which typically occurs upon delivery to the Customer. The Company’s payment terms are approximately 30 days in the United States and consistent with prevailing practice in international markets.
Revenues from product sales are recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from (a) invoice discounts for prompt payment and distribution fees, (b) government and private payor rebates, chargebacks, discounts and fees and (c) costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves are classified as reductions to “Accounts receivable, net” if payable to a Customer or “Accrued expenses” if payable to a third-party.  Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns.  The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.  Actual amounts of consideration ultimately received may differ from the Company’s estimates.  If actual results vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.
Invoice Discounts and Distribution Fees: The Company generally provides invoice discounts on product sales to its Customers for prompt payment and pays fees for distribution services, such as fees for certain data that Customers provide to the Company. The Company estimates that, based on its experience, its Customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.
Rebates, Chargebacks, Discounts and Fees: The Company contracts with government agencies (its “Third-party Payors”) so that products will be eligible for purchase by, or partial or full reimbursement from, such Third-party Payors. The Company estimates the rebates, chargebacks, discounts and fees it will provide to Third-party Payors and deducts
these estimated amounts from its gross product revenues at the time the revenues are recognized. For each product, the Company estimates the aggregate rebates, chargebacks and discounts that it will provide to Third-party Payors based upon (i) the Company’s contracts with these Third-party Payors, (ii) the government-mandated discounts and fees applicable to government-funded programs, (iii) information obtained from the Company’s Customers and other third-party data regarding the payor mix for such product and (iv) historical experience.
Other Incentives: Other incentives that the Company offers include co-pay mitigation rebates provided by the Company to commercially insured patients who have coverage and who reside in states that permit co-pay mitigation programs. Based upon the terms of the Company’s co-pay mitigation programs, the Company estimates average co-pay mitigation amounts for each of its products in order to establish appropriate accruals.
The Company makes significant estimates and judgments that materially affect its recognition of net product revenues. The Company adjusts its estimated rebates, chargebacks and discounts based on new information, including information regarding actual rebates, chargebacks and discounts for its products, as it becomes available. Claims by third-party payors for rebates, chargebacks and discounts frequently are submitted to the Company significantly after the related sales, potentially resulting in adjustments in the period in which the new information becomes known. The Company’s credits to product revenue related to prior period sales have not been significant and primarily related to rebates and discounts.
The Company excludes taxes collected from Customers relating to product sales and remitted to governmental authorities from revenues.
Contract Liabilities
The Company recorded contract liabilities of $62.3 million and $24.9 million as of December 31, 2019 and 2018, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement the Company can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees.  The Company defers a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. The Company’s product revenue contracts include performance obligations that are one year or less.
The Company’s contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as the Company’s fiscal year. In these markets the Company recognizes revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year. During the year ended December 31, 2019, the Company recorded $24.9 million of revenues that were recorded as contract liabilities at the beginning of the year.
French Early Access Programs
Pursuant to ASC 605, Revenue Recognition (“ASC 605”), which was applicable until December 31, 2017, the Company only recognized revenues from product sales if it determined that the price was fixed or determinable at the time of delivery. If the Company determined that the price was not fixed or determinable, it deferred the recognition of revenues. If the Company was able to determine that the price was fixed or determinable, it recognized the net product revenues associated with the units.
In 2015, the Company began distributing ORKAMBI through early access programs in France and remained engaged in reimbursement discussions with the French government until November 2019, when the Company reached an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs. From the time the Company began distributing ORKAMBI through early access programs in France, it expected the difference between the amounts collected based on the invoiced amount and the final amount for ORKAMBI distributed through early access programs would be returned to the French government. As a result, the Company has classified a refund liability related to the early access programs in France within “Accrued expenses” on its consolidated balance sheets.
Pursuant to the revenue recognition accounting guidance that was applicable until December 31, 2017, the Company’s ORKAMBI net product revenues for 2015, 2016 and 2017 did not include any net product revenues from sales of ORKAMBI in France because the price was not fixed or determinable at the time of delivery. Upon adopting ASC 606 in 2018, the Company recorded an $8.3 million cumulative effect adjustment to “Accumulated deficit” primarily related to shipments of ORKAMBI under the early access programs in France. The Company determined the amount of the adjustment based upon (i) the status of reimbursement discussions in France upon adoption, (ii) its estimate of the amount of consideration it expected to retain related to ORKAMBI sales in France that occurred on or prior to December 31, 2017 that would not be subject to a significant reversal in amounts recognized and (iii) recognition of costs previously deferred related to the ORKAMBI sales in France. Please refer to Recent Accounting Pronouncements included in this Note A, “Nature of Business and Accounting Policies,” below for more information regarding the revenue recognition guidance adopted as of January 1, 2018.
For ORKAMBI sales in France that occurred after December 31, 2017 under the early access programs, the Company recognized net product revenues based on a transaction price that reflected the Company’s estimate of consideration it expected to retain that would not be subject to a significant reversal in amounts recognized. When determining if variable consideration should be constrained, the Company considers whether there are factors outside its control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. The Company recognized ORKAMBI net product revenues from sales in France based on this estimate from the first quarter of 2018 through the third quarter of 2019. Upon reaching an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs in November 2019, the Company updated the transaction price to reflect the final amount for ORKAMBI distributed through early access programs. As a result, the Company recognized net product revenues of $155.8 million related to prior period ORKAMBI early access program sales in the fourth quarter of 2019 because the updated transaction price for ORKAMBI distributed through these programs exceeded the Company’s previous estimate of the consideration it expected to retain that would not be subject to a significant reversal in amounts recognized. Additionally, the Company’s refund liability no longer requires estimation as of December 31, 2019 and will be paid to the French government in 2020.
Collaborative and Royalty Revenues
The Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms of these agreements typically include payment to the Company related to one or more of the following: nonrefundable, upfront license fees; development and commercial milestones; funding of research and/or development activities; and royalties on net sales of licensed products. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaborator.
For each collaborative research, development and/or commercialization agreement that results in revenue, the Company identifies all material performance obligations, which may include a license to intellectual property and know-how, research and development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimate of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.
Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. In order to account for these agreements, the Company must develop assumptions that require judgment to determine the standalone selling price, which may include (i) the probability of obtaining marketing approval for the drug candidate, (ii) estimates regarding the timing of and the expected costs to develop and commercialize the drug candidate, (iii) estimates of future cash flows from potential product sales with respect to the drug candidate and (iv) appropriate discount and tax rates. Standalone selling prices used to perform the initial allocation are not updated after contract
inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.
Upfront License Fees: If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related nonrefundable, upfront license fees based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license.  For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.  The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Development and Regulatory Milestone Payments: Depending on facts and circumstances, the Company may conclude that it is appropriate to include certain milestones in the estimated transaction price or that it is appropriate to fully constrain the milestones. A milestone payment is included in the transaction price in the reporting period that the Company concludes that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods. This may result in revenues from certain milestones and a corresponding contract asset being recorded in a reporting period before the milestone is achieved. Milestone payments that have not been included in the transaction price to date are fully constrained until the Company concludes that their achievement is probable and that recognition of the related revenue will not result in a significant reversal in amounts recognized in future periods. The Company re-evaluates the probability of achievement of such development milestones and any related constraint each reporting period and adjusts its estimate of the overall transaction price, including the amount of collaborative revenue that it has recorded, if necessary. The Company has not recorded any significant development or regulatory milestone revenues the three years ended December 31, 2019.
Research and Development Activities/Transition Services: If the Company is entitled to reimbursement from its collaborators for specified research and development expenses, it accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as collaborative revenues or an offset to research and development expenses in accordance with the provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations.
Sales-based Milestone and Royalty Payments: The Company’s collaborators may be required to pay the Company sales-based milestones or royalties on future sales of commercial products.  The Company recognizes revenues related to sales-based milestone and royalties upon the later to occur of (i) achievement of the collaborator’s underlying sales or (ii) satisfaction of any performance obligation(s) related to these sales, in each case assuming the license to the Company’s intellectual property is deemed to be the predominant item to which the sales-based milestones and/or royalties relate. The Company has not recorded any sales-based milestones or royalties revenues during the three years ended December 31, 2019.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentration of credit risk consist principally of money market funds and marketable securities. The Company places these investments with highly rated financial institutions, and, by policy, limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company also maintains a foreign currency hedging program that includes foreign currency forward contracts with several counterparties. The Company has not experienced any credit losses related to these financial instruments and does not believe it is exposed to any significant credit risk related to these instruments.
The Company also is subject to credit risk from its accounts receivable related to its product sales and collaborators. The Company evaluates the creditworthiness of each of its customers and has determined that all of its material customers are
creditworthy. To date, the Company has not experienced significant losses with respect to the collection of its accounts receivable. The Company believes that its allowance for doubtful accounts was adequate at December 31, 2019. Please refer to Note R, “Segment Information,” for further information.
Cash and Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.
Marketable Securities
As of December 31, 2019, the Company’s marketable securities consisted of investments in available-for-sale debt securities, including government-sponsored enterprise securities, corporate debt securities and commercial paper, and corporate equity securities with readily determinable fair values. The Company classifies marketable securities available to fund current operations as current assets on its consolidated balance sheets. Marketable securities are classified as long-term assets on the consolidated balance sheets if (i) they have been in an unrealized loss position for longer than one year and (ii) the Company has the ability and intent to hold them (a) until the carrying value is recovered and (b) such holding period may be longer than one year. The Company’s marketable securities are stated at fair value. The fair value of these securities is based on quoted prices for identical or similar assets.
The Company records unrealized gains (losses) on available-for-sale debt securities as a component of “Accumulated other comprehensive (loss) income,” which is a separate component of shareholders’ equity on its consolidated balance sheet, until such gains and losses are realized.
Pursuant to the adoption of Accounting Standards Update (“ASU”) 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”) on January 1, 2018, the Company began recording changes in the fair value of its investments in corporate equity securities to “Other income (expense), net” in the Company’s consolidated statements of operations. Prior to its adoption of ASU 2016-01 in 2018, the Company recorded changes in the fair value of its investments in corporate equity securities to “Accumulated other comprehensive (loss) income.”
The Company reviews investments in marketable debt securities for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers whether it has an intent to sell, or whether it is more likely than not that the Company will be required to sell, the investment before recovery of the investment’s amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company’s investment policy, the severity and the duration of the impairment and changes in value subsequent to year-end. If a decline in the fair value is considered other-than-temporary, based on available evidence, the unrealized loss is transferred from other comprehensive income (loss) to the consolidated statements of operations.
Realized gains and losses are determined using the specific identification method and are included in “Other income (expense), net” in the consolidated statements of operations.
Accounts Receivable
The Company deducts invoice discounts for prompt payment and fees for distribution services from its accounts receivable based on its experience that the Company’s Customers will earn these discounts and fees. The Company’s estimates for its allowance for doubtful accounts, which have not been significant to date, are determined based on existing contractual payment terms and historical payment patterns.
Stock-based Compensation Expense
The Company expenses the fair value of employee stock options and other forms of stock-based employee compensation over the associated employee service period on a straight-line basis. Stock-based compensation expense is determined based on the fair value of the award at the grant date and is adjusted each period to reflect actual forfeitures and the outcomes of certain performance conditions.
For awards with performance conditions in which the award does not vest unless the performance condition is met, the Company recognizes expense if, and to the extent that, the Company estimates that achievement of the performance condition is probable. If the Company concludes that vesting is probable, it recognizes expense from the date it reaches this conclusion through the estimated vesting date.
The Company provides to employees who have rendered a certain number of years’ to the Company and meet certain age requirements, partial or full acceleration of vesting of these equity awards, subject to certain conditions including a notification period, upon a termination of employment other than for cause. Approximately 5% of the Company’s employees were eligible for partial or full acceleration of any of their equity awards as of December 31, 2019. The Company recognizes stock-based compensation expense related to these awards over a service period reflecting qualified employees’ eligibility for partial or full acceleration of vesting.
Research and Development Expenses
The Company expenses as incurred all research and development expenses, including amounts funded by research and development collaborations. The Company capitalizes nonrefundable advance payments made by the Company for research and development activities and expenses the payments as the related goods are delivered or the related services are performed.
Research and development expenses are comprised of costs incurred by the Company in performing research and development activities, including salary and benefits; stock-based compensation expense; outsourced services and other direct expenses, including clinical trial and pharmaceutical development costs; collaboration and asset acquisition payments; expenses associated with drug supplies that are not being capitalized; and infrastructure costs, including facilities costs and depreciation expense.
Inventories
The Company values its inventories at the lower-of-cost or net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and writes down any excess and obsolete inventories to their net realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases are capitalized and recorded upon sale in “Cost of sales” in the consolidated statements of operations. Shipping and handling costs incurred for product shipments are recorded as incurred in “Cost of sales” in the consolidated statements of operations.
The Company capitalizes inventories produced in preparation for initiating sales of a drug candidate when the related drug candidate is considered to have a high likelihood of regulatory approval and the related costs are expected to be recoverable through sales of the inventories. In determining whether or not to capitalize such inventories, the Company evaluates, among other factors, information regarding the drug candidate’s safety and efficacy, the status of regulatory submissions and communications with regulatory authorities and the outlook for commercial sales, including the existence of current or anticipated competitive drugs and the availability of reimbursement. In addition, the Company evaluates risks associated with manufacturing the drug candidate and the remaining shelf-life of the inventories.
Property and Equipment
Property and equipment are recorded at cost. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset, generally seven to ten years for furniture and equipment, three to five years for computers and software and for leasehold improvements, the shorter of the useful life of the improvements or the estimated remaining life of the associated lease. Maintenance and repairs to an asset that do not improve or extend its life are charged to operations. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the Company’s consolidated statements of operations. The Company performs an assessment of the fair value of the assets if indicators of impairment are identified during a reporting period and records the assets at the lower of the net book value or the fair value of the assets.
The Company capitalizes internal costs incurred to develop software for internal use during the application development stage. Amortization of capitalized internally developed software costs is recorded in depreciation expense over the useful life of the related asset.
Leases
The Company adopted ASU 2016-02, Leases (Topic 842) (“ASC 842”) as of January 1, 2019. Under ASC 842, the Company determines whether the arrangement contains a lease at the inception of an arrangement. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its consolidated balance sheet and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12 months.
A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.
Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease.
The Company does not separate lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.
Finance leases are recorded in “Property and equipment, net,” “Other current liabilities” and “Long-term finance lease liabilities” and operating leases are recorded in “Other assets,” “Other current liabilities” and “Other long-term liabilities” on the Company’s consolidated balance sheet.
Prior to the adoption of ASC 842 on January 1, 2019, the Company applied build-to-suit accounting and was the deemed owner of its leased corporate headquarters in Boston and research site in San Diego, for which it was recognizing depreciation expense over the buildings’ useful lives and imputed interest on the corresponding construction financing lease obligations. The Company also recorded leases for equipment as capital leases pursuant to the accounting guidance that was effective until December 31, 2018.
The assets and liabilities associated with the Company’s capital lease agreements were recorded at the present value of the minimum lease payments at the inception of the lease agreement. The assets were depreciated using the straight-line method over the shorter of the useful life of the related asset or the remaining life of the associated lease. Amortization of capital lease assets was included in depreciation expense.
Income Taxes
Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax bases of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. On a periodic basis, the Company reassesses the valuation allowance on its deferred income tax assets weighing positive and negative evidence to assess the recoverability of its deferred tax assets. The Company includes, among other things, its recent financial performance and its future projections in this periodic assessment.
The Company records liabilities related to uncertain tax positions by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company does not believe any such uncertain tax positions currently pending will have a material adverse effect on its consolidated financial statements.
Variable Interest Entities
The Company reviews each collaboration agreement pursuant to which it licenses assets owned by a collaborator in order to determine whether or not it has a variable interest via the license agreement with the collaborator and if the variable interest is a variable interest in the collaborator as a whole. In assessing whether the Company has a variable interest in the collaborator as a whole, the Company considers and makes judgments regarding the purpose and design of the entity, the value of the licensed assets to the collaborator, the value of the collaborator’s total assets and the significant activities of the collaborator. If the Company has a variable interest in the collaborator as a whole, the Company assesses whether or not the Company is the primary beneficiary of that VIE based on a number of factors, including (i) which party has the power to direct the activities that most significantly affect the VIE’s economic performance, (ii) the parties’ contractual rights and responsibilities pursuant to the collaboration agreement and (iii) which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE. If the Company determines it is the primary beneficiary of a VIE at the onset of the collaboration agreement, the collaboration is treated as a business combination and the Company consolidates the financial statements of the VIE into the Company’s consolidated financial statements. On a quarterly basis, the Company evaluates whether it continues to be the primary beneficiary of any consolidated VIEs. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, it deconsolidates the VIE in the period that the determination is made.
Fair Value of In-process Research and Development Assets and Contingent Payments
The present-value models the Company uses to estimate the fair values of in-process research and development assets and contingent payments pursuant to collaborations and acquisitions incorporate significant assumptions.
The Company’s discounted cash flow models pertaining to in-process research and development assets include: (i) assumptions regarding the probability of obtaining marketing approval for a drug candidate; (ii) the timing of and the expected costs to develop and commercialize a drug candidate; (iii) estimates of future cash flows from potential product sales with respect to a drug candidate; and (iv) appropriate discount and tax rates.
The Company bases its estimates of the probability of achieving the milestones relevant to the fair value of contingent payments, which could include milestone, royalty and option payments, on industry data. Estimates included in the discounted cash flow models pertaining to contingent payments also include: (i) estimate regarding the timing of the relevant development and commercial milestones and royalties, (ii) and appropriate discount rates. Please refer to Note E, “Fair Value Measurements,” for further information.
In-process Research and Development Assets
The Company records the fair value of in-process research and development assets as of the transaction date of a business combination. Each of these assets is accounted for as an indefinite-lived intangible asset and is maintained on the Company’s consolidated balance sheet until either the project underlying it is completed or the asset becomes impaired. If the asset becomes impaired or is abandoned, the carrying value of the related intangible asset is written down to its fair value, and an impairment charge is recorded in the period in which the impairment occurs. If a project is completed, the carrying
value of the related intangible asset is amortized as a part of “Cost of sales” over the remaining estimated life of the asset beginning in the period in which the project is completed. In-process research and development assets are tested for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist.
In-process research and development that is acquired in a transaction that does not qualify as a business combination under GAAP and that does not have an alternative future use is expensed in the period in which it is acquired.
Goodwill
The difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is allocated to goodwill. Goodwill is evaluated for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist.
Deconsolidation
Upon the occurrence of certain events and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its subsidiaries, including consolidated VIEs. If the Company determines it no longer has a controlling interest, the subsidiary is deconsolidated. The Company records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i) the aggregate of (a) the fair value of any consideration received, (b) the fair value of any retained noncontrolling investment in the former subsidiary and (c) the carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii) the carrying amount of the former subsidiary’s assets and liabilities.
Discontinued Operations
The Company assesses whether a deconsolidation is required to be presented as discontinued operations in its consolidated financial statements on the deconsolidation date. This assessment is based on whether or not the deconsolidation represents a strategic shift that has or will have a major effect on the Company’s operations or financial results. If the Company determines that a deconsolidation requires presentation as a discontinued operation on the deconsolidation date, or at any point during the one year period following such date, it will present the former subsidiary as a discontinued operation in current and comparative period financial statements.
Embedded Derivatives
Embedded derivatives are required to be bifurcated from the host instruments and recorded at fair value if the derivatives are not clearly and closely related to the host instruments on the date of issuance. The Company did not have any material embedded derivatives that required bifurcation recorded on its consolidated balance sheets as of December 31, 2019 and 2018, respectively.
Hedging Activities
The Company recognizes the fair value of hedging instruments that are designated and qualify as hedging instruments pursuant to GAAP, foreign currency forward contracts, as either assets or liabilities on the consolidated balance sheets. Changes in the fair value of these instruments are recorded each period in “Accumulated other comprehensive (loss) income” as unrealized gains and losses until the forecasted underlying transaction occurs. Unrealized gains and losses on these foreign currency forward contracts are included in “Prepaid expenses and other current assets” or “Other assets,” and “Other current liabilities” or “Other long-term liabilities,” respectively, on the Company’s consolidated balance sheets depending on the remaining period until their contractual maturity. Realized gains and losses for the effective portion of such contracts are recognized in “Product revenues, net” in the consolidated statement of operations in the same period that it recognizes the product revenues that were impacted by the hedged foreign exchange rate changes. The Company classifies the cash flows from hedging instruments in the same category as the cash flows from the hedged items.
Certain of the Company’s hedging instruments are subject to master netting arrangements to reduce the risk arising from such transactions with its counterparties. The Company presents unrealized gains and losses on its foreign currency forward contracts on a gross basis within its consolidated balance sheets.
The Company also enters into foreign currency forward contracts with contractual maturities of less than one month designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities including intercompany balances. These contracts are not designated as hedging instruments pursuant to GAAP. Realized gains and losses for such contracts are recognized in “Other income (expense), net” in the consolidated statement of operations each period.
Restructuring Expenses
The Company records costs and liabilities associated with exit and disposal activities based on estimates of fair value in the period the liabilities are incurred. The Company’s exit and disposal activities have primarily been associated with the Company’s facilities, but also have included the termination of employees in some cases. The Company’s initial estimate of its liabilities for net ongoing costs associated with its facility obligations are recorded at fair value on the cease use date. On a quarterly basis, the Company evaluates and adjusts these liabilities as appropriate for changes in circumstances. Changes to the Company’s estimate of these liabilities are recorded as additional restructuring expenses (credits). These costs are included in “Restructuring (income) expenses” on the Company’s consolidated statements of operations.
The Company has adopted several plans to restructure its facilities and operations for which it has incurred restructuring expenses. The only significant restructuring event during the three years ended December 31, 2019 commenced in February 2017 upon the Company’s decision to consolidate its research activities into its Boston, Milton Park and San Diego locations. The Company closed its research site in Canada as a result of this decision affecting approximately 70 positions. The Company’s lease for its research site in Canada expired in October 2018. As of December 31, 2019 and 2018, the Company has no restructuring liabilities recorded on its consolidated balance sheet and does not anticipate any additional charges related to this restructuring event in the future.
Comprehensive Income (Loss)
Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss), which includes foreign currency translation adjustments and unrealized gains and losses on foreign currency forward contracts and certain marketable securities. For purposes of comprehensive income (loss) disclosures, the Company records provisions for or benefits from income taxes related to the unrealized gains and losses on foreign currency forward contracts and certain marketable securities. The Company does not record provisions for or benefits from income taxes related to the cumulative translation adjustment, as the Company intends to permanently reinvest undistributed earnings in its foreign subsidiaries.
Foreign Currency Translation and Transactions
The majority of the Company’s operations occur in entities that have the U.S. dollar denominated as their functional currency. The assets and liabilities of the Company’s entities with functional currencies other than the U.S. dollar are translated into U.S. dollars at rates of exchange in effect at the end of the year. Revenue and expense amounts for these entities are translated using the average exchange rates for the period. Net unrealized gains and losses resulting from foreign currency translation are included in “Accumulated other comprehensive (loss) income.” Net foreign currency exchange transaction losses, which are included in “Other income (expense), net” on the Company’s consolidated statement of operations, were $5.2 million, $1.1 million and $5.5 million for 2019, 2018 and 2017, respectively. These net foreign currency exchange losses are presented net of the impact of the foreign currency forward contracts designed to mitigate their effect on the Company’s consolidated statement of operations.
Net Loss Per Share Attributable to Vertex Common Shareholders
Basic and diluted net loss per share attributable to Vertex common shareholders are presented in conformity with the two-class method required for participating securities. Under the two-class method, earnings are allocated to (i) Vertex common shares, excluding unvested restricted stock, and (ii) participating securities, based on their respective weighted-average shares outstanding for the period. Shares of unvested restricted stock granted under the Company’s Amended and Restated 2006 Stock and Option Plan have the non-forfeitable right to receive dividends on an equal basis with other outstanding common stock. As a result, these unvested shares of restricted stock are considered participating securities under the two-class method. Potentially dilutive shares result from the assumed exercise of outstanding stock options (the proceeds of which are then assumed to have been used to repurchase outstanding stock using the treasury stock method).
Basic net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.
Recently Adopted Accounting Standards
Leases
In 2016, the Financial Accounting Standards Board (“FASB”) issued ASC 842, which amends a number of aspects of lease accounting and requires entities to recognize right-of-use assets and liabilities on the balance sheet. ASC 842 became effective on January 1, 2019.
Until December 31, 2018, the Company applied build-to-suit accounting and was the deemed owner of its leased corporate headquarters in Boston and research site in San Diego, for which it was recognizing depreciation expense over the buildings’ useful lives and imputed interest on the corresponding construction financing lease obligations. Under the amended guidance that became effective January 1, 2019, the Company accounts for these buildings as finance leases, resulting in increased depreciation expense over the respective lease terms of approximately 15 years, which are significantly shorter than the buildings’ useful lives of 40 years. The amended guidance also results in a reduction in imputed interest expense in the initial years of each finance lease term.
In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”), which offered a transition option to entities adopting ASC 842. Under ASU 2018-11, entities could elect to apply ASC 842 using a modified-retrospective adoption approach resulting in a cumulative effect adjustment to accumulated deficit at the beginning of the year in which the new lease standard is adopted, rather than adjustments to the earliest comparative period presented in their financial statements. The Company adopted ASC 842 using the modified-retrospective method. As of January 1, 2019, the Company recorded a cumulative effect adjustment to increase its “Accumulated deficit” by $40.3 million related to the adjustments to its build-to-suit leases described in the previous paragraph.
The Company elected the package of transition practical expedients for leases that commenced prior to January 1, 2019, allowing it not to reassess (i) whether any expired or existing contracts contain leases, (ii) the lease classification for any expired or existing leases and (iii) the initial indirect costs for any existing leases.
Additionally, the Company recorded, upon adoption of ASC 842 on January 1, 2019, operating lease assets of $61.7 million and corresponding liabilities of $71.9 million related to its real estate leases that are not treated as finance leases under ASC 842. The difference between these assets and liabilities was primarily attributable to prepaid or accrued lease payments. The Company also reclassified amounts that were recorded as “Capital lease obligations, current portion” and “Capital lease obligations, excluding current portion” as of December 31, 2018 to “Other current liabilities” and “Long-term finance lease liabilities,” respectively, on January 1, 2019. These adjustments had no impact on the Company’s consolidated statement of operations and had no impact on the Company’s accumulated deficit.
The cumulative effect of applying ASC 842 on the Company’s consolidated balance sheet as of January 1, 2019 was as follows:
 
Balance as of
 
 
 
Balance as of
 
December 31, 2018 ^
 
Adjustments
 
January 1, 2019
Assets
(in thousands)
Prepaid expenses and other current assets
$
140,819

 
$
(2,930
)
 
$
137,889

Property and equipment, net
812,005

 
(53,920
)
 
758,085

Deferred tax assets
1,499,672

 
11,236

 
1,510,908

Other assets
—

 
61,674

 
61,674

Total assets
$
6,245,898

 
$
16,060

 
$
6,261,958

Liabilities and Shareholders’ Equity
 
 
 
 
 
Capital lease obligations, current portion
$
9,817

 
$
(9,817
)
 
$
—

Other current liabilities
40,589

 
34,304

 
74,893

Capital lease obligations, excluding current portion
19,658

 
(19,658
)
 
—

Construction financing lease obligation, excluding current portion
561,892

 
(561,892
)
 
—

Long-term finance lease liabilities
—

 
569,487

 
569,487

Other long-term liabilities
26,280

 
43,946

 
70,226

Accumulated deficit
(2,989,478
)
 
(40,310
)
 
(3,029,788
)
Total liabilities and shareholders’ equity
$
6,245,898

 
$
16,060

 
$
6,261,958

^ As reported in the Company’s 2018 Annual Report on Form 10-K.

“Other assets” and “Other long-term liabilities” in the table above relate primarily to the Company’s operating leases. Please refer to Note M, “Leases,” for further information regarding the Company’s leases as well as certain disclosures required by ASC 842.
Derivatives and Hedging
In 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815) (“ASU 2017-12”), which helps simplify certain aspects of hedge accounting and enables entities to more accurately present their risk management activities in their financial statements. ASU 2017-12 became effective January 1, 2019. The adoption of ASU 2017-12 did not have a significant effect on the Company’s consolidated financial statements.
Revenue Recognition
In 2014, the FASB issued ASC 606. The new guidance became effective January 1, 2018. ASC 606 applies a more principles-based approach to recognizing revenue. Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted ASC 606 on January 1, 2018 using the modified-retrospective adoption method for all contracts that were not completed as of the date of adoption. Under the modified-retrospective method, the Company recognized the cumulative effect of applying the standard within “Accumulated deficit” on its consolidated balance sheet as of January 1, 2018.
For all reporting periods, the Company has not disclosed the value of unsatisfied performance obligations for all product revenue contracts with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. 
Based on the Company’s review of existing customer contracts as of January 1, 2018, it concluded that the only significant impact that the adoption of ASC 606 had on its financial statements related to shipments of ORKAMBI under early access programs in France. Prior to the adoption of ASC 606, the Company did not recognize revenue on the proceeds received from sales of ORKAMBI under early access programs in France because the price was not fixed or determinable based on the status of ongoing pricing discussions. As of January 1, 2018, the Company recorded a cumulative effect
adjustment to its accumulated deficit of $8.3 million related to the adoption of ASC 606, which primarily represented the Company’s estimated amount of consideration it expected to retain related to these shipments that would not be subject to a significant reversal in amounts recognized, net of costs previously deferred related to these shipments. Please refer to “Product Revenues, Net” above for further information related to the impact of the new revenue recognition on these sales.
The impact of adoption on the Company’s consolidated statement of operations for the year ended December 31, 2018 was as follows:
 
Year Ended December 31, 2018
 
As Reported
under ASC 606
 
Balances
without Adoption of ASC 606
 
Effect of Change
Higher/(Lower)
 
(in thousands)
Product revenues, net
$
3,038,325

 
$
3,019,484

 
$
18,841

Cost of sales
409,539

 
402,925

 
6,614

Income from operations
635,150

 
622,923

 
12,227

Net income attributable to Vertex
$
2,096,896

 
$
2,084,669

 
$
12,227

 
 
 
 
 
 
Amounts per share attributable to Vertex common shareholders:
 
 
 
 
 
Net income:
 
 
 
 
 
Basic
$
8.24

 
$
8.20

 
$
0.04

Diluted
$
8.09

 
$
8.04

 
$
0.05


ASC 606 did not have an aggregate impact on the Company’s net cash provided by operating activities, but resulted in offsetting changes in certain assets and liabilities presented within net cash provided by operating activities in the Company’s consolidated statement of cash flows.
Equity Investments
In 2016, the FASB issued ASU 2016-01, which amended guidance related to the recording of financial assets and financial liabilities. Under ASU 2016-01, equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of an investee) are measured at fair value with changes in fair value recognized in net income (loss). However, an entity has the option to measure equity investments without readily determinable fair values at (i) fair value or (ii) cost adjusted for changes in observable prices minus impairment. Changes in measurement under either alternative are recognized in net income (loss). ASU 2016-01 became effective January 1, 2018 and required the modified-retrospective adoption method. As of January 1, 2018, the Company held publicly traded equity investments and equity investments accounted for under the cost method. As a result, in 2018, the Company recorded a $25.1 million cumulative effect adjustment to “Accumulated deficit” related to its publicly traded equity investments equal to the unrealized gain, net of tax, that was recorded in “Accumulated other comprehensive (loss) income” as of December 31, 2017. The adoption of ASU 2016-01 had no effect on the Company’s equity investments accounted for under the cost method because the original cost basis of these investments was recorded on the Company’s consolidated balance sheet as of December 31, 2017. In 2019 and 2018, the Company recorded net unrealized gains of $132.5 million and $2.6 million, respectively, to “Other income (expense), net” in its consolidated statement of operations related to the change in fair value of its equity investments.
Intra-Entity Transfers
In 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”), which removes the previous exception in GAAP prohibiting an entity from recognizing current and deferred income tax expenses or benefits related to the transfer of assets, other than inventory, within the consolidated entity. The exception to defer the recognition of any tax impact on the transfer of inventory within the consolidated entity until it is sold to a third party remains unaffected. ASU 2016-16 became effective January 1, 2018. In 2018, upon adoption of ASU 2016-16, the Company recorded a deferred tax asset and corresponding full valuation allowance of $204.7 million equal to the unamortized cost of
intellectual property rights transferred to the United Kingdom in 2014 multiplied by an appropriate statutory rate. There was no cumulative effect adjustment to “Accumulated deficit” using the modified-retrospective adoption method.
Goodwill
In 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) (“ASU 2017-04”) related to measurements of goodwill. ASU 2017-04 modifies the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value, which eliminates Step 2 from the goodwill impairment test. An entity would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to the related reporting unit. The Company early adopted ASU 2017-04 and utilized this approach for annual and interim goodwill impairment tests conducted after January 1, 2018. The adoption of ASU 2017-04 did not have a significant effect on the Company’s consolidated financial statements.
Cash Flows - Restricted Cash
In 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) Restricted Cash (“ASU 2016-18”), which requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and restricted cash. Therefore, amounts described as restricted cash should be included with cash and cash equivalents when reconciling the beginning of period and end of period amounts shown on the statement of cash flows.  ASU 2016-18 became effective January 1, 2018 and was effective on a retrospective basis. The cash, cash equivalents and restricted cash balances for the years ended December 31, 2019 through 2016, which are presented in the Company’s consolidated statements of cash flows subsequent to the adoption of ASU 2016-18, consisted of the following:
 
As of December 31,
 
2019
 
2018
 
2017
 
2016
 
(in thousands)
Cash and cash equivalents
$
3,109,322

 
$
2,650,134

 
$
1,665,412

 
$
1,183,945

Prepaid expenses and other current assets
8,004

 
4,910

 
2,114

 
47,762

Other assets
3,355

 
3,209

 
—

 
—

Cash, cash equivalents and restricted cash per statement of cash flows
$
3,120,681

 
$
2,658,253

 
$
1,667,526

 
$
1,231,707


The Company’s restricted cash, if any, is included in “Prepaid expenses and other current assets” and “Other assets” in its consolidated balance sheets. As of December 31, 2017 and 2016, the Company recorded BioAxone’s cash and cash equivalents as “Prepaid expenses and other current assets” because the Company did not have any interest in or control over BioAxone’s cash and cash equivalents.
Stock-Based Compensation - Improvements
In 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”), which simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 became effective January 1, 2017. ASU 2016-09 eliminated the requirement that excess tax benefits were realized as a reduction in current taxes payable before the associated tax benefit could be recognized as an increase in additional paid-in capital. This created a deferred tax asset of $410.8 million relating to federal and state net operating losses (“NOLs”) that were fully reserved by an equal increase in the Company’s valuation allowance as of January 1, 2017. The Company recorded deferred tax assets of $404.7 million relating to federal NOLs and $6.1 million relating to state NOLs, both of which were offset by a full valuation allowance. Upon adoption, the Company also elected to change its accounting policy to account for forfeitures of options and awards as they occur. The change was applied on a modified-retrospective basis with a cumulative effect adjustment to increase “Accumulated deficit” by $9.4 million as of January 1, 2017. This change also resulted in an increase to the deferred tax asset of $3.4 million, which was offset by a full valuation allowance. As a result, there was no cumulative effect adjustment to accumulated deficit related to income taxes. The provisions related to the recognition of excess tax benefits in the Company’s consolidated statement of
operations and classification in the consolidated statement of cash flows were adopted prospectively, and as such, the prior periods were not retrospectively adjusted.
Recently Issued Accounting Standards
Internal-Use Software
In 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”), which clarifies the accounting for implementation costs in cloud computing arrangements.  ASU 2018-15 was effective on January 1, 2020. The Company expects the adoption of ASU 2018-15 will result in an insignificant amount of additional assets recorded on its consolidated balance sheet.
Fair Value Measurement
In 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which modifies the disclosure requirements for fair value measurements. ASU 2018-13 was effective on January 1, 2020. The Company expects the adoption of ASU 2018-13 will result in additional disclosures related to its assets and liabilities that are valued based on Level 3 inputs.
Credit Losses
In 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 was effective on January 1, 2020. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on its consolidated financial statements.
XML 76 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Nature of Business and Accounting Policies - Foreign Currency Gain (Loss) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Accounting Policies [Abstract]      
Derivative term (less than) 1 month    
Foreign Currency Translation      
Net foreign currency transaction loss $ 5.2 $ 1.1 $ 5.5
XML 77 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Nature of Business and Accounting Policies - Intra-Equity Transfers (Details) - USD ($)
Dec. 31, 2019
Jan. 01, 2019
Dec. 31, 2018
Jan. 01, 2018
Jan. 01, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Deferred tax assets $ 1,626,358,000   $ 1,880,125,000    
Cumulative effect adjustment for adoption of new accounting guidance   $ (40,310,000)   $ 9,229,000 $ 0
Accounting Standards Update 2016-16          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Deferred tax assets       204,700,000  
Accumulated Deficit          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative effect adjustment for adoption of new accounting guidance   $ (40,310,000)   33,349,000 $ (9,371,000)
Accumulated Deficit | Accounting standards update 2016-01          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative effect adjustment for adoption of new accounting guidance       $ 0  
XML 78 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Marketable Securities and Equity Investments (Tables)
 12 Months Ended
Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]  
Summary of cash, cash equivalents and marketable securities
A summary of the Company’s cash equivalents and marketable securities, which are recorded at fair value (and do not include $2.3 billion and $1.4 billion of cash as of December 31, 2019 and 2018, respectively), is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of December 31, 2019
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
791,039

 
$
—

 
$
—

 
$
791,039

Corporate debt securities
6,070

 
—

 
—

 
6,070

Commercial paper
29,470

 
3

 
(1
)
 
29,472

Total cash equivalents
826,579

 
3

 
(1
)
 
826,581

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
12,689

 
44

 
—

 
12,733

Corporate debt securities
301,458

 
391

 
(50
)
 
301,799

Commercial paper
102,240

 
121

 
(5
)
 
102,356

Total marketable debt securities
416,387

 
556

 
(55
)
 
416,888

Corporate equity securities
113,829

 
168,255

 
—

 
282,084

Total marketable securities
$
530,216

 
$
168,811

 
$
(55
)
 
$
698,972

 
 
 
 
 
 
 
 
As of December 31, 2018
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
1,226,603

 
$
—

 
$
—

 
$
1,226,603

U.S. Treasury securities
5,967

 
—

 
(1
)
 
5,966

Government-sponsored enterprise securities
7,124

 
—

 
(1
)
 
7,123

Commercial paper
58,271

 
—

 
(3
)
 
58,268

Total cash equivalents
1,297,965

 
—

 
(5
)
 
1,297,960

Marketable securities:
 
 
 
 
 
 
 
U.S Treasury securities
6,026

 
—

 
—

 
6,026

Government-sponsored enterprise securities
10,704

 
—

 
—

 
10,704

Corporate debt securities
234,088

 
27

 
(450
)
 
233,665

Commercial paper
100,498

 
—

 
(108
)
 
100,390

Total marketable debt securities
351,316

 
27

 
(558
)
 
350,785

Corporate equity securities
133,157

 
40,619

 
(6,453
)
 
167,323

Total marketable securities
$
484,473

 
$
40,646

 
$
(7,011
)
 
$
518,108

Available-for-sale debt securities were classified on the Company’s consolidated balance sheets as follows:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Cash and cash equivalents
$
826,581

 
$
1,297,960

Marketable securities
416,888

 
350,785

Total
$
1,243,469

 
$
1,648,745


Available-for-sale debt securities by contractual maturity were as follows:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Matures within one year
$
1,137,942

 
$
1,647,500

Matures after one year through five years
105,527

 
1,245

Total
$
1,243,469

 
$
1,648,745
XML 79 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborative Arrangements (Tables)
 12 Months Ended
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of collaborative arrangement summary of items related to variable interest entities
An aggregate summary of net loss attributable to noncontrolling interest related to the Company’s VIEs for the years ended December 31, 2018 and 2017 was as follows:
 
2018
 
2017
 
(in thousands)
Loss attributable to noncontrolling interest before benefit from income taxes and changes in fair value of contingent payments
$
31,191

 
$
223,379

Benefit from income taxes
(3,668
)
 
(114,090
)
(Increase) decrease in fair value of contingent payments
(17,730
)
 
62,560

Net loss attributable to noncontrolling interest
$
9,793

 
$
171,849
XML 80 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2019
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
Property and equipment, net consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Buildings
$
648,003

 
$
657,438

Furniture and equipment
317,567

 
280,908

Software
167,547

 
162,601

Leasehold improvements
241,178

 
103,428

Computers
63,325

 
59,073

Total property and equipment, gross
1,437,620

 
1,263,448

Less: accumulated depreciation
(692,540
)
 
(451,443
)
Total property and equipment, net
$
745,080

 
$
812,005
XML 81 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements
 12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements
The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability.
The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. The Company maintains strategic investments separately from the investment policy that governs its other cash, cash equivalents and marketable securities as described in Note F, “Marketable Securities and Equity Investments.” As of December 31, 2019, the Company’s investments were in money market funds, government-sponsored enterprise securities, corporate debt securities, commercial paper and corporate equity securities. Additionally, the Company utilizes foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on its consolidated statement of operations.
As of December 31, 2019, the Company’s financial assets and liabilities that were subject to fair value measurements were valued using both observable and unobservable inputs. The Company’s financial assets valued based on Level 1 inputs consisted of money market funds, government-sponsored enterprise securities and corporate equity securities. The Company’s financial assets and liabilities valued based on Level 2 inputs consisted of certain corporate equity securities as described below, corporate debt securities, commercial paper, which consisted of investments in highly-rated investment-grade corporations and foreign currency forward contracts with reputable and creditworthy counterparties. As discussed further below, the Company’s financial liabilities valued based on Level 3 inputs consisted of acquisition related contingent milestones. During 2019, 2018 and 2017, the Company did not record any other-than-temporary impairment charges related to its financial assets.
The following tables set forth the Company’s financial assets and liabilities subject to fair value measurements (and does not include $2.3 billion and $1.4 billion of cash as of December 31, 2019 and 2018, respectively):
 
Fair Value Measurements as of December 31, 2019
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
791,039

 
$
791,039

 
$
—

 
$
—

Corporate debt securities
6,070

 
—

 
6,070

 
—

Commercial paper
29,472

 
—

 
29,472

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
282,084

 
261,797

 
20,287

 
—

Government-sponsored enterprise securities
12,733

 
12,733

 
—

 
—

Corporate debt securities
301,799

 
—

 
301,799

 
—

Commercial paper
102,356

 
—

 
102,356

 
—

Prepaid expenses and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
9,725

 
—

 
9,725

 
—

Total financial assets
$
1,535,278

 
$
1,065,569

 
$
469,709

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other current liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(5,533
)
 
$
—

 
$
(5,533
)
 
$
—

Long-term contingent consideration
(176,500
)
 
—

 
—

 
(176,500
)
Other long-term liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
(1,821
)
 
—

 
(1,821
)
 
—

Total financial liabilities
$
(183,854
)
 
$
—

 
$
(7,354
)
 
$
(176,500
)

 
Fair Value Measurements as of December 31, 2018
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
1,226,603

 
$
1,226,603

 
$
—

 
$
—

U.S. Treasury securities
5,966

 
5,966

 
—

 
—

Government-sponsored enterprise securities
7,123

 
7,123

 
—

 
—

Commercial paper
58,268

 
—

 
58,268

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
167,323

 
153,733

 
13,590

 
—

U.S. Treasury securities
6,026

 
6,026

 
—

 
—

Government-sponsored enterprise securities
10,704

 
10,704

 
—

 
—

Corporate debt securities
233,665

 
—

 
233,665

 
—

Commercial paper
100,390

 
—

 
100,390

 
—

Prepaid expenses and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
19,023

 
—

 
19,023

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
1,514

 
—

 
1,514

 
—

Total financial assets
$
1,836,605

 
$
1,410,155

 
$
426,450

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other current liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(340
)
 
$
—

 
$
(340
)
 
$
—

Other long-term liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
(108
)
 
—

 
(108
)
 
—

Total financial liabilities
$
(448
)
 
$
—

 
$
(448
)
 
$
—


Please refer to Note F, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
Fair Value of Corporate Equity Securities
The Company maintains strategic investments in corporate equity securities separately from the investment policy that governs its other cash, cash equivalents and marketable securities. The Company classifies its investments in publicly traded companies as “Marketable securities” on its consolidated balance sheets. Generally, the Company’s investments in the common stock of these publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of the Company’s investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments. During the year ended December 31, 2019, the Company transferred the fair value of one of its strategic investments in a publicly traded company from Level 2 to Level 1 upon the expiration of transfer restrictions associated with this investment. Please refer to Note F, “Marketable Securities and Equity Investments,” for further information on these investments.
Fair Value of Contingent Consideration
The Company’s contingent consideration liabilities, which are related to development and regulatory milestones potentially payable to Exonics’ former equity holders, are classified as Level 3 within the valuation hierarchy. The Company bases its estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to rare diseases. The discount rates used in the valuation model for contingent payments represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and
commercialization of a drug candidate in the pharmaceutical industry, the Company's estimates regarding the fair value of contingent consideration will change in the future, resulting in adjustments to the fair value of the Company’s contingent consideration liabilities, and the effect of any such adjustments could be material.
The following table represents a rollforward of the fair value of the Company’s contingent consideration liabilities:
 
Year Ended December 31, 2019
 
(in thousands)
Balance at December 31, 2018
$
—

Contingent consideration related to acquisition of Exonics
172,041

Increase in fair value of contingent payments
4,459

Balance at December 31, 2019
$
176,500


The “Increase in fair value of contingent payments” in the table above was due to changes in market interest rates and the time value of money.
Fair Value of Intangible Asset    
The fair value of the Company’s in-process research and development intangible assets, which totaled $400.0 million as of December 31, 2019, was determined through discounted cash flow models utilizing Level 3 fair value inputs. Please refer to Note C, “Acquisitions,” for further information on the key assumptions utilized to determine the fair value of the in-process research and development assets that the Company acquired as a result of its acquisitions of Semma and Exonics in 2019.
XML 83 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Inventories
 12 Months Ended
Dec. 31, 2019
Inventory Disclosure [Abstract]  
Inventories
Inventories
Inventories consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Raw materials
$
26,247

 
$
9,677

Work-in-process
107,021

 
87,944

Finished goods
34,234

 
26,739

Total
$
167,502

 
$
124,360
ZIP 84 0000875320-20-000007-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000875320-20-000007-xbrl.zip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

QS+*("-2,42%$9)3 3#*HX(CV@$:Y%* M *G/#LN\X^N41*I3 "%/$21*:_P1AD8H1JSE!(LE:T[A#<8*NFFB[I@J<6[DSSP,\ M#_ \H OJ *>-HP]*)2G0,K;YA301#,HZ%EN#9"VQ\+69P"G4/?8:AM

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�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�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

#[G#LTX83 M18*OQ ;3+K-#Z(U;64T[$'1+,-X5;S>?_ZPXB&9!?=;[,N(S^4^#Q WX!MF M@KA$ZF2-[K:-2ZX'=$NN)+FZI-8=DNAK@5UHG?4)3D$(8P10%!/?@ZY/TP!X@3O@B#&4>EA"?^OFU=,U MHYX2!.O53S/C5*J1FF#6JHQRRQ3*Z9W2\BLH[ MYU6)J()Y:AJJRJ-N"2V_]DI.2!:BT$<88984@P#[Q.]@8$ #WS4AH<*-FY=0 M:$9"Q>G5*Z%&F#4KH7R3SV()'1C5(*'2SGE=$BIOGJ*$*O*H54(_WQ=UD=\R MT5G U(4(^, #B><'H0?3,!E0I%$4:5=0B;8-"^@!B0$9E:%8HXH:8M>%1. M\.QN1O'#FF4/7;=LCG&1+C4U[1:S9YX&],X GT_I M/[P4Y6;2W\M4CY)E#1Y\+6JMPU1I$=?&KSYM[V]M]D=L?RFV9S]? #_&,:4> M)DF&*8F]J"M-S(%E'I8JNSN3NL20N ]N M^VUP&[]9$%$'734D&O(PD) 4@3CPDLM:KIR7#*[L? MZNJQJ+??VW?SBG_ORL?NJM1&](:=)CZOZ_'T5,I);0^MD]H;IT7WYOWM&X9O MJ$G:0IR4TE6UW'%GYNV5'GNH/<$U'<5G<8K;W48?U^MCCQ 3SX05O0S.&S$T MVU*9Z&/J2?ZJ>T2A:XZ$7A2%[*-)E/I)'"+6Q- (SK1A=(>F*'NF@U@Y)TF))I;_C2M2/\U@[+G[9!(%,5U\ M+>HOEY_C$NZ]W?"6AT0WCC+#J/S6-73%URZSIO@Y&D$X7;D*[J, MN3*1&LV1])I]\WY[7]1]8\=U66$*_,QE_0$D/FLF]"C!?;LN2;#0R_'Z6C.\ MNM/"VH^Q]0&8XC*S.JN2J_>3$#IBEL64J^.VAWC\V,ODW"HNXT_"L8:E?"6N MY=?R+]$ALIX_FDH+DBR]]EQ:U]?$E/0L]B@"M0B.FAXB$H4D"7&8>&D6 YC$ M/H'#/-KUPP2(Y60F6C:>H,G'"?DIRLL\B,Q>-+)IP9@S9=FE.8]V]D9.AWYA M'/7MIB3#U 48A##BMW%Q#.C0+@B)KV5&)-'>G).BXAL_W\C/.]LX/3J0*#]# M4G" U9,D%7O$YDG*3(F%1M;"MNXJIW?AF?6V0^M'C8,( >RG;L"$ +L4>@G3 M^*'Q*,$R45%;H^8'YQ'4?EV8#\?SL:IAJ%Z*G*)<70R:VLFV(5[J-ZHRVD&U M1$D6DY,,11F3 9Q&3 < B8=S+_P5^DSU#+E,&S/LP$BO5XSF4?XHBBD*1VS* M.$>8K$@8Y-,$82JM3@[$K1!+"219$7Y#^[&H9-3*D M-L3VCS,,^%41R%;A@F&!&4[AN- *)2K]./:\KN#0E=?(K%^0FIE OW M>V##D:^CIW%Z='.JU3E3PG*E3+&->J5NS%7!&LG12,4ZF@)!$$0D3A,09S1- MB)]0+^[;A<0'0ANI^EHSK%OOJLW=&_;W'IXD!PJ+Y4;'G-#JG#Z^K1YY*O:( M#3YEIL16YS[_'P#RQR1PP5"=/X)#"-+Q)SOZ?I)KL:[:>W/DVV.Q:8IFD21^%L HBE$:D\R%&4C)@ 2[5/R4 MF:'V38OX,6HG/\!VZAYW>]]P=4#N%#UT&;4RY!N1,#"_6R1CQ(E'CA ['X\] M<@3:(?9X1":XS.\9QXTJE%W>>#3J !OBF6$+J^FZL]RB0#L'RJIF M^SG_LBX^%]^V*2/ECX6/XR1), K\ %*/TLS%(4QH"CQ "0O),DL!JFV87@!H M)_O+2K;TH#)E8DN44[ E%VCZ%4F.R?F]1>5P6$Z+2SA_UK-$P=+9K.+[0X[-W M-_M]K>\WSD./5[TDBA7Z6M3Y7?&Q>,C+S; C^KFH'QJ^ M"%$V2UZN_V.^+9J/Q9I7_M]6W96_,["9YR+L$A"F'O1\"+$;TP$L1B 1SMSG M@VA8B@=SWN2=/4X]&-3G_?PD0M,MH?=&.36W2B(EG=&_ O.%U^%:.=T?;.+3 MM[V'>[.[/>P\/MCFM<4YOG;.M^MO1XV8F,W8#B:G,Z^@.:G,?"[J% MV*3)F!,NS;+F][H%TS(+2*BL&HD2.4S;SJ?=X^.ZW3/)UUG>W--U]>?;S6U5 M/[3C] Q%#'S?3P%(D8^0[Z,L3.,!A8M )IR<&&C;<-9Q#-99,K3.+8/KE >\ M$G'%!/4">(A5EYOB[% M3X/,6Q 835I73=-_97??^7+IA0/)%Q8&0@1#2A,2DL '+)RZJ9_M@RI,A.;: M)MLWOFO/(=^<']K7L+IIQ!FB>_[S^D$VR'4NN'9GR9IU3P5JKQXF,.1'%D8PT3X/(]/SC:"'DMGN)[J%_8J[N,K#AL4"'!=YS39>\03J1#\44 MW3[WJ:]LGKTAV-EP>(R;>^XL%(Q9JM(C^UKXOQ((IO6O':%A8INK.4>4EO#1 M(CB"=O(NXAFP@& W]:(L36,0>TF"?.KO@>&,:(@=.N',%SBZ[;*3N+$\KKNG M)VIH==VHD#&7U[3%BVZ;XR1/E*8<*O58<*(P6(QPAS7\@'B MEXJO+N5K], W49KWM^]WVV:;;WC!05S4Y=?V6LB'JBG; E%GZ%S@4X1BS ]G M9Z%+TP3[-(M(POP4@4QH+V-J3!.&BL-Z[C^*U1U/1]^VY?\4WB.?S&.RP<$> M9ZE'B,$&IS>"?^_(#.=@A[,WQ*(H,(SMN'&Z)\P.WY4?5.#*9_V0CBHVNDXLM EZS M*'QHXELHD$SM6]M"RN3V7PPN\WA"806KJHOR;D.^\9OH=T56;;9UOMPVSP+L M0^%Y)(P\XD(4<4@)]M(D 'N(<82DKMM,"FS"J4IOC3.8X^SM45Z_FL!QTBM9 M=OELQ)K617?=.'MCVE\?%K:OZ%2Y#> MWC;%MMV<.=P9/6L98!]BZ*;8)S%-PHBP*17-6+L,#H ^E"I"JJ&]R28M8M(^-:-RBGU =WSI?'8!%B#MBJ[JI-P.N=1JT7EU5^ULR8M;=S/^ M_$*GBPA,"."'ECS -Q6(3[.81H$?1#!2U#6EIEZ5I*F1*:MFQGE4%K*^D(8] M&O8<54+R-8ICVY1KG#$714L#1Z)ZU=?O^-*TR>$"!Q!C/PO3"/[_U5UK;^.X M%?V^OT) BW87R!02)8I4%UB I*@VP.Y,.C/ME_U@.+:2<=>Q4C_FL;^^U-.R M$\LD14I:8!_)).-[>*YXR$M=WLL\'N.$AA"X<0Q8R!/*E2J^*7ZT93TB(S1[ M.66@8WIH4C6-Z: +/C/RN.@\[E6+A<:6!T"$,/ CY()8A#N4(5;:0@#';JC^ MU*M:L/SPUQVVRXY'?U=;A34YDUM\[=.EMN:6>)IV*\ZO-::!5]I7>;FJ(+H\ M3DE(M,?PJI[T8T165GZ9;W]+]_EZ_2%=Y!<66HV7788QCH*8!N)?EX38]T%E M,6!(35SZV+$L,4=HSJ[!IB8TO5B4DYNA"%03G19W1U@CM7SJ8*A#?DSP.@T1 M,C*2S/Q3I[C/613E&7;OTT4JPG!A^6VZ;UK!QR3R_,!+X@!&/N4L\$AE$@8A M4#J$Z&7(]I:_PN9L&W WSB95K/3VR03QTQ N,T,YWT29XT=6NFXWG\6'9]MO MPM(,<49 $B4<>6$4>H!3%-4F $B4TM24/MBR--58!N\NUR:A8UYH<36->: ' M/3/PK*@]YW?;]'F^6E:M'IS'#C(XHL_>4]C@:G)&$4>PC M&HCU#7@$01?2R@;U$XQF^[REN,:1X-5/5IIC#0CI.5:V0I><3B:(TC@'-,I1 MK_._$0_]9 _[I,F:AGAH8N\ZW%-D0*K$X-TVKT.Q_W8GGHZ]D"'^O\.J:,4D MOFY7<"[ZS&=-GWF2!T=BTWQX.A0U$>/T602?JZ*8E/B;Y"G;[E>_E]757)S M*.0,^@ &) +8Q35JAIE6:AB]%S-H)2+V4BM%(,._+M:'_!K;/[)L^66U7@OA#%W.:.@% M :8T@CCB264ZIH@G:N&U 8/6P^X:H];.QPRGE4VR>UF*RW3 *A\WV# MT:E!7KXJ9^F XSIOG0')08YTM6X>+T(17[O^7M9I$]I1_G M7QL$,T(8"RF/H0\93PC%#.+:(* AF7U.M_>9K++U,*0R =N8%-(L2VS.?OYU ME,.1R^1TS#(#C$YC;ID82&;\:5-,63Z>L+P5HZYBJA!R'%*?AI@2EU(.0!C4 MMKCG4Z5,92T+EO<"!2BM;8 F87+KOGVNU!;ZDJ9FC6\@#9QX_!HK'0+3C\5I M:$O/,9QG%QM@1+JB]?'2A0AV/NRSQ6^?LK6@:Y>'3_MO3386CV*?()CX4>2' M?A")C0&JS(L?A4KU[HP9M:P[[3M)^7'&AT_S;5HA_. :R9+\ M=-.8KN?IDOG)!",QQD%"?;%IQXC6.W?.71YH3E!5 M,Y:G9)WLNSXB5,R1[D.AW+Y@(/;4-@:M3D&04\PLCWW(1@$!*"O(17QA+QC=(N0=/$4)F*SR4LO0Q% M5=HDW\S:9TSQ%6U-5H5HY(S#4UXD<@TUB9R&S/0=Q(7\PEZ<*,C+]I N7\K: MC.>7*Z,8>PR3A(0P<+E?VT.")46%T;1B7V1R8$UVU>#3Y75:NF=,3RHG,VGZ MCN/EO#'"C-(9X2O60C=DR$.,>*$'7$"#",2UM1 #I1>(NC8&.2=EKMBR8?I-BL ME$*TR"U2[ =)S/-;/W%,XP#A.ID7AP%$2J4M^MBQG5MSA%9L^Q=M<&HJT8M- M.=48BDC%@/B,0R;%H15=Z2"H0V=,T#H-W3$RDLS\0Z?8Z.=%BN'MICK[NBN/ MO,A^OUW='XJB91^S?(N4]X_(UN)#'V\W0@?2W3$;",6 TYBA*.()AI#@)*C> MG6"$4:1T5V!@:);5[[7DWK08E6*"X= >DY/+"3M+36'; _EKE7Y]XS2#<:K1 M..WA./O,.1V04X]HM!Q(LP[I4/21/#^-16"LP9_W^AG3!PIEKLK[; 7:_\S7 MAW0&"'$]#W+$,>:(00#K@EH84<1#M>N9.A:LOV9J0#F['-6-\V?W;Z[G/,^W MSN<_I\D=GDVU29[7;Y;E:10&L8_]9M35# MBWHYX;?-N9IZ'\G^4))= !+Z79 X>+&P%G\JR<;*H%Y MMFF9$9OL($K<.(J#P$<>X(CXM1G/3Z":)"E_O/W7W@6BBV($7?=U.;IQ ,0W M4>074@0@O/$0J'_M=9&Z<<3/GM-%WOMG??D2FR&_R,?UUARB'LP+3XRO5.>< M7(G?M>B;AD;IPW\E4N_!@W2B^G*Y*IO0W\U7R]M-]?JS97U&,/0\+V:)Y[F0 M0D 26MT$Q#AT,5#*6.]OSG(8?43HY-4AWZPVSJ($J7A3Q@"Q4PY '//(H#0FL48@_CQ2OY1BU M;5OQCG#K"LAMP,[W:P'V!S%S<^#*UP7->D%2$4=T@*(\MK@O;W^<8'5*L,[W M.=P?RKIGV8,C, ]^HTJ%T"[QM.2:B2BIK=&]O)-ED459C7V?[N>K3;KD\^U& M!&.[DR*4#ZO%:C^#P/>"O!%6!+%+8^3ZK#[HBT**E5[7&# WH)(N2TC#SM/K M%'5,38/\3F,VFAQ09NU9'.-UZHQC3B'Q0X;]$'IQ!&E4;[I($'*EFO,#01HD MK6QW\27J'_'EFO67:M).FX8@##UH*R_1%#GOD5X>KW8+L?<_;%NMH7W.0X\F M*$EX%";B_\3'D1N"R"-AX/MNSSQR'9/6%W7AJET1Q2HFD9FB5"[H&8%-M5BG M!NBT$#I'B,ZOH_6:EZ.N0TT-N'DZ(Z9MCOCQS!_"#T=,A\RZP>#1T ME?TQCX4*:/W/A-0<,@T-M3,TO=,@'?XT]/3C=K[9K%A$M!S">=G:P*J>:)MPR.;TT,JC+2FF. M,PV-?)ON_[W9IO-UGO>4-X MS?]COMKD2EW!X#&F@<<"(C; 4>Q!&I"D@I%$ MR%,Z/#=NW+)NOA/J^'F^6N=S]8V8U&\^S,6DC=/[O7-L;*^MFH;X5];/X:E7 M5-)W[/;&:>MI#JUY_7A&_TW+10_"1;MY7B%U*JHJQ;6#_2WNGDR2.6+(_JV8&MO>,?PFT+!JDGY3Z]8,YY_]O-JDM_OT:3>C,8OB",(P<%WQ1"$4X^J5)'-#\8V%'#1Y MX]/*0\MQ.P5P.\EH"DXQFI!FQQ]6D])D7#%F9EI#:?_L-'7O_&&T5G-X>EEJ MNCS*7UI[W>IAM2B.[/.H6 ):U7CG+MVNLF5]K[*I9R:@)I@%OH\P1$P$ MS=!+:J@HD7L]."K (79=VB4.V_>>G5_?BY_6<;"BP(_C>[E%8/)N5\\D&=;C MEB[4FO=*QUHSZD,PC?5H7 I>7/,=W1]*;5,OK*DT?:A&Y(5JAZPV<=@^<+U6_,2Y+P;@;,]'H+8,6765W&HS%2^I+2H2 M%5(J#[U /U[ME!Y4=ZP40SAP&@O"("-]K7/O(.R.$;;,O"1B( IHA!/,24B M1^,*HH<8]F>;]+'(D1\G:KF*3TIAHE)A7@Q%?@O[E!WR-AA'M4^7Y8!ETGUF^IOQ7*TP$[*7&\.^=NB7!$^YT"=9_%-44Q(I2]P+TZ[M7Q8.M6$ MF9V6J2[X$]"<')OS85 25=HF#T6F9D-D?5(E&QUWC/]22K@1SB:0[FUF')GI MI^E_EE\]=-W]9^(_]S/=^E/W_T?4$L#!!0 ( !J&35 'EPMI6A8! M ))W#@ 5 =G)T>"TR,#$Y,3(S,5]P&UL['U9EQLWEN;[_ J/Y]EE M[$N?J>Z#U:UNV=)(LJO?XE"9D2FVF8SL(%-6UJ\?@&0P-RZQ,QA*5TG*) .( MNWS O;BXN/B___;M9O;#US1?3+/YWW^$?P,__I#.+[++Z?SZ[S_^_O$G]=&\ M>?/CO_WK__J___NGG_Y+?WC[@\TN[F[2^?('DZ>397KYPU_3Y9FG=:,?5C_,IO,__R7^]7FR2'_XMIC^R^+B2WHS>9M= M3):K=W]9+F__Y>>?__KKK[]]^YS/_I;EUS\C /#/VU9[GXB__50\]E/\Z">( M?L+P;]\6ES_^$#B<+U;O+O&2XO%O+Y[_"Z^>AE+*GU??;A]=3'<]&+J%/__7 MKV\_KOC\:3I?+"?SB_3'?_U?/_RP%D>>S=(/Z=4/\=_?/[QYTLG7?/GM;Q?9 MS<_QRY_519#YW2R*^]WR2YJ;[.8V3[^D\\7T:_HFZ.LF?9LM%H&B5<=?\O3J M[S_&+H(PH(1H+8K_4[&;Y?UM^O=9VA873SMKA8G_N9LNIG&TE:#QY;,MDV"R,!KRY?LOD_QF+:<7DUEY M)%3LJ&7BW;=L/KU8? KJF]RN7KE0EY>K[R:S-_.K+) 2?ZG!3LVNNV>P'5ZZ M)?MC>G,SZ4(KM3KNFKDV^.B6Y+(SXKX6;9"S592>S*(%_O@E39=KMH\25J)M MQR26U7'Y+CHFN*3*2_?0 KEFLOCB9]E?_YY>7@?']DUPQ?*5#UMV!)7NH UB ML]EL\CG+PX3R-55Y/IE?IZM7'27R6,,NB5/7UWEZ'7R:/Z:IG\Z#1J=UIMRV M^N^253W-)L&NI>'?Q<4TK);21?#:FC)8JM+=/[,26X! MMV4[[I*Y_[R_"0)6\_5ZZLW\[?0BK*92%::,M-(TW]8+NF3VUS2_^/,_KR>3 MIDSMZZA+XM]/\C >/K8W;1[KL$MFRGDZ)9NW0NC-S72Y-I?SR[ L7@9?)7DTKV,8V>N^?S?6#=_G%E\DBC=]TP^^QU_3'^+N[9=QIB#LX MX8L_TL5R\]B[VU6 I5W^*[ZM/S&\3_/5XC"X!3JHY/+#XF[Q/OQIE_V2;^F/ M[0]! _GT8OGPY;-/?I]/5[:E?5DT>75_ OH8%BJAQ]MBJ.;9=3ZY:5<2I=[1 M(\N;C]9#?4'/S&XFGZ>3D_L6%CS31?2Z.V"_XBO[$TC954J-SEIA M8K[(9M/+& YY' DN0?"1AET2%U:=P47_DJZ"';4IW=E+RV1_7(:_5^N)=U=% M%+N2; ]VT"6Q]5(<:G;7/R.U(52W[PY9?'>;YI-2>07E>^B0W)5Y_I+-+M-\ ML9[;PB3W6Q;$-U^&AK/5#L\RS8/W4I>?&J]HA>&O:?Y^)_O9@RV\W$WR M>6 KNL0K[H_1L._Y#D@I:>Z/-.N L'*V^7"K%LCRDVG^QV1VE_Z:3A9W>;GM MQH.-NB*J23I'[0Z[8F;[89S(-Y&^99Q1II>;V?#M=/(Y1OG*QT1;?U%GS!>; MN&JQ2%?+PDI.G&HG[FK5'V+NKJX#UY1-QE!U$%;IH MC^!R0V#GPRT0L?:C/TV^'2=AQZ/M$A =_&R^]BG7'Z\V$K*OTYBP[[-\$V?W M>7;SJ%E)Y;;^HG:9MYLX1/AEUVQ=GS]2^5V#C4LCWR'KEMJT_NOT_GTYN[F4<;3[_/+-/^03F9N$4.I-63>I.?6V/MU$HA8@7(;UUYM!FY" M#_/KU6-U1T?3WEMC\^/=;>@BBGOUE MF5ZJKT&5UZ'IS60Z+[3X*YCOZ9/EK>'%\S&?YQTG,;_B\?&BA M[V.@.9]<+.\FL\V4538'MC\*>A37Q[N;FTE^O]Y#C]]^#12OLWQW==&RJ)J] MO4IB-7>&.?5]-IN6R;6OU$E?1!=? M5HWKM-)Y7TR^ $B;3![KO"\FPVP8C/[^V(SUO6ZO)NE:Z?ZI6/] MF"!J]N3?QQ$RUU9F8&%X,>*RR)F[O#;VQ&W/E7Q 3?((\^YJV/;-5 M?5E?0BBW>JO151L,9.O@B;J);RJKC4.-6B!JEXDZ1M.A-AV15'516*6/CDC> M24):5N_U>^R(G7(CZWC+%LC[?W>3?)GFL_MM*J6=+">_SR=WE]-@(]T?HW!_BT[(V3.5 MZ?NB&F])D#3ON1/V-DL$??]+&@_>WGZ97C1FK'R?7;*TT/=!PI=AH=>4D;T] M=4+^QVE8J\4LCOG2W"V6V4WY2%.MSCIAHMQD/EV\CE]EIJYJ]TLSY\TB]729:R6 M#MF*@5V]M4QIL ?M$ON\PY;I?9_FT^S2S5L6\>YN.Z']XS(X0%U0_[+CENG_ M%.;VM%W*7W;9-LU93/MKE^877;9'ZS.'\S\WS\=^ M#U:4KG%O0?IMF+SBM.[Q4_7D\GMSW%F_SF= M+1?%)ZNY_B< -U=+_)_-Q\GFA/?GQ2K?I"!C%B7R]Q_#*Y/=#R8*$:$@TW)^_;=LF<9$L5D6CQM^"M+5 MX=5_'F"V=!]!#MA#89WE4AKD"4"2%')P4-LR"5*.R#( M^A%O8*88LC_O'+,]C>:=_MT9#&KHN.%*.6HT-\H*AYB'&GG)M*7:NH'!"S/2GL#[ M 2\L\4:%Z9\'#Z_@7BDZLDFJ(0+V M6[[V1'P"@/V6+N-1[%L(_#[V4<.7[RC*[G^>4%36JYS*>?[U;'(9;9NO3?7GRUTF_B MA:+6(:6@84!B2I#>\F\@@@W AL<*ME-(_C037\%&+!5CT\7T>K[R8//_=Q>& MU=5]O,'@T75::=7)L%[WB0B>#7<:"@>, %0( _A6<@*2!I@E8\7L"15P N@6 M? 46GS!P9$JMV5-B$2-> \*HU9AH0)E56R-B39/("/V. -F!K$^ O7WK^RJH M.]Q'0C27PENL"+1:&^TH,(4,@)=-EKOL.\);JU(>$-+B&'H[G:=OENG-H0!= MU:X2;8VTDE)& CD<6[%9JUF N_C&METDO,KF,=](7*#^G%D_(^T:$HP=KZ MV.ERG8$0IOUW5[&>W_%]FBY>%R7KA2$8X-A;Z0+/>-ED(##/9T![QL M<+KJ;Z?D^3YNX&5V=[DZ#).O,/%H/?@I.UQ%OM0^?)T7)-9P(@VT3DE%C"-8 MD*TJE<"][N3=[LD^:AOOIX7AT0W_'O38UR@X-)WH]"J+]RD]U<6B$.P!Z#?H M->$ >P8M1TXKPQ%#!O)"3I U6I\-T&\9%-+[4]LYNCH]N3@)]-(@2718SPBG MF$)0;Q9+0:1&-%DPEH_R'DL''?4X.*$ZAS#O-YS@MYP#![A53F$-%$1!#9[J M@G,%59/TPNJAWQ>9O*-&< ?ZZ0N99BVQ0/*ZT/J[J]_2OQX=5,^G\XOI[2PP MM);9IO+/H[-[._!:O].$4&F8HHX@YCT*8@*$%E*RA,MQQ8L'A>+>M/:ZYGRZ M5M$$06>(50!H 9UW8NO,08Y DYF[F>0?HZ, MTH0:B$D\14")-WKF#;!-TGSY?LOD_QFK>Y&/ODA MLRX&/*+<4<",ME);JX4U4DF E5;,4>1/> #MP61L:[\]TI"^?_3;L4-H5;M* MK N6C057--@8YH7F5L)"*L*J)OE_YS8)E ;(7HO?B54 MGD_FU^O[4 -)UWFZ^GG/L;-*[1-%"712L^ Q,4NQ#7,;W?*#Y<@,27?JSKH7 M?NM@VA*S][19E>:)-,Q!SS&@/C 2R"#.;;CQG)I21_^'#Z6.-%P&/\T$W@ ^ MN]R,P^$+=YG8!+UM.^4;0OM[J-P M58LO5KV\C@'*++]7M[%*^F16V8&K_ZK$*6D9T]!A@I06,2-6;#5G^/.VM5@;F_IX0'M\@@B9DE@2.)/5$;'CE $M)> M,KA&B+O61%X;5COB._&6J>GEYDJI/]ZX?3@JT311&"B%$9 08*2\$@3B@@NE M0)/5:>6,J:]I_CD[.^BT+^6^5QV/*/^8!C%.ENGL?G/MSC\WY3DF%^O(XG8> M?M@4>"Q+DRV6FQJXER46+AV].7%<2481UA 8$WXD7FS')M;(C"N#JE5,#U-% MO6X@N6_9?'JQ^/0EC.#;5?R@PI6\9[ZE1+VU1&K$%-%4JC!A668PI P0Y00K MY4B,;TM)8@"A81P0JB&5F@/K"ZE0PD=60*P=@#3=4JHF\]YRA;-5(FB0XA,C MK^\_!3*.5#P\VC;! %M,%7/2.2J95,KP@F?&Z?>^[50:$L^S>EL6_(G!%JD^ M6@GQ:-O$Z3" ,;6.,!E<4V(%A@7/TJF136HM8J N2;'),\$$34U MF'4@WG/.E-%&4 \0L$03K92E%* -IX98U.10T WSTYIO>K*O"]T%9O)G[+- MV"IX2!>_Y(_NG=J!L&--$^,5PT%D@'DA&6'$$;'E.(AV]--5#>5GG^P/4[#-F1QLFWD '(0UFGECMN 6%"L%(\,H')T;')=]J&IQ5 M8DV=%RQ,BH54A'(CNVBI'8 TWG^O)//SBUE;[PRR*F[X*-;4C@QBC35?.69=3;Z#B%E[ MPCE!"DI).236 .8+BHEUWP$B:FJP9,RZDGC/.6:-#+<$4P <9]Y#I!TO!,"5^OK,=-+G^7_R/(_5Q=PW4Z7^\^XU>DK 09A M14WP+$7@$4&%4"$\!@09_\9:#95G_0J]Y>-$N])@WDXGGZ>S=27(/)TLTG6! MRI>UT\H=.ZKUBH1* #B2&G-A*<(\" 864O'*-#D47'F:._WQI#I@/)TVQAR8 M!)X@B[#34%G(8Y0L.!T;21#5\WG+S@N-MXK*'N1]0N0]G(QZ$%!U2Z)ABK?$3S["Q[0VGVA8=5C> W\\OT:CJ?+M.WTZ_QJO7E9'X] MW2+_ %;*-$\XA@):BSPB,E[3[CA"VY$0_M< 1P.\[+03%'4@YW.TP"LQQ,+V MZPK[1^'9^;L3C+FU JL$?9&(H&W:T(>7/$FJQ_^G6![:$KJ=<_\8WIS,_DN MC[$#KAAA4#K-/+?&* \A O%Z"@S"6J)4"&M\V^B0JP#0(!A.D82(&>Q5D J% M,@PI+9J4!!QP8*\90)INHU>3>4V[NT#,(EC# M#8&+O;OB!Y]/K$(:>*:IY<%4 J:P%1N>3&!N)+5MFZOT)38:"[/^/E2>FO!4 MK)[[*4\GR]6>AL]RFZ[X6BRF<2?#I+-C58\K=Y1@&S,#%--&4QY7XY?00RJIRT'AOLN#0,ZC5_"B D3).2)@." M2F\N2KOB'D=.GX<,L9C%IN/M2F'FA)QO>,9.R2:)-P,R3:UIOG).7S7YUK9' M+T(C;^87?SMLF0XT2: Q,*PC(;622R"@C$5>5A,K1)Z+D?BW'6@QZT3 YYS9 MIZR7V!!&!;/,2&D%EFO108ND:U*":8 G\4YIP^K*?-2)+3%S$ADL'/- \S"& ML0F2"$*)OB)K4L#^/":R&J!HE-A22=YCVKC%R S%B]WQ/$F M\]P ??5.D-:!G$^[/S7&K2B)!=<0*D8]!APJ!:Q>W8G.$0:FW*;+^+:B!"8: M!(>.QEMD 6.06UQ(Q;!&]08&;&>: :3I5E0UF==>6O5V22=W'D%&*"2 (TX M(,9!38T'E"N*1W9C5'?JKG5)9S7AMPZFEB_I=(0AP;T0S 4I>2J0-AMN/)-C M.:G9D8;K7-)93>!#"?-(J"$WF'K"%#12"VS)9D@1Y,5(:GAUH\BRD9YJ,CZ_ M/8J8FZL LI13JQ6E1!-53,O4RR93S0#7/9U;K7;%/8X]"BVAX0A"[+7DQ#*J ML2R&$"#?P56:U31?>8^BFGQ?8NJ\95M3%J.;_QM'^IDS$$-BJ*$0<6^\DJ#@ M5(E&M[V,(=+?HB6H*_-S/,8PI(.$DG+!D')>"L*X=YQ)5TC;\4:'O"I/EB<_ MY%4:>OT>):RFH[Y&Q/L\NTWSY?W[V615/S-2O*JE^5MZ*!)[J%E"") 8*Z*H M0Q1KSBUA!:<>DB:;] /TO#O!8HOR'>*A5&<04\&V&.*@\L1*K^B& RJL:3)? M5;;(9SM?U93FF/8V'?=,::D)"L\W)6L7>QI6!A;VA D+L(?8 M<8"A5H((1V,M=5;N -GI,[""$G2@XL^6LK"*[A(#0*S*'&9"!C FP@;<"R*Q MH!AAHK^G3*S20&F0B553[GU9GP=67AK;8%R/F]K5_%$-K*V\*3&$*R*4L9Q1 M)AT2VK@@SS"S8N,M;[(J&7!TKR,NXE0<&= -![![5$A&!+,49*^.>WS?=I M[AX4X -FYQ?3IW6(IHN+6;:XRTM-'Y7[2L(<2SQ TA@ (?$2,Z<+N83Q,K(; MA%M!2-:OS$\Z YSZ[$'[$X& $!,3O(R 'JYA6-]JA8R33E/#E"ME$3N:""*I MZ6,#8C8K\^,<'VV;&*N= @""8'(TY&$I#TW!-W%D)%F:K2+@^4!O6<9]>:_N MYG:6W:?IY@K&E_0?P-71M@F%Q#"@+1;& 6]0F#2WTJ0$-JDN,4!T*YHN3LBSR=OL"/4M"KCONQ; ?7L?C(K9]7VM$B,E(P#Q8S"U#'L%3&R MX(]Y,;(,A>YL63OR[0L_GR;?TL7&83R.G1U/)]0*@I@#AL7P$B(:,U;P!5&C MG.7*9?O/&3?-9=MKOM1>01S+E-K;,($<@EAWT ;>('/&,:XWW#KG99-5V@ + M]W>'I%;%W+,AJX2G_3QJ%O?P$79*A[6NUISZPE@[0U63.R"J;U]W?AM3Y\:L ML81[G9IJ!9&.M RCAEBJ& ,(T? #=-JY@E^OQW9(LXL04KL2KKT 6Y%1+/U* M33=EFB6>0F7"!?:((,#A#:=>"];$? UPLFD;3!V(N'ZUDO5EKBL:WGV> M3:_7&_-[6-XW^53K)=&6< ;BT5L&E=0L+!P8L@!J*5@PUR,+!W4R%W4J\5Z] MH8]W\\O\OOHZ;5^[!"@."88.KNXN<"3>+K<=.12.["[(KB:G-F5\8N^ZNE>= M (F4@E( 0H WPAK.M_QQV:C86_6@4>?KLTXQU%BZIT+/H^S[ZLNSEXT32 *K MFF@$K/(&.HPA67/-@'"@R27U [1Z?:S0&@NY_C[LY=?HNL7[QA_*3F6/#FSL MW70]UC"AP@#F*0J&V@DM(TP1[ M[XP47"+D/,'>A;&UX1@RQ)MX30.T<%V"JUU)G]Z#JN4Y)Z%MXVG-F1\TGSG$Q_T:S_=&6M*(#1":,*$9T&;80%DN!-> MQKO+2]W,U/6AJI<[;#7.2QWK)%%".HLL(H88Z#54!JI"$D+X[R@!NC0F]IZ$ M:EG8O1J/382@#MI*M4]$6'%2A(51AA&%&=)F*UZC91.3,L"=BRZ UH6<>\78 M@_&K#;,2722<0!^KBWE/37#2L*7$>B.0QQ00)9M4*!B@,]P9TMH7=><^3"Q9 MZ&?97_^>7EZ'!>*;>9##W:I@_:E/;-DTGWY=U4=_1%10V892=1&^6@GXX61< M"1>G0:\)!,'\4$BAM PZ#8'2Z\0? XU"I-1.1+Q\-I_#;\Z&T[W;Y'8#?>Q$] M<4P)990#7LM /=9VRXE#:B3WG P9(EFK&NH!:R]O(S\,N!VWEQO (#'6"N3SG4+,$:&HPEMPHJ@2E7ANA"DYC ML;9Q11T&;,0ZT%;_N"Q2D#^%]Q^]>^=0LT1 ;X/0+!)(ZC#\E+#%.'8 DB8I M*0,R<^TJ?2^2&LNWMXSP+$^GUW/W[>)+O",M_/K7)+\\:@@/-0N<"FR%Y$A1 MCYV"4IM"?%[JL56::$?IS]/!VY-O7TC:,VL?,94'6B4<0<&5QX(9)Q0+,F3% MA.X1,J6VQ,XG:GH&EK(]99T8E$(,V%T5Y0B93!"A2\6L9'MD/9 MBM;+(:F6?/O"TH?T:SJ_VZ01KF?Z?TR77\S=8AEXR8_:S%+MDWBQ?; 90FL) M =>*0>+]"C(RC1/I/)"*ZLT M9Y)[!*%$&[DBH'BC^6N0J9_=H*P#4?<%LHTS8=-%<#++N&F[&R38?"(>H!W8XS MZ/3(=BR;JODH:FI)M;_HUYK.6-3[15[%40M9HG6B 2!"$Z4(-O$NC?"CWO - M@R!'MM'87/TOXF!MB[@O: 5S?KDE_BB4=CR=:&.-M#9>UNT X,!07(Q!Z!4: M62'_UJ'37*2GW!O:>@-O2]RN7:Z#A#$1G$;#,48L9NH:;''!O;&NW^/'KSY6 M1WKK-[,ZNPEZ_Q*6*2LFHO0B[8]S%=."H0_IQ6RR6$ROIANIIE=9GGZ:?#N: M?MW&2Q)E ;# 8>/#?,*D4XPA9#QW-IXW-R,+A[0-K9WIVB?0RTGGY-^RY4&' M9"O@PY=S-^X[P4@ $[0&G >08.D))D%FU'*!#99-]C,&Z!ITC.6^U=$7A'^? MY^ED%N\N*FA]-]^?1'X K]4Z2@P1SE*BN,3.6H##*M(4>J"@W\O#SQZJPH H)LY!)H)DTFS',+ M+S;'9/<*&,862>W-D<1J:)V7G".K';- :@\+;IEV36*(Y[;2:LG7;$O6W1_3 MVM:%"?)0>1Z3;IX8V-Z/9[W+KR?SZ3\GQ56\V6QZN4;5_/+](Q[?76UO,]NN M@,N<16^E_X1)JCGC!&OFO0(.&>-7-Z1!9JF!)[RD:Y]&J]W35Z&71$,5!@E@ M4!+%C*"*,UC(@A,YLBV(GO&3]:67TTTUZOHZ3Z^#B/Z8ICMO*#SQ@='SF)$0 M)0XH P 7W H""%7K>H(.2295J=K6S^6WI_#;0YF%?3I50:-K^O8=[JS74>(8 MBBQZ"Y )*P3C@Y-6<*D40*]S30-D9#VJIB^?^8])/HWDO9D'=:6+I9LO5T=: M];UY$N%[=[7ZYOY(/DB=[A(-,%.2(:X1AM=$7QA] M3O!.UNZ/YHA4Z2:!SBE#H",><6,@DHBBC204('YD9Q6Z! M&S[OP_R8S3]>3-/Y1;IX,[_XVUZC=O#Y!!KKF7=> 8VU0%1QO:4W3-@CN5RJ M&Q5F[0NX-B#T-%/?LGD:_EV41L7!1HG5VA" L":44,A<6'8C9 $PX5=/P9B, M4*?0:%/*M?%1Q\L#P_]D:WWP-<-'[:IRFR,=/G:Q".% M/<420@*5)B+\*0Q0K"HQDB+(/2)]@%KKM]I"S!\ILHRF\[O R>9^E&R^4,ME M/OU\MUS5[,UB/=^8BA2T$9Y:"^C .&BC^X2'Z40)01 1AE&$J9;%+I!!@/:S M)^OMGLO^P_Y]@[#G>4?>M5DOV/@T^3;)M-I+>)#T_N>%@G'@B)C#,8, M812K6M,BJF DL$T6T@.:F<\ ITU5TQ?T]-TB6*W%PF0WGZ?S8K<\RB;(/^Z; M3R\WP^MQ,,NL*DR]F:N;[&Z^C+9Q9Y/MK5;P )1[HB !QJFPF+'. "*#=RBD MW.K3,M9D:)1?^'WOD_@PE=W;2>%T^6#%#EFK0O0'ADWEOA+,O-#$!R% )K%V M$@-;R 08#7K)C/_>!T#7:CM=*J*>9I.7 <;7!,0R:68@UD-#\2H "*F&3$./ M,:7 0HH@T:46U-W([_CZ-Y9W7D%W]]>?PD^+P&-TT(_=5M'^RQ(M"!6.A-6W MQ9(JC1PC&\D2 !O5@QQ04.Y$:-Q[A=B)U/<])49*3*R"A".LF?#:&&6C9(*F M8HU8WVLA^>Z!?4IHM9$\64U;8TZ>U!1"8P#$@DNF,%'"X)4DB-(8RY'50>T6 M+$V2)ZOI86B[)6TG3TH;:S@R09FD5@3O6GH3I2$5E)"/[?[0;H#2+'FRF@;Z MB\Q>!CKGTV7Z-MB3R\!+,"C3P%4\\1R3NE8KQI4\CQ8MK]13HH,1(M8!@V@0 MBT%,DLXIH0;$9H9^,D 8*"3PR1 $0O.PP-HM0&S7!O1['E-61ANNH\%((BUQ!.0ES\'< E=K*+)\(7TW*O07JFL_-;TM4%V[S-0EE',+@ M$D3' C '&==^JQSK1U:(;0!V= !:[&UU>W,[F>:1ZG=7S]W2![]X%OWB;8VZ M7[+L\J_I;'8 _TVZ32S&SB,6?&I.83!<2%@=) 4]%E"$M=TXYN?3@NSY8K@_ M?9TNK\+DT\5M_BDLP":WZ=UR>K%0UZ]9%:6*]T#J/0D&G'%GG=6*$&J] <\XH+92G:2I:0D2Q;3H3&[K,JJJEO^"$;3JPA M$#M(+3/$8@6D*?@QSH]D:30$0-0*V513S]!#-M0A+!7TT&K*)?+"&UYP0R ? MR>T2'6FX3LBFFL#KP^?#FX_O/SSQLWXY'*_9WR*1UA-)G0Y^+&<"2^*E+VB6 MQ#;)M3X7D-168]:%B.O#XM-_@;#:SDRV9>@(*O8U2+1UP!(&L).,2& E;J@ M6'&HQK&EWP,H6I+P:_1N_Y(<0,RPYY1)#Z$)RW!!1"%)2W"3PM0#PNJ 7*H! M:+%US^M#T'_H](M-OZ:S[#9^Y._F,0I3U0G;WU/B.<% DK"F4BQ&;A0BVS'/ M@6LRJP[(U)X6'F7 MOI_, M@Q:Y;;06(M D"VR N]?#A?A)U-G^[!S)_)1MBI7]=A<7J^^N/DWRZ[0ZP@]V MEA#GC?)*42ID&.TQ](;^6ULG%Z^YE"4V;7&S$J$E +8:>PU M=%IK"1B24%.G="D_Z#6'8E> D')N,' .&Z0)UDHBR@O)&HM'%K?J&8W=YU!4 M4]_P$<*2^-(TA*I WS6+D- MKTQ@[+\#<-56?]:W^%_WX/>O]H0&D$HLD Y:$F$6\%86DF04-YDE![@I- "3 M/ MGN<>/ 0>:.2\)08(!+FD%F['O+>GA4?#/?AJ*JH-0W5Y.8T<3F9/ M:#P"N<.M$JF8)8 QX"&G05^(:;2AG6L%FECT 4Z$IX=7J^HX743P/X) 0G_O MOTSRF\G%RF&9S%Z+TI8-MD#HM"1&>"?BSC'SP8AZ(RDFEC&L2AW@?0W][?)+ ME&!4BW@E'S?,>81]<)DWDA5>-=E<'J"Y[!F-W8?^JJEO^*$_:C!60%M B7-4 M42%C\;TU/TK8)KF^ X3C*0%1*_1733U##_UA@\-:S!KD Q=02R4%+K@)R[7O M(3I37\.U[@*N)/#:\-GK;!TI>G.L76(IU,%G#<)7%GK,G+%Z0S_W3HVDJELW M*LVZ$_1KX&[_HLM [V!877FO",'*T=A#9E0E]9U!>$1@S'2@'$DF+0_> M-K0%/]++D:Q8AP"(>N&12NH9>GB$8&TYA%YQPIA6!A,!MMQ8/Y)87$<:KA,> MJ2;PVO!9.UV/4V<.AT7V/9\$&IED#@I+%8, 6(*W](9%^TANJNE&A5G[ JX- MB%^#$"[N9I/\4WIS.POV/(9B#F/B0).$2^&9U5!#X(3&@0>B-E1[H1J=5QQ0 MR*%[6+0GX_HI%'E@3D^S97KQ99[-LNMIF>+AAULE6@#O#78L7N 4:PE+[ O: M#5)-JI8-Z,AV]_AH5V4VPQP'/&^4/#7!N'"X&V]32]UCURCG/ MJ"5"$@^YQ]0)Z L)F6"FQN&4#A_'?6EP7'4L0.!6(Z&8P]!#HC@4I. =&MTD M+CSV$D&MHK<3=9UN>_;7-+_X\S^#S%^W8'[26FPA"4MO;[B3 MP"A-<*G*B:_;L#LKV!ID%(/>Z)C^)9@4'!:2M;1<_O_YK'1Z1F,/EWQ44M_P MMV%M<"TH())R:K@F),;I-_QH7_(VG_.!XRD!46L;MIIZAKX-BPP13D)L9!"9 MHF$4BT)66A@SDAME.M)PG6W8:@*OO^NV<3 M$AR =1R %GL*83^*#KW/L^M\LA/5[722('0 MUQ(5O>*V$YWUA-SW>=HA>/?UGE *#.!0&04)AM)93 KGWFK5J"CSV+=B>L!O M2VK['O<8%0288\P@%D!RKIQAN)"09*[)89*Q[]*T"NR^-'@..40B#$YB 87 M&02%P\::@B-F\>L=#3UALJEF3K=)^'Z2AXX^7DS3^47Z6M*J]"DYYRG& C&) MK49*&LL),@Y93:43KE0<[W6S<&?XQ"I.G)": @84I B% ;21+'+XM:15$S3V ML%E827U]!6+?A,GK*KB]R_1M8.#R3;P#ZGH:Z%6+11HW*'Z=_'>6F]EDL=BS MQ5BSI\11)HW6FF#/'4/"(E7(0SG)1A:&.B6@LCX5-1#@/O#PV^0FW;MCV:"W M!!,BI;? 8ZJQ8)XJ5LPMRDC6Q,4<(( [0TTU=+:@B;X0NJG]\8S^?9NB)5HE M2BHBF%%66D2#N\P]\5L^A1G9P8A.D9!U)?6^T/5'6)Y$,Q"(3H-*ERZL\)?3 M- S$E4RF5].+C7^T^N;^B/6NTUTB*;9 :^QBEB>'V)I@A3:205@T"?P,,"(_ M(!/>@[9ZRP1X1O!.UNZ/&O JW21< *: D9A"B#CCVENYD81F;BS7E_0#EN=[ M]=WIX:0SZ_W[?'HSR>]U.@]&*:PV\_NCIKQ:1_&@!Z+, 6)LL%L6(,9M(0V+ M^$@RH+H%2IEYLBT-##^?UTNAG#$\>.&:"VBA,%NQ22^:W!DRP!W' =CG+M4S M]'Q>Q0TU'D%@)9>QO@/U?#M&"?TN\WE+:[A./F\U@=>&SXM]D"-54O8]GX0Y M5'ME+5!!)B3N]9AB'64X^"[*DM=68=:^@&L#0D\S]2V;I^'?16E4'&R4Q(NO M@W777E/K=9QG26%XC2&0CF,AV3TTVI3R:RKX_BURA@G#T@0_$8)X/[)E&!>2 M9-(U*2$XP(R7 3A6 ]!B._Y7O>KC*![: !AAZB472!LA4$$IYFPDOM5IE7R\ M^G@U+?2W$7:1W:2?)M_UAY*]-C3(L&&> B#ZP")9\# (+4B>&X% M;73\! H:U<5O4'MYG8RS:,4WET]WRQYV*V9Q=T:]^UB=A>O,OPERR[_ MFLYFA_#8H-L$&BRM1-"Q,#BA%6'V55M)>=#D5-8 8QS# &U_^AI(-L$+-GP0 MP!^3V5UJIXN+6;:XRP\E@[70>Y ;,\ [Q)!$/);1%!86SZ?(>'A@2/5&0. @ MY(*+K' 0DC V5;^4C>IL%(^#URNA\T\ MO9XL-\^.>N ,4[FU%W![G#2U7.;3SW?+N*#]E#V;'1YLY+Z57K->$\V]0-0$ MDVF#>TBL=+38H+62F29^#WNU!R^7A+VJJUNHVO0B3R>+,-0^?4FW1NOX@&N$ MY+HO300"R!FA,??<(LV(<]M!SA!H$FOCKT"O"?2>M-F7/Q38>7S$X)?)=/XN M?YLM%GNK6Y9LF4@*-, 8:B6=!M0Y08I IV.4-KD40+SZ'WO\CW:5N!L\-'?%1P IF&6&)"C#.& ,8E".LMZ #5Y6[F+&E=CV^$?+R[B:E%[ZY6 M /Z0QNM-+C]E^U+P5@K^%%2J P5_[K.O';\VX=QR13SAV 9V&>)0L$*"RLB1 MW6W:,^JRP2JRAWGMYF:Z+&;_K6MP,3WAG': IH>H38FYJU(_B7>QU)5V5"L< MUZJ04$:PI1@;A8DME?K2N3P>Z#XT(Y5KF&CO$1**2FLI%-XPSF7!,11CR0;K M& TO-K];%/DI1_]3 9WX6/V)9@03BS$*[%=)@8Y)BI5P6D4\*%#N"$+IF,!E M>C/?IEJ;V62ZO];1SH<38@WRWC'E)1 PIB4945!K.6ZR^7#^H[FL)K.6Q=P@ M(:58I!?K\NFAA)0=#R? 41R+TW+E(!*"&D^W3$O4*/HXR%2!S@'1AIA/.:5_ M2+]FLZ_A5Q/4-EWZR<4JWO.=3NY :"2-5X89"RS6)*@=$8.##IFUI1)INI%' MC*V$U<<3'1TK9;*W32(XB8=D''5:"@DIHNZRY M%#O7_-Y,_V=/)"3\QR%#EGD@PXH$ PT+NHFG(SG16%-7SS5=2V9=ZOK7Z3P6 M!SRH[2?/)%YS'0/K!C.$!= .>+&A76O+FYPW'**^JVHL:T=NG>I\71#RL,X? M/Y.0P#)U2BL) .1 0 MDAH02ZTV0!#)MRCVH%&08$!(:-_6MR304T#D:%F.EP\G!B"B*9,.T,"2#[:2 MN((KBN#(RAC65^H!=-229&^YI9/%BLBCY3&>/I@$^R'%159W/LRV;R+$O5+B[/+N,FY[Y45P\?S0!0E&/G-4D_ ]2S[THAHRQ M7C<),PS0L+2(C(:2[.T$\!,C>L3M>/EP0HGE2AM&8Z4BSZS38056<,4;E7,: MX!&@]AV/QB(]#5".UP3;\7AB+$&8$N6QH=QHR2% 6\Z$'%O,LH%J#Z*DEC3[ MPLGC(7+4W+Q\./$T3+1!,DY!AXR@"&VG2:N%;5+7Q/BN):)(X-T#'I%V<-)?G*6:3@ONW M)2J.'&R7\.#$&8,-LM)I[ E19CLJ""1-2MX,\#QG^TY+F](])9+,71X%J+,\ MS_Z*^^>3V_#-SL,V=;H) ]0JY1!U<=;%CCGIBCBC9RB25V&7X*.)K,R<*K331(6C9I!:S4+WJ,0W/FPB"RF:*9&$N[O!DX]"+R_ M U.?EV_FBV5^%_,ABK3T&+)8Y4[22!WPHI8 ,UY0261 M3!>B=@*0D57YZ&86ZTS>P2)')OJ;SR?J\X/HH1E!#^C7- QT?HJ[VS5RE M&B?20*&!E=JB,%@8AYJJ@A/,29/8T)FX60WGJR[$W I@-EOHCVER^LVG!P-[ M"#![&R?4<,2)M,8K@IAPQJ$BUNJXD$UFF@%>'-@Q8-H2RXT=UE9Z=0MA# M&<&\O$7\C[8]? M J@7ZF[Y)L<1 MPG8$VN#TT9:$/[)EN@C+#C>Y^+(BIX0E>-$FT82&2 2JT:7,0XPLM A7>W7"PG\UCZLR)T'K5,"( VEB_D"CD+F)).(2!@6&);( %H*G MOE"'LA1Q-[>S[#XM2JV=O"1"W>4'!M!83:G&F'D*L964>",I1DI[4LZ8=K5? M<36=IZM#FZLJ=D&+4?*;(QEJ/K^;S!Y_N7*)-EK9Q,4/;F0T[CVA*,QV(/A7 MF@ O#2-4 V^4"0+5(+C0HU[.E ;.BRV-O@7?WP;;3LY,MEA^2"^RZ_D1M[=4 M^P0SAS&B/OR)EWH&(7!=R)UHU&1W9/A+IY9!UTBT0[-$ZP?O\HLODT4:OSE7 MD\2)E)A[11CE*&Y?6!$O^'3Q>*YBIE2^0C<6*M))I*3;DMN-$(-]FJ'R"4ZBER#QIJ2;!V MR'^O5W'XSM CS1(3)V3-(=&240&I@U(6U)-F]Y4-6/]559=U)M&^YH>C4^>^ MF?-MB2S]YITG3B)#A)-2,82\$559[XEN1\?D MI9_O'QYY3.F[JZ#SZ?SZ??@[V[7.;[/[!'NKO'">0>NXWO>B)#IEV&-(8/@CK8XWGQ42DI8UF:8' MF*MP=L!N26_-D%U'8&XV7=U9MMT9*. MZ5@>&2MHE=RN50S"8F0':$\Z&@:IT=Y6GW&M_"&]W=*?7>>3F[45VZR!'B4_ M?GA/Z)5=?K#+_.0@P^ MW':AO:9^;\CT8%"Q7H\)DAQAA(W0P"@!&'#";>1C"4!-(MH#O.OTU+-ZYPH: M_'P>N%Y]\8]T>OUEF5ZJ]9G>E8]6#-_W97R97@A(O ;8F%AA'0"N(:06%-;4 M4HN:N/SE+U/]+H;'$/4YE!RI1_G&X8L_TL5R\]B[VU6.X;FF2B%@H&0< (\Y M$4!Y@+4W/,QP'DNH2HVN@UJ8O!6_*7S*Z=\'Y OGY7PI!2AEN*M50@&!SB ML=K(E CFJ035\;W[=JA6T[RY3"M=$OP[&ZTU%+JN0R47\*#R\6;^=X]G&Y> ME%@5W!NHA$/"N"!(H3PKI!G6$R,K&3JRP=%(EX.(9CSV4]VW-+^8E@A25^HL M4=8C31V@P8OWV$ ;ULG;^0+!?DY4RS7"Y^GUJE;5]X3QKC5V+C-\$.15.EW> MQ1/&W4_S.]Z64(>I-8@8A&!8UPKOC-_(E2*.92\[E-_Q2#BY2L]EJ+AOM]-U M[D(?0V7'VQ+#.;96 \V$BK<3(*F*Q2$ETC=9.93?SGP=*J=3Z;D,E=,NL#D0 MCF$ G*,.,J.X87@[_O"N! MTE$FM10*QHJ'3!-7:)=R"WJ],*R?83*06&M359P+O!\*MC_4PUR4V''I]+V) M5L@3[;T"#'$2\TS]UN)J09HDO@\P/W@@D&]3)><"_T=6[-E&;Q%46&WX]N,: M':(@H9P)ZA1P IM@7J5V=CO]" -[/6U^+CL2+2&Z.\^I18T/9L3M/2JY,_3< MU:AKCXH$0@]Y<*NIA1YIYC$0=*,'9GBC._1&N-%QHC%W,GV?S;@KF#SYT*M$ M2.(XEA)(ZQ1''F@E/-YJ U$^LK*V(QU]7:K\; ;@CBC\J89@15(2) F1#!)F M%:1><.44*31"F6\R",=T0FW8@[!;I9_-,-P1X3^=):Q$2J*MXU;'&T8ACI[2?<:+Q5I*"A#HNC;%"20:$I&$EOO7^.8>J26V0RK[F][KE MU:*":A4;#AS06"XSW"<=JU4%.=Y/9V^E5>F"OJDXW"?,*\9@6!8%VR&/A M49%"R,/JL\G6TP!]K(;0ZT'"O4ZPGX^/GL^5SRN*7G0:CR7X;7?..V3!.QP>-6@)D&& M$RHTPQ@3IV,."2OF5@Z8;U+C>4#;2&."52>XV%,64* F^60#K#C3AG?3KD3/9;GXR/ \ MY;N?@,S3=R8, !*4)BQ@1@. /;2Q$N$N5Y5%Z$*ZN#5^2(J)9 %([D:N/LA, 3M]#8&SNI>)B*)L1QA+R%6 M2FB+8'$@31!(= .$#[!B6%LQOQ.)OR:$%_GR$7S#;\^A&SY*/D2*]US$].3[ MQ")!&8>&X( M-&2[;R&5;G2(?8CZKZK!K%WY#7ZE^[:G*Y6L!)19CPWFBG$-!2Y*JTB S,@N MICV=C3J9RGH%>JE-^O4V+6:04N4-]HX@P+%"L BJ*A&6Z>.8[DZA]EV(JR/S MP4^1^[*W/V7+R:RWN&"9UR?62BLY,@K0H"OE(!%L*_E@J!J@?8 %=8>5,=*F M9OH:$^_S[")-+Q<^R+9J*;&C;1/MI/$DJ $III0F(/A?!<]82=0 C7*T:&Q; MK$.ILAR&QE66WTSF%^N!]&%QMW@?_IQK=65AF,%84TBE0U((BF%8$TB*4:PW M0DKEB;P&/--$::$Q$YQXC8#DD'+,"SDRX\9]$7UI$'46\*PF_K[L4BS"'LNQ M'[Z'_M%3"3?4.>V)!-P9YBEQM)"D4T(TJ:0T0!B=0/]96[+O&4-'+Z%_\EPB M+028 2&DIQH;32W1!2\@F-IQX:B6%G> 04PQ1LY>$O-R*Y@KHF!<@NQ%N0[')Q]^BMK 6?;7A+#J67, M,2U%6 !P"*@MYF]/+!I9_?&^<%97OGWA;$UK>.41#^G)1FDA_,%'1O;)YX&Y^&5?XOTUNTJ/.5A>O2S#C$DM' MC%=@MR/D2>5APMCAK@/2T23[!1 M' 61$Z$EA0H14/ '/1H9T$X+D>=AT594,IA9]<3;\=QB;SUE$D!'A''QXM9" M:B!,(PV /,1R4B?W!'I76>T3-[LI/3C0'U_^_FF27Z?+7Z?SZ4-N=K7Z;3&=;Z(:[8!X7^^)\I)X MKJ6RF%'O).&<%;)PJ-$6S!"=BK. ;TO*:AFXG_=36SCY>V\M:J/;Q#+/)1(^ M>&V< J,1MG;#/?'*-@M<'C?YW[\F:^6.9WJ[7VN^67-/_T M93+?I+A%]M/+)UF4?C+-.\NL;410XK#6&@E .<9<4X&)+B)/1##9)'%I@$4D MSG%,]:G?\Q]]OV7SKRMY/+I7[22C;A\1_)"O#$3> F$Y6AK0:\C&F7=7:-7E88$*024XTI8KX*W0:A1Q5H08JA?+U7J$>;]C\9: M(#C_@?CT*IR3C,.G)"0",R*1$)G8PK_CF4 -M+^^8^_ MI[[W )9W"1!,*X(4! H88#FU>@L1'&;#7N+7YW!G^5A&8"/]G_\(W-R$<^)! M^(**A &A$/<0!7RXL'KQ5!5Z0)+")H&5\L'YUW'8WSAL"H'S'XI#7!5R+#1" M'@GJ.'(",,=PH0.*8!-S6'G/8. WOHQE(#:#P/D/P]ZO@6]&44)8P)"R@%,0 MW!:JG66RT(^5I,GAGP&6^QAE4+1-!9__ -Q.0,]JKZW6RC9X8J?=#RQ/7B*Y MX$XJH,-_0H2)'3-?:(Y VJ3$_'<84VUIE/1O2-L&ROD/\8-7D ]DG%>D,>'2 M6&X 5HI:IP'D$A<)S+D_,?ZT\#;,,%QD\W2,64YCVZL=XN3\Q_KC^Y5'^9 KT)@0I0$'%H@'<#( M"%'A?A(KH-I"J+N M[INJ)/YAEQ>30,EX<2VT5" ./#/6%;Q0!WH->9]349'2&#A87JR:] ?CC)Y! M>3'N$%9:"VC#+&&(C>1R9'6(3PN7K#O%G B$5<&WX4TI3[G27@H++$,, M&E)8(J,$;E(6H?(^5EB4?OA*@FO^&4ZF_[2@C+/!2< M>>DU" ,JB%:10@Y&X9'%1VIBH,&5$-7D.QRV]8JRWAP<1U3US@G"@#N)24<,V98AA)3;=24Z")SS9 7)[>]^]=98,'^IG7 MVPHSF _NOS60(:6TLI(500 7[%Z34. G=4^X7O:>EO5]#JB43:@D]46>H2T M#HMJ9QG5 B*F"AUX:WO=4#S_LV'-8'ZRL]750'#^ W%X];9BL7[,/&.8#_C6B=_]P.PD?;/?_P-K]Z68 902B@T#"(")-"N6&LXZ4&3*W)? MZVT-<00VTO_YC\"AUMNB-")% 6B9!H3SF 2[]40P;5+HY[7>UA#'85,(G/]0 M'.*J$$&",":8,R2U:$PHU M64Q^AS'5ED;)$,_T5@/*^0_Q,=;;(DQ8A[&1%'&I(190%,L5;Z%H,MC/\YS" M=S/0NT7*^8_V,5;<8M91):6+$7IN-+%*%G%";Y0:68[9ZUCO!R?G/];'57'+ M.2HLCA?^4NZ$UR9>MUAH3_LF69)@7UOKOH]KD-\?*M>RBO MWY%XYT5PF2W#RDANC?6>%W*AGO5ZJ]8(*\T!6#+O<"F 53Y*U1/HZ7!+SA7?VV.J:\YA%TL(W>\)D$.40Z9 M!@A)K!$2R,E"DF$YWR2 .\[+"'M?'#;76J_X_WRZI\<&3)!89S;UA:QU +30O=5%'-QR9V62Q"$NU/)TL[O+[ ME2:.E>W?VR8ASCI(J!!"4N\5\)*A@D\$99/(Z@#++=15$Z=["O1.O$:Z:!\!QH9#D&.%8CW_!M M84G/_WR U;YST[Z,>_-R(I$O;?3=\DN63_^97JJ;[&Z^/!C7+-=#XC3R@#KL M$98>$:X4= 7_-(SC<5FW5A'QW GJ1.(G0MREO<,V\']FYX1YQUES80X#8T6R_8VT3P2'6TF(*(?+>:.ENDT2$EI+Q1 R%N!8%C,\,)M MM1BJ?HH*C1&1W2EA,#L8FX_6&:NKC\YU^X)[&30;DPN"'H)1"I,& ]P3J;5$ MS)UP^^*\;BE&1%MAC1'0*LDPQQJ*C1P546,+0]4%46>W%%<3?TV3M\B7C^ ; M?GL.W?!1\B%2O&?'Y,GW"2;$6ZP8PXX ::SBC!8T:RQ&MK8[@:ZSYE+O'"E[ M@YO/GDBL<1J#X,@A9:#5)AA.7= -@N$0";V@/U LZ,GU7U5C6CMSZ6OP4%V(>V4I__%C"B"#000\U M(\PYK3@V!2?6HY'=DG4Z^]""\/N&T=$-]6<7L (.E74TK.RT$$AHAA38<@/A MR))WZBER#QIJ2;#^+FA<64X>KRS#,_C(#NB!-HE&P@'FO>&.$$ZDI8'P#=U* M-SH8.&#-5U5:UHTXF\% /:4!L!(PV-,FP1XPR15TTF$B'<*(^PW=!DHPLKW* MUF#0CC@'?R;C;3]7WE&*J:708TL!PY[)(,5":M+K)C&2 >X!G-ZAZ5UE+1^0 MJU5-X&ZY6(;9>SJ_WELYO>M7)M!:;*!PV#AO29 3!X7"3# ?(UF[G0)FQP_6 MG4*#@Y_@UUQM9J*%^CJ9SN+,XK-\5>&FBVG_R"L3:IDR-LK4>AWT'@/(A80Y M!"/+.#C!&!F8!L]FC#S4KMHPOMV^['*8[']K0J#P@A)@G& !M/O<1$3L\R) M)I:KA\M=%-7&.Q('+'62AB46M-Q#S DN0KO1 M.VZ2R3W C(U3#X03J&Q0^1V;-".,HD%<#!0N*,L)'%8.O"K6)N2*\Z&?(V(6$,,:Y!7* :+230 M7!><:*C'=CQR(+ XM'=832-#WSODE$*KE=7:(^0!QA:*@AOAX,AFKWJ*/+QW M6$V"M8.H[N9VEMVGZ=J]*9)Q RF']XV.-$LTT!I2Z(R&*A8T1S[\O*:>">E' M%LRLJ[JL,XF>-G!2>SXM4S2BW;P ?WRUKS M!U=;<[J[M"2UO6;^8%'%+(F?6:1,LM32>?H!2";KQDN2R$1F4;;=;E4ID8G8 ML0%$! (!@AQ7#*5-DGKRCJ.8Y%0S&F)(<9@K8?^*?0,#YK66ELM,O/NL7>I M/W#7.W8),YN\+0A. (*26Z2IU$Y*[&N+D7N;=4O4$(V0X3*S VUUPTSVK')9[R#(I.;A MUP5"4;I6"0("C.'<*^=L+:UA+&<]?S-;>T/C9FOJZH:1]P7+ M@*0&"BPM M$SCO;,;IF02N?$P-[,G21#HV=[^NK&%5IWZ$G_DA&2X0L=?EW M$!+B"1;62:>H$U#N1J,'(">O^LU<.3((=G:AKH[(^=PDABR3G =?%P30R."T M<^(ULSH.2>AWTNJL\HMOYI*1P9&S+75U1,[G5C&\R"5J]KY "*+6H&C*2"*H M2^"#(Z>K>FK(WZ^L(R%_!L^4<;XTO<%B 0S5D60HQ-( M;+HF7M7R>F=SLCO>S T=@^-G:_IZDUM5OUU\6C#W@T$Y22%T0$D3AS\6#F!6 MHPL%R]GA'6((Z^IV>-O3[=L<.?._JL56[/O)^<>NVOELP((PAYSEJ5 S95!Q MNT-:Z*P#)=>^>78!73L=/5F:?9-CZ,]OW_H80R\^&Z332B-%E4)6&&>!T[A& M6CN4$["^]FV^@8VA/,V^R3%4GU=[]JEU' ZW(/@L52I9EG!F'_/0Q680J@I0PHP3W1GN!Z=UH:E'5QZ+7OU[8T2-\<":YS M$#]KHJLODUF"2H^FZ0;ODS=;#Z2; 2BBB:0>2HX%,"S2LMXOE1:#G%+$U[Z_ M_=:&-/6[Y.SW#U9OZ][$"1PS& EJ9748,D(>)Q3&3?DOWOY;\WZS5;R MFUPX7TM];!XJME">V:V@C=/> ".<,EQ").0Z#W.M*>AXSO;;V=D+L8.?Y[_@ M@'P;NA]*[9+UWL[;JTK"L134608$$4! 3C0V!%N*,6)*LT9'T1KN[3_95MO" M]X0[+Y'\%+'3\<7_/K2S?]G;@M&:(YP.E4NDH016>UK+2R').28RP#V82Y4] M+PUTL;7VU-;NDPI$ZG8U^1ZE.\G']EX>%"6(;)#W=DK2RLIQ?;2>NEI M-+PR3S]4$=G)[>K1/'OQFS]GDU7VK-[J9].!"62)UD10([BBV'M7(VT9R3G@ M,L!X?CU\M[N:+^Q1!W([Z5 SR:>7$L\G>YG>"B).%9)I"*RE6 MSBO"\19+2:W)F=\'&-YNB]T]JF HALW!2DZMV^1G?BD8KAD PJQ+O#IJA?:/ M>$*1?3R7@4UY?MAL['KU6UZB\:]#&*L"X8?'/G M)[/8H,WH5B+GM;/7%1MJ5\GS%I$MM0IM.FD>%@FN MQG1Y\7R "$DN$)8\&HZ*RU1A9R,;1\)FG0(>(&LN5>Q>?N1!68HF9K3\&GV( M]*^T'GX?3=/=-6IE1HO%SVAY_7,T?3A6Y;I1^P"8D YC!2!/!T,X1@YL9<>2 M\2L+3&?J?]X]PJ78]?MH\>]JE>R;C]7MPR).OU6-RQ%.'6D5@!%"2&(UB?\ MQ40TB[9R$L.S)J0!QI#;95)[N!9;Q&YOYP^1[1^JVRHR/_;\CVIUFD#'F@5O ME8280&\)E5@[0Z#:2DH)0SGU*0<8EVV702T"6XI"[V;?8^?FBY^QIT0TE[4D"&55IQY@X+)=BF0 68H2[Q?5M]$DW2L3??0J7<>Z M^EHMGL%PA"D-6@>L/.?&)\>"*D>\4@CNAH*6.<=-!A@;;)= [>/;B\O5U-4* MRALM,-"J9,Q0C2I1$ H@:0R-,UJ[U8.WKBQW^ M82JEW#)Z0/#CEM:Q9H$2[Z+YB)"(_W!*,6:DEE1BD1,H&*QQGAUO:A'14MSY M^WP^_FLRG1[A2?U(P)Y;3Y@E5EF'L 4^^J8;"2S#+J>RQ&"M\6Q.7(A>.:]L M-9I]F40'?1C]V$AQATN%&02D3\7,126J<5UH8*FHID>)?_C&?W9YTW_8^'QAU@FFLF= *:.T0VJVSUD&< M<]IU@"5)6^)*&U"6]>Y/NO4!6BX4A4P:*$&<)!6A=6S".4YR8C_G%_\LY,^W MM&5Z)G:E-/_;9/1Y,EUOE]0'1+[.IU$CR\8'DYJ^(J0#T8I3CZ7$#!,9EU9> M(R MRSD;.$#_N],TC8XP[X%US;,X#C<**81@E!6">(VCO2:X]KNQ!5S.(? ! M[L&WK_S#[,I#NO1>ZOO1S[1QUWP7]7F#X(F3@F,(O!*(Q;$)O=M*Y^,/5W8U M=!MJ/K")FH5K0=8L'J(V7L%PG#C[VP3GH(JC2D CE%>,$N#J8(3G43G7M;IU MPYU6H"WJ6YU%G@,M @/,<,B-@BR:A$@3B6PM7[0#KBPRW %UV@&V/^OG+*LG M+NO :^2LA0ABH"Q"?.M#"@ \R4EW/C]HW+D7U@%=LC$MQ92G>VQUIW\V"N2< M:!F 0)8"RIFBCBJFXT"QM;Q(9%DZ9Z]6)0* G=O,[0)^\0:^&7V;I!&9NG'S M>3KYLM;.:#9.9UU6BX?;]./6'YU]>7SB**E:>G/ !"FKI(I#4XGX!T3->J\7 MQ\&KJ"YZ;/Q-DZX?A92:]?3#SBG4'M3%JCR\ N'=;)LG\SZE;D:5 MKE:+R>>']8&K3_,TC:9:Y_-I[,J7=[.HM&K99$NGW0\%;I'3UG IG1>4*A$= M]RV:7'"9DZ&#F26G04T>"]SP=D%( IOL+73J<:BBB]4$@ MP35W1<^1%REYVQ,M7I^ER51%R15Z6\SPY)'S%X^&]4TO'EAI"<$<(L=5;99R MB+..ZPTR3C<0= M*JD4:3]4J]%D5HW=:)'N=5D^.[9V-[D]>F/FZ<:!(@Q).@.:[@O6E@.\V_>1 M3(MKNREH&-1L72]OR_/NW.,.3CA-%69&8+8N4:EEO0 IPMR5'>P>"*M[T=U0 M$M$S$M # 4YS#0P#7A&/%')^>\98:&MYCGD@A\?6DC'Q-O!^9%CI,I_OUWA^ MK5:3V]'T>:>NK>:GUBJ"[[FR#"B-HGKDIO!JG'F0O^BVF"[B;U$C-XNU1..U MW_V^6JPKSS8.R1UZ00!2,QVG-PL5D4!8[J&K$7 .YZ3G#C"UNUU2'(V\M81X M/_'>EWEV0O,254UU=Y6$05N[*<\.)\N@CE/KGTY,: ,PGUI&4@U MO M@,>:6485UX+06EYAP=4%R@JSZG*H>]B+NL#6:M Z<(\I$!1X C%W1 "M_&YZ M)C3G=,(@ UX=4JQ]N'N@V1DFUI%6@3"&/,/>(H8QCTA*:FLYHSU0-J_M:FB5 M"7-O=#II61UH$1!CG'EEC0>.2.HD>QPN1*&<9(T!YK:5I=%%$/=&H68&U;%F M02L)*946&J@,Y9BE"U*WDC),KBS?K"R9+L>Y:#QQ!\KRYBY=8^"G\[\&<7W0 MKC/GA1!?-0L0.>2]I<9&.X-YP^,J@(QQ!'+O,&F4 ]*-M*D^>^SN^\7\^R3B MJW_^N4REN6Z^K0^.[&Y62Z<\UTFW#^D8U+?MJ9(FN+3S@4 \I (BRQ670'&O MM%,U@B"">K6AQPPRS0>@B7+N_OQNLDJY$D<]^_JA@ F$TI'D5&(;%U2J"=M) M(:Z@NH],WU@VBR6!B$:O,PR18AC5D("B62[I4VJ:]M@' Y9&MW">Z9V2G'O:6'\^.=IU>S" MA'.:!X$X]SQ:79AJ#:%5U,*-Y (XZ'/.K0]P#ATL+SO052F61K@6J1[-3[KWI:,UP:$I+8",0+COS'3T3T1.Z1,5F'] >YN M#W9@%-1AN?-MRRI^*UVS;:OOU72^OCWKW2S">5L=M8%.M P8*4Z$<9!RP:/= M!Y"G6WDAA%G5_ :XE3Y8SK:KIE*TK$VRF]G'T;1*H^U[M87W""6/M K26N8( MA<*ZN,I@#@!4M9S:DIQ=MN:;\<]M\4^_+BO;TU31XGTUB&O$MM?T'N'CP39! M ,FMD4PZBC''1D9OHY818)=3.:'YD;/_>H;MJ:C'8%N-RK801(.-N>8O"19' MHYQ9)*! G"%OD4^/-HN M *0AQLQ8QCEU"$NJ9"TK.AO=L]V&280!E;UJIG/CL-?E]C+(>Z79B^NZSF7:B^:!8*X!5 00 MX*2A3G-8!U 1AUEUIP>X.]07V?)0[SGG9 ?1I;0[^)9@G924"!EG>4:%H,K7 M:9,"R?AWU[4%TPO[V@*_% F;)^2VAL[$)@XG>/> MGI_\U'F=JI[3G3O32\_LW$3:.SS^=.8'@E$4(.8Q\,P9JX'UHA[;F%N:LS$S MP 34DL>?NM5$L>-/HY_K>.RGN;K]S\-D4=7I*=6F=FR2?/LW1VOIG/&:P*$A MWFM!5,0".FSC!%(CH9G(J29P:2"Q^\W"TBQZ>9*J.P7U1E7U?329)K?-SQ=I MH_,Q ]%6GX_-K6>^*6@$""9<2^LA$UA%T&NO$'NGJP MFHU_'ZU2GW_>W%U&U\O>&-)"$T>N!!C":)7%_^SVN @D*"=C8X"ASKZ)6T1) M?9'XYN[38I1R0Q][_H]J.KZ;+R:[-*@S&-SD=<$0:3%%5#AJE')2:52O0,0@ ME5,48(#!TX'1MP,-]68C1-DB4*N?[Z>CV2J.RW2TYMLIQC9^2<"6&22E1HYQ M'^'G5-L="L*J(F'67]A":$LSI_EYX(;Z;8]6CQUZ6D=S#\D:M H"^(@.=Y!K MJXD4-(ZSNN\6BIS9KWDN^B_BS[>OC][FNC_FJZI9>MJIID$QHGDTI &6UG#D MM-N==:*&@AS/9[CIYT.;W/*4TM_>YH<(UV)R&W6V#H+-QLV.0YSWH@ ^9G9UJI[P:/^YHW.FT!.O"L @YQRF MTCJ*D&1(XSHS@7I6*C7]5Y]3V]52:=[Z^>*IL[;.0-@#90/:-GQ30$)P;BU6 MSEL(XKI#,=ZM.8[EY)' 02:I#X2PW>AG>)OYK6S8!^ 58U0*$8% 2J1:&'4@ MC7$%6PNA[4NLPE+41 MQ8PF.2;N ,M'E7(<[;KZM96\8TF_]NX$(Y9 $*?V79K?TYN@5XW';:BE%Q@U U6\IIO)^,8E8?1M-:VF.\/!HN^"T].GD#4<" M*>@@I+R.6$>$<@FUJY/+]J"?SN9E/(W'F2;[OE7\X=#E,HW8A M#AF0=GRQ3GF,U'.KZZF<8YYU(^C;22CIFDI=J"*;2C>IG%X4Z.%V75IOKF8 M<7'EWDZ7\[MS)J]3[8*CBE#+E) <0 0I@UC7(X;PK#M&+DW3N-KEL N-Y*9G M+.?/:+Z#H/$L=MYK(F8 8:$8\ I !PSWNJY\SK7@.>;7FTO@*#.==:J@4K[ MXZBYN?LM'2:)#DQ4\^18J/%@FZ#C)$VLII)H:CS5D,AZB E&>,[YRS>7PU'* M!VA+&WU$$)^XT.OMICV8-8P)-GA38!HJK0TAT*?KIZS$HCZ%*H06.>QLGKYQ M[:9>&>4,;]NFE:V9H"0@$$F*"2#$"0N1KTOD" ]9SBI^03'!OG852W&T,\64 MHJ>[NZMN5S=W[L?MNK;\A[CB1?N&0EE.Q*8Q5ZFE G&K#"1'P;"W=J(4,Z1C_-C5)TO"IT,DD%K[$V, MGZZ&0P :0& DEYKHI4EV-8YYE)!FY.E>G;=J&]K34<&+E:_&,?/5,.O35E) MK3)$4=;-N.1S#'3AEB%KG/.9 )< M+ *ZN>3C9O$^VL3;']8'FY:3S7[7CVJ\J>]=EQX[=D_F!6\+4F#N (Q+.D6> M&8K-[BBT\DZ6+>KYYHG7O0:*N0;SV?>HCMCIF[MUNN7F7LV44GR*>M_/ET,DX[QSN+<[E.ZHTO_%K-EI/OU>/M1L][5_U85;-Q M-?Z_"G@9C];PIC?14]K3QR;>QGEO"HY!(KPQ0-(X'QB@E?4.H*0LH !H%(OL M;&/Y;K(Z<2_YXT/13$,"6T"UQT!8;JDDLI:$:9)U.GJ X[PK/;_>][T,X%++ MQGH'^L!X7I=1C4;9_H!O@]&4__+HRVH< ?**&*@YL$@06Z.&D,ZI@S)$.[L0 M+8LKIF\Z_SF+O9]._D\U_L=\NKYF^?%"T5V--;6(9M_LBXT_SKYLQ*_!N(#D MN9\,2G CL(,"6 (,4M$A(COETF9KR]N9D4M2LN%H**S!OL=(DJRV>?]1C;]4 MM;CJ+JK_0W4['2V7D[O)[89-L_%EX^*2S\2)SA-NK#?>*&^EYM2X+9+007YE M1?\'.!8*:*UO_C\.]\=Q;B/*W]=Y\YVM#N=^+,XJSEL,$>3,&@>=3Y&R+:J> M95VB-L (T #'0C'=]3TBDFA^OJ@F7V;F(7)B=OOSTV(T6XYNZT&>?IIN6+2[ M"3EC5.1],$"IG'6, 62)%ND<"Z_76TB\N;+TN0&.C*+Z&\+HR.3Z3G*"."1, M6.VCS2@5HQX]S@O>Y43U!YC3-E#F7JB-[Q+OGL_7ZS5OUHM)I\? M5JEJZ:=YVM>8SU910;%/7^K]V:-; JU^*4CAA %*4>N!AM0[OPM]0:Y]F6L\ M^LC8[#2(TZ^6!L#Z[EC>""_*7'1B@#%88LNI0A30G7>CN2YB;10LS#@ 7G>@ MEP'P^#*.!F24B2L=Y]PCJZ4@4>RMG$@@GU/E:( VPP#8=R;B0]N>?;_&^6NU MFMR.IL^[^DOLU4(0C48OTLUJ1E))B"+..,EV(C4J%@ 3,20$E[S'S;]?73R$DX=89QJRRS6*!:(DTEO"X; M+ENO+P]/Y8!YX1*T7*R>T"+^])(2\58X M*5X_'V3LNN>&*H,E,HQ)B/Q6)BDAR"K/,QQFY*OT-3>RP2Q8GBSU]_?J_G.U M.)Y(_OAG0HX&V9&OQOC .MPUKLF'^]:D8G MH7H7_WCLT,GKAX,6CD1G75AB*5.4(LY8+96/=MAUD*4E&Z,U',M55?U>S1ZJ M33GUV=K,_M=D]=4\+%?1!%\T<,(:OB$HXZB(#C@%!D-FB#6T'G JSI_7>HCI M @*\*IO:!< #(9C[L%M@G&',C).$42$P\USL<*=>YM0W M/YMXWZO%YWG'U&N=+^?QL04=E-OW7ZY- _V.YNO[#WL:079II3S5X0," 0R'1 4GA,+,3$V*WT5@"6<]AU@-N,K5.K$Y1+<4P_+---#4LS MO_\\F:W5MREP_B5"F383)^/MQJ%:+%)IV?5^HEE7F7TWVU1025EO>YO\-AE] MGDPGJY_':N 4ZD&05FD",."*.^0-D0;5X3R'C]_1^%6GPY>M/"OL>C"0T0<=1JG2Y$]-AZ2VO)6-1&T:SAMS?1MH!IL1*' M]]]&DT6=S+**0V#R>5IMJIF]FXVKN[A K*II7![&.W\Z&;E_3:;3(ZS*>6V@ M"C"FHPL'C#)1!RQZ X04!Y@"X&U M('Y@EZOA+4 Y5Z*>77BZ^Q,0G?BU&7@6RYOY+N,YH= MBYTU:!V4U"XZ3A@ ;@!$!EJUDUMHD+.W-,#B BV2J'UPRY%JT]/348X73\8I M62GD'$(T0H0=E9J3C3P*$"IS-K2;6]FEKWYLE3,Y>!;-Z/]C/IL_GR9/T^5X MPZ IHQ#ZZ(1"&ST*R('C6VDA5J3,;KGDZGT^5O2S2 I9VCU-=70J.??8W93P5X$9S"Q@ LF]'HL M:RY$K0=G5JI+*#)4JV'=.ZFD6OM]'E#<];!*R5!A1)*IAS M6F/.E*GEDYSE;(H.^<*8MDB8"VC!#.;SZF 3H!F1T8UF4$6!I-.XED(1DV.Y MG7\M\EN:FR[&L!03_JA6CS-?9NV8L]\5X@2*O!(*4>TXEYJJVL.)OX(R)U9U MQEW&;]@EZ!KR7FC8E&+!FCB6O%>(0^,E0X9 5\O"I,XQF>#Y.3QO:5[*P;$4 M)]QH,8O,35>K?OP: 6J0)'BH21#",8B8B:A@%Z=@2Q6J)>0\+]GKNK,$6X*T M+]+HT7)R>P9CUL\'90 &!G)&/=5,*>#H-N:OL+/:7UOFHNUL8^--CFT&60R8.>TN0S84L3Y5S7Y M\C5V3T6L1U^J/Q[28;2;NW7/ESN,Y]58 08@:(!P)JQ1%% MI,ZN4 1&-R-GAAI@;F"+"UK'4 ^-?*<6P+/>$YCF'DDLB4W[44Q;Z7=8&&9S MTIT'N3!V1Y8+67F)&GJFY'82?R7*^:0\]*;@J%\7-O5Q2G "$Z PJ/'0$!0] M5_TKT+(E13P2LW#1I77'O\ZG4/!:$5]8P8'7\+R<(4ZU]+8FG_LIJ"69J M\^5&ZN5 EDO:O[^?S]:K\$E>O'HV .6%A]+(.&RPL8H!(VJ9%-971H[+U/GZ M5H(L$$L10XW'DZ22T?3]:#)^-S.C;Y/5:'J2)$?;!4ZC/X44!5Y; :*!%XVZ MG4W'=$[^_@!WM%HA3)N %B//[>W#_<,T>;"'ZB.?)E+3=P2FM(+6$@^5Y 1R M0SBK,< 6YUB]9T>52P12VJ%51_"6.T&[BDMS-:YW7T[R:7^#(#140 DBB6+" M<>BQ0[5T-N]$T0 /@[1"G5:0+):DLS= =I(MQYH%A1BA@$1/ 0J!#2#@<42@ M4F="WA9G6L2S>(CFM\M*84)'-'=*:V T9-Q*(\ .*FMSRFT/,K[?=CCF4B0+ M)K _N]'TW>QU,/-#Y+N?+_X:+8X?6CSK3<'0.,5J;;&V:3\MCA6]PT-2471# MLY=M],:$>)WPWB'0Q2:F,S8E7^]V:4:T) 00#3TEF',,5"V3PS3GTOFSR?-M M??%)5/!BU2F%.M/[R[DK$^UR2]M+Z5N^=[B=#P0LG2-1 9HSX!W@F,"=8: C M@"67T*OC:A\J*A;6W/BVJ6#:W5UUN[JY^Z/Z*[J\J6I4$G QF=U.ODTCN)N[ MEV[NU'C^+0E]+/YY\4N#Q1"K:/5 #"S46"/F'G<7/,L)E XP\:T4A8LII.@Q M]!-WVA\A:)/F@3ICH]6$K4->.Z"%!W*WF4%13K1LD)7K2I&Q _"'>K*24VT( M)8XRHU(XT%OI:BD$HJQD_..:*'0QQ$7MQ@_5MX?%[=>(P_CI]84;V_>437BT M<6#$>"=X_)_$\0]>,K>SEJ7T.2&3YN4R2I^L+&KPM8G_$%CWS]'TX7B>W8FV M@7JL";?<8 J\$A1PLYN2=00W@W/-2UC\BIR[!/ZBE'NW7#[L&R;N_MMT_K.J MRR6\GXZ.>0WGOBH ;1E+-3J4!,AC91@TNVAX'B$'6,ZB*!.[4T//Q%R/I59X M>>A-:6W@PF"D*=,1$P^,>8RY$IQC])U?3N/::=F2%LHE"_W/P[;:T*?Y@825 M]4C[G!:!Y"1%#VG-@@]5A'(Y657;RS@VXG^H;N=?9NNWG%K@N_YT$-I#Y)"! M7D2WT2#EPX>;^L.A+%%-YKOCGW=2\7 MDQ19W15(G*TBM'N8WL5G K/I>A*C@3"(0X$1L7:7U.,%R6'U /<0NV;U '34 MW][1.O)UUF;0ND7 /-I5TCL.$)34QL4,[Q)?C7)9=SPVW]ZY:M- M(.2,K(N4(>V<)![O4L^T]5GGGL[>7]EL%+K9^#IHE GV?[>TG^^7$IOF"1T30N(IYCYC1QCBL/E2$"&1-- M[48+>2M=M_/;AW4&8OS0@9X_?21PX5'R#C1S4;/.,Y.2F#<=QPID7J?9[FC* M@'W>BOC-9O*+=:9FLX?1]$/U+0[5$[I[^F@P@AKF&3?&$"\0QM;(K1!6&IL3 MEQK0D:)VM9\!8,%^O2#9:XR=H\.S98 VEVKLX>2L)HH,$TT756S'B;)Z9 M8C-D;>;@T+$Z/RU&L^5D$[5I,+!?/AY2M#/ZO,)!:YU5G BX$T;QK*-= SJ= MT_+4G@=B1XS8Q#3\9+JMQW. "2\?"Q(KR7U8_5%_6E]C.5G^,[@_-[/L>#=;#=+DM\MQ+;*#@2-I:"(),S@+/AJS' M+!@ZU65*;%O$J64-Y_IXADDIEXN?9CX^KMJC+8.S'F-%"4R'F)'22(-ZHG(, M\)PE_/S;1-[$6&\3STXI\VGTX]TX@C*YF]RN.]M@%3C0)@#N,8*.L3@&C/$0 M4V)JL11 .1/"@!(DVJ1).TAV2A U'D>5++?_^FTRJ_9=\WWT^6"DX3S=:&,- M5TJSN.*16AQ/2(X[/Z 4A3:)D8]B"5*8M'FQ^#3_:U\^RY&G@].&4^(DPNG4 MLJ2:0E&+8C7/VN4+]XOY]\GL]KC%L;])0,)1BPSE M0 '%\.F)&'9 EZO)\O5Z/I_S?Y=M(XLO[WLL>(4@H]P ( F% M4GMD:P2B0Y1UA2F\N@AC)GH=J?[38I0V^3_^O/\\GQ[0^[-G D=88"M$G*^, MH!9R(4'=;0Y85N7; 5W,W([2+"['[=?1[,OU9&8\KY'@[%*,2>XH-(( MJT4T7%$M!$,TR\:[NE!C"PAV:O;_JYI.__\X#H5)_F89%0V.Q2IP4F0OMP7*W[ MFP3L")))"$VPH01:4L>Q+85S>HI"3[Y4=K4;;#I_8 M)-S7)$ )M,1>(VR#^:3O7#NAT9B<^J\79U$;=\ #OE@+NO%E_B,O3WQ?ROU==T:',T M.SZJ][8("&JOI?. ,VB(%D2Z>H**/Y.P77W<-:Q[-;PD0\%J/IN]FX^O&_J^,3_XMG Z4RX0&DC8:, M<$A")6HQ%'-9@W_0L;@\(+K:2=\XCWZRO!U-_]]JM#A^2.?0XR&N1-!:"(%5 MU@LCO$4[883,NNH4#302UQ(6'9_5>>R>C[\YY,(=>#IP)ZB1&B,4":FAYX#" MK2@HR9X $EUGC+E(&&6NT,K*/^R *3=47:0,-E.0!T M/":7C\W06)4[GIG<40 M)R"5$RO'5Q=4ZPK61Q9U5!JBOH M3E!K)^#YYQM7B,@OOO*R(T>J1YQJ$EC$ M4G +@'-2,&JY999@2S$P%"K0*#.[C)3'ANO)-D$2(BD#WIJXIE"(G::REE,P MD3-$![2;U9ZZ7]Z[W1*PQ0>I3;3Z4/:!-UF,DVJI?N1*@-5XU2-+\5*'S9J MO;E[Q:M4*^@(-NU^*# !*5_0/V8'+N^H<.O!@EQRD@2U!(*7?PO)'"+,V<*9YW&&A[K^R+I MRPJ\@U%HOP,GI;/:^?UH-L ]39P#]>A??'PT&[_XS9^SR6IYD"!GOR-HS[S6R"-I MH./.4D9V<@FLW?G@>P^$1AF1$$6!QTDSJ1R M6DK6"#*9=>1S@//<=;@;EVJO%/__J%:/]WVJ[Z/)=%-D^DFBSK8TM1XM)[<- MHFX7OC%H990V43O>:1$!$A38W?P@:58)@^&QNSRMYGVHJ1<:-R5G -(98U0$ MC1#I-1-"N*TL$EE=-&I9XD+8SG5^C&-GHEV*.7_.QJE<92JO7XWK8;;&9[I6 M>#7^-'\_6JPFMY-OH_59M=UH78-TA&RYKPZ&2N1*JF1. MPOZ CF?UQ*NP3E&*J)3F?TU1HHZ7L:>_*^+ MW;:B>G65MET_UPW:-DO;"\RG%'1N*6.,4@QJ;!5 .*O S84NSD FRXLYT<2_ MN0S^PC6B?M':)O_\H %%-QSSI%TUE&$ MG*LM(H6C\7U=.YSE>5Q<11=OKC?HZ6INMZ:2N[NK;E>'+L?.>E^PGA$K@'=< M08VIL7@7C%!89-UT\:8=\%Q*EM1*SR&B+53G7+Q]YIN"B$L,UDI@!XV!1F$& MZU&I@<@JIGF^^SZ@ &9;$V>W^N@K5'3:%#W0(D ?S>YHQCB"&64X2@AK\T9; MD.66#ZBH4[:]@ 3OO*IPEUKUVLOV/(NQ;7TL0!/]=Z4-E1 XY!01A&Q1Q<[;*\O-[9#,/6FD\\7. MCR:+?XZF#]7OU6CYL'@> "R^UNUZ8R?+V^D\=6C98+T[UBQP$'6OC:.>*441 MP=;Y=0$#E(P+U>@:Y'+2-IDGCK8+PC/BO#)2> 2!]%084\O+95:=OP&N7^VH M?MX=P/V,8#4>3])K4MG#N_GB?OW.OFME=#&Z'<9Q3D=$>.X%I-)X1:Q7#A"H M/&0]UKW)GY+&7LQM_&/RTG45_;#XP^3Z9KP^(:AZJ0@A.B>#IJQRAE464:@6C[ M:& H5HOOR7%Y-XO&7OSK M^>PVJFRM/C.:WCY,UW_\,)]._7SQUVAQ+/#:Y6<#U4Y8BRBG4A/ 230Z88VV MSJM1^-:FEL;$.V0&]*^?4OYN?0U&=&8^3V:;_A^?K/85H7HDV+ZV\BQ,'+NC:>A=ZM*R2IZYN M__,P6:[MXWVY+FU_(CAFO)0>4\"]@@Y!R&I4K$ XZZJM 4_%0R!SS[H!* X4,IZRS$A1J7]4+S%WS$ CY&OCP^?_Z>Z77V: M[VUZC7$QZJSBSC/,F8?$FW3C)#(<&:\UQK!1$+A(7.RYHO;,PO&!/^:SQ;-) M^53%Y]:^$1P&$'$*"-9>Q#%+/) ['%W654AO+>+5F%+'(U[%E%',>!M-X\Q3 M??Q:5:O?$@&2FH\7:C[4)'"F#"(AE7-8YCB+7L,7_ESEG5 9(MWQE-V#/1<@6-,8HK&6RE/T";#E7N?N,[0Q(2]'D_:+Z-IJ, MW8]OU6Q9I7EYW?/M'8D-^=/\)8%X2=,MR-(K+B6Q5 FU&W\1H>ORXSH@5F=8 M%YV8MMU]9@,TF:0.M0M",[$6UQIM ?;(RWIT6:VS#AL-,*[;U835$KQ%J13- MQ-L+V72D:=#:$6$PT$8(0B5PQ*!:8JG\E175ZHI0[2%O-564(MQC;?G] M7=__VS/NE#C_M<$*@1!RQ I%%69<*;:;[K%1.:0=H/G?!F4.7CK1.?JE>/K[ M?%;]_'VT^'>U\@^S\6D&[F\0!%=$$8&M2%GP2"B \58ZYPTJRJT2U:G+4&'> M ?;%EMSZFE];?5X]'HXZ2;"C[4(42V% M96TJH%BUOX^?%FL[Y.<93#O<*%B2Q $ ",&A2M=D2EU+J9C-R3<]V_&\VNFL M-?S+L>SOZ2+T6=IT_OAM/EO.HP[=+,X#WQ:393J?<=9,=\GK J1 (^ \9])Z M9 RSAM7(1-LZ)VWT; _VBIG9N6;*+#R:X40 0:X@5B5'(&:B2Q-HUJ"[R=.$LVG^:# M446Q:GQQR5B=XZGL;Q"B'T: H$QXRC3S!BAH:^E 7(.N+>C2#S5>%NAK0Q=O MUB_6!A$D$*%44Z$@@KO-9Z_TM=WJ.0B^M::-7\E+!H1J1HB#6D&/"7=.D!H9 MX8F_+J-R(#SM7$^O&?QV]N('H:.W&-IM)X"A!(]NLZ501_F,E)R*;5J" ="A MG'LR!GC+U4#(EJ^(8N&,.%E-OLSW/4T&UTZT#%3+5 MI$_EZ+G1 DKI?"VWU"HG=CO =78 ;;6=5*,XJM MD*[&@F-X9=<7M$V0)E-B2] 7I^&Z),YR#0ILOO:^;A4T=]%G2VL*)2XZ]U(0 M5LLI#;M6TZY=#AQB6C;>??(*7<0K5 >,O$%Q8'(O.:+1>Z=QQ=C*B:3."N4/ M<,NI/UY=AG>?O,(7\6K;*E")51(N >4\0P)"M),3^)SPW "WB/KCU65X%^=5 MAC7[6WUC6A,FMO&=0(1AV!DGL-82 VND%S66SLJ<\_8##"T/R./H07NE1L)& MM#T%I!I4,CO9-GBO.+9$6)MR%(@0TJM:9BS!E94>Z8DO+^]A;%DK_1[6WB/' ML5W@IN\(6GI#2+2>.7:$:@)!G;AED$#NRK(U6^1$HR/:^8@7F__JVWW]?/$Q M=OXQ/>)YLL2Q:;#A*X+U%*HH,$KUPKV"P/,:@6AVV9R(X=D^38G$S>Y8UQ'D MI4AGJT4<*>GZP),%=5\^&J(HA*6$4PFTL1AJ2NK]; RA3&![ MM\\NL )PYX15,<^L>&@:+GPU7PUFKY1\K2%)>5=-?89,0B1*(1RV1=X\\0K5U.E+BY@_"<@Y\Z-_5*$;%5[!^95O+&C75,_+IN MS0#4&2JU)X1KH!63G#$)&)*0DVA>-0JL="/MQ]NOU?AA6MW%($>$Z@:H#!T7:H-1^.0DJM8(\RUNOST^L1 M]<\G/QU8K<^C=O970I1C?:\2@E([3J(=P&2-HQ59]W0,.:ND&V*75D?GR^4_ MJO&7V-_>EL9'_^O)V:@X7VS[I6[C7VV"W.=$;#+>&ISW"B(O+([_590:Q"#! MEB*GJ46@41;68+!J,MGDO#8HCY6'QBL@&*+4:NX?T8+JRM)MB_#J8(2B<_64 MFFT>17J[P6[U&J4Y?;O7@R M,"0P=(@:*24WUG$';"T3M->6G%]$^P=GBTL0+Q;);/$>.L$\U"JEAA,L'<>$ M8E9+&&V]G)M3!LVI,_7;]#:Y\^#LDS YM\D119C!VC! "%3 6J_(5DKOH5/7 M19I\93>_3>X\9$OQI_@U8=@Z 0F$TACJO=;L!$_$/NI8XVIPY M]M( *^MT1:+V$"[%J5W 9CGY,FOBINUO$*1SVEN*.:0>":!>41YQ+'H2@@AAX!48=,-&"0Y82P!VA.M[62 MM0AI>?*D/?T4E$_5/$^N:<>:!><$54 ZA(SQ%F)-S$Y2KT".+S; F:@=I1]D M4C:^Q4ZB=%!R%P!EN*)21 =4.IINX=H&O72_DQGU/UT M_E>RVS;)F&JUR[DX/?DW ! KB,=#<1XN2"P@(V2$!]-7.11=P8?\4U 7, MY:>D74]O[EX<-&XT1QUN'HQBB#)F(;46.8-IE')QEB\:/>K\7$>;!.L MWB',9+L33_FSV;Y7!<(@MTI(0RW5W+!H7-2K/XI>1Q#=? 8(4DIJS&R0*5,X4,VA#OD%'YR?@7Z>;"!6ZY6#WA;OSI)6_CK\*' M%.TX$ )_]O?!4,BI]L+*N"@SBH0E8H<2MU>;6MN9;N?Y*'?.C(-QR1=/!$T! MH XHHB%"G/N(P#9%W0@ 2$Z9FP&QXT)=O=3T19AUJ>O?)[/)_R88 M;J*E! PE3!CL,?5HUW=J44[NX1#U?:[&YNW@UJG.1S].Z_SI,\$:I#'51B)M MJ&.,O#G2*BA@I.!. M.BH=@Y)J+!ZYS>"575E0SD)H'_N>.79RW_QHNT T5=3**!Q$D!G!H=$[696X MLBV&5K3>C$D7X5LZHWG^;5U&(>4=)2&VAT(:9S4?:QY2=69A,2!1:F,8UQYM M,Y>,) !>B17;,@L.)#>W"/2;3A$3%CCME6 VE1>QQF%;2^J1R4F6'W2*6*E% ML47PWW(R671%&9(,0ZF5 !AK71]%,!)S=V5)TNTH_9QDLO/P?=/)9!H*9+$ MJ4 )6U$J?DQ0T:";E*/VL9+*S\'US9WL\)$C("!5.M:PHAZJV&E1F M^L^@4\I*+7>MP/X63P$1PH&!$FF( <-620MJ5T=ASJ[L)J5<-3<]!70>JJ5X M$[V'\>ZII<&?M]&\0*?]41I.%6<>Y(,P1ML,*DIQ"U0.\ZG<@ZVE'VBG/Y$_5 MXO[FKH[H-"+I\R8!68RXP)@I0[EC2!)?KQ<:.WQE[F8A-APN3YH#?GEZ_3%/ M*AU-U?W\X>AE2H>:1'-$(D(,M01X8!Q&ELE:0B*OK0Y_W_3* K]4RO_-W=VR M6JV>5<1>_C?]_U4M9*R$)H1B"*R" C.H^/K*!& ,MK:1:=KY\G-F)6S%'*:( MIFUVXB.E&=>RELD \]_4ZO.U?Z(2]GF(O^7\ \B1U5X+0VRG8 M":]@U(6KY6)4YIA&@W:4VEJ^+D6R6%;O'J]G>T_@:3_B=.. M$1,02(@2-6\ MO>:/XX)I>[793!?H_64>;]O@#J1.0RM%:)0B*?&> ^@ Q0((QFMKP'&MK^3X M6Q=4N*0FS7EHE^?9NI>[_O]],5\NSZL&3 M*<>@<8C3/4;A@P6VW P% :@54%D1W/M4R-M$K MK]$7SN,];P@8(.!24%-I0 BB5CNXDU^1 MG"KV@XZQ=.,CYR,\$$>YU8*&A''F%=;6>>:\H\);M47 "TAI$8=Y"!9!%CTN M+7)X'OI]1(>W/7WNC#4/U1Q[05 $"$X,]H9#Y"3T6->CVV/NKBS9IASI6@2] M/\I%2,YB6'P^,!V-:PF !P(*@C'@E-:R2YQYFK% MNV[\MH"PE@Y8)]-_4D*<1V0WO(C.B>4,\)QM#W-:RQH8PIK:@Y_==2="!-ND M;7,J+8=<WMS=/*R6J]%L_&R< MO)\O)^M37FL=?XI:U;%C_SZ"6TM?"! 0KY2P%'MD&/1:6E)CR(&YVE2$#MDV M'X*F2BWMC](=/0/[;K:KZ'9SYR>ST>QV,IJ^KQ9W\\5]NLGZ/,ZW]*UT4 UX M2Q!4$5R&(&)8;S$E5K(S"H!(B[2D8(>DX"HGA^,ZJ@"VR/[BZBJ_(_3$V&_,YP:M [ $6PRU M)4YXR;B+BZ W4>H(!L D9^=R@%&%/FC:OA;*LV^SNWL!\?8U# XJAZ4#P&.) M@"?QS]'8$IY30CGF97?+KYQS+2B@, M,(JH<0)#K--(CAX&Y-&F:E99NIBL34;UL68!>*"A5<(KK 2"AF,J=M(:D&/N M#-#5;47O>RNTMP)OR1%KYO??YK-J[7)O?AWGMO>+^??),KXR6F:ZFE5WDY6/ M(#YIUO3V4.J M/["IUSZ?+7457<'JB7I^G\SFB\GJY[M9'$S5Y7L'B@3\T?-A5H= M,/NWT9EVR;]]:1#:>P.<))!:CB2+Z,@M2D08GK,;/, @\Y5S_S*E#ICZEX(_ M#/,I8)[2")R!!!B+N52 NEH/!/(K.SYVY8.K$ N*E;U]6"2E[@3MB% ._,$5]-4[Y4J\D M.LW#0RT#]1QK )WCQ'-G/#5(U?(RJ7/.[PS0XB]!C/U<;$D!I0FW,:,N(=R! MEH$31) P&G+"E6<11:MK>8UU5Y;+T2/AVE% 8<*M]]FC/?%;U/LE\]SQ]H$9 MB(U(5Z\S*QPF3@FZE9T2<&VI%/V1KU4U#,,.O-C6"YXZ(2TUV '%E!!*VYVT M3*.RUYIU[OOT1[IV\"]WV&*CMG;=CHRW!H,T@Q18G$[?4'P3B-LF),ZFL3I:=BF(DK3\)EY>SD9 MF[PFF&@$$2$$$R@:RHYS#<46"6:(RMF6&N"JW"P[2#\BEH,57:6RR1$12IG7O& ML%%ESPT4VAKL(J,J%]F2J9XUY^,/VW)O<=I]/--P?2F=U&NA'//,&LR@YTB+ M."=HXS!UQ*E&YW<[BGH]R;I]K98&&YU-V@%9X[9&@/>&__B'TS\.=ITEW)O_QN" M]]90@(&PE)!4UHS+Y&F]ER?,.=DF<.X\)L)*K@Q%G&@%U&ZLD*P+1@;HVW?#E;91[FU&>NX' MGC,3/6\9G!2*'H-^JR*A;SY/)U]&!XI1-FH7F!>0,Z !I4PZ1 SENQ& M%<@Q]?FOS9@\I-MCRJ.?FSIT\-:DYHV#P9"BY!0;J32C6%&"=\$?#'*,,_%K MJ(^1)LNZXYN,+S-M\(,N@3CWAB4"C1O=#B= MSO]*M1S/H=/KUG'JU8@YSZ*/0#DCT!H-:[D!55FU!"Z]MN6:V)4->6]4^^/$ MQ2RO'P_.6B&(M21=^H4] @KO]LP015EWYIX?5K^VB>I\A(N=R=@/Q'EWF35_ M2?#4<*()=7&YATQPX/EN!$E/[>%-RES@>[A^GJ2:??+^;1OUC]?#\= MS=*!]W3$_5LZU=YL)FORID U!1AIX6&R&D7-;"S%(B6.442AGO/61=\.3S? M=:"'?GGY]_E\_-=D.EW78*CWO%[N@36X[CGSW8$1S8"TT>2P!*.H&&VWTP6S MB*HR$V?_QE[WM.U.*?T2^$"Q7-$J,!1-$2L&HMJ"6WZA"N?._ MS(2:BW^__&M6,^EDVX P2LF[T;4W#' L+(U.V%9F$-$MLOO^*TR$EX/>+]%2 M>/KYM5;G$V[/.P('+,[R7E+M+< 4 (VBY(8[#S'!A3;,?YG)+E\#O85?GDAQ M9B3F>VXF.Z!4:IZGWT!C-(OA*(L ]D4HJXV"CC=PN M9?V5JDM:ZR5PS$3_1@!F'!"0U[K S.5LJ@\PU[\55O98!?(\;14_T/A\XCIP MMD[5!=W2H>&'R*:?C^VCY=-D3FGC.X%[RE)B@XTV!R$NKC1*;[&,1/ Y!:W> M6+PZC_G]Z*-G;N\_\'[T3OLSWQ2@E0H*Y;BC.,52J3([/#(+R@_PA$-!?K:$ M>,\,?%D%)(TA.XFV9$)[,IJ>S\13;PR$L731C0%":AOM<\.9K?&Q7EW9Z8B" MC&P9^9Z9N3MI=L%L^-@V.(VBQ\ MPC4/MZNTQ[@UC,_GZ+ZW!+I>$(3GQ%GM!($2\=T0)JS1'8=OYRQ%03*V@/9 M)DPWB_"L1]-E+O;^]P2MG%;1%B$>(A[7#6,IVV$!75!@YOL3,R.GO7=>"CYUFR-3V4XO">39@XX%[$ M#?8*Y7[<5LN4P%&'N>[G#T=3&]O^5'#*"&V)X!8B( 632H$:46:R+HBZX"3* MFZ1VSSJY^-1EDW[;]--R/IV,US_>W/USM)BDJ\CKW002BF4^K^&=V\Q6HR2@&+]_/E M9%,U-)NH1UX;4(1>:*=]5 7A .,:R58J[,.IE]P6N8Z^=@>_CV;N.MSKFK\ M/P]-]_1/OB%(JAB%%$ ,J,1 T+1R;.4GAF;MQ__:VSZ94!>G6G9U8&G2&21% M% *,<\>40GXG'\-9A4/?7'G@3"IE05LRF^R/T2)EG7ROKB]M3'B/,(\C%6MA MHF6MO"4(: (YXLG?DHVU"%#Y(Q7!.F-%XY02"*) MJ*/$2U9+AO*N#WIC25B-=3PO G6I25\_+">SZ$>JV_\\3#8&D?HQ.69/'&@1 ME%<>2F8PMUI"'<&S8BM?E!OE9#4-B$K=J7W>!TRSL=_^[VZ_WRX$."1)L%0H237F$ +J<".N\=>:T=S=A_?""LNU.*\ M$X"+336C:=J$__BUJE8ID:[)DG6@2<"*4L TY<)#P)4DG)JMA-#&F?LZ,G'+ MK5GMX-PGDTZO5@<;Q0%H-,+ &6==MPHRF4M)1;LVI:I;&4W8,]%R+972O+X MXG3@\0"QH5!#K;U&S'@#&!,[ #(*M#V-GAPKMJ.UHB\"-52MG?X/@H(SC"? XJJR10&+D2"V=Y2+'7Q]0N+^8[=,* MROUQZ*3=.+7 ME]'M&\WJRWV?]N6$^=.@;? *,NX\(DBEDO$RNHZVEL, GE4#\BVPXUQUSKL% MN%C]BFW735IK%X>)=/3YN !320@$T=B+NA">*$;CRALG9J.%R3J(.$!CIS7R MM EJ*<(\.QKY_SPL)LOQY#;I["1U3K0,0A.+F;/<(R0]C#_I9+X!S;P WN5X MY0.RSP(J0&SS#A'F3762Z5J\Q\C),K>HOWVB-," MIA>;-]6U?W!>T .-@B .&@P@E(KA['ADL':LL/&LIP;A@;$ M@L[=I%91+C6+O#[Z]S(X51^7.9E[?^ZK@A 24&)\0!(&-=I!'"]X\+\\>?_=P5]R\G@2MQNU\?U\>D./>(^.8 M !@H2B3BU0Y#)*8Y[^U'9.;WQ/'1Z:?UIGVP0/:QCA^+]<,B;4?SY>9K\;%8 MI!)1Y6VM%_=Y'09A*(JF"L82(:(AB?^K[AJ(<3!GTQ_1F:%C1@Z*^6".C/Y+ M[BB;9A%GU BB7#PX,5C)[1B;2&Z;GE:_[@$>BEC/C.VZ]>R/-PI(Q779QSGD MG+>44^=P=1]&,94YT5 C*KW;$XTZP_5BR])Q"3X]_/6?XGKSN73?[^>[O)!- M5JQ&'0<)G2/, ^VU08@)A\T!+<&R4B>-*#W-4(M9G]B/D*E_E)O>R/IZWRD' M/8QZEYA;)[S'2NDJ5DG:I]6XWG0&F\OSM1/XAZ+LJWZOLQZ>$ZT"9L A:0B M@$(#D/:JLFVEMC#G#F)$Z6IZHEEWP Y%H#^7J\,1_/$H=,JP.](B<*V 8MA MKZA32@J##_)1!'*NST>4.Z8GXG0#ZH5)D!^R%>^V]N?2;WMC3:RD5X! MP:BU0FL*+,&68H*XM>:")2$^77\M;AX6Q=7M;OPODOE7T1WJ2710U,WGJ T= M!_3WJ9")O)Z#T)( R3WS!%'CC0805I@QX[.J1(]G7>B4/2^C*@;5P&!!/ >I MGM;=.9+*H 5;&_<:#+2,:P(0%!(H K" O,+) )USOAO1U=(P3.T;_?R+H^># M>:T@RM&TU&>XV,OW!*.5]IC*.(VA4I@X8=@>'^&ES/&6C>B:J0]VCD$?PZ^J M/U>5?W:+VV)%;=1C\!RH%.[ MN]GJQY/M8#?WOA1QBD49ZE"Q9A=!$^XX8LS&L<3]!#+W.#>YP#F'T1'=;_7* MO7Z@'O+T>>1,/;V,4UH#)Y6VV$J-O3=6&.$=DD+(N!'5RQG=CZPO4MO='E&) M^WZ]>+A)Q5;O=L\MBU74T3+^(%T S.[FRUUR\6+SL%JN/Y:+A=]Y7DX UO=7 M!X"HMD[&?TLAM=,.*URA3AT=)N9R%&M,;?Z5HU;1VW/X*^[BP=XJ(&6$'D$+ M(3L 3\2@KRFC]3PO;SYM9JM-KT0<#VEJ7B T4]+E+Q!6*>AN?0C%VU8+?5@E MU7S8JOAI-MQ6=PE-OB (9!%ARFHFG,>08ZW0#KT(*,KR'H[0)_/6R-VO-D[[Y&C^?M+!_&7OZP52GWQ.HA59C&+7(+%:<>2[ELC;D,5#>#JW($,(FYISMB2WE@"JX MY&IQZ1NARRP:!D(JF4&0.6E8M,#CVHZ\581K BVJ92SV'\MX$[>>Y7Q3O)]_ M*WZ2ZEAEDW8=!6LHB$:6]4"G1P*8V7@TWR'"O# 32T[8$UM.Q"YVKH+A,F"> M'+K^\?OL/^7*+&;K]=GTJHUZ"D8#QZ3'B')NJ?#>2;O'@QLA[;0HV1=9?LJC MV:<21D+*1QG^F-V=KZO2HK? N;..,=%G(A;3.:W\^N]8V5?-_CTSMRFNX")UIRR.+>)XD!!%(]5>V0$4UEE M>$=X.SW0]CR )H;BZ,L!OU[1^NSFW*2;8#706'&'"(-(2JG9 78!E,FY(QOA M&MDO6"L@8 ZR#0G7C#CL>?(N[C. MN50X.>>6<43OHOMG14< C^2ZYNGUP?L3!4ARN@M,44V1M=@+"R"7G+AJ*540 M95W8C(AZX[U-;*N)@2]L3LIS_N;F9/-@M)4>$JN DC3NX!2RRL13T<2;6)!% MO^1X_0ZG2_P'6QWO[F?S5=H2TFQ]/N1'B19)HD,\[,M@S]=6R8QN [&4*8$8 MT1@9#4UC\&D[5.F/FI9@%;KK0 +NZ3GDAK+8>BDC9NI)/+9-F!WG^R ME3N#=\@9>^D \1XF+O?&:DT@@5H(Q+713,;3MP0&.21J79[U+.O'V3^_SR+- MY[/%^H\B&@H?HQ97WTX^ISS?.###F+<,>@T=(9'%DI%*.C"A$%,,V3BM."( (DXKN7'\T=2. M#3VRJS.4!V=7'&P=&L6/!:D,1 8:3P0!2&F")*\DD?%$-*B[M]S,%F^7+\WA M'-(^O7B=A:[-4QA/$21J"VE ,*':48CV4%--1:T22/V_3=R/?Y_NJE5!A5-= M! 80<$9 0ZFGB K 1,5:ZC7/2>?QQDS5VGPX\?JP0ZA[G]OOMPE"+C:A=U]? M8PX__V" %AG/H^J% DS9N.92H*1W1#BE@:JUX?0ET7I=%''73T5>=Z.N,U5/ M-4O)[+B/6XF,9#><2>2EWDNK+583"0C+5779&Z)#F5Z[(3^6*VS(GF,-@R/< M"NLL3L\/C(M_(;Z2UAL\L<=#G?*G(TP'6L?5S.R&1E,L*=2>$\,)4_5RC/4Y3[?#M<7Z>C6_/U3M.#M)7VT5 MCPW&.R\]4I!A"+C3X" KL'YB663:*OK5&=H%H$,M\!]695Q/-C\^+&;+C5K> MN/]YF-^GRVG]XW,ITRHR[+6: _%,OT008L& MT=EWF\\_&(!UG@(&*>%IF6>:&5M)0S&8V"&F4_V6'0+;DB;KU>8)1>+?7M(C M_BA\3&'71S:Q9[\/0C@.J9>8 BN-AE'<2G3&%%BG5NBTB M^M?SO7?IL*%=W596SRD;(*?/@*DCPAJ%"4,"IP+T!ASF@R(3"TSHW&X8$/M+ M\S)E*GL4X.CI-Z>[P)!%W ,9_V<%< (Y7>F ?R?_Q\T<#]7$IYQ0+ 3F'WF#+435*0%E.%%5C@VE: MG,A'>]@KX)=;_OL:[[3/M Q "0<@P!) X;R'6O#J*,$]A_;"G=(G?''0UHOKVZ?AXJ]W-!.M0G6 .,MHUI8BHBVP&BQ'[=P MADWL@7/7#.D:WZ%6'K4J9BG2H0 M]CGV\ILY^.>O,1W!V]'"LJY87%UHU5QQA_/'%. M)-71@ M,-L;#&LQ/PSP_%ZN[JUM3+K?11?"LR7RB;1!6. LTM(9)Q* #6%>> M"\$$SO'PU*]S^69YU1?.EXS'_5@LBW]FBR1 PX#<)RV#DHA*$D\A*$XC282' MICI\"LZRTODWKD'YUGG5%GSZ:A<&_-KUTYUO+VZGX7V_V$XD=TQM6NXZ"T5Y!CZW6 M"@H*XCQP<"]A7'-MCJM:_B(,ZAOTH8RD%R]D_,/F857LHU@^S'YL1;(/Q;.? M?WKX:['?K*.D)S,]YO<>K.628"TUPE@ZA0AG[H";%EG^23!]MEY.%GH MN[S9C=)]OR^6Z],O>5[Y?%#08B6Y@P0Z;ZQT#E7G8PFIRHII_(7\X%V VWI+ MW:^]6\ZNW]W=/VRV:02W56\^SC:OD:)6NQ#/( )PZXF!5 (-D#X$:4N#15:H MR*_B N\8Y('>9.K9(KD]/GTMBLW+:DT[KE=5PM_/9W_-%]NB8F_US:94#FN@ M-"72$^R)(\ AX^)2[SU!OI8?MFX SA-WTL?YEZ^;J]L_]V#^MBK71T]&Y]H% M*Z.];I"&#'N%HX7E#-C*H $0$DTD5CE7@65_D ZU[3\UM&]VL_ 8<\XU"8XA MGEQ*PG%-I& J2E5)Z'161?=1+N]9I.D8S:'X\0 M]HSK2DZCLTS&YK>:O>?-ZH@UW0&::R8^)>X9R_#I1P,#F*64LPK2N!@Z8#VC MU2BQRPKT&V&ZM"YVF'P4+[&I7/VUF'_9:FB]3P95J*C M-8O@84E4-1.5=743V6=P:(];3#:J[8/%GV8AVA;/V _@B9 M93(>DD4\B L20:QD(TSF7$$WOC1\ PM*_Q!?>(?ZHUQ>M]VD'MN&>+2S'@(+ M&.8((&P%\)7,@+F<%"&-[Q;? *WZ K;]6A2_=;-ZN$Y?OULCY\LOCR,ZR9)F M'03 %;!$0QKGA84>(QG'4DG$94[80N-+Q#= E5[1O<09NEHQ?]1:>LZT#)!X M@($'TOM4X1$Z ?A>7F28R=R&09P(!_E('E>:NWC? M"E>Z0?,RL2SU?;PGVP69) -"2.RU0 0)1@XKJ/59Q7!A8S?O&]J9ND3U,@PZ MK([GW7^G&P9E+4$LA2U#QJ153NF#M!RH'/YEQA#7'4PA'^:2E3R*UQO7"7&K.H. E,.EU3@JW0I8+ MGY+G[^53EN6D#X#-7!1Z_U0@D1;1!S#HMJ=28 &GXMG:2 M\,83CRY8;_(9O*]&SWXL4HJ3F_3LTL_7U[/%_U?,3F78;=ECT)9+I>*.1XV, M>Z"3D-@*(R/J9=9_LQ%.M0ERXB33']B7.!5^M_S\3YF$J'M>KM%3\"2. MR+AM%#B-RQ_6$9,]'@ZZ'*_O^".E^B-?#LAC(UW\SJ(KVAWZ2N46@>+"$80A M\9H"1&&%B; X)PG)*%-(#$J\MC"/C'J^?%AUQ+Q#5P$XK;0U.IX0D,.&>@ / MB$"15??Y:K(K9[>9D&8^&/06L(5: 0D(I0AK)FL\-"[&-H1U2O!&D([ M'EI5KP#?+:\7#S?I56#UFRRV'>\VV(B]T\8)9X5AT'#PB!2S-N<^IGZ8F]R1 M<%E\2:ES/T]GL>L,^/%0],-.V?\U6SP45[=_%)L7O\\BZKG. R#""N^1==)8 M[P3BDE6H&63QD*%V$UHS.\9]*#]_>7=?+M/X]B^0]X_LWZK+7SK+"9%QMZ*8 M()N2$6+#C:$ ,]7RT7$?UV^F7->_NTT?#M*P5"K*:]%!,B)8S@EN M_([ZVFH]>>?6 L=!TXZD\=6E_-//!H\IL\1@ABW'$ LO$*IDTHCDF,'C]Z.W MY48NC"-X:JSNRM5F_K];G=4,>#W10W T7B&)$PY8:DTTC-7R8^MS[$,QKK$ MM--__5?(&?A>@E^5L7T^[]&)5H$J9*E@W &'HV1*,7B04SJ6\YQLK,M1YSS* MPW0H[OS7;#5/=33JV#0_?398K1$0$,0#'(( "ZH4W\E$&&(\9]L:_RUXOG]O+NU$KR_(.!.JH 5-Z9QT'AE0R,)U55Z_YQ=7@H8:YIFU#^ 9R.CSS MGYCR[FZ^V;I(_DP!4X\5*=YV\"%S6#&"3+0%H@($M((2[Y 4$E.(3:U,H_U( M5%7ZB*O%?XKKS>?R:J6^18S3KN++U?,SL_[Q^^P_Y:IJL\U:MRV==0*);KX@ M$,LXBHN7]D!#*27VV%4(8NQS@G3&>AQI09\CI:,&Q;[EUO%&"P\CX(@DWL3E MF (& !6"5]@D;]*T>#DTH3JK4=Q,39>F\! UBK7UB%%-B"7:,6&B3D2%"" F M)]QV1,0=D#E=U"ANII3V::?R:A1CXHS2 @AKG>+"4([5?I2,8C.19P+#*/)< MA>)F6+=FQ#93T8M$[J>)<;Q%T,A [JQTD@L+,$?Q^PYC9EEQK2-R^0W/C\X@ MO\PKPYM=?L;W-6H6GVX8I=5<2:29Y,I1 PT1E?T0L60Y1M>("'9AHZL775R& M>4<#VYH^OS_745"*2 FHP1AR(:7 3N *#2U83KKG$6V-75.C74&1=IB/C(&U MGM(U[BMP:GEZYV"A)9)#2>@3LX&RG-(V(UPA+\O#UK"/CXIU'MBUZ"UX1+#U M#".AO>41"\\/4]0/G<]\^G1L"_SH"%GGV5WSSN*ARKM4/< :19 %/-5'WZ/" M!2 Y0=HC?'AW:3JVQ7U\;*SQ&*]Y9X$X+YDU5'#-K7%$0*\K5)!1.:>9$3[' MNS@;6^(^,C;6>J+7N*\ &.)*48 8T1 ZK(R CS,TJP+%"!_I79:+K6$?&17S M"1B4!R#N"Y2(.!TI=8RYRLG.TZS,H-T(G^Y=EG8-P1XH#.3W61SM-DG^U>U! M$+6\.>2R?I8HZPU7PB-00&H4(A%J!J%)B7]VZ!,'&*^5+K;_V-\G0#^A3@UI MZW<21%SG".; <&(BVZE%R%=(<$^R2E^.;Z]I2X,:.98[P?<2$>:'O'=/AO]' MG,.?_RD6WXK?R^7FZRE;NVE7 1N!-/">8J*HM3C:?+9"1'&85?!Y?(SK@RIU M,GYWIX&Q<#*=%S[_4V90<=]#8 @S"Z35"ANMH-$([".YB"<23^1J=$0,; ?\ MJ(B7O'FYU$M]!,\94,!*KWF*'\2&5 =>X@U$.1ON"+VP8R%?"^C'1+_DO86 T'+8VI:_"OE:(#\J[LV_Y:Y\J8N@E:&4<$XT M<]I@8IA0%0*2@$%K9/XZW&N._%BXIY)3K@,"/NLGI)*1#$-J&<70*@U-=1>7 MPDMM3OWX$?I61\#"'/C'0L4,]@4I4EU Z60\;0EGA!::51+'>9E3F6B$7M41 M$*XAXA?EV)_+F_GZNGQ8;HH;]_VZ6*_57?I;4\(=ZR*,\;( M_L1%080CY[0QWDQHER)A1UJX*".;,B] H22RG%DBA+.602AT)1N&6>\01IB\ M[%+4:@CS92XG6]]7-.DF,(XIYPI(I#GAQ,7EWE9(,*9SHGM'Z+WKZ,:B1X2' MRU*P7A?%D9H][>XNVG89N!=$XCB-.1,>"<&9Q!5"D..<4\0([S#Z(<]/&1(& MT<78V'K^5J-A3T%3;2E10#"#@8)6 @0K/*B%$UL?1\7-=BH8)27/W'&]Q_AHV4()8R3FF9N0IET%2Q@04!! $3:: MH6A6[:UT"JVE.9431W@C,CI:MM#!*%EYVD7=M*L -?%:<&RMI#Z:-!1+5B$2 M#WXY^1I'>%T=TYHR@PPQD.#*I('4\QS_XPCO5T9%Q8;8CX)]+6Y< M6O47J".R#O0V)>"M5] !SP74 MR$,GHLVB*ODBMCFY&4=X#S,(T;J!NGV"L,>+H-GR)O.J);/'0 W56D'%$',* M" [< 4/$;5:VGQ&Z;S)O788%NPN"I=19IS?\>C+X,%*84\Y@Y01 3*)A MGXK\VDQLIY)A"7CDUB2OPX B=N/,P(B+7 R7\4!7NIH3M1^\[WW7Q*V41V& M>'0G5"-M@92>VFB#X"H2#L$(_*!W(__2L(U2AJ/AN6N0#GH-3DNHA&"<>$&H MXH)@M)<= V]S/-#-+T-^<4+F:&8X5G9&Q "=4%1J(SA$!@(:+1)92<@\FDC. MGK?!O8;*Z)EN#2XZ.N@U1'2%P\:#:( 89Z&CARA,#)G+.:/4O^[XE8G8D69Z M9F4>^X)UV%%CD)+2(429HZ#"#U/'^#0N.4;,LH8:&"AOV:>'^_M%D7"8++6_+U=UL5U?FC68IX\HB&4UIIH !PG@!.99>8XLM,[C6FMK?%7NY MJY'RI&C/N2IT)UH%06$4CDO*4.06!X(HN)?5>>YAQLP>X8N*MHI^Y2:\&T"' MNN_6#^OY,NU-U__S,%_/MYIZO2K0CEDZD_E&G MFB[[0/:2S$E_7!7%T=ILM=L&!+F60FC*(&)$,AAMHTIFYM5$"K%UIOD:3,K! MM[41^JFXNYM%<\E]+Y?SZW5*[CN[+QXV\<^G"VF=;1BD)X1NKYVX%) P QS: M2^ QEA-;;SK4:-DCS$.&%/Z\_+ZO443K3,L@L%$.*X3B5!.<4FR5K.1%UDZL M1DP?VUBW"+=>>JISQRXZ\5PDUNN?#E8 2B$3PJ>2@PAZ2F@UUGBYXP6R.&WA$O.E$OR=C M/%L">HF,+>^6$>ABO=D/^6K9-(7+\0Z"UW'YE1YM7],S3PVP>S )L'E)P4>T M*?5!IUX O@2]/JSFR^OY_6Q18U$ZV2XP3)'S5A-I 76:,(U9)2M6.B>$KG'T MTK=B]5?Y1NF4BVQKR^;C_,O7S=7MG^MB6R3CZJ]-M/^+FW=+]_WZZVSY)=4_ M?>XE/F?]M.\QJ)2YUT(AF5)&**@U10>9.: :H9,)Q:BJ?2K4CC,=%P!LJ&! 6F:W M_@2 @!8&UGK#UJ-$IEQOMLA^CECJ^$5_GQ/MYQ:!6"&EM"H9!1Y%ND#+]C)Z MY\#$+C+:*O@G%V(78+8VL'>UY]3RYDE7TE3O2'/65?Y>]'[;6F02_!.>L1@X0#X:#BG$:3 M:X\#!!CD6,'C?R?<=OWI#^#V-ZG77XN;AT51WOYWD8R7XD9]B];UE^)CD:[_ M*B/[<[&Z2_%I=A][^'&V*=8?BT5*-[$IGU@+9Q>QWKXPQ#.RLM !IA%&!.-H MO_D*,:O Q%*\=;'JC447K=F[_>XS48'U:-F\IR (40#H!51BA!EF!:5C%"! MG(H/(TS>U@7?>@=Y%*F'&N^[+7H+3&'FO73,40+BU(*:F,,$PS)GL1MA9K;. M[/^^@1Z*@-7*?77[K/+TQ^VLJBX.?G*5G=^B.^T_1!UA"Q#S"G+F 9,.5L8R MXM[FA/$W?[7T5DAZ">@O3-MG=_)1-#.[GZ='%YUPMD'G@3H+->)&:P$$DE+M M R.WJ%F3<^O4_'73&R=L?[@/Y/T\;Q.K%S;Q6WV PABC@F)N%$1>4<<,X-'0 MWIXXHTYJ!2?6M-A/@GKN/KE6X\"P1>E9.J%02AGM1P'P7AI%C9E8T8ZVJBQ[ MQO42KJ^S,Q:>F!/-.@K2>Z!E7!M%W&2U]2X>42HT"*0YL5,C8ED?]#CA%.L< M]\L$>&;QL&E7P?(XLX4$W'H4M\^X;S-=(6*PS?%#C,C;/P 3>T:^M9?KQ4B> MFAP-=\S7FL:C@K'.2V"<5I0I0AA#E13,UWM^.G[^]+A?=H#J"';+IU)\*%;7 M1>WRI.<["A@R!0@$"@O+)$9.$UNAH0#/\02,?+?,(T?]O3(?]5'LEK8849Z: MH1<7#J0V*::.FI3]Q!%B32JI()F#2K-:#KF&X2Q7MZ^33'V+R">U^7+U:?:, M:D>2VG31;,%EA0!F+.=MU-M>0FI3X[6PE6&T,5CBD]DB MV?:?OA;%YGUB0(V<.4>:!..A)!)I$:>'L]I;0"L)D>=J2L>MP-"=@@8@"9PS+AJ)I)*)J:SL)V^$+4V5^_+ G0EI2YJL5YLG M%(E_>TF/^*,G*_!NF_^]V'PM;QZ-@)]_6A1_S.Z*(YM;;I>!81"/"31.1X&Y MQ]PX+2IDC!53\O$,O?D-K)L^67MLF$:<./3=&;JM],)YXZW"(I(KY2.4##G*3)6/Z[@ M&--AJY_URI:NE%?V 6SVTYGFB^_[$PGENNHZ>&QEQ)4Y()WE'')"T!X% K'( M>00XHA=:%]D&+Z2CH6S]),L9'WJP"'A.*+1(,HFD$1Y6CAMB\53>'P^OZ%=< MY0VQ'HHE3[Q\?C9?_==L\;"]^EN4ZX?5J?3@IQL&9I)XWF,"M'-.ZK3P[J5E M(*O"Q'3,]WQF=:J%P3AW=Q_'NLVR=OO*->UK9'N]18BV 9;42^X,39=6PEA; MR9>97VHZNV,'+.L$_J'H]6%57A?%S=I' !,25[?'L4DW&R=XU[2K%(BVS3PA MA38<820)7:TFIF41*PS>#BB5\T7YV&W:A@LE]E^S(\C3:-?I^$7 MITAWLEW@Q %K+"8N'K !X4006,F**,ZY'1_16^:+4ZY+)0Q%N)>! _\]WWPM M'S91E)OYXH[3\77:?P2" N-7&Z6WE+:,P8!5&5M*<:ZP1 MO6>^.%&'4M!XHL1>@)D,C\<6^HP*=O(Z#U<"G8@K811M" M2RX!,!5BWOW",6>UJ51>4!]#;;!UA=H67(XR??ZZ*A^^?$UEEY-XZRZ)?/8[ M@K->2Y"J[7HDF/&4.UYAR"7/N3(;D6]PA)SN6C7CH/?CWUJS]_%O 7F O.*. M:>JU(YP3H/8(6"=1SHOPYB[%WHK6CH:'N;K;ZL3.QSS^&^-5, M/NXIB?Q "$JLHAZI5Q@!3:!'V$!8:[%_V\\&&--< PX405A"@XSSHD* Y#E& MWK8)5YL:73X;:*:-85]TS],#HPC.0X+OS*N!(RU"E(=8J)CU6Y*1AJ?#J^^UBUN?5;+F.2DN(?"I6W^;7\^67J]M7A%A_C@-;O_ZK MLZ\,NOR:(!% @$@N-!' HFAR2%,A*>#4(LVS^52.1A7M8S+C[$T64[DL?NS, M)O^PO#E3!_ADHX"DQT2F.4V22]Q@ANA^Y)01/#$274;I+VMY=J6-]CPJ5_?E M:K9YX7VU#\4SA\X97C7I)!!D@>)0IH!#*HT0[+"-,"!\SC.]$;HS1L"S'K4S MV,W_I\^K8K9^6#VQB\^^R#K>*%B)!14:"(N@-HIB;6TEI94RQ^H;42#4*#C8 MN3:&X]QOY;=BM4S"?[HOE^LR:M2ELJ?WJ_GZI3NF!AN;=Q>L 1X9;2333G-* M&;?5+B E93E[\HCBHT;&T][U-%A(>WEW5ZP2/!]F]\7Q3?SDYX/D.EK5'D+$ MN=5$(4.A-(!;S+4D M"LA*-NQUSH8\HFBH<9&L T4,?J-U6Z[6SUQ39_EVKFG@P$M!,5/.QPF&"8!B MCQ^.HF,_C?BF45&O8YVT/OV^9I,V._K6[R'$F40M-,1Z:9520$N\MQ$P9,;E M9"P>H7^E.Q670\#=GD+_Y]/_:6(P-J17)[T'3B2@0'NJ&.-Q9FJ ]P,PORCW+S;GF]>+@I;OZ)@TI;_VQY\\(":.KTZ^H; K=Q M(S$8$@A3Z1X-O<85)L(.^V@[*OBO\DT2]&(*N518_%G3[_4& 1@%L7)""2PM M43Q:NJ"2SA(WJ%/E3=*M4WRGFHF":V^D@ (Y[1@W4%-:H8"%,1/9UZ#)XK :4"V%L*#1;:5:Y*C*6#PZ9K MZBU@XC.(>$8Q@KA3E6)LY>3"H, M)(,Y?!W5B>=B5.U;)9=_.53CE%AYOPBB.N>UT(CN MDB].P\XU<2G^/7>I/K.4]6Q],N"_:5=!4DZ$@@01;I2VS%E3&374.9"3@FU$ M!Z,^*'*&?1TC/Q(N7E\_W#TLDNGUBH6LDVU2?)Y];T_0>OT'ZS3T@/-4@BC^ M"T #P0$[HG.B:H MY728:Z"A3E4C9G2.5BYOJ';_Q-TP;0%F6@JAG8R3V$*U1X!!K"<6A#L@(3M" M_%+WC_[;'_-HR-=)U'3^\)3?>5#04XJ(@*^T@%P J:P#VW%>O+3%3&D^DVMHE*%&#C2TT<$F.G;T[ MJM\X$ :!-PPZ@>(?+ $05HXS;JS,20\QP@//R'B7I8MQ,/#]ZQ=#]1L'Q9R- M(DO+4^ ,\-IA44G-$9[6[<_HB=A")9].UXL2'DETX42DV]CS7R>QJ(> M*VT,0I['+4-R:[@$#$E(H[9PK5)+_2!QCMF?OI:K33SAWKU4WN>H+AW']/<) MA/([#\YHP;6-=IRC4$I&A/ 52IUHOJ.- H1:&X((,<(Z#Z "G!%L M*09*Q+VEUJ[;CZ17JR^SY?Q_M]HSZ87N8GZS_C6_ MW\[,U]169Y7I]7N#HG$R.2$]8JE2(.)>X0IOJ,G4,@=T0+QRO.H9QUI4_?*/ MV6H5^_]67#K/>M=KE&8:,R 98!!8!!&PCFXW"!0M5.EK5?3+>*;R>C+[)@]2 M7N\A>*T@Y1(YKP4@%@K!2"47T"*G8N;;6@MJ*_C<:Y).@![J2N&/A_3$^NKV MZKY(\W;YY5/QY5SQRZ-M I%24*4]E1IP$1&G(_+4-@7OHB8D1L88*"T3B@!MN#$4,N\4KN5Z[&E>%_\\&?>J7,8_7A=; M)5RMS-?9\DOQ;OGT$_/E]?P^GHB.5.+HI-_@ ( VKH"6"H"(<@X#=,"+J)RR MN&]KLZE-G)?KPX#P#Q9Z>_.?A_WZX,O5"0G/5.1HU$^P0$&.E &* V>\W5;: MVF-A&W,ZF"'KMXT%PAAUV2&D< M3YD>.Z]?73HT"?TDW&;'6S_O/^9K8IXD<9 M@*\EN#R=^ZQUAX$PX2"0EL<_ !IM3 ],)3%5:&*^Y#REEQ= ?*AE*DJQV.8PAX5?29C#KA&>YRZS27:I@6$# M$0]#/5N\9(?(PDPS+\1:,<.WJ2,^O1AGF(3L4:SZF MT_^RN'&SU3+.G_/Y%E]O$""4PFNFL*$"$YCR"Y*==-Q)(2?Y4J2UALL>(!W, M.=ER07Y_(A]C9WT'AR&DEAOK&5:2 T(]KS!32.W+R3=R_%N^:%8S MR?8HZ;SZ5?67U %B*"_ JY<9G892TE!4?AY7G*) KY9/7/XG^'JF94#("P^D M!!P;IB5%G.!*WOB+'!?=A$X?^93L5@_CN'KRY:J8?UF:AZCAY?6/2K"I74 1 MYK@S%AAOM<90.,2X \3)=+/@%+[W[3J7 N^N;DVY/"?GL2:!"HND M@X!R 1$DBIIH0NREC/\,&J,P2(+U#A1>]H+M4)O*B^F[+3*TV.GN_'PYWSC" M& \['&$;#5$B 0%$R .,1NEJ3S]/MSL35Y'0?A'-9*2J@@ M=-8*[P#8(Z8QICGO($?H%NV".C_Y1@?$_VU?#$*24@(IP&2T&J5AACJSE]5@ M+"9V[3P4,1K=##93P=NZ&?3. :J]L,)""!BWA-!*-D%X3DZF$=*K(SW7NAEL MANQ;NQFD3AJ",8(&(8&!$\KAO706,)23L7"$O,G4<+V;P6:0#D68YDOQF>VN M78?!.PL%$ "*RJ4DHGTJW.W*9E^ M*CPTD&:&XJ^=QQ$GKV&AB\T_1;$\*5+RSMU&M=9FOQ"*V)P3E] 1U-_ V5QQYY:S%53DI.D(]'U!T64$J0435#.C!5K@3#W8( MD&;9X0*_[M M):GBCT*<1CI9Y\+V&-+7%R#@?? * 7B>6X!=)1 JQ63E6%)/,@J3#_"$F 7.N$- MKJ=?]943C.L()]IC3@GU$%*N=(621FIB]QU#TJJ[1T[-=#3P.NTCR%7D?*HA M8^(9O;PK5N[[]>+A)DJFUNLB_G-S.GJX16\!2 4)I])[Q9DT0 -1X1*/5.K? MF^:NN-N_<@9;?LMUG'F_E>7-4ZOJ4_D(_&O+Z]%&04++K"+.0^&]3NYN0RLI MO< Y5VY31TGR9F2>*]\.LT@Z93 0#LCI"*0X<,, MBC .ZDT9XHG7!=F5#_]P^1\VM0CU['-!)58!5\BN2E>:O>9F\*>^/_2CD(JM:#?J]^OD K0"0":P-4-H(@#VJ# '& MA,Q9Y49XENU%3>Y%\@,$.D-'I]W$P#;^OU<4I%@C5P3FB-M.=0&;R7#6,G)L:NCO1&&UM)@"0SVROT\^YY"#S?KWU:G MHV)>;Q" PD@AQYP#4#E%93S>5])IYB;VCG9 -OR4<;L#^'_52'UOC*=08Z>9 MIT3'O057;B>:BC%.:_>^'$D'4]$XKBW?%[-U,;F+2JF]E1YRK)WP4'/ "40$ M*>$]%M3I?R\JGUL6S#+D!-+: HFCE8$PI!5>3NJ)U1WL@CB=7E0V@W_ %[KW MQ6KSX\-BMMS$Q2.YM^^32/I'.ER=\>36:!VX2%DZK*4(< %UA!R1#!'WC.% MW<1R)@_$D9_?_':LAXOS+XW[[$5FC=;!$L:=P]0X 1@S"#O*DMP8 "#YU)(J M=\J$NBQKC?90+-,/$;0XW?&,F$LM)@0Q_?20.I@;<50.RITX8Y)@6( MVA+, HP.,]. B7EZ.M)SO?)%C9!]:P'$WD#$%#2*4RNM--C[RA]+L])ZG0#B9D"/(\839<9XHJK23(II=?&8 HFW M%FIO265;Q/,MGAC)\M3?*,:S'<#_QGBF4!QB4G5S[XQ%43%&6NO 'C-F;981 M-\*4N9?998?6TE#,?I\R2A9^ODSEB+;!2I^+U=W5;96($IY@[MFV07MNM5.( M>RZ2#+I?#I.\8C"5EO[JX>!#"G^OB]F'Q?GY[*BJK1NL0 M)SLW0FD-J(.:":PHWEVY6QWAG5B)L\LQL'M=_*JAR,A@ [B5 $.O1(2*67_0 M@-/\7U=Q-XP=3$5#$?F09W6[ 7R:VF@L M.:$!JPQ^%J7-N1J=D!,GGXY=:N$RC'L_G_TU7\PW/VIS[= B$*Z4158X!V6J MUQ6/?=5=(",&YFS3$SK$=,VRMO@/YM79OF.J\UCAV0<#!E0AAA37W%(FG22$ M5](837*.Q(T3XT[[X)$%_'"GC.)^-K]QW^^+Y3K5V;W:?"U6NZ&;AU5"^.0I MXVSKP)C37GE$C5;*"OAP>YI[AQO%!S@U KK M(29>$P4)IM7JS9W(JD PPB-C1[SI#,_!K.W'Q?&4A?WXJ> !1% Y334R!@$ M"*N@X=Z!G/0/(SR[=<2+]@ .:Q:?-8>#=@180>**QQ70R!-$*C=%7!5=3E*M MYH>J6RE;QI8Q M$.WYDGZRVUV?R'HH;]B813G=!6HHQT8PPZB$*6!8&UQ)JPS,*8$^PFO!WK@U MH XNO)K]42ZOVRYHCVV#C78(PEQ @C2PB.MJP G(96?V$GM4FM::\!;+VLF M?NMF]7"=OGX7AA'Y_SBBD^QIUD$05" %:!1)(,H@(/AP)A'2FQQ?XP@/=?TN M77VA/M1B]33BYW"94VNI.M,R"*YD3VBS&YUKMG6,=X_W(L$LF_ZS^ M^WQL;SCOIU<02(X5@LHK9J0&"EFO'""642-K.4WZD3250UU?W;X8^X_=OS]' MR'7\WK]/2%VO@P"4YM!)2H5A3@'$G;85 D1D'=]'Z)+L@@HOLY'U@?-0&\J? MZSCEW7HSOXN;WZG[M^F4P_IXJQ#--66@EI0HRBU' MC@IMO<=4&V)T5M;J$?H9>^!5=^ .=_>Q_AI-V?2?9'=_FRW2[7?]E:M6^T"] M44A8H876U+(XG[P[;.Y,Y+PH&6&L?Q_$Z@'FH2CV^VSU=[%)C[$_%=I-UR];8C?@F>=4' MS,,94W?I1<)NXRZVKDY3KAOMA/5Z"!9 QXTC7#(DE6':>[^3WU&(08Y#H;D? M\2W2K!^@ASLSKHOX75]M/((LRNVKA;2Q1YD>HC8^E;>;?R*P38Z.+?H+%A+# MK)$1'!RAIRY:H14V,B[]&224OP0)AX!]*$J^6\;3<-1O ^?IL29!.B84Y]!C M@R@W' .!*PD%U5EIM<$OP:R.H+WXL[CZ9*K;19 2((*E-5;$><0)0A)5"'@# MRUPQQ297S&AZ,3(6SEJ1?PQ??$;0# M>MW7<: W6VW]UVPU3T?;=\L(?;'>N C-YL=9?T3M/@+6AG@GK13: JNQT%Y4 M&&"=EW[TEW')]X)UZ[CQ=\NX"5_'1;,Z0L1M^.DI8O>F,9TEMD"DO7GVXZZ> M5[[;+PA*$@.00@*2N&X[!1FW%2+,BIST!'#:?ON+*J(U-7\KRYM_YHM%'%.< M(;/EEWF<*[MAOEO>%+?SY7Q3O)]_*VYV/ZQ)R,QN@W9<$T80Q<@IRB6G2!X. M/DCFI,>#T_;X7P#^H?;A$U)5OSJ[#]?N(R@/+"+&EU>S].=6 IH<]_GFZM5G!7WY7JV4-=1 MFNUM_]4J5>E+KR ?5NF!1Y-;SJZ^) AG4IE2IZQ4EFO+4]Z6/8I2DN\<4X9=;A@]C G M4 3]&C<;/4,^DA>U^X"%I[$*-CU/7TSGD6U<%P3#C#A)E68""6I-4HI$-A+- MU#H(]2/II^NOQU'M2FP\MBZ/T@??% ,OTCE:4\4Z:X1NN@>7H1 RW'B".""8S_JN2F0$^L MEF?W=*@;2]8:\HM3+8U[5R2\#=4>6P=," ?4*.:]TEY C.4!4PY0EOMU?%3K ME EU6=8:[<'\"0_Q3)!,G#AJ/_^>_K0^6Y7X>*,0IZCE0.)43 \:0238V6Y1 M2FB]S[H&?T.<:J/WEYZ!KD!N??E8/138YK[9/Q8XRHTS+8(D7BEB+.%0*I[" M<[VNQHRERTG<-T)/41_$Z!;AE@O,>K5YLKC$O[U<6.*/PL>4E/R(+?3L]T%2 M9KQ14%(#'38(>^,/3-8TIQ+$"%G1F[63 VKO1#BZ9+SX1( ^$A\K8[!6#EH* MA:'5N+GV$[%'6NKJI:9;8=:GKG^?+^=W#WI\]OV\SI]^)G#&.9;0*"H5T-M:CG _=A1_E),5:$0+ M?B.5S.6=( M6\0OSK/'*NYMB/:D!GR M12;M*X.NIW;)([Q$)ITBI2&(&)DTM$MG:P'02HWADN>9(J*JGF;7J'_/<[:7 M8+GS1AO@/*%,64N8!!46".&<#$XC7!&Z(,71JYZNP1XP#4=(I%ZT_G->DVR<+\:ALU85IBV]J17;RMGS]Y6/AO4:<=Z[0X"- 8( M#:U2V'A.D1&@6JVAEC8KM\T;8$E3O98#@'R1I28ML]M%=UVLOCT6 ZV[[AQI M'A2R$B,$)#8_0C[+*CE =ZK2E M;O[SL-YLV>_+U8GE]HR7NE$_@3@$-?>>>JIHNOIST%18*.\F%J$W["8VA$:& M8F<*;+VZ53?E?=+RV1#RUSX>E$48Q&-D-#NQ0$I!3 Z2 40GYN'N2>LOZUWD M SW8 G>0_]-FMKR9K6[6?][?S#9%_#P!\BRG:K4/1DIF #40619W"(N)LGO9 M*39@8M=Q>>I_N4[U /!0Y(HCWFRGTZYR;XJC+Y1&.;D@U[D.SNX[>,L=<@A)8!!0VD'KX $S8'+\GR-, MGG*9S7%H+0W%[-$R09Q1A"L9>5<0.R M%M>;J]L7@.[A>K?\4*SFY,7YN:[OOU MXN$F!2&MUZEXU\WGV?>3)Z'&O07L/$XUFI@4#O%X7L!:/DYQDI-,M[%].FWR M]J^=<824/<:+FMGZ:_I_.IQ^FRVV;HQMF-YF-;]. 77Q=U,+-X,4,XBA31>N M5%DJN (.(,4-$TC36N>]GK;-B':J8?1"(1LS6ZU^1%'^:[9X.!565JM]4%0+ M[0$@2B"J)4>6PDI^'U?<:9TNNB#"RSVN!Y@'C84^3.T/+),[MMZWZ#I@ "0BVC7#HE/2;1 M2MUC19S)>0#7W.M<;F:+M\;+(>$?B=F>LN'KV3J]<[E+F1UF4WP- KER@!/L M)030[)\43W(L[+5]CY&17GM-(=+.(^$L)T)5)T^D:L&?QO.[C0>DL MPU:)])+< *P=JF3UU(-I46T@7C0*+FRF@;<57 BAHMES*<^-?*6'N!SXZ#SGJ8'P4YS M#"P]^/00$E.+8.I'ZW4>X#<#NG5&F5,/MAF0[OMUL5['=5T7R^)VOCF=>:95 M9P%P"8!VPCC@G=0><'38(H!"$\NIEJ?L M)_L,6*6TOL8BI8"BV,9CT,'^E%CEN,I':(\-QK(N0?_W36R*H*?"^*@>BS$6 M3#L&%*,59D:ZG(/#Y-[$MK7FAM;24,R^NM_&62R_O"_7ZVU(ZFVY.A8U<[Y1 M(%@J[./Y2C'FX@$+(WYP&U%")U)_[P*L*'M2P:_ZRM H(EBJ>4R0LL(#9YPX M+ 1"#>-MD3NB+HLO*>/UYPGS=3!-#>8XWBOXT8^U7A>;]1_%J9BIXXVBX6,$ MM8Y1:A4U1GN'2"6EBO/X7Y=,-T3L3 7CB"W<6C73B1Q,65$U3!6+L6/;-')J MOW=9)AR_8';YQV>8IYPZRYL=>=>OLG?].:I&Q_']?>J:H-,O"HX8K#7"1$)I MD;'*8W- %+&)&61=4.MHR;D+Z&.P6ZWG16E.O"!J1N':O06F%+4:4"\11-YR M!JES &H"L&&,32PG<*\\[0OT_G>\,GU^ME!W"9Q+1\7;:(A^VYJL[Y:I@$TU MT?_OXN9+RBMP'7\UWT35V?GZ>E&NXV9=8_/+Z#5H$1<+ZAB4" .-I 1@ES!. M:L\TN& IU4>ISD7*O_AD@'$]5 P2)@S1A!O*/*ID O$<.ZW]:1#M_V3QYB ^ MU ZT1\ 6Z_F7Y4Z3IV^\7V\0@#).&0*U,< "XHV!MI(."36Q6H6M=5OV .;E MJ'(VUN]8D_0*&AL?P:&,.$F \L)5$BK-)_;T)E?-9UG3"M7A7#:[<18W:KT? M^N,J?#[R[WSK "UA!#-!K#1Q[DG# =_);0 E4UM\\M7_TT[5-<3#4>N5??VW MB$5RS^L?>V&VA0]3E<.O\_LSNUN[#H/G'L6%GP(I(:&4&<-AA8Z&+B=T>82G MJ*YVOT' 'GAW?#K:NMOCSVV"5LAI%:U.A&6*Q?4KG Z#<&0@-]]0)RJ&24E6R06LGYI'L0,>OY%+)1?62 M^^+'^?KO%KM?U2S8Y!9S1$$A+0;0Q;.PJR0U)JMZV AOROKD"H<\A4TP0*,94ZE]TJ_2B3LO$=BDF^7!7Q9.&^ M7V\O:?PN5.;L_G6J63SD6&NDEQIX:YTF45A029HB9*?*I!REE[WAVY))Z]7F M"8OBWUXR*/XHF&W&O.MC3Y5??B18@1BVU'. H 5<(J .(S>4#IH#>OP;5"9\ M]12_KC2_+J[_SY?RV_]UO?_&G?:KO[W4?O7SH!:+_1B3;_[8#G3JXP%X;S#6 MCC)B:;34K!'P,$ET5H#/B-:+]MHL.\=P&&JX/S^>HD+\=W/\AE&[42=G>_QUD(120;FD3#GNH(6 Z6K80L"<1XDCLOKZ47MS_(;W M0;RO\9;KE4\'DY(4>\8B%IQ(9X0!LI)+(I7C0:?CX45_[JJV2 [/D,_%ZN[J MMCH?UXN!>M8D& D\Q#G'(@'9XTSV,>:Y'F M>9- H6',&YZJTVJB!4*X6C@QM=@,:68.47*J']ID@=I[9.R'57E?K#8_U/(F M!?+>)T?NQ0)CJ\%\6,R6FZK9M@-(IQBD&+!5 $=92!@BV%$-L.:07 M? )R=.R/P9IUHN.;=!.D8,09Y;UU% M+K6>Z0H/2>FB\G1VA0W:4@X%^D2"F>1M$95Y/9^=>:'\ M]&.!*R8$P8P"+"4GT0ZQN)*&:CKHE=$0.W6'^OUIWVX-ZT6FZZM3N+CX$Y=^ M)Z^RW!HIXKF>0*>(\(A P#V11C)H\"@>_HH/6/=)-^)B"J1NL@D0,"$,V]8\Y8ZI4] M ,OB47=JNTOWA*AK,[8&_>)DJQ5 5:-UQ)0CJ*!RQA *K%$2BKW$X0W M2K)URH6Z/&N-]U \TP\1M#J1P,\_&+0P#F*)* +I4:.%V/E*&A%WA5]D3VRC MW[)#8 <+OWM8+;<9_Z+P?OX]_>E\J9#CC0*!S DG%5?">Z^!Q0Y74J;*D-.X M6!^"/IV!/-@3A/+N_B%B_JF\W?P3X7L75;C9!()!*9T41 WJ!B[,K;D868MTFP-O#NBFOOL\DR MN\UG5X]*-9[66T=:!&8&0YL;88=9Q$=2)5!FA6]><^J(KX:9X=*IU]T"F7K+[Y9'Z9K?7I MQ?3F=I5?_[;<+,XZU6+.U.7E)G=G=O78ZYZR$=[EB]7T_PX=@73UZ2"BH1HW M.IJF8HO&,>E]L>\6QHJ195UHDE;YH"75NUY]L\B7E73JNF' CGN!H?2&4\0$ MU\2J[6BE,KA.--<@ W-:8&8K2'>M1WO1H"5GI)-,):R43\7^XK9^[[.4@.LZ MGKCR.]VNTV /3(6V(JJNE.>!SL>_S[(71G$0HB-JMJE/!,FDMB+:P7RU63VVE@]3$'U;@0?KVAPK%D ",2I#"%4PA,4C7U'"C>*U-+4 M<:.S7X*2+:#<2_A;SU4*V@US(S)*P%OK#:642VV$Q2FMMJ2"46F&&+!>*TQ] M'R=-J/>48@"8L41PQB'5VY%S#1WY11POYS.A= !(1:A;G^3_?3]91,1G#YLU M<3J9V;_>SJ_SQ=W&+CTG3_N9;PI(8A,%PS6@T IO MXJKNUW<&"/(0RE)SH0=,RFB"@]9S,'Q_NH-K;XC$6"()+%$<>X#BSC6*45.H5"D[N>06 M>'_J9?)9['J^N46D%HN4@6N]FMTLLLUQ^J$0^&HO"LH!9"71&G/)+::.4U^, MTF(YLKR?K7$@[U (E3TMA[JSU ^['AT(>3^K?7!6"@4$LX "!;%W4!7C,8KZ M.K$0 R)5V\+.VX>^<2KM.G,PGOVF3Z?+MZI#_KM\3KQ/ST4A!2$4Z$U%$:G5U+K[?98O(MNU]-+Y?JS7'A'VX1)%4$22B$D1A!0SQG=C=L M@T92E*Y])C0&<65:?,@6EW^]>S-1D_F56L1QZFF^RBYOY_DLOYFFLHV7_SI. MD_)O"%AHJAQ1R&M($)!&^,*6L^.IY=L^;5J#O#*-SK'!WA^)RJS^LA!'IKW3 MBB&GXSB]A<85(W5.U(G8&)I.ZLCB[4(.71WC763?L_E]YB.010JL/Z:K6W._ M7.5WV<+]N)S=I_MBZ=0R_O_JZ^3'$4=&A;<%(;3Q!FK"M0)>$<9$LM3 :WZ/9V.59OC[*B"KQG\D5LCT*7Q^B+S]'G3Y?Q9]^F/R8 MWMW??9C.LCBD>?9Y\K"&[MRM73-?#5QH[H$UV&$DK01KBVQY/TOEG*?SU6UVD?F??^&C M&*H I(;[J$><8G=1?8M!8?-;XX>M[SX<+ F MKN<.*JL()2GK!/=HVUNCF1N)T[)U6>8- UW1V"]5C.;S(K^ZOUQ]6GS)%M^G MEX<2!QUZ-#AF9+HI(8#VC!@MF:7;D7B-[$A2;S0ARKQ1)#O@1"HDO^W@X1HU M1Y\/4FJAL9 "L,(@ #H[9@T,%:/Q/5=7Z3/N5$;S X#?5-_3]X^_^FYX("A M$&+/)6/4,8&==L58I,0C">YI2)[/P_LJ(]G,ECSNJ"[RA\EL]7#B*.18HZ $ M-]8*[XRT'$%)8-Q:;7J.,1=U:B<.:$/<+ <:A[7&EO7GU?"D>_I@@PB"2HY\ M&'6D8-2R:&+9;8^)0;4B_09$A 9MB$;Q[-B5O"RQRWKZ:$"6E5-6A)H'&B:I?,FFV>+R2S=%+^ZF\ZG"8FT5SS- MJ'(O" P(C%&T$P35'B#D&2B<#HP^+L/7P2%A%ZF(&B=7*SAWQ3)]OXPK_')I M\KL_I_.U )/A%\<3H8Q_6TZC)+=RW4>#F]OTU[?S346T34F]%YJ\GT[^G,ZF MJP=XA*8=]2!8)RPR&AJFF+7<2)?2.&[P%T#7,>(&F&"U<98/4TP=KNJKQ?WE MZGX1>Q\'M;C)CF5_>^GQP*4"BDKHM(X+C9<:P*UG2'.->!U+L'P6EJY3#+6Q ME->%MBO2O+W[-IDNTCSX=/TDN?7R[?PJNXZKQ"J;Q37B:K>Q3I;NW]/9[ BY MZKPV$('B_HVX.).,-E4^O"P^K6QN:^#9%4,^?5LOT_.;3>3;^^.93U]X.ABB M%-4$PQ3F1H!3$OAB7 ;*.CPY/Q"Q-9ZTY$"K#VAG"][\>UR=DW;<='6-1?Q) MVG9/OT=K;W[,B5:B=? (2NVY\=P"PZ%(ZWPQ[@AA'1OJ;".^S+Z:KAT>WI,QM*;!G=9M?[?7P M,4NJPUX$HBTUEF%"A 2$1PES4LC!&5HG67*NA\@HO@E++PF8.TPX#AV[L2&*V"%!K,=4&=L M\>5V4NJ:Z:$F 1!D&7<68NT)PL8H4BS)TG)8IP84+!_4LU,XJ]?$E89 [8LV M>K*<7I[!F?7S0="4VYNAJ!@ZPUUSIMJ@';JZY9._C7 MO5[[X_8WXLO$Q5=\8Q#>20DPP$P"+84 MCA),#!B#^KHJZ'E'VE_B6L']:Y8 M^4>6LO1D5RIJ@,E-]O$^W6_\=+T>V?+3_6J94OO$X9Y:&<]Z3TB7)AVR1F%G M&5+664P*+!RE=E8,P9(+$$# FG MK-*LQZ):^R1DQTNSK!UB):KK5'I?4)!$)" 3F,>_,'%WA M""@:@2[E&.EFE'M"EIK_IUL'K)E46@+*&/!$"P*T*L:..1M).H7F*/#L\E;3 M$/1D=T9 YX5A1G/I%1$6*&\DQ5 366I>UQM M+_]%/H9U($>$>3&?S(H<"BG@^WV>/ 3?HVFZOCEP*+UC,R\."A@%C<.8:4BA MM$1342!F*!I9+HSZQ#FX\G> ?L5=;ZE<@%^B^-;7\MYD^CF9'4D2 M>?#YH)&TPCF0(L\%5<)HA+=C@O'WD9F871$@;Q[Z5NFTF6B/>W@TM>3!YP/4 M7'@/-=9<0\LQD5H78]($C"17;4-RS9M'M!Q+E@5-EMGEOV[R[_]YF>[T+AX2 M4WCQ'XDH_!%1MC\.OWUY@17[?PQ 8V@!5#IV&D*G(<&[#@,_%HW2D-#RFO!U M(.\W^HB\W^B@H71,.T\(YAX0B*$NE")"1M4Y&QI00I-VY'TV?*?E?:A"7G+) MFO5GIQM?Z?0JRZ_C3W]+]UROUNIL.9E?[7[R+EI<5_G=B9IZ]5X;E!->2FN0 M),YCAAG7H!@]Q*#;ZX2OA#P] %^==IN./>G6"4X=:1--,,@XDX10B8&1T#O@ MBWY+7RL$8D"Y/]H@3'.H=I>JXRP;_?V17+=U7QDBLM1"280C#F!+K4"V0,C% MW>@X5KF>]DD=2Z>ST.-\?GF_2'AO^GLL^OC)HT$X;)5P3 !FI3?IT*& $,?= MQ,@\/>T+_FF$_ ,;R'2#_L%88P^8:XM5TABSKW&QHB44FUSS&85P+Y2 M:9YQ^X2A4IJB!!;%6.BXA>"^0"PJX#IU: >H*>H3IUF?\'GHOPZ?L'(.,>&= M)=XRB36@RA1C@DZ/;.WIB@"E?,+G0?\Z?,+I:@I,=>&U\)IQZ8%RQ9B(0G4R MW@Z(3@W)M91/^#Q$!^ 39D1**)CG-AI7E$C,&-Q-$@7K%)49&@7J"^VY3_@\ M^-K4"NX^!2@<]-\\?20 3(AU7!."?%2/*0T:V/9<*V'KA&T/:-O<2K<0)7HTESJ/Z*3F#"(%$VI6H4R%$*!2:L0,CY6DE+ M!K2:];0QZE@Z'?.WQP):.&IW@XRQA#C%#)3.%YK"" SKI,L?Y-6Y]@G40*FM M\X32G[]YJ1^V=3+'Y&6FQJ5LJ#KNJS32,BY\&%FHC8UVBW6HQXM'Q=6V7:K@ M[1B.'AX=:A,"$$@)T,1*FX$CY]4+U<,LU5W$$ E!OM8Y#$;N)BTVWR9TZJ:!>4:3/N5$;S,HN MJJ\7;]\I_U4==TK]_%0 "EAK7?H-VU011F)1](W86C%APQ1T'?GD3>%86<9? M_OW!NG>?XA_OW.]OCTOZI6<#$)@R8[E4G&B4RE,ALS/ZD"^U:QB^8=*"O!M ML[KS^>*=^J!/B/NGAR(?>0JQU5)#*)PD !"\6]WJU1<$K ZWOWRY64Z\),VRXHFL.PLH>*96Z RATF5WQD@ M1MH(0R# &CBEA?:RP,@[,;)*X,/8B'8MM5_HE(D;!) $5A/@@*1(PMVV3Q ^ MLJ#1#OC3Q"'363+IX9#IR_1F/KV>7D[FJ]UL'],Y$[ (6LX%A%0P#937T,+X M!_6 1Q*4,C/;&67DT&4V7VV*&EU,EW^=\O6_W" P PU1A",-XGJO&4"*%2/4 ML-Q]C=L+^EG=V 90[6J1>=99_? U=N" [Y$JV (I=Q2@QUF<267BGM1 MC),C.Y)T(4T)^Q1W*@/;&X%2?P]ZV4NT"D0+RX&5..XV!)2>Q;\4X\32C,37 MWJC$3VJ@JNAVQJ(HD.GJ6;]/[O:/M@M>$<\0P*F"EDM.#*'!=JS"<%UG]_\: MF%1%ZD^9U""^/2YI.IM?WMY-%G^=OZ[]U#0H3+VSUBE *),2.F!W(T[EV<:U MOV]_<:N#;G]\*CI]_C+WI&F(0X-> <\L5E8CZQABNQGD<*YE-OR>E?)([AYH$IP1'J?2-U%I;AKB$!5X2&USG M9/0U+&E-T:/!L@=?#Y8CU@*FJ94&LZM]TH5&XR4G7TD M/L.Z LV;A[)RC,6'RW?9$_>S NE%APGDHPQ7V_)X("73BG ME$9R1#EB&Q9Z72@K"SN:*!'0W-PO)LO+Q?3;X0W'L<<#$19!PQS'PC)'G1"( M%KUUV(\HE*YAP3<#:&]NC_%Y7 MKK.JN/;&GL_9(OU@7KYJS M[8'>ONVWBIW2DV5V9?*[;]E\N6[O?J2_9KT9@/OBHPG9?;\NLMEDE;JZ7"W7 M9W%@Q"A.F>5:.4B8EY:X;0%4*(7KT9@L/3#]>&!E M-$O--P=)C<$:.1Z1\DP*X2-T6\RP(IWFSVK?,.R*8'F?0NI7*_5]PV&HRHFJ MN(!A YWD%+G('(E]\BHP !T2NM2Y<=O&_IZ#CP>H%HO)_&:=^CN:<\]XJOZ> M+*[*)U.J^8W #!+$&PLXP Q#ZSEA6QP],K42*(U/894FW4%SOUMQ=67=OYU' M99;M,MJ_W]::.1$4>Z158)XHA=WZE-L +JV4KABG,7IL]>V[YT?>EBQZYMS) MT-FC[8*'4#ECD>&60J6-XTP58V78X''QKA&IEV-2)7R[.U1:KN+<2X&:IV^& M/'TV ((58]BF;;72E"MNMZL" M'$'4F42L/R?7:"5 _5[N[.+[/XK5LUO[+9 M]VR6?TL@;&WUD]PIT3H(HC5Q4!/%@+68(TI=,6YDQ,CRAK?#IN9QKIY(+)O% MAV[>9/-L,9G%#JFKN^E\NEP[S[YGIYAS]CN"59S$05"BJ9>.2(\PV(X+ J_J M:*,!1=&TPY^VT>XLC']M$)Z^;OW3)U4C .TSRJRZJG'HG]!5%YRW=VW6?Z09=$*6"VFE^O2-?GE7Y^^G0Y%+]$T MN#B[F;?0"&_C#@DC(HI1(.1UG?CD =*I7R+DK')-L%:0R&@ M3#IAG2).QD$68Z0>U:GA.\S@BR$PL&FQU%9NZPY\OH^;G#CJ-+ARBNU LP"$ MIXPP@8CF'$6#EN_6":1 K6M6 ]PU#()2+LP,M MXBX<:,P$,U)*BZB- T4%:(BB.KP;8/#^('C7K$@J*S(_G<=/3R>S\F0JU2YP MA8FTSBMJ,<(L783831D-8)UH_K-3\_XBE&I#,)6)]3&?5^56B:8!.4>%9!YP M;^).7SE =^L\Y+B.^<7^H==A>C4OFZY6R]_CAB4%8![WQ3UZ*J1;F\0 8A2- MJ[Y10JGB[ ,Q+>MDJANB-=:[)ZXZ]AUSZ*0#[:?G O&..68(\(Y:BZ40E&[' M@B4"(PONJ23%EYE0";^>?;+K:1!G2IQ-G^:GSR+/>$L@6L$[B/N')L&9,".2AYLA*V6 AH1Y9XJC.N54:X M>H1%>?/Q]%[E91N]E>\$:R#V6@/L"<,H12C K;6*B$9T9(DK^K/RAR"]0;#[ MX.ZAI2\%9ZF1TBF1LI3F2_4?/_&J+Y95DV)G-<,91ZO.S.H:, M)0@3J('1VA)+Y Y; \U(]C.],^*I]5!3#KTANW/I[ ]?CQ=/3J6.K"YCP1(A?7>8L619M#;*)9"1I0" M,)(29BTQZR6=V8=8.C=#-TG.7@;TZ^2'SN;9]72U*?9Y,*O-,$J;^S*#:GGV4VZQ__UE7.[%\ET=CEI@U-V]?*P MMIW_F*T^71^O/'S>BP+A2 &NM!"",Z6$P'B'1OQ?IPG 5OEJ,GO%!&T5^D$I MV#UH*5??97XSG_Y?7$^RQ33?I LQDV_3*,ST4W67*K74U;CG?S$(Y9$SS$$: M=QYQSBN2:D9O\.6.U(E)*W^2\ NJX-9%-2R=7%L7!XV1U8://NRI"T\)F@#TO[WMPLUOIDG[BI3&ZQVN\.T##$3(1(>H:0 M)LZA8L5B'.&1U>/LP?W0EZ@&1>^/^?Q[MHP3> WF\FNR"I]N3S_FJW]GJ_WJ M4I?V5;X9+% IF;;Q@H*HD #GN@CET%R+.@;&@!P7/7"RRFSH0(*O?I9L;#"? M+[8_2L\=<_)UVY'@M&326>8L3.=;GDA?2,-@I3J]P_O/?.I)K(,_;=R!22TID8!2 MAJST7&M4Q+L: <86X]FC%3=LP0Y^HNT&II;+^[L-)&I^]2%;W>97^2R_>2A3 M%*C]KP>AL&',Q2TDQ@)K[8$1.]R=&UO(ZBN<4*T)\U5.HN0"29EB?L]G\36S MZ>KA(NJ1KB;1RU\/7!' C2$68D^B\2(4+(P9*RP9R2GP()GM1"J=_&A V*JHO^+OT.OX'U[M3G"M [!.5N(Q[:2ZFE%# M$/*K7*J* =OI]^E5-M^5^.C:)'SZ_9""U GAW $A(9$.2:AV:@S6*GX^IIW5 M:UNR&I)WP_':1V]B[&LWI^"=Q4VV^C"=3^_N[\Z+Z:[VC8 IA]9$J3&-$ & M+5@P'.@[YEVC/7)S_:Y_KF&T%(2K'$&B)$';< 6UM\%[&)=+'Q=+IY1R M2,-==F>'H:M3G(G_,U\ZV80T*-_![S\>CW5SL'5R\][09Y)T\0GR_WA5]6MUFBZ^WD_EP M(@^:[F.P'$0S&!JM. 8*:"]5$2,2?ZDZ1ZCRGZG9R=3LF1/[>=U'0>KU3?=_ MZE$_+0VLI6#19''4JFCF:P>]$!(P)+R6%ME2*7M;4L^[] ;-W&G9U5$_IF[; M^F9@UG@#'*'.0H$YT)*@ F>*Q,@*M'9%RH/UJOL57U<6S&.83ZX*AW. E)@8 M#7\I>,V5-YQ;Y)4'"% 9(=W@Z20:6[70GJ9#OT*KG3HPO_YMOMA-RY>W[H\7 M]V,\;N;%05."F*1&&X"($\I+PK8(>&%('2T^P./DCFG;BXPZVVR^D*SI\2Q[ ME&1NF8SK#3WV>XB3#&_G0T%*2"RQ&!LB$+#6QXU[@29 >F2%CGJW6WJ0V5!F MP,&28JU.AQI?#1X1A@RQ'%(,@&14*E[@C 2O^ YT;W0FPA/]B^P_I MMX3"?_W'_P-02P$"% ,4 " :ADU0-4NES/T/ ?5 & M @ $ 83$P:S(P,3DM97AH:6)I=#$P,3&AI8FET,C$Q+FAT;5!+ 0(4 Q0 M ( !J&35#F3XDO7P0 % 4 7 " 6@O !A,3!K,C Q M.2UE>&AI8FET,C,Q+FAT;5!+ 0(4 Q0 ( !J&35 AFI=%20@ -,X 7 M " ?PS !A,3!K,C Q.2UE>&AI8FET,S$Q+FAT;5!+ 0(4 M Q0 ( !J&35"V#Q[70@@ +DW 7 " 7H\ !A,3!K M,C Q.2UE>&AI8FET,S$R+FAT;5!+ 0(4 Q0 ( !J&35"88\Q6K@4 (HO M 7 " ?%$ !A,3!K,C Q.2UE>&AI8FET,S(Q+FAT;5!+ M 0(4 Q0 ( !J&35#N0IU<$@L #&AI8FET-#(N:'1M4$L! A0#% @ &H9-4(]U=S9,)04 M7==! !$ ( !&E8 &$R,#$Y,3!K+6UA:6XN:'1M4$L! A0# M% @ &H9-4.),P[)3=@ VJ0 P ( !E7L% &-A<'1U M JSON 85 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a201910k-main.htm": { "axisCustom": 2, "axisStandard": 37, "contextCount": 517, "dts": { "calculationLink": { "local": [ "vrtx-20191231_cal.xml" ] }, "definitionLink": { "local": [ "vrtx-20191231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "a201910k-main.htm" ] }, "labelLink": { "local": [ "vrtx-20191231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "vrtx-20191231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "vrtx-20191231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 936, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 57, "http://www.vrtx.com/20191231": 6, "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 69 }, "keyCustom": 98, "keyStandard": 539, "memberCustom": 65, "memberStandard": 80, "nsprefix": "vrtx", "nsuri": "http://www.vrtx.com/20191231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.vrtx.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Collaborative Arrangements", "role": "http://www.vrtx.com/role/CollaborativeArrangements", "shortName": "Collaborative Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418405 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Outstanding and Vested Stock Options (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Outstanding and Vested Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418406 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Stock Options Outstanding and Exercisable (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Stock Options Outstanding and Exercisable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418407 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Restricted Stock and Restricted Stock Units and PSUs (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Restricted Stock and Restricted Stock Units and PSUs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember", "decimals": "INF", "first": true, "lang": null, "name": "vrtx:ShareBasedCompensationByShareBasedPaymentAwardAwardPercentageOfTargetMinimum", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418408 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Performance-based RSUs (PSUs) (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Performance-based RSUs (PSUs) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R104": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD_us-gaap_PlanNameAxis_vrtx_EmployeeStockPurchasePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "vrtx:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofPurchasePeriods", "reportCount": 1, "unique": true, "unitRef": "period", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418409 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Employee Stock Purchase Plan (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeStockPurchasePlanDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Employee Stock Purchase Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD_us-gaap_PlanNameAxis_vrtx_EmployeeStockPurchasePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "vrtx:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofPurchasePeriods", "reportCount": 1, "unique": true, "unitRef": "period", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418410 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Employee Benefits (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeBenefitsDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Employee Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420402 - Disclosure - Stock-based Compensation Expense - (Details)", "role": "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails", "shortName": "Stock-based Compensation Expense - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421402 - Disclosure - Income Taxes - Components of Income and Provision for (Benefit from) Income Taxes (Details)", "role": "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails", "shortName": "Income Taxes - Components of Income and Provision for (Benefit from) Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421403 - Disclosure - Income Taxes - Effective Income Tax Reconciliation (Details)", "role": "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails", "shortName": "Income Taxes - Effective Income Tax Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "vrtx:IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R109": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421404 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Acquisitions", "role": "http://www.vrtx.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421405 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "role": "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails", "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R111": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421406 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)", "role": "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R112": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q3_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422401 - Disclosure - Commitments and Contingencies - Revolving Credit Facility (Details)", "role": "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails", "shortName": "Commitments and Contingencies - Revolving Credit Facility (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q3_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R113": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "vrtx:IndemnificationClaims", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422402 - Disclosure - Commitments and Contingencies - Contingencies (Details)", "role": "http://www.vrtx.com/role/CommitmentsAndContingenciesContingenciesDetails", "shortName": "Commitments and Contingencies - Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "vrtx:IndemnificationClaims", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R114": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423402 - Disclosure - Segment Information - Revenues by Product (Details)", "role": "http://www.vrtx.com/role/SegmentInformationRevenuesByProductDetails", "shortName": "Segment Information - Revenues by Product (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_vrtx_TRIKAFTAMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R115": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423403 - Disclosure - Segment Information - Revenue by Geographic Location (Details)", "role": "http://www.vrtx.com/role/SegmentInformationRevenueByGeographicLocationDetails", "shortName": "Segment Information - Revenue by Geographic Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD_srt_StatementGeographicalAxis_country_US", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R116": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD_srt_MajorCustomersAxis_vrtx_McKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423404 - Disclosure - Segment Information - Significant Customers (Details)", "role": "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails", "shortName": "Segment Information - Significant Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD_srt_MajorCustomersAxis_vrtx_McKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R117": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423405 - Disclosure - Segment Information - Property and Equipment, Net by Location (Details)", "role": "http://www.vrtx.com/role/SegmentInformationPropertyAndEquipmentNetByLocationDetails", "shortName": "Segment Information - Property and Equipment, Net by Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R118": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424402 - Disclosure - Quarterly Financial Data (unaudited) - Quarterly Financial Data (Details)", "role": "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails", "shortName": "Quarterly Financial Data (unaudited) - Quarterly Financial Data (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R119": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424403 - Disclosure - Quarterly Financial Data (unaudited) - Additional Information (Details)", "role": "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedAdditionalInformationDetails", "shortName": "Quarterly Financial Data (unaudited) - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2018Q4QTD_vrtx_CollaborativeArrangementsByAgreementAxis_vrtx_MerckKGaAandArborBiotechnologiesInc.Member", "decimals": "-5", "lang": null, "name": "vrtx:CollaborativeArrangementDevelopmentandCommercializationRightsPotentialMaximumMilestonePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Earnings Per Share", "role": "http://www.vrtx.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Fair Value Measurements", "role": "http://www.vrtx.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Marketable Securities and Equity Investments", "role": "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestments", "shortName": "Marketable Securities and Equity Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss", "shortName": "Accumulated Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Hedging", "role": "http://www.vrtx.com/role/Hedging", "shortName": "Hedging", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Inventories", "role": "http://www.vrtx.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Property and Equipment", "role": "http://www.vrtx.com/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Intangible Assets and Goodwill", "role": "http://www.vrtx.com/role/IntangibleAssetsAndGoodwill", "shortName": "Intangible Assets and Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Consolidated Statements of Operations", "role": "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": null }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Additional Balance Sheet Detail", "role": "http://www.vrtx.com/role/AdditionalBalanceSheetDetail", "shortName": "Additional Balance Sheet Detail", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - Leases", "role": "http://www.vrtx.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vrtx:CommonStockPreferredStockAndEquityPlansDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - Common Stock, Preferred Stock and Equity Plans", "role": "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlans", "shortName": "Common Stock, Preferred Stock and Equity Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vrtx:CommonStockPreferredStockAndEquityPlansDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120100 - Disclosure - Stock-based Compensation Expense", "role": "http://www.vrtx.com/role/StockBasedCompensationExpense", "shortName": "Stock-based Compensation Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121100 - Disclosure - Income Taxes", "role": "http://www.vrtx.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122100 - Disclosure - Commitments and Contingencies", "role": "http://www.vrtx.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123100 - Disclosure - Segment Information", "role": "http://www.vrtx.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124100 - Disclosure - Quarterly Financial Data (unaudited)", "role": "http://www.vrtx.com/role/QuarterlyFinancialDataUnaudited", "shortName": "Quarterly Financial Data (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Nature of Business and Accounting Policies (Policies)", "role": "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies", "shortName": "Nature of Business and Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - Nature of Business and Accounting Policies (Tables)", "role": "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesTables", "shortName": "Nature of Business and Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "role": "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vrtx:ScheduleOfCollaborativeArrangementSummaryOfItemsRelatedToVariableInterestEntitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - Collaborative Arrangements (Tables)", "role": "http://www.vrtx.com/role/CollaborativeArrangementsTables", "shortName": "Collaborative Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vrtx:ScheduleOfCollaborativeArrangementSummaryOfItemsRelatedToVariableInterestEntitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Acquisitions (Tables)", "role": "http://www.vrtx.com/role/AcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.vrtx.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.vrtx.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Marketable Securities and Equity Investments (Tables)", "role": "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsTables", "shortName": "Marketable Securities and Equity Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Hedging (Tables)", "role": "http://www.vrtx.com/role/HedgingTables", "shortName": "Hedging (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - Inventories (Tables)", "role": "http://www.vrtx.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - Property and Equipment (Tables)", "role": "http://www.vrtx.com/role/PropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - Additional Balance Sheet Detail (Tables)", "role": "http://www.vrtx.com/role/AdditionalBalanceSheetDetailTables", "shortName": "Additional Balance Sheet Detail (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1002001 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)", "role": "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical", "shortName": "Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - Leases (Tables)", "role": "http://www.vrtx.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vrtx:ScheduleOfStockAndStockOptionEquityPlansTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318301 - Disclosure - Common Stock, Preferred Stock and Equity Plans (Tables)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansTables", "shortName": "Common Stock, Preferred Stock and Equity Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vrtx:ScheduleOfStockAndStockOptionEquityPlansTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320301 - Disclosure - Stock-based Compensation Expense (Tables)", "role": "http://www.vrtx.com/role/StockBasedCompensationExpenseTables", "shortName": "Stock-based Compensation Expense (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321301 - Disclosure - Income Taxes (Tables)", "role": "http://www.vrtx.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2323301 - Disclosure - Segment Information (Tables)", "role": "http://www.vrtx.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324301 - Disclosure - Quarterly Financial Data (unaudited) (Tables)", "role": "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedTables", "shortName": "Quarterly Financial Data (unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-8", "first": true, "lang": null, "name": "vrtx:CashCashEquivalentsAndMarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - Nature of Business and Accounting Policies - Business Narrative (Details)", "role": "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesBusinessNarrativeDetails", "shortName": "Nature of Business and Accounting Policies - Business Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-8", "first": true, "lang": null, "name": "vrtx:CashCashEquivalentsAndMarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401404 - Disclosure - Nature of Business and Accounting Policies - Revenue Recognition (Details)", "role": "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRevenueRecognitionDetails", "shortName": "Nature of Business and Accounting Policies - Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "vrtx:Percentageofemployeeseligibleforaccelerationofequityawards", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401405 - Disclosure - Nature of Business and Accounting Policies - Share-Based Compensation (Details)", "role": "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesShareBasedCompensationDetails", "shortName": "Nature of Business and Accounting Policies - Share-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "vrtx:Percentageofemployeeseligibleforaccelerationofequityawards", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401406 - Disclosure - Nature of Business and Accounting Policies - Property and Equipment (Details)", "role": "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPropertyAndEquipmentDetails", "shortName": "Nature of Business and Accounting Policies - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Consolidated Balance Sheets", "role": "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD_us-gaap_RestructuringPlanAxis_vrtx_ResearchandDevelopmentRestructuringMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated", "reportCount": 1, "unique": true, "unitRef": "position", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401407 - Disclosure - Nature of Business and Accounting Policies - Restructuring Expenses (Details)", "role": "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRestructuringExpensesDetails", "shortName": "Nature of Business and Accounting Policies - Restructuring Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD_us-gaap_RestructuringPlanAxis_vrtx_ResearchandDevelopmentRestructuringMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated", "reportCount": 1, "unique": true, "unitRef": "position", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401408 - Disclosure - Nature of Business and Accounting Policies - Foreign Currency Gain (Loss) (Details)", "role": "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesForeignCurrencyGainLossDetails", "shortName": "Nature of Business and Accounting Policies - Foreign Currency Gain (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "I2019Q1JAN1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeaseTermOfContract1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401409 - Disclosure - Nature of Business and Accounting Policies - Leases (Details)", "role": "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails", "shortName": "Nature of Business and Accounting Policies - Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "I2019Q1JAN1", "decimals": "-3", "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "I2019Q1JAN1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401410 - Disclosure - Nature of Business and Accounting Policies - Impact of Adopted to the Condensed Consolidated Statement of Operations (Details)", "role": "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails", "shortName": "Nature of Business and Accounting Policies - Impact of Adopted to the Condensed Consolidated Statement of Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2018Q4YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "I2019Q1JAN1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401411 - Disclosure - Nature of Business and Accounting Policies - Equity Investments (Details)", "role": "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesEquityInvestmentsDetails", "shortName": "Nature of Business and Accounting Policies - Equity Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_vrtx_AccountingStandardsUpdate201601FinancialInstrumentsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember", "decimals": "-5", "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401412 - Disclosure - Nature of Business and Accounting Policies - Intra-Equity Transfers (Details)", "role": "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesIntraEquityTransfersDetails", "shortName": "Nature of Business and Accounting Policies - Intra-Equity Transfers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member", "decimals": "-5", "lang": null, "name": "us-gaap:DeferredTaxAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401413 - Disclosure - Nature of Business and Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)", "role": "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails", "shortName": "Nature of Business and Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2017Q4", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "I2019Q1JAN1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401414 - Disclosure - Nature of Business and Accounting Policies - Stock-Based Compensation - Improvement (Details)", "role": "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails", "shortName": "Nature of Business and Accounting Policies - Stock-Based Compensation - Improvement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "I2017Q1JAN1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_vrtx_AccountingStandardsUpdate201609ExcessTaxBenefitMember", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "vrtx:CollaborativeArrangementInvestmentinCollaborativePartnerAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - Collaborative Arrangements - CRISPR Therapeutics AG (Details)", "role": "http://www.vrtx.com/role/CollaborativeArrangementsCrisprTherapeuticsAgDetails", "shortName": "Collaborative Arrangements - CRISPR Therapeutics AG (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4QTD_vrtx_CollaborativeArrangementsByAgreementAxis_vrtx_CRISPRTherapeuticsAGMember", "decimals": "-5", "lang": null, "name": "vrtx:CollaborativeArrangementResearchDevelopmentFunding", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "vrtx:CollaborativeArrangementInvestmentinCollaborativePartnerAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - Collaborative Arrangements - Kymera and Other In-License Agreements (Details)", "role": "http://www.vrtx.com/role/CollaborativeArrangementsKymeraAndOtherInLicenseAgreementsDetails", "shortName": "Collaborative Arrangements - Kymera and Other In-License Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "D2019Q2MAY_vrtx_CollaborativeArrangementsByAgreementAxis_vrtx_KymeraTherapeuticsMember", "decimals": "-5", "lang": null, "name": "vrtx:CollaborativeArrangementUpFrontLicenseFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003501 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - Collaborative Arrangements - Parion Sciences, Inc. (Details)", "role": "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails", "shortName": "Collaborative Arrangements - Parion Sciences, Inc. (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2017Q3QTD_vrtx_CollaborativeArrangementsByAgreementAxis_vrtx_ParionSciencesInc.Member", "decimals": "-5", "lang": null, "name": "vrtx:IncomeTaxExpenseBenefitAttributableToIntangibleAssetImpairment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2018Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402405 - Disclosure - Collaborative Arrangements - BioAxone Biosciences, Inc. (Details)", "role": "http://www.vrtx.com/role/CollaborativeArrangementsBioaxoneBiosciencesIncDetails", "shortName": "Collaborative Arrangements - BioAxone Biosciences, Inc. (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402406 - Disclosure - Collaborative Arrangements - Aggregate VIE Financial Information (Details)", "role": "http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails", "shortName": "Collaborative Arrangements - Aggregate VIE Financial Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2018Q4YTD_vrtx_CollaborativeArrangementsByAgreementAxis_vrtx_BioAxoneBiosciencesInc.Member", "decimals": "-5", "lang": null, "name": "vrtx:CollaborativeArrangementUpFrontLicenseFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "D2017Q1Jan01-Jan31_vrtx_CollaborativeArrangementsByAgreementAxis_vrtx_MerckKGaAMember", "decimals": "INF", "first": true, "lang": null, "name": "vrtx:CollaborativeArrangementRightToLicenseNumberOfDevelopmentPrograms", "reportCount": 1, "unique": true, "unitRef": "development_program", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402407 - Disclosure - Collaborative Arrangements - Merck KGaA (Details)", "role": "http://www.vrtx.com/role/CollaborativeArrangementsMerckKgaaDetails", "shortName": "Collaborative Arrangements - Merck KGaA (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "D2017Q1Jan01-Jan31_vrtx_CollaborativeArrangementsByAgreementAxis_vrtx_MerckKGaAMember", "decimals": "INF", "first": true, "lang": null, "name": "vrtx:CollaborativeArrangementRightToLicenseNumberOfDevelopmentPrograms", "reportCount": 1, "unique": true, "unitRef": "development_program", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2017Q4YTD_vrtx_CollaborativeArrangementsByAgreementAxis_vrtx_JanssenPharmaceuticalsInc.Member", "decimals": "-5", "first": true, "lang": null, "name": "vrtx:CollaborativeRevenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402408 - Disclosure - Collaborative Arrangements - Janssen Pharmaceuticals, Inc. (Details)", "role": "http://www.vrtx.com/role/CollaborativeArrangementsJanssenPharmaceuticalsIncDetails", "shortName": "Collaborative Arrangements - Janssen Pharmaceuticals, Inc. (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2017Q4YTD_vrtx_CollaborativeArrangementsByAgreementAxis_vrtx_JanssenPharmaceuticalsInc.Member", "decimals": "-5", "first": true, "lang": null, "name": "vrtx:CollaborativeRevenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2016Q4YTD_vrtx_CollaborativeArrangementsByAgreementAxis_vrtx_CysticFibrosisFoundationTherapeuticsIncorporatedMember", "decimals": "INF", "first": true, "lang": null, "name": "vrtx:CollaborativeArrangementResearchDevelopmentFunding", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402409 - Disclosure - Collaborative Arrangements - Cystic Fibrosis Foundation Therapeutics Incorporated (Details)", "role": "http://www.vrtx.com/role/CollaborativeArrangementsCysticFibrosisFoundationTherapeuticsIncorporatedDetails", "shortName": "Collaborative Arrangements - Cystic Fibrosis Foundation Therapeutics Incorporated (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2016Q4YTD_vrtx_CollaborativeArrangementsByAgreementAxis_vrtx_CysticFibrosisFoundationTherapeuticsIncorporatedMember", "decimals": "INF", "first": true, "lang": null, "name": "vrtx:CollaborativeArrangementResearchDevelopmentFunding", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "D2019Q3SD_us-gaap_BusinessAcquisitionAxis_vrtx_ExonicsTherapeuticsMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Acquisitions - Exonics Therapeutics - Additional Information (Details)", "role": "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsAdditionalInformationDetails", "shortName": "Acquisitions - Exonics Therapeutics - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "D2019Q3SD_us-gaap_BusinessAcquisitionAxis_vrtx_ExonicsTherapeuticsMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "vrtx:BusinessCombinationContingentConsiderationLiabilityIncreaseFromAcquisitions", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - Acquisitions - Exonics Therapeutics (Details)", "role": "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsDetails", "shortName": "Acquisitions - Exonics Therapeutics (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "D2019Q3SD_us-gaap_BusinessAcquisitionAxis_vrtx_ExonicsTherapeuticsMember", "decimals": "-3", "lang": null, "name": "vrtx:PaymentsToAcquireBusinessesAdjustedForWorkingCapital", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherIndefiniteLivedIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - Acquisitions - Semma Therapeutics - Additional Information (Details)", "role": "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsAdditionalInformationDetails", "shortName": "Acquisitions - Semma Therapeutics - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "I2019Q4oct10_srt_ProductOrServiceAxis_vrtx_PreClinicalTreatmentsForDeviceAssistedCellsMember_us-gaap_BusinessAcquisitionAxis_vrtx_SemmaTherapeuticsInc.Member", "decimals": "-5", "lang": null, "name": "us-gaap:OtherIndefiniteLivedIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "I2019Q1JAN1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403405 - Disclosure - Acquisitions - Semma Therapeutics (Details)", "role": "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsDetails", "shortName": "Acquisitions - Semma Therapeutics (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "I2019Q4oct10_us-gaap_BusinessAcquisitionAxis_vrtx_SemmaTherapeuticsInc.Member", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Consolidated Statements of Shareholders' Equity and Noncontrolling Interest", "role": "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest", "shortName": "Consolidated Statements of Shareholders' Equity and Noncontrolling Interest", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2017Q4YTD_vrtx_CollaborativeArrangementsByAgreementAxis_vrtx_ConcertPharmaceuticalsMember", "decimals": "-5", "first": true, "lang": null, "name": "vrtx:CollaborativeArrangementDevelopmentandCommercializationRightsPotentialMaximumMilestonePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403406 - Disclosure - Acquisitions - Concert Pharmaceuticals (Details)", "role": "http://www.vrtx.com/role/AcquisitionsConcertPharmaceuticalsDetails", "shortName": "Acquisitions - Concert Pharmaceuticals (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2017Q4YTD_vrtx_CollaborativeArrangementsByAgreementAxis_vrtx_ConcertPharmaceuticalsMember", "decimals": "-5", "first": true, "lang": null, "name": "vrtx:CollaborativeArrangementDevelopmentandCommercializationRightsPotentialMaximumMilestonePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Earnings Per Share (Details)", "role": "http://www.vrtx.com/role/EarningsPerShareDetails", "shortName": "Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details)", "role": "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "shortName": "Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405404 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details)", "role": "http://www.vrtx.com/role/FairValueMeasurementsFairValueOfContingentConsiderationLiabilitiesDetails", "shortName": "Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails", "shortName": "Marketable Securities and Equity Investments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_vrtx_CRISPRTherapeuticsAGMember", "decimals": "-5", "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails", "shortName": "Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "vrtx:DebtandEquitySecuritiesCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406404 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesByContractualMaturityDetails", "shortName": "Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Hedging - Narrative (Details)", "role": "http://www.vrtx.com/role/HedgingNarrativeDetails", "shortName": "Hedging - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006000 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - - Notional Amount (Details)", "role": "http://www.vrtx.com/role/NotionalAmountDetails", "shortName": "- Notional Amount (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - - Cash Flow Hedging Instruments (Details)", "role": "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails", "shortName": "- Cash Flow Hedging Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_RevenueFromContractWithCustomerMember", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:OffsettingAssetsTableTextBlock", "us-gaap:OffsettingLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408405 - Disclosure - Hedging - Derivative Fair Value (Details)", "role": "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "shortName": "Hedging - Derivative Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:OffsettingAssetsTableTextBlock", "us-gaap:OffsettingLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408406 - Disclosure - Hedging - Offsetting Derivatives (Details)", "role": "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "shortName": "Hedging - Offsetting Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:OffsettingAssetsTableTextBlock", "us-gaap:OffsettingLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember", "decimals": "-3", "lang": null, "name": "us-gaap:DerivativeAssetFairValueGrossLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - Inventories (Details)", "role": "http://www.vrtx.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "vrtx:PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - Property and Equipment - Property and Equipment, Net (Details)", "role": "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails", "shortName": "Property and Equipment - Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "vrtx:PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413403 - Disclosure - Property and Equipment - Narrative (Details)", "role": "http://www.vrtx.com/role/PropertyAndEquipmentNarrativeDetails", "shortName": "Property and Equipment - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2018Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OtherIndefiniteLivedIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414401 - Disclosure - Intangible Assets and Goodwill (Details)", "role": "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails", "shortName": "Intangible Assets and Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4_vrtx_CollaborativeArrangementsByAgreementAxis_vrtx_ExonicsTherapeuticsMember", "decimals": "-5", "lang": null, "name": "us-gaap:OtherIndefiniteLivedIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - Additional Balance Sheet Detail (Details)", "role": "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails", "shortName": "Additional Balance Sheet Detail (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "I2019Q1JAN1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeaseTermOfContract1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416402 - Disclosure - Leases - Additional Information (Details)", "role": "http://www.vrtx.com/role/LeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2018Q4", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Nature of Business and Accounting Policies", "role": "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPolicies", "shortName": "Nature of Business and Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416403 - Disclosure - Leases - Components of Lease Expense (Details)", "role": "http://www.vrtx.com/role/LeasesComponentsOfLeaseExpenseDetails", "shortName": "Leases - Components of Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "vrtx:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "vrtx:FinanceLeaseRightOfUseAssetGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416404 - Disclosure - Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details)", "role": "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails", "shortName": "Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "vrtx:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "vrtx:FinanceLeaseRightOfUseAssetGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416405 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details)", "role": "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails", "shortName": "Leases - Maturities of Operating and Financing Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "vrtx:ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesRelatedtoLeasesTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416406 - Disclosure - Leases - Weighted-Average Remaining Lease Terms and Discount Rates (Details)", "role": "http://www.vrtx.com/role/LeasesWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails", "shortName": "Leases - Weighted-Average Remaining Lease Terms and Discount Rates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "vrtx:ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesRelatedtoLeasesTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "vrtx:LeaseSupplementalCashFlowInformationTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416407 - Disclosure - Leases - Supplemental Cash Flow Information (Details)", "role": "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails", "shortName": "Leases - Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "vrtx:LeaseSupplementalCashFlowInformationTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416408 - Disclosure - Leases - Future Minimum Commitments Under Real Estate Leases (Details)", "role": "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails", "shortName": "Leases - Future Minimum Commitments Under Real Estate Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416409 - Disclosure - Leases - Capital Leases (Details)", "role": "http://www.vrtx.com/role/LeasesCapitalLeasesDetails", "shortName": "Leases - Capital Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418402 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Common Stock and Preferred Stock (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansCommonStockAndPreferredStockDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Common Stock and Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "lang": null, "name": "vrtx:CommonStockVotesPerEachShare", "reportCount": 1, "unique": true, "unitRef": "vote", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockRepurchasedDuringPeriodValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418403 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Share Repurchase Program (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansShareRepurchaseProgramDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Share Repurchase Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2018Q4_us-gaap_ShareRepurchaseProgramAxis_vrtx_ShareRepurchaseProgram2018Member", "decimals": "INF", "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "vrtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418404 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Stock and Option Plans (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockAndOptionPlansDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Stock and Option Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "vrtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910k-main.htm", "contextRef": "I2017Q1JAN1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - a201910k-main.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - a201910k-main.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 157, "tag": { "country_GB": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED KINGDOM", "terseLabel": "United Kingdom" } } }, "localname": "GB", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyAndEquipmentNetByLocationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyAndEquipmentNetByLocationDetails", "http://www.vrtx.com/role/SegmentInformationRevenueByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "currency_AUD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Australia, Dollars", "terseLabel": "Australian dollar" } } }, "localname": "AUD", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_CAD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Canada, Dollars", "terseLabel": "Canadian dollar" } } }, "localname": "CAD", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "Euro" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_GBP": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "United Kingdom, Pounds", "terseLabel": "British pound sterling" } } }, "localname": "GBP", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r545" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r544" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r542" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r546" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r546" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r546" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r547" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r546" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r546" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r546" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r546" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r541" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r543" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationRevenueByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r189", "r272", "r277", "r529" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockAndOptionPlansDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/LeasesAdditionalInformationDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/LeasesAdditionalInformationDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r186", "r272", "r275", "r526", "r527" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsAdditionalInformationDetails", "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails", "http://www.vrtx.com/role/SegmentInformationRevenuesByProductDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsAdditionalInformationDetails", "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails", "http://www.vrtx.com/role/SegmentInformationRevenuesByProductDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockAndOptionPlansDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/LeasesAdditionalInformationDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockAndOptionPlansDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/LeasesAdditionalInformationDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r539" ], "lang": { "en-US": { "role": { "label": "Name of Property [Axis]", "terseLabel": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails", "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Name of Property [Domain]", "terseLabel": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails", "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r142", "r144", "r145", "r146" ], "lang": { "en-US": { "role": { "label": "Restatement Adjustment [Member]", "terseLabel": "Adjustments" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Axis]", "terseLabel": "Restatement [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Domain]", "terseLabel": "Restatement [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r144", "r145", "r146" ], "lang": { "en-US": { "role": { "label": "Previously Reported [Member]", "terseLabel": "Previously Reported" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyAndEquipmentNetByLocationDetails", "http://www.vrtx.com/role/SegmentInformationRevenueByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r188", "r272", "r276", "r528", "r535", "r538" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyAndEquipmentNetByLocationDetails", "http://www.vrtx.com/role/SegmentInformationRevenueByGeographicLocationDetails" ], "xbrltype": "stringItemType" }, "srt_WeightedAverageMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "Accounting Standards Update 2014-09" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201601Member": { "auth_ref": [ "r452" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.", "label": "Accounting Standards Update 2016-01 [Member]", "terseLabel": "Accounting standards update 2016-01" } } }, "localname": "AccountingStandardsUpdate201601Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesIntraEquityTransfersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r469" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201616Member": { "auth_ref": [ "r364", "r365" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-16 Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.", "label": "Accounting Standards Update 2016-16 [Member]", "terseLabel": "Accounting Standards Update 2016-16" } } }, "localname": "AccountingStandardsUpdate201616Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesIntraEquityTransfersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r2", "r23", "r191", "r192", "r273" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r8", "r9", "r46" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Royalty payable" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r38", "r246" ], "calculation": { "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r77", "r87", "r398" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "On Foreign Currency Forward Contracts" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": { "auth_ref": [ "r69", "r77", "r79", "r398" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent.", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]", "terseLabel": "On Foreign Currency Forward Contracts" } } }, "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r70", "r71", "r72", "r77", "r79" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "On Available-For-Sale Debt Securities" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r74", "r76", "r77" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r73", "r77", "r79", "r399" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "AOCI Attributable to Parent", "verboseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r68", "r77", "r79", "r399" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustment" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Additional Balance Sheet Detail" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetail" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r24" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r141" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesEquityInvestmentsDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesIntraEquityTransfersDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRevenueRecognitionDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r285", "r287", "r328", "r329" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r287", "r321", "r327" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "verboseLabel": "Allocated stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, after Tax", "totalLabel": "Total stock-based compensation included in costs and expenses, net of tax" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Area of real estate property (in square feet)" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r184", "r500", "r515" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets", "verboseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r55" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r439" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Financial instruments carried at fair value (asset position):" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r204" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r205" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r202", "r219" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetailsCalc2": { "order": 1.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Available-for-sale [Abstract]", "terseLabel": "Available-for-sale Debt Securities" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r206", "r208", "r510" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesByContractualMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value", "terseLabel": "Matures after one year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r206", "r207", "r509" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesByContractualMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value", "terseLabel": "Matures within one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r199", "r203", "r219" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesByContractualMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Fair Value", "totalLabel": "Total", "verboseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesByContractualMaturityDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableforsaleSecuritiesMember": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities [Member]", "terseLabel": "Total marketable debt securities" } } }, "localname": "AvailableforsaleSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r288", "r324" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r419", "r423" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Buildings" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails", "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsDetails", "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r371", "r372" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsDetails", "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsConcertPharmaceuticalsDetails", "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r377", "r378", "r381" ], "calculation": { "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total purchase price", "totalLabel": "Total purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r117", "r384" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "negatedLabel": "(Increase) decrease in fair value of contingent payments", "terseLabel": "Increase in fair value of contingent consideration", "verboseLabel": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails", "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails", "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/FairValueMeasurementsFairValueOfContingentConsiderationLiabilitiesDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r376", "r379", "r383" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Balance at December 31, 2019", "periodStartLabel": "Balance at December 31, 2018" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFairValueOfContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r376", "r380" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "negatedLabel": "Long-term contingent consideration", "terseLabel": "Long-term contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r385" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r373" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r340", "r373" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Deferred tax liability", "terseLabel": "Business combination, recognized identifiable assets acquired and liabilities assumed, deferred tax liabilities, current" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsDetails", "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r373" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Net other assets", "verboseLabel": "Net other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": { "auth_ref": [ "r370" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.", "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed", "terseLabel": "Collaborative arrangement, transaction costs" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsConcertPharmaceuticalsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Calculated under guidance for revenue recognition in effect prior to change to new guidance for revenue from contract with customer when using transition method for cumulative effect in period including initial date of application.", "label": "Calculated under Revenue Guidance in Effect before Topic 606 [Member]", "terseLabel": "Balances without Adoption of ASC 606" } } }, "localname": "CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalLeaseObligations": { "auth_ref": [ "r19", "r468", "r517" ], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.", "label": "Capital Lease Obligations", "totalLabel": "Total finance lease liabilities" } } }, "localname": "CapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsCurrent": { "auth_ref": [ "r17", "r467", "r468" ], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer.", "label": "Capital Lease Obligations, Current", "terseLabel": "Capital lease obligations, current portion", "verboseLabel": "Capital lease obligations, current portion" } } }, "localname": "CapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsNoncurrent": { "auth_ref": [ "r49", "r467", "r468" ], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.", "label": "Capital Lease Obligations, Noncurrent", "terseLabel": "Capital lease obligations, excluding current portion", "verboseLabel": "Capital lease obligations, excluding current portion" } } }, "localname": "CapitalLeaseObligationsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasedAssetsGross": { "auth_ref": [ "r466" ], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "vrtx_CapitalLeasedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of leased physical assets used in the normal conduct of business to produce goods and services.", "label": "Capital Leased Assets, Gross", "terseLabel": "Property and equipment, net" } } }, "localname": "CapitalLeasedAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r468" ], "calculation": { "http://www.vrtx.com/role/LeasesCapitalLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases.", "label": "Capital Leases, Future Minimum Payments Due", "totalLabel": "Total payments" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesCapitalLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r468" ], "calculation": { "http://www.vrtx.com/role/LeasesCapitalLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due in Five Years", "terseLabel": "2023" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesCapitalLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r468" ], "calculation": { "http://www.vrtx.com/role/LeasesCapitalLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due in Four Years", "terseLabel": "2022" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesCapitalLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r468" ], "calculation": { "http://www.vrtx.com/role/LeasesCapitalLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due in Three Years", "terseLabel": "2021" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesCapitalLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r468" ], "calculation": { "http://www.vrtx.com/role/LeasesCapitalLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due in Two Years", "terseLabel": "2020" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesCapitalLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r468" ], "calculation": { "http://www.vrtx.com/role/LeasesCapitalLeasesDetails": { "order": 6.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesCapitalLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments": { "auth_ref": [ "r468" ], "calculation": { "http://www.vrtx.com/role/LeasesCapitalLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount necessary to reduce net minimum lease payments to present value for capital leases.", "label": "Capital Leases, Future Minimum Payments, Interest Included in Payments", "negatedTerseLabel": "Less: amount representing interest" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesCapitalLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments": { "auth_ref": [ "r468" ], "calculation": { "http://www.vrtx.com/role/LeasesCapitalLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.", "label": "Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments", "totalLabel": "Present value of payments" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesCapitalLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesCapitalLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments, Remainder of Fiscal Year", "terseLabel": "2019" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesCapitalLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r35", "r532", "r533" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r35", "r120" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "vrtx_CashCashEquivalentsAvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents", "verboseLabel": "Fair Value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r12", "r121", "r128" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r12", "r210" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "terseLabel": "Marketable Securities and Equity Investments" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r114", "r120", "r126" ], "calculation": { "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash\u2014end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash\u2014beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash per statement of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r114", "r456" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r416" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r264", "r265", "r266", "r267" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassificationOfVariableInterestEntityDomain": { "auth_ref": [ "r402", "r404", "r406", "r407" ], "lang": { "en-US": { "role": { "documentation": "Categorization of Variable Interest Entities (VIE) for consolidation and (or) disclosure purposes, whether individually or in aggregate, by: (1) VIEs consolidated because the entity is the primary beneficiary, (2) VIEs not consolidated because the entity is not the primary beneficiary, and (3) VIEs or potential VIEs that are not consolidated because necessary information is not available. In general, a VIE is a corporation, partnership, trust, or any other legal structure used for business purposes that either (a) does not have equity investors with voting rights or (b) has equity investors that do not provide sufficient financial resources for the entity to support its activities. A VIE often holds financial assets, including loans or receivables, real estate or other property. A VIE may be essentially passive or it may engage in research and development or other activities on behalf of another company.", "label": "Variable Interest Entity, Classification [Domain]", "terseLabel": "Variable Interest Entity, Classification [Domain]" } } }, "localname": "ClassificationOfVariableInterestEntityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails", "http://www.vrtx.com/role/CollaborativeArrangementsBioaxoneBiosciencesIncDetails", "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails", "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r386", "r387", "r389" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborative Arrangements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsBioaxoneBiosciencesIncDetails", "http://www.vrtx.com/role/CollaborativeArrangementsCrisprTherapeuticsAgDetails", "http://www.vrtx.com/role/CollaborativeArrangementsCysticFibrosisFoundationTherapeuticsIncorporatedDetails", "http://www.vrtx.com/role/CollaborativeArrangementsJanssenPharmaceuticalsIncDetails", "http://www.vrtx.com/role/CollaborativeArrangementsKymeraAndOtherInLicenseAgreementsDetails", "http://www.vrtx.com/role/CollaborativeArrangementsMerckKgaaDetails", "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper", "verboseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r51", "r259", "r505", "r522" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansCommonStockAndPreferredStockDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r262" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01 par value; 500,000 shares authorized, 258,993 and 255,172 shares issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r127", "r293" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Stock-based Compensation Expense" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "verboseLabel": "Deferred tax assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r82", "r84", "r85" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income attributable to Vertex" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r82", "r84", "r393", "r394", "r410" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "negatedLabel": "Comprehensive loss attributable to noncontrolling interest" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r82", "r84", "r392", "r410" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computers" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r234", "r237", "r375" ], "lang": { "en-US": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Software" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r174", "r175", "r449", "r450" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r174", "r175", "r449", "r450", "r531" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r174", "r175", "r449", "r450", "r531" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r170", "r512" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r174", "r175", "r449", "r450" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk percentage (less than for CVS/Caremark 2017 revenue)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r173", "r174", "r175", "r176", "r449", "r451" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r174", "r175", "r449", "r450" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "auth_ref": [ "r128", "r401", "r403", "r405" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "terseLabel": "Variable Interest Entities" } } }, "localname": "ConsolidationVariableInterestEntityPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r269", "r270", "r273" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r274" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenues related to performance obligations" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r123", "r124", "r125" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Issued", "terseLabel": "Issuances of common stock from employee benefit plans receivable" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r281", "r283", "r530" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r95" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r93" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": { "auth_ref": [ "r128", "r253", "r254", "r257" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.", "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]", "terseLabel": "Restructuring Expenses" } } }, "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditConcentrationRiskMember": { "auth_ref": [ "r451" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.", "label": "Credit Concentration Risk [Member]", "terseLabel": "Credit Concentration Risk" } } }, "localname": "CreditConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "negatedLabel": "Cumulative effect adjustment for adoption of new accounting guidance", "negatedTerseLabel": "Cumulative effect adjustment for adoption of new accounting guidance", "terseLabel": "Cumulative effect adjustment for adoption of new accounting guidance", "verboseLabel": "Cumulative effect adjustment to accumulated deficit" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesEquityInvestmentsDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesIntraEquityTransfersDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRevenueRecognitionDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r132", "r361", "r366" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r136", "r363" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r132", "r361", "r366" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current taxes:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r132", "r361", "r366" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r48" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate (percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeconsolidationGainOrLossAmount": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.", "label": "Deconsolidation, Gain (Loss), Amount", "negatedLabel": "Deconsolidation,loss, amount" } } }, "localname": "DeconsolidationGainOrLossAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r132", "r362", "r366" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r132", "r362", "r366" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r356" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets", "verboseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r118", "r132", "r362", "r366" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total deferred taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred taxes:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r132", "r362", "r366" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r334", "r359", "r360" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets, Deferred Income", "terseLabel": "Deferred revenues" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r353" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "terseLabel": "Deferred tax assets", "totalLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesIntraEquityTransfersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r356" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Unrealized gain" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r354" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r333", "r359", "r360" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "terseLabel": "Operating loss carryforwards, not subject to expiration" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Operating loss carryforwards, subject to expiration" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r334", "r359", "r360" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r358", "r359", "r360" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r333", "r359", "r360" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r355" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "terseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails", "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r334", "r359", "r360" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "negatedLabel": "Acquired intangibles" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesInvestments": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).", "label": "Deferred Tax Liabilities, Investments", "negatedLabel": "Unrealized gain" } } }, "localname": "DeferredTaxLiabilitiesInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r334", "r359", "r360" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "Deferred Tax Liabilities, Leasing Arrangements", "negatedTerseLabel": "Operating lease liabilities" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r334", "r359", "r360" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedTerseLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome": { "auth_ref": [ "r334", "r359", "r360" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.", "label": "Deferred Tax Liabilities, Tax Deferred Income", "negatedTerseLabel": "Deferred revenue" } } }, "localname": "DeferredTaxLiabilitiesTaxDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r284" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Defined contribution plan, cost" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Maximum percentage of annual compensation contributed by the participant (percent)" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeBenefitsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r118", "r244" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/PropertyAndEquipmentNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r118", "r182" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "auth_ref": [ "r57", "r66", "r421" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssets", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Asset, Fair Value, Gross Liability", "negatedTerseLabel": "Gross Amounts Offset" } } }, "localname": "DerivativeAssetFairValueGrossLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r60", "r64" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.", "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "totalLabel": "Legal Offset" } } }, "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r59", "r64" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.", "label": "Derivative Asset, Not Offset, Policy Election Deduction", "negatedTerseLabel": "Gross Amounts Not Offset" } } }, "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r58", "r63", "r448" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Foreign currency forward contracts", "totalLabel": "Gross Amounts Presented" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r56", "r65", "r421", "r496" ], "calculation": { "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Gross Amounts Recognized", "totalLabel": "Total assets" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r56", "r65", "r421", "r496" ], "calculation": { "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "negatedTerseLabel": "Gross Amounts Recognized", "negatedTotalLabel": "Total liabilities" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r420", "r422", "r428", "r430" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r438" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Hedging" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/Hedging" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r417", "r420", "r428" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r417", "r420", "r428", "r430", "r431", "r435", "r436" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r427", "r429" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "terseLabel": "Gain (loss) on derivatives not designated as hedging instruments" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r58", "r63", "r448" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 }, "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "negatedLabel": "Foreign currency forward contracts", "negatedTotalLabel": "Gross Amounts Presented" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "auth_ref": [ "r57", "r66", "r421" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Liability, Fair Value, Gross Asset", "terseLabel": "Gross Amounts Offset" } } }, "localname": "DerivativeLiabilityFairValueGrossAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r60", "r64" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.", "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "negatedTotalLabel": "Legal Offset" } } }, "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r59", "r64" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.", "label": "Derivative Liability, Not Offset, Policy Election Deduction", "terseLabel": "Gross Amounts Not Offset" } } }, "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r413", "r415" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount of foreign currency forward contract", "verboseLabel": "Notional amount of foreign currency forward contract" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r137", "r412", "r414", "r415", "r417", "r418", "r424", "r428", "r432", "r434", "r436" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTermOfContract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Term of Contract", "terseLabel": "Derivative term", "verboseLabel": "Derivative term (less than)" } } }, "localname": "DerivativeTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesForeignCurrencyGainLossDetails", "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r128", "r138", "r412", "r414", "r417", "r418", "r433" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Embedded Derivatives and Hedging Activities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r417" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as hedging instruments" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.", "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]", "terseLabel": "Effect of Change Higher/(Lower)" } } }, "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r331" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation Expense" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpense" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r288", "r324" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Stock-based compensation expense by type of award" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "netLabel": "Net income:", "terseLabel": "Net income:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r92", "r142", "r151", "r154", "r155", "r156", "r160", "r507", "r524" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income (loss) attributable to Vertex per common share (usd per share)", "verboseLabel": "Basic (usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/EarningsPerShareDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Amounts per share attributable to Vertex common shareholders:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Shares used in per share calculations:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r92", "r142", "r151", "r154", "r155", "r156", "r160", "r507", "r524" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income (loss) attributable to Vertex per common share (usd per share)", "verboseLabel": "Diluted (usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/EarningsPerShareDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r128", "r157", "r158", "r159" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share Attributable to Vertex Common Stockholders" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r161" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r456" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of changes in exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "auth_ref": [ "r330", "r341" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount", "terseLabel": "Officer\u2019s compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement, Additional Disclosure [Abstract]", "terseLabel": "Type of award:" } } }, "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r322" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Amount Capitalized", "negatedTerseLabel": "Stock-based compensation expense related to inventories" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r323" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized Expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r323" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average Recognition Period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r321" ], "calculation": { "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, Tax Benefit", "negatedTerseLabel": "Income tax effect" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee stock purchase plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options", "verboseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationRevenuesByProductDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r262" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesEquityInvestmentsDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesIntraEquityTransfersDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRevenueRecognitionDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r447" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "vrtx_DebtandEquitySecuritiesFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Fair Value" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract]", "terseLabel": "Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract]" } } }, "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesFvNiCost": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetailsCalc2": { "order": 2.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.", "label": "Equity Securities, FV-NI, Cost", "terseLabel": "Amortized Cost" } } }, "localname": "EquitySecuritiesFvNiCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "auth_ref": [ "r212" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r212" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedLabel": "Gains on equity securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": { "auth_ref": [ "r212" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Loss", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "EquitySecuritiesFvNiUnrealizedLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r13", "r18", "r210", "r504", "r513", "r534" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "verboseLabel": "Corporate equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r211" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity securities without readily determinable fair value, amount" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EurodollarMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.", "label": "Eurodollar [Member]", "terseLabel": "Eurodollar" } } }, "localname": "EurodollarMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair value of financial assets and liabilities" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r439", "r440", "r441", "r445" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFairValueOfContingentConsiderationLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r281", "r282", "r283", "r440", "r492" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r439", "r440", "r442", "r443", "r446" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Fair Value by Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r444" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r281", "r282", "r283", "r440", "r493" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r281", "r282", "r283", "r440", "r494" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r281", "r282", "r283", "r440", "r495" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r444", "r446" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r472", "r479", "r489" ], "calculation": { "http://www.vrtx.com/role/LeasesComponentsOfLeaseExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r474", "r483" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r471", "r488" ], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiability", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "totalLabel": "Present value of lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails", "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r471" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails": { "order": 4.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r488" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Finance lease, liability, maturity" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r471" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "verboseLabel": "Long-term finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r488" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetailsCalc3": { "order": 1.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r488" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r488" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in next fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r488" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r488" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r488" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r488" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r488" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityUndiscountedExcessAmount", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: amount representing interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r473", "r483" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Payments on finance leases", "verboseLabel": "Financing cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r470" ], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance Lease, Right-of-Use Asset", "totalLabel": "Total finance lease assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r472", "r479", "r489" ], "calculation": { "http://www.vrtx.com/role/LeasesComponentsOfLeaseExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of leased assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r486", "r489" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r485", "r489" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r214", "r215", "r216", "r217", "r218", "r220", "r221", "r222", "r223" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Financial Liabilities Fair Value Disclosure [Abstract]", "terseLabel": "Financial instruments carried at fair value (liability position):" } } }, "localname": "FinancialLiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue": { "auth_ref": [ "r422" ], "calculation": { "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets designated as cash flow hedging instruments.", "label": "Foreign Currency Cash Flow Hedge Asset at Fair Value", "terseLabel": "Fair value - assets" } } }, "localname": "ForeignCurrencyCashFlowHedgeAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue": { "auth_ref": [ "r422" ], "calculation": { "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments.", "label": "Foreign Currency Cash Flow Hedge Liability at Fair Value", "negatedTerseLabel": "Fair value - liabilities" } } }, "localname": "ForeignCurrencyCashFlowHedgeLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r453", "r454", "r455" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedLabel": "Net foreign currency transaction loss" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesForeignCurrencyGainLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r128", "r455", "r458" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation and Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCurrencyTranslationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Foreign Currency Translation [Abstract]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTranslationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesForeignCurrencyGainLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign currency forward contracts" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPropertyAndEquipmentDetails", "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfInvestments": { "auth_ref": [ "r118" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.", "label": "Gain (Loss) on Sale of Investments", "negatedTerseLabel": "Deconsolidation of VIE" } } }, "localname": "GainLossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r230", "r231" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets and Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IntangibleAssetsAndGoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r128", "r232" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r417", "r431" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r417" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r417" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/NotionalAmountDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r118", "r239" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Intangible asset impairment charges" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsBioaxoneBiosciencesIncDetails", "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails", "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r201" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other than Temporary Impairment Losses, Investments", "terseLabel": "Other-than-temporary declines in fair value of available-for-sale debt securities" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": { "auth_ref": [ "r390", "r392" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest", "negatedLabel": "Loss attributable to noncontrolling interest before benefit from income taxes and changes in fair value of contingent payments" } } }, "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r135" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "United States" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r135" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r135" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "Income (loss) before provision for (benefit from) income taxes", "totalLabel": "Income (loss) before provision for (benefit from) income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails", "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]", "terseLabel": "Components of income (loss) before provision for (benefit from) income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r248" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r369" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r132", "r183", "r367" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for (benefit from) income taxes", "totalLabel": "Provision for (benefit from) income taxes", "verboseLabel": "(Benefit from) provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails", "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails", "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails", "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r86", "r128", "r338", "r339", "r351", "r352", "r357", "r368", "r537" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r337", "r341", "r342" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Benefit from income taxes attributable to valuation allowances" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r336", "r341", "r342" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "terseLabel": "Tax rate change" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r130", "r341", "r342" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Foreign income tax rate differential" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r131", "r341", "r342" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Expected provision for (benefit from) income taxes" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "auth_ref": [ "r341", "r342" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount", "terseLabel": "Permanent items" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r341", "r342" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount", "terseLabel": "Stock compensation (benefit) shortfalls and cancellations" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r341" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 12.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r131", "r341", "r342" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State taxes, net of federal benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "auth_ref": [ "r341", "r342" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount", "negatedLabel": "Tax credits" } } }, "localname": "IncomeTaxReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r122" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r117" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r117" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r117" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r117" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r117" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Deferred income taxes (including benefit from valuation allowance release in 2018)" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r117" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r117" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with funds and investments that are not available for withdrawal or use (such as assets held in escrow or contractually limited as to use or disposition) and are associated with underlying transactions that are classified as investing activities.", "label": "Increase (Decrease) in Restricted Cash and Investments", "negatedLabel": "Decrease in restricted cash due to deconsolidation of VIE" } } }, "localname": "IncreaseDecreaseInRestrictedCashAndInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r152", "r158" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Share-based payment arrangements (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r235", "r238" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsBioaxoneBiosciencesIncDetails", "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails", "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure": { "auth_ref": [ "r439" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure", "terseLabel": "Fair value of intangible asset" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r235", "r238" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsBioaxoneBiosciencesIncDetails", "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails", "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Information about effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Axis]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Domain]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r233", "r236" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r89", "r181", "r459", "r460", "r508" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r112", "r115", "r122" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r27", "r228" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r1", "r53", "r225" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.vrtx.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r11", "r54", "r128", "r164", "r226", "r227" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r29", "r228" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r28", "r228" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r97" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "terseLabel": "Interest income", "verboseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r439" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Marketable securities, fair value, investment in common stock" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Rental expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r487", "r489" ], "calculation": { "http://www.vrtx.com/role/LeasesComponentsOfLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Net lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Finance lease cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesComponentsOfLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r487" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseTermOfContract1": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Finance Lease, Term of Contract", "terseLabel": "Option to extend lease term", "verboseLabel": "Length of lease" } } }, "localname": "LesseeFinanceLeaseTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r490" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r478" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r476" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r488" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lessee, operating lease, liability, maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r488" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetailsCalc3": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r488" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r488" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentDueNextTwelveMonths", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r488" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r488" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r488" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r488" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r488" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityUndiscountedExcessAmount", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: amount representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Optional term of lease agreement (in years)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r490" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessor, Lease, Description [Line Items]", "terseLabel": "Lessor, Lease, Description [Line Items]" } } }, "localname": "LessorLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorLeaseDescriptionTable": { "auth_ref": [ "r491" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessor's leases.", "label": "Lessor, Lease, Description [Table]", "terseLabel": "Lessor, Lease, Description [Table]" } } }, "localname": "LessorLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r44" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r26", "r502", "r520" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders\u2019 Equity", "verboseLabel": "Liabilities and Shareholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r439" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "negatedTotalLabel": "Total financial liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Line of credit facility, current borrowing capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r42", "r133" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r3", "r45" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r511" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "verboseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r114" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r114" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r114", "r116", "r119" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r80", "r83", "r91", "r119", "r158", "r506", "r523" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income attributable to Vertex", "verboseLabel": "Net income attributable to Vertex common shareholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/EarningsPerShareDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Net income:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r80", "r83", "r396", "r409" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net loss attributable to noncontrolling interest", "negatedTerseLabel": "Loss attributable to noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails", "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r142", "r149" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income attributable to Vertex common shareholders\u2014basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Basic net income attributable to Vertex per common share calculation:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r149", "r150" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net income attributable to Vertex common shareholders\u2014diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Diluted net income attributable to Vertex per common share calculation:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesEquityInvestmentsDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesIntraEquityTransfersDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRevenueRecognitionDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r141", "r143" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesEquityInvestmentsDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesIntraEquityTransfersDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRevenueRecognitionDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted/Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r123", "r124", "r125" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "terseLabel": "Capitalization of costs related to construction financing lease obligation" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r187" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Total long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyAndEquipmentNetByLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r417" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not designated as hedging instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesBusinessNarrativeDetails", "http://www.vrtx.com/role/SegmentInformationRevenuesByProductDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OffsettingAssetsTableTextBlock": { "auth_ref": [ "r61", "r62" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements.", "label": "Offsetting Assets [Table Text Block]", "terseLabel": "Derivatives Offsetting" } } }, "localname": "OffsettingAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OffsettingDerivativeAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Offsetting Derivative Assets [Abstract]", "terseLabel": "Offsetting Derivative Assets [Abstract]" } } }, "localname": "OffsettingDerivativeAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingDerivativeLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Offsetting Derivative Liabilities [Abstract]", "terseLabel": "Offsetting Derivative Liabilities [Abstract]" } } }, "localname": "OffsettingDerivativeLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingLiabilitiesTableTextBlock": { "auth_ref": [ "r61", "r62" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements.", "label": "Offsetting Liabilities [Table Text Block]", "terseLabel": "Derivatives Offsetting" } } }, "localname": "OffsettingLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations", "verboseLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r480", "r489" ], "calculation": { "http://www.vrtx.com/role/LeasesComponentsOfLeaseExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r471" ], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiability", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liabilities", "totalLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails", "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r471" ], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r471" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liabilities", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails", "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r475", "r483" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r470" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease assets", "verboseLabel": "Total operating lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r486", "r489" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r485", "r489" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r461", "r462" ], "calculation": { "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r461", "r462" ], "calculation": { "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals": { "auth_ref": [ "r463" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contractually required future rental payments receivable on noncancelable subleasing arrangements.", "label": "Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals", "terseLabel": "Sublease income 2018" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r461", "r462" ], "calculation": { "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r461", "r462" ], "calculation": { "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r461", "r462" ], "calculation": { "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r461", "r462" ], "calculation": { "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r461", "r462" ], "calculation": { "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails": { "order": 6.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r358" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r140", "r147", "r180", "r411" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Nature of Business and Accounting Policies" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r8", "r9", "r10", "r46" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r16", "r499", "r514" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "terseLabel": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r419", "r435" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r77", "r87" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other comprehensive (loss) income before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r69", "r74" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Unrealized (losses) gains on foreign currency forward contracts, net of tax of $7.0 million, $(7.1) million and $3.4 million, respectively" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax", "terseLabel": "Unrealized (losses) gains on foreign currency forward contracts, tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r74", "r78", "r425" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Gain (loss) on derivatives designated as hedging instruments" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r67", "r457" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r81", "r84", "r87", "r262" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total changes in other comprehensive (loss) income", "verboseLabel": "Other comprehensive (loss) income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Changes in other comprehensive (loss) income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r69", "r74", "r437" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax", "terseLabel": "Unrealized (losses) gains on foreign currency forward contracts, net of tax of $7.0 million, $(7.1) million and $3.4 million, respectively" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax": { "auth_ref": [ "r69", "r75" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit), before reclassification adjustments, related to increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax", "terseLabel": "Unrealized (losses) gains on foreign currency forward contracts, tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r70", "r74" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax", "terseLabel": "Unrealized holding gains on marketable securities, net of tax of zero, zero and $(2.7) million, respectively" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "auth_ref": [ "r71", "r75" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax", "terseLabel": "Unrealized holding gains (losses) on marketable securities, tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Other Current Liabilities [Table Text Block]", "terseLabel": "Summary Other Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r238" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.", "label": "Other Indefinite-lived Intangible Assets", "terseLabel": "Intangible asset" } } }, "localname": "OtherIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsDetails", "http://www.vrtx.com/role/FairValueMeasurementsFairValueOfContingentConsiderationLiabilitiesDetails", "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other Intangible Assets" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsBioaxoneBiosciencesIncDetails", "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails", "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r46" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "totalLabel": "Total" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Liabilities, Current [Abstract]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "totalLabel": "Total", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Liabilities, Noncurrent [Abstract]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r119" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash items, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Table Text Block]", "terseLabel": "Summary of Other Long Term Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r98" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other nonoperating income (expense)", "verboseLabel": "Other (expense) income, net" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherSundryLiabilitiesCurrent": { "auth_ref": [ "r46", "r260" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.", "label": "Other Sundry Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherSundryLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSundryLiabilitiesNoncurrent": { "auth_ref": [ "r20", "r501", "r516" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.", "label": "Other Sundry Liabilities, Noncurrent", "terseLabel": "Other" } } }, "localname": "OtherSundryLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total Vertex Shareholders' Equity" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r101", "r106", "r139" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other investing activities" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r109" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecurities": { "auth_ref": [ "r103", "r200" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.", "label": "Payments to Acquire Available-for-sale Securities", "negatedLabel": "Purchases of available-for-sale debt securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r99", "r102", "r200" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchases of available-for-sale debt securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r104", "r382" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Payments to acquire businesses" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r104" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Payments to acquire businesses, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "auth_ref": [ "r104" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.", "label": "Payments to Acquire in Process Research and Development", "negatedTerseLabel": "Purchase of in-process research and development" } } }, "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireNotesReceivable": { "auth_ref": [ "r102" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.", "label": "Payments to Acquire Notes Receivable", "negatedTerseLabel": "Investment in note receivable" } } }, "localname": "PaymentsToAcquireNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r105" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Expenditures for property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance-based RSUs" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r288", "r324" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeStockPurchasePlanDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockAndOptionPlansDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeStockPurchasePlanDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockAndOptionPlansDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansCommonStockAndPreferredStockDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansCommonStockAndPreferredStockDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansCommonStockAndPreferredStockDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r21" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.01 par value; 1,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r33", "r34" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r107", "r325" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Issuances of common stock under benefit plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r108", "r111", "r139" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing activities" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r99", "r100", "r200" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale", "terseLabel": "Maturities of available-for-sale debt securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r99", "r100", "r200" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-sale", "terseLabel": "Gross realized gains or losses" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale of securities classified as trading securities and held for investment purposes. Excludes proceeds from trading securities purchased and held principally for the purpose of selling them in the near term (thus held for only a short period of time).", "label": "Proceeds from Sale of Debt and Equity Securities, FV-NI, Held-for-investment", "terseLabel": "Sale of equity securities" } } }, "localname": "ProceedsFromSaleOfTradingSecuritiesHeldforinvestment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r107", "r325" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Total cash received from employees as a result of employee stock option exercises" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r275" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product revenues, net", "verboseLabel": "Product" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails", "http://www.vrtx.com/role/SegmentInformationRevenuesByProductDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r80", "r83", "r113", "r184", "r185", "r392", "r395", "r397", "r409", "r410" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r38", "r247" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]", "verboseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPropertyAndEquipmentDetails", "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r37", "r245" ], "calculation": { "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "verboseLabel": "Total property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPropertyAndEquipmentDetails", "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r14", "r15", "r247", "r521" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails", "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r36", "r128", "r247" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r14", "r247" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r14", "r245" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]", "verboseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPropertyAndEquipmentDetails", "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property and equipment useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseByMajorPropertyClassTable": { "auth_ref": [ "r465" ], "lang": { "en-US": { "role": { "documentation": "A listing by major property class of the amount of lessor property under a leasing agreement, and available for lease (not currently under lease), at cost, between the lessor and the lessee as of the balance sheet date.", "label": "Property Subject to or Available for Operating Lease, by Major Property Class [Table]", "terseLabel": "Property Subject to or Available for Operating Lease, by Major Property Class [Table]" } } }, "localname": "PropertySubjectToOrAvailableForOperatingLeaseByMajorPropertyClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Quarterly Financial Data (unaudited)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/QuarterlyFinancialDataUnaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r525" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.", "label": "Realized Investment Gains (Losses)", "terseLabel": "Realized investment gains (losses)" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r77", "r79", "r87" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive income (loss)" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r110", "r134" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedTerseLabel": "Payments on revolving credit facility" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r332", "r540" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expenses", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "Acquired in-process research and development" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r39", "r128", "r241", "r242", "r540" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r12", "r120", "r126" ], "calculation": { "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r6", "r16", "r120", "r126", "r536" ], "calculation": { "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Unvested restricted stock and restricted stock units (including PSUs)", "verboseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails", "http://www.vrtx.com/role/EarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (excluding PSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of positions eliminated during the period as a result of restructuring activities.", "label": "Restructuring and Related Cost, Number of Positions Eliminated", "terseLabel": "Number of positions eliminated" } } }, "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRestructuringExpensesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r118", "r250", "r253", "r256" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "negatedTerseLabel": "Restructuring (income) expenses", "terseLabel": "Restructuring (income) expenses" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRestructuringExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRestructuringExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRestructuringExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r263", "r519" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesEquityInvestmentsDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesIntraEquityTransfersDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRevenueRecognitionDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r271", "r272" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Product revenues, net", "verboseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRevenueRecognitionDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedAdditionalInformationDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails", "http://www.vrtx.com/role/SegmentInformationRevenueByGeographicLocationDetails", "http://www.vrtx.com/role/SegmentInformationRevenuesByProductDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r174" ], "lang": { "en-US": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Product revenues, net" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r129", "r280" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]", "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]", "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyAndEquipmentNetByLocationDetails", "http://www.vrtx.com/role/SegmentInformationRevenueByGeographicLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r484", "r489" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Finance leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r484", "r489" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r174" ], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenues, Gross" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of Accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r77" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Reclassifications out of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of antidilutive securities excluded from computation of earnings per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "terseLabel": "Schedule of fair value of our contingent consideration liabilities" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r371", "r372" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsConcertPharmaceuticalsDetails", "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r371", "r372" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of business price consideration" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Summary of cash, cash equivalents and marketable securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r388" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsBioaxoneBiosciencesIncDetails", "http://www.vrtx.com/role/CollaborativeArrangementsCrisprTherapeuticsAgDetails", "http://www.vrtx.com/role/CollaborativeArrangementsCysticFibrosisFoundationTherapeuticsIncorporatedDetails", "http://www.vrtx.com/role/CollaborativeArrangementsJanssenPharmaceuticalsIncDetails", "http://www.vrtx.com/role/CollaborativeArrangementsKymeraAndOtherInLicenseAgreementsDetails", "http://www.vrtx.com/role/CollaborativeArrangementsMerckKgaaDetails", "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r363" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of components of provision for (benefit from) income taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r356" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r420", "r428", "r431" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Derivative Instruments, Gain (Loss)" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of earning per share, basic and diluted, by common shares" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r287", "r320", "r327" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Stock-based compensation expense by line item" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationRevenuesByProductDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Revenues by Product" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r439", "r440" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Financial assets and liabilities subject to fair value measurements (excluding restricted cash and cash equivalents (VIE))" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": { "auth_ref": [ "r422" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.", "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]", "terseLabel": "Schedule of Foreign Exchange Contracts" } } }, "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock": { "auth_ref": [ "r468" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.", "label": "Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]", "terseLabel": "Schedule of future minimum lease payments for capital leases" } } }, "localname": "ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r464" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of future minimum rental payments for operating leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of components of income (loss) before provision for (benefit from) income taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r238", "r240" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets by Major Class [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r11", "r30", "r31", "r32" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories by Type" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r141", "r143", "r162", "r163", "r166" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]", "terseLabel": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "auth_ref": [ "r413" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "terseLabel": "Schedule of Cash Flow Hedging Instruments" } } }, "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r38", "r247" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPropertyAndEquipmentDetails", "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Schedule of quarterly financial data" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of purchase price assumed assets and liabilities" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r12", "r126", "r498", "r518" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash and Cash Equivalents" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r251", "r252", "r255" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRestructuringExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r94", "r188" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "verboseLabel": "Revenues and Property and Equipment by Location" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r88", "r90", "r188" ], "lang": { "en-US": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyAndEquipmentNetByLocationDetails", "http://www.vrtx.com/role/SegmentInformationRevenueByGeographicLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r288", "r324" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeStockPurchasePlanDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockAndOptionPlansDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of employee stock purchase plan activity.", "label": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]", "terseLabel": "Shares issued under Employee Stock Purchase Plan" } } }, "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Stock options outstanding and exercisable" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r295", "r308", "r311" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Outstanding and vested options" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r314" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of assumptions used to estimate the grant date fair value employee stock purchase plan" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r314" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of assumptions used to estimate the grant date fair value of options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Restricted stock and restricted stock units activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r173", "r174", "r175", "r176", "r449", "r451" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "verboseLabel": "Significant Customers" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r190" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r96", "r224" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Sales, general and administrative expenses", "verboseLabel": "Sales, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r117" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Restricted stock and Restricted Stock Units, weighted-average grant-date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant-date fair value, cancelled (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value (usd per share)", "verboseLabel": "Weighted-average grant-date fair value, granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "End of the period (in shares)", "periodStartLabel": "Beginning of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted stock and Restricted Stock Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-average grant-date fair value, as of the end of the period (usd per share)", "periodStartLabel": "Weighted-average grant-date fair value, as of the beginning of the period (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r310" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Restricted stock vested in period, total fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant-date fair value, vested (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Weighted-average assumptions for options and ESPP subscriptions granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": { "auth_ref": [ "r317" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments", "terseLabel": "Expected annual dividends" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected stock price volatility (percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r318" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate (percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeStockPurchasePlanDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockAndOptionPlansDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional shares authorized (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockAndOptionPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Additional awards authorized for grant (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockAndOptionPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted-average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r298" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Stock options exercisable at end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r298" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price exercisable at the end of the period (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r310" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value of stock options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r302" ], "lang": { "en-US": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Stock options expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Stock options forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r299" ], "lang": { "en-US": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Stock options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant-date fair value, granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r324" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r297", "r324" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Stock options outstanding at end of period (in shares)", "periodStartLabel": "Stock options outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted-average exercise price outstanding at end of period (usd per share)", "periodStartLabel": "Weighted-average exercise price outstanding at beginning of period (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": { "auth_ref": [ "r286", "r324" ], "lang": { "en-US": { "role": { "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased", "terseLabel": "Average price paid per share (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeStockPurchasePlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r286", "r292" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, exercised (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, expired (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, forfeited (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche One [Member]", "terseLabel": "Tranche one" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Three [Member]", "terseLabel": "Tranche three" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Tranche two" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": { "auth_ref": [ "r294" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.", "label": "Share-based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]", "terseLabel": "PSU activity" } } }, "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r313" ], "lang": { "en-US": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]", "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]", "terseLabel": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]", "terseLabel": "Stock options outstanding and exercisable" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Exercise price, low end of range (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r307" ], "lang": { "en-US": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "terseLabel": "Options exercisable (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "terseLabel": "Options outstanding (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "terseLabel": "Exercise price, high end of range (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Market share price (usd per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting rights percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "auth_ref": [ "r320" ], "calculation": { "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount", "terseLabel": "Stock-based compensation expense" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r290" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockAndOptionPlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r315", "r326" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term of options (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r324" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average Remaining Contractual Life, exercisable (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r312" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average Remaining Contractual Life, outstanding (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r298" ], "lang": { "en-US": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Options exercisable, weighted-average exercise price (usd per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "terseLabel": "Options outstanding, weighted-average exercise price (usd per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r312" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options outstanding, weighted-average remaining contractual life" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (shares)", "periodStartLabel": "Balance (shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "sharesItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r52", "r262" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesEquityInvestmentsDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesIntraEquityTransfersDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRevenueRecognitionDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "verboseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "terseLabel": "Issuance of common stock under benefit plans (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r21", "r22", "r262", "r263" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Number of shares (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r21", "r22", "r262", "r263", "r300" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Stock options exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Value, Employee Benefit Plan", "terseLabel": "Issuance of common stock under benefit plans" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Number of shares authorized to be repurchased" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "terseLabel": "Increase in the number of shares authorized for issuance (shares)" } } }, "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Number of shares remaining for repurchases" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r21", "r22", "r262", "r263" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Repurchases of common stock (shares)", "terseLabel": "Repurchases of common stock (shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansShareRepurchaseProgramDetails", "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r21", "r22", "r262", "r263" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Repurchases of common stock", "terseLabel": "Repurchases of common stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansShareRepurchaseProgramDetails", "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r390", "r391", "r408" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Other VIE activity" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r482", "r489" ], "calculation": { "http://www.vrtx.com/role/LeasesComponentsOfLeaseExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedTerseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "auth_ref": [ "r344", "r350", "r352" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Summary of Income Tax Contingencies [Table Text Block]", "terseLabel": "Summary of income tax contingencies" } } }, "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r358" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforwards" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Tax related accruals" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r193", "r194", "r195", "r196", "r197", "r198" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r497" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesEquityInvestmentsDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesIntraEquityTransfersDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRevenueRecognitionDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": { "auth_ref": [ "r281", "r503" ], "lang": { "en-US": { "role": { "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).", "label": "US Government-sponsored Enterprises Debt Securities [Member]", "terseLabel": "Government-sponsored enterprise securities", "verboseLabel": "Government-sponsored enterprise securities" } } }, "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r281", "r283", "r503" ], "lang": { "en-US": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury securities", "verboseLabel": "U.S. Treasury securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UndistributedEarningsDiluted": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed. Includes the adjustments resulting from the assumption that dilutive securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.", "label": "Undistributed Earnings, Diluted", "negatedLabel": "Less: Undistributed earnings allocated to participating securities" } } }, "localname": "UndistributedEarningsDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "auth_ref": [ "r153" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.", "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic", "negatedTerseLabel": "Less: Undistributed earnings allocated to participating securities" } } }, "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments": { "auth_ref": [ "r426" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain (loss) related to derivatives designated as cash flow hedging instruments, recorded in results of operations to the extent that the cash flow hedge is determined to be ineffective.", "label": "Unrealized Gain (Loss) on Cash Flow Hedging Instruments", "terseLabel": "Gain (loss) on cash flow hedging instruments" } } }, "localname": "UnrealizedGainLossOnCashFlowHedgingInstruments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r118" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.", "label": "Unrealized Gain (Loss) on Investments", "terseLabel": "Unrealized gains to other (expense) income, net" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesEquityInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r335", "r346" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of the period", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r347" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Decreases related to prior period tax positions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r349" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedTerseLabel": "Settlement with Tax Authorities" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r343" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Income tax penalties and interest accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r348" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increases related to current period tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r347" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Increases related to prior period tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r168", "r169", "r171", "r172", "r177", "r178", "r179" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r337" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "negatedTerseLabel": "Decrease in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis": { "auth_ref": [ "r402", "r404", "r407" ], "lang": { "en-US": { "role": { "documentation": "Information by category of Variable Interest Entity (VIE).", "label": "Variable Interest Entities [Axis]", "terseLabel": "Variable Interest Entities [Axis]" } } }, "localname": "VariableInterestEntitiesByClassificationOfEntityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails", "http://www.vrtx.com/role/CollaborativeArrangementsBioaxoneBiosciencesIncDetails", "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails", "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryDoesNotHoldMajorityVotingInterestDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]", "terseLabel": "Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]" } } }, "localname": "VariableInterestEntityPrimaryBeneficiaryDoesNotHoldMajorityVotingInterestDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "auth_ref": [ "r402" ], "lang": { "en-US": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Primary Beneficiary" } } }, "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails", "http://www.vrtx.com/role/CollaborativeArrangementsBioaxoneBiosciencesIncDetails", "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails", "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r481", "r489" ], "calculation": { "http://www.vrtx.com/role/LeasesComponentsOfLeaseExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r150", "r156" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted-average shares used to compute diluted net income per common share (in shares)", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/EarningsPerShareDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Shares used in per share calculations:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r148", "r156" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic weighted-average common shares outstanding", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/EarningsPerShareDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "sharesItemType" }, "vrtx_AccountingStandardsUpdate201601FinancialInstrumentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-01, Financial Instruments [Member]", "label": "Accounting Standards Update 2016-01, Financial Instruments [Member]", "terseLabel": "Accounting standards update 2016-01, financial instruments" } } }, "localname": "AccountingStandardsUpdate201601FinancialInstrumentsMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesEquityInvestmentsDetails" ], "xbrltype": "domainItemType" }, "vrtx_AccountingStandardsUpdate201609ExcessTaxBenefitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-09, Excess Tax Benefit", "label": "Accounting Standards Update 2016-09, Excess Tax Benefit [Member]", "terseLabel": "Accounting standards update 2016-09, excess tax benefit" } } }, "localname": "AccountingStandardsUpdate201609ExcessTaxBenefitMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails" ], "xbrltype": "domainItemType" }, "vrtx_AccountingStandardsUpdate201609ForfeitureRateComponentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-09, Forfeiture Rate Component", "label": "Accounting Standards Update 2016-09, Forfeiture Rate Component [Member]", "terseLabel": "Accounting standards update 2016-09, forfeiture rate component" } } }, "localname": "AccountingStandardsUpdate201609ForfeitureRateComponentMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails" ], "xbrltype": "domainItemType" }, "vrtx_AccredoCurascriptMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accredo/Curascript [Member]", "label": "Accredo/Curascript [Member]", "terseLabel": "Accredo/Curascript" } } }, "localname": "AccredoCurascriptMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "vrtx_AccruedResearchDevelopmentAndCommercialContractCosts": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for R&D and commercial of the entity. It is used to reflect the current portion of liabilities (due within one year or within the normal operating cycle, if longer).", "label": "Accrued Research Development and Commercial Contract Costs", "terseLabel": "Research, development and commercial contract costs" } } }, "localname": "AccruedResearchDevelopmentAndCommercialContractCosts", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accumulated Net Equity Investment Gain (Loss) Attributable to Parent [Member]", "label": "Accumulated Net Equity Investment Gain (Loss) Attributable to Parent [Member]", "terseLabel": "On Equity Securities" } } }, "localname": "AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "vrtx_AcquisitionRelatedDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Acquisition Related Development And Regulatory Potential Milestone Payments Maximum", "label": "Acquisition Related Development And Regulatory Potential Milestone Payments Maximum", "terseLabel": "Acquisition related development and regulatory potential milestone payments maximum" } } }, "localname": "AcquisitionRelatedDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_AdditionalCollaborativeFunding": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the additional annual funding under collaborative agreement 2016 amendment for research and development.", "label": "Additional Collaborative Funding", "terseLabel": "Additional collaborative funding" } } }, "localname": "AdditionalCollaborativeFunding", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsCysticFibrosisFoundationTherapeuticsIncorporatedDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_AdvanceFromCollaboratorNoncurrent": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Advance From Collaborator", "label": "Advance From Collaborator, Noncurrent", "terseLabel": "Advance from collaborator" } } }, "localname": "AdvanceFromCollaboratorNoncurrent", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_AggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Aggregate intrinsic value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "AggregateIntrinsicValueAbstract", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "stringItemType" }, "vrtx_AmountofOptionalRenewalTerms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount of Optional Renewal Terms", "label": "Amount of Optional Renewal Terms", "terseLabel": "Amount of optional renewal terms" } } }, "localname": "AmountofOptionalRenewalTerms", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vrtx_ArborBiotechnologiesInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arbor Biotechnologies, Inc. [Member]", "label": "Arbor Biotechnologies, Inc. [Member]", "terseLabel": "Arbor" } } }, "localname": "ArborBiotechnologiesInc.Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsKymeraAndOtherInLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "vrtx_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets And Liabilities, Lessee [Table Text Block]", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Components of lease in balance sheets" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "vrtx_BioAxoneBiosciencesInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BioAxone Biosciences Inc.", "label": "BioAxone Biosciences Inc. [Member]", "terseLabel": "BioAxone Biosciences, Inc" } } }, "localname": "BioAxoneBiosciencesInc.Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails", "http://www.vrtx.com/role/CollaborativeArrangementsBioaxoneBiosciencesIncDetails", "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails", "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "vrtx_BusinessCombinationConsiderationVIE": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of the consideration from the Company to VIE that does not constitute consideration transferred pursuant to ASC 805, Business Combinations.", "label": "Business Combination, Consideration VIE", "verboseLabel": "Collaborative arrangement, purchase price" } } }, "localname": "BusinessCombinationConsiderationVIE", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AcquisitionsConcertPharmaceuticalsDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_BusinessCombinationContingentConsiderationLiabilityIncreaseFromAcquisitions": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Contingent Consideration, Liability, Increase From Acquisitions", "label": "Business Combination, Contingent Consideration, Liability, Increase From Acquisitions", "terseLabel": "Contingent consideration related to acquisition of Exonics", "verboseLabel": "Fair value of contingent development and regulatory payments" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityIncreaseFromAcquisitions", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsDetails", "http://www.vrtx.com/role/FairValueMeasurementsFairValueOfContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CRISPRTherapeuticsAGMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CRISPR Therapeutics AG", "label": "CRISPR Therapeutics AG [Member]", "terseLabel": "CRISPR Therapeutics" } } }, "localname": "CRISPRTherapeuticsAGMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsCrisprTherapeuticsAgDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_CTX001CoCoAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CTX001 Co-Co Agreement [Member]", "label": "CTX001 Co-Co Agreement [Member]", "terseLabel": "CTX001 Co-Co Agreement" } } }, "localname": "CTX001CoCoAgreementMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsCrisprTherapeuticsAgDetails" ], "xbrltype": "domainItemType" }, "vrtx_CapitalLeaseObligationandConstructionFinancingObligationNoncurrent": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Capital Lease Obligation and Construction Financing Obligation, Noncurrent", "label": "Capital Lease Obligation and Construction Financing Obligation, Noncurrent", "verboseLabel": "Capital lease obligations, excluding current portion" } } }, "localname": "CapitalLeaseObligationandConstructionFinancingObligationNoncurrent", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "vrtx_CapitalLeaseObligationsOtherLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_CapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Capital Lease Obligations, Other Liabilities, Current", "label": "Capital Lease Obligations, Other Liabilities, Current", "terseLabel": "Capital lease obligations", "verboseLabel": "Other current liabilities" } } }, "localname": "CapitalLeaseObligationsOtherLiabilitiesCurrent", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails", "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CapitalLeasedAssets": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Capital Leased Assets", "label": "Capital Leased Assets", "totalLabel": "Total finance lease assets" } } }, "localname": "CapitalLeasedAssets", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CapitalleasesImputedInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Capital leases, Imputed Interest Rate", "label": "Capital leases, Imputed Interest Rate", "terseLabel": "Capital leases, imputed interest rate" } } }, "localname": "CapitalleasesImputedInterestRate", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vrtx_CashAndMoneyMarketFundsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time.", "label": "Cash and Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "CashAndMoneyMarketFundsMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "vrtx_CashCashEquivalentsAndMarketableSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the carrying value as of the balance sheet date of cash, cash equivalents and marketable securities.", "label": "Cash, Cash Equivalents and Marketable Securities", "terseLabel": "Cash, cash equivalents and marketable securities" } } }, "localname": "CashCashEquivalentsAndMarketableSecurities", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesBusinessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CashCashEquivalentsAvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of cash and cash equivalents and debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any.", "label": "Cash, Cash Equivalents, Available-for-sale Securities, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "CashCashEquivalentsAvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CashCashEquivalentsAvailableforsaleSecuritiesGrossUnrealizedGain": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "vrtx_CashCashEquivalentsAvailableForSaleSecuritiesAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This item represents the gross unrealized gains for cash, cash equivalents and securities which are categorized neither as held-to-maturity nor trading securities. Such gross unrealized gains are the excess of the fair value over the carrying value as of the reporting date.", "label": "Cash, Cash Equivalents, Available-for-sale Securities, Gross Unrealized Gain", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "CashCashEquivalentsAvailableforsaleSecuritiesGrossUnrealizedGain", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CashCashEquivalentsAvailableforsaleSecuritiesUnrealizedLossGross": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "vrtx_CashCashEquivalentsAvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the gross unrealized losses for cash, cash equivalents and securities which are categorized neither as held-to-maturity nor trading securities. Such gross unrealized losses are the excess of the carrying value over the fair value as of the reporting date.", "label": "Cash, Cash Equivalents, Available-for-sale Securities, Unrealized Loss, Gross", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "CashCashEquivalentsAvailableforsaleSecuritiesUnrealizedLossGross", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CashFlowLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash Flow, Lessee [Abstract]", "label": "Cash Flow, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashFlowLesseeAbstract", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "vrtx_CollaborativeArrangementAdditionalMaximumMilestonePaymentsBasedonRegulatoryApproval": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Additional Maximum Milestone Payments Based on Regulatory Approval", "label": "Collaborative Arrangement, Additional Maximum Milestone Payments Based on Regulatory Approval", "terseLabel": "Collaborative arrangement, additional maximum milestone payments based on regulatory approval" } } }, "localname": "CollaborativeArrangementAdditionalMaximumMilestonePaymentsBasedonRegulatoryApproval", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AcquisitionsConcertPharmaceuticalsDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementAgreementDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Listing of significant collaboration agreements.", "label": "Collaborative Arrangement Agreement [Domain]", "terseLabel": "Collaborative Arrangement Agreement [Domain]" } } }, "localname": "CollaborativeArrangementAgreementDomain", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AcquisitionsConcertPharmaceuticalsDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsDetails", "http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails", "http://www.vrtx.com/role/CollaborativeArrangementsBioaxoneBiosciencesIncDetails", "http://www.vrtx.com/role/CollaborativeArrangementsCrisprTherapeuticsAgDetails", "http://www.vrtx.com/role/CollaborativeArrangementsCysticFibrosisFoundationTherapeuticsIncorporatedDetails", "http://www.vrtx.com/role/CollaborativeArrangementsJanssenPharmaceuticalsIncDetails", "http://www.vrtx.com/role/CollaborativeArrangementsKymeraAndOtherInLicenseAgreementsDetails", "http://www.vrtx.com/role/CollaborativeArrangementsMerckKgaaDetails", "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails", "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRevenueRecognitionDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_CollaborativeArrangementDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized.", "label": "Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum", "terseLabel": "Collaborative arrangement development and regulatory potential milestone payments maximum" } } }, "localname": "CollaborativeArrangementDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsCrisprTherapeuticsAgDetails", "http://www.vrtx.com/role/CollaborativeArrangementsKymeraAndOtherInLicenseAgreementsDetails", "http://www.vrtx.com/role/CollaborativeArrangementsMerckKgaaDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementDevelopmentandCommercializationRightsPotentialMaximumMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Development and Commercialization Rights Potential Maximum Milestone Payments", "label": "Collaborative Arrangement, Development and Commercialization Rights Potential Maximum Milestone Payments", "terseLabel": "Collaborative arrangement, development and commercialization rights potential maximum milestone payments" } } }, "localname": "CollaborativeArrangementDevelopmentandCommercializationRightsPotentialMaximumMilestonePayments", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AcquisitionsConcertPharmaceuticalsDetails", "http://www.vrtx.com/role/CollaborativeArrangementsCrisprTherapeuticsAgDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementInvestmentinCollaborativePartnerAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Investment in Collaborative Partner, Amount", "label": "Collaborative Arrangement, Investment in Collaborative Partner, Amount", "terseLabel": "Investment in collaborative partner, pursuant to convertible loan agreement" } } }, "localname": "CollaborativeArrangementInvestmentinCollaborativePartnerAmount", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsCrisprTherapeuticsAgDetails", "http://www.vrtx.com/role/CollaborativeArrangementsKymeraAndOtherInLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementResearchDevelopmentFunding": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the funding under collaborative agreement 2016 amendment for research and development.", "label": "Collaborative Arrangement Research Development Funding", "terseLabel": "Collaborative funding" } } }, "localname": "CollaborativeArrangementResearchDevelopmentFunding", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AcquisitionsConcertPharmaceuticalsDetails", "http://www.vrtx.com/role/CollaborativeArrangementsCrisprTherapeuticsAgDetails", "http://www.vrtx.com/role/CollaborativeArrangementsCysticFibrosisFoundationTherapeuticsIncorporatedDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementResearchandDevelopmentExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement Research and Development Expenses", "label": "Collaborative Arrangement Research and Development Expenses", "terseLabel": "Collaborative arrangement research and development expenses" } } }, "localname": "CollaborativeArrangementResearchandDevelopmentExpenses", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsCrisprTherapeuticsAgDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementRightToLicenseNumberOfDevelopmentPrograms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Right To License, Number Of Development Programs", "label": "Collaborative Arrangement, Right To License, Number Of Development Programs", "terseLabel": "Right to license, number of development programs" } } }, "localname": "CollaborativeArrangementRightToLicenseNumberOfDevelopmentPrograms", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsMerckKgaaDetails" ], "xbrltype": "integerItemType" }, "vrtx_CollaborativeArrangementRightToLicenseNumberOfTargets": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Right To License, Number Of Targets", "label": "Collaborative Arrangement, Right To License, Number Of Targets", "terseLabel": "Right to license, number of targets (up to)" } } }, "localname": "CollaborativeArrangementRightToLicenseNumberOfTargets", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsCrisprTherapeuticsAgDetails", "http://www.vrtx.com/role/CollaborativeArrangementsKymeraAndOtherInLicenseAgreementsDetails" ], "xbrltype": "integerItemType" }, "vrtx_CollaborativeArrangementRighttoLicenseNumberOfClinicalStagePrograms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Right To License, Number Of Clinical Stage Programs", "label": "Collaborative Arrangement, Right to License, Number Of Clinical Stage Programs", "terseLabel": "Right to license, number of clinical stage programs" } } }, "localname": "CollaborativeArrangementRighttoLicenseNumberOfClinicalStagePrograms", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsMerckKgaaDetails" ], "xbrltype": "integerItemType" }, "vrtx_CollaborativeArrangementRighttoLicenseNumberOfPreClinicalStagePrograms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Right to License, Number Of Pre-Clinical Stage Programs", "label": "Collaborative Arrangement, Right to License, Number Of Pre-Clinical Stage Programs", "terseLabel": "Number of pre-clinical stage programs" } } }, "localname": "CollaborativeArrangementRighttoLicenseNumberOfPreClinicalStagePrograms", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsMerckKgaaDetails" ], "xbrltype": "integerItemType" }, "vrtx_CollaborativeArrangementUpFrontLicenseFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of the up-front license fee paid by the entity pursuant to a collaborative arrangement.", "label": "Collaborative Arrangement Up-front License Fee", "terseLabel": "Up-front payment" } } }, "localname": "CollaborativeArrangementUpFrontLicenseFee", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails", "http://www.vrtx.com/role/CollaborativeArrangementsKymeraAndOtherInLicenseAgreementsDetails", "http://www.vrtx.com/role/CollaborativeArrangementsMerckKgaaDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementsByAgreementAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Significant terms of collaboration arrangements, by individual agreement.", "label": "Collaborative Arrangements by Agreement [Axis]", "terseLabel": "Collaborative Arrangements by Agreement [Axis]" } } }, "localname": "CollaborativeArrangementsByAgreementAxis", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AcquisitionsConcertPharmaceuticalsDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsDetails", "http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails", "http://www.vrtx.com/role/CollaborativeArrangementsBioaxoneBiosciencesIncDetails", "http://www.vrtx.com/role/CollaborativeArrangementsCrisprTherapeuticsAgDetails", "http://www.vrtx.com/role/CollaborativeArrangementsCysticFibrosisFoundationTherapeuticsIncorporatedDetails", "http://www.vrtx.com/role/CollaborativeArrangementsJanssenPharmaceuticalsIncDetails", "http://www.vrtx.com/role/CollaborativeArrangementsKymeraAndOtherInLicenseAgreementsDetails", "http://www.vrtx.com/role/CollaborativeArrangementsMerckKgaaDetails", "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails", "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRevenueRecognitionDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vrtx_CollaborativeRevenues": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate revenue from collaborative revenues. It includes the revenues earned by the entity from nonrefundable, up-front license fees; net reimbursements of research and/or development efforts, including manufacturing services; and milestone payments.", "label": "Collaborative Revenues", "terseLabel": "Collaborative and royalty revenues" } } }, "localname": "CollaborativeRevenues", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsJanssenPharmaceuticalsIncDetails", "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeandRoyaltyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative and Royalty [Member]", "label": "Collaborative and Royalty [Member]", "terseLabel": "Collaborative and royalty revenues" } } }, "localname": "CollaborativeandRoyaltyMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "domainItemType" }, "vrtx_CommercialPaperNotIncludedwithCashandCashEquivalentsDueWithinOneYearMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commercial Paper, Not Included with Cash and Cash Equivalents, Due Within One Year", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents, Due Within One Year [Member]", "verboseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedwithCashandCashEquivalentsDueWithinOneYearMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "vrtx_CommonStockPreferredStockAndEquityPlansDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosures related to shares available for future issuance, descriptions of the stock and option plans, and the rights associated with each share.", "label": "Common Stock, Preferred Stock and Equity Plans Disclosure [Text Block]", "terseLabel": "Common Stock, Preferred Stock and Equity Plans" } } }, "localname": "CommonStockPreferredStockAndEquityPlansDisclosureTextBlock", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlans" ], "xbrltype": "textBlockItemType" }, "vrtx_CommonStockVotesPerEachShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock, Votes Per Each Share", "label": "Common Stock, Votes Per Each Share", "terseLabel": "Common stock, number of votes per share" } } }, "localname": "CommonStockVotesPerEachShare", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansCommonStockAndPreferredStockDetails" ], "xbrltype": "integerItemType" }, "vrtx_CompensatoryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Compensatory [Member]", "label": "Compensatory [Member]", "terseLabel": "Compensatory" } } }, "localname": "CompensatoryMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_ComputersAndSoftwareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the computer and software used in business.", "label": "Computers and Software [Member]", "terseLabel": "Computers and software" } } }, "localname": "ComputersAndSoftwareMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "vrtx_ConcertPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Concert Pharmaceuticals", "label": "Concert Pharmaceuticals [Member]", "terseLabel": "Concert Pharmaceuticals" } } }, "localname": "ConcertPharmaceuticalsMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AcquisitionsConcertPharmaceuticalsDetails" ], "xbrltype": "domainItemType" }, "vrtx_ConstructionFinancingObligationNoncurrent": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the noncurrent portion of a lease liability recorded as a result of capitalizing the landlord's costs of constructing facilities associated with building leases.", "label": "Construction Financing Obligation, Noncurrent", "terseLabel": "Construction financing lease obligation, excluding current portion", "verboseLabel": "Construction financing lease obligation, excluding current portion" } } }, "localname": "ConstructionFinancingObligationNoncurrent", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails", "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_ContingentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of material contingent liabilities outstanding", "label": "Contingent Liabilities", "terseLabel": "Contingent liabilities" } } }, "localname": "ContingentLiabilities", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CorporateDebtSecuritiesDueWithinOneYearMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Corporate Debt Securities, Due Within One Year [Member]", "label": "Corporate Debt Securities, Due Within One Year [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesDueWithinOneYearMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "vrtx_CysticFibrosisFoundationTherapeuticsIncorporatedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaboration agreement entered into with Cystic Fibrosis Foundation Therapeutics Inc., for the development, manufacture and commercialization of a product of the entity.", "label": "Cystic Fibrosis Foundation Therapeutics Incorporated [Member]", "terseLabel": "Cystic Fibrosis Foundation Therapeutics Incorporated" } } }, "localname": "CysticFibrosisFoundationTherapeuticsIncorporatedMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsCysticFibrosisFoundationTherapeuticsIncorporatedDetails" ], "xbrltype": "domainItemType" }, "vrtx_DebtCovenantConsolidatedLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consolidated leverage ratio that must be maintained in order to be in compliance with debt covenants.", "label": "Debt Covenant, Consolidated Leverage Ratio", "terseLabel": "Debt covenant, consolidated leverage ratio" } } }, "localname": "DebtCovenantConsolidatedLeverageRatio", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "pureItemType" }, "vrtx_DebtCovenantMinimumConsolidatedEBITDA": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum consolidated EBITDA that must be maintained in order to be in compliance with debt covenants.", "label": "Debt Covenant, Minimum Consolidated EBITDA", "terseLabel": "Debt covenant, minimum consolidated EBITDA" } } }, "localname": "DebtCovenantMinimumConsolidatedEBITDA", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesCost": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt and Equity Securities, Cost", "label": "Debt and Equity Securities, Cost", "totalLabel": "Amortized Cost" } } }, "localname": "DebtandEquitySecuritiesCost", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesFairValue": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt and Equity Securities, Fair Value", "label": "Debt and Equity Securities, Fair Value", "totalLabel": "Fair Value" } } }, "localname": "DebtandEquitySecuritiesFairValue", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesUnrealizedGain": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt and Equity Securities, Unrealized Gain", "label": "Debt and Equity Securities, Unrealized Gain", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "DebtandEquitySecuritiesUnrealizedGain", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesUnrealizedLoss": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt and Equity Securities, Unrealized Loss", "label": "Debt and Equity Securities, Unrealized Loss", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "DebtandEquitySecuritiesUnrealizedLoss", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DeconsolidationandDiscountedOperationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deconsolidation and Discounted Operations [Policy Text Block]", "label": "Deconsolidation and Discounted Operations [Policy Text Block]", "terseLabel": "Deconsolidation and Discounted Operations" } } }, "localname": "DeconsolidationandDiscountedOperationsPolicyTextBlock", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vrtx_DeferredTaxAssetsAccruedExpensesAndOther": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from currently nondeductible expenses in accrued and other expenses, which can only be deducted for tax purposes when such items are actually incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.", "label": "Deferred Tax Assets, Accrued Expenses and Other", "terseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsAccruedExpensesAndOther", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DeferredTaxAssetsIntangibles": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets related to intangible assets.", "label": "Deferred Tax Assets Intangibles", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsIntangibles", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DeferredTaxAssetsLeaseObligation": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Lease Obligation", "label": "Deferred Tax Assets, Lease Obligation", "terseLabel": "Finance lease liabilities" } } }, "localname": "DeferredTaxAssetsLeaseObligation", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DeferredTaxAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets [Member]", "label": "Deferred Tax Assets [Member]", "terseLabel": "Deferred Tax Assets" } } }, "localname": "DeferredTaxAssetsMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "vrtx_DeferredTaxAssetsOperatingLeaseAssets": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Operating Lease Assets", "label": "Deferred Tax Assets, Operating Lease Assets", "terseLabel": "Operating lease assets" } } }, "localname": "DeferredTaxAssetsOperatingLeaseAssets", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DomesticandForeignTaxAuthorityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Domestic and Foreign Tax Authority [Member]", "label": "Domestic and Foreign Tax Authority [Member]", "terseLabel": "Domestic and Foreign Tax Authority" } } }, "localname": "DomesticandForeignTaxAuthorityMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "vrtx_EffectiveIncomeTaxRateReconciliationDeconsolidationOfVariableInterestEntityAmount": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 10.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Deconsolidation Of Variable Interest Entity, Amount", "label": "Effective Income Tax Rate Reconciliation, Deconsolidation Of Variable Interest Entity, Amount", "negatedTerseLabel": "Deconsolidation of VIE" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeconsolidationOfVariableInterestEntityAmount", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_EffectiveIncomeTaxRateReconciliationUncertianTaxPositionsAmount": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 11.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Uncertian Tax Positions, Amount", "label": "Effective Income Tax Rate Reconciliation, Uncertian Tax Positions, Amount", "terseLabel": "Uncertain tax positions" } } }, "localname": "EffectiveIncomeTaxRateReconciliationUncertianTaxPositionsAmount", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_EmployeeRestrictedStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An arrangement whereby certain members of senior management are entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.", "label": "Employee Restricted Stock Option [Member]", "terseLabel": "Restricted stock and restricted stock units (including PSUs)" } } }, "localname": "EmployeeRestrictedStockOptionMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "vrtx_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee Stock Purchase Plan [Member]", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "ESPP share issuances" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeStockPurchasePlanDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangeFromDollars120.01toDollars140.0Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range From Dollars 120.01 to Dollars 140.0", "label": "Exercise Price Range From Dollars 120.01 to Dollars 140.0 [Member]", "terseLabel": "$120.01\u2013$140.00" } } }, "localname": "ExercisePriceRangeFromDollars120.01toDollars140.0Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangeFromDollars140.01toDollars160.0Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range From Dollars 140.01 to Dollars 160.0", "label": "Exercise Price Range From Dollars 140.01 to Dollars 160.0 [Member]", "terseLabel": "$140.01\u2013$160.00" } } }, "localname": "ExercisePriceRangeFromDollars140.01toDollars160.0Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangeFromDollars160.01toDollars180.00Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range From Dollars 160.01 to Dollars 180.00 [Member]", "label": "Exercise Price Range From Dollars 160.01 to Dollars 180.00 [Member]", "terseLabel": "$160.01\u2013$180.00" } } }, "localname": "ExercisePriceRangeFromDollars160.01toDollars180.00Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangeFromDollars180.01toDollars189.38Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range From Dollars 180.01 to Dollars 189.38 [Member]", "label": "Exercise Price Range From Dollars 180.01 to Dollars 189.38 [Member]", "terseLabel": "$180.01\u2013$189.38" } } }, "localname": "ExercisePriceRangeFromDollars180.01toDollars189.38Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangeFromDollars29.07toDollars40.00Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range From Dollars 29.07 to Dollars 40.00 [Member]", "label": "Exercise Price Range From Dollars 29.07 to Dollars 40.00 [Member]", "terseLabel": "$29.07\u2013$40.00" } } }, "localname": "ExercisePriceRangeFromDollars29.07toDollars40.00Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangefromDollars100.01toDollars120.00Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the range of exercise prices from $100.01 to $120.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information.", "label": "Exercise Price Range from Dollars 100.01 to Dollars 120.00 [Member]", "terseLabel": "$100.01\u2013$120.00" } } }, "localname": "ExercisePriceRangefromDollars100.01toDollars120.00Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangefromDollars40.01toDollars60.00Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the range of exercise prices from $40.01 to $60.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information.", "label": "Exercise Price Range from Dollars 40.01 to Dollars 60.00 [Member]", "terseLabel": "$40.01\u2013$60.00" } } }, "localname": "ExercisePriceRangefromDollars40.01toDollars60.00Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangefromDollars60.01toDollars80.00Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the range of exercise prices from $60.01 to $80.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information.", "label": "Exercise Price Range from Dollars 60.01 to Dollars 80.00 [Member]", "terseLabel": "$60.01\u2013$80.00" } } }, "localname": "ExercisePriceRangefromDollars60.01toDollars80.00Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangefromDollars80.01toDollars100.00Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the range of exercise prices from $80.01 to $100.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information.", "label": "Exercise Price Range from Dollars 80.01 to Dollars 100.00 [Member]", "terseLabel": "$80.01\u2013$100.00" } } }, "localname": "ExercisePriceRangefromDollars80.01toDollars100.00Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExonicsTherapeuticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exonics Therapeutics [Member]", "label": "Exonics Therapeutics [Member]", "terseLabel": "Exonics Therapeutics" } } }, "localname": "ExonicsTherapeuticsMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsDetails", "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "vrtx_FanPierLeasesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the fan pier leases.", "label": "Fan Pier Leases [Member]", "terseLabel": "Fan Pier Leases", "verboseLabel": "Corporate Headquarters" } } }, "localname": "FanPierLeasesMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails", "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails" ], "xbrltype": "domainItemType" }, "vrtx_FinanceLeasandOperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance Leas and Operating Lease, Liabilities, Payments, Due [Abstract]", "label": "Finance Leas and Operating Lease, Liabilities, Payments, Due [Abstract]", "terseLabel": "Total" } } }, "localname": "FinanceLeasandOperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetailsCalc2": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance Lease And Operating Lease, Liability", "label": "Finance Lease And Operating Lease, Liability", "totalLabel": "Present value of lease liabilities" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiability", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentDueNextTwelveMonths": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance Lease And Operating Lease, Liability, Payment, Due Next Twelve Months", "label": "Finance Lease And Operating Lease, Liability, Payment, Due Next Twelve Months", "totalLabel": "2020" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiabilityPaymentDueNextTwelveMonths", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentDueYearThree": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance Lease And Operating Lease, Liability, Payment, Due Year Three", "label": "Finance Lease And Operating Lease, Liability, Payment, Due Year Three", "totalLabel": "2022" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiabilityPaymentDueYearThree", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentDueYearTwo": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance Lease And Operating Lease, Liability, Payment, Due Year Two", "label": "Finance Lease And Operating Lease, Liability, Payment, Due Year Two", "totalLabel": "2021" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiabilityPaymentDueYearTwo", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetailsCalc3": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance Lease And Operating Lease, Liability, Payments, Due", "label": "Finance Lease And Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance Lease And Operating Lease, Liability, Payments, Due After Year Five", "label": "Finance Lease And Operating Lease, Liability, Payments, Due After Year Five", "totalLabel": "Thereafter" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance Lease And Operating Lease, Liability, Payments, Due Year Five", "label": "Finance Lease And Operating Lease, Liability, Payments, Due Year Five", "totalLabel": "2024" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance Lease And Operating Lease, Liability, Payments, Due Year Four", "label": "Finance Lease And Operating Lease, Liability, Payments, Due Year Four", "totalLabel": "2023" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetailsCalc2": { "order": 1.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance Lease And Operating Lease, Liability, Undiscounted Excess Amount", "label": "Finance Lease And Operating Lease, Liability, Undiscounted Excess Amount", "totalLabel": "Less: amount representing interest" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseRightOfUseAssetGross": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finance Lease, Right-Of-Use Asset, Gross", "label": "Finance Lease, Right-Of-Use Asset, Gross", "terseLabel": "Property and equipment, net" } } }, "localname": "FinanceLeaseRightOfUseAssetGross", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeasesOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_CapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance Leases, Other Current Liabilities", "label": "Finance Leases, Other Current Liabilities", "terseLabel": "Other current liabilities" } } }, "localname": "FinanceLeasesOtherCurrentLiabilities", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinancialPerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial Performance Shares", "label": "Financial Performance Shares [Member]", "terseLabel": "Financial performance shares" } } }, "localname": "FinancialPerformanceSharesMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "vrtx_FuturePaymentsToAcquireBusinesses": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments made in future to acquire businesses.", "label": "Future Payments To Acquire Businesses", "terseLabel": "Future payments to acquire businesses" } } }, "localname": "FuturePaymentsToAcquireBusinesses", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_GoodwillAndIntangibleAssetsIndefiniteLivedAssetsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Describes an entity's accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.", "label": "Goodwill and Intangible Assets Indefinite-Lived Assets [Policy Text Block]", "terseLabel": "In-process Research and Development Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIndefiniteLivedAssetsPolicyTextBlock", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vrtx_InProcessResearchAndDevelopmentAssetsAndContingentPaymentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets and contingent payments of an acquired entity to be used in the research and development activities of the combined enterprise.", "label": "In-process Research and Development Assets and Contingent Payments [Policy Text Block]", "terseLabel": "Fair Value of In-process Research and Development Assets and Contingent Payments" } } }, "localname": "InProcessResearchAndDevelopmentAssetsAndContingentPaymentsPolicyTextBlock", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vrtx_IncomeTaxBenefitResultingintheReleaseofValuationAllowance": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Income Tax (Benefit) Resulting in the Release of Valuation Allowance", "label": "Income Tax (Benefit) Resulting in the Release of Valuation Allowance", "terseLabel": "Income tax (benefit) resulting in the release of valuation allowance" } } }, "localname": "IncomeTaxBenefitResultingintheReleaseofValuationAllowance", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_IncomeTaxExpenseBenefitAttributableToDecreaseInTheFairValueOfContingentConsiderationLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Income Tax Expense (Benefit), Attributable To Decrease In The Fair Value Of Contingent Consideration Liability", "label": "Income Tax Expense (Benefit), Attributable To Decrease In The Fair Value Of Contingent Consideration Liability", "terseLabel": "Income tax expense (benefit), attributable to decrease in the fair value of contingent consideration liability" } } }, "localname": "IncomeTaxExpenseBenefitAttributableToDecreaseInTheFairValueOfContingentConsiderationLiability", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_IncomeTaxExpenseBenefitAttributableToIntangibleAssetImpairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Income Tax Expense (Benefit), Attributable To Intangible Asset Impairment", "label": "Income Tax Expense (Benefit), Attributable To Intangible Asset Impairment", "terseLabel": "Income tax expense (benefit), attributable to intangible asset impairment" } } }, "localname": "IncomeTaxExpenseBenefitAttributableToIntangibleAssetImpairment", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This block of text may be used to disclose all or parts of the required information for reconciliation of income tax provisions.", "label": "Income Tax Expense (Benefit) Continuing Operations, Income Tax Reconciliation [Table Text Block]", "terseLabel": "Reconciliation of the provision for (benefit from) income taxes" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationTableTextBlock", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "vrtx_IncrementalCommonSharesAttributabletoDilutiveEffectOther": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/EarningsPerShareDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Incremental Common Shares Attributable to Dilutive Effect, Other", "label": "Incremental Common Shares Attributable to Dilutive Effect, Other", "terseLabel": "Employee stock purchase plan (in shares)" } } }, "localname": "IncrementalCommonSharesAttributabletoDilutiveEffectOther", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "vrtx_IndemnificationClaims": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of indemnification claims currently outstanding", "label": "Indemnification Claims", "terseLabel": "Indemnification claims" } } }, "localname": "IndemnificationClaims", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_InterimReportingLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Interim Reporting [Table]", "label": "Interim Reporting [Line Items]", "terseLabel": "Interim Reporting [Line Items]" } } }, "localname": "InterimReportingLineItems", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "stringItemType" }, "vrtx_InterimReportingTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interim Reporting [Table]", "label": "Interim Reporting [Table]", "terseLabel": "Interim Reporting [Table]" } } }, "localname": "InterimReportingTable", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails" ], "xbrltype": "stringItemType" }, "vrtx_JanssenPharmaceuticalsInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaboration agreement entered into with Janssen Pharmaceutical, N.V. for the development, manufacture and commercialization of a product of the entity.", "label": "Janssen Pharmaceuticals, Inc. [Member]", "terseLabel": "Janssen" } } }, "localname": "JanssenPharmaceuticalsInc.Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsJanssenPharmaceuticalsIncDetails" ], "xbrltype": "domainItemType" }, "vrtx_KalydecoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "KALYDECO inventories, net", "label": "KALYDECO [Member]", "terseLabel": "KALYDECO" } } }, "localname": "KalydecoMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationRevenuesByProductDetails" ], "xbrltype": "domainItemType" }, "vrtx_KymeraTherapeuticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Kymera Therapeutics [Member]", "label": "Kymera Therapeutics [Member]", "terseLabel": "Kymera Therapeutics" } } }, "localname": "KymeraTherapeuticsMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsKymeraAndOtherInLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "vrtx_LeaseAgreementNumberOfLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of leases entered by the reporting entity.", "label": "Lease Agreement, Number of Leases", "terseLabel": "Number of leases" } } }, "localname": "LeaseAgreementNumberOfLeases", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vrtx_LeaseAgreementsNumberOfBuildings": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents number of buildings under lease agreements.", "label": "Lease Agreements Number of Buildings", "terseLabel": "Lease agreements number of buildings" } } }, "localname": "LeaseAgreementsNumberOfBuildings", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vrtx_LeaseSupplementalCashFlowInformationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease, Supplemental Cash Flow Information [Table Text Block]", "label": "Lease, Supplemental Cash Flow Information [Table Text Block]", "terseLabel": "Supplemental cash flow information" } } }, "localname": "LeaseSupplementalCashFlowInformationTableTextBlock", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "vrtx_LesseeLeasingArrangementsCapitalLeasesRenewalTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee Leasing Arrangements, Capital Leases, Renewal Term", "label": "Lessee Leasing Arrangements, Capital Leases, Renewal Term", "terseLabel": "Optional renewal term length" } } }, "localname": "LesseeLeasingArrangementsCapitalLeasesRenewalTerm", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vrtx_LesseeLeasingArrangementsCapitalLeasesTermofContract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee Leasing Arrangements, Capital Leases, Term of Contract", "label": "Lessee Leasing Arrangements, Capital Leases, Term of Contract", "terseLabel": "Length of lease" } } }, "localname": "LesseeLeasingArrangementsCapitalLeasesTermofContract", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vrtx_LineOfCreditFacilityAdditionalBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increased borrowing capacity available in the future.", "label": "Line Of Credit Facility Additional Borrowing Capacity", "terseLabel": "Line of credit facility, additional borrowing capacity" } } }, "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_McKessonCorporationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "McKesson Corporation [Member]", "label": "McKesson Corporation [Member]", "terseLabel": "McKesson Corporation" } } }, "localname": "McKessonCorporationMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "vrtx_MerckKGaAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Merck KGaA", "label": "Merck KGaA [Member]", "terseLabel": "Merck KGaA" } } }, "localname": "MerckKGaAMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsMerckKgaaDetails" ], "xbrltype": "domainItemType" }, "vrtx_MerckKGaAandArborBiotechnologiesInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Merck KGaA and Arbor Biotechnologies, Inc. [Member]", "label": "Merck KGaA and Arbor Biotechnologies, Inc. [Member]", "terseLabel": "Merck KGaA and Arbor" } } }, "localname": "MerckKGaAandArborBiotechnologiesInc.Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_MolecularTemplatesIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Molecular Templates, Inc [Member]", "label": "Molecular Templates, Inc [Member]", "terseLabel": "Molecular Templates, Inc" } } }, "localname": "MolecularTemplatesIncMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsKymeraAndOtherInLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "vrtx_NakedIsletsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Naked Islets [Member]", "label": "Naked Islets [Member]", "terseLabel": "Naked Islets" } } }, "localname": "NakedIsletsMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_NonCompensatoryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Non Compensatory [Member]", "label": "Non Compensatory [Member]", "terseLabel": "Non Compensatory" } } }, "localname": "NonCompensatoryMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_NonFinancialPerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Non-Financial Performance Shares", "label": "Non-Financial Performance Shares [Member]", "terseLabel": "Non-financial performance shares" } } }, "localname": "NonFinancialPerformanceSharesMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "vrtx_NoncontrollingInterestIncreaseDecreaseFromDeconsolidationVariableInterestEntity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Noncontrolling Interest, Increase (Decrease) From Deconsolidation, Variable Interest Entity", "label": "Noncontrolling Interest, Increase (Decrease) From Deconsolidation, Variable Interest Entity", "terseLabel": "VIE noncontrolling interest upon deconsolidation" } } }, "localname": "NoncontrollingInterestIncreaseDecreaseFromDeconsolidationVariableInterestEntity", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest" ], "xbrltype": "monetaryItemType" }, "vrtx_ORKAMBIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ORKAMBI [Member]", "label": "ORKAMBI [Member]", "terseLabel": "ORKAMBI" } } }, "localname": "ORKAMBIMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRevenueRecognitionDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedAdditionalInformationDetails", "http://www.vrtx.com/role/SegmentInformationRevenuesByProductDetails" ], "xbrltype": "domainItemType" }, "vrtx_OperatingLossAndTaxCreditCarryforwardsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization and tax credit carryforwards.", "label": "Operating Loss and Tax Credit, Carryforwards [Table]", "terseLabel": "Operating Loss and Tax Credit, Carryforwards [Table]" } } }, "localname": "OperatingLossAndTaxCreditCarryforwardsTable", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "vrtx_OtherContractLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other Contract liabilities, Current", "label": "Other Contract Liabilities Current", "terseLabel": "Contract liabilities" } } }, "localname": "OtherContractLiabilitiesCurrent", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_OtherCountriesOutsideoftheUnitedStatesandEuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Countries Outside of the United States and Europe [Member]", "label": "Other Countries Outside of the United States and Europe [Member]", "terseLabel": "Other" } } }, "localname": "OtherCountriesOutsideoftheUnitedStatesandEuropeMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationRevenueByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "vrtx_OtherCountriesOutsideoftheUnitedStatesandtheUnitedKingdomMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Countries Outside of the United States and the United Kingdom [Member]", "label": "Other Countries Outside of the United States and the United Kingdom [Member]", "terseLabel": "Other" } } }, "localname": "OtherCountriesOutsideoftheUnitedStatesandtheUnitedKingdomMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyAndEquipmentNetByLocationDetails" ], "xbrltype": "domainItemType" }, "vrtx_OtherLiabilitiesExcludingCapitalLeaseObligationsCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other Liabilities, Excluding Capital Lease Obligations, Current", "label": "Other Liabilities, Excluding Capital Lease Obligations, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesExcludingCapitalLeaseObligationsCurrent", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_OtherOperatingLeasesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the other operating leases.", "label": "Other Operating Leases [Member]", "terseLabel": "Other Leases" } } }, "localname": "OtherOperatingLeasesMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails" ], "xbrltype": "domainItemType" }, "vrtx_OutsidetheUnitedStatesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outside the United States [Member]", "label": "Outside the United States [Member]", "terseLabel": "Total revenues outside of the United States" } } }, "localname": "OutsidetheUnitedStatesMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyAndEquipmentNetByLocationDetails", "http://www.vrtx.com/role/SegmentInformationRevenueByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "vrtx_ParionSciencesInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Parion Sciences, Inc.", "label": "Parion Sciences, Inc. [Member]", "terseLabel": "Parion Sciences, Inc" } } }, "localname": "ParionSciencesInc.Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails", "http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails", "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "vrtx_PaymentsToAcquireBusinessesAdjustedForWorkingCapital": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments To Acquire Businesses, Adjusted For Working Capital", "label": "Payments To Acquire Businesses, Adjusted For Working Capital", "terseLabel": "Upfront payment (adjusted for customary working capital adjustments)" } } }, "localname": "PaymentsToAcquireBusinessesAdjustedForWorkingCapital", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_PaymentsonConstructionFinancingLeaseObligations": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments on Construction Financing Lease Obligations", "label": "Payments on Construction Financing Lease Obligations", "negatedTerseLabel": "Payments on capital lease and construction financing lease obligations" } } }, "localname": "PaymentsonConstructionFinancingLeaseObligations", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vrtx_PaymenttoAcquirePreferredStock": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payment to Acquire Preferred Stock", "label": "Payment to Acquire Preferred Stock", "negatedTerseLabel": "Investment in equity securities" } } }, "localname": "PaymenttoAcquirePreferredStock", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vrtx_Percentageofemployeeseligibleforaccelerationofequityawards": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of employees eligible for acceleration of equity awards", "label": "Percentage of employees eligible for acceleration of equity awards", "terseLabel": "Percentage of employees eligible for acceleration of equity awards (less than) (percent)" } } }, "localname": "Percentageofemployeeseligibleforaccelerationofequityawards", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "vrtx_PreClinicalTreatmentsForDeviceAssistedCellsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pre-Clinical Treatments For Device-Assisted Cells [Member]", "label": "Pre-Clinical Treatments For Device-Assisted Cells [Member]", "terseLabel": "Pre-Clinical Treatments For Device-Assisted Cells" } } }, "localname": "PreClinicalTreatmentsForDeviceAssistedCellsMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_ProceedsFromCollaborativeFunding": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From Collaborative Funding", "label": "Proceeds From Collaborative Funding", "terseLabel": "Advance from collaborator" } } }, "localname": "ProceedsFromCollaborativeFunding", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vrtx_ProceedsOnConstructionCapitalLeaseObligations": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds On Construction Capital Lease Obligations", "label": "Proceeds On Construction Capital Lease Obligations", "terseLabel": "Proceeds related to capital lease and construction financing lease obligations" } } }, "localname": "ProceedsOnConstructionCapitalLeaseObligations", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vrtx_ProductSalesAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of product sales allowances and reserves that reflect a liability established to represent expected future costs.", "label": "Product Sales Accrued Liabilities", "terseLabel": "Product revenue allowances" } } }, "localname": "ProductSalesAccruedLiabilities", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails": { "order": 2.0, "parentTag": "vrtx_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, Accumulated Depreciation And Amortization", "label": "Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, Accumulated Depreciation And Amortization", "negatedTerseLabel": "Less: accumulated depreciation" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, After Accumulated Depreciation And Amortization", "label": "Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, After Accumulated Depreciation And Amortization", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails": { "order": 1.0, "parentTag": "vrtx_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, Before Accumulated Depreciation And Amortization", "label": "Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, Before Accumulated Depreciation And Amortization", "terseLabel": "Total property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_RepaymentsofCollaborativeFunding": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Repayments of Collaborative Funding", "label": "Repayments of Collaborative Funding", "negatedTerseLabel": "Repayments of advanced funding" } } }, "localname": "RepaymentsofCollaborativeFunding", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vrtx_ResearchandDevelopmentRestructuringMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Research and Development Restructuring", "label": "Research and Development Restructuring [Member]", "terseLabel": "Research and development restructuring" } } }, "localname": "ResearchandDevelopmentRestructuringMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRestructuringExpensesDetails" ], "xbrltype": "domainItemType" }, "vrtx_RestrictedStockandRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted Stock and Restricted Stock Units", "label": "Restricted Stock and Restricted Stock Units [Member]", "terseLabel": "Restricted stock and restricted stock units (including PSUs)" } } }, "localname": "RestrictedStockandRestrictedStockUnitsMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "vrtx_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]", "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]", "terseLabel": "Right-of-use assets obtained in exchange for lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "vrtx_SYMDEKOSYMKEVIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "SYMDEKO/SYMKEVI [Member]", "label": "SYMDEKO/SYMKEVI [Member]", "terseLabel": "SYMDEKO/SYMKEVI" } } }, "localname": "SYMDEKOSYMKEVIMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationRevenuesByProductDetails" ], "xbrltype": "domainItemType" }, "vrtx_SanDiegoLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "San Diego Lease [Member]", "label": "San Diego Lease [Member]", "verboseLabel": "San Diego Lease" } } }, "localname": "SanDiegoLeaseMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items]", "terseLabel": "Summary of cash, cash equivalents and marketable securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "vrtx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of the cash and cash equivalents and available-for-sale investments held by the entity.", "label": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table]", "terseLabel": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "vrtx_ScheduleOfCollaborativeArrangementAgreementsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Schedule of Collaborative Arrangement Agreements [Line Items]", "terseLabel": "Schedule of Collaborative Arrangement Agreements [Line Items]" } } }, "localname": "ScheduleOfCollaborativeArrangementAgreementsLineItems", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vrtx_ScheduleOfCollaborativeArrangementAgreementsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A schedule reflecting significant collaboration agreements in which the entity is a participant.", "label": "Schedule of Collaborative Arrangement Agreements [Table]", "terseLabel": "Schedule of Collaborative Arrangement Agreements [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementAgreementsTable", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails", "http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vrtx_ScheduleOfCollaborativeArrangementSummaryOfItemsRelatedToVariableInterestEntitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents details pertaining to Variable Interest Entities assets and liabilities included in the company's condensed consolidated balance sheets.", "label": "Schedule Of Collaborative Arrangement Summary Of Items Related To Variable Interest Entities [Table Text Block]", "terseLabel": "Schedule of collaborative arrangement summary of items related to variable interest entities" } } }, "localname": "ScheduleOfCollaborativeArrangementSummaryOfItemsRelatedToVariableInterestEntitiesTableTextBlock", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsTables" ], "xbrltype": "textBlockItemType" }, "vrtx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This element represents the grouping of share-based compensation award types.", "label": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type [Axis]", "terseLabel": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type [Axis]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAxis", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "vrtx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This element represents an individual share-based compensation award type.", "label": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type [Domain]", "terseLabel": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type [Domain]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeDomain", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "vrtx_ScheduleOfStockAndStockOptionEquityPlansTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This schedule discloses the information pertaining to stock and stock option plans relating to the entity's equity.", "label": "Schedule of Stock and Stock Option, Equity Plans [Table Text Block]", "terseLabel": "Schedule of stock and stock equity plans" } } }, "localname": "ScheduleOfStockAndStockOptionEquityPlansTableTextBlock", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansTables" ], "xbrltype": "textBlockItemType" }, "vrtx_ScheduleofUnrecognizedSharebasedCompensationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure as of the latest balance-sheet date presented of the total compensation cost related to outstanding, nonvested share-based compensation awards not yet recognized, net of estimated forfeitures, and the weighted average period over which those unrecognized costs are expected to be reported.", "label": "Schedule of Unrecognized Share-based Compensation Expense [Table Text Block]", "terseLabel": "Unrecognized stock-based compensation expense, net of estimated forfeitures" } } }, "localname": "ScheduleofUnrecognizedSharebasedCompensationExpenseTableTextBlock", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseTables" ], "xbrltype": "textBlockItemType" }, "vrtx_ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesRelatedtoLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related to Leases [Table Text Block]", "label": "Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related to Leases [Table Text Block]", "terseLabel": "Weighted-average remaining lease terms and discount rates" } } }, "localname": "ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesRelatedtoLeasesTableTextBlock", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "vrtx_SellingGeneralAndAdministrativeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The allocation (or location) of expense to (in) selling, general and administrative expense.", "label": "Selling General and Administrative Expense [Member]", "terseLabel": "Sales, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpenseMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "vrtx_SemmaTherapeuticsInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Semma Therapeutics, Inc. [Member]", "label": "Semma Therapeutics, Inc. [Member]", "terseLabel": "Semma Therapeutics, Inc." } } }, "localname": "SemmaTherapeuticsInc.Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsDetails", "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "vrtx_SemmaandExonicsTherapeuticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Semma and Exonics Therapeutics [Member]", "label": "Semma and Exonics Therapeutics [Member]", "terseLabel": "Semma and Exonics Therapeutics" } } }, "localname": "SemmaandExonicsTherapeuticsMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_ShareBasedCompensationAllocationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Share-based Compensation Allocation [Abstract]", "terseLabel": "Stock-based compensation expense:" } } }, "localname": "ShareBasedCompensationAllocationAbstract", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "vrtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployeePurchasePricePercentageOfFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This element represents the percentage of the fair market value of the entity's common stock on the first day of the applicable offering period or last day of the applicable purchase period that eligible employees may purchase shares of the entity's common stock under the employee stock purchase plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Eligible Employee Purchase Price Percentage of Fair Value", "terseLabel": "Eligible employee purchase price percentage of fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployeePurchasePricePercentageOfFairValue", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeStockPurchasePlanDetails" ], "xbrltype": "percentItemType" }, "vrtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOutstandingNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Outstanding, Number", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Outstanding, Number", "terseLabel": "Awards outstanding (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOutstandingNumber", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockAndOptionPlansDetails" ], "xbrltype": "sharesItemType" }, "vrtx_ShareBasedCompensationByShareBasedPaymentAwardAwardPercentageOfTargetMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-Based Compensation By Share-Based Payment Award, Award Percentage Of Target, Maximum", "label": "Share-Based Compensation By Share-Based Payment Award, Award Percentage Of Target, Maximum", "terseLabel": "Potential awards, percent of target shares, maximum" } } }, "localname": "ShareBasedCompensationByShareBasedPaymentAwardAwardPercentageOfTargetMaximum", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "percentItemType" }, "vrtx_ShareBasedCompensationByShareBasedPaymentAwardAwardPercentageOfTargetMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-Based Compensation By Share-Based Payment Award, Award Percentage Of Target, Minimum", "label": "Share-Based Compensation By Share-Based Payment Award, Award Percentage Of Target, Minimum", "terseLabel": "Potential awards, percent of target shares, minimum" } } }, "localname": "ShareBasedCompensationByShareBasedPaymentAwardAwardPercentageOfTargetMinimum", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "percentItemType" }, "vrtx_ShareBasedCompensationByShareBasedPaymentAwardPercentofAwardsinTranche": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-Based Compensation By Share-Based Payment Award, Percent of Awards in Tranche", "label": "Share-Based Compensation By Share-Based Payment Award, Percent of Awards in Tranche", "terseLabel": "Percent of awards in tranche" } } }, "localname": "ShareBasedCompensationByShareBasedPaymentAwardPercentofAwardsinTranche", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails" ], "xbrltype": "percentItemType" }, "vrtx_ShareBasedCompensationbyShareBasedPaymentAwardPerformancePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-Based Compensation by Share-Based Payment Award, Performance Period", "label": "Share-Based Compensation by Share-Based Payment Award, Performance Period", "terseLabel": "Performance period" } } }, "localname": "ShareBasedCompensationbyShareBasedPaymentAwardPerformancePeriod", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails", "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails" ], "xbrltype": "durationItemType" }, "vrtx_ShareRepurchaseProgram2018Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share Repurchase Program 2018 [Member]", "label": "Share Repurchase Program 2018 [Member]", "terseLabel": "Share Repurchase Program 2018" } } }, "localname": "ShareRepurchaseProgram2018Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "vrtx_ShareRepurchaseProgram2019Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share Repurchase Program [Member]", "label": "Share Repurchase Program 2019 [Member]", "terseLabel": "Share Repurchase Program 2019" } } }, "localname": "ShareRepurchaseProgram2019Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "vrtx_SharebasedCompensationArrangementbySharebasedPaymentAwardDurationofPurchasePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Duration of Purchase Period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Duration of Purchase Period", "terseLabel": "Duration of purchase period" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardDurationofPurchasePeriod", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeStockPurchasePlanDetails" ], "xbrltype": "durationItemType" }, "vrtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofPurchasePeriods": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Purchase Periods", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Purchase Periods", "terseLabel": "Number of purchase periods" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofPurchasePeriods", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeStockPurchasePlanDetails" ], "xbrltype": "integerItemType" }, "vrtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOfferingPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Offering Period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Offering Period", "terseLabel": "Offering period (in months)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOfferingPeriod", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeStockPurchasePlanDetails" ], "xbrltype": "durationItemType" }, "vrtx_StockAndOptionPlan2006Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The element describes the details pertaining to the 2006 Stock and Option Plan.", "label": "Stock and Option Plan 2006 [Member]", "terseLabel": "2006 Stock and Option Plan" } } }, "localname": "StockAndOptionPlan2006Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockAndOptionPlansDetails" ], "xbrltype": "domainItemType" }, "vrtx_StockandOptionPlan2013Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock and Option Plan 2013 [Member]", "label": "Stock and Option Plan 2013 [Member]", "terseLabel": "2013 Stock and Option Plan" } } }, "localname": "StockandOptionPlan2013Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockAndOptionPlansDetails" ], "xbrltype": "domainItemType" }, "vrtx_TRIKAFTAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "TRIKAFTA [Member]", "label": "TRIKAFTA [Member]", "terseLabel": "TRIKAFTA" } } }, "localname": "TRIKAFTAMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationRevenuesByProductDetails" ], "xbrltype": "domainItemType" }, "vrtx_TaxCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Tax Carryforwards [Line Items]", "terseLabel": "Tax Carryforwards [Line Items]" } } }, "localname": "TaxCarryforwardsLineItems", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "vrtx_U.S.GovernmentSponsoredEnterprisesDebtSecuritiesDueWithinOneYearMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "U.S. Government Sponsored Enterprises Debt Securities, Due Within One Year [Member]", "label": "U.S. Government Sponsored Enterprises Debt Securities, Due Within One Year [Member]", "terseLabel": "Government-sponsored enterprise securities" } } }, "localname": "U.S.GovernmentSponsoredEnterprisesDebtSecuritiesDueWithinOneYearMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "vrtx_USTreasurySecuritiesDueWithinOneYearMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "US Treasury Securities, Due Within One Year [Member]", "label": "US Treasury Securities, Due Within One Year [Member]", "terseLabel": "U.S Treasury securities" } } }, "localname": "USTreasurySecuritiesDueWithinOneYearMember", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "vrtx_WalgreenCo.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Walgreen Co. [Member]", "label": "Walgreen Co. [Member]", "terseLabel": "Walgreen Co." } } }, "localname": "WalgreenCo.Member", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "vrtx_WeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted Average Discount Rate [Abstract]", "label": "Weighted Average Discount Rate [Abstract]", "terseLabel": "Weighted-average discount rate (in percent)" } } }, "localname": "WeightedAverageDiscountRateAbstract", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "stringItemType" }, "vrtx_WeightedAverageRemainingContractualLifeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Weighted Average, Remaining Contractual Life [Abstract]", "terseLabel": "Weighted-average Remaining Contractual Life" } } }, "localname": "WeightedAverageRemainingContractualLifeAbstract", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails" ], "xbrltype": "stringItemType" }, "vrtx_WeightedAverageRemainingLeaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted-Average Remaining Lease [Abstract]", "label": "Weighted-Average Remaining Lease [Abstract]", "terseLabel": "Weighted-average remaining lease term (in years)" } } }, "localname": "WeightedAverageRemainingLeaseAbstract", "nsuri": "http://www.vrtx.com/20191231", "presentation": [ "http://www.vrtx.com/role/LeasesWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 16 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r147": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r161": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.10-01.(b)(6))", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699" }, "r167": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e4975-111524" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5212-111524" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5093-111524" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "8B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=SL6284393-111563" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r229": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r258": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r268": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=117330312&loc=d3e23163-113944" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32059-109318" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r369": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r385": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r389": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2AA", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759068-111685" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5710-111685" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5747-111685" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r411": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998890-113959" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993" }, "r438": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=117336053&loc=SL75039408-165497" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164653&loc=d3e41551-112718" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164758&loc=d3e45014-112735" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164758&loc=d3e45023-112735" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119202524&loc=SL77919359-209981" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.3(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28)", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r541": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r542": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r543": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r544": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r545": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r546": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r547": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)(i)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-03(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585" } }, "version": "2.1" } XML 86 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-based Compensation Expense
 12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Stock-based Compensation Expense
Stock-based Compensation Expense
The Company recognizes share-based payments to employees as compensation expense using the fair value method. The fair value of stock options and shares purchased pursuant to the ESPP is calculated using the Black-Scholes option pricing model. The fair value of restricted stock and restricted stock units, including PSUs, is based on the intrinsic value on the date of grant. Stock-based compensation, measured at the grant date based on the fair value of the award, is typically recognized as expense ratably over the requisite service period.
The effect of stock-based compensation expense during the three years ended December 31, 2019 was as follows:
 
2019
 
2018
 
2017
 
(in thousands)
Stock-based compensation expense by line item:
 
 
 
 
 
Cost of sales
$
5,575

 
$
4,543

 
$
2,500

Research and development expenses
224,558

 
203,112

 
181,900

Sales, general and administrative expenses
130,356

 
117,392

 
108,836

Total stock-based compensation expense included in costs and expenses
360,489

 
325,047

 
293,236

Income tax effect
(124,225
)
 
—

 
—

Total stock-based compensation included in costs and expenses, net of tax
$
236,264

 
$
325,047

 
$
293,236


The Company maintained a valuation allowance on the majority of its NOLs and other deferred tax assets until December 31, 2018. Therefore, there was no “Income tax effect” of stock-based compensation expense for the years ended December 31, 2018 and 2017.
The stock-based compensation expense by type of award during the three years ended December 31, 2019 was as follows:
 
2019
 
2018
 
2017
 
(in thousands)
Stock-based compensation expense by type of award:
 
 
 
 
 
Restricted stock and restricted stock units (including PSUs)
$
254,276

 
$
207,845

 
$
181,258

Stock options
96,737

 
107,854

 
105,367

ESPP share issuances
11,196

 
9,933

 
9,017

Stock-based compensation expense related to inventories
(1,720
)
 
(585
)
 
(2,406
)
Total stock-based compensation expense included in costs and expenses
$
360,489

 
$
325,047

 
$
293,236


The Company capitalizes stock-based compensation expense to inventories, all of which is attributable to employees who support the Company’s manufacturing operations for the Company’s products.
The following table sets forth the Company’s unrecognized stock-based compensation expense as of December 31, 2019, by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of December 31, 2019
 
Unrecognized Expense
 
Weighted-average Recognition Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Restricted stock and restricted stock units (including PSUs)
$
374,185

 
2.05
Stock options
$
130,153

 
2.50
ESPP share issuances
$
4,724

 
0.55

Stock Options
The Company issues stock options with service conditions, which are generally the vesting periods of the awards. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. The Black-Scholes option pricing model uses the option exercise price as well as estimates and assumptions related to the expected price volatility of the Company’s stock, the rate of return on risk-free investments, the expected period during which the options will be outstanding, and the expected dividend yield for the Company’s stock to estimate the fair value of a stock option on the grant date. The options granted during 2019, 2018 and 2017 had a weighted-average grant-date fair value per share of $61.32, $60.83 and $43.27, respectively.
The fair value of each option granted during 2019, 2018 and 2017 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:
 
2019
 
2018
 
2017
Expected stock price volatility
36.99
%
 
40.50
%
 
45.31
%
Risk-free interest rate
2.32
%
 
2.61
%
 
1.94
%
Expected term of options (in years)
4.27

 
4.55

 
4.68

Expected annual dividends
—

 
—

 
—


The weighted-average valuation assumptions were determined as follows:
•
Expected stock price volatility: Expected stock price volatility is calculated using the trailing one month average of daily implied volatilities prior to the grant date. Implied volatility is based on options to purchase the Company’s stock with remaining terms of greater than one year that are regularly traded in the market.
•
Risk-free interest rate: The Company bases the risk-free interest rate on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected option term.
•
Expected term of options: The expected term of options represents the period of time options are expected to be outstanding. The Company uses historical data to estimate employee exercise and post-vest termination behavior. The Company believes that all groups of employees exhibit similar exercise and post-vest termination behavior and therefore does not stratify employees into multiple groups in determining the expected term of options.
•
Expected annual dividends: The estimate for annual dividends is $0.00 because the Company has not historically paid, and does not intend for the foreseeable future to pay, a dividend.
Restricted Stock, Restricted Stock Units and Performance-based Restricted Stock Units
The Company awards restricted stock and restricted stock units with service conditions, which are generally the vesting periods of the awards.
The Company grants PSUs to certain members of senior management. Half of the PSUs contain financial goals as the performance metric and the other half contain non-financial goals. A target number of shares is established for each award, however the actual number of shares that are issued when an award vests may range from zero to 200% of the target amount depending upon the level of achievement of the applicable performance metric. The financial-based PSUs vest in three equal installments over a three-year period and are expensed ratably over that same period based upon an assessment of the likely level of achievement. The non-financial based PSUs cliff vest at the end of the three-year performance period and are expensed on a straight-line basis over that same period based upon an assessment of the likely level of achievement.
Prior to 2017, the Company also awarded, to certain members of senior management, on an annual basis, restricted stock and restricted stock units that vested upon the earlier of the satisfaction of (i) a performance condition or (ii) a service condition.
Employee Stock Purchase Plan
The weighted-average fair value of each purchase right granted during 2019, 2018 and 2017 was $47.79, $44.04 and $35.90, respectively. The following table reflects the weighted-average assumptions used in the Black-Scholes option pricing model for 2019, 2018 and 2017:
 
2019
 
2018
 
2017
Expected stock price volatility
33.43
%
 
36.51
%
 
39.09
%
Risk-free interest rate
2.08
%
 
2.36
%
 
1.24
%
Expected term (in years)
0.74

 
0.75

 
0.75

Expected annual dividends
—

 
—

 
—


The expected stock price volatility for ESPP offerings is based on implied volatility. The Company bases the risk-free interest rate on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term. The expected term represents purchases and purchase periods that take place within the offering period. The expected annual dividends estimate is $0.00 because the Company has not historically paid, and does not for the foreseeable future intend to pay, a dividend.

XML 87 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Quarterly Financial Data (unaudited)
 12 Months Ended
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Data (unaudited)
Quarterly Financial Data (unaudited)
The following tables set forth the Company’s quarterly financial data for the two years ended December 31, 2019:
 
Three Months Ended
 
March 31,
2019
 
June 30,
2019
 
September 30,
2019
 
December 31,
2019
 
(in thousands, except per share amounts)
Revenues:
 
 
 
 
 
 
 
Product revenues, net (1)
$
857,253

 
$
940,380

 
$
949,828

 
$
1,413,265

Collaborative and royalty revenues
1,182

 
913

 
—

 
—

Total revenues
858,435

 
941,293

 
949,828

 
1,413,265

Costs and expenses:
 
 
 
 
 
 
 
Cost of sales
95,092

 
135,740

 
131,914

 
185,012

Research and development expenses (2)
339,490

 
379,091

 
555,948

 
480,011

Sales, general and administrative expenses
147,045

 
156,502

 
159,674

 
195,277

Change in fair value of contingent consideration
—

 
—

 
2,959

 
1,500

Total costs and expenses
581,627

 
671,333

 
850,495

 
861,800

Income from operations
276,808

 
269,960

 
99,333

 
551,465

Interest income
15,615

 
18,076

 
17,628

 
12,359

Interest expense
(14,868
)
 
(14,837
)
 
(14,548
)
 
(14,249
)
Other income (expense), net (3)
42,610

 
53,939

 
(31,747
)
 
127,375

Income before provision for income taxes
320,165

 
327,138

 
70,666

 
676,950

Provision for income taxes (4)
51,534

 
59,711

 
13,148

 
93,716

Net income attributable to Vertex
$
268,631

 
$
267,427

 
$
57,518

 
$
583,234

 
 
 
 
 
 
 
 
Amounts per share attributable to Vertex common shareholders:
 
 
 
 
 
 
 
Net income:
 
 
 
 
 
 
 
    Basic
$
1.05

 
$
1.04

 
$
0.22

 
$
2.26

    Diluted
$
1.03

 
$
1.03

 
$
0.22

 
$
2.23

Shares used in per share calculations:
 
 
 
 
 
 
 
    Basic
255,695

 
256,154

 
256,946

 
258,003

    Diluted
260,175

 
259,822

 
260,473

 
262,108

 
Three Months Ended
 
March 31,
2018
 
June 30,
2018
 
September 30,
2018
 
December 31,
2018
 
(in thousands, except per share amounts)
Revenues:
 
 
 
 
 
 
 
Product revenues, net
$
637,729

 
$
749,912

 
$
782,511

 
$
868,173

Collaborative and royalty revenues
3,070

 
2,245

 
2,024

 
1,933

Total revenues
640,799

 
752,157

 
784,535

 
870,106

Costs and expenses:
 
 
 
 
 
 
 
Cost of sales
71,613

 
104,382

 
111,255

 
122,289

Research and development expenses (2)
310,553

 
337,532

 
330,510

 
437,881

Sales, general and administrative expenses
129,808

 
137,303

 
137,295

 
153,210

Restructuring (income) expenses
(76
)
 
62

 
(174
)
 
4

Intangible asset impairment charge
—

 
—

 
—

 
29,000

Total costs and expenses
511,898

 
579,279

 
578,886

 
742,384

Income from operations
128,901

 
172,878

 
205,649

 
127,722

Interest income
5,789

 
8,049

 
10,543

 
13,971

Interest expense
(16,886
)
 
(18,155
)
 
(18,686
)
 
(18,744
)
Other income (expense), net (3)
96,838

 
53,819

 
(60,995
)
 
(90,452
)
Income before (benefit from) provision for income taxes
214,642

 
216,591

 
136,511

 
32,497

(Benefit from) provision for income taxes (4)
(12,659
)
 
10,341

 
8,055

 
(1,492,599
)
Net income
227,301

 
206,250

 
128,456

 
1,525,096

(Income) loss attributable to noncontrolling interest (5)
(17,038
)
 
1,110

 
290

 
25,431

Net income attributable to Vertex
$
210,263

 
$
207,360

 
$
128,746

 
$
1,550,527

 
 
 
 
 
 
 
 
Amounts per share attributable to Vertex common shareholders:
 
 
 
 
 
 
 
Net income:
 
 
 
 
 
 
 
    Basic
$
0.83

 
$
0.82

 
$
0.51

 
$
6.08

    Diluted
$
0.81

 
$
0.80

 
$
0.50

 
$
5.97

Shares used in per share calculations:
 
 
 
 
 
 
 
    Basic
253,231

 
254,135

 
254,905

 
254,868

    Diluted
258,526

 
258,584

 
259,788

 
259,812


1.
In the fourth quarter of 2019, the Company updated its transaction price and recognized net product revenues of $155.8 million related to prior period ORKAMBI sales upon reaching a reimbursement agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs. See Note A, “Nature of Business and Accounting Policies.”
2.
In the third quarter of 2019, the Company incurred research and development expenses of $175.0 million related to its CRISPR DMD/DM1 Agreement. In the fourth quarter of 2018, the Company incurred research and development expenses of $95.0 million to related license agreements with Merck KGaA, Darmstadt, Germany, and Arbor. See Note B, “Collaborative Arrangements.”
3.
In 2019 and 2018, “Other income (expense), net” was primarily related to changes in the fair value of the Company’s equity investment in CRISPR. See Note F, “Marketable Securities and Equity Investments.”
4.
In the fourth quarter of 2018, the Company released the valuation allowance on the majority of its NOLs and other deferred tax assets as of December 31, 2018 resulting in a benefit from income taxes of $1.56 billion. Starting in 2019, the Company began recording a provision for income taxes approximating statutory rates on its pre-tax income. See Note P, “Income Taxes.”
5.
In 2018, the Company had a noncontrolling interest in BioAxone, which it consolidated as a VIE until December 31, 2018. Following the deconsolidation of BioAxone as of December 31, 2018, the Company did not have a noncontrolling interest in any entities in 2019. See Note B, “Collaborative Arrangements.”
XML 88 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Nature of Business and Accounting Policies - Business Narrative (Details)
$ in Billions
 12 Months Ended
Dec. 31, 2019
USD ($)
segment
Accounting Policies [Abstract]  
Cash, cash equivalents and marketable securities | $ $ 3.8
Number of operating segments | segment 1
XML 89 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-based Compensation Expense (Tables)
 12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Stock-based compensation expense by line item
The effect of stock-based compensation expense during the three years ended December 31, 2019 was as follows:
 
2019
 
2018
 
2017
 
(in thousands)
Stock-based compensation expense by line item:
 
 
 
 
 
Cost of sales
$
5,575

 
$
4,543

 
$
2,500

Research and development expenses
224,558

 
203,112

 
181,900

Sales, general and administrative expenses
130,356

 
117,392

 
108,836

Total stock-based compensation expense included in costs and expenses
360,489

 
325,047

 
293,236

Income tax effect
(124,225
)
 
—

 
—

Total stock-based compensation included in costs and expenses, net of tax
$
236,264

 
$
325,047

 
$
293,236
Stock-based compensation expense by type of award
The stock-based compensation expense by type of award during the three years ended December 31, 2019 was as follows:
 
2019
 
2018
 
2017
 
(in thousands)
Stock-based compensation expense by type of award:
 
 
 
 
 
Restricted stock and restricted stock units (including PSUs)
$
254,276

 
$
207,845

 
$
181,258

Stock options
96,737

 
107,854

 
105,367

ESPP share issuances
11,196

 
9,933

 
9,017

Stock-based compensation expense related to inventories
(1,720
)
 
(585
)
 
(2,406
)
Total stock-based compensation expense included in costs and expenses
$
360,489

 
$
325,047

 
$
293,236
Unrecognized stock-based compensation expense, net of estimated forfeitures
The following table sets forth the Company’s unrecognized stock-based compensation expense as of December 31, 2019, by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of December 31, 2019
 
Unrecognized Expense
 
Weighted-average Recognition Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Restricted stock and restricted stock units (including PSUs)
$
374,185

 
2.05
Stock options
$
130,153

 
2.50
ESPP share issuances
$
4,724

 
0.55
Schedule of assumptions used to estimate the grant date fair value of options
The fair value of each option granted during 2019, 2018 and 2017 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:
 
2019
 
2018
 
2017
Expected stock price volatility
36.99
%
 
40.50
%
 
45.31
%
Risk-free interest rate
2.32
%
 
2.61
%
 
1.94
%
Expected term of options (in years)
4.27

 
4.55

 
4.68

Expected annual dividends
—

 
—

 
—
Schedule of assumptions used to estimate the grant date fair value employee stock purchase plan The following table reflects the weighted-average assumptions used in the Black-Scholes option pricing model for 2019, 2018 and 2017:
 
2019
 
2018
 
2017
Expected stock price volatility
33.43
%
 
36.51
%
 
39.09
%
Risk-free interest rate
2.08
%
 
2.36
%
 
1.24
%
Expected term (in years)
0.74

 
0.75

 
0.75

Expected annual dividends
—

 
—

 
—
XML 90 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 91 R91.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Jan. 01, 2019
Dec. 31, 2018
Leases [Abstract]      
Property and equipment, net $ 445,336    
Property and equipment, net     $ 640,952
Total finance lease assets 445,336    
Total finance lease assets     640,952
Capital lease obligations, current portion     9,817
Other current liabilities 38,795    
Other current liabilities     5,271
Capital lease obligations, excluding current portion     19,658
Construction financing lease obligation, excluding current portion     561,892
Long-term finance lease liabilities 538,576 $ 569,487  
Present value of lease liabilities 577,371    
Total finance lease liabilities     $ 596,638
Total operating lease assets 88,202    
Other current liabilities 11,504    
Long-term operating lease liabilities 84,292    
Present value of lease liabilities $ 95,796    
XML 92 R108.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Effective Income Tax Reconciliation (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]                      
Income (loss) before provision for (benefit from) income taxes $ 676,950 $ 70,666 $ 327,138 $ 320,165 $ 32,497 $ 136,511 $ 216,591 $ 214,642 $ 1,394,919 $ 600,241 $ (15,689)
Expected provision for (benefit from) income taxes                 292,933 126,051 (5,491)
State taxes, net of federal benefit                 8,478 8,680 4,742
Foreign income tax rate differential                 6,178 23,427 77,801
Tax credits                 (59,459) (52,629) (58,204)
Benefit from income taxes attributable to valuation allowances                 (2,672) (1,563,169) (575,801)
Permanent items                 4,822 1,421 15,324
Tax rate change                 0 0 575,192
Stock compensation (benefit) shortfalls and cancellations                 (56,324) (49,044) (21,453)
Officer’s compensation                 10,666 8,310 6,501
Deconsolidation of VIE                 0 (9,390) (126,183)
Uncertain tax positions                 14,070 15,431 0
Other                 (583) 4,050 248
Provision for (benefit from) income taxes $ 93,716 $ 13,148 $ 59,711 $ 51,534 $ (1,492,599) $ 8,055 $ 10,341 $ (12,659) $ 218,109 $ (1,486,862) $ (107,324)
EXCEL 93 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ν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end XML 94 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborative Arrangements - BioAxone Biosciences, Inc. (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2018
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Intangible asset impairment charges   $ 29,000 $ 0 $ 0 $ 0 $ 0 $ 29,000 $ 255,340
Variable Interest Entity, Primary Beneficiary | Other Intangible Assets | BioAxone Biosciences, Inc                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Intangible asset impairment charges $ 29,000           $ 29,000 $ 29,000

XML 95 R65.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborative Arrangements - Cystic Fibrosis Foundation Therapeutics Incorporated (Details) - Cystic Fibrosis Foundation Therapeutics Incorporated
 12 Months Ended
Dec. 31, 2016
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Collaborative funding $ 75,000,000.0
Additional collaborative funding $ 6,000,000.0
XML 96 R95.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Future Minimum Commitments Under Real Estate Leases (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
Operating Leased Assets [Line Items]  
2019 $ 85,071
2020 95,986
2021 94,245
2022 93,761
2023 94,071
Thereafter 575,191
Total minimum lease payments 1,038,325
Fan Pier Leases  
Operating Leased Assets [Line Items]  
2019 66,540
2020 72,589
2021 72,589
2022 72,589
2023 72,589
Thereafter 389,855
Total minimum lease payments 746,751
Other Leases  
Operating Leased Assets [Line Items]  
2019 18,531
2020 23,397
2021 21,656
2022 21,172
2023 21,482
Thereafter 185,336
Total minimum lease payments $ 291,574
XML 97 R104.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Common Stock, Preferred Stock and Equity Plans - Employee Stock Purchase Plan (Details) - ESPP share issuances
 12 Months Ended
Dec. 31, 2019
period
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Offering period (in months) 12 months
Number of purchase periods | period 2
Duration of purchase period 6 months
Eligible employee purchase price percentage of fair value 85.00%
Increase in the number of shares authorized for issuance (shares) 2,000,000
Number of shares authorized (shares) 2,199,376
Number of shares (shares) 202,693,000
Average price paid per share (usd per share) | $ / shares $ 138.18
XML 98 R99.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Common Stock, Preferred Stock and Equity Plans - Stock and Option Plans (Details) - shares
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Awards outstanding (shares) 10,229,110    
Additional awards authorized for grant (shares) 15,778,703    
2013 Stock and Option Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Awards outstanding (shares) 9,577,268    
Additional awards authorized for grant (shares) 15,778,703    
Additional shares authorized (shares) 5,000,000 8,000,000 6,750,000
2006 Stock and Option Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Awards outstanding (shares) 651,842    
Additional awards authorized for grant (shares) 0    
Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expiration period 10 years    
XML 99 R69.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions - Semma Therapeutics (Details) - USD ($)
Oct. 10, 2019
Dec. 31, 2019
Jan. 01, 2019
Dec. 31, 2018
Business Acquisition [Line Items]        
Property and equipment, net     $ 758,085,000 $ 812,005,000
Goodwill   $ 1,002,158,000   50,384,000
Intangible asset   400,000,000.0   $ 0
Semma Therapeutics, Inc.        
Business Acquisition [Line Items]        
Cash and cash equivalents $ 29,331,000      
Property and equipment, net 17,111,000      
Deferred tax liability   (54,200,000)    
Net other assets 2,849,000      
Total purchase price 936,764,000      
Semma Therapeutics, Inc.        
Business Acquisition [Line Items]        
Goodwill 554,633,000 554,600,000    
Intangible asset 387,000,000 $ 387,000,000.0    
Deferred tax liability $ (54,160,000)      
XML 100 R100.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Common Stock, Preferred Stock and Equity Plans - Outstanding and Vested Stock Options (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Stock Options      
Stock options outstanding at beginning of period (in shares) 8,551    
Stock options granted (in shares) 1,521    
Stock options exercised (in shares) (3,327)    
Stock options forfeited (in shares) (467)    
Stock options expired (in shares) (6)    
Stock options outstanding at end of period (in shares) 6,272 8,551  
Stock options exercisable at end of period (in shares) 3,333    
Weighted-average Exercise Price      
Weighted-average exercise price outstanding at beginning of period (usd per share) $ 111.46    
Weighted average exercise price, granted (usd per share) 184.50    
Weighted average exercise price, exercised (usd per share) 95.57    
Weighted average exercise price, forfeited (usd per share) 146.59    
Weighted average exercise price, expired (usd per share) 182.96    
Weighted-average exercise price outstanding at end of period (usd per share) 134.92 $ 111.46  
Weighted average exercise price exercisable at the end of the period (usd per share) $ 114.15    
Weighted-average Remaining Contractual Life      
Weighted-average Remaining Contractual Life, outstanding (in years) 7 years 1 month 13 days    
Weighted-average Remaining Contractual Life, exercisable (in years) 6 years 21 days    
Aggregate Intrinsic Value      
Aggregate intrinsic value, outstanding $ 522,740    
Aggregate intrinsic value, exercisable 346,943    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total intrinsic value of stock options exercised 325,900 $ 258,200 $ 302,800
Total cash received from employees as a result of employee stock option exercises $ 317,800 $ 263,400 $ 323,300
Weighted Average      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Market share price (usd per share) $ 218.26    
XML 101 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Shareholders' Equity and Noncontrolling Interest - USD ($)
shares in Thousands, $ in Thousands
Total
Total Vertex Shareholders' Equity
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Noncontrolling Interest
Balance (shares) at Dec. 31, 2016     248,301        
Balance at Dec. 31, 2016 $ 1,338,191 $ 1,156,582 $ 2,450 $ 6,506,795 $ 21,173 $ (5,373,836) $ 181,609
Increase (Decrease) in Stockholders' Equity              
Other comprehensive (loss) income, net of tax (32,745) (32,745)     (32,745)    
Net income (loss) 91,635 263,484       263,484 (171,849)
Issuance of common stock under benefit plans (shares)     4,952        
Issuance of common stock under benefit plans 345,673 345,616 $ 62 345,554     57
Stock-based compensation expense 295,642 295,642   295,642      
VIE noncontrolling interest upon deconsolidation 3,910           3,910
Balance (shares) at Dec. 31, 2017     253,253        
Balance at Dec. 31, 2017 2,042,306 2,028,579 $ 2,512 7,157,362 (11,572) (5,119,723) 13,727
Increase (Decrease) in Stockholders' Equity              
Other comprehensive (loss) income, net of tax 36,351 36,351     36,351    
Net income (loss) 2,087,103 2,096,896       2,096,896 (9,793)
Repurchases of common stock (shares)     (2,094)        
Repurchases of common stock (350,043) (350,043) $ (21) (350,022)      
Issuance of common stock under benefit plans (shares)     4,013        
Issuance of common stock under benefit plans 288,535 288,535 $ 55 288,480      
Stock-based compensation expense 325,656 325,656   325,656      
VIE noncontrolling interest upon deconsolidation (3,540)           (3,540)
Other VIE activity (394)           (394)
Balance (shares) at Dec. 31, 2018     255,172        
Balance at Dec. 31, 2018 4,435,203 4,435,203 $ 2,546 7,421,476 659 (2,989,478) 0
Increase (Decrease) in Stockholders' Equity              
Other comprehensive (loss) income, net of tax (2,632) (2,632)     (2,632)    
Net income (loss) 1,176,810 1,176,810       1,176,810  
Repurchases of common stock (shares)     (1,074)        
Repurchases of common stock (192,015) (192,015) $ (10) (192,005)      
Issuance of common stock under benefit plans (shares)     4,895        
Issuance of common stock under benefit plans 345,979 345,979 $ 53 345,926      
Stock-based compensation expense 362,209 362,209   362,209      
Balance (shares) at Dec. 31, 2019     258,993        
Balance at Dec. 31, 2019 $ 6,085,244 $ 6,085,244 $ 2,589 $ 7,937,606 $ (1,973) $ (1,852,978) $ 0
XML 102 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Statement of Comprehensive Income [Abstract]      
Net income $ 1,176,810 $ 2,087,103 $ 91,635
Changes in other comprehensive (loss) income:      
Unrealized holding gains on marketable securities, net of tax of zero, zero and $(2.7) million, respectively 1,039 58 6,954
Unrealized (losses) gains on foreign currency forward contracts, net of tax of $7.0 million, $(7.1) million and $3.4 million, respectively (14,003)    
Unrealized (losses) gains on foreign currency forward contracts, net of tax of $7.0 million, $(7.1) million and $3.4 million, respectively   27,438 (26,530)
Foreign currency translation adjustment 10,332 8,855 (13,169)
Total changes in other comprehensive (loss) income (2,632) 36,351 (32,745)
Comprehensive income 1,174,178 2,123,454 58,890
Comprehensive loss attributable to noncontrolling interest 0 9,793 171,849
Comprehensive income attributable to Vertex $ 1,174,178 $ 2,133,247 $ 230,739
XML 103 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 517 637 1 false 157 0 false 16 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.vrtx.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - Consolidated Statements of Operations Sheet http://www.vrtx.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 2 false false R3.htm 1002000 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Statements 3 false false R4.htm 1002001 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) Sheet http://www.vrtx.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) Statements 4 false false R5.htm 1003000 - Statement - Consolidated Balance Sheets Sheet http://www.vrtx.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 5 false false R6.htm 1003501 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 1004000 - Statement - Consolidated Statements of Shareholders' Equity and Noncontrolling Interest Sheet http://www.vrtx.com/role/ConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest Consolidated Statements of Shareholders' Equity and Noncontrolling Interest Statements 7 false false R8.htm 1006000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.vrtx.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 2101100 - Disclosure - Nature of Business and Accounting Policies Sheet http://www.vrtx.com/role/NatureOfBusinessAndAccountingPolicies Nature of Business and Accounting Policies Notes 9 false false R10.htm 2102100 - Disclosure - Collaborative Arrangements Sheet http://www.vrtx.com/role/CollaborativeArrangements Collaborative Arrangements Notes 10 false false R11.htm 2103100 - Disclosure - Acquisitions Sheet http://www.vrtx.com/role/Acquisitions Acquisitions Notes 11 false false R12.htm 2104100 - Disclosure - Earnings Per Share Sheet http://www.vrtx.com/role/EarningsPerShare Earnings Per Share Notes 12 false false R13.htm 2105100 - Disclosure - Fair Value Measurements Sheet http://www.vrtx.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 2106100 - Disclosure - Marketable Securities and Equity Investments Sheet http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestments Marketable Securities and Equity Investments Notes 14 false false R15.htm 2107100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 15 false false R16.htm 2108100 - Disclosure - Hedging Sheet http://www.vrtx.com/role/Hedging Hedging Notes 16 false false R17.htm 2110100 - Disclosure - Inventories Sheet http://www.vrtx.com/role/Inventories Inventories Notes 17 false false R18.htm 2113100 - Disclosure - Property and Equipment Sheet http://www.vrtx.com/role/PropertyAndEquipment Property and Equipment Notes 18 false false R19.htm 2114100 - Disclosure - Intangible Assets and Goodwill Sheet http://www.vrtx.com/role/IntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 19 false false R20.htm 2115100 - Disclosure - Additional Balance Sheet Detail Sheet http://www.vrtx.com/role/AdditionalBalanceSheetDetail Additional Balance Sheet Detail Notes 20 false false R21.htm 2116100 - Disclosure - Leases Sheet http://www.vrtx.com/role/Leases Leases Notes 21 false false R22.htm 2118100 - Disclosure - Common Stock, Preferred Stock and Equity Plans Sheet http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlans Common Stock, Preferred Stock and Equity Plans Notes 22 false false R23.htm 2120100 - Disclosure - Stock-based Compensation Expense Sheet http://www.vrtx.com/role/StockBasedCompensationExpense Stock-based Compensation Expense Notes 23 false false R24.htm 2121100 - Disclosure - Income Taxes Sheet http://www.vrtx.com/role/IncomeTaxes Income Taxes Notes 24 false false R25.htm 2122100 - Disclosure - Commitments and Contingencies Sheet http://www.vrtx.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 25 false false R26.htm 2123100 - Disclosure - Segment Information Sheet http://www.vrtx.com/role/SegmentInformation Segment Information Notes 26 false false R27.htm 2124100 - Disclosure - Quarterly Financial Data (unaudited) Sheet http://www.vrtx.com/role/QuarterlyFinancialDataUnaudited Quarterly Financial Data (unaudited) Notes 27 false false R28.htm 2201201 - Disclosure - Nature of Business and Accounting Policies (Policies) Sheet http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPolicies Nature of Business and Accounting Policies (Policies) Policies http://www.vrtx.com/role/NatureOfBusinessAndAccountingPolicies 28 false false R29.htm 2301302 - Disclosure - Nature of Business and Accounting Policies (Tables) Sheet http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesTables Nature of Business and Accounting Policies (Tables) Tables http://www.vrtx.com/role/NatureOfBusinessAndAccountingPolicies 29 false false R30.htm 2302301 - Disclosure - Collaborative Arrangements (Tables) Sheet http://www.vrtx.com/role/CollaborativeArrangementsTables Collaborative Arrangements (Tables) Tables http://www.vrtx.com/role/CollaborativeArrangements 30 false false R31.htm 2303301 - Disclosure - Acquisitions (Tables) Sheet http://www.vrtx.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://www.vrtx.com/role/Acquisitions 31 false false R32.htm 2304301 - Disclosure - Earnings Per Share (Tables) Sheet http://www.vrtx.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.vrtx.com/role/EarningsPerShare 32 false false R33.htm 2305301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.vrtx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.vrtx.com/role/FairValueMeasurements 33 false false R34.htm 2306301 - Disclosure - Marketable Securities and Equity Investments (Tables) Sheet http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsTables Marketable Securities and Equity Investments (Tables) Tables http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestments 34 false false R35.htm 2307301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss 35 false false R36.htm 2308301 - Disclosure - Hedging (Tables) Sheet http://www.vrtx.com/role/HedgingTables Hedging (Tables) Tables http://www.vrtx.com/role/Hedging 36 false false R37.htm 2310301 - Disclosure - Inventories (Tables) Sheet http://www.vrtx.com/role/InventoriesTables Inventories (Tables) Tables http://www.vrtx.com/role/Inventories 37 false false R38.htm 2313301 - Disclosure - Property and Equipment (Tables) Sheet http://www.vrtx.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.vrtx.com/role/PropertyAndEquipment 38 false false R39.htm 2315301 - Disclosure - Additional Balance Sheet Detail (Tables) Sheet http://www.vrtx.com/role/AdditionalBalanceSheetDetailTables Additional Balance Sheet Detail (Tables) Tables http://www.vrtx.com/role/AdditionalBalanceSheetDetail 39 false false R40.htm 2316301 - Disclosure - Leases (Tables) Sheet http://www.vrtx.com/role/LeasesTables Leases (Tables) Tables http://www.vrtx.com/role/Leases 40 false false R41.htm 2318301 - Disclosure - Common Stock, Preferred Stock and Equity Plans (Tables) Sheet http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansTables Common Stock, Preferred Stock and Equity Plans (Tables) Tables http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlans 41 false false R42.htm 2320301 - Disclosure - Stock-based Compensation Expense (Tables) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseTables Stock-based Compensation Expense (Tables) Tables http://www.vrtx.com/role/StockBasedCompensationExpense 42 false false R43.htm 2321301 - Disclosure - Income Taxes (Tables) Sheet http://www.vrtx.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.vrtx.com/role/IncomeTaxes 43 false false R44.htm 2323301 - Disclosure - Segment Information (Tables) Sheet http://www.vrtx.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.vrtx.com/role/SegmentInformation 44 false false R45.htm 2324301 - Disclosure - Quarterly Financial Data (unaudited) (Tables) Sheet http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedTables Quarterly Financial Data (unaudited) (Tables) Tables http://www.vrtx.com/role/QuarterlyFinancialDataUnaudited 45 false false R46.htm 2401403 - Disclosure - Nature of Business and Accounting Policies - Business Narrative (Details) Sheet http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesBusinessNarrativeDetails Nature of Business and Accounting Policies - Business Narrative (Details) Details 46 false false R47.htm 2401404 - Disclosure - Nature of Business and Accounting Policies - Revenue Recognition (Details) Sheet http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRevenueRecognitionDetails Nature of Business and Accounting Policies - Revenue Recognition (Details) Details 47 false false R48.htm 2401405 - Disclosure - Nature of Business and Accounting Policies - Share-Based Compensation (Details) Sheet http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesShareBasedCompensationDetails Nature of Business and Accounting Policies - Share-Based Compensation (Details) Details 48 false false R49.htm 2401406 - Disclosure - Nature of Business and Accounting Policies - Property and Equipment (Details) Sheet http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesPropertyAndEquipmentDetails Nature of Business and Accounting Policies - Property and Equipment (Details) Details 49 false false R50.htm 2401407 - Disclosure - Nature of Business and Accounting Policies - Restructuring Expenses (Details) Sheet http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesRestructuringExpensesDetails Nature of Business and Accounting Policies - Restructuring Expenses (Details) Details 50 false false R51.htm 2401408 - Disclosure - Nature of Business and Accounting Policies - Foreign Currency Gain (Loss) (Details) Sheet http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesForeignCurrencyGainLossDetails Nature of Business and Accounting Policies - Foreign Currency Gain (Loss) (Details) Details 51 false false R52.htm 2401409 - Disclosure - Nature of Business and Accounting Policies - Leases (Details) Sheet http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesLeasesDetails Nature of Business and Accounting Policies - Leases (Details) Details http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesTables 52 false false R53.htm 2401410 - Disclosure - Nature of Business and Accounting Policies - Impact of Adopted to the Condensed Consolidated Statement of Operations (Details) Sheet http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesImpactOfAdoptedToCondensedConsolidatedStatementOfOperationsDetails Nature of Business and Accounting Policies - Impact of Adopted to the Condensed Consolidated Statement of Operations (Details) Details 53 false false R54.htm 2401411 - Disclosure - Nature of Business and Accounting Policies - Equity Investments (Details) Sheet http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesEquityInvestmentsDetails Nature of Business and Accounting Policies - Equity Investments (Details) Details 54 false false R55.htm 2401412 - Disclosure - Nature of Business and Accounting Policies - Intra-Equity Transfers (Details) Sheet http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesIntraEquityTransfersDetails Nature of Business and Accounting Policies - Intra-Equity Transfers (Details) Details 55 false false R56.htm 2401413 - Disclosure - Nature of Business and Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) Sheet http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails Nature of Business and Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) Details 56 false false R57.htm 2401414 - Disclosure - Nature of Business and Accounting Policies - Stock-Based Compensation - Improvement (Details) Sheet http://www.vrtx.com/role/NatureOfBusinessAndAccountingPoliciesStockBasedCompensationImprovementDetails Nature of Business and Accounting Policies - Stock-Based Compensation - Improvement (Details) Details 57 false false R58.htm 2402402 - Disclosure - Collaborative Arrangements - CRISPR Therapeutics AG (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsCrisprTherapeuticsAgDetails Collaborative Arrangements - CRISPR Therapeutics AG (Details) Details 58 false false R59.htm 2402403 - Disclosure - Collaborative Arrangements - Kymera and Other In-License Agreements (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsKymeraAndOtherInLicenseAgreementsDetails Collaborative Arrangements - Kymera and Other In-License Agreements (Details) Details 59 false false R60.htm 2402404 - Disclosure - Collaborative Arrangements - Parion Sciences, Inc. (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails Collaborative Arrangements - Parion Sciences, Inc. (Details) Details 60 false false R61.htm 2402405 - Disclosure - Collaborative Arrangements - BioAxone Biosciences, Inc. (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsBioaxoneBiosciencesIncDetails Collaborative Arrangements - BioAxone Biosciences, Inc. (Details) Details 61 false false R62.htm 2402406 - Disclosure - Collaborative Arrangements - Aggregate VIE Financial Information (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails Collaborative Arrangements - Aggregate VIE Financial Information (Details) Details 62 false false R63.htm 2402407 - Disclosure - Collaborative Arrangements - Merck KGaA (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsMerckKgaaDetails Collaborative Arrangements - Merck KGaA (Details) Details 63 false false R64.htm 2402408 - Disclosure - Collaborative Arrangements - Janssen Pharmaceuticals, Inc. (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsJanssenPharmaceuticalsIncDetails Collaborative Arrangements - Janssen Pharmaceuticals, Inc. (Details) Details 64 false false R65.htm 2402409 - Disclosure - Collaborative Arrangements - Cystic Fibrosis Foundation Therapeutics Incorporated (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsCysticFibrosisFoundationTherapeuticsIncorporatedDetails Collaborative Arrangements - Cystic Fibrosis Foundation Therapeutics Incorporated (Details) Details 65 false false R66.htm 2403402 - Disclosure - Acquisitions - Exonics Therapeutics - Additional Information (Details) Sheet http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsAdditionalInformationDetails Acquisitions - Exonics Therapeutics - Additional Information (Details) Details 66 false false R67.htm 2403403 - Disclosure - Acquisitions - Exonics Therapeutics (Details) Sheet http://www.vrtx.com/role/AcquisitionsExonicsTherapeuticsDetails Acquisitions - Exonics Therapeutics (Details) Details 67 false false R68.htm 2403404 - Disclosure - Acquisitions - Semma Therapeutics - Additional Information (Details) Sheet http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsAdditionalInformationDetails Acquisitions - Semma Therapeutics - Additional Information (Details) Details 68 false false R69.htm 2403405 - Disclosure - Acquisitions - Semma Therapeutics (Details) Sheet http://www.vrtx.com/role/AcquisitionsSemmaTherapeuticsDetails Acquisitions - Semma Therapeutics (Details) Details 69 false false R70.htm 2403406 - Disclosure - Acquisitions - Concert Pharmaceuticals (Details) Sheet http://www.vrtx.com/role/AcquisitionsConcertPharmaceuticalsDetails Acquisitions - Concert Pharmaceuticals (Details) Details 70 false false R71.htm 2404402 - Disclosure - Earnings Per Share (Details) Sheet http://www.vrtx.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.vrtx.com/role/EarningsPerShareTables 71 false false R72.htm 2405402 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 72 false false R73.htm 2405403 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) Details 73 false false R74.htm 2405404 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsFairValueOfContingentConsiderationLiabilitiesDetails Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) Details 74 false false R75.htm 2406402 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails Marketable Securities and Equity Investments - Additional Information (Details) Details 75 false false R76.htm 2406403 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) Details 76 false false R77.htm 2406404 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesByContractualMaturityDetails Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) Details 77 false false R78.htm 2407402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables 78 false false R79.htm 2408402 - Disclosure - Hedging - Narrative (Details) Sheet http://www.vrtx.com/role/HedgingNarrativeDetails Hedging - Narrative (Details) Details 79 false false R80.htm 2408403 - Disclosure - - Notional Amount (Details) Sheet http://www.vrtx.com/role/NotionalAmountDetails - Notional Amount (Details) Details 80 false false R81.htm 2408404 - Disclosure - - Cash Flow Hedging Instruments (Details) Sheet http://www.vrtx.com/role/CashFlowHedgingInstrumentsDetails - Cash Flow Hedging Instruments (Details) Details 81 false false R82.htm 2408405 - Disclosure - Hedging - Derivative Fair Value (Details) Sheet http://www.vrtx.com/role/HedgingDerivativeFairValueDetails Hedging - Derivative Fair Value (Details) Details 82 false false R83.htm 2408406 - Disclosure - Hedging - Offsetting Derivatives (Details) Sheet http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails Hedging - Offsetting Derivatives (Details) Details 83 false false R84.htm 2410402 - Disclosure - Inventories (Details) Sheet http://www.vrtx.com/role/InventoriesDetails Inventories (Details) Details http://www.vrtx.com/role/InventoriesTables 84 false false R85.htm 2413402 - Disclosure - Property and Equipment - Property and Equipment, Net (Details) Sheet http://www.vrtx.com/role/PropertyAndEquipmentPropertyAndEquipmentNetDetails Property and Equipment - Property and Equipment, Net (Details) Details 85 false false R86.htm 2413403 - Disclosure - Property and Equipment - Narrative (Details) Sheet http://www.vrtx.com/role/PropertyAndEquipmentNarrativeDetails Property and Equipment - Narrative (Details) Details 86 false false R87.htm 2414401 - Disclosure - Intangible Assets and Goodwill (Details) Sheet http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails Intangible Assets and Goodwill (Details) Details http://www.vrtx.com/role/IntangibleAssetsAndGoodwill 87 false false R88.htm 2415402 - Disclosure - Additional Balance Sheet Detail (Details) Sheet http://www.vrtx.com/role/AdditionalBalanceSheetDetailDetails Additional Balance Sheet Detail (Details) Details http://www.vrtx.com/role/AdditionalBalanceSheetDetailTables 88 false false R89.htm 2416402 - Disclosure - Leases - Additional Information (Details) Sheet http://www.vrtx.com/role/LeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 89 false false R90.htm 2416403 - Disclosure - Leases - Components of Lease Expense (Details) Sheet http://www.vrtx.com/role/LeasesComponentsOfLeaseExpenseDetails Leases - Components of Lease Expense (Details) Details 90 false false R91.htm 2416404 - Disclosure - Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details) Sheet http://www.vrtx.com/role/LeasesBalanceSheetClassificationOfLeaseAssetsAndLiabilitiesDetails Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details) Details 91 false false R92.htm 2416405 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details) Sheet http://www.vrtx.com/role/LeasesMaturitiesOfOperatingAndFinancingLeaseLiabilitiesDetails Leases - Maturities of Operating and Financing Lease Liabilities (Details) Details 92 false false R93.htm 2416406 - Disclosure - Leases - Weighted-Average Remaining Lease Terms and Discount Rates (Details) Sheet http://www.vrtx.com/role/LeasesWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails Leases - Weighted-Average Remaining Lease Terms and Discount Rates (Details) Details 93 false false R94.htm 2416407 - Disclosure - Leases - Supplemental Cash Flow Information (Details) Sheet http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails Leases - Supplemental Cash Flow Information (Details) Details 94 false false R95.htm 2416408 - Disclosure - Leases - Future Minimum Commitments Under Real Estate Leases (Details) Sheet http://www.vrtx.com/role/LeasesFutureMinimumCommitmentsUnderRealEstateLeasesDetails Leases - Future Minimum Commitments Under Real Estate Leases (Details) Details 95 false false R96.htm 2416409 - Disclosure - Leases - Capital Leases (Details) Sheet http://www.vrtx.com/role/LeasesCapitalLeasesDetails Leases - Capital Leases (Details) Details 96 false false R97.htm 2418402 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Common Stock and Preferred Stock (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansCommonStockAndPreferredStockDetails Common Stock, Preferred Stock and Equity Plans - Common Stock and Preferred Stock (Details) Details 97 false false R98.htm 2418403 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Share Repurchase Program (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansShareRepurchaseProgramDetails Common Stock, Preferred Stock and Equity Plans - Share Repurchase Program (Details) Details 98 false false R99.htm 2418404 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Stock and Option Plans (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockAndOptionPlansDetails Common Stock, Preferred Stock and Equity Plans - Stock and Option Plans (Details) Details 99 false false R100.htm 2418405 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Outstanding and Vested Stock Options (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansOutstandingAndVestedStockOptionsDetails Common Stock, Preferred Stock and Equity Plans - Outstanding and Vested Stock Options (Details) Details 100 false false R101.htm 2418406 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Stock Options Outstanding and Exercisable (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansStockOptionsOutstandingAndExercisableDetails Common Stock, Preferred Stock and Equity Plans - Stock Options Outstanding and Exercisable (Details) Details 101 false false R102.htm 2418407 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Restricted Stock and Restricted Stock Units and PSUs (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansRestrictedStockAndRestrictedStockUnitsAndPsusDetails Common Stock, Preferred Stock and Equity Plans - Restricted Stock and Restricted Stock Units and PSUs (Details) Details 102 false false R103.htm 2418408 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Performance-based RSUs (PSUs) (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansPerformanceBasedRsusPsusDetails Common Stock, Preferred Stock and Equity Plans - Performance-based RSUs (PSUs) (Details) Details 103 false false R104.htm 2418409 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Employee Stock Purchase Plan (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeStockPurchasePlanDetails Common Stock, Preferred Stock and Equity Plans - Employee Stock Purchase Plan (Details) Details 104 false false R105.htm 2418410 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Employee Benefits (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockAndEquityPlansEmployeeBenefitsDetails Common Stock, Preferred Stock and Equity Plans - Employee Benefits (Details) Details 105 false false R106.htm 2420402 - Disclosure - Stock-based Compensation Expense - (Details) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseDetails Stock-based Compensation Expense - (Details) Details http://www.vrtx.com/role/StockBasedCompensationExpenseTables 106 false false R107.htm 2421402 - Disclosure - Income Taxes - Components of Income and Provision for (Benefit from) Income Taxes (Details) Sheet http://www.vrtx.com/role/IncomeTaxesComponentsOfIncomeAndProvisionForBenefitFromIncomeTaxesDetails Income Taxes - Components of Income and Provision for (Benefit from) Income Taxes (Details) Details 107 false false R108.htm 2421403 - Disclosure - Income Taxes - Effective Income Tax Reconciliation (Details) Sheet http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails Income Taxes - Effective Income Tax Reconciliation (Details) Details 108 false false R109.htm 2421404 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.vrtx.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 109 false false R110.htm 2421405 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details) Sheet http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails Income Taxes - Deferred Tax Assets and Liabilities (Details) Details 110 false false R111.htm 2421406 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) Sheet http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails Income Taxes - Unrecognized Tax Benefits (Details) Details 111 false false R112.htm 2422401 - Disclosure - Commitments and Contingencies - Revolving Credit Facility (Details) Sheet http://www.vrtx.com/role/CommitmentsAndContingenciesRevolvingCreditFacilityDetails Commitments and Contingencies - Revolving Credit Facility (Details) Details 112 false false R113.htm 2422402 - Disclosure - Commitments and Contingencies - Contingencies (Details) Sheet http://www.vrtx.com/role/CommitmentsAndContingenciesContingenciesDetails Commitments and Contingencies - Contingencies (Details) Details 113 false false R114.htm 2423402 - Disclosure - Segment Information - Revenues by Product (Details) Sheet http://www.vrtx.com/role/SegmentInformationRevenuesByProductDetails Segment Information - Revenues by Product (Details) Details 114 false false R115.htm 2423403 - Disclosure - Segment Information - Revenue by Geographic Location (Details) Sheet http://www.vrtx.com/role/SegmentInformationRevenueByGeographicLocationDetails Segment Information - Revenue by Geographic Location (Details) Details 115 false false R116.htm 2423404 - Disclosure - Segment Information - Significant Customers (Details) Sheet http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails Segment Information - Significant Customers (Details) Details 116 false false R117.htm 2423405 - Disclosure - Segment Information - Property and Equipment, Net by Location (Details) Sheet http://www.vrtx.com/role/SegmentInformationPropertyAndEquipmentNetByLocationDetails Segment Information - Property and Equipment, Net by Location (Details) Details 117 false false R118.htm 2424402 - Disclosure - Quarterly Financial Data (unaudited) - Quarterly Financial Data (Details) Sheet http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedQuarterlyFinancialDataDetails Quarterly Financial Data (unaudited) - Quarterly Financial Data (Details) Details http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedTables 118 false false R119.htm 2424403 - Disclosure - Quarterly Financial Data (unaudited) - Additional Information (Details) Sheet http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedAdditionalInformationDetails Quarterly Financial Data (unaudited) - Additional Information (Details) Details http://www.vrtx.com/role/QuarterlyFinancialDataUnauditedTables 119 false false R9999.htm Uncategorized Items - a201910k-main.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - a201910k-main.htm Cover 120 false false All Reports Book All Reports a201910k-main.htm a10k2019-exhibit1017.htm a10k2019-exhibit1035.htm a10k2019-exhibit211.htm a10k2019-exhibit231.htm a10k2019-exhibit311.htm a10k2019-exhibit312.htm a10k2019-exhibit321.htm a10k2019-exhibit42.htm vrtx-20191231.xsd vrtx-20191231_cal.xml vrtx-20191231_def.xml vrtx-20191231_lab.xml vrtx-20191231_pre.xml capture2.jpg chart-4a9cf4c4b68f5058a30.jpg chart-642b38eab6d652b2af8a01.jpg kalydecoa09.jpg orkambia15.jpg symdekoa05.jpg symkevikalydecolockup4ca05.jpg trikaftarlogoa02.jpg http://xbrl.sec.gov/currency/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 104 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Nature of Business and Accounting Policies - Impact of Adopted to the Condensed Consolidated Statement of Operations (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Jan. 01, 2019
Jan. 01, 2018
Jan. 01, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                            
Cumulative effect adjustment for adoption of new accounting guidance                       $ (40,310) $ 9,229 $ 0
Product revenues, net $ 1,413,265 $ 949,828 $ 941,293 $ 858,435 $ 870,106 $ 784,535 $ 752,157 $ 640,799 $ 4,162,821 $ 3,047,597 $ 2,488,652      
Cost of sales 185,012 131,914 135,740 95,092 122,289 111,255 104,382 71,613 547,758 409,539 275,119      
Income from operations 551,465 99,333 269,960 276,808 127,722 205,649 172,878 128,901 1,197,566 635,150 123,243      
Net income attributable to Vertex common shareholders $ 583,234 $ 57,518 $ 267,427 $ 268,631 $ 1,550,527 $ 128,746 $ 207,360 $ 210,263 $ 1,176,810 $ 2,096,896 $ 263,484      
Net income:                            
Basic (usd per share) $ 2.26 $ 0.22 $ 1.04 $ 1.05 $ 6.08 $ 0.51 $ 0.82 $ 0.83 $ 4.58 $ 8.24 $ 1.06      
Diluted (usd per share) $ 2.23 $ 0.22 $ 1.03 $ 1.03 $ 5.97 $ 0.50 $ 0.80 $ 0.81 $ 4.51 $ 8.09 $ 1.04      
Product                            
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                            
Product revenues, net $ 1,413,265 $ 949,828 $ 940,380 $ 857,253 $ 868,173 $ 782,511 $ 749,912 $ 637,729 $ 4,160,726 $ 3,038,325 $ 2,165,480      
Balances without Adoption of ASC 606                            
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                            
Cost of sales                   402,925        
Income from operations                   622,923        
Net income attributable to Vertex common shareholders                   $ 2,084,669        
Net income:                            
Basic (usd per share)                   $ 8.20        
Diluted (usd per share)                   $ 8.04        
Balances without Adoption of ASC 606 | Product                            
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                            
Product revenues, net                   $ 3,019,484        
Effect of Change Higher/(Lower) | Accounting Standards Update 2014-09                            
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                            
Cost of sales                   6,614        
Income from operations                   12,227        
Net income attributable to Vertex common shareholders                   $ 12,227        
Net income:                            
Basic (usd per share)                   $ 0.04        
Diluted (usd per share)                   $ 0.05        
Effect of Change Higher/(Lower) | Accounting Standards Update 2014-09 | Product                            
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                            
Product revenues, net                   $ 18,841        
Accumulated Deficit                            
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                            
Cumulative effect adjustment for adoption of new accounting guidance                       $ (40,310) 33,349 $ (9,371)
Accumulated Deficit | Accounting Standards Update 2014-09                            
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                            
Cumulative effect adjustment for adoption of new accounting guidance                         $ 8,300  
XML 105 R57.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Nature of Business and Accounting Policies - Stock-Based Compensation - Improvement (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Jan. 01, 2019
Dec. 31, 2018
Jan. 01, 2018
Jan. 01, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative effect adjustment for adoption of new accounting guidance   $ 40,310   $ (9,229) $ 0
Deferred tax assets $ 1,190,815 1,510,908 $ 1,499,672    
Accounting standards update 2016-09, excess tax benefit          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Operating loss carryforwards         410,800
Deferred tax assets         3,400
Domestic Tax Authority          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Operating loss carryforwards 1,500,000        
Domestic Tax Authority | Accounting standards update 2016-09, excess tax benefit          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Operating loss carryforwards         404,700
State and Local Jurisdiction          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Operating loss carryforwards $ 903,700        
State and Local Jurisdiction | Accounting standards update 2016-09, excess tax benefit          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Operating loss carryforwards         6,100
Accumulated Deficit          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative effect adjustment for adoption of new accounting guidance   $ 40,310   $ (33,349) 9,371
Accumulated Deficit | Accounting standards update 2016-09, forfeiture rate component          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative effect adjustment for adoption of new accounting guidance         $ 9,400
XML 106 R78.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Jan. 01, 2019
Jan. 01, 2018
Jan. 01, 2017
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]            
Balance $ 4,435,203 $ 2,042,306 $ 1,338,191      
Other comprehensive (loss) income before reclassifications 22,884 34,577 (35,390)      
Amounts reclassified from accumulated other comprehensive income (loss) (25,516) 1,774 2,645      
Total changes in other comprehensive (loss) income (2,632) 36,351 (32,745)      
Cumulative effect adjustment for adoption of new accounting guidance       $ (40,310) $ 9,229 $ 0
Balance 6,085,244 4,435,203 2,042,306      
Foreign Currency Translation Adjustment            
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]            
Balance (11,227) (21,031) (7,862)      
Other comprehensive (loss) income before reclassifications 10,332 8,855 (13,169)      
Amounts reclassified from accumulated other comprehensive income (loss) 0 0 0      
Total changes in other comprehensive (loss) income 10,332 8,855 (13,169)      
Cumulative effect adjustment for adoption of new accounting guidance         949  
Balance (895) (11,227) (21,031)      
On Available-For-Sale Debt Securities            
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]            
Balance (536) (594) (10)      
Other comprehensive (loss) income before reclassifications 1,039 58 (584)      
Amounts reclassified from accumulated other comprehensive income (loss) 0 0 0      
Total changes in other comprehensive (loss) income 1,039 58 (584)      
Cumulative effect adjustment for adoption of new accounting guidance         0  
Balance 503 (536) (594)      
On Equity Securities            
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]            
Balance 0 25,069 17,531      
Other comprehensive (loss) income before reclassifications 0 0 7,538      
Amounts reclassified from accumulated other comprehensive income (loss) 0 0 0      
Total changes in other comprehensive (loss) income 0 0 7,538      
Cumulative effect adjustment for adoption of new accounting guidance         (25,069)  
Balance 0 0 25,069      
On Foreign Currency Forward Contracts            
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]            
Balance 12,422 (15,016) 11,514      
Other comprehensive (loss) income before reclassifications   25,664 (29,175)      
Amounts reclassified from accumulated other comprehensive income (loss)   1,774 2,645      
Total changes in other comprehensive (loss) income   27,438 (26,530)      
Cumulative effect adjustment for adoption of new accounting guidance         0  
Balance   12,422 (15,016)      
On Foreign Currency Forward Contracts            
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]            
Other comprehensive (loss) income before reclassifications 11,513          
Amounts reclassified from accumulated other comprehensive income (loss) (25,516)          
Total changes in other comprehensive (loss) income (14,003)          
Balance (1,581)          
AOCI Attributable to Parent            
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]            
Balance 659 (11,572) 21,173      
Total changes in other comprehensive (loss) income (2,632) 36,351 (32,745)      
Cumulative effect adjustment for adoption of new accounting guidance         $ (24,120)  
Balance $ (1,973) $ 659 $ (11,572)      
XML 107 R111.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Balance at beginning of the period $ 19,549 $ 3,814 $ 0
Increases related to current period tax positions 14,407 9,704 3,814
Increases related to prior period tax positions 598 6,031 0
Decreases related to prior period tax positions (156) 0 0
Settlement with Tax Authorities (478) 0 0
Balance at end of period $ 33,920 $ 19,549 $ 3,814
XML 108 R88.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Additional Balance Sheet Detail (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Jan. 01, 2019
Dec. 31, 2018
Accrued expenses      
Payroll and benefits $ 159,464   $ 124,753
Research, development and commercial contract costs 105,663   115,300
Product revenue allowances 641,368   550,002
Royalty payable 98,578   101,108
Tax related accruals 72,293   43,281
Other 39,546   24,455
Total 1,116,912   958,899
Other current liabilities      
Contract liabilities 62,332   24,870
Finance lease liabilities 30,293    
Capital lease obligations     5,271
Other 37,680   20,265
Total 130,305   50,406
Other long-term liabilities      
Advance from collaborator 88,762   82,573
Operating lease liabilities 84,292    
Other 10,264   26,280
Total $ 183,318 $ 70,226 $ 108,853
XML 109 R115.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Information - Revenue by Geographic Location (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Revenues $ 1,413,265 $ 949,828 $ 941,293 $ 858,435 $ 870,106 $ 784,535 $ 752,157 $ 640,799 $ 4,162,821 $ 3,047,597 $ 2,488,652
United States                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Revenues                 3,062,555 2,365,079 1,986,786
Europe                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Revenues                 885,762 543,179 420,317
Other                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Revenues                 214,504 139,339 81,549
Total revenues outside of the United States                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Revenues                 $ 1,100,266 $ 682,518 $ 501,866
XML 110 R84.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Inventories (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Inventory Disclosure [Abstract]    
Raw materials $ 26,247 $ 9,677
Work-in-process 107,021 87,944
Finished goods 34,234 26,739
Total $ 167,502 $ 124,360
XML 111 R74.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]              
Balance at December 31, 2018       $ 0 $ 0    
Contingent consideration related to acquisition of Exonics         172,041,000    
Increase in fair value of contingent consideration $ 1,500,000 $ 2,959,000 $ 0 $ 0 4,459,000 $ 0 $ 0
Balance at December 31, 2019 176,500,000       176,500,000 0  
Intangible asset $ 400,000,000.0       $ 400,000,000.0 $ 0  
XML 112 R119.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Quarterly Financial Data (unaudited) - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Schedule of Collaborative Arrangement Agreements [Line Items]                      
Product revenues, net $ 1,413,265 $ 949,828 $ 941,293 $ 858,435 $ 870,106 $ 784,535 $ 752,157 $ 640,799 $ 4,162,821 $ 3,047,597 $ 2,488,652
Income tax (benefit) resulting in the release of valuation allowance         (1,560,000)            
ORKAMBI                      
Schedule of Collaborative Arrangement Agreements [Line Items]                      
Product revenues, net $ 155,800                    
CRISPR Therapeutics                      
Schedule of Collaborative Arrangement Agreements [Line Items]                      
Collaborative arrangement, development and commercialization rights potential maximum milestone payments   $ 175,000                  
Merck KGaA and Arbor                      
Schedule of Collaborative Arrangement Agreements [Line Items]                      
Collaborative arrangement, development and commercialization rights potential maximum milestone payments         $ 95,000            
XML 113 R70.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions - Concert Pharmaceuticals (Details) - Concert Pharmaceuticals
$ in Millions
 12 Months Ended
Dec. 31, 2017
USD ($)
Business Acquisition [Line Items]  
Collaborative arrangement, development and commercialization rights potential maximum milestone payments $ 160.0
Collaborative arrangement, additional maximum milestone payments based on regulatory approval 90.0
Collaborative funding 160.0
Collaborative arrangement, purchase price 165.1
Collaborative arrangement, transaction costs $ 5.1
XML 114 R80.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
- Notional Amount (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Derivative [Line Items]    
Derivative term 1 month  
Designated as hedging instruments | Cash Flow Hedging | Foreign currency forward contracts    
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 728,386 $ 505,218
Designated as hedging instruments | Cash Flow Hedging | Foreign currency forward contracts | Euro    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 501,197 335,179
Designated as hedging instruments | Cash Flow Hedging | Foreign currency forward contracts | Australian dollar    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 89,705 52,820
Designated as hedging instruments | Cash Flow Hedging | Foreign currency forward contracts | British pound sterling    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 87,032 73,460
Designated as hedging instruments | Cash Flow Hedging | Foreign currency forward contracts | Canadian dollar    
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 50,452 $ 43,759
XML 115 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions
 12 Months Ended
Dec. 31, 2019
Business Combinations [Abstract]  
Acquisitions
Acquisitions
Business Acquisitions
Exonics Therapeutics, Inc.
On July 16, 2019, the Company completed its acquisition of Exonics Therapeutics, Inc. (“Exonics”), a privately held biotechnology company focused on creating transformative gene-editing therapies to repair mutations that cause DMD and other severe neuromuscular diseases, including DM1. The Company acquired Exonics for an upfront payment of approximately $245.0 million, customary working capital adjustments and approximately $70.0 million in deferred payments. Exonics’ equity holders may receive an additional $728.0 million upon the successful achievement of specified development and regulatory milestones for the DMD and DM1 programs.
The Company concluded that Exonics’ intellectual property, assembled workforce and scientific expertise, has the potential to produce therapies for patients with DMD and DM1; therefore, it accounted for the acquisition as a business combination. The Company determined that the purchase price related to the Exonics business combination was $438.4 million, which consisted of (i) the upfront payment as adjusted for customary working capital adjustments, and (ii) the estimated fair value related to $678.3 million of contingent development and regulatory milestones attributable to the purchase of Exonics’ outstanding shares on July 16, 2019. The remaining portion, or $49.7 million, of the development and regulatory milestones and the $70.0 million in deferred payments were determined to be compensatory, as they relate to post-acquisition services, and will be expensed to “Research and development expenses” as incurred.
The purchase price consisted of the following:
 
(in thousands)
Upfront payment (adjusted for customary working capital adjustments)
$
266,315

Fair value of contingent development and regulatory payments
172,041

Total purchase price
$
438,356


The Company’s methodology for determining the fair value of the contingent development and regulatory payments is described in Note E, “Fair Value Measurements.”
The Company allocated the purchase price to the following assets acquired and liabilities assumed:
 
July 16, 2019
 
(in thousands)
Cash and cash equivalents
$
19,535

Goodwill
397,141

Intangible asset
13,000

Net other assets
8,680

Total purchase price
$
438,356


The “Goodwill” represents the difference between the fair value of the consideration transferred and the fair value of the assets and liabilities acquired. The goodwill was attributable to Exonics’ technological expertise, assembled workforce, the potential additional therapeutic programs that may be discovered utilizing Exonics’ DMD and DM1 programs and synergies
from combining these programs with the Company’s current gene-editing capabilities through its collaboration with CRISPR. None of the goodwill is expected to be deductible for income tax purposes. The “Intangible asset” is a single in-process research and development asset related to Exonics’ DMD and DM1 programs. The Company concluded that the intangible asset was a single asset based on similarities between the DMD and DM1 programs including (i) their pre-clinical stage of development, (ii) the development activities and technologies necessary to further develop them, which will be managed on a combined basis, (iii) anticipated pricing and (iv) patient populations. The fair value of the intangible asset was determined through a discounted cash flow analysis utilizing Level 3 fair value inputs related to the development and commercialization of therapies for DMD and DM1. As of December 31, 2019, the Company’s accounting for the Exonics business combination is complete.
Semma Therapeutics, Inc.
On October 10, 2019, the Company completed its acquisition of Semma Therapeutics, Inc. (“Semma”), a privately held biotechnology company primarily focused on the use of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes. The Company acquired Semma in exchange for a purchase price of $936.8 million.
The Company allocated the purchase price to the following assets acquired and liabilities assumed:
 
October 10, 2019
 
(in thousands)
Cash and cash equivalents
$
29,331

Property and equipment, net
17,111

Goodwill
554,633

Intangible assets
387,000

Deferred tax liability
(54,160
)
Net other assets
2,849

Total purchase price
$
936,764


The “Goodwill” represents the difference between the fair value of the consideration transferred and the fair value of the assets and liabilities acquired. The goodwill was attributable to the technological expertise in cell therapy of Semma’s assembled workforce, the potential synergies from combining Semma’s proprietary platform with the Company’s clinical development capabilities and the potential additional therapeutic programs that may be discovered utilizing Semma’s proprietary platform. None of the goodwill is expected to be deductible for income tax purposes.
The “Intangible assets” are in-process research and development assets of $379.0 million and $8.0 million related to Semma’s pre-clinical treatments for device-assisted cells and naked islets, respectively. Semma produces human pancreatic beta cells, or islets, that could potentially help type 1 diabetes patients produce appropriate levels of insulin and safely control hypoglycemia. The “naked islets treatment” is intended for a small portion of the type 1 diabetes patient population who are already receiving immunosuppression therapy and can receive the islets without their immune system destroying them. For the majority of type 1 diabetes patients, who are not receiving immunosuppression therapy, Semma is seeking to develop a “device-assisted cells treatment” alternative, which includes a novel device that is designed to encapsulate and protect the islets from the immune system. The device could potentially enable durable implantation without the need for ongoing immunosuppressive therapy.
The Company determined that device-assisted cells and the naked islets were two separate assets based on, among other things, (i) the separate type 1 diabetes patient populations expected to receive the treatments and (ii) the clinical and regulatory risks and costs associated with developing the islets versus developing and manufacturing the device.
The fair values of the intangible assets were determined through a discounted cash flow analysis utilizing Level 3 fair value inputs including (i) assumptions regarding the probability of obtaining marketing approval for the treatments;(ii) estimates regarding the timing of and the expected costs to develop and commercialize the treatments; (iii) estimates of future cash flows from potential product sales with respect to treatments; and (iv) appropriate discount and tax rates.
The Company’s “Deferred tax liability” in the table above is recorded as a reduction to “Deferred tax assets” on the Company’s consolidated balance sheet.
As of December 31, 2019, the Company’s accounting for the Exonics and Semma business combinations is complete. The Company has not provided pro forma information because the operations of Exonics and Semma did not have a material effect on its consolidated financial statements. The Company’s consolidated financial statements reflect the operations of Exonics and Semma as of December 31, 2019 and for the periods from July 16, 2019 and October 10, 2019 to December 31, 2019, respectively.
Asset Acquisition
Concert Pharmaceuticals
In 2017, the Company acquired certain CF assets including VX-561 (the “Concert Assets”) from Concert Pharmaceuticals Inc. (“Concert”) pursuant to an asset purchase agreement (the “Concert Agreement”). VX-561 is an investigational CFTR potentiator that has the potential to be used as part of combination regimens of CFTR modulators to treat CF. Pursuant to the Concert Agreement, the Company paid Concert $160.0 million in cash for the Concert Assets. If VX-561 is approved as part of a combination regimen to treat CF, Concert could receive up to an additional $90.0 million in milestones based on regulatory approval in the United States and reimbursement in the United Kingdom, Germany or France. The Company determined that substantially all of the fair value of the Concert Agreement was attributable to a single in-process research and development asset, VX-561, which did not constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development asset. Thus, the Company recorded the $160.0 million upfront payment to “Research and development expenses” in 2017. The total cost of the transaction was $165.1 million including $5.1 million of transaction costs that were recorded to “Sales, general and administrative expenses.”
XML 116 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accumulated Other Comprehensive Income (Loss)
 12 Months Ended
Dec. 31, 2019
Equity [Abstract]  
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
 
 
 
Unrealized Holding Gains (Losses), Net of Tax
 
 
 
Foreign Currency Translation Adjustment
 
On Available-For-Sale Debt Securities
 
On Equity Securities
 
On Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2016
$
(7,862
)
 
$
(10
)
 
$
17,531

 
$
11,514

 
$
21,173

Other comprehensive (loss) income before reclassifications
(13,169
)
 
(584
)
 
7,538

 
(29,175
)
 
(35,390
)
Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
—

 
2,645

 
2,645

Net current period other comprehensive (loss) income
(13,169
)
 
(584
)
 
7,538

 
(26,530
)
 
(32,745
)
Balance at December 31, 2017
$
(21,031
)
 
$
(594
)
 
$
25,069

 
$
(15,016
)
 
$
(11,572
)
Other comprehensive income before reclassifications
8,855

 
58

 
—

 
25,664

 
34,577

Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
—

 
1,774

 
1,774

Net current period other comprehensive income
8,855

 
58

 
—

 
27,438

 
36,351

Amounts reclassified to accumulated deficit pursuant to adoption of new accounting standard
949

 
—

 
(25,069
)
 
—

 
(24,120
)
Balance as of December 31, 2018
$
(11,227
)
 
$
(536
)
 
$
—

 
$
12,422

 
$
659

Other comprehensive income before reclassifications
10,332

 
1,039

 
—

 
11,513

 
22,884

Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
—

 
(25,516
)
 
(25,516
)
Net current period other comprehensive income (loss)
10,332

 
1,039

 
—

 
(14,003
)
 
(2,632
)
Balance as of December 31, 2019
$
(895
)
 
$
503

 
$
—

 
$
(1,581
)
 
$
(1,973
)
XML 117 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets and Goodwill
 12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill
Intangible Assets and Goodwill
Intangible Assets
As of December 31, 2019, the Company had $400.0 million of in-process research and development intangible assets classified as “Other assets” on its consolidated balance sheet. As of December 31, 2018, the Company had no in-process research and development intangible assets recorded on its consolidated balance sheet. In 2019, the Company recorded $387.0 million and $13.0 million of in-process research and development intangible assets related to its acquisitions of Semma and Exonics, respectively. In 2018 and 2017, the Company recorded intangible asset impairment charges of $29.0 million related to VX-210 that was licensed from BioAxone in 2014 and $255.3 million related to Parion’s pulmonary ENaC platform, respectively. Please refer to Note B, “Collaborative Arrangements,” for further information regarding the events and circumstances associated with these impairment charges.
Goodwill
As of December 31, 2019 and December 31, 2018, goodwill of $1.00 billion and $50.4 million was recorded on the Company’s consolidated balance sheet. During 2019, the Company recorded goodwill of $554.6 million and $397.1 million related to its acquisitions of Semma and Exonics, respectively.
Please refer to “Note C, “Acquisitions,” for further information on the in-process research and development intangible assets and goodwill that the Company acquired in 2019.
XML 118 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Hedging (Tables)
 12 Months Ended
Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Cash Flow Hedging Instruments
The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP:
 
As of December 31,
 
2019
 
2018
Foreign Currency
(in thousands)
Euro
$
501,197

 
$
335,179

Australian dollar
89,705

 
52,820

British pound sterling
87,032

 
73,460

Canadian dollar
50,452

 
43,759

Total foreign currency forward contracts
$
728,386

 
$
505,218
Derivative Instruments, Gain (Loss)
During the three years ended December 31, 2019, the Company recognized the following related to foreign currency forward contacts in its consolidated statements of operations:
 
December 31,
 
2019
 
2018
 
2017
 
(in thousands)
Designated as hedging instruments - Reclassified from AOCI
 
 
 
 
 
Product revenues, net
$
32,546

 
$
(1,252
)
 
$
768

Not designated as hedging instruments
 
 
 
 
 
Other income (expense), net
$
4,838

 
$
623

 
$
14,129

 
 
 
 
 
 
Total reported in the Consolidated Statement of Operations
 
 
 
 
 
Product revenues, net
$
4,160,726

 
$
3,038,325

 
$
2,165,480

Other income (expense), net
$
192,177

 
$
(790
)
 
$
(81,382
)
Schedule of Foreign Exchange Contracts
The following table summarizes the fair value of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on its consolidated balance sheets:
As of December 31, 2019
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid expenses and other current assets
 
$
9,725

 
Other current liabilities
 
$
(5,533
)
Other assets
 
—

 
Other long-term liabilities
 
(1,821
)
Total assets
 
$
9,725

 
Total liabilities
 
$
(7,354
)
As of December 31, 2018
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid expenses and other current assets
 
$
19,023

 
Other current liabilities
 
$
(340
)
Other assets
 
1,514

 
Other long-term liabilities
 
(108
)
Total assets
 
$
20,537

 
Total liabilities
 
$
(448
)
Derivatives Offsetting
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company’s consolidated balance sheets:
 
As of December 31, 2019
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
9,725

 
$
—

 
$
9,725

 
$
(7,354
)
 
$
2,371

Total liabilities
(7,354
)
 
—

 
(7,354
)
 
7,354

 
—

 
As of December 31, 2018
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
20,537

 
$
—

 
$
20,537

 
$
(448
)
 
$
20,089

Total liabilities
(448
)
 
—

 
(448
)
 
448

 
—
Derivatives Offsetting
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company’s consolidated balance sheets:
 
As of December 31, 2019
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
9,725

 
$
—

 
$
9,725

 
$
(7,354
)
 
$
2,371

Total liabilities
(7,354
)
 
—

 
(7,354
)
 
7,354

 
—

 
As of December 31, 2018
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
20,537

 
$
—

 
$
20,537

 
$
(448
)
 
$
20,089

Total liabilities
(448
)
 
—

 
(448
)
 
448

 
—
XML 119 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings Per Share (Tables)
 12 Months Ended
Dec. 31, 2019
Earnings Per Share [Abstract]  
Schedule of earning per share, basic and diluted, by common shares
The following table sets forth the computation of basic and diluted net income per share for the periods ended:
 
2019
 
2018
 
2017
 
(in thousands, except per share amounts)
Basic net income attributable to Vertex per common share calculation:
 
 
 
 
 
Net income attributable to Vertex common shareholders
$
1,176,810

 
$
2,096,896

 
$
263,484

Less: Undistributed earnings allocated to participating securities
—

 
(501
)
 
(293
)
Net income attributable to Vertex common shareholders—basic
$
1,176,810

 
$
2,096,395

 
$
263,191

 
 
 
 
 
 
Basic weighted-average common shares outstanding
256,728

 
254,292

 
248,858

Basic net income attributable to Vertex per common share
$
4.58

 
$
8.24

 
$
1.06

 
 
 
 
 
 
Diluted net income attributable to Vertex per common share calculation:
 
 
 
 
 
Net income attributable to Vertex common shareholders
$
1,176,810

 
$
2,096,896

 
$
263,484

Less: Undistributed earnings allocated to participating securities
—

 
(492
)
 
(288
)
Net income attributable to Vertex common shareholders—diluted
$
1,176,810

 
$
2,096,404

 
$
263,196

 
 
 
 
 
 
Weighted-average shares used to compute basic net income per common share
256,728

 
254,292

 
248,858

Effect of potentially dilutive securities:
 
 
 
 
 
Stock options
2,231

 
2,913

 
2,797

Restricted stock and restricted stock units (including PSUs)
1,700

 
1,963

 
1,542

Employee stock purchase program
14

 
17

 
28

Weighted-average shares used to compute diluted net income per common share
260,673

 
259,185

 
253,225

Diluted net income attributable to Vertex per common share
$
4.51

 
$
8.09

 
$
1.04
Schedule of antidilutive securities excluded from computation of earnings per share
The Company did not include the securities in the following table in the computation of the net income per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period.
 
2019
 
2018
 
2017
 
(in thousands)
Stock options
2,833

 
2,217

 
3,554

Unvested restricted stock and restricted stock units (including PSUs)
6

 
5

 
411
XML 120 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Nature of Business and Accounting Policies - Leases (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Jan. 01, 2019
Dec. 31, 2018
Jan. 01, 2018
Jan. 01, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Length of lease   15 years      
Cumulative effect adjustment for adoption of new accounting guidance   $ (40,310)   $ 9,229 $ 0
Operating lease assets $ 88,202        
Present value of lease liabilities 95,796        
Assets          
Prepaid expenses and other current assets 213,515 137,889 $ 140,819    
Property and equipment, net   758,085 812,005    
Deferred tax assets 1,190,815 1,510,908 1,499,672    
Other assets   61,674      
Total assets 8,318,465 6,261,958 6,245,898    
Liabilities and Shareholders’ Equity          
Capital lease obligations, current portion     9,817    
Other current liabilities   74,893      
Capital lease obligations, excluding current portion     19,658    
Construction financing lease obligation, excluding current portion     561,892    
Long-term finance lease liabilities 538,576 569,487      
Other long-term liabilities 183,318 70,226 108,853    
Accumulated deficit (1,852,978) (3,029,788) (2,989,478)    
Total liabilities and shareholders’ equity $ 8,318,465 6,261,958 6,245,898    
Accounting Standards Update 2016-02          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Operating lease assets   61,700      
Present value of lease liabilities   71,900      
Accumulated Deficit          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative effect adjustment for adoption of new accounting guidance   (40,310)   $ 33,349 $ (9,371)
Accumulated Deficit | Accounting Standards Update 2016-02          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative effect adjustment for adoption of new accounting guidance   40,300      
Previously Reported          
Assets          
Prepaid expenses and other current assets     140,819    
Property and equipment, net     812,005    
Deferred tax assets     1,499,672    
Total assets     6,245,898    
Liabilities and Shareholders’ Equity          
Capital lease obligations, current portion     9,817    
Other current liabilities     40,589    
Capital lease obligations, excluding current portion     19,658    
Construction financing lease obligation, excluding current portion     561,892    
Other long-term liabilities     26,280    
Accumulated deficit     (2,989,478)    
Total liabilities and shareholders’ equity     $ 6,245,898    
Adjustments | Accounting Standards Update 2016-02          
Assets          
Prepaid expenses and other current assets   (2,930)      
Property and equipment, net   (53,920)      
Deferred tax assets   11,236      
Other assets   61,674      
Total assets   16,060      
Liabilities and Shareholders’ Equity          
Capital lease obligations, current portion   (9,817)      
Other current liabilities   34,304      
Capital lease obligations, excluding current portion   (19,658)      
Construction financing lease obligation, excluding current portion   (561,892)      
Long-term finance lease liabilities   569,487      
Other long-term liabilities   43,946      
Accumulated deficit   (40,310)      
Total liabilities and shareholders’ equity   $ 16,060      
Buildings          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Property and equipment useful life 40 years        
XML 121 R56.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Nature of Business and Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Accounting Policies [Abstract]        
Cash and cash equivalents $ 3,109,322 $ 2,650,134 $ 1,665,412 $ 1,183,945
Prepaid expenses and other current assets 8,004 4,910 2,114 47,762
Other assets 3,355 3,209 0 0
Cash, cash equivalents and restricted cash per statement of cash flows $ 3,120,681 $ 2,658,253 $ 1,667,526 $ 1,231,707
XML 122 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2019
Dec. 31, 2018
Statement of Financial Position [Abstract]    
Preferred stock, par value (usd per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (shares) 1,000,000 1,000,000
Preferred stock, shares issued (shares) 0 0
Preferred stock, shares outstanding (shares) 0 0
Common stock, par value (usd per share) $ 0.01 $ 0.01
Common stock, shares authorized (shares) 500,000,000 500,000,000
Common stock, shares issued (shares) 258,993,000 255,172,000
Common stock, shares outstanding (shares) 258,993,000 255,172,000
XML 123 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenues:                      
Revenues $ 1,413,265 $ 949,828 $ 941,293 $ 858,435 $ 870,106 $ 784,535 $ 752,157 $ 640,799 $ 4,162,821 $ 3,047,597 $ 2,488,652
Costs and expenses:                      
Cost of sales 185,012 131,914 135,740 95,092 122,289 111,255 104,382 71,613 547,758 409,539 275,119
Research and development expenses 480,011 555,948 379,091 339,490 437,881 330,510 337,532 310,553 1,754,540 1,416,476 1,324,625
Sales, general and administrative expenses 195,277 159,674 156,502 147,045 153,210 137,295 137,303 129,808 658,498 557,616 496,079
Change in fair value of contingent consideration 1,500 2,959 0 0         4,459 0 0
Restructuring (income) expenses         (4) 174 (62) 76 0 (184) 14,246
Intangible asset impairment charges         29,000 0 0 0 0 29,000 255,340
Total costs and expenses 861,800 850,495 671,333 581,627 742,384 578,886 579,279 511,898 2,965,255 2,412,447 2,365,409
Income from operations 551,465 99,333 269,960 276,808 127,722 205,649 172,878 128,901 1,197,566 635,150 123,243
Interest income 12,359 17,628 18,076 15,615 13,971 10,543 8,049 5,789 63,678 38,352 11,748
Interest expense (14,249) (14,548) (14,837) (14,868) (18,744) (18,686) (18,155) (16,886) (58,502) (72,471) (69,298)
Other income (expense), net 127,375 (31,747) 53,939 42,610 (90,452) (60,995) 53,819 96,838 192,177 (790) (81,382)
Income (loss) before provision for (benefit from) income taxes 676,950 70,666 327,138 320,165 32,497 136,511 216,591 214,642 1,394,919 600,241 (15,689)
Provision for (benefit from) income taxes 93,716 13,148 59,711 51,534 (1,492,599) 8,055 10,341 (12,659) 218,109 (1,486,862) (107,324)
Net income         1,525,096 128,456 206,250 227,301 1,176,810 2,087,103 91,635
Loss attributable to noncontrolling interest         25,431 290 1,110 (17,038) 0 9,793 171,849
Net income attributable to Vertex $ 583,234 $ 57,518 $ 267,427 $ 268,631 $ 1,550,527 $ 128,746 $ 207,360 $ 210,263 $ 1,176,810 $ 2,096,896 $ 263,484
Net income:                      
Basic (usd per share) $ 2.26 $ 0.22 $ 1.04 $ 1.05 $ 6.08 $ 0.51 $ 0.82 $ 0.83 $ 4.58 $ 8.24 $ 1.06
Diluted (usd per share) $ 2.23 $ 0.22 $ 1.03 $ 1.03 $ 5.97 $ 0.50 $ 0.80 $ 0.81 $ 4.51 $ 8.09 $ 1.04
Shares used in per share calculations:                      
Basic (in shares) 258,003 256,946 256,154 255,695 254,868 254,905 254,135 253,231 256,728 254,292 248,858
Diluted (in shares) 262,108 260,473 259,822 260,175 259,812 259,788 258,584 258,526 260,673 259,185 253,225
Product revenues, net                      
Revenues:                      
Revenues $ 1,413,265 $ 949,828 $ 940,380 $ 857,253 $ 868,173 $ 782,511 $ 749,912 $ 637,729 $ 4,160,726 $ 3,038,325 $ 2,165,480
Collaborative and royalty revenues                      
Revenues:                      
Revenues $ 0 $ 0 $ 913 $ 1,182 $ 1,933 $ 2,024 $ 2,245 $ 3,070 $ 2,095 $ 9,272 $ 323,172
XML 124 R85.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment - Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Jan. 01, 2019
Dec. 31, 2018
Property, Plant and Equipment [Line Items]      
Total property and equipment, gross $ 1,437,620    
Total property and equipment, gross     $ 1,263,448
Less: accumulated depreciation (692,540)    
Less: accumulated depreciation     (451,443)
Total property and equipment, net 745,080    
Total property and equipment, net   $ 758,085 812,005
Buildings      
Property, Plant and Equipment [Line Items]      
Total property and equipment, gross 648,003    
Total property and equipment, gross     657,438
Furniture and equipment      
Property, Plant and Equipment [Line Items]      
Total property and equipment, gross 317,567    
Total property and equipment, gross     280,908
Software      
Property, Plant and Equipment [Line Items]      
Total property and equipment, gross 167,547    
Total property and equipment, gross     162,601
Leasehold improvements      
Property, Plant and Equipment [Line Items]      
Total property and equipment, gross 241,178    
Total property and equipment, gross     103,428
Computers      
Property, Plant and Equipment [Line Items]      
Total property and equipment, gross $ 63,325    
Total property and equipment, gross     $ 59,073
XML 125 R75.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Marketable Securities and Equity Investments - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Summary of cash, cash equivalents and marketable securities      
Cash $ 2,300,000,000 $ 1,400,000,000  
Other-than-temporary declines in fair value of available-for-sale debt securities 0 0 $ 0
Gross realized gains or losses 0 0 $ 0
Unrealized gains to other (expense) income, net 132,500,000 2,600,000  
CRISPR Therapeutics      
Summary of cash, cash equivalents and marketable securities      
Marketable securities, fair value, investment in common stock 282,100,000 $ 167,300,000  
Realized investment gains (losses) 65,100,000    
Other assets      
Summary of cash, cash equivalents and marketable securities      
Equity securities without readily determinable fair value, amount $ 40,800,000    
XML 126 R71.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Basic net income attributable to Vertex per common share calculation:                      
Net income attributable to Vertex common shareholders $ 583,234 $ 57,518 $ 267,427 $ 268,631 $ 1,550,527 $ 128,746 $ 207,360 $ 210,263 $ 1,176,810 $ 2,096,896 $ 263,484
Less: Undistributed earnings allocated to participating securities                 0 (501) (293)
Net income attributable to Vertex common shareholders—basic                 $ 1,176,810 $ 2,096,395 $ 263,191
Basic weighted-average common shares outstanding 258,003 256,946 256,154 255,695 254,868 254,905 254,135 253,231 256,728 254,292 248,858
Basic net income (loss) attributable to Vertex per common share (usd per share) $ 2.26 $ 0.22 $ 1.04 $ 1.05 $ 6.08 $ 0.51 $ 0.82 $ 0.83 $ 4.58 $ 8.24 $ 1.06
Diluted net income attributable to Vertex per common share calculation:                      
Less: Undistributed earnings allocated to participating securities                 $ 0 $ (492) $ (288)
Net income attributable to Vertex common shareholders—diluted                 $ 1,176,810 $ 2,096,404 $ 263,196
Employee stock purchase plan (in shares)                 14 17 28
Weighted-average shares used to compute diluted net income per common share (in shares) 262,108 260,473 259,822 260,175 259,812 259,788 258,584 258,526 260,673 259,185 253,225
Diluted net income (loss) attributable to Vertex per common share (usd per share) $ 2.23 $ 0.22 $ 1.03 $ 1.03 $ 5.97 $ 0.50 $ 0.80 $ 0.81 $ 4.51 $ 8.09 $ 1.04
Stock options                      
Diluted net income attributable to Vertex per common share calculation:                      
Share-based payment arrangements (in shares)                 2,231 2,913 2,797
Antidilutive securities excluded from computation of earnings per share (in shares)                 2,833 2,217 3,554
Unvested restricted stock and restricted stock units (including PSUs)                      
Diluted net income attributable to Vertex per common share calculation:                      
Antidilutive securities excluded from computation of earnings per share (in shares)                 6 5 411
Restricted stock and restricted stock units (including PSUs)                      
Diluted net income attributable to Vertex per common share calculation:                      
Share-based payment arrangements (in shares)                 1,700 1,963 1,542
XML 127 R118.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Quarterly Financial Data (unaudited) - Quarterly Financial Data (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenues:                      
Product revenues, net $ 1,413,265 $ 949,828 $ 941,293 $ 858,435 $ 870,106 $ 784,535 $ 752,157 $ 640,799 $ 4,162,821 $ 3,047,597 $ 2,488,652
Costs and expenses:                      
Cost of sales 185,012 131,914 135,740 95,092 122,289 111,255 104,382 71,613 547,758 409,539 275,119
Research and development expenses 480,011 555,948 379,091 339,490 437,881 330,510 337,532 310,553 1,754,540 1,416,476 1,324,625
Sales, general and administrative expenses 195,277 159,674 156,502 147,045 153,210 137,295 137,303 129,808 658,498 557,616 496,079
Increase in fair value of contingent consideration 1,500 2,959 0 0         4,459 0 0
Restructuring (income) expenses         4 (174) 62 (76) 0 184 (14,246)
Intangible asset impairment charges         29,000 0 0 0 0 29,000 255,340
Total costs and expenses 861,800 850,495 671,333 581,627 742,384 578,886 579,279 511,898 2,965,255 2,412,447 2,365,409
Income from operations 551,465 99,333 269,960 276,808 127,722 205,649 172,878 128,901 1,197,566 635,150 123,243
Interest income 12,359 17,628 18,076 15,615 13,971 10,543 8,049 5,789 63,678 38,352 11,748
Interest expense (14,249) (14,548) (14,837) (14,868) (18,744) (18,686) (18,155) (16,886) (58,502) (72,471) (69,298)
Other income (expense), net 127,375 (31,747) 53,939 42,610 (90,452) (60,995) 53,819 96,838 192,177 (790) (81,382)
Income (loss) before provision for (benefit from) income taxes 676,950 70,666 327,138 320,165 32,497 136,511 216,591 214,642 1,394,919 600,241 (15,689)
(Benefit from) provision for income taxes 93,716 13,148 59,711 51,534 (1,492,599) 8,055 10,341 (12,659) 218,109 (1,486,862) (107,324)
Net income         1,525,096 128,456 206,250 227,301 1,176,810 2,087,103 91,635
Loss attributable to noncontrolling interest         25,431 290 1,110 (17,038) 0 9,793 171,849
Net income attributable to Vertex $ 583,234 $ 57,518 $ 267,427 $ 268,631 $ 1,550,527 $ 128,746 $ 207,360 $ 210,263 $ 1,176,810 $ 2,096,896 $ 263,484
Net income:                      
Basic (usd per share) $ 2.26 $ 0.22 $ 1.04 $ 1.05 $ 6.08 $ 0.51 $ 0.82 $ 0.83 $ 4.58 $ 8.24 $ 1.06
Diluted (usd per share) $ 2.23 $ 0.22 $ 1.03 $ 1.03 $ 5.97 $ 0.50 $ 0.80 $ 0.81 $ 4.51 $ 8.09 $ 1.04
Shares used in per share calculations:                      
Basic (in shares) 258,003 256,946 256,154 255,695 254,868 254,905 254,135 253,231 256,728 254,292 248,858
Diluted (in shares) 262,108 260,473 259,822 260,175 259,812 259,788 258,584 258,526 260,673 259,185 253,225
Product revenues, net                      
Revenues:                      
Product revenues, net $ 1,413,265 $ 949,828 $ 940,380 $ 857,253 $ 868,173 $ 782,511 $ 749,912 $ 637,729 $ 4,160,726 $ 3,038,325 $ 2,165,480
Collaborative and royalty revenues                      
Revenues:                      
Product revenues, net $ 0 $ 0 $ 913 $ 1,182 $ 1,933 $ 2,024 $ 2,245 $ 3,070 $ 2,095 $ 9,272 $ 323,172
XML 128 R81.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
- Cash Flow Hedging Instruments (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Derivative Instruments, Gain (Loss) [Line Items]                      
Product revenues, net $ 1,413,265 $ 949,828 $ 941,293 $ 858,435 $ 870,106 $ 784,535 $ 752,157 $ 640,799 $ 4,162,821 $ 3,047,597 $ 2,488,652
Other income (expense), net 127,375 (31,747) 53,939 42,610 (90,452) (60,995) 53,819 96,838 192,177 (790) (81,382)
Foreign currency forward contracts | Product revenues, net | Designated as hedging instruments                      
Derivative Instruments, Gain (Loss) [Line Items]                      
Gain (loss) on derivatives designated as hedging instruments                 32,546    
Gain (loss) on cash flow hedging instruments                   (1,252) 768
Foreign currency forward contracts | Other (expense) income, net                      
Derivative Instruments, Gain (Loss) [Line Items]                      
Gain (loss) on derivatives not designated as hedging instruments                 4,838    
Foreign currency forward contracts | Other (expense) income, net | Not designated as hedging instrument                      
Derivative Instruments, Gain (Loss) [Line Items]                      
Gain (loss) on cash flow hedging instruments                   623 14,129
Product                      
Derivative Instruments, Gain (Loss) [Line Items]                      
Product revenues, net $ 1,413,265 $ 949,828 $ 940,380 $ 857,253 $ 868,173 $ 782,511 $ 749,912 $ 637,729 $ 4,160,726 $ 3,038,325 $ 2,165,480
XML 129 R110.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Deferred tax assets:    
Net operating loss $ 512,256 $ 882,014
Tax credit carryforwards 549,543 487,635
Intangible assets 275,290 241,775
Deferred revenues 18,833 19,311
Stock-based compensation 85,199 93,915
Accrued expenses 44,367 17,795
Finance lease liabilities 119,160 130,849
Operating lease assets 13,114  
Other 8,596 6,831
Gross deferred tax assets 1,626,358 1,880,125
Valuation allowance (205,192) (168,491)
Total deferred tax assets 1,421,166 1,711,634
Deferred tax liabilities:    
Property and equipment (101,235) (128,407)
Acquired intangibles (87,160) 0
Deferred revenue 0 (73,357)
Unrealized gain (28,838) (10,198)
Operating lease liabilities (13,118)  
Unrealized gain $ 1,190,815 $ 1,499,672
XML 130 R79.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Hedging - Narrative (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2019
USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Derivative term 1 month
Foreign currency forward contracts | Not designated as hedging instrument  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Derivative term 1 month
Foreign currency forward contracts | Not designated as hedging instrument | Cash Flow Hedging  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Notional amount of foreign currency forward contract $ 412.1
Minimum | Foreign currency forward contracts | Cash Flow Hedging  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Derivative term 1 month
Maximum | Foreign currency forward contracts | Cash Flow Hedging  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Derivative term 18 months
XML 131 R89.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Additional Information (Details)
ft² in Thousands, $ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
ft²
term
Dec. 31, 2011
ft²
lease
building
Jan. 01, 2019
Lessee, Lease, Description [Line Items]            
Option to extend lease term           15 years
Sublease income 2018 | $   $ 6.2        
Rental expense | $   $ 17.3 $ 19.2      
Corporate Headquarters            
Lessee, Lease, Description [Line Items]            
Number of leases | lease         2  
Area of real estate property (in square feet) | ft²         1,100  
Lease agreements number of buildings | building         2  
Option to extend lease term         15 years  
Optional term of lease agreement (in years)         10 years  
San Diego Lease            
Lessee, Lease, Description [Line Items]            
Area of real estate property (in square feet) | ft²       170    
Length of lease       16 years    
Amount of optional renewal terms | term       2    
Optional renewal term length       5 years    
Minimum            
Lessee, Lease, Description [Line Items]            
Capital leases, imputed interest rate 1.00%          
Maximum            
Lessee, Lease, Description [Line Items]            
Capital leases, imputed interest rate 6.00%          
Buildings            
Lessee, Lease, Description [Line Items]            
Property and equipment useful life 40 years          
XML 132 R114.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Information - Revenues by Product (Details)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
segment
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Segment Reporting [Abstract]                      
Number of operating segments | segment                 1    
Revenue from External Customer [Line Items]                      
Product revenues, net $ 1,413,265 $ 949,828 $ 941,293 $ 858,435 $ 870,106 $ 784,535 $ 752,157 $ 640,799 $ 4,162,821 $ 3,047,597 $ 2,488,652
TRIKAFTA                      
Revenue from External Customer [Line Items]                      
Product revenues, net                 420,105 0 0
SYMDEKO/SYMKEVI                      
Revenue from External Customer [Line Items]                      
Product revenues, net                 1,417,668 768,657 0
ORKAMBI                      
Revenue from External Customer [Line Items]                      
Product revenues, net                 1,331,891 1,262,166 1,320,850
KALYDECO                      
Revenue from External Customer [Line Items]                      
Product revenues, net                 991,062 1,007,502 844,630
Product                      
Revenue from External Customer [Line Items]                      
Product revenues, net $ 1,413,265 $ 949,828 $ 940,380 $ 857,253 $ 868,173 $ 782,511 $ 749,912 $ 637,729 $ 4,160,726 $ 3,038,325 $ 2,165,480
XML 133 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment
 12 Months Ended
Dec. 31, 2019
Property, Plant and Equipment [Abstract]  
Property and Equipment
Property and Equipment
Property and equipment, net consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Buildings
$
648,003

 
$
657,438

Furniture and equipment
317,567

 
280,908

Software
167,547

 
162,601

Leasehold improvements
241,178

 
103,428

Computers
63,325

 
59,073

Total property and equipment, gross
1,437,620

 
1,263,448

Less: accumulated depreciation
(692,540
)
 
(451,443
)
Total property and equipment, net
$
745,080

 
$
812,005


The Company recorded depreciation expense of $106.9 million, $72.4 million and $61.4 million in 2019, 2018 and 2017, respectively. The Company’s capital lease amortization is included in depreciation expense.
XML 134 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborative Arrangements
 12 Months Ended
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaborative Arrangements
Collaborative Arrangements
The Company has entered into numerous agreements pursuant to which it collaborates with third parties on research, development and commercialization programs, including in-license and out-license agreements.
In-license Agreements
The Company has entered into a number of license agreements in order to advance and obtain access to technologies and services related to its research and early-development activities. The Company is generally required to make an upfront payment upon execution of the license agreement; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from the collaboration.
Pursuant to the terms of its in-license agreements, the Company’s collaborators typically lead the discovery efforts and the Company leads all preclinical, development and commercialization activities associated with the advancement of any drug candidates and funds all expenses.
The Company typically can terminate its in-license agreements by providing advance notice to its collaborators; the required length of notice is dependent on whether any product developed under the license agreement has received marketing approval. The Company’s license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.
CRISPR Therapeutics AG
In 2015, the Company entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. The Company had the exclusive right to license certain CRISPR Cas9-based targets. In the fourth quarter of 2019, the Company paid an aggregate of $30.0 million to exclusively license three CRISPR-Cas9-based targets, including CF, pursuant to the CRISPR Agreement. The Company recorded the $30.0 million total option payment to “Research and development expenses” in the fourth quarter of 2019. For each of the three targets that the Company elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on net product sales.
In 2017, the Company entered into a co-development and co-commercialization agreement with CRISPR pursuant to the terms of the CRISPR Agreement, under which the Company and CRISPR are co-developing and will co-commercialize CTX001 (the “CTX001 Co-Co Agreement”) for the treatment of hemoglobinopathy, including treatments for sickle cell disease and beta-thalassemia. As part of the collaboration, the Company and CRISPR share equally all development costs and potential worldwide revenues related to potential hemoglobinopathy treatments, including treatments for beta-thalassemia and sickle cell disease. The Company concluded that the CTX001 Co-Co Agreement is a cost-sharing arrangement, which results in the net impact of the arrangement being recorded in “Research and development expenses” in its consolidated statements of operations. During the years ended December 31, 2019 and 2018, the net expense related to the CTX001 Co-Co Agreement was $30.1 million and $19.7 million, respectively. Net expense related to the CTX001 Co-Co Agreement during the year ended December 31, 2017 was not significant.
In July 2019, the Company entered into a separate strategic collaboration and license agreement (the “CRISPR DMD/DM1 Agreement”) with CRISPR. Pursuant to this agreement, the Company received an exclusive worldwide license to CRISPR’s existing and future intellectual property for duchenne muscular dystrophy (“DMD”) and myotonic dystrophy type 1 (“DM1”) and the Company made an upfront payment of $175.0 million to CRISPR. The Company concluded that it did not have any alternative future use for the acquired in-process research and development and recorded the upfront payment to “Research and development expenses” in the third quarter of 2019. CRISPR has the potential to receive up to $825.0 million in research, development, regulatory and commercial milestones for the DMD and DM1 programs as well as royalties on net product sales. CRISPR has the option to co-develop and co-commercialize all DM1 products globally and forego the milestones and royalties associated with the DM1 program. The Company will fund all expenses associated with the
collaboration except for research costs for specified guide RNA research conducted by CRISPR, which the Company and CRISPR will share equally.
Please refer to Note F, “Marketable Securities and Equity Investments,” for information regarding the Company’s investment in CRISPR’s common stock.
Kymera Therapeutics Inc.
In May 2019, the Company entered into a strategic research and development collaboration agreement with Kymera Therapeutics Inc. (“Kymera”) to advance small molecule protein degraders against multiple targets. Kymera’s proprietary platform technology is being applied in the collaboration activities in exchange for an upfront payment of $50.0 million. The Company has the exclusive right to license up to six protein targets, for each of which Kymera may receive up to $170.0 million in payments, including development, regulatory and commercial milestones as well as royalties on net product sales. In addition to the upfront payment, the Company purchased $20.0 million of Kymera’s preferred stock. The Company determined that the fair value of its investment in Kymera’s preferred stock, which does not have a readily determinable fair value, approximated $20.0 million and classified the investment in “Other assets.”
The Company determined that substantially all of the fair value of the Kymera collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development and recorded the $50.0 million upfront payment to “Research and development expenses.”
Other In-License Agreements
In addition to the collaborative arrangements described above, the Company has entered into additional in-license agreements that it does not consider to be individually significant to its financial statements. In addition to the payments described above, the Company recorded upfront, option and milestone payments totaling $63.3 million in 2019, $46.9 million in 2018 and $8.7 million in 2017 to “Research and development expenses,” which included a $25.9 million upfront payment to Molecular Templates, Inc. (“Molecular”) in 2019 and a $30.0 million upfront payment to Arbor Biotechnologies, Inc. (“Arbor”) in 2018.
For Molecular and Arbor and several other in-license agreements that are not individually significant to the Company’s financial statements. The Company determined that substantially all of the fair value of each individual agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development associated with the agreements and recorded the related portion of the upfront payments to “Research and development expenses.” Please refer to Note E, “Fair Value Measurements,” and Note F, “Marketable Securities and Equity Investments,” for further information regarding the Company’s investments in its collaborators.
Variable Interest Entities (VIEs)
The Company licensed rights to certain drug candidates from these third-party collaborators, which has resulted in the consolidation of the third-parties’ financial statements into the Company’s consolidated financial statements as VIEs for certain periods of time. The Company deconsolidated the financial statements of Parion as of September 30, 2017 and BioAxone as of December 31, 2018 from its consolidated financial statements. As of December 31, 2018, and continuing through 2019, the Company had no consolidated VIEs reflected in its financial statements. Please refer to Note K, “Intangible Assets and Goodwill,” for further information regarding the impairment of Parion’s pulmonary ENaC platform and BioAxone’s VX-210 program that were related to these collaborations.
Parion Sciences, Inc.
In 2015, the Company entered into a strategic collaboration and license agreement (the “Parion Agreement”) with Parion to develop investigational epithelial sodium channel (“ENaC”) inhibitors for the potential treatment of CF and all other pulmonary diseases. The Parion Agreement was terminated in January 2020.  Following execution of the Parion Agreement, the Company determined that it had a variable interest in Parion via the Parion Agreement, and that the variable interest
represented a variable interest in Parion as a whole because the fair value of the ENaC inhibitors represented more than half of the total fair value of Parion’s assets. The Company also concluded that it was the primary beneficiary as it had the power to direct the activities that most significantly affect the economic performance of Parion and that it had the obligation to absorb losses and right to receive benefits that potentially could be significant to Parion.  Accordingly, the Company consolidated Parion’s financial statements beginning in June 2015.
In the second quarter of 2017, Parion signed a license agreement with an affiliate of Shire plc related to the development of a drug candidate for the potential treatment of dry eye disease; however, the Company continued to consolidate Parion as a VIE because it determined that there was no substantive change in the design of Parion subsequent to Parion’s agreement with Shire. Based on the consolidation of Parion’s financial statements, during the year ended December 31, 2017, the Company recognized $40.0 million of collaborative revenues and (ii) a tax provision of $14.8 million, both of which were attributable to noncontrolling interest related to payments that Parion received from Shire in the year ended December 31, 2017.
As of September 30, 2017, the Company determined that the $255.3 million fair value of Parion’s pulmonary ENaC platform had declined significantly based on data received in September 2017 from a Phase 2 clinical trial of VX-371 that did not meet its primary efficacy endpoint. Based on this data, the Company evaluated the fair value of Parion’s pulmonary ENaC platform using the discounted cash flow approach from the perspective of a market participant and determined that the fair value of the intangible asset was zero as of September 30, 2017. The Company recorded a $255.3 million impairment charge in the third quarter of 2017. After evaluating the results of the clinical trial and based on the decrease in the fair value of Parion’s pulmonary ENaC platform relative to Parion’s other activities, the Company determined that it was no longer the primary beneficiary of Parion as it no longer had the power to direct the significant activities of Parion. Accordingly, the Company deconsolidated Parion as of September 30, 2017. The impairment charge, the decrease in the fair value of the contingent payments payable by the Company to Parion of $69.6 million and the benefit from income taxes of $126.2 million resulting from these charges that were recorded in the third quarter of 2017 were attributable to noncontrolling interest. The benefit from income taxes consisted of benefits of $97.7 million attributable to the impairment charge and $28.5 million attributable to the decrease in the fair value of contingent payments. The net effect of these charges and impact of the deconsolidation was a loss of $7.1 million recorded in “Other income (expense), net” attributable to Vertex in the consolidated statement of operations for the year ended December 31, 2017.
BioAxone Biosciences, Inc.
In 2014, the Company entered into a license and collaboration agreement (the “BioAxone Agreement”) with BioAxone, which resulted in the consolidation of BioAxone as a VIE beginning in October 2014.
In October 2018, the Company announced it would stop clinical development of VX-210 and terminate the Phase 2b clinical trial of VX-210 based on the recommendation of the clinical trial’s Data Safety Monitoring Board and the Company’s review of interim data. In December 2018, the Company notified BioAxone of its intent to terminate the BioAxone Agreement and executed a release that immediately allowed BioAxone to control development of its neurological programs other than VX-210 without the Company’s consent. As a result of this decision, the Company recorded a $29.0 million impairment charge related to VX-210 that was attributable to noncontrolling interest.
As a result, the Company deconsolidated BioAxone as of December 31, 2018 because it determined that it no longer was the primary beneficiary of BioAxone as it no longer had the power to direct the significant activities of BioAxone. The net impact of the deconsolidation was not material to the Company’s consolidated statement of operations.
The Company concluded that the deconsolidations of Parion and BioAxone, based on clinical data that did not meet expectations, were not developments that represented a significant strategic shift or had a material impact on the Company’s overall operations and financial results or its plans to focus on developing and commercializing therapies for the treatment of CF and advancing its research and development programs in additional diseases. Therefore, the Company did not present the results related to Parion and BioAxone as discontinued operations in its consolidated statements of operations for the three years ended December 31, 2019.
Aggregate VIE Financial Information
An aggregate summary of net loss attributable to noncontrolling interest related to the Company’s VIEs for the years ended December 31, 2018 and 2017 was as follows:
 
2018
 
2017
 
(in thousands)
Loss attributable to noncontrolling interest before benefit from income taxes and changes in fair value of contingent payments
$
31,191

 
$
223,379

Benefit from income taxes
(3,668
)
 
(114,090
)
(Increase) decrease in fair value of contingent payments
(17,730
)
 
62,560

Net loss attributable to noncontrolling interest
$
9,793

 
$
171,849


The increase in the noncontrolling interest holders’ claim to net assets with respect to the fair value of the contingent payments for the year ended December 31, 2018 was primarily due to the expiration of the Company’s option to purchase BioAxone that increased the probability that a $10.0 million license continuation fee for VX-210 would be paid. The decrease in the noncontrolling interest holders’ claim to net assets with respect to the fair value of the contingent payments for the year ended December 31, 2017 was primarily due to the decrease in the fair value of Parion’s pulmonary ENaC platform described above.
Out-license Agreements
The Company has entered into licensing agreements pursuant to which it has out-licensed rights to certain drug candidates to third-party collaborators. Pursuant to these out-license agreements, the Company’s collaborators become responsible for all costs related to the continued development of such drug candidates and obtain development and commercialization rights to these drug candidates. Depending on the terms of the agreements, the Company’s collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and may also be required to pay royalties on future sales, if any, of commercial products resulting from the collaboration. The termination provisions associated with these collaborations are generally the same as those described above related to the Company’s in-license agreements.
Merck KGaA, Darmstadt, Germany
In January 2017, the Company entered into a strategic collaboration and license agreement (the “Oncology Agreement”) with Merck KGaA, Darmstadt, Germany (the “Licensee”). Pursuant to the Oncology Agreement, the Company granted the Licensee an exclusive worldwide license to research, develop and commercialize four oncology research and development programs including two clinical-stage programs targeting DNA damage repair: its ataxia telangiectasia and Rad3-related protein kinase inhibitor program, or ATR program, including VX-970 and VX-803, and its DNA-dependent protein kinase inhibitor program, or DNA-PK program, including VX-984. In addition, the Company granted the Licensee exclusive, worldwide rights to two pre-clinical programs.
The Oncology Agreement provided for an upfront payment from the Licensee to the Company of $230.0 million. The Company evaluated the deliverables, primarily consisting of a license to the four programs and the obligation to complete certain fully-reimbursable research and development and transition activities as directed by the Licensee, pursuant to the Oncology Agreement, under the multiple element arrangement accounting guidance that was applicable in 2017. The Company concluded that the license had stand-alone value from the research and development and transition activities based on the resources and know-how possessed by the Licensee, and thus concluded that there are two units of accounting in the arrangement. The Company determined the relative selling price of the units of accounting based on the Company’s best estimate of selling price. The Company utilized key assumptions to determine the best estimate of selling price for the license, which included future potential net sales of licensed products, development timelines, reimbursement rates for personnel costs, discount rates, and estimated third-party development costs. The Company utilized a discounted cash flow model to determine its best estimate of selling price for the license and determined the best estimate of selling price for the research and development and transition activities based on what it would sell the services for separately. Given the significance of the best estimate of selling price for the license as compared to the best estimate of selling price for the
research and development and transition services, reasonable changes in the assumptions used in the discounted cash flow model would not have a significant impact on the relative selling price allocation. Based on this analysis, the Company recognized the $230.0 million upfront payment upon delivery of the license as well as research and development and transition activities during the year ended December 31, 2017. The Company records the reimbursement for the research and development and transition activities in its consolidated statements of operations as collaborative revenue primarily due to the fact that it is the primary obligor in the arrangement. The Company’s activities related to the research and development and transition activities under the Oncology Agreement were substantially complete as of December 31, 2017.
In December 2018, the Company entered into an agreement with Merck KGaA, Darmstadt, Germany (the “DNA-PK Agreement”) whereby the Company licensed the two lead Vertex DNA-PK compounds from its DNA-PK program for use in the field of gene integration for six specific indications. In exchange for this exclusive worldwide license to research, develop and commercialize the DNA-PK program for the specified indications within the field of gene integration, the Company made an upfront payment of $65.0 million. Merck KGaA, Darmstadt, Germany has the potential to receive additional milestones, primarily related to approval and reimbursement in various markets, as well as royalties on net product sales.
The Company evaluated the DNA-PK Agreement and concluded it represents a modification of the Oncology Agreement pursuant to ASC 606. As of December 2018, when the Company entered into the DNA-PK Agreement, the Company had completed its obligations under the Oncology Agreement, but the Oncology Agreement was an open contract pursuant to ASC 606 since the Company could receive future royalty payments from the commercialization of the licensed programs under the Oncology Agreement.
In applying ASC 606, the Company determined that the license granted under the DNA-PK Agreement is distinct from the license granted by the Company under the Oncology Agreement since the license to the two lead Vertex DNA-PK compounds is capable of being distinct as the Company is able to benefit from the license via its ability to internally develop and commercialize the two lead Vertex DNA-PK compounds in the six named indications in the field of gene-editing, and the license is not dependent on Merck KGaA, Darmstadt, Germany providing any specialized services to the Company. In addition, the license to the two lead Vertex DNA-PK compounds granted to the Company under the DNA-PK Agreement is distinct from the license granted by the Company under the Oncology Agreement as the rights conveyed in the licenses differ and both parties have the ability to commercially benefit from the licenses on their own. Furthermore, the consideration attributable to the license of the two lead Vertex DNA-PK compounds represents fair value. Therefore, the Company determined it should account for the DNA-PK Agreement as a separate agreement.
The Company determined that substantially all of the fair value of the DNA-PK Agreement was attributable to a single in-process research and development asset that did not constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development and recorded the $65.0 million payment to “Research and development expenses” accordingly.
Janssen Pharmaceuticals, Inc.
In 2014, the Company entered into an agreement with Janssen Pharmaceuticals, Inc. (“Janssen”). Pursuant to the agreement, Janssen has an exclusive worldwide license to develop and commercialize certain drug candidates for the treatment of influenza, including pimodivir. The Company recognized a $25.0 million milestone in 2017, based on a Phase 3 clinical trial that Janssen initiated.
Cystic Fibrosis Foundation
The Company has a research, development and commercialization agreement that was originally entered into in 2004 with Cystic Fibrosis Foundation (“CFF”), as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc. This agreement was most recently amended in 2016 (the “2016 Amendment”). Pursuant to the agreement, as amended, the Company agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor, and tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor). For combination products, such as ORKAMBI,
SYMDEKO/SYMKEVI and TRIKAFTA (elexacaftor, tezacaftor, and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product.
Pursuant to the 2016 Amendment, the Company received an upfront payment of $75.0 million and is receiving development funding from CFF of up to $6.0 million annually. The Company concluded that the upfront payment plus any future development funding represent a form of financing pursuant to ASC 730 and thus records the amounts as a liability on the consolidated balance sheet, primarily reflected in “Other long-term liabilities.” The Company reduces this liability over the estimated royalty term of the agreement and reflects the reductions as an offset to “Cost of sales” and as “Interest expense.”
XML 135 a201910k-main_htm.xml IDEA: XBRL DOCUMENT 0000875320 2019-01-01 2019-12-31 0000875320 2020-01-31 0000875320 2019-06-28 0000875320 2017-01-01 2017-12-31 0000875320 2018-01-01 2018-12-31 0000875320 us-gaap:ProductMember 2019-01-01 2019-12-31 0000875320 us-gaap:ProductMember 2018-01-01 2018-12-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2017-01-01 2017-12-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2019-01-01 2019-12-31 0000875320 us-gaap:ProductMember 2017-01-01 2017-12-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2018-01-01 2018-12-31 0000875320 2018-12-31 0000875320 2019-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000875320 us-gaap:CommonStockMember 2016-12-31 0000875320 us-gaap:CommonStockMember 2017-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 0000875320 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-12-31 0000875320 us-gaap:ParentMember 2018-01-01 2018-12-31 0000875320 us-gaap:ParentMember 2019-01-01 2019-12-31 0000875320 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000875320 us-gaap:ParentMember 2017-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000875320 us-gaap:ParentMember 2017-01-01 2017-12-31 0000875320 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000875320 us-gaap:ParentMember 2019-01-01 0000875320 us-gaap:NoncontrollingInterestMember 2017-12-31 0000875320 2016-12-31 0000875320 us-gaap:CommonStockMember 2019-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000875320 us-gaap:RetainedEarningsMember 2018-12-31 0000875320 2017-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000875320 us-gaap:ParentMember 2018-12-31 0000875320 us-gaap:NoncontrollingInterestMember 2018-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000875320 us-gaap:NoncontrollingInterestMember 2016-12-31 0000875320 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000875320 us-gaap:ParentMember 2019-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000875320 us-gaap:RetainedEarningsMember 2019-12-31 0000875320 us-gaap:CommonStockMember 2018-12-31 0000875320 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-12-31 0000875320 us-gaap:RetainedEarningsMember 2016-12-31 0000875320 2018-01-01 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 0000875320 us-gaap:RetainedEarningsMember 2017-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000875320 2017-01-01 0000875320 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000875320 2019-01-01 0000875320 us-gaap:ParentMember 2016-12-31 0000875320 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000875320 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000875320 us-gaap:ParentMember 2018-01-01 0000875320 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000875320 us-gaap:RetainedEarningsMember 2019-01-01 0000875320 us-gaap:NoncontrollingInterestMember 2019-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000875320 us-gaap:RetainedEarningsMember 2017-01-01 0000875320 us-gaap:RetainedEarningsMember 2018-01-01 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000875320 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0000875320 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0000875320 us-gaap:ProductMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0000875320 us-gaap:ProductMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0000875320 srt:RestatementAdjustmentMember us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000875320 srt:ScenarioPreviouslyReportedMember 2018-12-31 0000875320 vrtx:AccountingStandardsUpdate201609ForfeitureRateComponentMember us-gaap:RetainedEarningsMember 2017-01-01 0000875320 vrtx:AccountingStandardsUpdate201609ExcessTaxBenefitMember us-gaap:StateAndLocalJurisdictionMember 2017-01-01 0000875320 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000875320 vrtx:AccountingStandardsUpdate201609ExcessTaxBenefitMember 2017-01-01 0000875320 us-gaap:BuildingMember 2019-01-01 2019-12-31 0000875320 vrtx:ORKAMBIMember 2019-10-01 2019-12-31 0000875320 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-01-01 0000875320 vrtx:ResearchandDevelopmentRestructuringMember 2019-01-01 2019-12-31 0000875320 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0000875320 vrtx:AccountingStandardsUpdate201609ExcessTaxBenefitMember us-gaap:DomesticCountryMember 2017-01-01 0000875320 vrtx:AccountingStandardsUpdate201601FinancialInstrumentsMember us-gaap:RetainedEarningsMember 2018-01-01 0000875320 us-gaap:AccountingStandardsUpdate201601Member us-gaap:RetainedEarningsMember 2018-01-01 0000875320 us-gaap:AccountingStandardsUpdate201616Member 2018-01-01 0000875320 us-gaap:AccountingStandardsUpdate201602Member us-gaap:RetainedEarningsMember 2019-01-01 0000875320 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0000875320 srt:MaximumMember vrtx:ComputersAndSoftwareMember 2019-01-01 2019-12-31 0000875320 srt:MinimumMember vrtx:ComputersAndSoftwareMember 2019-01-01 2019-12-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2017-01-01 2017-12-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2018-01-01 2018-12-31 0000875320 vrtx:ParionSciencesInc.Member 2017-07-01 2017-09-30 0000875320 vrtx:KymeraTherapeuticsMember 2019-05-01 2019-05-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2017-01-01 2017-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-07-01 2019-07-31 0000875320 vrtx:MerckKGaAMember 2017-01-01 2017-01-31 0000875320 us-gaap:OtherIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesInc.Member 2018-12-01 2018-12-31 0000875320 vrtx:BioAxoneBiosciencesInc.Member 2018-01-01 2018-12-31 0000875320 vrtx:ArborBiotechnologiesInc.Member 2018-01-01 2018-12-31 0000875320 vrtx:MolecularTemplatesIncMember 2019-01-01 2019-12-31 0000875320 vrtx:JanssenPharmaceuticalsInc.Member 2017-01-01 2017-12-31 0000875320 vrtx:MerckKGaAMember 2017-01-01 2017-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-07-01 2019-09-30 0000875320 us-gaap:OtherIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2017-07-01 2017-09-30 0000875320 vrtx:CTX001CoCoAgreementMember 2018-01-01 2018-12-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2017-09-30 0000875320 vrtx:CTX001CoCoAgreementMember 2019-01-01 2019-12-31 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedMember 2016-01-01 2016-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-01-01 2019-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-10-01 2019-12-31 0000875320 vrtx:ParionSciencesInc.Member 2017-01-01 2017-12-31 0000875320 vrtx:MerckKGaAMember 2018-12-01 2018-12-31 0000875320 us-gaap:OtherIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2017-09-30 0000875320 vrtx:ExonicsTherapeuticsMember 2019-07-16 2019-07-16 0000875320 vrtx:SemmaTherapeuticsInc.Member 2019-10-10 2019-10-10 0000875320 vrtx:ConcertPharmaceuticalsMember 2017-01-01 2017-12-31 0000875320 vrtx:ExonicsTherapeuticsMember vrtx:CompensatoryMember 2019-07-16 2019-07-16 0000875320 vrtx:NakedIsletsMember vrtx:SemmaTherapeuticsInc.Member 2019-10-10 0000875320 vrtx:PreClinicalTreatmentsForDeviceAssistedCellsMember vrtx:SemmaTherapeuticsInc.Member 2019-10-10 0000875320 vrtx:ExonicsTherapeuticsMember vrtx:NonCompensatoryMember 2019-07-16 2019-07-16 0000875320 vrtx:SemmaTherapeuticsInc.Member 2019-10-10 0000875320 vrtx:SemmaTherapeuticsInc.Member 2019-10-10 0000875320 vrtx:ExonicsTherapeuticsMember 2019-07-16 0000875320 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000875320 vrtx:RestrictedStockandRestrictedStockUnitsMember 2017-01-01 2017-12-31 0000875320 vrtx:RestrictedStockandRestrictedStockUnitsMember 2018-01-01 2018-12-31 0000875320 vrtx:RestrictedStockandRestrictedStockUnitsMember 2019-01-01 2019-12-31 0000875320 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000875320 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0000875320 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0000875320 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0000875320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0000875320 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0000875320 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000875320 vrtx:CommercialPaperNotIncludedwithCashandCashEquivalentsDueWithinOneYearMember 2018-12-31 0000875320 us-gaap:CashEquivalentsMember 2018-12-31 0000875320 vrtx:CommercialPaperNotIncludedwithCashandCashEquivalentsDueWithinOneYearMember 2019-12-31 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-31 0000875320 us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:CommercialPaperMember 2018-12-31 0000875320 us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 vrtx:U.S.GovernmentSponsoredEnterprisesDebtSecuritiesDueWithinOneYearMember 2019-12-31 0000875320 vrtx:U.S.GovernmentSponsoredEnterprisesDebtSecuritiesDueWithinOneYearMember 2018-12-31 0000875320 us-gaap:AvailableforsaleSecuritiesMember 2018-12-31 0000875320 us-gaap:AvailableforsaleSecuritiesMember 2019-12-31 0000875320 vrtx:USTreasurySecuritiesDueWithinOneYearMember 2018-12-31 0000875320 vrtx:CashAndMoneyMarketFundsMember 2019-12-31 0000875320 us-gaap:EquitySecuritiesMember 2019-01-01 2019-12-31 0000875320 vrtx:CorporateDebtSecuritiesDueWithinOneYearMember 2018-12-31 0000875320 us-gaap:EquitySecuritiesMember 2018-12-31 0000875320 us-gaap:CashEquivalentsMember 2019-12-31 0000875320 vrtx:CashAndMoneyMarketFundsMember 2018-12-31 0000875320 us-gaap:USTreasurySecuritiesMember 2018-12-31 0000875320 vrtx:CorporateDebtSecuritiesDueWithinOneYearMember 2019-12-31 0000875320 us-gaap:EquitySecuritiesMember 2018-01-01 2018-12-31 0000875320 us-gaap:OtherAssetsMember 2019-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2018-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-01-01 2019-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-12-31 0000875320 vrtx:AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember 2019-01-01 2019-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000875320 vrtx:AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember 2019-12-31 0000875320 vrtx:AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember 2017-01-01 2017-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000875320 vrtx:AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember 2016-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-12-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-01-01 2017-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-12-31 0000875320 vrtx:AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember 2018-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000875320 vrtx:AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember 2018-01-01 2018-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000875320 vrtx:AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember 2018-01-01 0000875320 vrtx:AccumulatedNetEquityInvestmentGainLossAttributabletoParentMember 2017-12-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-12-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:RevenueFromContractWithCustomerMember 2017-01-01 2017-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:RevenueFromContractWithCustomerMember 2019-01-01 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:RevenueFromContractWithCustomerMember 2018-01-01 2018-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:NondesignatedMember 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-01-01 2019-12-31 0000875320 srt:MaximumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember 2018-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000875320 us-gaap:ForeignExchangeForwardMember 2019-12-31 0000875320 srt:MinimumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-12-31 0000875320 us-gaap:LeaseholdImprovementsMember 2018-12-31 0000875320 us-gaap:LeaseholdImprovementsMember 2019-12-31 0000875320 us-gaap:BuildingMember 2018-12-31 0000875320 us-gaap:BuildingMember 2019-12-31 0000875320 us-gaap:FurnitureAndFixturesMember 2019-12-31 0000875320 us-gaap:ComputerEquipmentMember 2019-12-31 0000875320 us-gaap:ComputerEquipmentMember 2018-12-31 0000875320 us-gaap:ComputerSoftwareIntangibleAssetMember 2018-12-31 0000875320 us-gaap:FurnitureAndFixturesMember 2018-12-31 0000875320 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-12-31 0000875320 us-gaap:OtherIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2017-01-01 2017-12-31 0000875320 vrtx:ExonicsTherapeuticsMember 2019-12-31 0000875320 vrtx:SemmaTherapeuticsInc.Member 2019-12-31 0000875320 us-gaap:OtherIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesInc.Member 2018-01-01 2018-12-31 0000875320 us-gaap:OtherIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesInc.Member 2017-01-01 2017-12-31 0000875320 vrtx:FanPierLeasesMember 2018-12-31 0000875320 vrtx:OtherOperatingLeasesMember 2018-12-31 0000875320 srt:MinimumMember 2019-01-01 2019-12-31 0000875320 vrtx:FanPierLeasesMember 2011-01-01 2011-12-31 0000875320 vrtx:SanDiegoLeaseMember 2015-12-31 0000875320 vrtx:FanPierLeasesMember 2011-12-31 0000875320 srt:MaximumMember 2019-01-01 2019-12-31 0000875320 vrtx:SanDiegoLeaseMember 2015-01-01 2015-12-31 0000875320 vrtx:SemmaandExonicsTherapeuticsMember 2019-01-01 2019-12-31 0000875320 vrtx:StockAndOptionPlan2006Member 2019-12-31 0000875320 vrtx:StockandOptionPlan2013Member 2019-12-31 0000875320 vrtx:ShareRepurchaseProgram2018Member 2018-01-01 2018-12-31 0000875320 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0000875320 vrtx:ShareRepurchaseProgram2019Member 2019-01-01 2019-12-31 0000875320 us-gaap:PerformanceSharesMember 2017-01-01 2017-12-31 0000875320 vrtx:ShareRepurchaseProgram2019Member 2019-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0000875320 us-gaap:PerformanceSharesMember 2019-01-01 2019-12-31 0000875320 vrtx:ShareRepurchaseProgram2018Member 2019-01-01 2019-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0000875320 vrtx:StockandOptionPlan2013Member 2018-01-01 2018-12-31 0000875320 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-01 2019-12-31 0000875320 vrtx:StockandOptionPlan2013Member 2019-01-01 2019-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2019-12-31 0000875320 vrtx:ShareRepurchaseProgram2019Member 2019-07-31 0000875320 vrtx:ShareRepurchaseProgram2018Member 2019-06-30 0000875320 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000875320 us-gaap:PerformanceSharesMember 2018-01-01 2018-12-31 0000875320 srt:WeightedAverageMember 2019-12-31 0000875320 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0000875320 vrtx:ShareRepurchaseProgram2018Member 2018-12-31 0000875320 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-01 2019-12-31 0000875320 vrtx:StockandOptionPlan2013Member 2017-01-01 2017-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars160.01toDollars180.00Member 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars140.01toDollars160.0Member 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars29.07toDollars40.00Member 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars120.01toDollars140.0Member 2019-12-31 0000875320 vrtx:ExercisePriceRangefromDollars40.01toDollars60.00Member 2019-12-31 0000875320 vrtx:ExercisePriceRangefromDollars100.01toDollars120.00Member 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars160.01toDollars180.00Member 2019-01-01 2019-12-31 0000875320 vrtx:ExercisePriceRangefromDollars80.01toDollars100.00Member 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars180.01toDollars189.38Member 2019-12-31 0000875320 vrtx:ExercisePriceRangefromDollars40.01toDollars60.00Member 2019-01-01 2019-12-31 0000875320 vrtx:ExercisePriceRangefromDollars60.01toDollars80.00Member 2019-01-01 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars29.07toDollars40.00Member 2019-01-01 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars120.01toDollars140.0Member 2019-01-01 2019-12-31 0000875320 vrtx:ExercisePriceRangefromDollars60.01toDollars80.00Member 2019-12-31 0000875320 vrtx:ExercisePriceRangefromDollars100.01toDollars120.00Member 2019-01-01 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars180.01toDollars189.38Member 2019-01-01 2019-12-31 0000875320 vrtx:ExercisePriceRangefromDollars80.01toDollars100.00Member 2019-01-01 2019-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars140.01toDollars160.0Member 2019-01-01 2019-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0000875320 us-gaap:RestrictedStockMember 2018-12-31 0000875320 us-gaap:RestrictedStockMember 2019-12-31 0000875320 us-gaap:PerformanceSharesMember 2019-12-31 0000875320 us-gaap:PerformanceSharesMember 2018-12-31 0000875320 vrtx:FinancialPerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-01 2019-12-31 0000875320 vrtx:FinancialPerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-01 2019-12-31 0000875320 vrtx:FinancialPerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2019-01-01 2019-12-31 0000875320 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0000875320 us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0000875320 us-gaap:EmployeeStockMember 2017-01-01 2017-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2017-01-01 2017-12-31 0000875320 us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0000875320 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0000875320 us-gaap:CostOfSalesMember 2017-01-01 2017-12-31 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2018-01-01 2018-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2017-01-01 2017-12-31 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2018-01-01 2018-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2017-01-01 2017-12-31 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2019-01-01 2019-12-31 0000875320 us-gaap:StockOptionMember 2019-01-01 2019-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2019-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2019-12-31 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2019-12-31 0000875320 vrtx:NonFinancialPerformanceSharesMember 2019-01-01 2019-12-31 0000875320 vrtx:FinancialPerformanceSharesMember 2019-01-01 2019-12-31 0000875320 us-gaap:ForeignCountryMember 2019-12-31 0000875320 vrtx:DomesticandForeignTaxAuthorityMember 2019-12-31 0000875320 us-gaap:DomesticCountryMember 2019-12-31 0000875320 2018-10-01 2018-12-31 0000875320 vrtx:SemmaTherapeuticsInc.Member 2019-12-31 0000875320 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2019-12-31 0000875320 vrtx:DeferredTaxAssetsMember 2019-12-31 0000875320 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0000875320 srt:MinimumMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember 2019-09-30 0000875320 srt:MinimumMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2019-09-30 0000875320 us-gaap:LineOfCreditMember 2019-09-30 0000875320 srt:MinimumMember us-gaap:LineOfCreditMember 2019-09-01 2019-09-30 0000875320 us-gaap:LetterOfCreditMember 2019-09-30 0000875320 us-gaap:LineOfCreditMember 2019-09-01 2019-09-30 0000875320 srt:MaximumMember us-gaap:LineOfCreditMember 2019-09-01 2019-09-30 0000875320 srt:MaximumMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember 2019-09-30 0000875320 srt:MaximumMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2019-09-30 0000875320 vrtx:WalgreenCo.Member us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0000875320 vrtx:AccredoCurascriptMember us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0000875320 vrtx:McKessonCorporationMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0000875320 vrtx:AccredoCurascriptMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0000875320 vrtx:AccredoCurascriptMember us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2017-01-01 2017-12-31 0000875320 vrtx:McKessonCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0000875320 vrtx:WalgreenCo.Member us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2017-01-01 2017-12-31 0000875320 vrtx:WalgreenCo.Member us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0000875320 vrtx:WalgreenCo.Member us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0000875320 vrtx:AccredoCurascriptMember us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0000875320 vrtx:McKessonCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2017-01-01 2017-12-31 0000875320 vrtx:McKessonCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0000875320 vrtx:McKessonCorporationMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0000875320 vrtx:AccredoCurascriptMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0000875320 vrtx:WalgreenCo.Member us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0000875320 vrtx:OtherCountriesOutsideoftheUnitedStatesandEuropeMember 2018-01-01 2018-12-31 0000875320 vrtx:OutsidetheUnitedStatesMember 2018-01-01 2018-12-31 0000875320 vrtx:OutsidetheUnitedStatesMember 2019-01-01 2019-12-31 0000875320 vrtx:OtherCountriesOutsideoftheUnitedStatesandEuropeMember 2017-01-01 2017-12-31 0000875320 country:US 2018-01-01 2018-12-31 0000875320 country:US 2019-01-01 2019-12-31 0000875320 srt:EuropeMember 2018-01-01 2018-12-31 0000875320 vrtx:OutsidetheUnitedStatesMember 2017-01-01 2017-12-31 0000875320 vrtx:OtherCountriesOutsideoftheUnitedStatesandEuropeMember 2019-01-01 2019-12-31 0000875320 srt:EuropeMember 2017-01-01 2017-12-31 0000875320 country:US 2017-01-01 2017-12-31 0000875320 srt:EuropeMember 2019-01-01 2019-12-31 0000875320 vrtx:OtherCountriesOutsideoftheUnitedStatesandtheUnitedKingdomMember 2018-12-31 0000875320 vrtx:OutsidetheUnitedStatesMember 2018-12-31 0000875320 vrtx:OtherCountriesOutsideoftheUnitedStatesandtheUnitedKingdomMember 2019-12-31 0000875320 country:US 2018-12-31 0000875320 country:GB 2019-12-31 0000875320 vrtx:OutsidetheUnitedStatesMember 2019-12-31 0000875320 country:GB 2018-12-31 0000875320 country:US 2019-12-31 0000875320 vrtx:KalydecoMember 2018-01-01 2018-12-31 0000875320 vrtx:SYMDEKOSYMKEVIMember 2017-01-01 2017-12-31 0000875320 vrtx:SYMDEKOSYMKEVIMember 2019-01-01 2019-12-31 0000875320 vrtx:KalydecoMember 2017-01-01 2017-12-31 0000875320 vrtx:SYMDEKOSYMKEVIMember 2018-01-01 2018-12-31 0000875320 vrtx:KalydecoMember 2019-01-01 2019-12-31 0000875320 vrtx:ORKAMBIMember 2017-01-01 2017-12-31 0000875320 vrtx:ORKAMBIMember 2018-01-01 2018-12-31 0000875320 vrtx:TRIKAFTAMember 2017-01-01 2017-12-31 0000875320 vrtx:ORKAMBIMember 2019-01-01 2019-12-31 0000875320 vrtx:TRIKAFTAMember 2019-01-01 2019-12-31 0000875320 vrtx:TRIKAFTAMember 2018-01-01 2018-12-31 0000875320 vrtx:MerckKGaAandArborBiotechnologiesInc.Member 2018-10-01 2018-12-31 0000875320 2019-01-01 2019-03-31 0000875320 2019-07-01 2019-09-30 0000875320 2019-04-01 2019-06-30 0000875320 2019-10-01 2019-12-31 0000875320 us-gaap:ProductMember 2019-10-01 2019-12-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2019-04-01 2019-06-30 0000875320 vrtx:CollaborativeandRoyaltyMember 2019-07-01 2019-09-30 0000875320 us-gaap:ProductMember 2019-07-01 2019-09-30 0000875320 us-gaap:ProductMember 2019-04-01 2019-06-30 0000875320 us-gaap:ProductMember 2019-01-01 2019-03-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2019-10-01 2019-12-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2019-01-01 2019-03-31 0000875320 2018-04-01 2018-06-30 0000875320 2018-07-01 2018-09-30 0000875320 2018-01-01 2018-03-31 0000875320 us-gaap:ProductMember 2018-04-01 2018-06-30 0000875320 vrtx:CollaborativeandRoyaltyMember 2018-07-01 2018-09-30 0000875320 vrtx:CollaborativeandRoyaltyMember 2018-01-01 2018-03-31 0000875320 us-gaap:ProductMember 2018-01-01 2018-03-31 0000875320 us-gaap:ProductMember 2018-10-01 2018-12-31 0000875320 us-gaap:ProductMember 2018-07-01 2018-09-30 0000875320 vrtx:CollaborativeandRoyaltyMember 2018-04-01 2018-06-30 0000875320 vrtx:CollaborativeandRoyaltyMember 2018-10-01 2018-12-31 shares vrtx:pre-clinical_stage_program iso4217:USD shares vrtx:segment iso4217:USD vrtx:clinical-stage_program pure vrtx:development_program vrtx:position vrtx:target vrtx:vote vrtx:lease utreg:sqft vrtx:term vrtx:period vrtx:building false --12-31 FY 2019 0000875320 VERTEX PHARMACEUTICALS INC / MA 0.01 0.01 500000000 255172000 258993000 255172000 258993000 P1M P1M 29000000 0 0 0 7000000 3400000 -7100000 -2700000 0 0 0.01 0.01 1000000 0 0 0 0 0 0 P5Y P7Y P3Y 33700000 P3Y P3Y P3Y P3Y 120.01 140.01 160.01 180.01 29.07 100.01 40.01 60.01 80.01 140.00 160.00 180.00 189.38 40 120.00 60 80 100 0.3333 0.3333 0.3333 0.0 P5Y P1Y P3Y P6M P12M 10-K true 2019-12-31 false 000-19319 MA 50 Northern Avenue Boston MA 04-3039129 02210 617 341-6100 Common Stock, $0.01 Par Value Per Share VRTX NASDAQ Yes No Yes Yes Large Accelerated Filer false false false 46700000000 259268593 <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Portions of the definitive proxy statement for the 2020 Annual Meeting of Shareholders, which we expect to hold on June 3, 2020, are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></div> 4160726000 3038325000 2165480000 2095000 9272000 323172000 4162821000 3047597000 2488652000 547758000 409539000 275119000 1754540000 1416476000 1324625000 658498000 557616000 496079000 4459000 0 0 0 -184000 14246000 0 29000000 255340000 2965255000 2412447000 2365409000 1197566000 635150000 123243000 63678000 38352000 11748000 58502000 72471000 69298000 192177000 -790000 -81382000 1394919000 600241000 -15689000 218109000 -1486862000 -107324000 1176810000 2087103000 91635000 0 -9793000 -171849000 1176810000 2096896000 263484000 4.58 8.24 1.06 4.51 8.09 1.04 256728000 254292000 248858000 260673000 259185000 253225000 1176810000 2087103000 91635000 1039000 58000 6954000 -14003000 27438000 -26530000 10332000 8855000 -13169000 -2632000 36351000 -32745000 1174178000 2123454000 58890000 0 -9793000 -171849000 1174178000 2133247000 230739000 3109322000 2650134000 698972000 518108000 633518000 409688000 167502000 124360000 213515000 140819000 4822829000 3843109000 745080000 812005000 1002158000 50384000 400000000 0 1190815000 1499672000 157583000 40728000 8318465000 6245898000 87610000 110987000 1116912000 958899000 130305000 50406000 1334827000 1120292000 538576000 581550000 176500000 0 183318000 108853000 2233221000 1810695000 0 0 0 0 2589000 2546000 7937606000 7421476000 -1973000 659000 -1852978000 -2989478000 6085244000 4435203000 8318465000 6245898000 248301000 2450000 6506795000 21173000 -5373836000 1156582000 181609000 1338191000 9371000 -9371000 0 -32745000 -32745000 -32745000 263484000 263484000 -171849000 91635000 4952000 62000 345554000 345616000 57000 345673000 295642000 295642000 295642000 3910000 3910000 253253000 2512000 7157362000 -11572000 -5119723000 2028579000 13727000 2042306000 -24120000 33349000 9229000 9229000 36351000 36351000 36351000 2096896000 2096896000 -9793000 2087103000 2094000 21000 350022000 350043000 350043000 4013000 55000 288480000 288535000 288535000 325656000 325656000 325656000 -3540000 -3540000 394000 394000 255172000 2546000 7421476000 659000 -2989478000 4435203000 0 4435203000 -40310000 -40310000 -40310000 -2632000 -2632000 -2632000 1176810000 1176810000 1176810000 1074000 10000 192005000 192015000 192015000 4895000 53000 345926000 345979000 345979000 362209000 362209000 362209000 258993000 2589000 7937606000 -1973000 -1852978000 6085244000 0 6085244000 1176810000 2087103000 91635000 360489000 325047000 293236000 106941000 72420000 61397000 167387000 -1512325000 -120513000 197597000 2558000 0 4459000 0 0 0 29000000 255340000 0 0 160000000 0 -1077000 -76644000 -16942000 -32502000 -14439000 225587000 108152000 71759000 64047000 31965000 47484000 -35440000 -16684000 111063000 -22785000 36554000 8753000 172881000 302755000 255178000 37997000 22144000 -20861000 1569330000 1270286000 844942000 1154212000 0 0 537196000 431918000 532581000 475924000 431576000 369214000 94936000 0 0 75451000 95524000 99421000 39319000 83471000 0 0 15000000 0 7896000 61602000 0 0 160000000 0 -75000 -1061000 -1235318000 -202158000 -483329000 343244000 289293000 344840000 192015000 350043000 0 39185000 12500000 7500000 12500000 10046000 20840000 34666000 5866000 5027000 4266000 0 33388000 19336000 0 0 300000000 -1951000 -394000 0 126773000 -71219000 68404000 1643000 -6182000 5802000 462428000 990727000 435819000 2658253000 1667526000 1231707000 3120681000 2658253000 1667526000 55554000 66458000 68696000 24730000 12402000 6414000 0 3389000 40855000 2820000 86000 844000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of Business and Accounting Policies</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Business</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vertex Pharmaceuticals Incorporated (“Vertex” or the “Company”) invests in scientific innovation to create transformative medicines for serious diseases. The Company’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (“CF”) and advancing research and development programs in other indications. The Company’s marketed products are TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor), which are approved to treat patients with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (“CFTR”) gene.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had cash, cash equivalents and marketable securities of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.8 billion</span></span><span style="font-family:inherit;font-size:10pt;">. The Company expects that cash flows from the sales of its products, together with the Company’s cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is subject to risks common to companies in its industry including, but not limited to, the dependence on revenues from its CF products, competition, uncertainty about clinical trial outcomes and regulatory approvals, uncertainties relating to pharmaceutical pricing and reimbursement, uncertainty related to international expansion, uncertain protection of proprietary technology, the need to comply with government regulations, share price volatility, dependence on collaborative relationships and potential product liability.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (“VIEs”). In 2017, the Company deconsolidated Parion Sciences, Inc. (“Parion”), a VIE the Company had consolidated since 2015. In </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company deconsolidated BioAxone Biosciences, Inc. (“BioAxone”), a VIE the Company had consolidated since 2014. As of December 31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018, the Company did not have any consolidated VIEs. All material intercompany balances and transactions have been eliminated. The Company operates in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> segment, pharmaceuticals. Please refer to </span><span style="font-size:10pt;">Note R, </span><span style="font-size:10pt;">“</span><span style="font-size:10pt;">Segment Information,</span><span style="font-size:10pt;">”</span><span style="font-family:inherit;font-size:10pt;"> for enterprise-wide disclosures regarding the Company’s revenues, major customers and long-lived assets by geographic area. The Company has reclassified certain items from the prior year’s consolidated financial statements to conform to the current year’s presentation.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these consolidated financial statements have been made in connection with (i) determining the transaction price of revenues, (ii) accounting for acquisitions, including intangible assets, goodwill and contingent consideration and (iii) evaluating deferred tax asset valuation allowances and the provision for income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to Accounting Standards Codification (“ASC”) 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers </span><span style="font-family:inherit;font-size:10pt;">(“</span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;">”), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that it transfers to the customer. Once a contract is determined to be within the scope of </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;"> at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon delivery. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product Revenues, Net</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sells its products principally to a limited number of specialty pharmacy and specialty distributors in the United States, which account for the largest portion of its total revenues, and makes international sales primarily to specialty distributors and retail chains, as well as hospitals and clinics, many of which are government-owned or supported (collectively, its “Customers”). The Company’s Customers in the United States subsequently resell the products to patients and health care providers. In accordance with </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;">, the Company recognizes net product revenues from sales when the Customers obtain control of the Company’s products, which typically occurs upon delivery to the Customer. The Company’s payment terms are approximately 30 days in the United States and consistent with prevailing practice in international markets. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues from product sales are recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from (a) invoice discounts for prompt payment and distribution fees, (b) government and private payor rebates, chargebacks, discounts and fees and (c) costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves are classified as reductions to “</span><span style="font-size:10pt;">Accounts receivable, net</span><span style="font-family:inherit;font-size:10pt;">” if payable to a Customer or “</span><span style="font-size:10pt;">Accrued expenses</span><span style="font-family:inherit;font-size:10pt;">” if payable to a third-party.  Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns.  The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.  Actual amounts of consideration ultimately received may differ from the Company’s estimates.  If actual results vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Invoice Discounts and Distribution Fees: </span><span style="font-family:inherit;font-size:10pt;">The Company generally provides invoice discounts on product sales to its Customers for prompt payment and pays fees for distribution services, such as fees for certain data that Customers provide to the Company. The Company estimates that, based on its experience, its Customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Rebates, Chargebacks, Discounts and Fees: </span><span style="font-family:inherit;font-size:10pt;">The Company contracts with government agencies (its “Third-party Payors”) so that products will be eligible for purchase by, or partial or full reimbursement from, such Third-party Payors. The Company estimates the rebates, chargebacks, discounts and fees it will provide to Third-party Payors and deducts </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">these estimated amounts from its gross product revenues at the time the revenues are recognized. For each product, the Company estimates the aggregate rebates, chargebacks and discounts that it will provide to Third-party Payors based upon (i) the Company’s contracts with these Third-party Payors, (ii) the government-mandated discounts and fees applicable to government-funded programs, (iii) information obtained from the Company’s Customers and other third-party data regarding the payor mix for such product and (iv) historical experience.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Incentives: </span><span style="font-family:inherit;font-size:10pt;">Other incentives that the Company offers include co-pay mitigation rebates provided by the Company to commercially insured patients who have coverage and who reside in states that permit co-pay mitigation programs. Based upon the terms of the Company’s co-pay mitigation programs, the Company estimates average co-pay mitigation amounts for each of its products in order to establish appropriate accruals.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company makes significant estimates and judgments that materially affect its recognition of net product revenues. The Company adjusts its estimated rebates, chargebacks and discounts based on new information, including information regarding actual rebates, chargebacks and discounts for its products, as it becomes available. Claims by third-party payors for rebates, chargebacks and discounts frequently are submitted to the Company significantly after the related sales, potentially resulting in adjustments in the period in which the new information becomes known. The Company’s credits to product revenue related to prior period sales have not been significant and primarily related to rebates and discounts. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company excludes taxes collected from Customers relating to product sales and remitted to governmental authorities from revenues. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Contract Liabilities</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded contract liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$62.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$24.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement the Company can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees.  The Company defers a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “</span><span style="font-size:10pt;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;">.” The deferred amount is recognized as revenue when the free products are shipped. The Company’s product revenue contracts include performance obligations that are one year or less.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as the Company’s fiscal year. In these markets the Company recognizes revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$24.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of revenues that were recorded as contract liabilities at the beginning of the year. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;background-color:#ffffff;font-style:normal;font-weight:normal;text-decoration:underline;">French Early Access Programs</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to ASC 605, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition </span><span style="font-family:inherit;font-size:10pt;">(“</span><span style="font-family:inherit;font-size:10pt;">ASC 605</span><span style="font-family:inherit;font-size:10pt;">”), which was applicable until December 31, 2017, the Company only recognized revenues from product sales if it determined that the price was fixed or determinable at the time of delivery. If the Company determined that the price was not fixed or determinable, it deferred the recognition of revenues. If the Company was able to determine that the price was fixed or determinable, it recognized the net product revenues associated with the units. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2015, the Company began distributing ORKAMBI through early access programs in France and remained engaged in reimbursement discussions with the French government until November 2019, when the Company reached an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs. From the time the Company began distributing ORKAMBI through early access programs in France, it expected the difference between the amounts collected based on the invoiced amount and the final amount for ORKAMBI distributed through early access programs would be returned to the French government. As a result, the Company has classified a refund liability related to the early access programs in France within “Accrued expenses” on its consolidated balance sheets. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the revenue recognition accounting guidance that was applicable until December 31, 2017, the Company’s ORKAMBI net product revenues for 2015, 2016 and 2017 did not include any net product revenues from sales of ORKAMBI in France because the price was not fixed or determinable at the time of delivery. Upon adopting </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;"> in 2018, the Company recorded an </span><span style="font-family:inherit;font-size:10pt;"><span>$8.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> cumulative effect adjustment to “</span><span style="font-size:10pt;">Accumulated deficit</span><span style="font-family:inherit;font-size:10pt;">” primarily related to shipments of ORKAMBI under the early access programs in France. The Company determined the amount of the adjustment based upon (i) the status of reimbursement discussions in France upon adoption, (ii) its estimate of the amount of consideration it expected to retain related to ORKAMBI sales in France that occurred on or prior to December 31, 2017 that would not be subject to a significant reversal in amounts recognized and (iii) recognition of costs previously deferred related to the ORKAMBI sales in France. Please refer to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements </span><span style="font-family:inherit;font-size:10pt;">included in this </span><span style="font-family:inherit;font-size:10pt;">Note A, “Nature of Business and Accounting Policies,”</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">below for more information regarding the revenue recognition guidance adopted as of January 1, 2018. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For ORKAMBI sales in France that occurred after December 31, 2017 under the early access programs, the Company recognized net product revenues based on a transaction price that reflected the Company’s estimate of consideration it expected to retain that would not be subject to a significant reversal in amounts recognized. When determining if variable consideration should be constrained, the Company considers whether there are factors outside its control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. The Company recognized ORKAMBI net product revenues from sales in France based on this estimate from the first quarter of 2018 through the third quarter of 2019. Upon reaching an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs in November 2019, the Company updated the transaction price to reflect the final amount for ORKAMBI distributed through early access programs. As a result, the Company recognized net product revenues of </span><span style="font-family:inherit;font-size:10pt;"><span>$155.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to prior period ORKAMBI early access program sales in the fourth quarter of 2019 because the updated transaction price for ORKAMBI distributed through these programs exceeded the Company’s previous estimate of the consideration it expected to retain that would not be subject to a significant reversal in amounts recognized. Additionally, the Company’s refund liability no longer requires estimation as of December 31, 2019 and will be paid to the French government in 2020. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaborative and Royalty Revenues</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms of these agreements typically include payment to the Company related to one or more of the following: nonrefundable, upfront license fees; development and commercial milestones; funding of research and/or development activities; and royalties on net sales of licensed products. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaborator.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For each collaborative research, development and/or commercialization agreement that results in revenue, the Company identifies all material performance obligations, which may include a license to intellectual property and know-how, research and development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimate of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. In order to account for these agreements, the Company must develop assumptions that require judgment to determine the standalone selling price, which may include (i) the probability of obtaining marketing approval for the drug candidate, (ii) estimates regarding the timing of and the expected costs to develop and commercialize the drug candidate, (iii) estimates of future cash flows from potential product sales with respect to the drug candidate and (iv) appropriate discount and tax rates. Standalone selling prices used to perform the initial allocation are not updated after contract </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Upfront License Fees: </span><span style="font-family:inherit;font-size:10pt;">If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related nonrefundable, upfront license fees based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license.  For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.  The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Development and Regulatory Milestone Payments: </span><span style="font-family:inherit;font-size:10pt;">Depending on facts and circumstances, the Company may conclude that it is appropriate to include certain milestones in the estimated transaction price or that it is appropriate to fully constrain the milestones. A milestone payment is included in the transaction price in the reporting period that the Company concludes that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods. This may result in revenues from certain milestones and a corresponding contract asset being recorded in a reporting period before the milestone is achieved. Milestone payments that have not been included in the transaction price to date are fully constrained until the Company concludes that their achievement is probable and that recognition of the related revenue will not result in a significant reversal in amounts recognized in future periods. The Company re-evaluates the probability of achievement of such development milestones and any related constraint each reporting period and adjusts its estimate of the overall transaction price, including the amount of collaborative revenue that it has recorded, if necessary. The Company has not recorded any significant development or regulatory milestone revenues the three years ended December 31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Activities/Transition Services: </span><span style="font-family:inherit;font-size:10pt;">If the Company is entitled to reimbursement from its collaborators for specified research and development expenses, it accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as collaborative revenues or an offset to research and development expenses in accordance with the provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sales-based Milestone and Royalty Payments: </span><span style="font-family:inherit;font-size:10pt;">The Company’s collaborators may be required to pay the Company sales-based milestones or royalties on future sales of commercial products.  The Company recognizes revenues related to sales-based milestone and royalties upon the later to occur of (i) achievement of the collaborator’s underlying sales or (ii) satisfaction of any performance obligation(s) related to these sales, in each case assuming the license to the Company’s intellectual property is deemed to be the predominant item to which the sales-based milestones and/or royalties relate. The Company has not recorded any sales-based milestones or royalties revenues during the three years ended December 31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Concentration of Credit Risk</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of money market funds and marketable securities. The Company places these investments with highly rated financial institutions, and, by policy, limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company also maintains a foreign currency hedging program that includes foreign currency forward contracts with several counterparties. The Company has not experienced any credit losses related to these financial instruments and does not believe it is exposed to any significant credit risk related to these instruments. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also is subject to credit risk from its accounts receivable related to its product sales and collaborators. The Company evaluates the creditworthiness of each of its customers and has determined that all of its material customers are </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">creditworthy. To date, the Company has not experienced significant losses with respect to the collection of its accounts receivable. The Company believes that its allowance for doubtful accounts was adequate at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. Please refer to </span><span style="font-size:10pt;">Note R, </span><span style="font-size:10pt;">“</span><span style="font-size:10pt;">Segment Information,</span><span style="font-size:10pt;">”</span><span style="font-family:inherit;font-size:10pt;"> for further information.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Cash and Cash Equivalents</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investments with original maturities of </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months or less at the date of purchase to be cash equivalents. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Marketable Securities </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company’s marketable securities consisted of investments in available-for-sale debt securities, including government-sponsored enterprise securities, corporate debt securities and commercial paper, and corporate equity securities with readily determinable fair values. The Company classifies marketable securities available to fund current operations as current assets on its consolidated balance sheets. Marketable securities are classified as long-term assets on the consolidated balance sheets if (i) they have been in an unrealized loss position for longer than one year and (ii) the Company has the ability and intent to hold them (a) until the carrying value is recovered and (b) such holding period may be longer than one year. The Company’s marketable securities are stated at fair value. The fair value of these securities is based on quoted prices for identical or similar assets. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> The Company records unrealized gains (losses) on available-for-sale debt securities as a component of “</span><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive (loss) income</span><span style="font-family:inherit;font-size:10pt;">,” which is a separate component of shareholders’ equity on its consolidated balance sheet, until such gains and losses are realized.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the adoption of Accounting Standards Update (“ASU”) 2016-01, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recognition and Measurement of Financial Assets and Financial Liabilities</span><span style="font-family:inherit;font-size:10pt;"> (“</span><span style="font-family:inherit;font-size:10pt;">ASU 2016-01</span><span style="font-family:inherit;font-size:10pt;">”) on January 1, 2018, the Company began recording changes in the fair value of its investments in corporate equity securities to “</span><span style="font-size:10pt;">Other income (expense), net</span><span style="font-family:inherit;font-size:10pt;">” in the Company’s consolidated statements of operations. Prior to its adoption of </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-01</span><span style="font-family:inherit;font-size:10pt;"> in 2018, the Company recorded changes in the fair value of its investments in corporate equity securities to “</span><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive (loss) income</span><span style="font-family:inherit;font-size:10pt;">.” </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company reviews investments in marketable debt securities for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers whether it has an intent to sell, or whether it is more likely than not that the Company will be required to sell, the investment before recovery of the investment’s amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company’s investment policy, the severity and the duration of the impairment and changes in value subsequent to year-end. If a decline in the fair value is considered other-than-temporary, based on available evidence, the unrealized loss is transferred from other comprehensive income (loss) to the consolidated statements of operations. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Realized gains and losses are determined using the specific identification method and are included in “</span><span style="font-size:10pt;">Other income (expense), net</span><span style="font-family:inherit;font-size:10pt;">” in the consolidated statements of operations. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Accounts Receivable </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company deducts invoice discounts for prompt payment and fees for distribution services from its accounts receivable based on its experience that the Company’s Customers will earn these discounts and fees. The Company’s estimates for its allowance for doubtful accounts, which have not been significant to date, are determined based on existing contractual payment terms and historical payment patterns. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Stock-based Compensation Expense</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company expenses the fair value of employee stock options and other forms of stock-based employee compensation over the associated employee service period on a straight-line basis. Stock-based compensation expense is determined based on the fair value of the award at the grant date and is adjusted each period to reflect actual forfeitures and the outcomes of certain performance conditions. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For awards with performance conditions in which the award does not vest unless the performance condition is met, the Company recognizes expense if, and to the extent that, the Company estimates that achievement of the performance condition is probable. If the Company concludes that vesting is probable, it recognizes expense from the date it reaches this conclusion through the estimated vesting date. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company provides to employees who have rendered a certain number of years’ to the Company and meet certain age requirements, partial or full acceleration of vesting of these equity awards, subject to certain conditions including a notification period, upon a termination of employment other than for cause. Approximately </span><span style="font-family:inherit;font-size:10pt;"><span>5%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s employees were eligible for partial or full acceleration of any of their equity awards as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company recognizes stock-based compensation expense related to these awards over a service period reflecting qualified employees’ eligibility for partial or full acceleration of vesting.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Research and Development Expenses</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company expenses as incurred all research and development expenses, including amounts funded by research and development collaborations. The Company capitalizes nonrefundable advance payments made by the Company for research and development activities and expenses the payments as the related goods are delivered or the related services are performed.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses are comprised of costs incurred by the Company in performing research and development activities, including salary and benefits; stock-based compensation expense; outsourced services and other direct expenses, including clinical trial and pharmaceutical development costs; collaboration and asset acquisition payments; expenses associated with drug supplies that are not being capitalized; and infrastructure costs, including facilities costs and depreciation expense.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Inventories</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company values its inventories at the lower-of-cost or net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and writes down any excess and obsolete inventories to their net realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases are capitalized and recorded upon sale in “</span><span style="font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;">” in the consolidated statements of operations. Shipping and handling costs incurred for product shipments are recorded as incurred in “</span><span style="font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;">” in the consolidated statements of operations.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company capitalizes inventories produced in preparation for initiating sales of a drug candidate when the related drug candidate is considered to have a high likelihood of regulatory approval and the related costs are expected to be recoverable through sales of the inventories. In determining whether or not to capitalize such inventories, the Company evaluates, among other factors, information regarding the drug candidate’s safety and efficacy, the status of regulatory submissions and communications with regulatory authorities and the outlook for commercial sales, including the existence of current or anticipated competitive drugs and the availability of reimbursement. In addition, the Company evaluates risks associated with manufacturing the drug candidate and the remaining shelf-life of the inventories. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Property and Equipment</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset, generally </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> for furniture and equipment, </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> years for computers and software and for leasehold improvements, the shorter of the useful life of the improvements or the estimated remaining life of the associated lease. Maintenance and repairs to an asset that do not improve or extend its life are charged to operations. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the Company’s consolidated statements of operations. The Company performs an assessment of the fair value of the assets if indicators of impairment are identified during a reporting period and records the assets at the lower of the net book value or the fair value of the assets.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company capitalizes internal costs incurred to develop software for internal use during the application development stage. Amortization of capitalized internally developed software costs is recorded in depreciation expense over the useful life of the related asset. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Leases</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted ASU 2016-02, Leases (Topic 842) (“ASC 842”) as of January 1, 2019. Under ASC 842, the Company determines whether the arrangement contains a lease at the inception of an arrangement. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its consolidated balance sheet and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12 months.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company does not separate lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases are recorded in “</span><span style="font-size:10pt;">Property and equipment, net</span><span style="font-family:inherit;font-size:10pt;">,” “</span><span style="font-size:10pt;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;">” and “</span><span style="font-size:10pt;">Long-term finance lease liabilities</span><span style="font-family:inherit;font-size:10pt;">” and operating leases are recorded in “</span><span style="font-size:10pt;">Other assets</span><span style="font-family:inherit;font-size:10pt;">,” “</span><span style="font-size:10pt;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;">” and “</span><span style="font-size:10pt;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;">” on the Company’s consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the adoption of ASC 842 on January 1, 2019, the Company applied build-to-suit accounting and was the deemed owner of its leased corporate headquarters in Boston and research site in San Diego, for which it was recognizing depreciation expense over the buildings’ useful lives and imputed interest on the corresponding construction financing lease obligations. The Company also recorded leases for equipment as capital leases pursuant to the accounting guidance that was effective until December 31, 2018.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The assets and liabilities associated with the Company’s capital lease agreements were recorded at the present value of the minimum lease payments at the inception of the lease agreement. The assets were depreciated using the straight-line method over the shorter of the useful life of the related asset or the remaining life of the associated lease. Amortization of capital lease assets was included in depreciation expense. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Income Taxes</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax bases of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. On a periodic basis, the Company reassesses the valuation allowance on its deferred income tax assets weighing positive and negative evidence to assess the recoverability of its deferred tax assets. The Company includes, among other things, its recent financial performance and its future projections in this periodic assessment. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records liabilities related to uncertain tax positions by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company does not believe any such uncertain tax positions currently pending will have a material adverse effect on its consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Variable Interest Entities</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company reviews each collaboration agreement pursuant to which it licenses assets owned by a collaborator in order to determine whether or not it has a variable interest via the license agreement with the collaborator and if the variable interest is a variable interest in the collaborator as a whole. In assessing whether the Company has a variable interest in the collaborator as a whole, the Company considers and makes judgments regarding the purpose and design of the entity, the value of the licensed assets to the collaborator, the value of the collaborator’s total assets and the significant activities of the collaborator. If the Company has a variable interest in the collaborator as a whole, the Company assesses whether or not the Company is the primary beneficiary of that VIE based on a number of factors, including (i) which party has the power to direct the activities that most significantly affect the VIE’s economic performance, (ii) the parties’ contractual rights and responsibilities pursuant to the collaboration agreement and (iii) which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE. If the Company determines it is the primary beneficiary of a VIE at the onset of the collaboration agreement, the collaboration is treated as a business combination and the Company consolidates the financial statements of the VIE into the Company’s consolidated financial statements. On a quarterly basis, the Company evaluates whether it continues to be the primary beneficiary of any consolidated VIEs. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, it deconsolidates the VIE in the period that the determination is made.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Fair Value of In-process Research and Development Assets and Contingent Payments </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The present-value models the Company uses to estimate the fair values of in-process research and development assets and contingent payments pursuant to collaborations and acquisitions incorporate significant assumptions. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s discounted cash flow models pertaining to in-process research and development assets include: (i) assumptions regarding the probability of obtaining marketing approval for a drug candidate; (ii) the timing of and the expected costs to develop and commercialize a drug candidate; (iii) estimates of future cash flows from potential product sales with respect to a drug candidate; and (iv) appropriate discount and tax rates. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company bases its estimates of the probability of achieving the milestones relevant to the fair value of contingent payments, which could include milestone, royalty and option payments, on industry data. Estimates included in the discounted cash flow models pertaining to contingent payments also include: (i) estimate regarding the timing of the relevant development and commercial milestones and royalties, (ii) and appropriate discount rates. Please refer to </span><span style="font-size:10pt;">Note E, </span><span style="font-size:10pt;">“</span><span style="font-size:10pt;">Fair Value Measurements,</span><span style="font-size:10pt;">”</span><span style="font-family:inherit;font-size:10pt;"> for further information.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">In-process Research and Development Assets</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records the fair value of in-process research and development assets as of the transaction date of a business combination. Each of these assets is accounted for as an indefinite-lived intangible asset and is maintained on the Company’s consolidated balance sheet until either the project underlying it is completed or the asset becomes impaired. If the asset becomes impaired or is abandoned, the carrying value of the related intangible asset is written down to its fair value, and an impairment charge is recorded in the period in which the impairment occurs. If a project is completed, the carrying </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">value of the related intangible asset is amortized as a part of “</span><span style="font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;">” over the remaining estimated life of the asset beginning in the period in which the project is completed. In-process research and development assets are tested for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development that is acquired in a transaction that does not qualify as a business combination under GAAP and that does not have an alternative future use is expensed in the period in which it is acquired.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Goodwill</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is allocated to goodwill. Goodwill is evaluated for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Deconsolidation</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon the occurrence of certain events and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its subsidiaries, including consolidated VIEs. If the Company determines it no longer has a controlling interest, the subsidiary is deconsolidated. The Company records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i) the aggregate of (a) the fair value of any consideration received, (b) the fair value of any retained noncontrolling investment in the former subsidiary and (c) the carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii) the carrying amount of the former subsidiary’s assets and liabilities. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Discontinued Operations</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assesses whether a deconsolidation is required to be presented as discontinued operations in its consolidated financial statements on the deconsolidation date. This assessment is based on whether or not the deconsolidation represents a strategic shift that has or will have a major effect on the Company’s operations or financial results. If the Company determines that a deconsolidation requires presentation as a discontinued operation on the deconsolidation date, or at any point during the one year period following such date, it will present the former subsidiary as a discontinued operation in current and comparative period financial statements.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Embedded Derivatives</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Embedded derivatives are required to be bifurcated from the host instruments and recorded at fair value if the derivatives are not clearly and closely related to the host instruments on the date of issuance. The Company did not have any material embedded derivatives that required bifurcation recorded on its consolidated balance sheets as of December 31, 2019 and 2018, respectively.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Hedging Activities</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes the fair value of hedging instruments that are designated and qualify as hedging instruments pursuant to GAAP, foreign currency forward contracts, as either assets or liabilities on the consolidated balance sheets. Changes in the fair value of these instruments are recorded each period in “</span><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive (loss) income</span><span style="font-family:inherit;font-size:10pt;">” as unrealized gains and losses until the forecasted underlying transaction occurs. Unrealized gains and losses on these foreign currency forward contracts are included in “</span><span style="font-size:10pt;">Prepaid expenses and other current assets</span><span style="font-family:inherit;font-size:10pt;">” or “</span><span style="font-size:10pt;">Other assets</span><span style="font-family:inherit;font-size:10pt;">,” and “</span><span style="font-size:10pt;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;">” or “</span><span style="font-size:10pt;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;">,” respectively, on the Company’s consolidated balance sheets depending on the remaining period until their contractual maturity. Realized gains and losses for the effective portion of such contracts are recognized in “</span><span style="font-size:10pt;">Product revenues, net</span><span style="font-family:inherit;font-size:10pt;">” in the consolidated statement of operations in the same period that it recognizes the product revenues that were impacted by the hedged foreign exchange rate changes. The Company classifies the cash flows from hedging instruments in the same category as the cash flows from the hedged items. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of the Company’s hedging instruments are subject to master netting arrangements to reduce the risk arising from such transactions with its counterparties. The Company presents unrealized gains and losses on its foreign currency forward contracts on a gross basis within its consolidated balance sheets. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also enters into foreign currency forward contracts with contractual maturities of less than </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> month designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities including intercompany balances. These contracts are not designated as hedging instruments pursuant to GAAP. Realized gains and losses for such contracts are recognized in “</span><span style="font-size:10pt;">Other income (expense), net</span><span style="font-family:inherit;font-size:10pt;">” in the consolidated statement of operations each period. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Restructuring Expenses</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records costs and liabilities associated with exit and disposal activities based on estimates of fair value in the period the liabilities are incurred. The Company’s exit and disposal activities have primarily been associated with the Company’s facilities, but also have included the termination of employees in some cases. The Company’s initial estimate of its liabilities for net ongoing costs associated with its facility obligations are recorded at fair value on the cease use date. On a quarterly basis, the Company evaluates and adjusts these liabilities as appropriate for changes in circumstances. Changes to the Company’s estimate of these liabilities are recorded as additional restructuring expenses (credits). These costs are included in “</span><span style="font-size:10pt;">Restructuring (income) expenses</span><span style="font-family:inherit;font-size:10pt;">” on the Company’s consolidated statements of operations.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has adopted several plans to restructure its facilities and operations for which it has incurred restructuring expenses. The only significant restructuring event during the three years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> commenced in February 2017 upon the Company’s decision to consolidate its research activities into its Boston, Milton Park and San Diego locations. The Company closed its research site in Canada as a result of this decision affecting approximately </span><span style="font-family:inherit;font-size:10pt;"><span>70</span></span><span style="font-family:inherit;font-size:10pt;"> positions. The Company’s lease for its research site in Canada expired in October 2018. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018, the Company has no restructuring liabilities recorded on its consolidated balance sheet and does not anticipate any additional charges related to this restructuring event in the future. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss), which includes foreign currency translation adjustments and unrealized gains and losses on foreign currency forward contracts and certain marketable securities. For purposes of comprehensive income (loss) disclosures, the Company records provisions for or benefits from income taxes related to the unrealized gains and losses on foreign currency forward contracts and certain marketable securities. The Company does not record provisions for or benefits from income taxes related to the cumulative translation adjustment, as the Company intends to permanently reinvest undistributed earnings in its foreign subsidiaries.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Foreign Currency Translation and Transactions</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of the Company’s operations occur in entities that have the U.S. dollar denominated as their functional currency. The assets and liabilities of the Company’s entities with functional currencies other than the U.S. dollar are translated into U.S. dollars at rates of exchange in effect at the end of the year. Revenue and expense amounts for these entities are translated using the average exchange rates for the period. Net unrealized gains and losses resulting from foreign currency translation are included in “</span><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive (loss) income</span><span style="font-family:inherit;font-size:10pt;">.” Net foreign currency exchange transaction losses, which are included in “</span><span style="font-size:10pt;">Other income (expense), net</span><span style="font-family:inherit;font-size:10pt;">” on the Company’s consolidated statement of operations, were </span><span style="font-family:inherit;font-size:10pt;"><span>$5.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. These net foreign currency exchange losses are presented net of the impact of the foreign currency forward contracts designed to mitigate their effect on the Company’s consolidated statement of operations.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Net Loss Per Share Attributable to Vertex Common Shareholders</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share attributable to Vertex common shareholders are presented in conformity with the two-class method required for participating securities. Under the two-class method, earnings are allocated to (i) Vertex common shares, excluding unvested restricted stock, and (ii) participating securities, based on their respective weighted-average shares outstanding for the period. Shares of unvested restricted stock granted under the Company’s Amended and Restated 2006 Stock and Option Plan have the non-forfeitable right to receive dividends on an equal basis with other outstanding common stock. As a result, these unvested shares of restricted stock are considered participating securities under the two-class method. Potentially dilutive shares result from the assumed exercise of outstanding stock options (the proceeds of which are then assumed to have been used to repurchase outstanding stock using the treasury stock method).</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Recently Adopted Accounting Standards</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2016, the Financial Accounting Standards Board (“FASB”) issued ASC 842, which amends a number of aspects of lease accounting and requires entities to recognize right-of-use assets and liabilities on the balance sheet. ASC 842 became effective on January 1, 2019. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Until December 31, 2018, the Company applied build-to-suit accounting and was the deemed owner of its leased corporate headquarters in Boston and research site in San Diego, for which it was recognizing depreciation expense over the buildings’ useful lives and imputed interest on the corresponding construction financing lease obligations. Under the amended guidance that became effective January 1, 2019, the Company accounts for these buildings as finance leases, resulting in increased depreciation expense over the respective lease terms of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">, which are significantly shorter than the buildings’ useful lives of </span><span style="font-family:inherit;font-size:10pt;"><span>40 years</span></span><span style="font-family:inherit;font-size:10pt;">. The amended guidance also results in a reduction in imputed interest expense in the initial years of each finance lease term.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2018, the FASB issued ASU 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;"> (“ASU 2018-11”), which offered a transition option to entities adopting ASC 842. Under ASU 2018-11, entities could elect to apply ASC 842 using a modified-retrospective adoption approach resulting in a cumulative effect adjustment to accumulated deficit at the beginning of the year in which the new lease standard is adopted, rather than adjustments to the earliest comparative period presented in their financial statements. The Company adopted ASC 842 using the modified-retrospective method. As of January 1, 2019, the Company recorded a cumulative effect adjustment to increase its “</span><span style="font-size:10pt;">Accumulated deficit</span><span style="font-family:inherit;font-size:10pt;">” by </span><span style="font-family:inherit;font-size:10pt;"><span>$40.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to the adjustments to its build-to-suit leases described in the previous paragraph.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company elected the package of transition practical expedients for leases that commenced prior to January 1, 2019, allowing it not to reassess (i) whether any expired or existing contracts contain leases, (ii) the lease classification for any expired or existing leases and (iii) the initial indirect costs for any existing leases.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, the Company recorded, upon adoption of ASC 842 on January 1, 2019, operating lease assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$61.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and corresponding liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$71.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to its real estate leases that are not treated as finance leases under ASC 842. The difference between these assets and liabilities was primarily attributable to prepaid or accrued lease payments. The Company also reclassified amounts that were recorded as “Capital lease obligations, current portion” and “Capital lease obligations, excluding current portion” as of December 31, 2018 to “</span><span style="font-size:10pt;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;">” and “</span><span style="font-size:10pt;">Long-term finance lease liabilities</span><span style="font-family:inherit;font-size:10pt;">,” respectively, on January 1, 2019. These adjustments had </span><span style="font-family:inherit;font-size:10pt;">no</span><span style="font-family:inherit;font-size:10pt;"> impact on the Company’s consolidated statement of operations and had </span><span style="font-family:inherit;font-size:10pt;">no</span><span style="font-family:inherit;font-size:10pt;"> impact on the Company’s accumulated deficit.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The cumulative effect of applying ASC 842 on the Company’s consolidated balance sheet as of January 1, 2019 was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance as of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance as of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">December 31, 2018 ^</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">January 1, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Assets</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>140,819</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,930</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>137,889</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>812,005</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(53,920</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>758,085</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,499,672</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,236</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,510,908</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>61,674</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>61,674</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,245,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>16,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,261,958</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Liabilities and Shareholders’ Equity</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Capital lease obligations, current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,817</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(9,817</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>40,589</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>34,304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>74,893</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Capital lease obligations, excluding current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,658</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(19,658</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Construction financing lease obligation, excluding current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>561,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(561,892</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Long-term finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>569,487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>569,487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>26,280</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>43,946</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>70,226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,989,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(40,310</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(3,029,788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities and shareholders’ equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,245,898</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>16,060</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,261,958</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="12" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;padding-top:16px;text-align:left;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;color:#000000;">^ As reported in the Company’s 2018 Annual Report on Form 10-K.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">“</span><span style="font-size:10pt;">Other assets</span><span style="font-family:inherit;font-size:10pt;">” and “</span><span style="font-size:10pt;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;">” in the table above relate primarily to the Company’s operating leases. Please refer to </span><span style="font-family:inherit;font-size:10pt;">Note M, “Leases,”</span><span style="font-family:inherit;font-size:10pt;"> for further information regarding the Company’s leases as well as certain disclosures required by ASC 842.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Derivatives and Hedging</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2017, the FASB issued ASU 2017-12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815) </span><span style="font-family:inherit;font-size:10pt;">(“ASU 2017-12”), which helps simplify certain aspects of hedge accounting and enables entities to more accurately present their risk management activities in their financial statements. ASU 2017-12 became effective January 1, 2019. The adoption of ASU 2017-12 did not have a significant effect on the Company’s consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2014, the FASB issued </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;">. The new guidance became effective January 1, 2018. </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;"> applies a more principles-based approach to recognizing revenue. Under </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;">, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;"> on January 1, 2018 using the modified-retrospective adoption method for all contracts that were not completed as of the date of adoption. Under the modified-retrospective method, the Company recognized the cumulative effect of applying the standard within “</span><span style="font-size:10pt;">Accumulated deficit</span><span style="font-family:inherit;font-size:10pt;">” on its consolidated balance sheet as of January 1, 2018. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For all reporting periods, the Company has not disclosed the value of unsatisfied performance obligations for all product revenue contracts with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules.  </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on the Company’s review of existing customer contracts as of January 1, 2018, it concluded that the only significant impact that the adoption of </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;"> had on its financial statements related to shipments of ORKAMBI under early access programs in France. Prior to the adoption of </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;">, the Company did not recognize revenue on the proceeds received from sales of ORKAMBI under early access programs in France because the price was not fixed or determinable based on the status of ongoing pricing discussions. As of January 1, 2018, the Company recorded a cumulative effect </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">adjustment to its accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to the adoption of </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;">, which primarily represented the Company’s estimated amount of consideration it expected to retain related to these shipments that would not be subject to a significant reversal in amounts recognized, net of costs previously deferred related to these shipments. Please refer to “Product Revenues, Net” above for further information related to the impact of the new revenue recognition on these sales. </span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The impact of adoption on the Company’s consolidated statement of operations for the year ended December 31, 2018 was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year Ended December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As Reported <br/>under ASC 606</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balances <br/>without Adoption of ASC 606</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Effect of Change<br/>Higher/(Lower)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,038,325</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,019,484</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>18,841</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cost of sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>409,539</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>402,925</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,614</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>635,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>622,923</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,227</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income attributable to Vertex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,096,896</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,084,669</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,227</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts per share attributable to Vertex common shareholders:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;"> did not have an aggregate impact on the Company’s net cash provided by operating activities, but resulted in offsetting changes in certain assets and liabilities presented within net cash provided by operating activities in the Company’s consolidated statement of cash flows. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Equity Investments</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-01</span><span style="font-family:inherit;font-size:10pt;">, which amended guidance related to the recording of financial assets and financial liabilities. Under </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-01</span><span style="font-family:inherit;font-size:10pt;">, equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of an investee) are measured at fair value with changes in fair value recognized in net income (loss). However, an entity has the option to measure equity investments without readily determinable fair values at (i) fair value or (ii) cost adjusted for changes in observable prices minus impairment. Changes in measurement under either alternative are recognized in net income (loss). </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-01</span><span style="font-family:inherit;font-size:10pt;"> became effective January 1, 2018 and required the modified-retrospective adoption method. As of January 1, 2018, the Company held publicly traded equity investments and equity investments accounted for under the cost method. As a result, in 2018, the Company recorded a </span><span style="font-family:inherit;font-size:10pt;"><span>$25.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> cumulative effect adjustment to “</span><span style="font-size:10pt;">Accumulated deficit</span><span style="font-family:inherit;font-size:10pt;">” related to its publicly traded equity investments equal to the unrealized gain, net of tax, that was recorded in “</span><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive (loss) income</span><span style="font-family:inherit;font-size:10pt;">” as of December 31, 2017. The adoption of </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-01</span><span style="font-family:inherit;font-size:10pt;"> had no effect on the Company’s equity investments accounted for under the cost method because the original cost basis of these investments was recorded on the Company’s consolidated balance sheet as of December 31, 2017. In 2019 and 2018, the Company recorded net unrealized gains of </span><span style="font-family:inherit;font-size:10pt;"><span>$132.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, to “</span><span style="font-size:10pt;">Other income (expense), net</span><span style="font-family:inherit;font-size:10pt;">” in its consolidated statement of operations related to the change in fair value of its equity investments.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intra-Entity Transfers</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued ASU 2016-16, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intra-Entity Transfers of Assets Other Than Inventory</span><span style="font-family:inherit;font-size:10pt;"> (“</span><span style="font-family:inherit;font-size:10pt;">ASU 2016-16</span><span style="font-family:inherit;font-size:10pt;">”), which removes the previous exception in GAAP prohibiting an entity from recognizing current and deferred income tax expenses or benefits related to the transfer of assets, other than inventory, within the consolidated entity. The exception to defer the recognition of any tax impact on the transfer of inventory within the consolidated entity until it is sold to a third party remains unaffected. </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-16</span><span style="font-family:inherit;font-size:10pt;"> became effective January 1, 2018. In 2018, upon adoption of </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-16</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded a deferred tax asset and corresponding full valuation allowance of </span><span style="font-family:inherit;font-size:10pt;"><span>$204.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> equal to the unamortized cost of </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">intellectual property rights transferred to the United Kingdom in 2014 multiplied by an appropriate statutory rate. There was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> cumulative effect adjustment to “</span><span style="font-size:10pt;">Accumulated deficit</span><span style="font-family:inherit;font-size:10pt;">” using the modified-retrospective adoption method.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Goodwill</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2017, the FASB issued ASU 2017-04, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350) </span><span style="font-family:inherit;font-size:10pt;">(“</span><span style="font-family:inherit;font-size:10pt;">ASU 2017-04</span><span style="font-family:inherit;font-size:10pt;">”) related to measurements of goodwill. </span><span style="font-family:inherit;font-size:10pt;">ASU 2017-04</span><span style="font-family:inherit;font-size:10pt;"> modifies the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value, which eliminates Step 2 from the goodwill impairment test. An entity would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to the related reporting unit. The Company early adopted </span><span style="font-family:inherit;font-size:10pt;">ASU 2017-04</span><span style="font-family:inherit;font-size:10pt;"> and utilized this approach for annual and interim goodwill impairment tests conducted after January 1, 2018. The adoption of </span><span style="font-family:inherit;font-size:10pt;">ASU 2017-04</span><span style="font-family:inherit;font-size:10pt;"> did not have a significant effect on the Company’s consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash Flows - Restricted Cash</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">In 2016, the FASB issued ASU 2016-18, </span><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230) Restricted Cash</span><span style="font-family:Times New Roman;font-size:10pt;"> (“</span><span style="font-family:Times New Roman;font-size:10pt;">ASU 2016-18</span><span style="font-family:Times New Roman;font-size:10pt;">”), which requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and restricted cash. Therefore, amounts described as restricted cash should be included with cash and cash equivalents when reconciling the beginning of period and end of period amounts shown on the statement of cash flows.  </span><span style="font-family:Times New Roman;font-size:10pt;">ASU 2016-18</span><span style="font-family:Times New Roman;font-size:10pt;"> became effective January 1, 2018 and was effective on a retrospective basis. The cash, cash equivalents and restricted cash balances for the years ended December 31, </span><span style="font-family:Times New Roman;font-size:10pt;">2019</span><span style="font-family:Times New Roman;font-size:10pt;"> through </span><span style="font-family:Times New Roman;font-size:10pt;">2016</span><span style="font-family:Times New Roman;font-size:10pt;">, which are presented in the Company’s consolidated statements of cash flows subsequent to the adoption of </span><span style="font-family:Times New Roman;font-size:10pt;">ASU 2016-18</span><span style="font-family:Times New Roman;font-size:10pt;">, consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,109,322</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,650,134</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,665,412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,183,945</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,004</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,910</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>47,762</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,209</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash, cash equivalents and restricted cash per statement of cash flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,120,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,658,253</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,667,526</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,231,707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s restricted cash, if any, is included in “</span><span style="font-size:10pt;">Prepaid expenses and other current assets</span><span style="font-family:inherit;font-size:10pt;">” and “</span><span style="font-size:10pt;">Other assets</span><span style="font-family:inherit;font-size:10pt;">” in its consolidated balance sheets. As of December 31, 2017 and 2016, the Company recorded BioAxone’s cash and cash equivalents as “</span><span style="font-size:10pt;">Prepaid expenses and other current assets</span><span style="font-family:inherit;font-size:10pt;">” because the Company did not have any interest in or control over BioAxone’s cash and cash equivalents. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation - Improvements</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued ASU 2016-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting </span><span style="font-family:inherit;font-size:10pt;">(“</span><span style="font-family:inherit;font-size:10pt;">ASU 2016-09</span><span style="font-family:inherit;font-size:10pt;">”), which simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-09</span><span style="font-family:inherit;font-size:10pt;"> became effective January 1, 2017. </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-09</span><span style="font-family:inherit;font-size:10pt;"> eliminated the requirement that excess tax benefits were realized as a reduction in current taxes payable before the associated tax benefit could be recognized as an increase in additional paid-in capital. This created a deferred tax asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$410.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> relating to federal and state net operating losses (“NOLs”) that were fully reserved by an equal increase in the Company’s valuation allowance as of January 1, 2017. The Company recorded deferred tax assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$404.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> relating to federal NOLs and </span><span style="font-family:inherit;font-size:10pt;"><span>$6.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> relating to state NOLs, both of which were offset by a full valuation allowance. Upon adoption, the Company also elected to change its accounting policy to account for forfeitures of options and awards as they occur. The change was applied on a modified-retrospective basis with a cumulative effect adjustment to increase “</span><span style="font-size:10pt;">Accumulated deficit</span><span style="font-family:inherit;font-size:10pt;">” by </span><span style="font-family:inherit;font-size:10pt;"><span>$9.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of January 1, 2017. This change also resulted in an increase to the deferred tax asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was offset by a full valuation allowance. As a result, there was no cumulative effect adjustment to accumulated deficit related to income taxes. The provisions related to the recognition of excess tax benefits in the Company’s consolidated statement of </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">operations and classification in the consolidated statement of cash flows were adopted prospectively, and as such, the prior periods were not retrospectively adjusted.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Recently Issued Accounting Standards</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Internal-Use Software</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2018, the FASB issued ASU 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract </span><span style="font-family:inherit;font-size:10pt;">(“</span><span style="font-family:inherit;font-size:10pt;">ASU 2018-15</span><span style="font-family:inherit;font-size:10pt;">”), which clarifies the accounting for implementation costs in cloud computing arrangements.  </span><span style="font-family:inherit;font-size:10pt;">ASU 2018-15</span><span style="font-family:inherit;font-size:10pt;"> was effective on January 1, 2020. The Company expects the adoption of </span><span style="font-family:inherit;font-size:10pt;">ASU 2018-15</span><span style="font-family:inherit;font-size:10pt;"> will result in an insignificant amount of additional assets recorded on its consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value Measurement</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2018, the FASB issued ASU 2018-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:inherit;font-size:10pt;"> (“</span><span style="font-family:inherit;font-size:10pt;">ASU 2018-13</span><span style="font-family:inherit;font-size:10pt;">”), which modifies the disclosure requirements for fair value measurements. </span><span style="font-family:inherit;font-size:10pt;">ASU 2018-13</span><span style="font-family:inherit;font-size:10pt;"> was effective on January 1, 2020. The Company expects the adoption of </span><span style="font-family:inherit;font-size:10pt;">ASU 2018-13</span><span style="font-family:inherit;font-size:10pt;"> will result in additional disclosures related to its assets and liabilities that are valued based on Level 3 inputs.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Credit Losses</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“</span><span style="font-family:inherit;font-size:10pt;">ASU 2016-13</span><span style="font-family:inherit;font-size:10pt;">”), which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-13</span><span style="font-family:inherit;font-size:10pt;"> requires allowances to be recorded instead of reducing the amortized cost of the investment. </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-13</span><span style="font-family:inherit;font-size:10pt;"> was effective on January 1, 2020. The Company does not expect the adoption of </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-13</span><span style="font-family:inherit;font-size:10pt;"> to have a significant impact on its consolidated financial statements.</span></div> 3800000000 <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Basis of Presentation</span></div><span style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (“VIEs”). In 2017, the Company deconsolidated Parion Sciences, Inc. (“Parion”), a VIE the Company had consolidated since 2015. In </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company deconsolidated BioAxone Biosciences, Inc. (“BioAxone”), a VIE the Company had consolidated since 2014. As of December 31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018, the Company did not have any consolidated VIEs. All material intercompany balances and transactions have been eliminated. The Company operates in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> segment, pharmaceuticals. Please refer to </span><span style="font-size:10pt;">Note R, </span><span style="font-size:10pt;">“</span><span style="font-size:10pt;">Segment Information,</span><span style="font-size:10pt;">”</span> for enterprise-wide disclosures regarding the Company’s revenues, major customers and long-lived assets by geographic area. 1 <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these consolidated financial statements have been made in connection with (i) determining the transaction price of revenues, (ii) accounting for acquisitions, including intangible assets, goodwill and contingent consideration and (iii) evaluating deferred tax asset valuation allowances and the provision for income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div> <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company makes significant estimates and judgments that materially affect its recognition of net product revenues. The Company adjusts its estimated rebates, chargebacks and discounts based on new information, including information regarding actual rebates, chargebacks and discounts for its products, as it becomes available. Claims by third-party payors for rebates, chargebacks and discounts frequently are submitted to the Company significantly after the related sales, potentially resulting in adjustments in the period in which the new information becomes known. The Company’s credits to product revenue related to prior period sales have not been significant and primarily related to rebates and discounts. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company excludes taxes collected from Customers relating to product sales and remitted to governmental authorities from revenues. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Contract Liabilities</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded contract liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$62.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$24.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement the Company can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees.  The Company defers a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “</span><span style="font-size:10pt;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;">.” The deferred amount is recognized as revenue when the free products are shipped. The Company’s product revenue contracts include performance obligations that are one year or less.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as the Company’s fiscal year. In these markets the Company recognizes revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$24.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of revenues that were recorded as contract liabilities at the beginning of the year. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;background-color:#ffffff;font-style:normal;font-weight:normal;text-decoration:underline;">French Early Access Programs</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to ASC 605, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition </span><span style="font-family:inherit;font-size:10pt;">(“</span><span style="font-family:inherit;font-size:10pt;">ASC 605</span><span style="font-family:inherit;font-size:10pt;">”), which was applicable until December 31, 2017, the Company only recognized revenues from product sales if it determined that the price was fixed or determinable at the time of delivery. If the Company determined that the price was not fixed or determinable, it deferred the recognition of revenues. If the Company was able to determine that the price was fixed or determinable, it recognized the net product revenues associated with the units. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2015, the Company began distributing ORKAMBI through early access programs in France and remained engaged in reimbursement discussions with the French government until November 2019, when the Company reached an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs. From the time the Company began distributing ORKAMBI through early access programs in France, it expected the difference between the amounts collected based on the invoiced amount and the final amount for ORKAMBI distributed through early access programs would be returned to the French government. As a result, the Company has classified a refund liability related to the early access programs in France within “Accrued expenses” on its consolidated balance sheets. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the revenue recognition accounting guidance that was applicable until December 31, 2017, the Company’s ORKAMBI net product revenues for 2015, 2016 and 2017 did not include any net product revenues from sales of ORKAMBI in France because the price was not fixed or determinable at the time of delivery. Upon adopting </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;"> in 2018, the Company recorded an </span><span style="font-family:inherit;font-size:10pt;"><span>$8.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> cumulative effect adjustment to “</span><span style="font-size:10pt;">Accumulated deficit</span><span style="font-family:inherit;font-size:10pt;">” primarily related to shipments of ORKAMBI under the early access programs in France. The Company determined the amount of the adjustment based upon (i) the status of reimbursement discussions in France upon adoption, (ii) its estimate of the amount of consideration it expected to retain related to ORKAMBI sales in France that occurred on or prior to December 31, 2017 that would not be subject to a significant reversal in amounts recognized and (iii) recognition of costs previously deferred related to the ORKAMBI sales in France. Please refer to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements </span><span style="font-family:inherit;font-size:10pt;">included in this </span><span style="font-family:inherit;font-size:10pt;">Note A, “Nature of Business and Accounting Policies,”</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">below for more information regarding the revenue recognition guidance adopted as of January 1, 2018. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For ORKAMBI sales in France that occurred after December 31, 2017 under the early access programs, the Company recognized net product revenues based on a transaction price that reflected the Company’s estimate of consideration it expected to retain that would not be subject to a significant reversal in amounts recognized. When determining if variable consideration should be constrained, the Company considers whether there are factors outside its control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. The Company recognized ORKAMBI net product revenues from sales in France based on this estimate from the first quarter of 2018 through the third quarter of 2019. Upon reaching an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs in November 2019, the Company updated the transaction price to reflect the final amount for ORKAMBI distributed through early access programs. As a result, the Company recognized net product revenues of </span><span style="font-family:inherit;font-size:10pt;"><span>$155.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to prior period ORKAMBI early access program sales in the fourth quarter of 2019 because the updated transaction price for ORKAMBI distributed through these programs exceeded the Company’s previous estimate of the consideration it expected to retain that would not be subject to a significant reversal in amounts recognized. Additionally, the Company’s refund liability no longer requires estimation as of December 31, 2019 and will be paid to the French government in 2020. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaborative and Royalty Revenues</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms of these agreements typically include payment to the Company related to one or more of the following: nonrefundable, upfront license fees; development and commercial milestones; funding of research and/or development activities; and royalties on net sales of licensed products. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaborator.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For each collaborative research, development and/or commercialization agreement that results in revenue, the Company identifies all material performance obligations, which may include a license to intellectual property and know-how, research and development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimate of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. In order to account for these agreements, the Company must develop assumptions that require judgment to determine the standalone selling price, which may include (i) the probability of obtaining marketing approval for the drug candidate, (ii) estimates regarding the timing of and the expected costs to develop and commercialize the drug candidate, (iii) estimates of future cash flows from potential product sales with respect to the drug candidate and (iv) appropriate discount and tax rates. Standalone selling prices used to perform the initial allocation are not updated after contract </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Upfront License Fees: </span><span style="font-family:inherit;font-size:10pt;">If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related nonrefundable, upfront license fees based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license.  For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.  The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Development and Regulatory Milestone Payments: </span><span style="font-family:inherit;font-size:10pt;">Depending on facts and circumstances, the Company may conclude that it is appropriate to include certain milestones in the estimated transaction price or that it is appropriate to fully constrain the milestones. A milestone payment is included in the transaction price in the reporting period that the Company concludes that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods. This may result in revenues from certain milestones and a corresponding contract asset being recorded in a reporting period before the milestone is achieved. Milestone payments that have not been included in the transaction price to date are fully constrained until the Company concludes that their achievement is probable and that recognition of the related revenue will not result in a significant reversal in amounts recognized in future periods. The Company re-evaluates the probability of achievement of such development milestones and any related constraint each reporting period and adjusts its estimate of the overall transaction price, including the amount of collaborative revenue that it has recorded, if necessary. The Company has not recorded any significant development or regulatory milestone revenues the three years ended December 31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Activities/Transition Services: </span><span style="font-family:inherit;font-size:10pt;">If the Company is entitled to reimbursement from its collaborators for specified research and development expenses, it accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as collaborative revenues or an offset to research and development expenses in accordance with the provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sales-based Milestone and Royalty Payments: </span><span style="font-family:inherit;font-size:10pt;">The Company’s collaborators may be required to pay the Company sales-based milestones or royalties on future sales of commercial products.  The Company recognizes revenues related to sales-based milestone and royalties upon the later to occur of (i) achievement of the collaborator’s underlying sales or (ii) satisfaction of any performance obligation(s) related to these sales, in each case assuming the license to the Company’s intellectual property is deemed to be the predominant item to which the sales-based milestones and/or royalties relate. The Company has not recorded any sales-based milestones or royalties revenues during the three years ended December 31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to Accounting Standards Codification (“ASC”) 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers </span><span style="font-family:inherit;font-size:10pt;">(“</span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;">”), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that it transfers to the customer. Once a contract is determined to be within the scope of </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;"> at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon delivery. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product Revenues, Net</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sells its products principally to a limited number of specialty pharmacy and specialty distributors in the United States, which account for the largest portion of its total revenues, and makes international sales primarily to specialty distributors and retail chains, as well as hospitals and clinics, many of which are government-owned or supported (collectively, its “Customers”). The Company’s Customers in the United States subsequently resell the products to patients and health care providers. In accordance with </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;">, the Company recognizes net product revenues from sales when the Customers obtain control of the Company’s products, which typically occurs upon delivery to the Customer. The Company’s payment terms are approximately 30 days in the United States and consistent with prevailing practice in international markets. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues from product sales are recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from (a) invoice discounts for prompt payment and distribution fees, (b) government and private payor rebates, chargebacks, discounts and fees and (c) costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves are classified as reductions to “</span><span style="font-size:10pt;">Accounts receivable, net</span><span style="font-family:inherit;font-size:10pt;">” if payable to a Customer or “</span><span style="font-size:10pt;">Accrued expenses</span><span style="font-family:inherit;font-size:10pt;">” if payable to a third-party.  Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns.  The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.  Actual amounts of consideration ultimately received may differ from the Company’s estimates.  If actual results vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Invoice Discounts and Distribution Fees: </span><span style="font-family:inherit;font-size:10pt;">The Company generally provides invoice discounts on product sales to its Customers for prompt payment and pays fees for distribution services, such as fees for certain data that Customers provide to the Company. The Company estimates that, based on its experience, its Customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Rebates, Chargebacks, Discounts and Fees: </span><span style="font-family:inherit;font-size:10pt;">The Company contracts with government agencies (its “Third-party Payors”) so that products will be eligible for purchase by, or partial or full reimbursement from, such Third-party Payors. The Company estimates the rebates, chargebacks, discounts and fees it will provide to Third-party Payors and deducts </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">these estimated amounts from its gross product revenues at the time the revenues are recognized. For each product, the Company estimates the aggregate rebates, chargebacks and discounts that it will provide to Third-party Payors based upon (i) the Company’s contracts with these Third-party Payors, (ii) the government-mandated discounts and fees applicable to government-funded programs, (iii) information obtained from the Company’s Customers and other third-party data regarding the payor mix for such product and (iv) historical experience.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Incentives: </span><span style="font-family:inherit;font-size:10pt;">Other incentives that the Company offers include co-pay mitigation rebates provided by the Company to commercially insured patients who have coverage and who reside in states that permit co-pay mitigation programs. Based upon the terms of the Company’s co-pay mitigation programs, the Company estimates average co-pay mitigation amounts for each of its products in order to establish appropriate accruals.</span></div> 62300000 24900000 24900000 8300000 155800000 <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Concentration of Credit Risk</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of money market funds and marketable securities. The Company places these investments with highly rated financial institutions, and, by policy, limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company also maintains a foreign currency hedging program that includes foreign currency forward contracts with several counterparties. The Company has not experienced any credit losses related to these financial instruments and does not believe it is exposed to any significant credit risk related to these instruments. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also is subject to credit risk from its accounts receivable related to its product sales and collaborators. The Company evaluates the creditworthiness of each of its customers and has determined that all of its material customers are </span></div><span style="font-family:inherit;font-size:10pt;">creditworthy. To date, the Company has not experienced significant losses with respect to the collection of its accounts receivable. The Company believes that its allowance for doubtful accounts was adequate at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span>. <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Cash and Cash Equivalents</span></div><span style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investments with original maturities of </span><span style="font-family:inherit;font-size:10pt;">three</span> months or less at the date of purchase to be cash equivalents. <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Marketable Securities </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company’s marketable securities consisted of investments in available-for-sale debt securities, including government-sponsored enterprise securities, corporate debt securities and commercial paper, and corporate equity securities with readily determinable fair values. The Company classifies marketable securities available to fund current operations as current assets on its consolidated balance sheets. Marketable securities are classified as long-term assets on the consolidated balance sheets if (i) they have been in an unrealized loss position for longer than one year and (ii) the Company has the ability and intent to hold them (a) until the carrying value is recovered and (b) such holding period may be longer than one year. The Company’s marketable securities are stated at fair value. The fair value of these securities is based on quoted prices for identical or similar assets. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> The Company records unrealized gains (losses) on available-for-sale debt securities as a component of “</span><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive (loss) income</span><span style="font-family:inherit;font-size:10pt;">,” which is a separate component of shareholders’ equity on its consolidated balance sheet, until such gains and losses are realized.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the adoption of Accounting Standards Update (“ASU”) 2016-01, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recognition and Measurement of Financial Assets and Financial Liabilities</span><span style="font-family:inherit;font-size:10pt;"> (“</span><span style="font-family:inherit;font-size:10pt;">ASU 2016-01</span><span style="font-family:inherit;font-size:10pt;">”) on January 1, 2018, the Company began recording changes in the fair value of its investments in corporate equity securities to “</span><span style="font-size:10pt;">Other income (expense), net</span><span style="font-family:inherit;font-size:10pt;">” in the Company’s consolidated statements of operations. Prior to its adoption of </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-01</span><span style="font-family:inherit;font-size:10pt;"> in 2018, the Company recorded changes in the fair value of its investments in corporate equity securities to “</span><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive (loss) income</span><span style="font-family:inherit;font-size:10pt;">.” </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company reviews investments in marketable debt securities for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers whether it has an intent to sell, or whether it is more likely than not that the Company will be required to sell, the investment before recovery of the investment’s amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company’s investment policy, the severity and the duration of the impairment and changes in value subsequent to year-end. If a decline in the fair value is considered other-than-temporary, based on available evidence, the unrealized loss is transferred from other comprehensive income (loss) to the consolidated statements of operations. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Realized gains and losses are determined using the specific identification method and are included in “</span><span style="font-size:10pt;">Other income (expense), net</span><span style="font-family:inherit;font-size:10pt;">” in the consolidated statements of operations. </span></div> <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Accounts Receivable </span></div>The Company deducts invoice discounts for prompt payment and fees for distribution services from its accounts receivable based on its experience that the Company’s Customers will earn these discounts and fees. The Company’s estimates for its allowance for doubtful accounts, which have not been significant to date, are determined based on existing contractual payment terms and historical payment patterns. <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Stock-based Compensation Expense</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company expenses the fair value of employee stock options and other forms of stock-based employee compensation over the associated employee service period on a straight-line basis. Stock-based compensation expense is determined based on the fair value of the award at the grant date and is adjusted each period to reflect actual forfeitures and the outcomes of certain performance conditions. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For awards with performance conditions in which the award does not vest unless the performance condition is met, the Company recognizes expense if, and to the extent that, the Company estimates that achievement of the performance condition is probable. If the Company concludes that vesting is probable, it recognizes expense from the date it reaches this conclusion through the estimated vesting date. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company provides to employees who have rendered a certain number of years’ to the Company and meet certain age requirements, partial or full acceleration of vesting of these equity awards, subject to certain conditions including a notification period, upon a termination of employment other than for cause. Approximately </span><span style="font-family:inherit;font-size:10pt;"><span>5%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s employees were eligible for partial or full acceleration of any of their equity awards as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company recognizes stock-based compensation expense related to these awards over a service period reflecting qualified employees’ eligibility for partial or full acceleration of vesting.</span></div> 0.05 <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Research and Development Expenses</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company expenses as incurred all research and development expenses, including amounts funded by research and development collaborations. The Company capitalizes nonrefundable advance payments made by the Company for research and development activities and expenses the payments as the related goods are delivered or the related services are performed.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses are comprised of costs incurred by the Company in performing research and development activities, including salary and benefits; stock-based compensation expense; outsourced services and other direct expenses, including clinical trial and pharmaceutical development costs; collaboration and asset acquisition payments; expenses associated with drug supplies that are not being capitalized; and infrastructure costs, including facilities costs and depreciation expense.</span></div> <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Inventories</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company values its inventories at the lower-of-cost or net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and writes down any excess and obsolete inventories to their net realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases are capitalized and recorded upon sale in “</span><span style="font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;">” in the consolidated statements of operations. Shipping and handling costs incurred for product shipments are recorded as incurred in “</span><span style="font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;">” in the consolidated statements of operations.</span></div>The Company capitalizes inventories produced in preparation for initiating sales of a drug candidate when the related drug candidate is considered to have a high likelihood of regulatory approval and the related costs are expected to be recoverable through sales of the inventories. In determining whether or not to capitalize such inventories, the Company evaluates, among other factors, information regarding the drug candidate’s safety and efficacy, the status of regulatory submissions and communications with regulatory authorities and the outlook for commercial sales, including the existence of current or anticipated competitive drugs and the availability of reimbursement. In addition, the Company evaluates risks associated with manufacturing the drug candidate and the remaining shelf-life of the inventories. <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Property and Equipment</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset, generally </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> for furniture and equipment, </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> years for computers and software and for leasehold improvements, the shorter of the useful life of the improvements or the estimated remaining life of the associated lease. Maintenance and repairs to an asset that do not improve or extend its life are charged to operations. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the Company’s consolidated statements of operations. The Company performs an assessment of the fair value of the assets if indicators of impairment are identified during a reporting period and records the assets at the lower of the net book value or the fair value of the assets.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company capitalizes internal costs incurred to develop software for internal use during the application development stage. Amortization of capitalized internally developed software costs is recorded in depreciation expense over the useful life of the related asset. </span></div> P10Y <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Leases</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted ASU 2016-02, Leases (Topic 842) (“ASC 842”) as of January 1, 2019. Under ASC 842, the Company determines whether the arrangement contains a lease at the inception of an arrangement. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its consolidated balance sheet and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12 months.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company does not separate lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases are recorded in “</span><span style="font-size:10pt;">Property and equipment, net</span><span style="font-family:inherit;font-size:10pt;">,” “</span><span style="font-size:10pt;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;">” and “</span><span style="font-size:10pt;">Long-term finance lease liabilities</span><span style="font-family:inherit;font-size:10pt;">” and operating leases are recorded in “</span><span style="font-size:10pt;">Other assets</span><span style="font-family:inherit;font-size:10pt;">,” “</span><span style="font-size:10pt;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;">” and “</span><span style="font-size:10pt;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;">” on the Company’s consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the adoption of ASC 842 on January 1, 2019, the Company applied build-to-suit accounting and was the deemed owner of its leased corporate headquarters in Boston and research site in San Diego, for which it was recognizing depreciation expense over the buildings’ useful lives and imputed interest on the corresponding construction financing lease obligations. The Company also recorded leases for equipment as capital leases pursuant to the accounting guidance that was effective until December 31, 2018.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The assets and liabilities associated with the Company’s capital lease agreements were recorded at the present value of the minimum lease payments at the inception of the lease agreement. The assets were depreciated using the straight-line method over the shorter of the useful life of the related asset or the remaining life of the associated lease. Amortization of capital lease assets was included in depreciation expense. </span></div> <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Income Taxes</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax bases of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. On a periodic basis, the Company reassesses the valuation allowance on its deferred income tax assets weighing positive and negative evidence to assess the recoverability of its deferred tax assets. The Company includes, among other things, its recent financial performance and its future projections in this periodic assessment. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records liabilities related to uncertain tax positions by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company does not believe any such uncertain tax positions currently pending will have a material adverse effect on its consolidated financial statements.</span></div> <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Variable Interest Entities</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company reviews each collaboration agreement pursuant to which it licenses assets owned by a collaborator in order to determine whether or not it has a variable interest via the license agreement with the collaborator and if the variable interest is a variable interest in the collaborator as a whole. In assessing whether the Company has a variable interest in the collaborator as a whole, the Company considers and makes judgments regarding the purpose and design of the entity, the value of the licensed assets to the collaborator, the value of the collaborator’s total assets and the significant activities of the collaborator. If the Company has a variable interest in the collaborator as a whole, the Company assesses whether or not the Company is the primary beneficiary of that VIE based on a number of factors, including (i) which party has the power to direct the activities that most significantly affect the VIE’s economic performance, (ii) the parties’ contractual rights and responsibilities pursuant to the collaboration agreement and (iii) which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE. If the Company determines it is the primary beneficiary of a VIE at the onset of the collaboration agreement, the collaboration is treated as a business combination and the Company consolidates the financial statements of the VIE into the Company’s consolidated financial statements. On a quarterly basis, the Company evaluates whether it continues to be the primary beneficiary of any consolidated VIEs. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, it deconsolidates the VIE in the period that the determination is made.</span></div> <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Fair Value of In-process Research and Development Assets and Contingent Payments </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The present-value models the Company uses to estimate the fair values of in-process research and development assets and contingent payments pursuant to collaborations and acquisitions incorporate significant assumptions. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s discounted cash flow models pertaining to in-process research and development assets include: (i) assumptions regarding the probability of obtaining marketing approval for a drug candidate; (ii) the timing of and the expected costs to develop and commercialize a drug candidate; (iii) estimates of future cash flows from potential product sales with respect to a drug candidate; and (iv) appropriate discount and tax rates. </span></div>The Company bases its estimates of the probability of achieving the milestones relevant to the fair value of contingent payments, which could include milestone, royalty and option payments, on industry data. Estimates included in the discounted cash flow models pertaining to contingent payments also include: (i) estimate regarding the timing of the relevant development and commercial milestones and royalties, (ii) and appropriate discount rates. <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">In-process Research and Development Assets</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records the fair value of in-process research and development assets as of the transaction date of a business combination. Each of these assets is accounted for as an indefinite-lived intangible asset and is maintained on the Company’s consolidated balance sheet until either the project underlying it is completed or the asset becomes impaired. If the asset becomes impaired or is abandoned, the carrying value of the related intangible asset is written down to its fair value, and an impairment charge is recorded in the period in which the impairment occurs. If a project is completed, the carrying </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">value of the related intangible asset is amortized as a part of “</span><span style="font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;">” over the remaining estimated life of the asset beginning in the period in which the project is completed. In-process research and development assets are tested for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development that is acquired in a transaction that does not qualify as a business combination under GAAP and that does not have an alternative future use is expensed in the period in which it is acquired.</span></div> <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Goodwill</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is allocated to goodwill. Goodwill is evaluated for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist. </span></div> <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Deconsolidation</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon the occurrence of certain events and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its subsidiaries, including consolidated VIEs. If the Company determines it no longer has a controlling interest, the subsidiary is deconsolidated. The Company records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i) the aggregate of (a) the fair value of any consideration received, (b) the fair value of any retained noncontrolling investment in the former subsidiary and (c) the carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii) the carrying amount of the former subsidiary’s assets and liabilities. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Discontinued Operations</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assesses whether a deconsolidation is required to be presented as discontinued operations in its consolidated financial statements on the deconsolidation date. This assessment is based on whether or not the deconsolidation represents a strategic shift that has or will have a major effect on the Company’s operations or financial results. If the Company determines that a deconsolidation requires presentation as a discontinued operation on the deconsolidation date, or at any point during the one year period following such date, it will present the former subsidiary as a discontinued operation in current and comparative period financial statements.</span></div> <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Embedded Derivatives</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Embedded derivatives are required to be bifurcated from the host instruments and recorded at fair value if the derivatives are not clearly and closely related to the host instruments on the date of issuance. The Company did not have any material embedded derivatives that required bifurcation recorded on its consolidated balance sheets as of December 31, 2019 and 2018, respectively.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Hedging Activities</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes the fair value of hedging instruments that are designated and qualify as hedging instruments pursuant to GAAP, foreign currency forward contracts, as either assets or liabilities on the consolidated balance sheets. Changes in the fair value of these instruments are recorded each period in “</span><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive (loss) income</span><span style="font-family:inherit;font-size:10pt;">” as unrealized gains and losses until the forecasted underlying transaction occurs. Unrealized gains and losses on these foreign currency forward contracts are included in “</span><span style="font-size:10pt;">Prepaid expenses and other current assets</span><span style="font-family:inherit;font-size:10pt;">” or “</span><span style="font-size:10pt;">Other assets</span><span style="font-family:inherit;font-size:10pt;">,” and “</span><span style="font-size:10pt;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;">” or “</span><span style="font-size:10pt;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;">,” respectively, on the Company’s consolidated balance sheets depending on the remaining period until their contractual maturity. Realized gains and losses for the effective portion of such contracts are recognized in “</span><span style="font-size:10pt;">Product revenues, net</span><span style="font-family:inherit;font-size:10pt;">” in the consolidated statement of operations in the same period that it recognizes the product revenues that were impacted by the hedged foreign exchange rate changes. The Company classifies the cash flows from hedging instruments in the same category as the cash flows from the hedged items. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of the Company’s hedging instruments are subject to master netting arrangements to reduce the risk arising from such transactions with its counterparties. The Company presents unrealized gains and losses on its foreign currency forward contracts on a gross basis within its consolidated balance sheets. </span></div><span style="font-family:inherit;font-size:10pt;">The Company also enters into foreign currency forward contracts with contractual maturities of less than </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> month designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities including intercompany balances. These contracts are not designated as hedging instruments pursuant to GAAP. Realized gains and losses for such contracts are recognized in “</span><span style="font-size:10pt;">Other income (expense), net</span>” in the consolidated statement of operations each period. <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Restructuring Expenses</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records costs and liabilities associated with exit and disposal activities based on estimates of fair value in the period the liabilities are incurred. The Company’s exit and disposal activities have primarily been associated with the Company’s facilities, but also have included the termination of employees in some cases. The Company’s initial estimate of its liabilities for net ongoing costs associated with its facility obligations are recorded at fair value on the cease use date. On a quarterly basis, the Company evaluates and adjusts these liabilities as appropriate for changes in circumstances. Changes to the Company’s estimate of these liabilities are recorded as additional restructuring expenses (credits). These costs are included in “</span><span style="font-size:10pt;">Restructuring (income) expenses</span><span style="font-family:inherit;font-size:10pt;">” on the Company’s consolidated statements of operations.</span></div> 70 <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss), which includes foreign currency translation adjustments and unrealized gains and losses on foreign currency forward contracts and certain marketable securities. For purposes of comprehensive income (loss) disclosures, the Company records provisions for or benefits from income taxes related to the unrealized gains and losses on foreign currency forward contracts and certain marketable securities. The Company does not record provisions for or benefits from income taxes related to the cumulative translation adjustment, as the Company intends to permanently reinvest undistributed earnings in its foreign subsidiaries.</span></div> <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Foreign Currency Translation and Transactions</span></div><span style="font-family:inherit;font-size:10pt;">The majority of the Company’s operations occur in entities that have the U.S. dollar denominated as their functional currency. The assets and liabilities of the Company’s entities with functional currencies other than the U.S. dollar are translated into U.S. dollars at rates of exchange in effect at the end of the year. Revenue and expense amounts for these entities are translated using the average exchange rates for the period. Net unrealized gains and losses resulting from foreign currency translation are included in “</span><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive (loss) income</span><span style="font-family:inherit;font-size:10pt;">.” Net foreign currency exchange transaction losses, which are included in “</span><span style="font-size:10pt;">Other income (expense), net</span>” on the Company’s consolidated statement of operations -5200000 -1100000 -5500000 <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Net Loss Per Share Attributable to Vertex Common Shareholders</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share attributable to Vertex common shareholders are presented in conformity with the two-class method required for participating securities. Under the two-class method, earnings are allocated to (i) Vertex common shares, excluding unvested restricted stock, and (ii) participating securities, based on their respective weighted-average shares outstanding for the period. Shares of unvested restricted stock granted under the Company’s Amended and Restated 2006 Stock and Option Plan have the non-forfeitable right to receive dividends on an equal basis with other outstanding common stock. As a result, these unvested shares of restricted stock are considered participating securities under the two-class method. Potentially dilutive shares result from the assumed exercise of outstanding stock options (the proceeds of which are then assumed to have been used to repurchase outstanding stock using the treasury stock method).</span></div>Basic net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Recently Adopted Accounting Standards</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2016, the Financial Accounting Standards Board (“FASB”) issued ASC 842, which amends a number of aspects of lease accounting and requires entities to recognize right-of-use assets and liabilities on the balance sheet. ASC 842 became effective on January 1, 2019. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Until December 31, 2018, the Company applied build-to-suit accounting and was the deemed owner of its leased corporate headquarters in Boston and research site in San Diego, for which it was recognizing depreciation expense over the buildings’ useful lives and imputed interest on the corresponding construction financing lease obligations. Under the amended guidance that became effective January 1, 2019, the Company accounts for these buildings as finance leases, resulting in increased depreciation expense over the respective lease terms of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">, which are significantly shorter than the buildings’ useful lives of </span><span style="font-family:inherit;font-size:10pt;"><span>40 years</span></span><span style="font-family:inherit;font-size:10pt;">. The amended guidance also results in a reduction in imputed interest expense in the initial years of each finance lease term.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2018, the FASB issued ASU 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;"> (“ASU 2018-11”), which offered a transition option to entities adopting ASC 842. Under ASU 2018-11, entities could elect to apply ASC 842 using a modified-retrospective adoption approach resulting in a cumulative effect adjustment to accumulated deficit at the beginning of the year in which the new lease standard is adopted, rather than adjustments to the earliest comparative period presented in their financial statements. The Company adopted ASC 842 using the modified-retrospective method. As of January 1, 2019, the Company recorded a cumulative effect adjustment to increase its “</span><span style="font-size:10pt;">Accumulated deficit</span><span style="font-family:inherit;font-size:10pt;">” by </span><span style="font-family:inherit;font-size:10pt;"><span>$40.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to the adjustments to its build-to-suit leases described in the previous paragraph.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company elected the package of transition practical expedients for leases that commenced prior to January 1, 2019, allowing it not to reassess (i) whether any expired or existing contracts contain leases, (ii) the lease classification for any expired or existing leases and (iii) the initial indirect costs for any existing leases.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, the Company recorded, upon adoption of ASC 842 on January 1, 2019, operating lease assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$61.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and corresponding liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$71.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to its real estate leases that are not treated as finance leases under ASC 842. The difference between these assets and liabilities was primarily attributable to prepaid or accrued lease payments. The Company also reclassified amounts that were recorded as “Capital lease obligations, current portion” and “Capital lease obligations, excluding current portion” as of December 31, 2018 to “</span><span style="font-size:10pt;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;">” and “</span><span style="font-size:10pt;">Long-term finance lease liabilities</span><span style="font-family:inherit;font-size:10pt;">,” respectively, on January 1, 2019. These adjustments had </span><span style="font-family:inherit;font-size:10pt;">no</span><span style="font-family:inherit;font-size:10pt;"> impact on the Company’s consolidated statement of operations and had </span><span style="font-family:inherit;font-size:10pt;">no</span><span style="font-family:inherit;font-size:10pt;"> impact on the Company’s accumulated deficit.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The cumulative effect of applying ASC 842 on the Company’s consolidated balance sheet as of January 1, 2019 was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance as of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance as of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">December 31, 2018 ^</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">January 1, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Assets</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>140,819</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,930</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>137,889</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>812,005</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(53,920</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>758,085</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,499,672</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,236</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,510,908</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>61,674</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>61,674</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,245,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>16,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,261,958</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Liabilities and Shareholders’ Equity</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Capital lease obligations, current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,817</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(9,817</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>40,589</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>34,304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>74,893</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Capital lease obligations, excluding current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,658</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(19,658</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Construction financing lease obligation, excluding current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>561,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(561,892</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Long-term finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>569,487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>569,487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>26,280</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>43,946</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>70,226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,989,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(40,310</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(3,029,788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities and shareholders’ equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,245,898</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>16,060</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,261,958</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="12" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;padding-top:16px;text-align:left;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;color:#000000;">^ As reported in the Company’s 2018 Annual Report on Form 10-K.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">“</span><span style="font-size:10pt;">Other assets</span><span style="font-family:inherit;font-size:10pt;">” and “</span><span style="font-size:10pt;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;">” in the table above relate primarily to the Company’s operating leases. Please refer to </span><span style="font-family:inherit;font-size:10pt;">Note M, “Leases,”</span><span style="font-family:inherit;font-size:10pt;"> for further information regarding the Company’s leases as well as certain disclosures required by ASC 842.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Derivatives and Hedging</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2017, the FASB issued ASU 2017-12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815) </span><span style="font-family:inherit;font-size:10pt;">(“ASU 2017-12”), which helps simplify certain aspects of hedge accounting and enables entities to more accurately present their risk management activities in their financial statements. ASU 2017-12 became effective January 1, 2019. The adoption of ASU 2017-12 did not have a significant effect on the Company’s consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2014, the FASB issued </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;">. The new guidance became effective January 1, 2018. </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;"> applies a more principles-based approach to recognizing revenue. Under </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;">, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;"> on January 1, 2018 using the modified-retrospective adoption method for all contracts that were not completed as of the date of adoption. Under the modified-retrospective method, the Company recognized the cumulative effect of applying the standard within “</span><span style="font-size:10pt;">Accumulated deficit</span><span style="font-family:inherit;font-size:10pt;">” on its consolidated balance sheet as of January 1, 2018. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For all reporting periods, the Company has not disclosed the value of unsatisfied performance obligations for all product revenue contracts with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules.  </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on the Company’s review of existing customer contracts as of January 1, 2018, it concluded that the only significant impact that the adoption of </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;"> had on its financial statements related to shipments of ORKAMBI under early access programs in France. Prior to the adoption of </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;">, the Company did not recognize revenue on the proceeds received from sales of ORKAMBI under early access programs in France because the price was not fixed or determinable based on the status of ongoing pricing discussions. As of January 1, 2018, the Company recorded a cumulative effect </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">adjustment to its accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to the adoption of </span><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;">, which primarily represented the Company’s estimated amount of consideration it expected to retain related to these shipments that would not be subject to a significant reversal in amounts recognized, net of costs previously deferred related to these shipments. Please refer to “Product Revenues, Net” above for further information related to the impact of the new revenue recognition on these sales. </span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The impact of adoption on the Company’s consolidated statement of operations for the year ended December 31, 2018 was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year Ended December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As Reported <br/>under ASC 606</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balances <br/>without Adoption of ASC 606</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Effect of Change<br/>Higher/(Lower)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,038,325</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,019,484</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>18,841</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cost of sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>409,539</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>402,925</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,614</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>635,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>622,923</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,227</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income attributable to Vertex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,096,896</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,084,669</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,227</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts per share attributable to Vertex common shareholders:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASC 606</span><span style="font-family:inherit;font-size:10pt;"> did not have an aggregate impact on the Company’s net cash provided by operating activities, but resulted in offsetting changes in certain assets and liabilities presented within net cash provided by operating activities in the Company’s consolidated statement of cash flows. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Equity Investments</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-01</span><span style="font-family:inherit;font-size:10pt;">, which amended guidance related to the recording of financial assets and financial liabilities. Under </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-01</span><span style="font-family:inherit;font-size:10pt;">, equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of an investee) are measured at fair value with changes in fair value recognized in net income (loss). However, an entity has the option to measure equity investments without readily determinable fair values at (i) fair value or (ii) cost adjusted for changes in observable prices minus impairment. Changes in measurement under either alternative are recognized in net income (loss). </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-01</span><span style="font-family:inherit;font-size:10pt;"> became effective January 1, 2018 and required the modified-retrospective adoption method. As of January 1, 2018, the Company held publicly traded equity investments and equity investments accounted for under the cost method. As a result, in 2018, the Company recorded a </span><span style="font-family:inherit;font-size:10pt;"><span>$25.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> cumulative effect adjustment to “</span><span style="font-size:10pt;">Accumulated deficit</span><span style="font-family:inherit;font-size:10pt;">” related to its publicly traded equity investments equal to the unrealized gain, net of tax, that was recorded in “</span><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive (loss) income</span><span style="font-family:inherit;font-size:10pt;">” as of December 31, 2017. The adoption of </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-01</span><span style="font-family:inherit;font-size:10pt;"> had no effect on the Company’s equity investments accounted for under the cost method because the original cost basis of these investments was recorded on the Company’s consolidated balance sheet as of December 31, 2017. In 2019 and 2018, the Company recorded net unrealized gains of </span><span style="font-family:inherit;font-size:10pt;"><span>$132.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, to “</span><span style="font-size:10pt;">Other income (expense), net</span><span style="font-family:inherit;font-size:10pt;">” in its consolidated statement of operations related to the change in fair value of its equity investments.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intra-Entity Transfers</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued ASU 2016-16, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intra-Entity Transfers of Assets Other Than Inventory</span><span style="font-family:inherit;font-size:10pt;"> (“</span><span style="font-family:inherit;font-size:10pt;">ASU 2016-16</span><span style="font-family:inherit;font-size:10pt;">”), which removes the previous exception in GAAP prohibiting an entity from recognizing current and deferred income tax expenses or benefits related to the transfer of assets, other than inventory, within the consolidated entity. The exception to defer the recognition of any tax impact on the transfer of inventory within the consolidated entity until it is sold to a third party remains unaffected. </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-16</span><span style="font-family:inherit;font-size:10pt;"> became effective January 1, 2018. In 2018, upon adoption of </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-16</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded a deferred tax asset and corresponding full valuation allowance of </span><span style="font-family:inherit;font-size:10pt;"><span>$204.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> equal to the unamortized cost of </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">intellectual property rights transferred to the United Kingdom in 2014 multiplied by an appropriate statutory rate. There was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> cumulative effect adjustment to “</span><span style="font-size:10pt;">Accumulated deficit</span><span style="font-family:inherit;font-size:10pt;">” using the modified-retrospective adoption method.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Goodwill</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2017, the FASB issued ASU 2017-04, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350) </span><span style="font-family:inherit;font-size:10pt;">(“</span><span style="font-family:inherit;font-size:10pt;">ASU 2017-04</span><span style="font-family:inherit;font-size:10pt;">”) related to measurements of goodwill. </span><span style="font-family:inherit;font-size:10pt;">ASU 2017-04</span><span style="font-family:inherit;font-size:10pt;"> modifies the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value, which eliminates Step 2 from the goodwill impairment test. An entity would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to the related reporting unit. The Company early adopted </span><span style="font-family:inherit;font-size:10pt;">ASU 2017-04</span><span style="font-family:inherit;font-size:10pt;"> and utilized this approach for annual and interim goodwill impairment tests conducted after January 1, 2018. The adoption of </span><span style="font-family:inherit;font-size:10pt;">ASU 2017-04</span><span style="font-family:inherit;font-size:10pt;"> did not have a significant effect on the Company’s consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash Flows - Restricted Cash</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">In 2016, the FASB issued ASU 2016-18, </span><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230) Restricted Cash</span><span style="font-family:Times New Roman;font-size:10pt;"> (“</span><span style="font-family:Times New Roman;font-size:10pt;">ASU 2016-18</span><span style="font-family:Times New Roman;font-size:10pt;">”), which requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and restricted cash. Therefore, amounts described as restricted cash should be included with cash and cash equivalents when reconciling the beginning of period and end of period amounts shown on the statement of cash flows.  </span><span style="font-family:Times New Roman;font-size:10pt;">ASU 2016-18</span><span style="font-family:Times New Roman;font-size:10pt;"> became effective January 1, 2018 and was effective on a retrospective basis. The cash, cash equivalents and restricted cash balances for the years ended December 31, </span><span style="font-family:Times New Roman;font-size:10pt;">2019</span><span style="font-family:Times New Roman;font-size:10pt;"> through </span><span style="font-family:Times New Roman;font-size:10pt;">2016</span><span style="font-family:Times New Roman;font-size:10pt;">, which are presented in the Company’s consolidated statements of cash flows subsequent to the adoption of </span><span style="font-family:Times New Roman;font-size:10pt;">ASU 2016-18</span><span style="font-family:Times New Roman;font-size:10pt;">, consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,109,322</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,650,134</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,665,412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,183,945</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,004</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,910</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>47,762</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,209</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash, cash equivalents and restricted cash per statement of cash flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,120,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,658,253</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,667,526</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,231,707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s restricted cash, if any, is included in “</span><span style="font-size:10pt;">Prepaid expenses and other current assets</span><span style="font-family:inherit;font-size:10pt;">” and “</span><span style="font-size:10pt;">Other assets</span><span style="font-family:inherit;font-size:10pt;">” in its consolidated balance sheets. As of December 31, 2017 and 2016, the Company recorded BioAxone’s cash and cash equivalents as “</span><span style="font-size:10pt;">Prepaid expenses and other current assets</span><span style="font-family:inherit;font-size:10pt;">” because the Company did not have any interest in or control over BioAxone’s cash and cash equivalents. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation - Improvements</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued ASU 2016-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting </span><span style="font-family:inherit;font-size:10pt;">(“</span><span style="font-family:inherit;font-size:10pt;">ASU 2016-09</span><span style="font-family:inherit;font-size:10pt;">”), which simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-09</span><span style="font-family:inherit;font-size:10pt;"> became effective January 1, 2017. </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-09</span><span style="font-family:inherit;font-size:10pt;"> eliminated the requirement that excess tax benefits were realized as a reduction in current taxes payable before the associated tax benefit could be recognized as an increase in additional paid-in capital. This created a deferred tax asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$410.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> relating to federal and state net operating losses (“NOLs”) that were fully reserved by an equal increase in the Company’s valuation allowance as of January 1, 2017. The Company recorded deferred tax assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$404.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> relating to federal NOLs and </span><span style="font-family:inherit;font-size:10pt;"><span>$6.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> relating to state NOLs, both of which were offset by a full valuation allowance. Upon adoption, the Company also elected to change its accounting policy to account for forfeitures of options and awards as they occur. The change was applied on a modified-retrospective basis with a cumulative effect adjustment to increase “</span><span style="font-size:10pt;">Accumulated deficit</span><span style="font-family:inherit;font-size:10pt;">” by </span><span style="font-family:inherit;font-size:10pt;"><span>$9.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of January 1, 2017. This change also resulted in an increase to the deferred tax asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was offset by a full valuation allowance. As a result, there was no cumulative effect adjustment to accumulated deficit related to income taxes. The provisions related to the recognition of excess tax benefits in the Company’s consolidated statement of </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">operations and classification in the consolidated statement of cash flows were adopted prospectively, and as such, the prior periods were not retrospectively adjusted.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Recently Issued Accounting Standards</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Internal-Use Software</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2018, the FASB issued ASU 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract </span><span style="font-family:inherit;font-size:10pt;">(“</span><span style="font-family:inherit;font-size:10pt;">ASU 2018-15</span><span style="font-family:inherit;font-size:10pt;">”), which clarifies the accounting for implementation costs in cloud computing arrangements.  </span><span style="font-family:inherit;font-size:10pt;">ASU 2018-15</span><span style="font-family:inherit;font-size:10pt;"> was effective on January 1, 2020. The Company expects the adoption of </span><span style="font-family:inherit;font-size:10pt;">ASU 2018-15</span><span style="font-family:inherit;font-size:10pt;"> will result in an insignificant amount of additional assets recorded on its consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value Measurement</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2018, the FASB issued ASU 2018-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:inherit;font-size:10pt;"> (“</span><span style="font-family:inherit;font-size:10pt;">ASU 2018-13</span><span style="font-family:inherit;font-size:10pt;">”), which modifies the disclosure requirements for fair value measurements. </span><span style="font-family:inherit;font-size:10pt;">ASU 2018-13</span><span style="font-family:inherit;font-size:10pt;"> was effective on January 1, 2020. The Company expects the adoption of </span><span style="font-family:inherit;font-size:10pt;">ASU 2018-13</span><span style="font-family:inherit;font-size:10pt;"> will result in additional disclosures related to its assets and liabilities that are valued based on Level 3 inputs.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Credit Losses</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“</span><span style="font-family:inherit;font-size:10pt;">ASU 2016-13</span><span style="font-family:inherit;font-size:10pt;">”), which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-13</span><span style="font-family:inherit;font-size:10pt;"> requires allowances to be recorded instead of reducing the amortized cost of the investment. </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-13</span><span style="font-family:inherit;font-size:10pt;"> was effective on January 1, 2020. The Company does not expect the adoption of </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-13</span><span style="font-family:inherit;font-size:10pt;"> to have a significant impact on its consolidated financial statements.</span></div> P15Y P40Y 40300000 61700000 71900000 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The cumulative effect of applying ASC 842 on the Company’s consolidated balance sheet as of January 1, 2019 was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance as of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance as of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">December 31, 2018 ^</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">January 1, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Assets</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>140,819</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,930</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>137,889</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>812,005</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(53,920</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>758,085</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,499,672</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,236</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,510,908</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>61,674</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>61,674</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,245,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>16,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,261,958</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Liabilities and Shareholders’ Equity</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Capital lease obligations, current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,817</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(9,817</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>40,589</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>34,304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>74,893</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Capital lease obligations, excluding current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,658</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(19,658</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Construction financing lease obligation, excluding current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>561,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(561,892</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Long-term finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>569,487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>569,487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>26,280</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>43,946</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>70,226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,989,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(40,310</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(3,029,788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities and shareholders’ equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,245,898</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>16,060</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,261,958</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="12" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;padding-top:16px;text-align:left;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;color:#000000;">^ As reported in the Company’s 2018 Annual Report on Form 10-K.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The impact of adoption on the Company’s consolidated statement of operations for the year ended December 31, 2018 was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year Ended December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As Reported <br/>under ASC 606</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balances <br/>without Adoption of ASC 606</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Effect of Change<br/>Higher/(Lower)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,038,325</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,019,484</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>18,841</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cost of sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>409,539</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>402,925</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,614</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>635,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>622,923</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,227</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income attributable to Vertex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,096,896</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,084,669</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,227</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts per share attributable to Vertex common shareholders:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 140819000 -2930000 137889000 812005000 -53920000 758085000 1499672000 11236000 1510908000 61674000 61674000 6245898000 16060000 6261958000 9817000 -9817000 40589000 34304000 74893000 19658000 -19658000 561892000 -561892000 569487000 569487000 26280000 43946000 70226000 -2989478000 -40310000 -3029788000 6245898000 16060000 6261958000 8300000 3038325000 3019484000 18841000 409539000 402925000 6614000 635150000 622923000 12227000 2096896000 2084669000 12227000 8.24 8.20 0.04 8.09 8.04 0.05 -25100000 132500000 2600000 204700000 0 The cash, cash equivalents and restricted cash balances for the years ended December 31, <span style="font-family:Times New Roman;font-size:10pt;">2019</span><span style="font-family:Times New Roman;font-size:10pt;"> through </span><span style="font-family:Times New Roman;font-size:10pt;">2016</span><span style="font-family:Times New Roman;font-size:10pt;">, which are presented in the Company’s consolidated statements of cash flows subsequent to the adoption of </span><span style="font-family:Times New Roman;font-size:10pt;">ASU 2016-18</span><span style="font-family:Times New Roman;font-size:10pt;">, consisted of the following:</span><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,109,322</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,650,134</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,665,412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,183,945</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,004</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,910</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>47,762</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,209</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash, cash equivalents and restricted cash per statement of cash flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,120,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,658,253</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,667,526</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,231,707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3109322000 2650134000 1665412000 1183945000 8004000 4910000 2114000 47762000 3355000 3209000 0 0 3120681000 2658253000 1667526000 1231707000 410800000 404700000 6100000 -9400000 3400000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has entered into numerous agreements pursuant to which it collaborates with third parties on research, development and commercialization programs, including in-license and out-license agreements. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">In-license Agreements</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has entered into a number of license agreements in order to advance and obtain access to technologies and services related to its research and early-development activities. The Company is generally required to make an upfront payment upon execution of the license agreement; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from the collaboration.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the terms of its in-license agreements, the Company’s collaborators typically lead the discovery efforts and the Company leads all preclinical, development and commercialization activities associated with the advancement of any drug candidates and funds all expenses. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company typically can terminate its in-license agreements by providing advance notice to its collaborators; the required length of notice is dependent on whether any product developed under the license agreement has received marketing approval. The Company’s license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">CRISPR Therapeutics AG</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2015, the Company entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. The Company had the exclusive right to license certain CRISPR Cas9-based targets. In the fourth quarter of 2019, the Company paid an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to exclusively license three CRISPR-Cas9-based targets, including CF, pursuant to the CRISPR Agreement. The Company recorded the </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> total option payment to “</span><span style="font-size:10pt;">Research and development expenses</span><span style="font-family:inherit;font-size:10pt;">” in the fourth quarter of 2019. For each of the three targets that the Company elected to license, CRISPR has the potential to receive up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$410.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in development, regulatory and commercial milestones as well as royalties on net product sales. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2017, the Company entered into a co-development and co-commercialization agreement with CRISPR pursuant to the terms of the CRISPR Agreement, under which the Company and CRISPR are co-developing and will co-commercialize CTX001 (the “CTX001 Co-Co Agreement”) for the treatment of hemoglobinopathy, including treatments for sickle cell disease and beta-thalassemia. As part of the collaboration, the Company and CRISPR share equally all development costs and potential worldwide revenues related to potential hemoglobinopathy treatments, including treatments for beta-thalassemia and sickle cell disease. The Company concluded that the CTX001 Co-Co Agreement is a cost-sharing arrangement, which results in the net impact of the arrangement being recorded in “</span><span style="font-size:10pt;">Research and development expenses</span><span style="font-family:inherit;font-size:10pt;">” in its consolidated statements of operations. During the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the net expense related to the CTX001 Co-Co Agreement was </span><span style="font-family:inherit;font-size:10pt;"><span>$30.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$19.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Net expense related to the CTX001 Co-Co Agreement during the year ended December 31, 2017 was not significant.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2019, the Company entered into a separate strategic collaboration and license agreement (the “CRISPR DMD/DM1 Agreement”) with CRISPR. Pursuant to this agreement, the Company received an exclusive worldwide license to CRISPR’s existing and future intellectual property for duchenne muscular dystrophy (“DMD”) and myotonic dystrophy type 1 (“DM1”) and the Company made an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$175.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to CRISPR. The Company concluded that it did not have any alternative future use for the acquired in-process research and development and recorded the upfront payment to “</span><span style="font-size:10pt;">Research and development expenses</span><span style="font-family:inherit;font-size:10pt;">” in the third quarter of 2019. CRISPR has the potential to receive up to </span><span style="font-family:inherit;font-size:10pt;"><span>$825.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in research, development, regulatory and commercial milestones for the DMD and DM1 programs as well as royalties on net product sales. CRISPR has the option to co-develop and co-commercialize all DM1 products globally and forego the milestones and royalties associated with the DM1 program. The Company will fund all expenses associated with the </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">collaboration except for research costs for specified guide RNA research conducted by CRISPR, which the Company and CRISPR will share equally.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Please refer to </span><span style="font-family:inherit;font-size:10pt;">Note F, “Marketable Securities and Equity Investments,”</span><span style="font-family:inherit;font-size:10pt;"> for information regarding the Company’s investment in CRISPR’s common stock.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Kymera Therapeutics Inc.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2019, the Company entered into a strategic research and development collaboration agreement with Kymera Therapeutics Inc. (“Kymera”) to advance small molecule protein degraders against multiple targets. Kymera’s proprietary platform technology is being applied in the collaboration activities in exchange for an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company has the exclusive right to license up to </span><span style="font-family:inherit;font-size:10pt;"><span>six</span></span><span style="font-family:inherit;font-size:10pt;"> protein targets, for each of which Kymera may receive up to </span><span style="font-family:inherit;font-size:10pt;"><span>$170.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments, including development, regulatory and commercial milestones as well as royalties on net product sales. In addition to the upfront payment, the Company purchased </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of Kymera’s preferred stock. The Company determined that the fair value of its investment in Kymera’s preferred stock, which does not have a readily determinable fair value, approximated </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and classified the investment in “</span><span style="font-size:10pt;">Other assets</span><span style="font-family:inherit;font-size:10pt;">.”</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that substantially all of the fair value of the Kymera collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development and recorded the </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment to “</span><span style="font-size:10pt;">Research and development expenses</span><span style="font-family:inherit;font-size:10pt;">.”</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other In-License Agreements</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the collaborative arrangements described above, the Company has entered into additional in-license agreements that it does not consider to be individually significant to its financial statements. In addition to the payments described above, the Company recorded upfront, option and milestone payments totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$63.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$46.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$8.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> to “</span><span style="font-size:10pt;">Research and development expenses</span><span style="font-family:inherit;font-size:10pt;">,” which included a </span><span style="font-family:inherit;font-size:10pt;color:#000000;"><span>$25.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment to Molecular Templates, Inc. (“Molecular”) in 2019 and a </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment to Arbor Biotechnologies, Inc. (“Arbor”) in 2018.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For Molecular and Arbor and several other in-license agreements that are not individually significant to the Company’s financial statements. The Company determined that substantially all of the fair value of each individual agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development associated with the agreements and recorded the related portion of the upfront payments to “</span><span style="font-size:10pt;">Research and development expenses</span><span style="font-family:inherit;font-size:10pt;">.” Please refer to </span><span style="font-size:10pt;">Note E, </span><span style="font-size:10pt;">“</span><span style="font-size:10pt;">Fair Value Measurements,</span><span style="font-size:10pt;">”</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">Note F, “Marketable Securities and Equity Investments,”</span><span style="font-family:inherit;font-size:10pt;"> for further information regarding the Company’s investments in its collaborators.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Variable Interest Entities (VIEs)</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company licensed rights to certain drug candidates from these third-party collaborators, which has resulted in the consolidation of the third-parties’ financial statements into the Company’s consolidated financial statements as VIEs for certain periods of time. The Company deconsolidated the financial statements of Parion as of September 30, 2017 and BioAxone as of December 31, 2018 from its consolidated financial statements. As of December 31, 2018, and continuing through 2019, the Company had no consolidated VIEs reflected in its financial statements. Please refer to </span><span style="font-size:10pt;">Note K, </span><span style="font-size:10pt;">“</span><span style="font-size:10pt;">Intangible Assets and Goodwill,</span><span style="font-size:10pt;">”</span><span style="font-family:inherit;font-size:10pt;"> for further information regarding the impairment of Parion’s pulmonary ENaC platform and BioAxone’s VX-210 program that were related to these collaborations.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Parion Sciences, Inc.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2015, the Company entered into a strategic collaboration and license agreement (the “Parion Agreement”) with Parion to develop investigational epithelial sodium channel (“ENaC”) inhibitors for the potential treatment of CF and all other pulmonary diseases. The Parion Agreement was terminated in January 2020.  Following execution of the Parion Agreement, the Company determined that it had a variable interest in Parion via the Parion Agreement, and that the variable interest </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">represented a variable interest in Parion as a whole because the fair value of the ENaC inhibitors represented more than half of the total fair value of Parion’s assets. The Company also concluded that it was the primary beneficiary as it had the power to direct the activities that most significantly affect the economic performance of Parion and that it had the obligation to absorb losses and right to receive benefits that potentially could be significant to Parion.  Accordingly, the Company consolidated Parion’s financial statements beginning in June 2015. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the second quarter of 2017, Parion signed a license agreement with an affiliate of Shire plc related to the development of a drug candidate for the potential treatment of dry eye disease; however, the Company continued to consolidate Parion as a VIE because it determined that there was no substantive change in the design of Parion subsequent to Parion’s agreement with Shire. Based on the consolidation of Parion’s financial statements, during the year ended December 31, 2017, the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$40.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of collaborative revenues and (ii) a tax provision of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, both of which were attributable to noncontrolling interest related to payments that Parion received from Shire in the year ended December 31, 2017. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of September 30, 2017, the Company determined that the </span><span style="font-family:inherit;font-size:10pt;"><span>$255.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> fair value of Parion’s pulmonary ENaC platform had declined significantly based on data received in September 2017 from a Phase 2 clinical trial of VX-371 that did not meet its primary efficacy endpoint. Based on this data, the Company evaluated the fair value of Parion’s pulmonary ENaC platform using the discounted cash flow approach from the perspective of a market participant and determined that the fair value of the intangible asset was </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;"> as of September 30, 2017. The Company recorded a </span><span style="font-family:inherit;font-size:10pt;"><span>$255.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> impairment charge in the third quarter of 2017. After evaluating the results of the clinical trial and based on the decrease in the fair value of Parion’s pulmonary ENaC platform relative to Parion’s other activities, the Company determined that it was no longer the primary beneficiary of Parion as it no longer had the power to direct the significant activities of Parion. Accordingly, the Company deconsolidated Parion as of September 30, 2017. The impairment charge, the decrease in the fair value of the contingent payments payable by the Company to Parion of </span><span style="font-family:inherit;font-size:10pt;"><span>$69.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and the benefit from income taxes of </span><span style="font-family:inherit;font-size:10pt;"><span>$126.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> resulting from these charges that were recorded in the third quarter of 2017 were attributable to noncontrolling interest. The benefit from income taxes consisted of benefits of </span><span style="font-family:inherit;font-size:10pt;"><span>$97.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> attributable to the impairment charge and </span><span style="font-family:inherit;font-size:10pt;"><span>$28.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> attributable to the decrease in the fair value of contingent payments. The net effect of these charges and impact of the deconsolidation was a loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> recorded in “</span><span style="font-size:10pt;">Other income (expense), net</span><span style="font-family:inherit;font-size:10pt;">” attributable to Vertex in the consolidated statement of operations for the year ended December 31, 2017. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">BioAxone Biosciences, Inc.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2014, the Company entered into a license and collaboration agreement (the “BioAxone Agreement”) with BioAxone, which resulted in the consolidation of BioAxone as a VIE beginning in October 2014. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2018, the Company announced it would stop clinical development of VX-210 and terminate the Phase 2b clinical trial of VX-210 based on the recommendation of the clinical trial’s Data Safety Monitoring Board and the Company’s review of interim data. In December 2018, the Company notified BioAxone of its intent to terminate the BioAxone Agreement and executed a release that immediately allowed BioAxone to control development of its neurological programs other than VX-210 without the Company’s consent. As a result of this decision, the Company recorded a </span><span style="font-family:inherit;font-size:10pt;"><span>$29.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> impairment charge related to VX-210 that was attributable to noncontrolling interest.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result, the Company deconsolidated BioAxone as of December 31, 2018 because it determined that it no longer was the primary beneficiary of BioAxone as it no longer had the power to direct the significant activities of BioAxone. The net impact of the deconsolidation was not material to the Company’s consolidated statement of operations. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company concluded that the deconsolidations of Parion and BioAxone, based on clinical data that did not meet expectations, were not developments that represented a significant strategic shift or had a material impact on the Company’s overall operations and financial results or its plans to focus on developing and commercializing therapies for the treatment of CF and advancing its research and development programs in additional diseases. Therefore, the Company did not present the results related to Parion and BioAxone as discontinued operations in its consolidated statements of operations for the three years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate VIE Financial Information</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">An aggregate summary of net loss attributable to noncontrolling interest related to the Company’s VIEs for the years ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2018</span><span style="font-family:Times New Roman;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;">2017</span><span style="font-family:Times New Roman;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.90476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Loss attributable to noncontrolling interest before benefit from income taxes and changes in fair value of contingent payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>31,191</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>223,379</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Benefit from income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(3,668</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(114,090</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">(Increase) decrease in fair value of contingent payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(17,730</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>62,560</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net loss attributable to noncontrolling interest</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,793</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>171,849</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The increase in the noncontrolling interest holders’ claim to net assets with respect to the fair value of the contingent payments for the year ended December 31, 2018 was primarily due to the expiration of the Company’s option to purchase BioAxone that increased the probability that a </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> license continuation fee for VX-210 would be paid. The decrease in the noncontrolling interest holders’ claim to net assets with respect to the fair value of the contingent payments for the year ended December 31, 2017 was primarily due to the decrease in the fair value of Parion’s pulmonary ENaC platform described above.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Out-license Agreements</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has entered into licensing agreements pursuant to which it has out-licensed rights to certain drug candidates to third-party collaborators. Pursuant to these out-license agreements, the Company’s collaborators become responsible for all costs related to the continued development of such drug candidates and obtain development and commercialization rights to these drug candidates. Depending on the terms of the agreements, the Company’s collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and may also be required to pay royalties on future sales, if any, of commercial products resulting from the collaboration. The termination provisions associated with these collaborations are generally the same as those described above related to the Company’s in-license agreements.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Merck KGaA, Darmstadt, Germany</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the Company entered into a strategic collaboration and license agreement (the “Oncology Agreement”) with Merck KGaA, Darmstadt, Germany (the “Licensee”). Pursuant to the Oncology Agreement, the Company granted the Licensee an exclusive worldwide license to research, develop and commercialize </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> oncology research and development programs including </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> clinical-stage programs targeting DNA damage repair: its ataxia telangiectasia and Rad3-related protein kinase inhibitor program, or ATR program, including VX-970 and VX-803, and its DNA-dependent protein kinase inhibitor program, or DNA-PK program, including VX-984. In addition, the Company granted the Licensee exclusive, worldwide rights to </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> pre-clinical programs.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Oncology Agreement provided for an upfront payment from the Licensee to the Company of </span><span style="font-family:inherit;font-size:10pt;"><span>$230.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company evaluated the deliverables, primarily consisting of a license to the </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> programs and the obligation to complete certain fully-reimbursable research and development and transition activities as directed by the Licensee, pursuant to the Oncology Agreement, under the multiple element arrangement accounting guidance that was applicable in 2017. The Company concluded that the license had stand-alone value from the research and development and transition activities based on the resources and know-how possessed by the Licensee, and thus concluded that there are two units of accounting in the arrangement. The Company determined the relative selling price of the units of accounting based on the Company’s best estimate of selling price. The Company utilized key assumptions to determine the best estimate of selling price for the license, which included future potential net sales of licensed products, development timelines, reimbursement rates for personnel costs, discount rates, and estimated third-party development costs. The Company utilized a discounted cash flow model to determine its best estimate of selling price for the license and determined the best estimate of selling price for the research and development and transition activities based on what it would sell the services for separately. Given the significance of the best estimate of selling price for the license as compared to the best estimate of selling price for the </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">research and development and transition services, reasonable changes in the assumptions used in the discounted cash flow model would not have a significant impact on the relative selling price allocation. Based on this analysis, the Company recognized the </span><span style="font-family:inherit;font-size:10pt;"><span>$230.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment upon delivery of the license as well as research and development and transition activities during the year ended December 31, 2017. The Company records the reimbursement for the research and development and transition activities in its consolidated statements of operations as collaborative revenue primarily due to the fact that it is the primary obligor in the arrangement. The Company’s activities related to the research and development and transition activities under the Oncology Agreement were substantially complete as of December 31, 2017.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2018, the Company entered into an agreement with Merck KGaA, Darmstadt, Germany (the “DNA-PK Agreement”) whereby the Company licensed the two lead Vertex DNA-PK compounds from its DNA-PK program for use in the field of gene integration for six specific indications. In exchange for this exclusive worldwide license to research, develop and commercialize the DNA-PK program for the specified indications within the field of gene integration, the Company made an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$65.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. Merck KGaA, Darmstadt, Germany has the potential to receive additional milestones, primarily related to approval and reimbursement in various markets, as well as royalties on net product sales.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluated the DNA-PK Agreement and concluded it represents a modification of the Oncology Agreement pursuant to ASC 606. As of December 2018, when the Company entered into the DNA-PK Agreement, the Company had completed its obligations under the Oncology Agreement, but the Oncology Agreement was an open contract pursuant to ASC 606 since the Company could receive future royalty payments from the commercialization of the licensed programs under the Oncology Agreement. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In applying ASC 606, the Company determined that the license granted under the DNA-PK Agreement is distinct from the license granted by the Company under the Oncology Agreement since the license to the two lead Vertex DNA-PK compounds is capable of being distinct as the Company is able to benefit from the license via its ability to internally develop and commercialize the two lead Vertex DNA-PK compounds in the six named indications in the field of gene-editing, and the license is not dependent on Merck KGaA, Darmstadt, Germany providing any specialized services to the Company. In addition, the license to the two lead Vertex DNA-PK compounds granted to the Company under the DNA-PK Agreement is distinct from the license granted by the Company under the Oncology Agreement as the rights conveyed in the licenses differ and both parties have the ability to commercially benefit from the licenses on their own. Furthermore, the consideration attributable to the license of the two lead Vertex DNA-PK compounds represents fair value. Therefore, the Company determined it should account for the DNA-PK Agreement as a separate agreement.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that substantially all of the fair value of the DNA-PK Agreement was attributable to a single in-process research and development asset that did not constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development and recorded the </span><span style="font-family:inherit;font-size:10pt;"><span>$65.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> payment to “</span><span style="font-size:10pt;">Research and development expenses</span><span style="font-family:inherit;font-size:10pt;">” accordingly. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Janssen Pharmaceuticals, Inc.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2014, the Company entered into an agreement with Janssen Pharmaceuticals, Inc. (“Janssen”). Pursuant to the agreement, Janssen has an exclusive worldwide license to develop and commercialize certain drug candidates for the treatment of influenza, including pimodivir. The Company recognized a </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone in 2017, based on a Phase 3 clinical trial that Janssen initiated. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Cystic Fibrosis Foundation</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a research, development and commercialization agreement that was originally entered into in 2004 with Cystic Fibrosis Foundation (“</span><span style="font-family:inherit;font-size:10pt;">CFF</span><span style="font-family:inherit;font-size:10pt;">”), as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc. This agreement was most recently amended in 2016 (the “2016 Amendment”). Pursuant to the agreement, as amended, the Company agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor, and tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor). For combination products, such as ORKAMBI, </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SYMDEKO/SYMKEVI and TRIKAFTA (elexacaftor, tezacaftor, and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the 2016 Amendment, the Company received an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and is receiving development funding from </span><span style="font-family:inherit;font-size:10pt;">CFF</span><span style="font-family:inherit;font-size:10pt;"> of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$6.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> annually. The Company concluded that the upfront payment plus any future development funding represent a form of financing pursuant to ASC 730 and thus records the amounts as a liability on the consolidated balance sheet, primarily reflected in “</span><span style="font-size:10pt;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;">.” The Company reduces this liability over the estimated royalty term of the agreement and reflects the reductions as an offset to “</span><span style="font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;">” and as “</span><span style="font-size:10pt;">Interest expense</span><span style="font-family:inherit;font-size:10pt;">.”</span></div> 30000000.0 30000000.0 410000000.0 30100000 19700000 175000000.0 825000000.0 50000000.0 6 170000000.0 20000000.0 20000000.0 50000000.0 63300000 46900000 8700000 25900000 30000000.0 40000000.0 14800000 255300000 0 255300000 -69600000 -126200000 -97700000 -28500000 -7100000 29000000.0 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">An aggregate summary of net loss attributable to noncontrolling interest related to the Company’s VIEs for the years ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2018</span><span style="font-family:Times New Roman;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;">2017</span><span style="font-family:Times New Roman;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.90476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Loss attributable to noncontrolling interest before benefit from income taxes and changes in fair value of contingent payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>31,191</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>223,379</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Benefit from income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(3,668</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(114,090</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">(Increase) decrease in fair value of contingent payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(17,730</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>62,560</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net loss attributable to noncontrolling interest</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,793</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>171,849</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -31191000 -223379000 -3668000 -114090000 17730000 -62560000 -9793000 -171849000 10000000.0 4 2 2 230000000.0 4 230000000.0 65000000.0 65000000.0 25000000.0 75000000.0 6000000.0 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisitions </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Business Acquisitions</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exonics Therapeutics, Inc.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 16, 2019, the Company completed its acquisition of Exonics Therapeutics, Inc. (“Exonics”), a privately held biotechnology company focused on creating transformative gene-editing therapies to repair mutations that cause DMD and other severe neuromuscular diseases, including DM1. The Company acquired Exonics for an upfront payment of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$245.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, customary working capital adjustments and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in deferred payments. Exonics’ equity holders may receive an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$728.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the successful achievement of specified development and regulatory milestones for the DMD and DM1 programs.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company concluded that Exonics’ intellectual property, assembled workforce and scientific expertise, has the potential to produce therapies for patients with DMD and DM1; therefore, it accounted for the acquisition as a business combination. The Company determined that the purchase price related to the Exonics business combination was </span><span style="font-family:inherit;font-size:10pt;"><span>$438.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, which consisted of (i) the upfront payment as adjusted for customary working capital adjustments, and (ii) the estimated fair value related to </span><span style="font-family:inherit;font-size:10pt;"><span>$678.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> of contingent development and regulatory milestones attributable to the purchase of Exonics’ outstanding shares on July 16, 2019. The remaining portion, or </span><span style="font-family:inherit;font-size:10pt;"><span>$49.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, of the development and regulatory milestones and the </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in deferred payments were determined to be compensatory, as they relate to post-acquisition services, and will be expensed to “</span><span style="font-size:10pt;">Research and development expenses</span><span style="font-family:inherit;font-size:10pt;">” as incurred.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The purchase price consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.5873015873016%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Upfront payment (adjusted for customary working capital adjustments)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>266,315</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Fair value of contingent development and regulatory payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>172,041</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>438,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s methodology for determining the fair value of the contingent development and regulatory payments is described in </span><span style="font-size:10pt;">Note E, “Fair Value Measurements.”</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The Company allocated the purchase price to the following assets acquired and liabilities assumed:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.5873015873016%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">July 16, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,535</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>397,141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Intangible asset</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>13,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,680</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>438,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The “</span><span style="font-family:inherit;font-size:10pt;">Goodwill</span><span style="font-family:inherit;font-size:10pt;">” represents the difference between the fair value of the consideration transferred and the fair value of the assets and liabilities acquired. The goodwill was attributable to Exonics’ technological expertise, assembled workforce, the potential additional therapeutic programs that may be discovered utilizing Exonics’ DMD and DM1 programs and synergies </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">from combining these programs with the Company’s current gene-editing capabilities through its collaboration with CRISPR. None of the goodwill is expected to be deductible for income tax purposes. The “</span><span style="font-family:inherit;font-size:10pt;">Intangible asset</span><span style="font-family:inherit;font-size:10pt;">” is a single in-process research and development asset related to Exonics’ DMD and DM1 programs. The Company concluded that the intangible asset was a single asset based on similarities between the DMD and DM1 programs including (i) their pre-clinical stage of development, (ii) the development activities and technologies necessary to further develop them, which will be managed on a combined basis, (iii) anticipated pricing and (iv) patient populations. The fair value of the intangible asset was determined through a discounted cash flow analysis utilizing Level 3 fair value inputs related to the development and commercialization of therapies for DMD and DM1. As of December 31, 2019, the Company’s accounting for the Exonics business combination is complete.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Semma Therapeutics, Inc.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 10, 2019, the Company completed its acquisition of Semma Therapeutics, Inc. (“Semma”), a privately held biotechnology company primarily focused on the use of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes. The Company acquired Semma in exchange for a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$936.8 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The Company allocated the purchase price to the following assets acquired and liabilities assumed:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.5873015873016%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">October 10, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,331</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17,111</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>554,633</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>387,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(54,160</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,849</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>936,764</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The “</span><span style="font-family:inherit;font-size:10pt;">Goodwill</span><span style="font-family:inherit;font-size:10pt;">” represents the difference between the fair value of the consideration transferred and the fair value of the assets and liabilities acquired. The goodwill was attributable to the technological expertise in cell therapy of Semma’s assembled workforce, the potential synergies from combining Semma’s proprietary platform with the Company’s clinical development capabilities and the potential additional therapeutic programs that may be discovered utilizing Semma’s proprietary platform. None of the goodwill is expected to be deductible for income tax purposes. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The “</span><span style="font-family:inherit;font-size:10pt;">Intangible assets</span><span style="font-family:inherit;font-size:10pt;">” are in-process research and development assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$379.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$8.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to Semma’s pre-clinical treatments for device-assisted cells and naked islets, respectively. Semma produces human pancreatic beta cells, or islets, that could potentially help type 1 diabetes patients produce appropriate levels of insulin and safely control hypoglycemia. The “naked islets treatment” is intended for a small portion of the type 1 diabetes patient population who are already receiving immunosuppression therapy and can receive the islets without their immune system destroying them. For the majority of type 1 diabetes patients, who are not receiving immunosuppression therapy, Semma is seeking to develop a “device-assisted cells treatment” alternative, which includes a novel device that is designed to encapsulate and protect the islets from the immune system. The device could potentially enable durable implantation without the need for ongoing immunosuppressive therapy.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that device-assisted cells and the naked islets were two separate assets based on, among other things, (i) the separate type 1 diabetes patient populations expected to receive the treatments and (ii) the clinical and regulatory risks and costs associated with developing the islets versus developing and manufacturing the device. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair values of the intangible assets were determined through a discounted cash flow analysis utilizing Level 3 fair value inputs including (i) assumptions regarding the probability of obtaining marketing approval for the treatments;(ii) estimates regarding the timing of and the expected costs to develop and commercialize the treatments; (iii) estimates of future cash flows from potential product sales with respect to treatments; and (iv) appropriate discount and tax rates.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s “</span><span style="font-family:inherit;font-size:10pt;">Deferred tax liability</span><span style="font-family:inherit;font-size:10pt;">” in the table above is recorded as a reduction to “</span><span style="font-size:10pt;">Deferred tax assets</span><span style="font-family:inherit;font-size:10pt;">” on the Company’s consolidated balance sheet. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2019, the Company’s accounting for the Exonics and Semma business combinations is complete. The Company has not provided pro forma information because the operations of Exonics and Semma did not have a material effect on its consolidated financial statements. The Company’s consolidated financial statements reflect the operations of Exonics and Semma as of December 31, 2019 and for the periods from July 16, 2019 and October 10, 2019 to December 31, 2019, respectively.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Asset Acquisition</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Concert Pharmaceuticals</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2017, the Company acquired certain CF assets including VX-561 (the “Concert Assets”) from Concert Pharmaceuticals Inc. (“Concert”) pursuant to an asset purchase agreement (the “Concert Agreement”). VX-561 is an investigational CFTR potentiator that has the potential to be used as part of combination regimens of CFTR modulators to treat CF. Pursuant to the Concert Agreement, the Company paid Concert </span><span style="font-family:inherit;font-size:10pt;"><span>$160.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash for the Concert Assets. If VX-561 is approved as part of a combination regimen to treat CF, Concert could receive up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$90.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in milestones based on regulatory approval in the United States and reimbursement in the United Kingdom, Germany or France. The Company determined that substantially all of the fair value of the Concert Agreement was attributable to a single in-process research and development asset, VX-561, which did not constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development asset. Thus, the Company recorded the </span><span style="font-family:inherit;font-size:10pt;"><span>$160.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment to “</span><span style="font-size:10pt;">Research and development expenses</span><span style="font-family:inherit;font-size:10pt;">” in 2017. The total cost of the transaction was </span><span style="font-family:inherit;font-size:10pt;"><span>$165.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> including </span><span style="font-family:inherit;font-size:10pt;"><span>$5.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of transaction costs that were recorded to “</span><span style="font-size:10pt;">Sales, general and administrative expenses</span><span style="font-family:inherit;font-size:10pt;">.”</span></div> 245000000.0 70000000.0 728000000.0 438400000 678300000 49700000 70000000.0 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The purchase price consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.5873015873016%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Upfront payment (adjusted for customary working capital adjustments)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>266,315</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Fair value of contingent development and regulatory payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>172,041</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>438,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 266315000 172041000 438356000 19535000 397141000 13000000 8680000 438356000 936800000 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The Company allocated the purchase price to the following assets acquired and liabilities assumed:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.5873015873016%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">October 10, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,331</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17,111</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>554,633</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>387,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(54,160</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,849</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>936,764</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The Company allocated the purchase price to the following assets acquired and liabilities assumed:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.5873015873016%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">July 16, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,535</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>397,141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Intangible asset</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>13,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,680</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>438,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 29331000 17111000 554633000 387000000 54160000 2849000 936764000 379000000.0 8000000.0 160000000.0 90000000.0 160000000.0 165100000 5100000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Earnings Per Share</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock, restricted stock units and performance-based restricted stock units, or “PSUs,” that have been issued but are not yet vested. Diluted net income per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. </span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table sets forth the computation of basic and diluted net income per share for the periods ended:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands, except per share amounts)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Basic net income attributable to Vertex per common share calculation:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income attributable to Vertex common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,176,810</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,096,896</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>263,484</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Less: Undistributed earnings allocated to participating securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(501</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(293</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income attributable to Vertex common shareholders—basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,176,810</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,096,395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>263,191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Basic weighted-average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>256,728</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>254,292</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>248,858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Basic net income attributable to Vertex per common share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.24</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.06</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Diluted net income attributable to Vertex per common share calculation:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income attributable to Vertex common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,176,810</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,096,896</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>263,484</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Less: Undistributed earnings allocated to participating securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(492</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income attributable to Vertex common shareholders—diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,176,810</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,096,404</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>263,196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Weighted-average shares used to compute basic net income per common share</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>256,728</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>254,292</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>248,858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Effect of potentially dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,797</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Restricted stock and restricted stock units (including PSUs)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,700</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,963</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,542</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Employee stock purchase program</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Weighted-average shares used to compute diluted net income per common share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>260,673</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>259,185</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>253,225</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Diluted net income attributable to Vertex per common share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4.51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The Company did not include the securities in the following table in the computation of the net income per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,217</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,554</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Unvested restricted stock and restricted stock units (including PSUs)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>411</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table sets forth the computation of basic and diluted net income per share for the periods ended:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands, except per share amounts)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Basic net income attributable to Vertex per common share calculation:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income attributable to Vertex common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,176,810</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,096,896</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>263,484</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Less: Undistributed earnings allocated to participating securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(501</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(293</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income attributable to Vertex common shareholders—basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,176,810</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,096,395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>263,191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Basic weighted-average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>256,728</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>254,292</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>248,858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Basic net income attributable to Vertex per common share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.24</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.06</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Diluted net income attributable to Vertex per common share calculation:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income attributable to Vertex common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,176,810</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,096,896</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>263,484</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Less: Undistributed earnings allocated to participating securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(492</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income attributable to Vertex common shareholders—diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,176,810</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,096,404</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>263,196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Weighted-average shares used to compute basic net income per common share</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>256,728</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>254,292</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>248,858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Effect of potentially dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,797</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Restricted stock and restricted stock units (including PSUs)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,700</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,963</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,542</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Employee stock purchase program</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Weighted-average shares used to compute diluted net income per common share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>260,673</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>259,185</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>253,225</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Diluted net income attributable to Vertex per common share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4.51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1176810000 2096896000 263484000 0 501000 293000 1176810000 2096395000 263191000 256728000 254292000 248858000 4.58 8.24 1.06 1176810000 2096896000 263484000 0 492000 288000 1176810000 2096404000 263196000 256728000 254292000 248858000 2231000 2913000 2797000 1700000 1963000 1542000 14000 17000 28000 260673000 259185000 253225000 4.51 8.09 1.04 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The Company did not include the securities in the following table in the computation of the net income per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,217</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,554</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Unvested restricted stock and restricted stock units (including PSUs)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>411</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2833000 2217000 3554000 6000 5000 411000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:11%;"/><td style="width:89%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Level 1:</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Level 2:</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Level 3:</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability.</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. The Company maintains strategic investments separately from the investment policy that governs its other cash, cash equivalents and marketable securities as described in </span><span style="font-family:inherit;font-size:10pt;">Note F, “Marketable Securities and Equity Investments.”</span><span style="font-family:inherit;font-size:10pt;"> As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company’s investments were in money market funds, government-sponsored enterprise securities, corporate debt securities, commercial paper and corporate equity securities. Additionally, the Company utilizes foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on its consolidated statement of operations.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company’s financial assets and liabilities that were subject to fair value measurements were valued using both observable and unobservable inputs. The Company’s financial assets valued based on Level 1 inputs consisted of money market funds, government-sponsored enterprise securities and corporate equity securities. The Company’s financial assets and liabilities valued based on Level 2 inputs consisted of certain corporate equity securities as described below, corporate debt securities, commercial paper, which consisted of investments in highly-rated investment-grade corporations and foreign currency forward contracts with reputable and creditworthy counterparties. As discussed further below, the Company’s financial liabilities valued based on Level 3 inputs consisted of acquisition related contingent milestones. During </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company did not record any other-than-temporary impairment charges related to its financial assets. </span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following tables set forth the Company’s financial assets and liabilities subject to fair value measurements </span><span style="font-family:inherit;font-size:10pt;">(and does not include </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$2.3 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of cash as of December 31, </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively)</span><span style="font-family:Times New Roman;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Fair Value Measurements as of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value Hierarchy</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financial instruments carried at fair value (asset position):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>791,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>791,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>282,084</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>261,797</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,287</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>301,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>301,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total financial assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,535,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,065,569</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>469,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financial instruments carried at fair value (liability position):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,533</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,533</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Long-term contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(176,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(176,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,821</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,821</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total financial liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(183,854</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(176,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value Measurements as of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value Hierarchy</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financial instruments carried at fair value (asset position):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,226,603</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,226,603</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">U.S. Treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,966</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,966</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,123</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,123</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>58,268</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>58,268</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>167,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>153,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>13,590</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">U.S. Treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,026</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,026</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,704</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,704</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>233,665</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>233,665</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>100,390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>100,390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,023</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,023</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,514</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,514</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total financial assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,836,605</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,410,155</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>426,450</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financial instruments carried at fair value (liability position):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(340</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(340</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(108</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(108</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total financial liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(448</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(448</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Please refer to </span><span style="font-family:inherit;font-size:10pt;">Note F, “Marketable Securities and Equity Investments,”</span><span style="font-family:inherit;font-size:10pt;"> for the carrying amount and related unrealized gains (losses) by type of investment.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Fair Value of Corporate Equity Securities</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company maintains strategic investments in corporate equity securities separately from the investment policy that governs its other cash, cash equivalents and marketable securities. The Company classifies its investments in publicly traded companies as “</span><span style="font-size:10pt;">Marketable securities</span><span style="font-family:inherit;font-size:10pt;">” on its consolidated balance sheets. Generally, the Company’s investments in the common stock of these publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of the Company’s investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments. During the year ended December 31, 2019, the Company transferred the fair value of one of its strategic investments in a publicly traded company from Level 2 to Level 1 upon the expiration of transfer restrictions associated with this investment. Please refer to </span><span style="font-family:inherit;font-size:10pt;">Note F, “Marketable Securities and Equity Investments,”</span><span style="font-family:inherit;font-size:10pt;"> for further information on these investments.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Fair Value of Contingent Consideration</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s contingent consideration liabilities, which are related to development and regulatory milestones potentially payable to Exonics’ former equity holders, are classified as Level 3 within the valuation hierarchy. The Company bases its estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to rare diseases. The discount rates used in the valuation model for contingent payments represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">commercialization of a drug candidate in the pharmaceutical industry, the Company's estimates regarding the fair value of contingent consideration will change in the future, resulting in adjustments to the fair value of the Company’s contingent consideration liabilities, and the effect of any such adjustments could be material.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table represents a rollforward of the fair value of the Company’s contingent consideration liabilities:</span></div><div style="line-height:120%;padding-bottom:9px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.46825396825396%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year Ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Contingent consideration related to acquisition of Exonics</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>172,041</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Increase in fair value of contingent payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,459</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>176,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The “</span><span style="font-family:inherit;font-size:10pt;">Increase in fair value of contingent payments</span><span style="font-family:inherit;font-size:10pt;">” in the table above was due to changes in market interest rates and the time value of money.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Fair Value of Intangible Asset</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">    </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the Company’s in-process research and development intangible assets, which totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$400.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, was determined through discounted cash flow models utilizing Level 3 fair value inputs. Please refer to </span><span style="font-family:inherit;font-size:10pt;">Note C, “Acquisitions,”</span><span style="font-family:inherit;font-size:10pt;"> for further information on the key assumptions utilized to determine the fair value of the in-process research and development assets that the Company acquired as a result of its acquisitions of Semma and Exonics in 2019.</span></div> <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following tables set forth the Company’s financial assets and liabilities subject to fair value measurements </span><span style="font-family:inherit;font-size:10pt;">(and does not include </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$2.3 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of cash as of December 31, </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively)</span><span style="font-family:Times New Roman;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Fair Value Measurements as of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value Hierarchy</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financial instruments carried at fair value (asset position):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>791,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>791,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>282,084</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>261,797</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,287</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>301,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>301,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total financial assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,535,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,065,569</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>469,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financial instruments carried at fair value (liability position):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,533</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,533</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Long-term contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(176,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(176,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,821</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,821</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total financial liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(183,854</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(176,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value Measurements as of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value Hierarchy</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financial instruments carried at fair value (asset position):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,226,603</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,226,603</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">U.S. Treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,966</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,966</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,123</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,123</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>58,268</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>58,268</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>167,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>153,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>13,590</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">U.S. Treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,026</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,026</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,704</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,704</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>233,665</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>233,665</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>100,390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>100,390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,023</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,023</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,514</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,514</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total financial assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,836,605</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,410,155</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>426,450</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financial instruments carried at fair value (liability position):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(340</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(340</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(108</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(108</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total financial liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(448</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(448</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2300000000 1400000000 791039000 791039000 0 0 6070000 0 6070000 0 29472000 0 29472000 0 282084000 261797000 20287000 0 12733000 12733000 0 0 301799000 0 301799000 0 102356000 0 102356000 0 9725000 0 9725000 0 1535278000 1065569000 469709000 0 5533000 0 5533000 0 176500000 0 0 176500000 1821000 0 1821000 0 183854000 0 7354000 176500000 1226603000 1226603000 0 0 5966000 5966000 0 0 7123000 7123000 0 0 58268000 0 58268000 0 167323000 153733000 13590000 0 6026000 6026000 0 0 10704000 10704000 0 0 233665000 0 233665000 0 100390000 0 100390000 0 19023000 0 19023000 0 1514000 0 1514000 0 1836605000 1410155000 426450000 0 340000 0 340000 0 108000 0 108000 0 448000 0 448000 0 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table represents a rollforward of the fair value of the Company’s contingent consideration liabilities:</span></div><div style="line-height:120%;padding-bottom:9px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.46825396825396%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year Ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Contingent consideration related to acquisition of Exonics</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>172,041</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Increase in fair value of contingent payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,459</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>176,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 172041000 4459000 176500000 400000000.0 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Marketable Securities and Equity Investments</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">A summary of the Company’s cash equivalents and marketable securities</span><span style="font-family:inherit;font-size:10pt;">, which are recorded at fair value (and do not include </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$2.3 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of cash as of December 31, </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively), </span><span style="font-family:Times New Roman;font-size:10pt;">is shown below:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.23015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross <br/>Unrealized <br/>Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross <br/>Unrealized <br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>791,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>791,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,470</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>826,579</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>826,581</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,689</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>301,458</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>391</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>301,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total marketable debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>416,387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>556</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>416,888</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>113,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>168,255</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>282,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>530,216</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>168,811</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>698,972</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,226,603</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,226,603</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">U.S. Treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,967</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,966</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>58,271</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>58,268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,297,965</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,297,960</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">U.S Treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,026</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,026</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>234,088</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(450</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>233,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>100,498</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>100,390</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total marketable debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>351,316</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>27</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(558</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>350,785</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>133,157</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>40,619</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(6,453</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>167,323</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>484,473</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>40,646</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,011</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>518,108</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Available-for-sale debt securities were classified on the Company’s consolidated balance sheets as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.53968253968253%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>826,581</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,297,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>416,888</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>350,785</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,243,469</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,648,745</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale debt securities by contractual maturity were as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Matures within one year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,137,942</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,647,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Matures after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>105,527</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,245</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,243,469</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,648,745</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a limited number of available-for-sale debt securities in insignificant loss positions as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, which it does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investments at maturity. The Company did not record any charges for other-than-temporary declines in the fair value of available-for-sale debt securities or gross realized gains or losses in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the total fair value of the Company’s strategic investments in the common stock of publicly traded companies, which was primarily related to its investment in CRISPR, was </span><span style="font-family:inherit;font-size:10pt;"><span>$282.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$167.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and was classified as “</span><span style="font-size:10pt;">Marketable securities</span><span style="font-family:inherit;font-size:10pt;">” on its consolidated balance sheets. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the adoption of </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-01</span><span style="font-family:inherit;font-size:10pt;"> on January 1, 2018, the Company began recording changes in the fair value of its investments in strategic corporate equity securities, which are primarily attributable to its investment in CRISPR, to “</span><span style="font-size:10pt;">Other income (expense), net</span><span style="font-family:inherit;font-size:10pt;">” in the Company’s consolidated statements of operations. Prior to its adoption of </span><span style="font-family:inherit;font-size:10pt;">ASU 2016-01</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded changes in the fair value of its investments in corporate equity securities to “</span><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive (loss) income</span><span style="font-family:inherit;font-size:10pt;">” on its consolidated balance sheet until the related gains or losses were realized. The Company continues to record unrealized gains (losses) on available-for-sale debt securities as a component of “</span><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive (loss) income</span><span style="font-family:inherit;font-size:10pt;">” until such gains and losses are realized.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded </span><span style="font-family:inherit;font-size:10pt;">unrealized gains</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>$132.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, which were primarily related to the Company’s strategic investment in CRISPR. As noted above, unrealized gains or losses were recorded to “</span><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive (loss) income</span><span style="font-family:inherit;font-size:10pt;">” during the year ended December 31, 2017. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded realized gains of </span><span style="font-family:inherit;font-size:10pt;"><span>$65.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to sales of CRISPR’s common stock. The Company utilized a weighted-average cost basis to calculate the realized gain. There were no sales of CRISPR’s common stock in the years ended December 31, 2018 or 2017. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the carrying value of the Company’s equity investments without readily determinable fair values, which are recorded in “</span><span style="font-size:10pt;">Other assets</span><span style="font-family:inherit;font-size:10pt;">” on its consolidated balance sheets, was </span><span style="font-family:inherit;font-size:10pt;"><span>$40.8 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div> <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">A summary of the Company’s cash equivalents and marketable securities</span><span style="font-family:inherit;font-size:10pt;">, which are recorded at fair value (and do not include </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$2.3 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of cash as of December 31, </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively), </span><span style="font-family:Times New Roman;font-size:10pt;">is shown below:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.23015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross <br/>Unrealized <br/>Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross <br/>Unrealized <br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>791,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>791,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,470</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>826,579</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>826,581</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,689</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>301,458</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>391</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>301,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total marketable debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>416,387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>556</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>416,888</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>113,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>168,255</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>282,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>530,216</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>168,811</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>698,972</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,226,603</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,226,603</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">U.S. Treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,967</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,966</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>58,271</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>58,268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,297,965</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,297,960</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">U.S Treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,026</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,026</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>234,088</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(450</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>233,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>100,498</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>100,390</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total marketable debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>351,316</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>27</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(558</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>350,785</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>133,157</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>40,619</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(6,453</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>167,323</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>484,473</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>40,646</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,011</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>518,108</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Available-for-sale debt securities were classified on the Company’s consolidated balance sheets as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.53968253968253%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>826,581</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,297,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>416,888</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>350,785</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,243,469</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,648,745</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale debt securities by contractual maturity were as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Matures within one year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,137,942</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,647,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Matures after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>105,527</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,245</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,243,469</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,648,745</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2300000000 1400000000 791039000 0 0 791039000 6070000 0 0 6070000 29470000 3000 1000 29472000 826579000 3000 1000 826581000 12689000 44000 0 12733000 301458000 391000 50000 301799000 102240000 121000 5000 102356000 416387000 556000 55000 416888000 113829000 168255000 0 282084000 530216000 168811000 55000 698972000 1226603000 0 0 1226603000 5967000 0 1000 5966000 7124000 0 1000 7123000 58271000 0 3000 58268000 1297965000 0 5000 1297960000 6026000 0 0 6026000 10704000 0 0 10704000 234088000 27000 450000 233665000 100498000 0 108000 100390000 351316000 27000 558000 350785000 133157000 40619000 6453000 167323000 484473000 40646000 7011000 518108000 826581000 1297960000 416888000 350785000 1243469000 1648745000 1137942000 1647500000 105527000 1245000 1243469000 1648745000 282100000 167300000 132500000 2600000 65100000 40800000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss) by component:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Unrealized Holding Gains (Losses), Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">On Available-For-Sale Debt Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">On Equity Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">On Foreign Currency Forward Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance at December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,862</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17,531</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,514</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>21,173</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other comprehensive (loss) income before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(13,169</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(584</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,538</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(29,175</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(35,390</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,645</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,645</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net current period other comprehensive (loss) income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(13,169</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(584</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,538</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(26,530</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(32,745</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(21,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(594</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25,069</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(15,016</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(11,572</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other comprehensive income before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,855</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25,664</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>34,577</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,774</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,774</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net current period other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,855</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>58</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>27,438</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>36,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts reclassified to accumulated deficit pursuant to adoption of new accounting standard</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>949</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(25,069</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(24,120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(11,227</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(536</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,422</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>659</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other comprehensive income before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,332</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,513</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>22,884</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(25,516</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(25,516</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net current period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,332</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,039</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(14,003</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,632</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(895</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>503</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,581</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss) by component:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Unrealized Holding Gains (Losses), Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">On Available-For-Sale Debt Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">On Equity Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">On Foreign Currency Forward Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance at December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,862</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17,531</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,514</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>21,173</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other comprehensive (loss) income before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(13,169</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(584</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,538</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(29,175</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(35,390</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,645</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,645</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net current period other comprehensive (loss) income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(13,169</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(584</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,538</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(26,530</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(32,745</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(21,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(594</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25,069</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(15,016</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(11,572</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other comprehensive income before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,855</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25,664</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>34,577</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,774</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,774</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net current period other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,855</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>58</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>27,438</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>36,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts reclassified to accumulated deficit pursuant to adoption of new accounting standard</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>949</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(25,069</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(24,120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(11,227</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(536</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,422</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>659</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other comprehensive income before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,332</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,513</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>22,884</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(25,516</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(25,516</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net current period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,332</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,039</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(14,003</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,632</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(895</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>503</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,581</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -7862000 -10000 17531000 11514000 21173000 -13169000 -584000 7538000 -29175000 -35390000 0 0 0 -2645000 -2645000 -13169000 -584000 7538000 -26530000 -32745000 -21031000 -594000 25069000 -15016000 -11572000 8855000 58000 0 25664000 34577000 0 0 0 -1774000 -1774000 8855000 58000 0 27438000 36351000 949000 0 -25069000 0 -24120000 -11227000 -536000 0 12422000 659000 10332000 1039000 0 11513000 22884000 0 0 0 25516000 25516000 10332000 1039000 0 -14003000 -2632000 -895000 503000 0 -1581000 -1973000 Hedging<div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Foreign currency forward contracts - Designated as hedging instruments</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company’s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>eighteen months</span></span><span style="font-family:inherit;font-size:10pt;">. The Company recognizes realized gains and losses for the effective portion of such contracts in “</span><span style="font-size:10pt;">Product revenues, net</span><span style="font-family:inherit;font-size:10pt;">” in its consolidated statements of operations in the same period that it recognizes the product revenues that were impacted by the hedged foreign exchange rate changes. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company’s risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, all hedges were determined to be highly effective.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the adoption of ASU 2017-12 on January 1, 2019, the Company did not record any ineffectiveness related to its foreign currency forward contracts that were designated as hedging instruments in the years ended December 31, 2018 and 2017. ASU 2017-12 eliminated the requirement to separately measure and report hedge ineffectiveness.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company considers the impact of its counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, credit risk did not change the fair value of the Company’s foreign currency forward contracts.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign Currency</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>501,197</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>335,179</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Australian dollar</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>89,705</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>52,820</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">British pound sterling</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>87,032</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>73,460</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Canadian dollar</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>50,452</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>43,759</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>728,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>505,218</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Foreign currency forward contracts - Not designated as hedging instruments</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also enters into foreign currency forward contracts with contractual maturities of less than </span><span style="font-family:inherit;font-size:10pt;"><span>one month</span></span><span style="font-family:inherit;font-size:10pt;"> that are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under GAAP. The Company recognizes realized gains and losses for such contracts in “</span><span style="font-size:10pt;">Other income (expense), net</span><span style="font-family:inherit;font-size:10pt;">” in its consolidated statements of operations each period. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the notional amount of the Company’s outstanding foreign currency forward contracts where hedge accounting under GAAP is not applied was </span><span style="font-family:inherit;font-size:10pt;"><span>$412.1 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">During the three years ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;">, the Company recognized the following related to foreign currency forward contacts in its consolidated statements of operations:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.61904761904762%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Designated as hedging instruments - Reclassified from AOCI</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>32,546</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,252</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Not designated as hedging instruments</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other income (expense), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,838</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>623</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Total reported in the Consolidated Statement of Operations</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,160,726</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,038,325</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,165,480</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other income (expense), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>192,177</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(790</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(81,382</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table summarizes the fair value of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on its consolidated balance sheets: </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Liabilities</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value</span></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,533</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,821</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Liabilities</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value</span></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,023</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(340</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,514</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(108</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,537</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(448</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company expects amounts that are related to foreign exchange forward contracts designated as cash flow hedges under GAAP recorded in “</span><span style="font-size:10pt;">Prepaid expenses and other current assets</span><span style="font-family:inherit;font-size:10pt;">” and “</span><span style="font-size:10pt;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;">” to be reclassified to earnings within twelve months.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company’s consolidated balance sheets: </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Presented</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Not Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Legal Offset</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign currency forward contracts</span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,371</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,354</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Presented</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Not Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Legal Offset</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign currency forward contracts</span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,537</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,537</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(448</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,089</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(448</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(448</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>448</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P18M <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign Currency</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>501,197</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>335,179</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Australian dollar</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>89,705</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>52,820</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">British pound sterling</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>87,032</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>73,460</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Canadian dollar</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>50,452</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>43,759</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>728,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>505,218</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 501197000 335179000 89705000 52820000 87032000 73460000 50452000 43759000 728386000 505218000 P1M 412100000 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">During the three years ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;">, the Company recognized the following related to foreign currency forward contacts in its consolidated statements of operations:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.61904761904762%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Designated as hedging instruments - Reclassified from AOCI</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>32,546</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,252</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Not designated as hedging instruments</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other income (expense), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,838</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>623</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Total reported in the Consolidated Statement of Operations</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,160,726</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,038,325</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,165,480</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other income (expense), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>192,177</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(790</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(81,382</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 32546000 -1252000 768000 4838000 623000 14129000 4160726000 3038325000 2165480000 192177000 -790000 -81382000 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table summarizes the fair value of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on its consolidated balance sheets: </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Liabilities</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value</span></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,533</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,821</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Liabilities</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value</span></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,023</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(340</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,514</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(108</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,537</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(448</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 9725000 5533000 0 1821000 9725000 7354000 19023000 340000 1514000 108000 20537000 448000 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company’s consolidated balance sheets: </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Presented</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Not Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Legal Offset</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign currency forward contracts</span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,371</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,354</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Presented</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Not Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Legal Offset</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign currency forward contracts</span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,537</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,537</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(448</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,089</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(448</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(448</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>448</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company’s consolidated balance sheets: </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Presented</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Not Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Legal Offset</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign currency forward contracts</span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,371</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,354</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Presented</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Not Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Legal Offset</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign currency forward contracts</span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,537</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,537</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(448</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,089</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(448</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(448</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>448</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 9725000 0 9725000 7354000 2371000 7354000 0 7354000 7354000 0 20537000 0 20537000 448000 20089000 448000 0 448000 448000 0 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Inventories consisted of the following: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>26,247</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,677</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>107,021</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>87,944</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>34,234</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>26,739</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>167,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>124,360</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Inventories consisted of the following: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>26,247</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,677</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>107,021</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>87,944</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>34,234</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>26,739</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>167,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>124,360</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 26247000 9677000 107021000 87944000 34234000 26739000 167502000 124360000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Property and equipment, net consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Buildings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>648,003</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>657,438</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Furniture and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>317,567</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>280,908</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Software</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>167,547</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>162,601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>241,178</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>103,428</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Computers</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>63,325</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>59,073</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total property and equipment, gross</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,437,620</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,263,448</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Less: accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(692,540</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(451,443</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>745,080</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>812,005</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">The Company recorded depreciation expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$106.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$72.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$61.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span>, respectively. The Company’s capital lease amortization is included in depreciation expense. <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Property and equipment, net consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Buildings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>648,003</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>657,438</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Furniture and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>317,567</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>280,908</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Software</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>167,547</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>162,601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>241,178</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>103,428</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Computers</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>63,325</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>59,073</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total property and equipment, gross</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,437,620</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,263,448</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Less: accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(692,540</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(451,443</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>745,080</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>812,005</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 648003000 657438000 317567000 280908000 167547000 162601000 241178000 103428000 63325000 59073000 1437620000 1263448000 692540000 451443000 745080000 812005000 106900000 72400000 61400000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets and Goodwill</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Intangible Assets</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2019, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$400.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of in-process research and development intangible assets classified as “</span><span style="font-size:10pt;">Other assets</span><span style="font-family:inherit;font-size:10pt;">” on its consolidated balance sheet. As of December 31, 2018, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> in-process research and development intangible assets recorded on its consolidated balance sheet. In 2019, the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$387.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$13.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of in-process research and development intangible assets related to its acquisitions of Semma and Exonics, respectively. In 2018 and 2017, the Company recorded intangible asset impairment charges of </span><span style="font-family:inherit;font-size:10pt;"><span>$29.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to VX-210 that was licensed from BioAxone in 2014 and </span><span style="font-family:inherit;font-size:10pt;"><span>$255.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to Parion’s pulmonary ENaC platform, respectively. Please refer to </span><span style="font-family:inherit;font-size:10pt;">Note B, “Collaborative Arrangements,”</span><span style="font-family:inherit;font-size:10pt;"> for further information regarding the events and circumstances associated with these impairment charges.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Goodwill</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, goodwill of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.00 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$50.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded on the Company’s consolidated balance sheet. During 2019, the Company recorded goodwill of </span><span style="font-family:inherit;font-size:10pt;"><span>$554.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$397.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to its acquisitions of Semma and Exonics, respectively.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Please refer to “</span><span style="font-family:inherit;font-size:10pt;">Note C, “Acquisitions,”</span><span style="font-family:inherit;font-size:10pt;"> for further information on the in-process research and development intangible assets and goodwill that the Company acquired in 2019.</span></div> 400000000.0 0 387000000.0 13000000.0 29000000.0 255300000 1000000000.00 50400000 554600000 397100000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Additional Balance Sheet Detail </span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Accrued expenses</span><span style="font-family:Times New Roman;font-size:10pt;"> consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Payroll and benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>159,464</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>124,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Research, development and commercial contract costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>105,663</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>115,300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Product revenue allowances</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>641,368</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>550,002</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Royalty payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>98,578</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>101,108</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Tax related accruals</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>72,293</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>43,281</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>39,546</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>24,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,116,912</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>958,899</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Other current liabilities</span><span style="font-family:Times New Roman;font-size:10pt;"> consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Contract liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>62,332</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>24,870</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>30,293</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,271</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>37,680</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,265</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>130,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>50,406</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Other long-term liabilities</span><span style="font-family:Times New Roman;font-size:10pt;"> consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Advance from collaborator</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>88,762</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>82,573</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>84,292</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>26,280</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>183,318</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>108,853</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Accrued expenses</span><span style="font-family:Times New Roman;font-size:10pt;"> consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Payroll and benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>159,464</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>124,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Research, development and commercial contract costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>105,663</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>115,300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Product revenue allowances</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>641,368</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>550,002</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Royalty payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>98,578</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>101,108</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Tax related accruals</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>72,293</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>43,281</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>39,546</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>24,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,116,912</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>958,899</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 159464000 124753000 105663000 115300000 641368000 550002000 98578000 101108000 72293000 43281000 39546000 24455000 1116912000 958899000 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Other current liabilities</span><span style="font-family:Times New Roman;font-size:10pt;"> consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Contract liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>62,332</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>24,870</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>30,293</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,271</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>37,680</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,265</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>130,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>50,406</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 62332000 24870000 30293000 5271000 37680000 20265000 130305000 50406000 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Other long-term liabilities</span><span style="font-family:Times New Roman;font-size:10pt;"> consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Advance from collaborator</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>88,762</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>82,573</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>84,292</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>26,280</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>183,318</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>108,853</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 88762000 82573000 84292000 10264000 26280000 183318000 108853000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Finance Leases</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s finance lease assets and liabilities primarily relate to its corporate headquarters in Boston and research site in San Diego (the “Buildings”). These Buildings are classified as finance leases because the present value of the sum of the lease payments associated with the Buildings exceeds substantially all of the fair value of the Buildings. The Company also has outstanding finance leases for equipment.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the adoption of ASC 842 on January 1, 2019, the Company was deemed for accounting purposes to be the owner of the Buildings during their construction periods and recorded project construction costs incurred by its landlords. Upon completion of the Buildings, the Company determined that the underlying leases did not meet the criteria for “sale-leaseback” treatment. Accordingly, the Company depreciated the Buildings over </span><span style="font-family:inherit;font-size:10pt;"><span>40 years</span></span><span style="font-family:inherit;font-size:10pt;"> and recorded interest expense associated with the financing obligations for the Buildings. The Company bifurcated the lease payments pursuant to the Buildings into (i) a portion that was allocated to the Buildings and (ii) a portion that is allocated to the land on which the Buildings were constructed. The portion of the lease obligations allocated to the land was treated as an operating lease.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to ASC 842, the Company adjusted the amounts recorded on its consolidated balance sheet as of January 1, 2019 for the Buildings to reflect the present value of the lease payments over the remaining lease term related to the Buildings. The finance lease assets associated with the Buildings are amortized to depreciation expense using the straight-line method over the remaining lease term, which is significantly shorter than the Buildings’ useful lives. The Company continues to record interest expense associated with the finance lease liabilities for the Buildings.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Corporate Headquarters</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2011, the Company entered into </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> lease agreements, pursuant to which the Company leases approximately </span><span style="font-family:inherit;font-size:10pt;"><span>1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space in </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> buildings in Boston, Massachusetts for a term of </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">. Base rent payments commenced in December 2013, and will continue through December 2028. The Company utilizes this initial period as its lease term. The Company has an option to extend the lease term for an additional </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">San Diego Lease</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2015, the Company entered into a lease agreement pursuant to which the Company leases approximately </span><span style="font-family:inherit;font-size:10pt;"><span>170,000</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space in San Diego, California for a term of </span><span style="font-family:inherit;font-size:10pt;"><span>16 years</span></span><span style="font-family:inherit;font-size:10pt;">. Base rent payments commenced in the second quarter of 2019, and will continue through May 2034. The Company utilizes this initial period as its lease term. The Company has an option to extend the lease term for up to </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> additional </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year terms. The Company placed this building into service in the second quarter of 2018.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Operating Leases</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s operating leases relate to its real estate leases that are not classified as finance leases.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Aggregate Lease Information Related to the Application of ASC 842 </span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following information is disclosed in accordance with ASC 842, which became effective January 1, 2019. The components of lease cost recorded in the Company’s consolidated statement of operations were as follows: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.53968253968254%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:29%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,972</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finance lease cost</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amortization of leased assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>49,778</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>52,839</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>27,997</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Sublease income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(6,391</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>136,195</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s variable lease cost during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> primarily related to operating expenses, taxes and insurance associated with its finance leases. The Company’s sublease income during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> primarily related to subleases for an insignificant portion of the Company’s corporate headquarters.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The Company’s leases are included on its consolidated balance sheets as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2018 ^</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Finance leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>445,336</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>640,952</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total finance lease assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>445,336</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>640,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Capital lease obligations, current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,817</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>38,795</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,271</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Capital lease obligations, excluding current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,658</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Construction financing lease obligation, excluding current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>561,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Long-term finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>538,576</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>577,371</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>596,638</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Operating leases</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>88,202</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total operating lease assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>88,202</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>84,292</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>95,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;padding-top:16px;text-align:left;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;color:#000000;">^ As reported in the Company’s 2018 Annual Report on Form 10-K.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Maturities of the Company’s finance and operating lease liabilities in accordance with ASC 842 as of </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;"> were as follows: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.34920634920636%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Finance Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>84,264</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14,598</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>98,862</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>89,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,347</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>87,092</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,610</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>99,702</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>85,257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,451</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>97,708</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>90,802</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,488</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,290</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>425,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>51,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>476,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>862,106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>115,305</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>977,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Less: amount representing interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(284,735</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(19,509</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(304,244</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>577,371</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>95,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>673,167</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The weighted-average remaining lease terms and discount rates related to the Company’s leases were as follows: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:69%;"/><td style="width:30%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Weighted-average remaining lease term (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9.74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9.70</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Weighted-average discount rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9.04</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3.75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Supplemental cash flow information related to the Company’s leases was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.34920634920636%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating cash flows from finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>50,527</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financing cash flows from finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>39,185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Right-of-use assets obtained in exchange for lease obligations</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating leases *</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>34,605</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;padding-left:26px;text-indent:-14px;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;color:#000000;">* Includes $33.7 million acquired in 2019 pursuant to the Company’s acquisitions of Semma and Exonics.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Additional Lease Information Related to the Application of ASC 840</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following information is disclosed in accordance with ASC 840, Leases (Topic 840) (“ASC 840”), which was applicable until December 31, 2018. As of December 31, 2018, future minimum commitments under the Company’s real estate leases with initial terms of more than one year were as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.14285714285714%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fan Pier <br/>Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Other <br/>Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Total Lease <br/>Commitments</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>66,540</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>18,531</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>85,071</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>72,589</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>23,397</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>95,986</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>72,589</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>21,656</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>94,245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>72,589</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>21,172</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>93,761</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>72,589</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>21,482</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>94,071</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>389,855</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>185,336</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>575,191</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>746,751</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>291,574</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,038,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2018, the Company’s total sublease income to be received related to its facility leases was </span><span style="font-family:inherit;font-size:10pt;"><span>$6.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. During 2018 and 2017, rental expenses were </span><span style="font-family:inherit;font-size:10pt;"><span>$17.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$19.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The capital leases, which were related to equipment and leasehold improvements, bore interest at rates ranging from less than </span><span style="font-family:Times New Roman;font-size:10pt;"><span>1%</span></span><span style="font-family:Times New Roman;font-size:10pt;"> to </span><span style="font-family:Times New Roman;font-size:10pt;"><span>6%</span></span><span style="font-family:Times New Roman;font-size:10pt;"> per year. The Company’s capital lease amortization was included in depreciation expense during 2018 and 2017. The following table set forth the Company’s future minimum payments due under capital leases as of December 31, 2018:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.71428571428571%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:65%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:31%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,770</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,649</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,974</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,085</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>32,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Less: amount representing interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,585</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Present value of payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,475</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Finance Leases</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s finance lease assets and liabilities primarily relate to its corporate headquarters in Boston and research site in San Diego (the “Buildings”). These Buildings are classified as finance leases because the present value of the sum of the lease payments associated with the Buildings exceeds substantially all of the fair value of the Buildings. The Company also has outstanding finance leases for equipment.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the adoption of ASC 842 on January 1, 2019, the Company was deemed for accounting purposes to be the owner of the Buildings during their construction periods and recorded project construction costs incurred by its landlords. Upon completion of the Buildings, the Company determined that the underlying leases did not meet the criteria for “sale-leaseback” treatment. Accordingly, the Company depreciated the Buildings over </span><span style="font-family:inherit;font-size:10pt;"><span>40 years</span></span><span style="font-family:inherit;font-size:10pt;"> and recorded interest expense associated with the financing obligations for the Buildings. The Company bifurcated the lease payments pursuant to the Buildings into (i) a portion that was allocated to the Buildings and (ii) a portion that is allocated to the land on which the Buildings were constructed. The portion of the lease obligations allocated to the land was treated as an operating lease.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to ASC 842, the Company adjusted the amounts recorded on its consolidated balance sheet as of January 1, 2019 for the Buildings to reflect the present value of the lease payments over the remaining lease term related to the Buildings. The finance lease assets associated with the Buildings are amortized to depreciation expense using the straight-line method over the remaining lease term, which is significantly shorter than the Buildings’ useful lives. The Company continues to record interest expense associated with the finance lease liabilities for the Buildings.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Corporate Headquarters</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2011, the Company entered into </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> lease agreements, pursuant to which the Company leases approximately </span><span style="font-family:inherit;font-size:10pt;"><span>1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space in </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> buildings in Boston, Massachusetts for a term of </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">. Base rent payments commenced in December 2013, and will continue through December 2028. The Company utilizes this initial period as its lease term. The Company has an option to extend the lease term for an additional </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">San Diego Lease</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2015, the Company entered into a lease agreement pursuant to which the Company leases approximately </span><span style="font-family:inherit;font-size:10pt;"><span>170,000</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space in San Diego, California for a term of </span><span style="font-family:inherit;font-size:10pt;"><span>16 years</span></span><span style="font-family:inherit;font-size:10pt;">. Base rent payments commenced in the second quarter of 2019, and will continue through May 2034. The Company utilizes this initial period as its lease term. The Company has an option to extend the lease term for up to </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> additional </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year terms. The Company placed this building into service in the second quarter of 2018.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Operating Leases</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s operating leases relate to its real estate leases that are not classified as finance leases.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Aggregate Lease Information Related to the Application of ASC 842 </span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following information is disclosed in accordance with ASC 842, which became effective January 1, 2019. The components of lease cost recorded in the Company’s consolidated statement of operations were as follows: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.53968253968254%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:29%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,972</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finance lease cost</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amortization of leased assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>49,778</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>52,839</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>27,997</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Sublease income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(6,391</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>136,195</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s variable lease cost during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> primarily related to operating expenses, taxes and insurance associated with its finance leases. The Company’s sublease income during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> primarily related to subleases for an insignificant portion of the Company’s corporate headquarters.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The Company’s leases are included on its consolidated balance sheets as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2018 ^</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Finance leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>445,336</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>640,952</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total finance lease assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>445,336</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>640,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Capital lease obligations, current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,817</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>38,795</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,271</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Capital lease obligations, excluding current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,658</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Construction financing lease obligation, excluding current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>561,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Long-term finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>538,576</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>577,371</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>596,638</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Operating leases</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>88,202</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total operating lease assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>88,202</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>84,292</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>95,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;padding-top:16px;text-align:left;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;color:#000000;">^ As reported in the Company’s 2018 Annual Report on Form 10-K.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Maturities of the Company’s finance and operating lease liabilities in accordance with ASC 842 as of </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;"> were as follows: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.34920634920636%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Finance Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>84,264</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14,598</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>98,862</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>89,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,347</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>87,092</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,610</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>99,702</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>85,257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,451</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>97,708</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>90,802</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,488</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,290</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>425,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>51,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>476,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>862,106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>115,305</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>977,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Less: amount representing interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(284,735</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(19,509</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(304,244</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>577,371</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>95,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>673,167</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The weighted-average remaining lease terms and discount rates related to the Company’s leases were as follows: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:69%;"/><td style="width:30%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Weighted-average remaining lease term (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9.74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9.70</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Weighted-average discount rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9.04</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3.75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Supplemental cash flow information related to the Company’s leases was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.34920634920636%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating cash flows from finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>50,527</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financing cash flows from finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>39,185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Right-of-use assets obtained in exchange for lease obligations</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating leases *</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>34,605</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;padding-left:26px;text-indent:-14px;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;color:#000000;">* Includes $33.7 million acquired in 2019 pursuant to the Company’s acquisitions of Semma and Exonics.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Additional Lease Information Related to the Application of ASC 840</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following information is disclosed in accordance with ASC 840, Leases (Topic 840) (“ASC 840”), which was applicable until December 31, 2018. As of December 31, 2018, future minimum commitments under the Company’s real estate leases with initial terms of more than one year were as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.14285714285714%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fan Pier <br/>Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Other <br/>Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Total Lease <br/>Commitments</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>66,540</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>18,531</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>85,071</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>72,589</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>23,397</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>95,986</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>72,589</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>21,656</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>94,245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>72,589</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>21,172</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>93,761</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>72,589</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>21,482</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>94,071</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>389,855</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>185,336</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>575,191</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>746,751</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>291,574</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,038,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2018, the Company’s total sublease income to be received related to its facility leases was </span><span style="font-family:inherit;font-size:10pt;"><span>$6.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. During 2018 and 2017, rental expenses were </span><span style="font-family:inherit;font-size:10pt;"><span>$17.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$19.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The capital leases, which were related to equipment and leasehold improvements, bore interest at rates ranging from less than </span><span style="font-family:Times New Roman;font-size:10pt;"><span>1%</span></span><span style="font-family:Times New Roman;font-size:10pt;"> to </span><span style="font-family:Times New Roman;font-size:10pt;"><span>6%</span></span><span style="font-family:Times New Roman;font-size:10pt;"> per year. The Company’s capital lease amortization was included in depreciation expense during 2018 and 2017. The following table set forth the Company’s future minimum payments due under capital leases as of December 31, 2018:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.71428571428571%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:65%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:31%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,770</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,649</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,974</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,085</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>32,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Less: amount representing interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,585</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Present value of payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,475</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P40Y 2 1100000 2 P15Y P10Y 170000 P16Y 2 The components of lease cost recorded in the Company’s consolidated statement of operations were as follows: <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.53968253968254%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:29%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,972</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finance lease cost</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amortization of leased assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>49,778</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>52,839</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>27,997</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Sublease income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(6,391</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>136,195</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 11972000 49778000 52839000 27997000 6391000 136195000 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The Company’s leases are included on its consolidated balance sheets as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2018 ^</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Finance leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>445,336</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>640,952</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total finance lease assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>445,336</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>640,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Capital lease obligations, current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,817</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>38,795</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,271</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Capital lease obligations, excluding current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,658</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Construction financing lease obligation, excluding current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>561,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Long-term finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>538,576</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>577,371</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>596,638</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Operating leases</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>88,202</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total operating lease assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>88,202</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>84,292</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>95,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;padding-top:16px;text-align:left;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;color:#000000;">^ As reported in the Company’s 2018 Annual Report on Form 10-K.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 445336000 640952000 445336000 640952000 9817000 38795000 5271000 19658000 561892000 538576000 577371000 596638000 88202000 88202000 11504000 84292000 95796000 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Maturities of the Company’s finance and operating lease liabilities in accordance with ASC 842 as of </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;"> were as follows: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.34920634920636%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Finance Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>84,264</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14,598</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>98,862</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>89,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,347</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>87,092</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,610</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>99,702</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>85,257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,451</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>97,708</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>90,802</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,488</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,290</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>425,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>51,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>476,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>862,106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>115,305</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>977,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Less: amount representing interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(284,735</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(19,509</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(304,244</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>577,371</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>95,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>673,167</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Maturities of the Company’s finance and operating lease liabilities in accordance with ASC 842 as of </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;"> were as follows: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.34920634920636%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Finance Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>84,264</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14,598</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>98,862</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>89,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,347</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>87,092</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,610</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>99,702</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>85,257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,451</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>97,708</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>90,802</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,488</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,290</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>425,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>51,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>476,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>862,106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>115,305</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>977,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Less: amount representing interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(284,735</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(19,509</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(304,244</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>577,371</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>95,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>673,167</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 84264000 14598000 98862000 89440000 12907000 102347000 87092000 12610000 99702000 85257000 12451000 97708000 90802000 11488000 102290000 425251000 51251000 476502000 862106000 115305000 977411000 284735000 19509000 304244000 577371000 95796000 673167000 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The weighted-average remaining lease terms and discount rates related to the Company’s leases were as follows: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:69%;"/><td style="width:30%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Weighted-average remaining lease term (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9.74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9.70</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Weighted-average discount rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9.04</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3.75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P9Y8M26D P9Y8M12D 0.0904 0.0375 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Supplemental cash flow information related to the Company’s leases was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.34920634920636%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating cash flows from finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>50,527</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financing cash flows from finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>39,185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Right-of-use assets obtained in exchange for lease obligations</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating leases *</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>34,605</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;padding-left:26px;text-indent:-14px;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;color:#000000;">* Includes $33.7 million acquired in 2019 pursuant to the Company’s acquisitions of Semma and Exonics.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 10650000 50527000 39185000 34605000 0 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following information is disclosed in accordance with ASC 840, Leases (Topic 840) (“ASC 840”), which was applicable until December 31, 2018. As of December 31, 2018, future minimum commitments under the Company’s real estate leases with initial terms of more than one year were as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.14285714285714%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fan Pier <br/>Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Other <br/>Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Total Lease <br/>Commitments</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>66,540</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>18,531</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>85,071</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>72,589</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>23,397</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>95,986</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>72,589</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>21,656</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>94,245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>72,589</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>21,172</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>93,761</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>72,589</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>21,482</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>94,071</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>389,855</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>185,336</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>575,191</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>746,751</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>291,574</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,038,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 66540000 18531000 85071000 72589000 23397000 95986000 72589000 21656000 94245000 72589000 21172000 93761000 72589000 21482000 94071000 389855000 185336000 575191000 746751000 291574000 1038325000 6200000 17300000 19200000 0.01 0.06 The following table set forth the Company’s future minimum payments due under capital leases as of December 31, 2018:<div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.71428571428571%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:65%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:31%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,770</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,649</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,974</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,085</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>32,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Less: amount representing interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,585</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Present value of payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,475</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 10770000 7282000 5649000 3300000 1974000 3085000 32060000 2585000 29475000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock, Preferred Stock and Equity Plans</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Common Stock and Preferred Stock</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is authorized to issue </span><span style="font-family:inherit;font-size:10pt;"><span>500,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. Holders of common stock are entitled to </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> vote per share. Holders of common stock are entitled to receive dividends, if and when declared by the Company’s Board of Directors, and to share ratably in the Company’s assets legally available for distribution to the Company’s shareholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption or conversion rights. The holders of common stock do not have cumulative voting rights.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is authorized to issue </span><span style="font-family:inherit;font-size:10pt;"><span>1,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by the Company’s shareholders. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock issued or outstanding. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Share Repurchase Program</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2018, the Company’s Board of Directors approved a share repurchase program (the “2018 Share Repurchase Program”), pursuant to which the Company was authorized to repurchase up to </span><span style="font-family:inherit;font-size:10pt;"><span>$500.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of its common stock between February 1, 2018 and December 31, 2019. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company repurchased </span><span style="font-family:inherit;font-size:10pt;"><span>832,186</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>2,093,891</span></span><span style="font-family:inherit;font-size:10pt;"> shares, respectively, of its common stock under the 2018 Share Repurchase Program for an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$350.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, including commissions and fees. As of June 30, 2019, the Company had repurchased the entire </span><span style="font-family:inherit;font-size:10pt;"><span>$500.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> it was authorized to repurchase of its common stock under the 2018 Share Repurchase Program.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2019, the Company’s Board of Directors approved a new share repurchase program (the “2019 Share Repurchase Program”), pursuant to which the Company is authorized to repurchase up to </span><span style="font-family:inherit;font-size:10pt;"><span>$500.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of its common stock between August 1, 2019 and December 31, 2020. The Company expects to fund further repurchases of its common stock through a combination of cash on hand and cash generated by operations. During the year ended December 31, 2019, the Company repurchased </span><span style="font-family:inherit;font-size:10pt;"><span>213,548</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock under the 2019 Share Repurchase Program for an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$36.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> including commissions and fees. As of December 31, 2019, there is a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$464.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> remaining for repurchases under the 2019 Share Repurchase Program.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the 2018 and 2019 Share Repurchase Programs, the Company is authorized to purchase shares from time to time through open market or privately negotiated transactions. Such purchases are made pursuant to Rule 10b5-1 plans or other means as determined by the Company’s management and in accordance with the requirements of the SEC.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Stock and Option Plans</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The purpose of each of the Company’s stock and option plans is to attract, retain and motivate its employees, consultants and directors. Awards granted under these plans can be nonstatutory stock options (“NSOs”), incentive stock options (“ISOs”), restricted stock units (“RSUs”) including performance-based RSUs (“PSUs”), restricted stock (“RSs”), or other equity-based awards, as specified in the individual plans.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Shares issued under all of the Company’s plans are funded through the issuance of new shares. The following table contains information about the Company’s equity plans:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Title of Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Group Eligible</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Type of Award <br/>Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Awards <br/>Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Additional Awards <br/>Authorized for <br/>Grant</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2013 Stock and Option Plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Employees, Non-employee Directors and Consultants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">NSO, <br/>RS, RSU and PSU</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,577,268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15,778,703</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2006 Stock and Option Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Employees, Non-employee Directors and Consultants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">NSO, <br/>RS and RSU</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>651,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,229,110</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15,778,703</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All options granted under the Company’s 2013 Stock and Option Plan (“2013 Plan”) and 2006 Stock and Option Plan (“2006 Plan”) were granted with an exercise price equal to the fair value of the underlying common stock on the date of grant. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the stock and option plan under which the Company is authorized to make new equity awards is the Company’s 2013 Plan. Under the 2013 Plan, no stock options can be awarded with an exercise price less than the fair market value on the date of grant. In the three years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company’s shareholders approved increases in the number of shares authorized for issuance pursuant to the 2013 Stock and Option Plan of (i) </span><span style="font-family:inherit;font-size:10pt;"><span>5,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares in 2019, (ii) </span><span style="font-family:inherit;font-size:10pt;"><span>8,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares in 2018 and (iii) </span><span style="font-family:inherit;font-size:10pt;"><span>6,750,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares in 2017.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the three years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, grants to current employees and directors primarily had a grant date that was the same as the date the award was approved by the Company’s Board of Directors. During the three years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, for grants to new employees and directors, the date of grant for awards was the employee’s first day of employment or the date the director was elected to the Company’s Board of Directors. All options awarded under the Company’s stock and option plans expire not more than </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;"> years from the grant date.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock Options</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table summarizes information related to the outstanding and exercisable options during the year ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;">: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Stock Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Weighted-average <br/>Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Weighted-average <br/>Remaining <br/>Contractual Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Aggregate Intrinsic <br/>Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(per share)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,551</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>111.46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,521</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>184.50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(3,327</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>95.57</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(467</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>146.59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Expired</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>182.96</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,272</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>134.92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7.12</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>522,740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Exercisable at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,333</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>114.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6.06</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>346,943</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value in the table above represents the total pre-tax amount, net of exercise price, that would have been received by option holders if all option holders had exercised all options with an exercise price lower than the market price on the last business day of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, which was </span><span style="font-family:inherit;font-size:10pt;"><span>$218.26</span></span><span style="font-family:inherit;font-size:10pt;"> based on the average of the high and low price of the Company’s common stock on that date.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$325.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$258.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$302.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The total cash received by the Company as a result of employee stock option exercises during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$317.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$263.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$323.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table summarizes information about stock options outstanding and exercisable at </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;">: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Options Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Options Exercisable</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Range of Exercise Prices</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Number <br/>Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Weighted-average <br/>Remaining <br/>Contractual Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Weighted-average <br/>Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Number <br/>Exercisable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Weighted-average <br/>Exercise Price</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(per share)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(per share)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$29.07–$40.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>37.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>37.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$40.01–$60.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.55</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>49.69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>49.69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$60.01–$80.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>74.55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>136</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>74.53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$80.01–$100.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,670</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6.25</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>89.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1144</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>90.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$100.01–$120.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>243</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5.11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>109.23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>241</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>109.17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$120.01–$140.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>454</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5.67</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>129.77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>129.85</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$140.01–$160.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,036</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>155.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>383</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>155.39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$160.01–$180.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>720</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.46</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>168.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>233</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>164.48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$180.01–$189.38</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,624</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>185.41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>364</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>184.85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,272</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7.12</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>134.92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,333</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>114.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Restricted Stock and Restricted Stock Units (excluding PSUs)</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table summarizes the restricted stock unit and restricted stock activity of the Company during the year ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;">: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:28%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Restricted Stock Units (excluding PSUs)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Restricted Stock</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Number of Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Weighted-average <br/>Grant-date <br/>Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Number of Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Weighted-average <br/>Grant-date <br/>Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(per share)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(per share)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,717</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>140.10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>480</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>104.91</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,717</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>181.87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(974</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>133.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>108.23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cancelled</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(329</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>149.83</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>100.79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,131</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>163.61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>92</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>91.97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total fair value of restricted stock units that vested during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (measured on the date of vesting) was </span><span style="font-family:inherit;font-size:10pt;"><span>$178.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$104.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$33.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The total fair value of restricted stock that vested during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (measured on the date of vesting) was </span><span style="font-family:inherit;font-size:10pt;"><span>$70.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$114.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$157.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Performance-based RSUs (PSUs)</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The potential range of shares issuable pursuant to the Company’s PSU awards range from </span><span style="font-family:inherit;font-size:10pt;"><span>0%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>200%</span></span><span style="font-family:inherit;font-size:10pt;"> of the target shares based on financial and non-financial measures. </span><span style="font-family:inherit;font-size:10pt;"><span>Fifty percent</span></span><span style="font-family:inherit;font-size:10pt;"> of PSUs that could be earned have a </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;">-year performance period with the amount actually earned dependent upon the Company’s financial performance and with vesting of the earned shares in three equal installments over a </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year period. The remaining </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> of PSUs that could be earned have a </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year performance period with the amount actually earned dependent upon the achievement of multiple clinical development milestones and with the earned shares cliff vesting at the end of the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year performance period.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table summarizes the PSU activity of the Company during the year ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.47619047619048%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:55%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Performance-Based RSU</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Number of Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Weighted-average <br/>Grant-date <br/>Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(per share)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Unvested at December 31, 2018 (1)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>759</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>110.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Granted (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>449</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>183.48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(403</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>109.23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cancelled</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>104.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>734</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>143.21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;color:#000000;">(1) “Unvested” represents the Company’s PSUs at target to the extent performance has not been certified plus the actual number of shares that continue to be subject to service conditions for which the performance has been achieved and certified.</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;color:#000000;">(2) “Granted” represents (i) the target number of shares issuable for grants during 2019 and (ii) any change in the number of shares issuable pursuant to outstanding PSUs based on performance certification during 2019.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total fair value of PSUs that vested during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (measured on the date of vesting) was </span><span style="font-family:inherit;font-size:10pt;"><span>$73.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;"><span>$23.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Employee Stock Purchase Plan</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has an employee stock purchase plan (the “ESPP”). The ESPP permits eligible employees to enroll in a </span><span style="font-family:inherit;font-size:10pt;">twelve</span><span style="font-family:inherit;font-size:10pt;">-month offering period comprising </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;">-month purchase periods. Participants may purchase shares of the Company’s common stock, through payroll deductions, at a price equal to </span><span style="font-family:inherit;font-size:10pt;"><span>85%</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair market value of the common stock on the first day of the applicable </span><span style="font-family:inherit;font-size:10pt;">twelve</span><span style="font-family:inherit;font-size:10pt;">-month offering period, or the last day of the applicable </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;">-month purchase period, whichever is lower. Purchase dates under the ESPP occur on or about May 14 and November 14 of each year. During 2019, the Company’s shareholders approved an increase in the number of shares authorized for issuance pursuant to the ESPP of </span><span style="font-family:inherit;font-size:10pt;"><span>2,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span>2,199,376</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock authorized for issuance pursuant to the ESPP.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">In </span><span style="font-family:Times New Roman;font-size:10pt;">2019</span><span style="font-family:Times New Roman;font-size:10pt;">, the following shares were issued to employees under the ESPP: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.38888888888889%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:33%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year Ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands, <br/>except per share amount)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Number of shares</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>202,693</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Average price paid per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>138.18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Employee Benefits</span></div><span style="font-family:inherit;font-size:10pt;">The Company has a 401(k) retirement plan (the “Vertex 401(k) Plan”) in which substantially all of its permanent U.S. employees are eligible to participate. Participants may contribute up to </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>60%</span></span><span style="font-family:inherit;font-size:10pt;"> of their annual compensation to the Vertex 401(k) Plan, subject to statutory limitations. The Company may declare discretionary matching contributions to the Vertex 401(k) Plan. The Company pays matching contributions in the form of cash. For the years ended December 31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company contributed approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$15.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$13.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$12.3 million</span></span> to the plan, respectively. 500000000 1 1000000 0 500000000.0 832186 2093891 150000000.0 350000000.0 500000000.0 500000000.0 213548 36000000.0 464000000.0 The following table contains information about the Company’s equity plans:<div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Title of Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Group Eligible</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Type of Award <br/>Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Awards <br/>Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Additional Awards <br/>Authorized for <br/>Grant</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2013 Stock and Option Plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Employees, Non-employee Directors and Consultants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">NSO, <br/>RS, RSU and PSU</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,577,268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15,778,703</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">2006 Stock and Option Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Employees, Non-employee Directors and Consultants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">NSO, <br/>RS and RSU</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>651,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,229,110</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15,778,703</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 9577268 15778703 651842 0 10229110 15778703 5000000 8000000 6750000 P10Y <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table summarizes information related to the outstanding and exercisable options during the year ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;">: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Stock Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Weighted-average <br/>Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Weighted-average <br/>Remaining <br/>Contractual Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Aggregate Intrinsic <br/>Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(per share)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,551</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>111.46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,521</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>184.50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(3,327</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>95.57</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(467</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>146.59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Expired</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>182.96</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,272</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>134.92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7.12</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>522,740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Exercisable at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,333</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>114.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6.06</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>346,943</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 8551000 111.46 1521000 184.50 3327000 95.57 467000 146.59 6000 182.96 6272000 134.92 P7Y1M13D 522740000 3333000 114.15 P6Y21D 346943000 218.26 325900000 258200000 302800000 317800000 263400000 323300000 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table summarizes information about stock options outstanding and exercisable at </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;">: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Options Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Options Exercisable</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Range of Exercise Prices</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Number <br/>Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Weighted-average <br/>Remaining <br/>Contractual Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Weighted-average <br/>Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Number <br/>Exercisable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Weighted-average <br/>Exercise Price</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(per share)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(per share)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$29.07–$40.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>37.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>37.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$40.01–$60.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.55</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>49.69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>49.69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$60.01–$80.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>74.55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>136</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>74.53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$80.01–$100.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,670</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6.25</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>89.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1144</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>90.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$100.01–$120.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>243</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5.11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>109.23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>241</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>109.17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$120.01–$140.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>454</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5.67</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>129.77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>129.85</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$140.01–$160.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,036</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>155.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>383</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>155.39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$160.01–$180.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>720</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.46</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>168.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>233</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>164.48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$180.01–$189.38</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,624</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>185.41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>364</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>184.85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,272</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7.12</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>134.92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,333</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>114.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 108000 P1Y6M29D 37.62 108000 37.62 277000 P2Y6M18D 49.69 277000 49.69 140000 P4Y3M21D 74.55 136000 74.53 1670000 P6Y3M 89.42 1144000 90.10 243000 P5Y1M9D 109.23 241000 109.17 454000 P5Y8M1D 129.77 447000 129.85 1036000 P8Y1M6D 155.50 383000 155.39 720000 P8Y5M15D 168.04 233000 164.48 1624000 P8Y10M24D 185.41 364000 184.85 6272000 P7Y1M13D 134.92 3333000 114.15 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table summarizes the restricted stock unit and restricted stock activity of the Company during the year ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;">: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:28%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Restricted Stock Units (excluding PSUs)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Restricted Stock</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Number of Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Weighted-average <br/>Grant-date <br/>Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Number of Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Weighted-average <br/>Grant-date <br/>Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(per share)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(per share)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,717</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>140.10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>480</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>104.91</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,717</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>181.87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(974</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>133.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>108.23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cancelled</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(329</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>149.83</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>100.79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,131</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>163.61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>92</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>91.97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2717000 140.10 480000 104.91 1717000 181.87 0 0 974000 133.15 375000 108.23 329000 149.83 13000 100.79 3131000 163.61 92000 91.97 178200000 104800000 33200000 70700000 114500000 157000000.0 0 2 0.50 0.50 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table summarizes the PSU activity of the Company during the year ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.47619047619048%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:55%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Performance-Based RSU</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Number of Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Weighted-average <br/>Grant-date <br/>Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(per share)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Unvested at December 31, 2018 (1)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>759</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>110.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Granted (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>449</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>183.48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(403</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>109.23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cancelled</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>104.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>734</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>143.21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;color:#000000;">(1) “Unvested” represents the Company’s PSUs at target to the extent performance has not been certified plus the actual number of shares that continue to be subject to service conditions for which the performance has been achieved and certified.</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;color:#000000;">(2) “Granted” represents (i) the target number of shares issuable for grants during 2019 and (ii) any change in the number of shares issuable pursuant to outstanding PSUs based on performance certification during 2019.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 759000 110.50 449000 183.48 403000 109.23 71000 104.61 734000 143.21 73300000 23200000 1300000 2 0.85 2000000 2199376 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">In </span><span style="font-family:Times New Roman;font-size:10pt;">2019</span><span style="font-family:Times New Roman;font-size:10pt;">, the following shares were issued to employees under the ESPP: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.38888888888889%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:33%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year Ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands, <br/>except per share amount)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Number of shares</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>202,693</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Average price paid per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>138.18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 202693000 138.18 0.60 15800000 13900000 12300000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based Compensation Expense</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes share-based payments to employees as compensation expense using the fair value method. The fair value of stock options and shares purchased pursuant to the ESPP is calculated using the Black-Scholes option pricing model. The fair value of restricted stock and restricted stock units, including PSUs, is based on the intrinsic value on the date of grant. Stock-based compensation, measured at the grant date based on the fair value of the award, is typically recognized as expense ratably over the requisite service period. </span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The effect of stock-based compensation expense during the three years ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock-based compensation expense by line item:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,543</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Research and development expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>224,558</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>203,112</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>181,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Sales, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>130,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>117,392</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>108,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>360,489</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>325,047</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>293,236</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(124,225</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total stock-based compensation included in costs and expenses, net of tax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>236,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>325,047</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>293,236</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company maintained a valuation allowance on the majority of its NOLs and other deferred tax assets until December 31, 2018. Therefore, there was </span><span style="font-family:inherit;font-size:10pt;">no</span><span style="font-family:inherit;font-size:10pt;"> “Income tax effect” of stock-based compensation expense for the years ended December 31, 2018 and 2017. </span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The stock-based compensation expense by type of award during the three years ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock-based compensation expense by type of award:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Restricted stock and restricted stock units (including PSUs)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>254,276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>207,845</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>181,258</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>96,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>107,854</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>105,367</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">ESPP share issuances</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,017</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock-based compensation expense related to inventories</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(585</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,406</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total stock-based compensation expense included in costs and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>360,489</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>325,047</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>293,236</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company capitalizes stock-based compensation expense to inventories, all of which is attributable to employees who support the Company’s manufacturing operations for the Company’s products.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table sets forth the Company’s unrecognized stock-based compensation expense as of </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;">, by type of award and the weighted-average period over which that expense is expected to be recognized: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.47619047619048%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Unrecognized Expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Weighted-average Recognition Period</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in years)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Type of award:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Restricted stock and restricted stock units (including PSUs)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>374,185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.05</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>130,153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.50</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">ESPP share issuances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,724</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.55</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Stock Options </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company issues stock options with service conditions, which are generally the vesting periods of the awards. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. The Black-Scholes option pricing model uses the option exercise price as well as estimates and assumptions related to the expected price volatility of the Company’s stock, the rate of return on risk-free investments, the expected period during which the options will be outstanding, and the expected dividend yield for the Company’s stock to estimate the fair value of a stock option on the grant date. The options granted during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> had a weighted-average grant-date fair value per share of </span><span style="font-family:inherit;font-size:10pt;"><span>$61.32</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$60.83</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$43.27</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The fair value of each option granted during </span><span style="font-family:Times New Roman;font-size:10pt;">2019</span><span style="font-family:Times New Roman;font-size:10pt;">, </span><span style="font-family:Times New Roman;font-size:10pt;">2018</span><span style="font-family:Times New Roman;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;">2017</span><span style="font-family:Times New Roman;font-size:10pt;"> was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.77777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:51%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Expected stock price volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>36.99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>40.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>45.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.32</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.61</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.94</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Expected term of options (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4.27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4.55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4.68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Expected annual dividends</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted-average valuation assumptions were determined as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Expected stock price volatility: </span><span style="font-family:inherit;font-size:10pt;">Expected stock price volatility is calculated using the trailing one month average of daily implied volatilities prior to the grant date. Implied volatility is based on options to purchase the Company’s stock with remaining terms of greater than one year that are regularly traded in the market. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Risk-free interest rate: </span><span style="font-family:inherit;font-size:10pt;">The Company bases the risk-free interest rate on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected option term.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Expected term of options: </span><span style="font-family:inherit;font-size:10pt;">The expected term of options represents the period of time options are expected to be outstanding. The Company uses historical data to estimate employee exercise and post-vest termination behavior. The Company believes that all groups of employees exhibit similar exercise and post-vest termination behavior and therefore does not stratify employees into multiple groups in determining the expected term of options.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Expected annual dividends: </span><span style="font-family:inherit;font-size:10pt;">The estimate for annual dividends is </span><span style="font-family:inherit;font-size:10pt;"><span>$0.00</span></span><span style="font-family:inherit;font-size:10pt;"> because the Company has not historically paid, and does not intend for the foreseeable future to pay, a dividend. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Restricted Stock, Restricted Stock Units and Performance-based Restricted Stock Units</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company awards restricted stock and restricted stock units with service conditions, which are generally the vesting periods of the awards. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company grants PSUs to certain members of senior management. Half of the PSUs contain financial goals as the performance metric and the other half contain non-financial goals. A target number of shares is established for each award, however the actual number of shares that are issued when an award vests may range from </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>200%</span></span><span style="font-family:inherit;font-size:10pt;"> of the target amount depending upon the level of achievement of the applicable performance metric. The financial-based PSUs vest in three equal installments over a </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year period and are expensed ratably over that same period based upon an assessment of the likely level of achievement. The non-financial based PSUs cliff vest at the end of the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year performance period and are expensed on a straight-line basis over that same period based upon an assessment of the likely level of achievement.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to 2017, the Company also awarded, to certain members of senior management, on an annual basis, restricted stock and restricted stock units that vested upon the earlier of the satisfaction of (i) a performance condition or (ii) a service condition.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Employee Stock Purchase Plan</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The weighted-average fair value of each purchase right granted during </span><span style="font-family:Times New Roman;font-size:10pt;">2019</span><span style="font-family:Times New Roman;font-size:10pt;">, </span><span style="font-family:Times New Roman;font-size:10pt;">2018</span><span style="font-family:Times New Roman;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;">2017</span><span style="font-family:Times New Roman;font-size:10pt;"> was </span><span style="font-family:Times New Roman;font-size:10pt;"><span>$47.79</span></span><span style="font-family:Times New Roman;font-size:10pt;">, </span><span style="font-family:Times New Roman;font-size:10pt;"><span>$44.04</span></span><span style="font-family:Times New Roman;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;"><span>$35.90</span></span><span style="font-family:Times New Roman;font-size:10pt;">, respectively. The following table reflects the weighted-average assumptions used in the Black-Scholes option pricing model for </span><span style="font-family:Times New Roman;font-size:10pt;">2019</span><span style="font-family:Times New Roman;font-size:10pt;">, </span><span style="font-family:Times New Roman;font-size:10pt;">2018</span><span style="font-family:Times New Roman;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;">2017</span><span style="font-family:Times New Roman;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.77777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:51%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Expected stock price volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>33.43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>36.51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>39.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.08</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Expected annual dividends</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The expected stock price volatility for ESPP offerings is based on implied volatility. The Company bases the risk-free interest rate on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term. The expected term represents purchases and purchase periods that take place within the offering period. The expected annual dividends estimate is </span><span style="font-family:inherit;font-size:10pt;"><span>$0.00</span></span><span style="font-family:inherit;font-size:10pt;"> because the Company has not historically paid, and does not for the foreseeable future intend to pay, a dividend.</span></div> <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The effect of stock-based compensation expense during the three years ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock-based compensation expense by line item:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,543</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Research and development expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>224,558</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>203,112</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>181,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Sales, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>130,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>117,392</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>108,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>360,489</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>325,047</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>293,236</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(124,225</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total stock-based compensation included in costs and expenses, net of tax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>236,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>325,047</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>293,236</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 5575000 4543000 2500000 224558000 203112000 181900000 130356000 117392000 108836000 360489000 325047000 293236000 124225000 0 0 236264000 325047000 293236000 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The stock-based compensation expense by type of award during the three years ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock-based compensation expense by type of award:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Restricted stock and restricted stock units (including PSUs)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>254,276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>207,845</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>181,258</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>96,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>107,854</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>105,367</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">ESPP share issuances</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,017</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock-based compensation expense related to inventories</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(585</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,406</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total stock-based compensation expense included in costs and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>360,489</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>325,047</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>293,236</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 254276000 207845000 181258000 96737000 107854000 105367000 11196000 9933000 9017000 1720000 585000 2406000 360489000 325047000 293236000 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table sets forth the Company’s unrecognized stock-based compensation expense as of </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;">, by type of award and the weighted-average period over which that expense is expected to be recognized: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.47619047619048%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Unrecognized Expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Weighted-average Recognition Period</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in years)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Type of award:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Restricted stock and restricted stock units (including PSUs)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>374,185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.05</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>130,153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.50</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">ESPP share issuances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,724</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.55</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 374185000 P2Y18D 130153000 P2Y6M 4724000 P0M16D 61.32 60.83 43.27 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The fair value of each option granted during </span><span style="font-family:Times New Roman;font-size:10pt;">2019</span><span style="font-family:Times New Roman;font-size:10pt;">, </span><span style="font-family:Times New Roman;font-size:10pt;">2018</span><span style="font-family:Times New Roman;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;">2017</span><span style="font-family:Times New Roman;font-size:10pt;"> was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.77777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:51%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Expected stock price volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>36.99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>40.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>45.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.32</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.61</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.94</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Expected term of options (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4.27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4.55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4.68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Expected annual dividends</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.3699 0.4050 0.4531 0.0232 0.0261 0.0194 P4Y3M7D P4Y6M18D P4Y8M4D 0 0 0 0.00 0 2 47.79 44.04 35.90 The following table reflects the weighted-average assumptions used in the Black-Scholes option pricing model for <span style="font-family:Times New Roman;font-size:10pt;">2019</span><span style="font-family:Times New Roman;font-size:10pt;">, </span><span style="font-family:Times New Roman;font-size:10pt;">2018</span><span style="font-family:Times New Roman;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;">2017</span><span style="font-family:Times New Roman;font-size:10pt;">:</span><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.77777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:51%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Expected stock price volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>33.43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>36.51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>39.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.08</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Expected annual dividends</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.3343 0.3651 0.3909 0.0208 0.0236 0.0124 P0M22D P0M22D P0M22D 0 0 0 0.00 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes </span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The components of </span><span style="font-family:Times New Roman;font-size:10pt;">income (loss) before provision for (benefit from) income taxes</span><span style="font-family:Times New Roman;font-size:10pt;"> during the three years ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;"> consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.6984126984127%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,263,379</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>812,086</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>330,340</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>131,540</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(211,845</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(346,029</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income (loss) before provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,394,919</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>600,241</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(15,689</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The components of the </span><span style="font-family:Times New Roman;font-size:10pt;">provision for (benefit from) income taxes</span><span style="font-family:Times New Roman;font-size:10pt;"> during the three years ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;"> consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.6984126984127%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Current taxes:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>772</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,559</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>37,194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">State</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>13,528</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,018</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,025</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total current taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>50,722</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25,390</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,160</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Deferred taxes:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>184,312</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,105,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(113,805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(24,797</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(364,919</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(3,222</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">State</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,872</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(42,280</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(10,457</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total deferred taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>167,387</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,512,252</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(127,484</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>218,109</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,486,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(107,324</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">A reconciliation of the </span><span style="font-family:Times New Roman;font-size:10pt;">provision for (benefit from) income taxes</span><span style="font-family:Times New Roman;font-size:10pt;"> as computed by applying the U.S. federal statutory rate of </span><span style="font-family:Times New Roman;font-size:10pt;">21%</span><span style="font-family:Times New Roman;font-size:10pt;"> for the years ended December 31, 2019 and 2018 and </span><span style="font-family:Times New Roman;font-size:10pt;">35%</span><span style="font-family:Times New Roman;font-size:10pt;"> for the year ended December 31, 2017 to the </span><span style="font-family:Times New Roman;font-size:10pt;">provision for (benefit from) income taxes</span><span style="font-family:Times New Roman;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.6984126984127%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income (loss) before provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,394,919</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>600,241</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(15,689</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Expected provision for (benefit from) income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>292,933</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>126,051</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,491</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">State taxes, net of federal benefit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,478</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,680</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,742</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign income tax rate differential</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,178</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>23,427</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>77,801</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(59,459</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(52,629</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(58,204</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Benefit from income taxes attributable to valuation allowances</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,672</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,563,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(575,801</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Permanent items</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,822</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,421</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15,324</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Tax rate change</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>575,192</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock compensation (benefit) shortfalls and cancellations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(56,324</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(49,044</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(21,453</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Officer’s compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,666</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,310</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,501</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Deconsolidation of VIE</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(9,390</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(126,183</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Uncertain tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14,070</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15,431</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(583</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,050</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>248</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>218,109</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,486,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(107,324</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is subject to U.S. federal, state, and foreign income taxes. The Company’s provision for income taxes in 2019 has increased compared to historical amounts due to the release of the Company’s valuation allowance on the majority of its NOLs and other deferred tax assets as of December 31, 2018. </span><span style="font-family:inherit;font-size:10pt;">Starting in 2019, the Company began recording a provision for income taxes approximating statutory rates on its pre-tax income</span><span style="font-family:inherit;font-size:10pt;">. The Company’s effective tax rate for 2019 is lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation and research and development tax credits partially offset by a change in the Company’s valuation allowance as well as the tax impact of officer compensation. Due to the Company's ability to offset its pre-tax income against previously benefited NOLs, the majority of its tax provision represents a non-cash expense until its NOLs have been fully utilized.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2019, the “</span><span style="font-family:inherit;font-size:10pt;">Benefit from income taxes attributable to valuation allowances</span><span style="font-family:inherit;font-size:10pt;">” in the tax rate reconciliation table above related to a release of a valuation allowance in the United Kingdom of </span><span style="font-family:inherit;font-size:10pt;"><span>$30.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to the execution of a reimbursement agreement in France in November 2019, partially offset by an increase in the valuation allowance in the United States on state credits and NOLs. In 2018, the change in the “</span><span style="font-family:inherit;font-size:10pt;">Benefit from income taxes attributable to valuation allowances</span><span style="font-family:inherit;font-size:10pt;">” was primarily related to the release of the Company’s valuation allowances on the majority of its NOLs and other deferred tax assets related to the United States and the United Kingdom. In 2017, the “</span><span style="font-family:inherit;font-size:10pt;">Benefit from income taxes attributable to valuation allowances</span><span style="font-family:inherit;font-size:10pt;">” was primarily due to the utilization of NOLs in the United States and a decrease in the U.S. federal corporate tax rate from </span><span style="font-family:inherit;font-size:10pt;">35%</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">21%</span><span style="font-family:inherit;font-size:10pt;"> partially offset by the adoption of ASU 2016-09. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2018 and 2017, “</span><span style="font-size:10pt;">Deconsolidation of VIE</span><span style="font-family:inherit;font-size:10pt;">” in the Company’s tax rate reconciliation above related to the impairments of VX-210 and Parion’s pulmonary ENaC platform, respectively, and the decreases in the Company’s fair value of the contingent payments to BioAxone and Parion associated with these deconsolidations, respectively. Please refer to </span><span style="font-size:10pt;">Note K, </span><span style="font-size:10pt;">“</span><span style="font-size:10pt;">Intangible Assets and Goodwill,</span><span style="font-size:10pt;">”</span><span style="font-family:inherit;font-size:10pt;"> for further information regarding these impairments.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company operates in foreign tax jurisdictions, which impose income taxes at different rates than the United States. The impact of these rate differences, which are primarily related to the Company’s operations in the United Kingdom, is included in the “</span><span style="font-size:10pt;">Foreign income tax rate differential</span><span style="font-family:inherit;font-size:10pt;">” in the Company’s tax rate reconciliation above. Other items that affected the Company’s tax rate reconciliation table were related to equity and executive compensation, research and development credits and Orphan Drug Credits during the three years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred taxes were as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net operating loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>512,256</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>882,014</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Tax credit carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>549,543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>487,635</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>275,290</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>241,775</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Deferred revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>18,833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,311</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>85,199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>93,915</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>44,367</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17,795</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>119,160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>130,849</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating lease assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>13,114</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">  Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,831</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Gross deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,626,358</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,880,125</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(205,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(168,491</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,421,166</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,711,634</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(101,235</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(128,407</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Acquired intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(87,160</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(73,357</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Unrealized gain</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(28,838</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(10,198</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(13,118</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,190,815</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,499,672</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2019, the Company completed acquisitions of Semma and Exonics, resulting in the inclusion of these entities deferred tax bases into the Company’s consolidated deferred tax assets and deferred tax liabilities. As of the acquisition date, Semma’s deferred tax liabilities were </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$54.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. Exonics’ deferred tax assets were not material to the Company’s financial statements.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On a periodic basis, the Company reassesses the valuation allowance on its deferred income tax assets weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In the fourth quarter of 2018, the Company assessed the valuation allowance and considered positive evidence, including significant cumulative consolidated and U.S. income over the three years ended December 31, 2018, revenue growth, clinical trial data from the Company’s triple combination regimens, competitor clinical progress and expectations regarding future profitability, and negative evidence, including the potential impact of competition on the Company’s projections and cumulative losses in one of the jurisdictions. After assessing both the positive evidence and the negative evidence, the Company determined it was more likely than not that its deferred tax assets would be realized in the future and released the valuation allowance on the majority of its NOLs and other deferred tax assets as of December 31, 2018, resulting in a benefit from income taxes of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.56 billion</span></span><span style="font-family:inherit;font-size:10pt;">.  As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company maintained a valuation allowance of </span><span style="font-family:inherit;font-size:10pt;"><span>$205.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> related primarily to U.S. state and foreign tax attributes.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had NOL carryforwards of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 billion</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 billion</span></span><span style="font-family:inherit;font-size:10pt;"> were subject to expiration and </span><span style="font-family:inherit;font-size:10pt;"><span>$181.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> had an indefinite carryforward period, and tax credits of </span><span style="font-family:inherit;font-size:10pt;"><span>$399.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for U.S. federal income tax purposes. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had NOL carryforwards of </span><span style="font-family:inherit;font-size:10pt;"><span>$903.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and tax credits of </span><span style="font-family:inherit;font-size:10pt;"><span>$161.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> for U.S. state income tax purposes. These U.S. federal and state NOL carryforwards and tax credits expire at various dates through 2039 and may be used to offset future federal and state income tax liabilities, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had foreign net operating loss carryforwards of </span><span style="font-family:inherit;font-size:10pt;"><span>$896.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, including </span><span style="font-family:inherit;font-size:10pt;"><span>$16.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> that were subject to expiration at various dates through 2039 and </span><span style="font-family:inherit;font-size:10pt;"><span>$880.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> that had an indefinite carryforward period.</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Unrecognized tax benefits during the three years ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;"> were as follows: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.6984126984127%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Balance at beginning of the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,549</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,814</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Increases related to current period tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14,407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,704</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,814</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Increases related to prior period tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>598</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Decreases related to prior period tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(156</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Settlement with Tax Authorities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(478</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Balance at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>33,920</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,814</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, the Company has classified </span><span style="font-family:inherit;font-size:10pt;"><span>$13.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$20.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of its unrecognized tax benefits as credits to “</span><span style="font-size:10pt;">Deferred tax assets</span><span style="font-family:inherit;font-size:10pt;">” and “</span><span style="font-size:10pt;">Accrued expenses</span><span style="font-family:inherit;font-size:10pt;">,” respectively, on its consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has reviewed the tax positions taken, or to be taken, in its tax returns for all tax years currently open to examination by a taxing authority. Unrecognized tax benefits represent the aggregate tax effect of differences between tax return positions and the benefits recognized in the financial statements. As of December 31, 2019 and 2018, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$33.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$19.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of gross unrecognized tax benefits, which would affect the Company’s tax rate if recognized. As of December 31, 2017, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$3.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> of gross unrecognized tax benefits, which would not affect the Company’s tax rate if recognized. The Company does not expect that its unrecognized tax benefits will materially change within the next twelve months. The Company accrues interest and penalties related to unrecognized tax benefits as a component of its “</span><span style="font-size:10pt;">Provision for (benefit from) income taxes</span><span style="font-family:inherit;font-size:10pt;">.” As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> significant interest or penalties were accrued. The Company did not recognize any material interest or penalties related to uncertain tax positions during the three years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, foreign earnings, which were not significant, have been retained indefinitely by the Company’s foreign subsidiaries for indefinite reinvestment. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company could be subject to withholding taxes payable to the various foreign countries.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company files U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States or any other major taxing jurisdiction for years before 2011, except where the Company has NOLs or tax credit carryforwards that originate before 2011. The Company has various income tax examinations ongoing at any time throughout the world. During the year ended December 31, 2019, the Company concluded tax examinations with Austria, Canada, Germany and Italy, with no material adjustments.</span></div> <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The components of </span><span style="font-family:Times New Roman;font-size:10pt;">income (loss) before provision for (benefit from) income taxes</span><span style="font-family:Times New Roman;font-size:10pt;"> during the three years ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;"> consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.6984126984127%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,263,379</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>812,086</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>330,340</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>131,540</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(211,845</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(346,029</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income (loss) before provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,394,919</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>600,241</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(15,689</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1263379000 812086000 330340000 131540000 -211845000 -346029000 1394919000 600241000 -15689000 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The components of the </span><span style="font-family:Times New Roman;font-size:10pt;">provision for (benefit from) income taxes</span><span style="font-family:Times New Roman;font-size:10pt;"> during the three years ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;"> consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.6984126984127%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Current taxes:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>772</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>11,559</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>37,194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">State</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>13,528</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,018</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,025</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total current taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>50,722</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25,390</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,160</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Deferred taxes:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>184,312</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,105,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(113,805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(24,797</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(364,919</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(3,222</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">State</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,872</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(42,280</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(10,457</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total deferred taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>167,387</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,512,252</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(127,484</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>218,109</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,486,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(107,324</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 772000 11559000 37194000 15600000 3576000 13528000 9018000 5025000 50722000 25390000 20160000 184312000 -1105053000 -113805000 -24797000 -364919000 -3222000 7872000 -42280000 -10457000 167387000 -1512252000 -127484000 218109000 -1486862000 -107324000 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">A reconciliation of the </span><span style="font-family:Times New Roman;font-size:10pt;">provision for (benefit from) income taxes</span><span style="font-family:Times New Roman;font-size:10pt;"> as computed by applying the U.S. federal statutory rate of </span><span style="font-family:Times New Roman;font-size:10pt;">21%</span><span style="font-family:Times New Roman;font-size:10pt;"> for the years ended December 31, 2019 and 2018 and </span><span style="font-family:Times New Roman;font-size:10pt;">35%</span><span style="font-family:Times New Roman;font-size:10pt;"> for the year ended December 31, 2017 to the </span><span style="font-family:Times New Roman;font-size:10pt;">provision for (benefit from) income taxes</span><span style="font-family:Times New Roman;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.6984126984127%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income (loss) before provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,394,919</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>600,241</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(15,689</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Expected provision for (benefit from) income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>292,933</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>126,051</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,491</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">State taxes, net of federal benefit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,478</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,680</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,742</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign income tax rate differential</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,178</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>23,427</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>77,801</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(59,459</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(52,629</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(58,204</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Benefit from income taxes attributable to valuation allowances</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,672</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,563,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(575,801</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Permanent items</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,822</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,421</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15,324</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Tax rate change</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>575,192</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock compensation (benefit) shortfalls and cancellations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(56,324</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(49,044</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(21,453</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Officer’s compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,666</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,310</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,501</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Deconsolidation of VIE</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(9,390</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(126,183</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Uncertain tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14,070</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15,431</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(583</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,050</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>248</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>218,109</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,486,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(107,324</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1394919000 600241000 -15689000 292933000 126051000 -5491000 8478000 8680000 4742000 6178000 23427000 77801000 59459000 52629000 58204000 -2672000 -1563169000 -575801000 4822000 1421000 15324000 0 0 575192000 -56324000 -49044000 -21453000 10666000 8310000 6501000 0 9390000 126183000 14070000 15431000 0 -583000 4050000 248000 218109000 -1486862000 -107324000 -30500000 The components of the deferred taxes were as follows:<div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net operating loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>512,256</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>882,014</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Tax credit carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>549,543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>487,635</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>275,290</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>241,775</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Deferred revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>18,833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,311</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>85,199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>93,915</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>44,367</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17,795</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>119,160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>130,849</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating lease assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>13,114</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">  Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,831</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Gross deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,626,358</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,880,125</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(205,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(168,491</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,421,166</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,711,634</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(101,235</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(128,407</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Acquired intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(87,160</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(73,357</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Unrealized gain</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(28,838</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(10,198</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(13,118</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,190,815</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,499,672</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 512256000 882014000 549543000 487635000 275290000 241775000 18833000 19311000 85199000 93915000 44367000 17795000 119160000 130849000 13114000 8596000 6831000 1626358000 1880125000 205192000 168491000 1421166000 1711634000 101235000 128407000 87160000 0 0 73357000 28838000 10198000 13118000 1190815000 1499672000 54200000 -1560000000 205200000 1500000000 1300000000 181100000 399000000.0 903700000 161700000 896900000 16000000.0 880900000 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Unrecognized tax benefits during the three years ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;"> were as follows: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.6984126984127%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Balance at beginning of the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,549</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,814</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Increases related to current period tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14,407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,704</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,814</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Increases related to prior period tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>598</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Decreases related to prior period tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(156</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Settlement with Tax Authorities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(478</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Balance at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>33,920</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,814</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 19549000 3814000 0 14407000 9704000 3814000 598000 6031000 0 156000 0 0 478000 0 0 33920000 19549000 3814000 13400000 20500000 33900000 19500000 3800000 0 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Revolving Credit Facility</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2019, the Company and certain of its subsidiaries entered into a Credit Agreement (the “2019 Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein. The 2019 Credit Agreement provides for a </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$500.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> unsecured revolving facility, which was not drawn upon at closing. Amounts drawn pursuant to the 2019 Credit Agreement, if any, may be used to finance the Company’s working capital needs, and for general corporate or other lawful purposes. The Company had no borrowings outstanding under the 2019 Credit Agreement as of December 31, 2019. The 2019 Credit Agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the borrowing capacity under the 2019 Credit Agreement be increased by an additional </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$500.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The 2019 Credit Agreement, which matures on September 17, 2024, supersedes the Company’s credit agreement entered into in 2016 with Bank of America, N.A serving in the same capacity. Additionally, the 2019 Credit Agreement provides a sublimit of </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for letters of credit.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Direct costs related to the 2019 Credit Agreement, which were not material to the Company’s financial statements, were deferred and will be recorded over the term of the 2019 Credit Agreement.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any amounts borrowed under the 2019 Credit Agreement will bear interest, at the Company's option, at either a base rate or a Eurocurrency rate, in each case plus an applicable margin. Under the 2019 Credit Agreement, the applicable margins on base rate loans range from </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>0.125%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>0.50%</span></span><span style="font-family:inherit;font-size:10pt;"> and the applicable margins on Eurocurrency loans range from </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>1.125%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>1.50%</span></span><span style="font-family:inherit;font-size:10pt;">, in each case based on the Company's consolidated leverage ratio (the ratio of the Company's total consolidated funded indebtedness to the Company's consolidated EBITDA for the most recently completed four fiscal quarter period).</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any amounts borrowed pursuant to the 2019 Credit Agreement are guaranteed by certain of the Company’s existing and future domestic subsidiaries, subject to certain exceptions.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The 2019 Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including financial covenants to maintain (i) subject to certain limited exceptions, a consolidated leverage ratio of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>3.50</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.00</span><span style="font-family:inherit;font-size:10pt;">, subject to an increase to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>4.00</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.00</span><span style="font-family:inherit;font-size:10pt;"> following a material acquisition and (ii) a consolidated interest coverage ratio (the ratio of the Company’s consolidated EBITDA to its consolidated interest expenses for the most recently completed four fiscal quarter period) of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>2.50</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.00</span><span style="font-family:inherit;font-size:10pt;">, in each case measured on a quarterly basis. The 2019 Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Guaranties and Indemnifications</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As permitted under Massachusetts law, the Company’s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors’ and officers’ liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. </span><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company, and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company’s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of the Company’s contractual obligations arising out of the research or clinical testing of the Company’s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company’s contractual obligations. The indemnification provisions appearing in the Company’s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Other Contingencies</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> material contingent liabilities accrued as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div> 500000000.0 500000000.0 50000000.0 0.00125 0.0050 0.01125 0.0150 3.50 4.00 2.50 0 0 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Segment Information</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment reporting is prepared on the same basis that the Company’s chief executive officer, who is the Company’s chief operating decision maker, manages the business, makes operating decisions and assesses performance. The Company operates in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> segment, pharmaceuticals. Enterprise-wide disclosures about revenues, significant customers, and property and equipment, net by location are presented below.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Revenues by Product</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Product revenues, net consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.73015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019<br/>(as reported under ASC 606)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018<br/>(as reported under ASC 606)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017<br/>(as reported under ASC 605)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">TRIKAFTA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>420,105</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">SYMDEKO/SYMKEVI</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,417,668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>768,657</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">ORKAMBI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,331,891</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,262,166</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,320,850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">KALYDECO</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>991,062</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,007,502</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>844,630</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total product revenues, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,160,726</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,038,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,165,480</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Revenues by Geographic Location</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Net product revenues are attributed to countries based on the location of the customer. Collaborative and royalty revenues are attributed to countries based on the location of the Company’s subsidiary associated with the collaborative arrangement related to such revenues. Total revenues from external customers and collaborators by geographic region consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.73015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019<br/>(as reported under ASC 606)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018<br/>(as reported under ASC 606)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017<br/>(as reported under ASC 605)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,062,555</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,365,079</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,986,786</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Outside of the United States</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>885,762</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>543,179</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>420,317</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>214,504</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>139,339</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>81,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total revenues outside of the United States</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,100,266</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>682,518</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>501,866</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,162,821</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,047,597</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,488,652</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Significant Customers</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Gross revenues and accounts receivable from each of the Company’s customers who individually accounted for </span><span style="font-family:Times New Roman;font-size:10pt;">10%</span><span style="font-family:Times New Roman;font-size:10pt;"> or more of total gross revenues and/or </span><span style="font-family:Times New Roman;font-size:10pt;">10%</span><span style="font-family:Times New Roman;font-size:10pt;"> or more of total gross accounts receivable consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.47619047619048%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:31%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Percent of Total Gross </span></div><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Percent of Gross Accounts Receivable</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019<br/>(as reported under ASC 606)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018<br/>(as reported under ASC 606)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017<br/>(as reported under ASC 605)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">McKesson Corporation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>&lt;10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Walgreen Co.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Accredo/Curascript</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Long-lived Assets by Location</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Long-lived assets by location consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.47619047619048%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>768,572</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>778,157</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Outside of the United States</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">United Kingdom</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>57,383</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>30,496</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,327</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,352</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total long-lived assets outside of the United States</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>64,710</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>33,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">      Total long-lived assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>833,282</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>812,005</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Product revenues, net consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.73015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019<br/>(as reported under ASC 606)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018<br/>(as reported under ASC 606)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017<br/>(as reported under ASC 605)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">TRIKAFTA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>420,105</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">SYMDEKO/SYMKEVI</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,417,668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>768,657</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">ORKAMBI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,331,891</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,262,166</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,320,850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">KALYDECO</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>991,062</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,007,502</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>844,630</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total product revenues, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,160,726</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,038,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,165,480</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 420105000 0 0 1417668000 768657000 0 1331891000 1262166000 1320850000 991062000 1007502000 844630000 4160726000 3038325000 2165480000 3062555000 2365079000 1986786000 885762000 543179000 420317000 214504000 139339000 81549000 1100266000 682518000 501866000 4162821000 3047597000 2488652000 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Gross revenues and accounts receivable from each of the Company’s customers who individually accounted for </span><span style="font-family:Times New Roman;font-size:10pt;">10%</span><span style="font-family:Times New Roman;font-size:10pt;"> or more of total gross revenues and/or </span><span style="font-family:Times New Roman;font-size:10pt;">10%</span><span style="font-family:Times New Roman;font-size:10pt;"> or more of total gross accounts receivable consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.47619047619048%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:31%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Percent of Total Gross </span></div><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Percent of Gross Accounts Receivable</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019<br/>(as reported under ASC 606)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018<br/>(as reported under ASC 606)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017<br/>(as reported under ASC 605)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">McKesson Corporation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>&lt;10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Walgreen Co.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Accredo/Curascript</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.17 0.14 0.10 0.22 0.16 0.15 0.20 0.17 0.14 0.16 0.14 0.14 0.14 0.15 0.10 <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Long-lived assets by location consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.47619047619048%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>768,572</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>778,157</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Outside of the United States</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">United Kingdom</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>57,383</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>30,496</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,327</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,352</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total long-lived assets outside of the United States</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>64,710</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>33,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">      Total long-lived assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>833,282</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>812,005</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Total revenues from external customers and collaborators by geographic region consisted of the following:<div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.73015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019<br/>(as reported under ASC 606)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2018<br/>(as reported under ASC 606)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2017<br/>(as reported under ASC 605)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,062,555</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,365,079</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,986,786</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Outside of the United States</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>885,762</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>543,179</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>420,317</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>214,504</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>139,339</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>81,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total revenues outside of the United States</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,100,266</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>682,518</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>501,866</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,162,821</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,047,597</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,488,652</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 768572000 778157000 57383000 30496000 7327000 3352000 64710000 33848000 833282000 812005000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarterly Financial Data (unaudited)</span></div><div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following tables set forth the Company’s quarterly financial data for the two years ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">March 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands, except per share amounts)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Product revenues, net (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>857,253</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>940,380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>949,828</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,413,265</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Collaborative and royalty revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,182</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>913</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>858,435</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>941,293</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>949,828</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,413,265</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Costs and expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cost of sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>95,092</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>135,740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>131,914</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>185,012</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Research and development expenses (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>339,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>379,091</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>555,948</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>480,011</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Sales, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>147,045</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>156,502</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>159,674</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>195,277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Change in fair value of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,959</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total costs and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>581,627</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>671,333</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>850,495</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>861,800</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>276,808</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>269,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>99,333</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>551,465</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15,615</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>18,076</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17,628</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,359</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(14,868</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(14,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(14,548</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(14,249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other income (expense), net (3)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>42,610</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>53,939</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(31,747</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>127,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income before provision for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>320,165</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>327,138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>70,666</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>676,950</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Provision for income taxes (4)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>51,534</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>59,711</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>13,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>93,716</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income attributable to Vertex</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>268,631</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>267,427</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>57,518</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>583,234</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts per share attributable to Vertex common shareholders:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">    Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.05</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">    Diluted </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Shares used in per share calculations:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">    Basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>255,695</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>256,154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>256,946</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>258,003</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">    Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>260,175</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>259,822</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>260,473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>262,108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">March 31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">June 30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">September 30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands, except per share amounts)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>637,729</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>749,912</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>782,511</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>868,173</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Collaborative and royalty revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,070</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,245</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,933</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>640,799</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>752,157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>784,535</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>870,106</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Costs and expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cost of sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>71,613</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>104,382</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>111,255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>122,289</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Research and development expenses (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>310,553</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>337,532</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>330,510</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>437,881</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Sales, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>129,808</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>137,303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>137,295</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>153,210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Restructuring (income) expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(174</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Intangible asset impairment charge</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total costs and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>511,898</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>579,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>578,886</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>742,384</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>128,901</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>172,878</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>205,649</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>127,722</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,789</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,049</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>13,971</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(16,886</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(18,155</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(18,686</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(18,744</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other income (expense), net (3)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>96,838</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>53,819</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(60,995</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(90,452</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income before (benefit from) provision for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>214,642</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>216,591</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>136,511</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>32,497</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">(Benefit from) provision for income taxes (4)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(12,659</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,055</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,492,599</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>227,301</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>206,250</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>128,456</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,525,096</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">(Income) loss attributable to noncontrolling interest (5)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(17,038</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,110</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>290</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25,431</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income attributable to Vertex</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>210,263</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>207,360</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>128,746</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,550,527</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts per share attributable to Vertex common shareholders:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">    Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.83</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.82</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">    Diluted </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5.97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Shares used in per share calculations:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">    Basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>253,231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>254,135</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>254,905</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>254,868</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">    Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>258,526</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>258,584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>259,788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>259,812</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Times New Roman;font-size:9pt;">1.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;">In the fourth quarter of 2019, the Company updated its transaction price and recognized net product revenues of </span><span style="font-family:Times New Roman;font-size:9pt;"><span>$155.8 million</span></span><span style="font-family:Times New Roman;font-size:9pt;"> related to prior period ORKAMBI sales upon reaching a reimbursement agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs. See </span><span style="font-family:Times New Roman;font-size:9pt;">Note A, “Nature of Business and Accounting Policies.”</span><span style="font-family:Times New Roman;font-size:9pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Times New Roman;font-size:9pt;">2.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;">In the third quarter of 2019, the Company incurred research and development expenses of </span><span style="font-family:Times New Roman;font-size:9pt;"><span>$175.0 million</span></span><span style="font-family:Times New Roman;font-size:9pt;"> related to its CRISPR DMD/DM1 Agreement. In the fourth quarter of 2018, the Company incurred research and development expenses of </span><span style="font-family:Times New Roman;font-size:9pt;"><span>$95.0 million</span></span><span style="font-family:Times New Roman;font-size:9pt;"> to related license agreements with Merck KGaA, Darmstadt, Germany, and Arbor. See </span><span style="font-family:Times New Roman;font-size:9pt;">Note B, “Collaborative Arrangements.”</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Times New Roman;font-size:9pt;">3.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;">In 2019 and 2018, “</span><span style="font-family:Times New Roman;font-size:9pt;">Other income (expense), net</span><span style="font-family:Times New Roman;font-size:9pt;">” was primarily related to changes in the fair value of the Company’s equity investment in CRISPR. See </span><span style="font-family:Times New Roman;font-size:9pt;">Note F, “Marketable Securities and Equity Investments.”</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Times New Roman;font-size:9pt;">4.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;">In the fourth quarter of 2018, the Company released the valuation allowance on the majority of its NOLs and other deferred tax assets as of December 31, 2018 resulting in a benefit from income taxes of </span><span style="font-family:Times New Roman;font-size:9pt;"><span>$1.56 billion</span></span><span style="font-family:Times New Roman;font-size:9pt;">. </span><span style="font-family:Times New Roman;font-size:9pt;">Starting in 2019, the Company began recording a provision for income taxes approximating statutory rates on its pre-tax income</span><span style="font-family:Times New Roman;font-size:9pt;">. See </span><span style="font-family:Times New Roman;font-size:9pt;">Note P, “Income Taxes.”</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Times New Roman;font-size:9pt;">5.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;">In 2018, the Company had a noncontrolling interest in BioAxone, which it consolidated as a VIE until December 31, 2018. Following the deconsolidation of BioAxone as of December 31, 2018, the Company did not have a noncontrolling interest in any entities in 2019. See </span><span style="font-family:Times New Roman;font-size:9pt;">Note B, “Collaborative Arrangements.”</span></div> <div style="line-height:120%;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following tables set forth the Company’s quarterly financial data for the two years ended </span><span style="font-family:Times New Roman;font-size:10pt;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">March 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands, except per share amounts)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Product revenues, net (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>857,253</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>940,380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>949,828</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,413,265</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Collaborative and royalty revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,182</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>913</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>858,435</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>941,293</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>949,828</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,413,265</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Costs and expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cost of sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>95,092</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>135,740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>131,914</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>185,012</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Research and development expenses (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>339,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>379,091</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>555,948</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>480,011</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Sales, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>147,045</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>156,502</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>159,674</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>195,277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Change in fair value of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,959</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total costs and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>581,627</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>671,333</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>850,495</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>861,800</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>276,808</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>269,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>99,333</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>551,465</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15,615</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>18,076</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17,628</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,359</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(14,868</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(14,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(14,548</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(14,249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other income (expense), net (3)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>42,610</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>53,939</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(31,747</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>127,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income before provision for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>320,165</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>327,138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>70,666</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>676,950</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Provision for income taxes (4)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>51,534</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>59,711</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>13,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>93,716</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income attributable to Vertex</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>268,631</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>267,427</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>57,518</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>583,234</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts per share attributable to Vertex common shareholders:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">    Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.05</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">    Diluted </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Shares used in per share calculations:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">    Basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>255,695</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>256,154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>256,946</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>258,003</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">    Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>260,175</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>259,822</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>260,473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>262,108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">March 31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">June 30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">September 30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands, except per share amounts)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>637,729</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>749,912</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>782,511</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>868,173</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Collaborative and royalty revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,070</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,245</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,933</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>640,799</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>752,157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>784,535</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>870,106</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Costs and expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cost of sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>71,613</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>104,382</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>111,255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>122,289</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Research and development expenses (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>310,553</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>337,532</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>330,510</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>437,881</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Sales, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>129,808</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>137,303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>137,295</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>153,210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Restructuring (income) expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(174</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Intangible asset impairment charge</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total costs and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>511,898</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>579,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>578,886</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>742,384</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>128,901</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>172,878</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>205,649</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>127,722</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,789</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,049</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>13,971</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(16,886</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(18,155</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(18,686</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(18,744</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other income (expense), net (3)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>96,838</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>53,819</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(60,995</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(90,452</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income before (benefit from) provision for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>214,642</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>216,591</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>136,511</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>32,497</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">(Benefit from) provision for income taxes (4)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(12,659</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,055</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,492,599</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>227,301</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>206,250</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>128,456</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,525,096</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">(Income) loss attributable to noncontrolling interest (5)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(17,038</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,110</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>290</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25,431</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income attributable to Vertex</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>210,263</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>207,360</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>128,746</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,550,527</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts per share attributable to Vertex common shareholders:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">    Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.83</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.82</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">    Diluted </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5.97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Shares used in per share calculations:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">    Basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>253,231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>254,135</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>254,905</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>254,868</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">    Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>258,526</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>258,584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>259,788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>259,812</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Times New Roman;font-size:9pt;">1.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;">In the fourth quarter of 2019, the Company updated its transaction price and recognized net product revenues of </span><span style="font-family:Times New Roman;font-size:9pt;"><span>$155.8 million</span></span><span style="font-family:Times New Roman;font-size:9pt;"> related to prior period ORKAMBI sales upon reaching a reimbursement agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs. See </span><span style="font-family:Times New Roman;font-size:9pt;">Note A, “Nature of Business and Accounting Policies.”</span><span style="font-family:Times New Roman;font-size:9pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Times New Roman;font-size:9pt;">2.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;">In the third quarter of 2019, the Company incurred research and development expenses of </span><span style="font-family:Times New Roman;font-size:9pt;"><span>$175.0 million</span></span><span style="font-family:Times New Roman;font-size:9pt;"> related to its CRISPR DMD/DM1 Agreement. In the fourth quarter of 2018, the Company incurred research and development expenses of </span><span style="font-family:Times New Roman;font-size:9pt;"><span>$95.0 million</span></span><span style="font-family:Times New Roman;font-size:9pt;"> to related license agreements with Merck KGaA, Darmstadt, Germany, and Arbor. See </span><span style="font-family:Times New Roman;font-size:9pt;">Note B, “Collaborative Arrangements.”</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Times New Roman;font-size:9pt;">3.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;">In 2019 and 2018, “</span><span style="font-family:Times New Roman;font-size:9pt;">Other income (expense), net</span><span style="font-family:Times New Roman;font-size:9pt;">” was primarily related to changes in the fair value of the Company’s equity investment in CRISPR. See </span><span style="font-family:Times New Roman;font-size:9pt;">Note F, “Marketable Securities and Equity Investments.”</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Times New Roman;font-size:9pt;">4.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;">In the fourth quarter of 2018, the Company released the valuation allowance on the majority of its NOLs and other deferred tax assets as of December 31, 2018 resulting in a benefit from income taxes of </span><span style="font-family:Times New Roman;font-size:9pt;"><span>$1.56 billion</span></span><span style="font-family:Times New Roman;font-size:9pt;">. </span><span style="font-family:Times New Roman;font-size:9pt;">Starting in 2019, the Company began recording a provision for income taxes approximating statutory rates on its pre-tax income</span><span style="font-family:Times New Roman;font-size:9pt;">. See </span><span style="font-family:Times New Roman;font-size:9pt;">Note P, “Income Taxes.”</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Times New Roman;font-size:9pt;">5.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;">In 2018, the Company had a noncontrolling interest in BioAxone, which it consolidated as a VIE until December 31, 2018. Following the deconsolidation of BioAxone as of December 31, 2018, the Company did not have a noncontrolling interest in any entities in 2019. See </span><span style="font-family:Times New Roman;font-size:9pt;">Note B, “Collaborative Arrangements.”</span></div> 857253000 940380000 949828000 1413265000 1182000 913000 0 0 858435000 941293000 949828000 1413265000 95092000 135740000 131914000 185012000 339490000 379091000 555948000 480011000 147045000 156502000 159674000 195277000 0 0 2959000 1500000 581627000 671333000 850495000 861800000 276808000 269960000 99333000 551465000 15615000 18076000 17628000 12359000 14868000 14837000 14548000 14249000 42610000 53939000 -31747000 127375000 320165000 327138000 70666000 676950000 51534000 59711000 13148000 93716000 268631000 267427000 57518000 583234000 1.05 1.04 0.22 2.26 1.03 1.03 0.22 2.23 255695000 256154000 256946000 258003000 260175000 259822000 260473000 262108000 637729000 749912000 782511000 868173000 3070000 2245000 2024000 1933000 640799000 752157000 784535000 870106000 71613000 104382000 111255000 122289000 310553000 337532000 330510000 437881000 129808000 137303000 137295000 153210000 76000 -62000 174000 -4000 0 0 0 29000000 511898000 579279000 578886000 742384000 128901000 172878000 205649000 127722000 5789000 8049000 10543000 13971000 16886000 18155000 18686000 18744000 96838000 53819000 -60995000 -90452000 214642000 216591000 136511000 32497000 -12659000 10341000 8055000 -1492599000 227301000 206250000 128456000 1525096000 17038000 -1110000 -290000 -25431000 210263000 207360000 128746000 1550527000 0.83 0.82 0.51 6.08 0.81 0.80 0.50 5.97 253231000 254135000 254905000 254868000 258526000 258584000 259788000 259812000 155800000 175000000.0 95000000.0 -1560000000 XML 136 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Marketable Securities and Equity Investments
 12 Months Ended
Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities and Equity Investments
Marketable Securities and Equity Investments
A summary of the Company’s cash equivalents and marketable securities, which are recorded at fair value (and do not include $2.3 billion and $1.4 billion of cash as of December 31, 2019 and 2018, respectively), is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of December 31, 2019
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
791,039

 
$
—

 
$
—

 
$
791,039

Corporate debt securities
6,070

 
—

 
—

 
6,070

Commercial paper
29,470

 
3

 
(1
)
 
29,472

Total cash equivalents
826,579

 
3

 
(1
)
 
826,581

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
12,689

 
44

 
—

 
12,733

Corporate debt securities
301,458

 
391

 
(50
)
 
301,799

Commercial paper
102,240

 
121

 
(5
)
 
102,356

Total marketable debt securities
416,387

 
556

 
(55
)
 
416,888

Corporate equity securities
113,829

 
168,255

 
—

 
282,084

Total marketable securities
$
530,216

 
$
168,811

 
$
(55
)
 
$
698,972

 
 
 
 
 
 
 
 
As of December 31, 2018
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
1,226,603

 
$
—

 
$
—

 
$
1,226,603

U.S. Treasury securities
5,967

 
—

 
(1
)
 
5,966

Government-sponsored enterprise securities
7,124

 
—

 
(1
)
 
7,123

Commercial paper
58,271

 
—

 
(3
)
 
58,268

Total cash equivalents
1,297,965

 
—

 
(5
)
 
1,297,960

Marketable securities:
 
 
 
 
 
 
 
U.S Treasury securities
6,026

 
—

 
—

 
6,026

Government-sponsored enterprise securities
10,704

 
—

 
—

 
10,704

Corporate debt securities
234,088

 
27

 
(450
)
 
233,665

Commercial paper
100,498

 
—

 
(108
)
 
100,390

Total marketable debt securities
351,316

 
27

 
(558
)
 
350,785

Corporate equity securities
133,157

 
40,619

 
(6,453
)
 
167,323

Total marketable securities
$
484,473

 
$
40,646

 
$
(7,011
)
 
$
518,108

Available-for-sale debt securities were classified on the Company’s consolidated balance sheets as follows:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Cash and cash equivalents
$
826,581

 
$
1,297,960

Marketable securities
416,888

 
350,785

Total
$
1,243,469

 
$
1,648,745


Available-for-sale debt securities by contractual maturity were as follows:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Matures within one year
$
1,137,942

 
$
1,647,500

Matures after one year through five years
105,527

 
1,245

Total
$
1,243,469

 
$
1,648,745


The Company has a limited number of available-for-sale debt securities in insignificant loss positions as of December 31, 2019, which it does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investments at maturity. The Company did not record any charges for other-than-temporary declines in the fair value of available-for-sale debt securities or gross realized gains or losses in 2019, 2018 or 2017.
As of December 31, 2019 and 2018, the total fair value of the Company’s strategic investments in the common stock of publicly traded companies, which was primarily related to its investment in CRISPR, was $282.1 million and $167.3 million, respectively, and was classified as “Marketable securities” on its consolidated balance sheets.
Pursuant to the adoption of ASU 2016-01 on January 1, 2018, the Company began recording changes in the fair value of its investments in strategic corporate equity securities, which are primarily attributable to its investment in CRISPR, to “Other income (expense), net” in the Company’s consolidated statements of operations. Prior to its adoption of ASU 2016-01, the Company recorded changes in the fair value of its investments in corporate equity securities to “Accumulated other comprehensive (loss) income” on its consolidated balance sheet until the related gains or losses were realized. The Company continues to record unrealized gains (losses) on available-for-sale debt securities as a component of “Accumulated other comprehensive (loss) income” until such gains and losses are realized.
During the year ended December 31, 2019 and 2018, the Company recorded unrealized gains of $132.5 million and $2.6 million, respectively, which were primarily related to the Company’s strategic investment in CRISPR. As noted above, unrealized gains or losses were recorded to “Accumulated other comprehensive (loss) income” during the year ended December 31, 2017.
During the year ended December 31, 2019, the Company recorded realized gains of $65.1 million related to sales of CRISPR’s common stock. The Company utilized a weighted-average cost basis to calculate the realized gain. There were no sales of CRISPR’s common stock in the years ended December 31, 2018 or 2017.
As of December 31, 2019, the carrying value of the Company’s equity investments without readily determinable fair values, which are recorded in “Other assets” on its consolidated balance sheets, was $40.8 million.
XML 137 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Inventories (Tables)
 12 Months Ended
Dec. 31, 2019
Inventory Disclosure [Abstract]  
Schedule of Inventories by Type
Inventories consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Raw materials
$
26,247

 
$
9,677

Work-in-process
107,021

 
87,944

Finished goods
34,234

 
26,739

Total
$
167,502

 
$
124,360
XML 138 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Financial assets and liabilities subject to fair value measurements (excluding restricted cash and cash equivalents (VIE))
The following tables set forth the Company’s financial assets and liabilities subject to fair value measurements (and does not include $2.3 billion and $1.4 billion of cash as of December 31, 2019 and 2018, respectively):
 
Fair Value Measurements as of December 31, 2019
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
791,039

 
$
791,039

 
$
—

 
$
—

Corporate debt securities
6,070

 
—

 
6,070

 
—

Commercial paper
29,472

 
—

 
29,472

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
282,084

 
261,797

 
20,287

 
—

Government-sponsored enterprise securities
12,733

 
12,733

 
—

 
—

Corporate debt securities
301,799

 
—

 
301,799

 
—

Commercial paper
102,356

 
—

 
102,356

 
—

Prepaid expenses and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
9,725

 
—

 
9,725

 
—

Total financial assets
$
1,535,278

 
$
1,065,569

 
$
469,709

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other current liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(5,533
)
 
$
—

 
$
(5,533
)
 
$
—

Long-term contingent consideration
(176,500
)
 
—

 
—

 
(176,500
)
Other long-term liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
(1,821
)
 
—

 
(1,821
)
 
—

Total financial liabilities
$
(183,854
)
 
$
—

 
$
(7,354
)
 
$
(176,500
)

 
Fair Value Measurements as of December 31, 2018
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
1,226,603

 
$
1,226,603

 
$
—

 
$
—

U.S. Treasury securities
5,966

 
5,966

 
—

 
—

Government-sponsored enterprise securities
7,123

 
7,123

 
—

 
—

Commercial paper
58,268

 
—

 
58,268

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
167,323

 
153,733

 
13,590

 
—

U.S. Treasury securities
6,026

 
6,026

 
—

 
—

Government-sponsored enterprise securities
10,704

 
10,704

 
—

 
—

Corporate debt securities
233,665

 
—

 
233,665

 
—

Commercial paper
100,390

 
—

 
100,390

 
—

Prepaid expenses and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
19,023

 
—

 
19,023

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
1,514

 
—

 
1,514

 
—

Total financial assets
$
1,836,605

 
$
1,410,155

 
$
426,450

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other current liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(340
)
 
$
—

 
$
(340
)
 
$
—

Other long-term liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
(108
)
 
—

 
(108
)
 
—

Total financial liabilities
$
(448
)
 
$
—

 
$
(448
)
 
$
—
Schedule of fair value of our contingent consideration liabilities
The following table represents a rollforward of the fair value of the Company’s contingent consideration liabilities:
 
Year Ended December 31, 2019
 
(in thousands)
Balance at December 31, 2018
$
—

Contingent consideration related to acquisition of Exonics
172,041

Increase in fair value of contingent payments
4,459

Balance at December 31, 2019
$
176,500
XML 139 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Common Stock, Preferred Stock and Equity Plans
 12 Months Ended
Dec. 31, 2019
Equity [Abstract]  
Common Stock, Preferred Stock and Equity Plans
Common Stock, Preferred Stock and Equity Plans
Common Stock and Preferred Stock
The Company is authorized to issue 500,000,000 shares of common stock. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by the Company’s Board of Directors, and to share ratably in the Company’s assets legally available for distribution to the Company’s shareholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption or conversion rights. The holders of common stock do not have cumulative voting rights.
The Company is authorized to issue 1,000,000 shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by the Company’s shareholders. As of December 31, 2019 and 2018, the Company had no shares of preferred stock issued or outstanding.
Share Repurchase Program
During 2018, the Company’s Board of Directors approved a share repurchase program (the “2018 Share Repurchase Program”), pursuant to which the Company was authorized to repurchase up to $500.0 million of its common stock between February 1, 2018 and December 31, 2019.
During the years ended December 31, 2019 and 2018, the Company repurchased 832,186 and 2,093,891 shares, respectively, of its common stock under the 2018 Share Repurchase Program for an aggregate of $150.0 million and $350.0 million, respectively, including commissions and fees. As of June 30, 2019, the Company had repurchased the entire $500.0 million it was authorized to repurchase of its common stock under the 2018 Share Repurchase Program.
In July 2019, the Company’s Board of Directors approved a new share repurchase program (the “2019 Share Repurchase Program”), pursuant to which the Company is authorized to repurchase up to $500.0 million of its common stock between August 1, 2019 and December 31, 2020. The Company expects to fund further repurchases of its common stock through a combination of cash on hand and cash generated by operations. During the year ended December 31, 2019, the Company repurchased 213,548 shares of its common stock under the 2019 Share Repurchase Program for an aggregate of $36.0 million including commissions and fees. As of December 31, 2019, there is a total of $464.0 million remaining for repurchases under the 2019 Share Repurchase Program.
Under the 2018 and 2019 Share Repurchase Programs, the Company is authorized to purchase shares from time to time through open market or privately negotiated transactions. Such purchases are made pursuant to Rule 10b5-1 plans or other means as determined by the Company’s management and in accordance with the requirements of the SEC.
Stock and Option Plans
The purpose of each of the Company’s stock and option plans is to attract, retain and motivate its employees, consultants and directors. Awards granted under these plans can be nonstatutory stock options (“NSOs”), incentive stock options (“ISOs”), restricted stock units (“RSUs”) including performance-based RSUs (“PSUs”), restricted stock (“RSs”), or other equity-based awards, as specified in the individual plans.
Shares issued under all of the Company’s plans are funded through the issuance of new shares. The following table contains information about the Company’s equity plans:
 
 
 
 
 
 
As of December 31, 2019
Title of Plan
 
Group Eligible
 
Type of Award
Granted
 
Awards
Outstanding
 
Additional Awards
Authorized for
Grant
2013 Stock and Option Plan
 
Employees, Non-employee Directors and Consultants
 
NSO,
RS, RSU and PSU
 
9,577,268

 
15,778,703

2006 Stock and Option Plan
 
Employees, Non-employee Directors and Consultants
 
NSO,
RS and RSU
 
651,842

 
—

 
 
 
 
Total
 
10,229,110

 
15,778,703


All options granted under the Company’s 2013 Stock and Option Plan (“2013 Plan”) and 2006 Stock and Option Plan (“2006 Plan”) were granted with an exercise price equal to the fair value of the underlying common stock on the date of grant. As of December 31, 2019, the stock and option plan under which the Company is authorized to make new equity awards is the Company’s 2013 Plan. Under the 2013 Plan, no stock options can be awarded with an exercise price less than the fair market value on the date of grant. In the three years ended December 31, 2019, the Company’s shareholders approved increases in the number of shares authorized for issuance pursuant to the 2013 Stock and Option Plan of (i) 5,000,000 shares in 2019, (ii) 8,000,000 shares in 2018 and (iii) 6,750,000 shares in 2017.
During the three years ended December 31, 2019, grants to current employees and directors primarily had a grant date that was the same as the date the award was approved by the Company’s Board of Directors. During the three years ended December 31, 2019, for grants to new employees and directors, the date of grant for awards was the employee’s first day of employment or the date the director was elected to the Company’s Board of Directors. All options awarded under the Company’s stock and option plans expire not more than 10 years from the grant date.
Stock Options
The following table summarizes information related to the outstanding and exercisable options during the year ended December 31, 2019:
 
Stock Options
 
Weighted-average
Exercise Price
 
Weighted-average
Remaining
Contractual Life
 
Aggregate Intrinsic
Value
 
(in thousands)
 
(per share)
 
(in years)
 
(in thousands)
Outstanding at December 31, 2018
8,551

 
$
111.46

 
 
 
 
Granted
1,521

 
$
184.50

 
 
 
 
Exercised
(3,327
)
 
$
95.57

 
 
 
 
Forfeited
(467
)
 
$
146.59

 
 
 
 
Expired
(6
)
 
$
182.96

 
 
 
 
Outstanding at December 31, 2019
6,272

 
$
134.92

 
7.12
 
$
522,740

Exercisable at December 31, 2019
3,333

 
$
114.15

 
6.06
 
$
346,943


The aggregate intrinsic value in the table above represents the total pre-tax amount, net of exercise price, that would have been received by option holders if all option holders had exercised all options with an exercise price lower than the market price on the last business day of 2019, which was $218.26 based on the average of the high and low price of the Company’s common stock on that date.
The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during 2019, 2018 and 2017 was $325.9 million, $258.2 million and $302.8 million, respectively. The total cash received by the Company as a result of employee stock option exercises during 2019, 2018 and 2017 was $317.8 million, $263.4 million and $323.3 million, respectively.
The following table summarizes information about stock options outstanding and exercisable at December 31, 2019:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
 
Weighted-average
Remaining
Contractual Life
 
Weighted-average
Exercise Price
 
Number
Exercisable
 
Weighted-average
Exercise Price
 
 
(in thousands)
 
(in years)
 
(per share)
 
(in thousands)
 
(per share)
$29.07–$40.00
 
108

 
1.58
 
$
37.62

 
108

 
$
37.62

$40.01–$60.00
 
277

 
2.55
 
$
49.69

 
277

 
$
49.69

$60.01–$80.00
 
140

 
4.31
 
$
74.55

 
136

 
$
74.53

$80.01–$100.00
 
1,670

 
6.25
 
$
89.42

 
1144

 
$
90.10

$100.01–$120.00
 
243

 
5.11
 
$
109.23

 
241

 
$
109.17

$120.01–$140.00
 
454

 
5.67
 
$
129.77

 
447

 
$
129.85

$140.01–$160.00
 
1,036

 
8.10
 
$
155.50

 
383

 
$
155.39

$160.01–$180.00
 
720

 
8.46
 
$
168.04

 
233

 
$
164.48

$180.01–$189.38
 
1,624

 
8.90
 
$
185.41

 
364

 
$
184.85

Total
 
6,272

 
7.12
 
$
134.92

 
3,333

 
$
114.15


Restricted Stock and Restricted Stock Units (excluding PSUs)
The following table summarizes the restricted stock unit and restricted stock activity of the Company during the year ended December 31, 2019:
 
Restricted Stock Units (excluding PSUs)
 
Restricted Stock
 
Number of Shares
 
Weighted-average
Grant-date
Fair Value
 
Number of Units
 
Weighted-average
Grant-date
Fair Value
 
(in thousands)
 
(per share)
 
(in thousands)
 
(per share)
Unvested at December 31, 2018
2,717

 
$
140.10

 
480

 
$
104.91

Granted
1,717

 
$
181.87

 
—

 
$
—

Vested
(974
)
 
$
133.15

 
(375
)
 
$
108.23

Cancelled
(329
)
 
$
149.83

 
(13
)
 
$
100.79

Unvested at December 31, 2019
3,131

 
$
163.61

 
92

 
$
91.97


The total fair value of restricted stock units that vested during 2019, 2018 and 2017 (measured on the date of vesting) was $178.2 million, $104.8 million and $33.2 million, respectively. The total fair value of restricted stock that vested during 2019, 2018 and 2017 (measured on the date of vesting) was $70.7 million, $114.5 million and $157.0 million, respectively.
Performance-based RSUs (PSUs)
The potential range of shares issuable pursuant to the Company’s PSU awards range from 0% to 200% of the target shares based on financial and non-financial measures. Fifty percent of PSUs that could be earned have a one-year performance period with the amount actually earned dependent upon the Company’s financial performance and with vesting of the earned shares in three equal installments over a three-year period. The remaining 50% of PSUs that could be earned have a three-year performance period with the amount actually earned dependent upon the achievement of multiple clinical development milestones and with the earned shares cliff vesting at the end of the three-year performance period.
The following table summarizes the PSU activity of the Company during the year ended December 31, 2019:
 
Performance-Based RSU
 
Number of Units
 
Weighted-average
Grant-date
Fair Value
 
(in thousands)
 
(per share)
Unvested at December 31, 2018 (1)
759

 
$
110.50

Granted (2)
449

 
$
183.48

Vested
(403
)
 
$
109.23

Cancelled
(71
)
 
$
104.61

Unvested at December 31, 2019
734

 
$
143.21

 
 
 
 
(1) “Unvested” represents the Company’s PSUs at target to the extent performance has not been certified plus the actual number of shares that continue to be subject to service conditions for which the performance has been achieved and certified.
(2) “Granted” represents (i) the target number of shares issuable for grants during 2019 and (ii) any change in the number of shares issuable pursuant to outstanding PSUs based on performance certification during 2019.

The total fair value of PSUs that vested during 2019, 2018 and 2017 (measured on the date of vesting) was $73.3 million $23.2 million and $1.3 million, respectively.
Employee Stock Purchase Plan
The Company has an employee stock purchase plan (the “ESPP”). The ESPP permits eligible employees to enroll in a twelve-month offering period comprising two six-month purchase periods. Participants may purchase shares of the Company’s common stock, through payroll deductions, at a price equal to 85% of the fair market value of the common stock on the first day of the applicable twelve-month offering period, or the last day of the applicable six-month purchase period, whichever is lower. Purchase dates under the ESPP occur on or about May 14 and November 14 of each year. During 2019, the Company’s shareholders approved an increase in the number of shares authorized for issuance pursuant to the ESPP of 2,000,000 shares. As of December 31, 2019, there were 2,199,376 shares of common stock authorized for issuance pursuant to the ESPP.
In 2019, the following shares were issued to employees under the ESPP:
 
Year Ended December 31, 2019
 
(in thousands,
except per share amount)
Number of shares
202,693

Average price paid per share
$
138.18


Employee Benefits
The Company has a 401(k) retirement plan (the “Vertex 401(k) Plan”) in which substantially all of its permanent U.S. employees are eligible to participate. Participants may contribute up to 60% of their annual compensation to the Vertex 401(k) Plan, subject to statutory limitations. The Company may declare discretionary matching contributions to the Vertex 401(k) Plan. The Company pays matching contributions in the form of cash. For the years ended December 31, 2019, 2018 and 2017, the Company contributed approximately $15.8 million, $13.9 million and $12.3 million to the plan, respectively.
XML 140 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Information
 12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Segment Information
Segment Information
Segment reporting is prepared on the same basis that the Company’s chief executive officer, who is the Company’s chief operating decision maker, manages the business, makes operating decisions and assesses performance. The Company operates in one segment, pharmaceuticals. Enterprise-wide disclosures about revenues, significant customers, and property and equipment, net by location are presented below.
Revenues by Product
Product revenues, net consisted of the following:
 
2019
(as reported under ASC 606)
 
2018
(as reported under ASC 606)
 
2017
(as reported under ASC 605)
 
(in thousands)
TRIKAFTA
$
420,105

 
$
—

 
$
—

SYMDEKO/SYMKEVI
1,417,668

 
768,657

 
—

ORKAMBI
1,331,891

 
1,262,166

 
1,320,850

KALYDECO
991,062

 
1,007,502

 
844,630

Total product revenues, net
$
4,160,726

 
$
3,038,325

 
$
2,165,480


Revenues by Geographic Location
Net product revenues are attributed to countries based on the location of the customer. Collaborative and royalty revenues are attributed to countries based on the location of the Company’s subsidiary associated with the collaborative arrangement related to such revenues. Total revenues from external customers and collaborators by geographic region consisted of the following:
 
2019
(as reported under ASC 606)
 
2018
(as reported under ASC 606)
 
2017
(as reported under ASC 605)
 
(in thousands)
United States
$
3,062,555

 
$
2,365,079

 
$
1,986,786

Outside of the United States
 
 
 
 
 
Europe
885,762

 
543,179

 
420,317

Other
214,504

 
139,339

 
81,549

Total revenues outside of the United States
1,100,266

 
682,518

 
501,866

Total revenues
$
4,162,821

 
$
3,047,597

 
$
2,488,652


Significant Customers
Gross revenues and accounts receivable from each of the Company’s customers who individually accounted for 10% or more of total gross revenues and/or 10% or more of total gross accounts receivable consisted of the following:
 
Percent of Total Gross
Revenues
 
Percent of Gross Accounts Receivable
 
Year Ended December 31,
 
As of December 31,
 
2019
(as reported under ASC 606)
 
2018
(as reported under ASC 606)
 
2017
(as reported under ASC 605)
 
2019
 
2018
McKesson Corporation
17
%
 
14
%
 
<10
%
 
22
%
 
16
%
Walgreen Co.
15
%
 
20
%
 
17
%
 
14
%
 
16
%
Accredo/Curascript
14
%
 
14
%
 
14
%
 
15
%
 
10
%

Long-lived Assets by Location
Long-lived assets by location consisted of the following:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
United States
$
768,572

 
$
778,157

Outside of the United States
 
 
 
United Kingdom
57,383

 
30,496

Other
7,327

 
3,352

Total long-lived assets outside of the United States
64,710

 
33,848

      Total long-lived assets
$
833,282

 
$
812,005
XML 141 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Nature of Business and Accounting Policies - Revenue Recognition (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Jan. 01, 2019
Jan. 01, 2018
Jan. 01, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                            
Contract liabilities $ 62,300       $ 24,900       $ 62,300 $ 24,900        
Revenues related to performance obligations                 24,900          
Cumulative effect adjustment to accumulated deficit                       $ (40,310) $ 9,229 $ 0
Revenues 1,413,265 $ 949,828 $ 941,293 $ 858,435 $ 870,106 $ 784,535 $ 752,157 $ 640,799 $ 4,162,821 $ 3,047,597 $ 2,488,652      
Accumulated Deficit                            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                            
Cumulative effect adjustment to accumulated deficit                       $ (40,310) 33,349 $ (9,371)
Accounting Standards Update 2014-09 | Accumulated Deficit                            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                            
Cumulative effect adjustment to accumulated deficit                         $ 8,300  
ORKAMBI                            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                            
Revenues $ 155,800                          
XML 142 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Schedule of components of income (loss) before provision for (benefit from) income taxes
The components of income (loss) before provision for (benefit from) income taxes during the three years ended December 31, 2019 consisted of the following:
 
2019
 
2018
 
2017
 
(in thousands)
United States
$
1,263,379

 
$
812,086

 
$
330,340

Foreign
131,540

 
(211,845
)
 
(346,029
)
Income (loss) before provision for (benefit from) income taxes
$
1,394,919

 
$
600,241

 
$
(15,689
)
Schedule of components of provision for (benefit from) income taxes
The components of the provision for (benefit from) income taxes during the three years ended December 31, 2019 consisted of the following:
 
2019
 
2018
 
2017
 
(in thousands)
Current taxes:
 
 
 
 
 
Federal
$
—

 
$
772

 
$
11,559

Foreign
37,194

 
15,600

 
3,576

State
13,528

 
9,018

 
5,025

Total current taxes
50,722

 
25,390

 
20,160

Deferred taxes:
 
 
 
 
 
Federal
184,312

 
(1,105,053
)
 
(113,805
)
Foreign
(24,797
)
 
(364,919
)
 
(3,222
)
State
7,872

 
(42,280
)
 
(10,457
)
Total deferred taxes
167,387

 
(1,512,252
)
 
(127,484
)
Provision for (benefit from) income taxes
$
218,109

 
$
(1,486,862
)
 
$
(107,324
)
Reconciliation of the provision for (benefit from) income taxes
A reconciliation of the provision for (benefit from) income taxes as computed by applying the U.S. federal statutory rate of 21% for the years ended December 31, 2019 and 2018 and 35% for the year ended December 31, 2017 to the provision for (benefit from) income taxes is as follows:
 
2019
 
2018
 
2017
 
(in thousands)
Income (loss) before provision for (benefit from) income taxes
$
1,394,919

 
$
600,241

 
$
(15,689
)
 
 
 
 
 
 
Expected provision for (benefit from) income taxes
292,933

 
126,051

 
(5,491
)
State taxes, net of federal benefit
8,478

 
8,680

 
4,742

Foreign income tax rate differential
6,178

 
23,427

 
77,801

Tax credits
(59,459
)
 
(52,629
)
 
(58,204
)
Benefit from income taxes attributable to valuation allowances
(2,672
)
 
(1,563,169
)
 
(575,801
)
Permanent items
4,822

 
1,421

 
15,324

Tax rate change
—

 
—

 
575,192

Stock compensation (benefit) shortfalls and cancellations
(56,324
)
 
(49,044
)
 
(21,453
)
Officer’s compensation
10,666

 
8,310

 
6,501

Deconsolidation of VIE
—

 
(9,390
)
 
(126,183
)
Uncertain tax positions
14,070

 
15,431

 
—

Other
(583
)
 
4,050

 
248

Provision for (benefit from) income taxes
$
218,109

 
$
(1,486,862
)
 
$
(107,324
)
Schedule of deferred tax assets and liabilities The components of the deferred taxes were as follows:
 
As of December 31,
 
2019
 
2018
 
(in thousands)
Deferred tax assets:
 
 
 
Net operating loss
$
512,256

 
$
882,014

Tax credit carryforwards
549,543

 
487,635

Intangible assets
275,290

 
241,775

Deferred revenues
18,833

 
19,311

Stock-based compensation
85,199

 
93,915

Accrued expenses
44,367

 
17,795

Finance lease liabilities
119,160

 
130,849

Operating lease assets
13,114

 
—

  Other
8,596

 
6,831

Gross deferred tax assets
1,626,358

 
1,880,125

Valuation allowance
(205,192
)
 
(168,491
)
Total deferred tax assets
1,421,166

 
1,711,634

Deferred tax liabilities:
 
 
 
Property and equipment
(101,235
)
 
(128,407
)
Acquired intangibles
(87,160
)
 
—

Deferred revenue
—

 
(73,357
)
Unrealized gain
(28,838
)
 
(10,198
)
Operating lease liabilities
(13,118
)
 
—

Net deferred tax assets
$
1,190,815

 
$
1,499,672
Summary of income tax contingencies
Unrecognized tax benefits during the three years ended December 31, 2019 were as follows:
 
2019
 
2018
 
2017
 
(in thousands)
Balance at beginning of the period
$
19,549

 
$
3,814

 
$
—

Increases related to current period tax positions
14,407

 
9,704

 
3,814

Increases related to prior period tax positions
598

 
6,031

 
—

Decreases related to prior period tax positions
(156
)
 
—

 
—

Settlement with Tax Authorities
(478
)
 
—

 
—

Balance at end of period
$
33,920

 
$
19,549

 
$
3,814
XML 143 R105.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Common Stock, Preferred Stock and Equity Plans - Employee Benefits (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Equity [Abstract]      
Maximum percentage of annual compensation contributed by the participant (percent) 60.00%    
Defined contribution plan, cost $ 15.8 $ 13.9 $ 12.3
XML 144 R98.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Common Stock, Preferred Stock and Equity Plans - Share Repurchase Program (Details) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Jul. 31, 2019
Jun. 30, 2019
Equity, Class of Treasury Stock [Line Items]        
Repurchases of common stock $ 192,015,000 $ 350,043,000    
Share Repurchase Program 2018        
Equity, Class of Treasury Stock [Line Items]        
Number of shares authorized to be repurchased   $ 500,000,000.0   $ 500,000,000.0
Repurchases of common stock (shares) 832,186 2,093,891    
Repurchases of common stock $ 150,000,000.0 $ 350,000,000.0    
Share Repurchase Program 2019        
Equity, Class of Treasury Stock [Line Items]        
Number of shares authorized to be repurchased     $ 500,000,000.0  
Repurchases of common stock (shares) 213,548      
Repurchases of common stock $ 36,000,000.0      
Number of shares remaining for repurchases $ 464,000,000.0      
XML 145 R101.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Common Stock, Preferred Stock and Equity Plans - Stock Options Outstanding and Exercisable (Details)
shares in Thousands
 12 Months Ended
Dec. 31, 2019
$ / shares
shares
Stock options outstanding and exercisable  
Options outstanding (in shares) | shares 6,272
Options outstanding, weighted-average remaining contractual life 7 years 1 month 13 days
Options outstanding, weighted-average exercise price (usd per share) $ 134.92
Options exercisable (in shares) | shares 3,333
Options exercisable, weighted-average exercise price (usd per share) $ 114.15
$29.07–$40.00  
Stock options outstanding and exercisable  
Exercise price, low end of range (usd per share) 29.07
Exercise price, high end of range (usd per share) $ 40
Options outstanding (in shares) | shares 108
Options outstanding, weighted-average remaining contractual life 1 year 6 months 29 days
Options outstanding, weighted-average exercise price (usd per share) $ 37.62
Options exercisable (in shares) | shares 108
Options exercisable, weighted-average exercise price (usd per share) $ 37.62
$40.01–$60.00  
Stock options outstanding and exercisable  
Exercise price, low end of range (usd per share) 40.01
Exercise price, high end of range (usd per share) $ 60
Options outstanding (in shares) | shares 277
Options outstanding, weighted-average remaining contractual life 2 years 6 months 18 days
Options outstanding, weighted-average exercise price (usd per share) $ 49.69
Options exercisable (in shares) | shares 277
Options exercisable, weighted-average exercise price (usd per share) $ 49.69
$60.01–$80.00  
Stock options outstanding and exercisable  
Exercise price, low end of range (usd per share) 60.01
Exercise price, high end of range (usd per share) $ 80
Options outstanding (in shares) | shares 140
Options outstanding, weighted-average remaining contractual life 4 years 3 months 21 days
Options outstanding, weighted-average exercise price (usd per share) $ 74.55
Options exercisable (in shares) | shares 136
Options exercisable, weighted-average exercise price (usd per share) $ 74.53
$80.01–$100.00  
Stock options outstanding and exercisable  
Exercise price, low end of range (usd per share) 80.01
Exercise price, high end of range (usd per share) $ 100
Options outstanding (in shares) | shares 1,670
Options outstanding, weighted-average remaining contractual life 6 years 3 months
Options outstanding, weighted-average exercise price (usd per share) $ 89.42
Options exercisable (in shares) | shares 1,144
Options exercisable, weighted-average exercise price (usd per share) $ 90.10
$100.01–$120.00  
Stock options outstanding and exercisable  
Exercise price, low end of range (usd per share) 100.01
Exercise price, high end of range (usd per share) $ 120.00
Options outstanding (in shares) | shares 243
Options outstanding, weighted-average remaining contractual life 5 years 1 month 9 days
Options outstanding, weighted-average exercise price (usd per share) $ 109.23
Options exercisable (in shares) | shares 241
Options exercisable, weighted-average exercise price (usd per share) $ 109.17
$120.01–$140.00  
Stock options outstanding and exercisable  
Exercise price, low end of range (usd per share) 120.01
Exercise price, high end of range (usd per share) $ 140.00
Options outstanding (in shares) | shares 454
Options outstanding, weighted-average remaining contractual life 5 years 8 months 1 day
Options outstanding, weighted-average exercise price (usd per share) $ 129.77
Options exercisable (in shares) | shares 447
Options exercisable, weighted-average exercise price (usd per share) $ 129.85
$140.01–$160.00  
Stock options outstanding and exercisable  
Exercise price, low end of range (usd per share) 140.01
Exercise price, high end of range (usd per share) $ 160.00
Options outstanding (in shares) | shares 1,036
Options outstanding, weighted-average remaining contractual life 8 years 1 month 6 days
Options outstanding, weighted-average exercise price (usd per share) $ 155.50
Options exercisable (in shares) | shares 383
Options exercisable, weighted-average exercise price (usd per share) $ 155.39
$160.01–$180.00  
Stock options outstanding and exercisable  
Exercise price, low end of range (usd per share) 160.01
Exercise price, high end of range (usd per share) $ 180.00
Options outstanding (in shares) | shares 720
Options outstanding, weighted-average remaining contractual life 8 years 5 months 15 days
Options outstanding, weighted-average exercise price (usd per share) $ 168.04
Options exercisable (in shares) | shares 233
Options exercisable, weighted-average exercise price (usd per share) $ 164.48
$180.01–$189.38  
Stock options outstanding and exercisable  
Exercise price, low end of range (usd per share) 180.01
Exercise price, high end of range (usd per share) $ 189.38
Options outstanding (in shares) | shares 1,624
Options outstanding, weighted-average remaining contractual life 8 years 10 months 24 days
Options outstanding, weighted-average exercise price (usd per share) $ 185.41
Options exercisable (in shares) | shares 364
Options exercisable, weighted-average exercise price (usd per share) $ 184.85
XML 146 R68.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions - Semma Therapeutics - Additional Information (Details) - USD ($)
Oct. 10, 2019
Dec. 31, 2019
Dec. 31, 2018
Business Acquisition [Line Items]      
Intangible asset   $ 400,000,000.0 $ 0
Semma Therapeutics, Inc.      
Business Acquisition [Line Items]      
Total purchase price $ 936,764,000    
Pre-Clinical Treatments For Device-Assisted Cells | Semma Therapeutics, Inc.      
Business Acquisition [Line Items]      
Intangible asset 379,000,000.0    
Naked Islets | Semma Therapeutics, Inc.      
Business Acquisition [Line Items]      
Intangible asset $ 8,000,000.0    
XML 147 R90.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Components of Lease Expense (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
USD ($)
Leases [Abstract]  
Operating lease cost $ 11,972
Finance lease cost  
Amortization of leased assets 49,778
Interest on lease liabilities 52,839
Variable lease cost 27,997
Sublease income (6,391)
Net lease cost $ 136,195
XML 148 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborative Arrangements - Parion Sciences, Inc. (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2018
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2017
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Provision for (benefit from) income taxes   $ 93,716,000 $ 13,148,000 $ 59,711,000 $ 51,534,000 $ (1,492,599,000) $ 8,055,000 $ 10,341,000 $ (12,659,000)   $ 218,109,000 $ (1,486,862,000) $ (107,324,000)
Intangible asset impairment charges           $ 29,000,000 $ 0 $ 0 $ 0   0 29,000,000 255,340,000
(Increase) decrease in fair value of contingent payments   $ (1,500,000) $ (2,959,000) $ 0 $ 0           $ (4,459,000) 0 0
Parion Sciences, Inc                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Provision for (benefit from) income taxes                   $ (126,200,000)      
(Increase) decrease in fair value of contingent payments                   69,600,000      
Income tax expense (benefit), attributable to intangible asset impairment                   (97,700,000)      
Income tax expense (benefit), attributable to decrease in the fair value of contingent consideration liability                   (28,500,000)      
Deconsolidation,loss, amount                         7,100,000
Variable Interest Entity, Primary Beneficiary                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Provision for (benefit from) income taxes                       (3,668,000) (114,090,000)
(Increase) decrease in fair value of contingent payments                       (17,730,000) 62,560,000
Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Collaborative and royalty revenues                         40,000,000.0
Provision for (benefit from) income taxes                         14,800,000
Fair value of intangible asset                   255,300,000      
Other Intangible Assets | Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Intangible asset impairment charges                   255,300,000     255,300,000
Fair value of intangible asset                   $ 0      
Other Intangible Assets | Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences, Inc                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Intangible asset impairment charges $ 29,000,000.0                     $ 29,000,000.0 $ 29,000,000
XML 149 R109.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Narrative (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2017
Dec. 31, 2016
Tax Carryforwards [Line Items]        
Decrease in valuation allowance   $ 30,500,000    
Income tax (benefit) resulting in the release of valuation allowance $ (1,560,000,000)      
Valuation allowance 168,491,000 205,192,000    
Unrecognized tax benefits $ 19,549,000 33,920,000 $ 3,814,000 $ 0
Income tax penalties and interest accrued   0    
Domestic and Foreign Tax Authority        
Tax Carryforwards [Line Items]        
Valuation allowance   205,200,000    
Domestic Tax Authority        
Tax Carryforwards [Line Items]        
Operating loss carryforwards   1,500,000,000    
Operating loss carryforwards, subject to expiration   1,300,000,000    
Operating loss carryforwards, not subject to expiration   181,100,000    
Tax credit carryforwards   399,000,000.0    
State and Local Jurisdiction        
Tax Carryforwards [Line Items]        
Operating loss carryforwards   903,700,000    
Tax credit carryforwards   161,700,000    
Foreign Tax Authority        
Tax Carryforwards [Line Items]        
Operating loss carryforwards   896,900,000    
Operating loss carryforwards, subject to expiration   16,000,000.0    
Operating loss carryforwards, not subject to expiration   880,900,000    
Deferred Tax Assets        
Tax Carryforwards [Line Items]        
Unrecognized tax benefits   13,400,000    
Accounts Payable and Accrued Liabilities        
Tax Carryforwards [Line Items]        
Unrecognized tax benefits   20,500,000    
Semma Therapeutics, Inc.        
Tax Carryforwards [Line Items]        
Business combination, recognized identifiable assets acquired and liabilities assumed, deferred tax liabilities, current   $ 54,200,000    
XML 150 R64.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborative Arrangements - Janssen Pharmaceuticals, Inc. (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2017
USD ($)
Janssen  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Collaborative and royalty revenues $ 25.0
XML 151 R94.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Supplemental Cash Flow Information (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
USD ($)
Cash paid for amounts included in the measurement of lease liabilities:  
Operating cash flows from operating leases $ 10,650
Operating cash flows from finance leases 50,527
Financing cash flows from finance leases 39,185
Right-of-use assets obtained in exchange for lease obligations  
Operating leases 34,605
Finance leases 0
Semma and Exonics Therapeutics  
Right-of-use assets obtained in exchange for lease obligations  
Operating leases $ 33,700

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c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